<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33475213</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6394</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Depression and anxiety</Title><ISOAbbreviation>Depress Anxiety</ISOAbbreviation></Journal><ArticleTitle>At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.</ArticleTitle><Pagination><StartPage>521</StartPage><EndPage>527</EndPage><MedlinePgn>521-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/da.23138</ELocationID><Abstract><AbstractText Label="INTRODUCTION">It is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real-world setting and the effects of the medication.</AbstractText><AbstractText Label="METHODS">Retrospective analysis using two large U.S. health care databases that included commercially insured and Medicaid patients. Patients treated with esketamine were identified and their baseline characteristics described and compared with the baseline characteristics of patients with treatment resistant depression (TRD) and with patients undergoing transcranial magnetic stimulation (TMS). To quantify the differences, standardized mean differences were calculated.</AbstractText><AbstractText Label="RESULTS">In the commercially insured database, 418 patients were treated with esketamine and 830,047 patients were in the TRD group. Large differences in baseline characteristics were observed. Patients in the esketamine group were more likely to have severe depression, suicidal thoughts, and prior treatments with TMS or electroconvulsive therapy than the TRD control group. Patients in the esketamine group had more comorbid psychiatric conditions (anxiety disorder, posttraumatic stress disorders, substance use disorders) and higher exposure to antipsychotics, antiepileptics, hypnotics and sedatives. In terms of general health, patients in the esketamine group had many more outpatient visits, were more likely to have chronic pain and higher Charlson comorbidity scores, a predicator of mortality. Results were similar for both the Medicaid and TMS populations.</AbstractText><AbstractText Label="CONCLUSION">Patients treated with esketamine have a higher burden of disease than other patients with TRD. In any real-world comparative effectiveness or safety study these differences need to be understood and accounted for to produce valid results.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Depression and Anxiety published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cepeda</LastName><ForeName>M Soledad</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-5159-6217</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canuso</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Depress Anxiety</MedlineTA><NlmUniqueID>9708816</NlmUniqueID><ISSNLinking>1091-4269</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>50LFG02TXD</RegistryNumber><NameOfSubstance UI="C000629870">Esketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061218" MajorTopicYN="Y">Depressive Disorder, Treatment-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">burden of disease</Keyword><Keyword MajorTopicYN="N">esketamine</Keyword><Keyword MajorTopicYN="N">observational studies</Keyword></KeywordList><CoiStatement>All authors are employees of Janssen Research &amp; Development, LLC and are stockholders of Johnson &amp; Johnson, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>8</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33475213</ArticleId><ArticleId IdType="pmc">PMC8248018</ArticleId><ArticleId IdType="doi">10.1002/da.23138</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Austin, P. C. (2009). Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics&#x2014;Simulation and Computation, 38(6), 1228&#x2013;1234. 10.1080/03610910902859574</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson, C. , Szukis, H. , Sheehan, J. J. , Alphs, L. , &amp; Yuce, H. (2020). An evaluation of the clinical and economic burden among older adult medicare&#x2010;covered beneficiaries with treatment&#x2010;resistant depression. The American Journal of Geriatric Psychiatry, 28(3), 350&#x2013;362. 10.1016/j.jagp.2019.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2019.10.012</ArticleId><ArticleId IdType="pubmed">31735488</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda, M. S. , Boston, R. , Farrar, J. T. , &amp; Strom, B. L. (2003). Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology, 158(3), 280&#x2013;287. 10.1093/aje/kwg115</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwg115</ArticleId><ArticleId IdType="pubmed">12882951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda, M. S. , Reps, J. , Fife, D. , Blacketer, C. , Stang, P. , &amp; Ryan, P. (2018). Finding treatment&#x2010;resistant depression in real&#x2010;world data: How a data&#x2010;driven approach compares with expert&#x2010;based heuristics. Depression and Anxiety, 35(3), 220&#x2013;228. 10.1002/da.22705</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22705</ArticleId><ArticleId IdType="pmc">PMC5873404</ArticleId><ArticleId IdType="pubmed">29244906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda, M. S. , Schuemie, M. , Kern, D. M. , Reps, J. , &amp; Canuso, C. (2020). Frequency of rehospitalization after hospitalization for suicidal ideation or suicidal behavior in patients with depression. Psychiatry Research, 285, 112810. 10.1016/j.psychres.2020.112810</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.112810</ArticleId><ArticleId IdType="pubmed">32062326</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson, M. E. , Pompei, P. , Ales, K. L. , &amp; MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373&#x2013;383. 10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly, E. J. , Trivedi, M. H. , Janik, A. , Li, H. , Zhang, Y. , Li, X. , Lane, R. , Lim, P. , Duca, A. R. , Hough, D. , Thase, M. E. , Zajecka, J. , Winokur, A. , Divacka, I. , Fagiolini, A. , Cubala, W. J. , Bitter, I. , Blier, P. , Shelton, R. C. , &#x2026; Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment&#x2010;resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893&#x2013;903. 10.1001/jamapsychiatry.2019.1189</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2019.1189</ArticleId><ArticleId IdType="pmc">PMC6551577</ArticleId><ArticleId IdType="pubmed">31166571</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, R. L. , Dunner, D. L. , Muller, J. S. , &amp; Stone, D. A. (2013). Medicare patient experience with vagus nerve stimulation for treatment&#x2010;resistant depression. J Med Econ, 16(1), 62&#x2013;74. 10.3111/13696998.2012.724745</Citation><ArticleIdList><ArticleId IdType="doi">10.3111/13696998.2012.724745</ArticleId><ArticleId IdType="pubmed">22954061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fife, D. , Reps, J. , Cepeda, M. S. , Stang, P. , Blacketer, M. , &amp; Singh, J. (2018). Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon, 4(7), e00707. 10.1016/j.heliyon.2018.e00707</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2018.e00707</ArticleId><ArticleId IdType="pmc">PMC6076365</ArticleId><ArticleId IdType="pubmed">30094377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. , Duke, J. D. , Shah, N. H. , Reich, C. G. , Huser, V. , Schuemie, M. J. , &amp; Ryan, P. B. (2015). Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers. Studies in Health and Technology Informatics, 216, 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern, D. M. , Cepeda, M. S. , Defalco, F. , &amp; Etropolski, M. (2020). Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019. BMC Psychiatry, 20(1), 4. 10.1186/s12888-019-2418-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-019-2418-7</ArticleId><ArticleId IdType="pmc">PMC6942399</ArticleId><ArticleId IdType="pubmed">31900133</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen, A. , Koponen, M. , &amp; Hartikainen, S. (2015). Systematic review: Representativeness of participants in RCTs of acetylcholinesterase inhibitors. PLoS One, 10(5), e0124500. 10.1371/journal.pone.0124500</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0124500</ArticleId><ArticleId IdType="pmc">PMC4416896</ArticleId><ArticleId IdType="pubmed">25933023</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, G. , Fife, D. , Wang, G. , Sheehan, J. J. , Bod&#xe9;n, R. , Brandt, L. , Brenner, P. , Reutfors, J. , &amp; DiBernardo, A. (2019). All&#x2010;cause mortality in patients with treatment&#x2010;resistant depression: A cohort study in the US population. Annals of General Psychiatry, 18, 23. 10.1186/s12991-019-0248-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12991-019-0248-0</ArticleId><ArticleId IdType="pmc">PMC6771113</ArticleId><ArticleId IdType="pubmed">31583010</ArticleId></ArticleIdList></Reference><Reference><Citation>McClintock, S. M. , Reti, I. M. , Carpenter, L. L. , McDonald, W. M. , Dubin, M. , Taylor, S. F. , Cook, I. A. , O'Reardon, J. , Husain, M. M. , Wall, C. , Krystal, A. D. , Sampson, S. M. , Morales, O. , Nelson, B. G. , Latoussakis, V. , George, M. S. , &amp; Lisanby, S. H. (2018). Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. Journal of Clinical Psychiatry, 79(1), 35&#x2013;48. 10.4088/JCP.16cs10905</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.16cs10905</ArticleId><ArticleId IdType="pmc">PMC5846193</ArticleId><ArticleId IdType="pubmed">28541649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, A. P. , Harrison, M. R. , George, D. J. , Abernethy, A. P. , Walker, M. S. , &amp; Hirsch, B. R. (2014). Clinical trial subjects compared to &#x201c;real world&#x201d; patients: Generalizability of renal cell carcinoma trials. Journal of Clinical Oncology, 32(15_suppl), 6510. 10.1200/jco.2014.32.15_suppl.6510</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2014.32.15_suppl.6510</ArticleId></ArticleIdList></Reference><Reference><Citation>Munk, N. E. , Knudsen, J. S. , Potteg&#xe5;rd, A. , Witte, D. R. , &amp; Thomsen, R. W. (2020). Differences between randomized clinical trial participants and real&#x2010;world empagliflozin users and the changes in their glycated hemoglobin levels. JAMA Network Open, 3(2), e1920949. 10.1001/jamanetworkopen.2019.20949</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.20949</ArticleId><ArticleId IdType="pubmed">32031651</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich, C. , Ryan, P. B. , Stang, P. E. , &amp; Rocca, M. (2012). Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. Journal of Biomedical Informatics, 45(4), 689&#x2013;696. 10.1016/j.jbi.2012.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker, N. , &amp; Van Gool, W. A. (2004). The age gap between patients in clinical studies and in the general population: A pitfall for dementia research. Lancet Neurology, 3(10), 627&#x2013;630. 10.1016/s1474-4422(04)00884-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(04)00884-1</ArticleId><ArticleId IdType="pubmed">15380160</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang, P. E. , Ryan, P. B. , Racoosin, J. A. , Overhage, J. M. , Hartzema, A. G. , Reich, C. , Welebob, E. , Scarnecchia, T. , &amp; Woodcock, J. (2010). Advancing the science for active surveillance: Rationale and design for the observational medical outcomes partnership. Annals of Internal Medicine, 153(9), 600&#x2013;606. 10.7326/0003-4819-153-9-201011020-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigo, D. V. , &amp; Baldessarini, R. J. (2009). Anticonvulsants in the treatment of major depressive disorder: An overview. Harvard Review of Psychiatry, 17(4), 231&#x2013;241. 10.1080/10673220903129814</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10673220903129814</ArticleId><ArticleId IdType="pubmed">19637072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33506478</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Patient Cohort Identification on Time Series Data Using the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>64</EndPage><MedlinePgn>57-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1721481</ELocationID><Abstract><AbstractText Label="BACKGROUND">The identification of patient cohorts for recruiting patients into clinical trials requires an evaluation of study-specific inclusion and exclusion criteria. These criteria are specified depending on corresponding clinical facts. Some of these facts may not be present in the clinical source systems and need to be calculated either in advance or at cohort query runtime (so-called feasibility query).</AbstractText><AbstractText Label="OBJECTIVES">We use the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) as the repository for our clinical data. However, Atlas, the graphical user interface of OMOP, does not offer the functionality to perform calculations on facts data. Therefore, we were in search for a different approach. The objective of this study is to investigate whether the Arden Syntax can be used for feasibility queries on the OMOP CDM to enable on-the-fly calculations at query runtime, to eliminate the need to precalculate data elements that are involved with researchers' criteria specification.</AbstractText><AbstractText Label="METHODS">We implemented a service that reads the facts from the OMOP repository and provides it in a form which an Arden Syntax Medical Logic Module (MLM) can process. Then, we implemented an MLM that applies the eligibility criteria to every patient data set and outputs the list of eligible cases (i.e., performs the feasibility query).</AbstractText><AbstractText Label="RESULTS">The study resulted in an MLM-based feasibility query that identifies cases of overventilation as an example of how an on-the-fly calculation can be realized. The algorithm is split into two MLMs to provide the reusability of the approach.</AbstractText><AbstractText Label="CONCLUSION">We found that MLMs are a suitable technology for feasibility queries on the OMOP CDM. Our method of performing on-the-fly calculations can be employed with any OMOP instance and without touching existing infrastructure like the Extract, Transform and Load pipeline. Therefore, we think that it is a well-suited method to perform on-the-fly calculations on OMOP.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg (FAU), Erlangen, Bayern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapsner</LastName><ForeName>Lorenz A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Medical Center for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Bayern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Center for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Bayern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg (FAU), Erlangen, Bayern, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Center for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Bayern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Mannheim University of Applied Sciences, Mannheim, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>28</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33506478</ArticleId><ArticleId IdType="pmc">PMC7840432</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1721481</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meystre S M, Heider P M, Kim Y, Aruch D B, Britten C D. Automatic trial eligibility surveillance based on unstructured clinical data. Int J Med Inform. 2019;129:13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717538</ArticleId><ArticleId IdType="pubmed">31445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Botsis T, Hartvigsen G, Chen F, Weng C. Secondary use of EHR: data quality issues and informatics opportunities. Summit Translat Bioinforma. 2010;2010:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041534</ArticleId><ArticleId IdType="pubmed">21347133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H. Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M. Transforming French Electronic Health Records into the Observational Medical Outcome Partnership's Common Data Model: a feasibility study. Appl Clin Inform. 2020;11(01):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn E K, Park M Y. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a Common Data Model for distributed network research. Healthc Inform Res. 2016;22(01):54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K E, Deppen S A, DuVall S L. Incrementally transforming electronic medical records into the Observational Medical Outcomes Partnership Common Data Model: a multidimensional quality assurance approach. Appl Clin Inform. 2019;10(05):794&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>Denney M J, Long D M, Armistead M G, Anderson J L, Conway B N. Validating the extract, transform, load process used to populate a large clinical research database. Int J Med Inform. 2016;94:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556907</ArticleId><ArticleId IdType="pubmed">27506144</ArticleId></ArticleIdList></Reference><Reference><Citation>Defining a cohort in Atlas through a ratio between two measurement values  OHDSI Forum Published January 9, 2020. Accessed January 9, 2020 at:https://forums.ohdsi.org/t/defining-a-cohort-in-atlas-through-a-ratio-between-two-measurement-values/6768.</Citation></Reference><Reference><Citation>Ross J, Tu S, Carini S, Sim I. Analysis of eligibility criteria complexity in clinical trials. Summit On Translat Bioinforma. 2010;2010:46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041539</ArticleId><ArticleId IdType="pubmed">21347148</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos I, Martin M, Kraus S. Effects of staff training and electronic event monitoring on long-term adherence to lung-protective ventilation recommendations. J Crit Care. 2018;43:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28826081</ArticleId></ArticleIdList></Reference><Reference><Citation>Mate S, Castellanos I, Ganslandt T, Prokosch H-U, Kraus S. Standards-based procedural phenotyping: the Arden Syntax on i2b2. Stud Health Technol Inform. 2017;243:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">28883166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ludemann P, Pryor T A, Wigertz O B, Clayton P D. Rationale for the Arden Syntax. Comput Biomed Res. 1994;27(04):291&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">7956129</ArticleId></ArticleIdList></Reference><Reference><Citation>Samwald M, Fehre K, de Bruin J, Adlassnig K-P. The Arden Syntax standard for clinical decision support: experiences and directions. J Biomed Inform. 2012;45(04):711&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">22342733</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Tu S W, Sim I, Richesson R. Formal representation of eligibility criteria: a literature review. J Biomed Inform. 2010;43(03):451&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878905</ArticleId><ArticleId IdType="pubmed">20034594</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S J, Ohno-Machado L, Mar P, Boxwala A A, Greenes R A.Enhancing Arden Syntax for clinical trial eligibility criteria. Proc AMIA Symp. Published online 19991188</Citation></Reference><Reference><Citation>Ohno-Machado L, Wang S J, Mar P, Boxwala A A.Decision support for clinical trial eligibility determination in breast cancer. Proc AMIA Symp. Published online 1999340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2232554</ArticleId><ArticleId IdType="pubmed">10566377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G. Writing Arden Syntax Medical Logic Modules. Comput Biol Med. 1994;24(05):331&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">7705066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus S. Generalizing the Arden Syntax to a common clinical application language. Stud Health Technol Inform. 2018;247:675&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">29678046</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald C J, Huff S M, Suico J G. LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem. 2003;49(04):624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus S, Toddenroth D, Staudigel M. Mapping the entire record-an alternative approach to data access from Medical Logic Modules. Appl Clin Inform. 2020;11(02):342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220797</ArticleId><ArticleId IdType="pubmed">32403139</ArticleId></ArticleIdList></Reference><Reference><Citation>Talend Inc  Open Source ESB: Talend Open Studio Free ESB Tool  https://www.talend.com/products/application-integration/esb-open-studio/. Accessed January 24, 2020</Citation></Reference><Reference><Citation>Wickham H, Fran&#xe7;ois R, Henry L, M&#xfc;ller K.dplyr: a grammar of data manipulation https://dplyr.tidyverse.org. Published online 2019</Citation></Reference><Reference><Citation>Murphy S N, Weber G, Mendis M. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010;17(02):124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar I N, Chen E S, Rosenau P T, Storer M B, Anderson B, Horbar J D. Using Arden Syntax to identify registry-eligible very low birth weight neonates from the electronic health record. AMIA Annu Symp Proc. 2014;2014:1028&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419950</ArticleId><ArticleId IdType="pubmed">25954412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietzelt M, Goltz U, Grunwald D. ARDEN2BYTECODE: a one-pass Arden Syntax compiler for service-oriented decision support systems based on the OSGi platform. Comput Methods Prog Biomed. 2012;106(02):114&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ryan P B, Ta C. Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc. 2019;26(04):294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Unberath P, Prokosch H U, Gr&#xfc;ndner J, Erpenbeck M, Maier C, Christoph J. EHR-independent predictive decision support architecture based on OMOP. Appl Clin Inform. 2020;11(03):399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269719</ArticleId><ArticleId IdType="pubmed">32492716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni P M. London: Springer; 2011. Metadata-Driven Software Systems in Biomedicine: Designing Systems That Can Adapt to Changing Knowledge.</Citation></Reference><Reference><Citation>Fowler M, Parsons R. Boston: Addison-Wesley; 2011. Domain-Specific Languages.</Citation></Reference><Reference><Citation>Fowler M.Business Readable DSLAccessed January 31, 2020 at:https://martinfowler.com/bliki/BusinessReadableDSL.html.</Citation></Reference><Reference><Citation>Sonntag D, Wennerberg P, Buitelaar P, Zillner S. 2010. Pillars of ontology treatment in the medical domain; pp. 162&#x2013;186.</Citation></Reference><Reference><Citation>Evans C C, Simonov K. Query combinators: domain specific query languages for medical research. Bioinformatics. 2019 doi: 10.1101/737619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/737619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33536436</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>The natural history of symptomatic COVID-19 during the first wave in Catalonia.</ArticleTitle><Pagination><StartPage>777</StartPage><MedlinePgn>777</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">777</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-21100-y</ELocationID><Abstract><AbstractText>The natural history of coronavirus disease 2019 (COVID-19) has yet to be fully described. Here, we use patient-level data from the Information System for Research in Primary Care (SIDIAP) to summarise COVID-19 outcomes in Catalonia, Spain. We included 5,586,521 individuals from the general population. Of these, 102,002 had an outpatient diagnosis of COVID-19, 16,901 were hospitalised with COVID-19, and 5273 died after either being diagnosed or hospitalised with COVID-19 between 1st March and 6th May 2020. Older age, being male, and having comorbidities were all generally associated with worse outcomes. These findings demonstrate the continued need to protect those at high risk of poor outcomes, particularly older people, from COVID-19 and provide appropriate care for those who develop symptomatic disease. While risks of hospitalisation and death were lower for younger populations, there is a need to limit their role in community transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teb&#xe9;</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biostatistics Unit at Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5990-6953</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1964-3546</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/N013468/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K501256/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SRF-2018-11-ST2-004</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>D.P.A. reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA&#x2019;s department and open for external participants. C.T. reports personal fees from Amgen, Boehringer ingelheim outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33536436</ArticleId><ArticleId IdType="pmc">PMC7858639</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-21100-y</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-21100-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilev, M. et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int. J. Epidemiol.10.1093/ije/dyaa140 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499657</ArticleId><ArticleId IdType="pubmed">32887982</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith GJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat. Commun. 2020;11:5749. doi: 10.1038/s41467-020-19478-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19478-2</ArticleId><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra, D. et al. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118,150 cases diagnosed in outpatient settings in Spain. Int. J. Epidemiol. 10.1093/ije/dyaa190 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665572</ArticleId><ArticleId IdType="pubmed">33118037</ArticleId></ArticleIdList></Reference><Reference><Citation>Poll&#xe1;n, M. et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet10.1016/S0140-6736(20)31483-5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Peng RD. What is the question? Science. 2015;347:1314&#x2013;1315. doi: 10.1126/science.aaa6146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa6146</ArticleId><ArticleId IdType="pubmed">25721505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, S. et al. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 10.1001/jamainternmed.2020.3596 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, E. J. et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature10.1038/s41586-020-2521-4 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet10.1016/S0140-6736(20)31304-0 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289564</ArticleId><ArticleId IdType="pubmed">32534626</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan, S. et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect. Dis. 10.1016/S1473-3099(20)30371-6 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228715</ArticleId><ArticleId IdType="pubmed">32422204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, F. K. et al. Modifiable and non-modifiable risk factors for COVID-19: results from UK Biobank. medRxiv10.1101/2020.04.28.20083295 (2020).</Citation></Reference><Reference><Citation>Qian, J., Zhao, L., Ye, R.-Z., Li, X.-J. &amp; Liu, Y.-L. Age-dependent gender differences of COVID-19 in mainland China: comparative study. Clin. Infect. Dis. 10.1093/cid/ciaa683 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314154</ArticleId><ArticleId IdType="pubmed">32473009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof, S. Y. et al. Obesity and mortality among patients diagnosed with COVID-19: results from an Integrated Health Care Organization. Ann. Intern. Med. 10.7326/M20-3742 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429998</ArticleId><ArticleId IdType="pubmed">32783686</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MDM, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP) Inform. Prim. Care. 2011;19:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat. Commun. 2020;11:5009. doi: 10.1038/s41467-020-18849-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Putter, H., Fiocco, M. &amp; Geskus, R. B. Tutorial in biostatistics: competing risks and multi-state models. Stat. Med.10.1002/sim (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17031868</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell, F. E. Regression Modeling Strategies. (Springer, New York, 2015). 10.1007/978-3-319-19425-7</Citation></Reference><Reference><Citation>Wickham H, et al. Welcome to the tidyverse. J. Open Source Softw. 2019;4:1&#x2013;6. doi: 10.21105/joss.01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wreede L, Fiocco M, Putter H. mstate: An R package for the analysis of competing risks and multi-state models. J. Stat. Softw. Artic. 2011;38:1&#x2013;30.</Citation></Reference><Reference><Citation>Harrell, F. E. rms: Regression modeling strategies. R package version 5.1-0. https://doi.org/https://CRAN.R-project.org/package=rms (2017).</Citation></Reference><Reference><Citation>Williams, R. D. et al. Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network. medRxiv10.1101/2020.05.26.20112649 (2020).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33549087</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>An empirical analysis of dealing with patients who are lost to follow-up when developing prognostic models using a cohort design.</ArticleTitle><Pagination><StartPage>43</StartPage><MedlinePgn>43</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">43</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-021-01408-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">Researchers developing prediction models are faced with numerous design choices that may impact model performance. One key decision is how to include patients who are lost to follow-up. In this paper we perform a large-scale empirical evaluation investigating the impact of this decision. In addition, we aim to provide guidelines for how to deal with loss to follow-up.</AbstractText><AbstractText Label="METHODS">We generate a partially synthetic dataset with complete follow-up and simulate loss to follow-up based either on random selection or on selection based on comorbidity. In addition to our synthetic data study we investigate 21 real-world data prediction problems. We compare four simple strategies for developing models when using a cohort design that encounters loss to follow-up. Three strategies employ a binary classifier with data that: (1) include all patients (including those lost to follow-up), (2) exclude all patients lost to follow-up or (3) only exclude patients lost to follow-up who do not have the outcome before being lost to follow-up. The fourth strategy uses a survival model with data that include all patients. We empirically evaluate the discrimination and calibration performance.</AbstractText><AbstractText Label="RESULTS">The partially synthetic data study results show that excluding patients who are lost to follow-up can introduce bias when loss to follow-up is common and does not occur at random. However, when loss to follow-up was completely at random, the choice of addressing it had negligible impact on model discrimination performance. Our empirical real-world data results showed that the four design choices investigated to deal with loss to follow-up resulted in comparable performance when the time-at-risk was 1-year but demonstrated differential bias when we looked into 3-year time-at-risk. Removing patients who are lost to follow-up before experiencing the outcome but keeping patients who are lost to follow-up after the outcome can bias a model and should be avoided.</AbstractText><AbstractText Label="CONCLUSION">Based on this study we therefore recommend (1) developing models using data that includes patients that are lost to follow-up and (2) evaluate the discrimination and calibration of models twice: on a test set including patients lost to follow-up and a test set excluding patients lost to follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA. jreps@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuthbert</LastName><ForeName>Alana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059012" MajorTopicYN="Y">Lost to Follow-Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Best practices</Keyword><Keyword MajorTopicYN="N">Censoring</Keyword><Keyword MajorTopicYN="N">Loss to follow-up</Keyword><Keyword MajorTopicYN="N">Model development</Keyword><Keyword MajorTopicYN="N">PatientLevelPrediction</Keyword><Keyword MajorTopicYN="N">Prognostic model</Keyword></KeywordList><CoiStatement>Jenna Reps is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Patrick Ryan is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Martijn Schuemie is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Peter Rijnbeek works for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research and Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>20</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33549087</ArticleId><ArticleId IdType="pmc">PMC7866757</ArticleId><ArticleId IdType="doi">10.1186/s12911-021-01408-x</ArticleId><ArticleId IdType="pii">10.1186/s12911-021-01408-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NICE Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2014.</Citation></Reference><Reference><Citation>Goldstein BA, Navar AM, Pencina MJ, Ioannidis J. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc. 2017;24(1):198&#x2013;208. doi: 10.1093/jamia/ocw042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;102:e1001381. doi: 10.1371/journal.pmed.1001381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001381</ArticleId><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Bang H, Kim DJ. How to establish clinical prediction models. Endocrinol Metab (Seoul) 2016;31(1):38&#x2013;44. doi: 10.3803/EnM.2016.31.1.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2016.31.1.38</ArticleId><ArticleId IdType="pmc">PMC4803559</ArticleId><ArticleId IdType="pubmed">26996421</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMC Med. 2015;131:1&#x2013;9. doi: 10.1186/s12916-014-0241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0241-z</ArticleId><ArticleId IdType="pmc">PMC4284921</ArticleId><ArticleId IdType="pubmed">25563062</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, Strickler HD, Gunter MJ. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer Epidemiol Prev Biomarkers. 2013;22(2):275&#x2013;285. doi: 10.1158/1055-9965.EPI-12-1050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-12-1050</ArticleId><ArticleId IdType="pmc">PMC3565022</ArticleId><ArticleId IdType="pubmed">23292084</ArticleId></ArticleIdList></Reference><Reference><Citation>Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left truncation. Am J Epidemiol. 2006;165(4):444&#x2013;452. doi: 10.1093/aje/kwk027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwk027</ArticleId><ArticleId IdType="pubmed">17150983</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi S, Hayashi Y, Nose Y, Maehara Y, Korenaga D, Sugimachi K. A comparison of the logistic regression and the cox proportional hazard models in retrospective studies on the prognosis of patients with castric cancer. J Surg Oncol. 1993;52(1):9&#x2013;13. doi: 10.1002/jso.2930520104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.2930520104</ArticleId><ArticleId IdType="pubmed">8441266</ArticleId></ArticleIdList></Reference><Reference><Citation>Peduzzi P, Holford T, Detre K, Chan YK. Comparison of the logistic and Cox regression models when outcome is determined in all patients after a fixed period of time. J Chronic Dis. 1987;40(8):761&#x2013;767. doi: 10.1016/0021-9681(87)90127-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90127-5</ArticleId><ArticleId IdType="pubmed">3597677</ArticleId></ArticleIdList></Reference><Reference><Citation>Vock, D.M., Wolfson, J., Bandyopadhyay, S., Adomavicius, G., Johnson, P.E., Vazquez-Benitez, G. and O&#x2019;Connor, P.J. Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting. <i>J Biomed Inf</i>. 2016;<i>61</i>:119&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893987</ArticleId><ArticleId IdType="pubmed">26992568</ArticleId></ArticleIdList></Reference><Reference><Citation>Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF. Development and validation of a claims-based prediction model for COPD severity. Respir Med. 2013;107(10):1568&#x2013;1577. doi: 10.1016/j.rmed.2013.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2013.05.012</ArticleId><ArticleId IdType="pubmed">23806285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran U, Reps J, Stang PE, Ryan PB. Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases. PLoS ONE. 2019;14(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919633</ArticleId><ArticleId IdType="pubmed">31851711</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai D, Dick P, To T, Wright JG. Development of pediatric comorbidity prediction model. Arch Pediatr Adolesc Med. 2006;160(3):293&#x2013;299. doi: 10.1001/archpedi.160.3.293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.160.3.293</ArticleId><ArticleId IdType="pubmed">16520449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Reps JM., Kostka KF., Ryan PB., Zou Y., et al. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS ONE.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472. doi: 10.1161/JAHA.113.000472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.113.000472</ArticleId><ArticleId IdType="pmc">PMC3959671</ArticleId><ArticleId IdType="pubmed">24584736</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for complex generalized linear models. <i>ACM Trans Model Comput Simul</i>. 2013;23:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bootkrajang, J. and Kab&#xe1;n, A., 2012, September. Label-noise robust logistic regression and its applications. In <i>Joint European conference on machine learning and knowledge discovery in databases</i> (pp. 143&#x2013;158). Springer, Berlin.</Citation></Reference><Reference><Citation>Natarajan, N., Dhillon, I.S., Ravikumar, P.K. and Tewari, A., 2013. Learning with noisy labels. In <i>Advances in neural information processing systems</i> (pp. 1196&#x2013;1204).</Citation></Reference><Reference><Citation>Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials&#x2014;a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi: 10.1186/s12874-017-0442-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-017-0442-1</ArticleId><ArticleId IdType="pmc">PMC5717805</ArticleId><ArticleId IdType="pubmed">29207961</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Janabi S, Alkaim AF. A nifty collaborative analysis to predicting a novel tool (DRFLLS) for missing values estimation. Soft Comput. 2020;24(1):555&#x2013;569. doi: 10.1007/s00500-019-03972-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00500-019-03972-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan TR, Lee KJ, Ryan P, Salter AB. Multiple imputation for handling missing outcome data when estimating the relative risk. BMC Med Res Methodol. 2017;17(1):134. doi: 10.1186/s12874-017-0414-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-017-0414-5</ArticleId><ArticleId IdType="pmc">PMC5588607</ArticleId><ArticleId IdType="pubmed">28877666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33554609</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-3084</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Circulation. Arrhythmia and electrophysiology</Title><ISOAbbreviation>Circ Arrhythm Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study.</ArticleTitle><Pagination><StartPage>e009115</StartPage><MedlinePgn>e009115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCEP.120.009115</ELocationID><Abstract><AbstractText>[Figure: see text].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics (A.O., G.H.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Pierre A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Elain Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajvani</LastName><ForeName>Utpal B</ForeName><Initials>UB</Initials><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics (A.O., G.H.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL136758</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Arrhythm Electrophysiol</MedlineTA><NlmUniqueID>101474365</NlmUniqueID><ISSNLinking>1941-3084</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017180" MajorTopicYN="N">Tachycardia, Ventricular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014693" MajorTopicYN="N">Ventricular Fibrillation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">propensity score</Keyword><Keyword MajorTopicYN="N">thiazolidinediones</Keyword><Keyword MajorTopicYN="N">ventricular fibrillation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>8</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33554609</ArticleId><ArticleId IdType="mid">NIHMS1673742</ArticleId><ArticleId IdType="pmc">PMC7969445</ArticleId><ArticleId IdType="doi">10.1161/CIRCEP.120.009115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States. Published online 2020:32.</Citation></Reference><Reference><Citation>Lin P-J, Kent DM, Winn A, Cohen JT, Neumann PJ. Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences. Am J Manag Care. 2015;21:e23&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25880265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk. Diabetes. 2014;63:1738&#x2013;1747. doi:10.2337/db13-0468</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0468</ArticleId><ArticleId IdType="pubmed">24757202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidaillet H, Granada JF, Chyou P o-H, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113:365&#x2013;370. doi:10.1016/S0002-9343(02)01253-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(02)01253-6</ArticleId><ArticleId IdType="pubmed">12401530</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Supplement 1):S1&#x2013;S2. doi:10.2337/dc20-Sint</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-Sint</ArticleId><ArticleId IdType="pubmed">31862741</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber AJ, Handelsman Y, Grunberger G, et al. Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM &#x2013; 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020;26:107&#x2013;139. doi:10.4158/CS-2019-0472</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/CS-2019-0472</ArticleId><ArticleId IdType="pubmed">32022600</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359:1577&#x2013;1589. doi:10.1056/NEJMoa0806470</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806470</ArticleId><ArticleId IdType="pubmed">18784090</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 7. Approaches to Glycemic Treatment. Diabetes Care. 2015;38(Supplement_1):S41&#x2013;S48. doi:10.2337/dc15-S010</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-S010</ArticleId><ArticleId IdType="pubmed">25537707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S-H, Wu L-S, Chiou M-J, Liu Jia-Rou, Yu Kuang-Hui, Kuo Chang-Fu, Wen M-S, Chen W-J, Yeh Y-H, See L-C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123. doi:10.1186/s12933-014-0123-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-014-0123-x</ArticleId><ArticleId IdType="pmc">PMC4149273</ArticleId><ArticleId IdType="pubmed">25106079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Ye S, Scalzo RL, Reusch JEB, Greyson CR, Schwartz GG. Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. Diabetologia. 2017;60:1550&#x2013;1558. doi:10.1007/s00125-017-4287-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4287-2</ArticleId><ArticleId IdType="pmc">PMC5798228</ArticleId><ArticleId IdType="pubmed">28497164</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamson DM, Chang S, Hansen LG. Health research data for the real world: the MarketScan databases. New York: Thompson Healthcare. Published online 2008:b28.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;senberg LH, van Zyl DG. The mechanism of action of oral antidiabetic drugs: A review of recent literature. JEMDSA. 2008;13:80&#x2013;88. doi:10.1080/22201009.2008.10872177</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22201009.2008.10872177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, Suchard MA, Schuemie MJ, DeFalco FJ, Perotte A, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113:7329&#x2013;7336. doi:10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepede MS, Suchard MA, Yang J, Tian Y, Schuler A, Ryan PB, Madigan D, Hripcsak G. How Confident Are We About Observational Findings in Health Care: A Benchmark Study. Harv Data Sci Rev. 2020;2: 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p -values. Stat Med. 2014;33:209&#x2013;218. doi:10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, et al. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Netw Open. 2018;1:e181755. doi:10.1001/jamanetworkopen.2018.1755</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1755</ArticleId><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi:10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou Y-S, Yang F-Y, Chen H-Y, Jong G-P. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLoS One. 2018;13:e0197245. doi:10.1371/journal.pone.0197245</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197245</ArticleId><ArticleId IdType="pmc">PMC6116917</ArticleId><ArticleId IdType="pubmed">30161122</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallisgaard JL, Lindhardt TB, Staerk L, Olesen JB, Torp-Pedersen C, Hansen ML, Gislason GH. Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2017;3:140&#x2013;146. doi:10.1093/ehjcvp/pvw036</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvw036</ArticleId><ArticleId IdType="pubmed">28028073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141:1227&#x2013;1234. doi:10.1161/CIRCULATIONAHA.119.044183</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.044183</ArticleId><ArticleId IdType="pubmed">31983236</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care. 2002;25:2244&#x2013;2248. doi:10.2337/diacare.25.12.2244</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.25.12.2244</ArticleId><ArticleId IdType="pubmed">12453968</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussel R Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and Atherothrombosis. Arch Intern Med. 2010;170:1892&#x2013;1899. doi:10.1001/archinternmed.2010.409</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2010.409</ArticleId><ArticleId IdType="pubmed">21098347</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock RH, Hougen I, Komenda P, Rigatto C, Clemens KK, Tangri N. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study. Mayo Clin Proc. 2020;95:90&#x2013;100. doi:10.1016/j.mayocp.2019.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2019.07.017</ArticleId><ArticleId IdType="pubmed">31902433</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JMM, Doney ASF, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AKF, Lang CC. Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. Am J Cardiol. 2010;106:1006&#x2013;1010. doi:10.1016/j.amjcard.2010.05.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.05.031</ArticleId><ArticleId IdType="pubmed">20854965</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves EM, Erande AS, Le C, Salcedo J, Hoang KC, Kumar S, Mohar DS, Saremi F, Im J, Agrawal Y, et al. Comparison of Epicardial Adipose Tissue Volume and Coronary Artery Disease Severity in Asymptomatic Adults With Versus Without Diabetes Mellitus. Am J Cardiol. 2014;114:686&#x2013;691. doi:10.1016/j.amjcard.2014.05.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2014.05.057</ArticleId><ArticleId IdType="pmc">PMC4216806</ArticleId><ArticleId IdType="pubmed">25037677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan R, Nelson A, Pathak RK, Middeldorp ME, Wong CX, Twomey DJ, Carbone A, Teo K, Agbaedeng T, Linz D, et al. Electroanatomical Remodeling of the Atria in Obesity. JACC: Clin Electrophysiol. 2018;4:1529&#x2013;1540. doi:10.1016/j.jacep.2018.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2018.08.014</ArticleId><ArticleId IdType="pubmed">30573116</ArticleId></ArticleIdList></Reference><Reference><Citation>Greulich S, Maxhera B, Vandenplas G, Herzfeld de Wiza D, Smiris K, Mueller H, Heinrichs J, Blumensatt M, Cuvelier C, Akhyari P, et al. Secretory Products From Epicardial Adipose Tissue of Patients With Type 2 Diabetes Mellitus Induce Cardiomyocyte Dysfunction. Circulation. 2012;126:2324&#x2013;2334. doi:10.1161/CIRCULATIONAHA.111.039586</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.039586</ArticleId><ArticleId IdType="pubmed">23065384</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph LC, Avula UMR, Wan EY, Reyes MV, Lakkadi KR, Subramanyam P, Nakanishi K, Homma S, Muchir A, Pajvani UB, et al. Dietary Saturated Fat Promotes Arrhythmia by Activating NOX2 (NADPH Oxidase 2). Circ Arrhythm Electrophysiol. 2019;12:e007573. doi:10.1161/CIRCEP.119.007573</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.119.007573</ArticleId><ArticleId IdType="pmc">PMC7004280</ArticleId><ArticleId IdType="pubmed">31665913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hookana E, Junttila MJ, Puurunen V-P, et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. Published online July 2011. doi:10.1016/j.hrthm.2011.06.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2011.06.031</ArticleId><ArticleId IdType="pubmed">21740887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulian A, Cancello R, Girola A, et al.``123414q `1AWE23Q `1 Obesity Facts. 2011;4:27&#x2013;33. doi:10.1159/000324582</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000324582</ArticleId><ArticleId IdType="pmc">PMC6444565</ArticleId><ArticleId IdType="pubmed">21372608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016;8:93&#x2013;100. doi:10.1093/jmcb/mjw011</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjw011</ArticleId><ArticleId IdType="pmc">PMC4816148</ArticleId><ArticleId IdType="pubmed">26993047</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfella R, Amarelli C, Cacciatore F, Balestrieri ML, Mansueto G, D&#x2019;Onofrio N, Esposito S, Mattucci I, Salerno G, De Feo M, et al. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. J Am Coll Cardiol. 2020;75:1249&#x2013;1262. doi:10.1016/j.jacc.2020.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.01.018</ArticleId><ArticleId IdType="pubmed">32192650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Liu Y, Tu T, Li B, Xiao Y, Ma Y, Qin F, Xie J, Zhou S, Liu Q. Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-&#x3b1;/VLCAD pathway. Lipids Health Dis. 2019;18:109. doi:10.1186/s12944-019-1059-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-019-1059-7</ArticleId><ArticleId IdType="pmc">PMC6511207</ArticleId><ArticleId IdType="pubmed">31077199</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-H, Hua N, Fu X, Pan Y-L, Li B, Li X-D. Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats. BMC Cardiovasc Disord. 2018;18:236. doi:10.1186/s12872-018-0950-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0950-x</ArticleId><ArticleId IdType="pmc">PMC6293565</ArticleId><ArticleId IdType="pubmed">30545309</ArticleId></ArticleIdList></Reference><Reference><Citation>Burl&#xe1; AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol. 2013;165:483&#x2013;487. doi:10.1016/j.ijcard.2011.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.09.012</ArticleId><ArticleId IdType="pubmed">21945710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33611874</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Incorporation of Korean Electronic Data Interchange Vocabulary into Observational Medical Outcomes Partnership Vocabulary.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>38</EndPage><MedlinePgn>29-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2021.27.1.29</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We incorporated the Korean Electronic Data Interchange (EDI) vocabulary into Observational Medical Outcomes Partnership (OMOP) vocabulary using a semi-automated process. The goal of this study was to improve the Korean EDI as a standard medical ontology in Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We incorporated the EDI vocabulary into OMOP vocabulary through four main steps. First, we improved the current classification of EDI domains and separated medical services into procedures and measurements. Second, each EDI concept was assigned a unique identifier and validity dates. Third, we built a vertical hierarchy between EDI concepts, fully describing child concepts through relationships and attributes and linking them to parent terms. Finally, we added an English definition for each EDI concept. We translated the Korean definitions of EDI concepts using Google.Cloud.Translation.V3, using a client library and manual translation. We evaluated the EDI using 11 auditing criteria for controlled vocabularies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We incorporated 313,431 concepts from the EDI to the OMOP Standardized Vocabularies. For 10 of the 11 auditing criteria, EDI showed a better quality index within the OMOP vocabulary than in the original EDI vocabulary.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incorporation of the EDI vocabulary into the OMOP Standardized Vocabularies allows better standardization to facilitate network research. Our research provides a promising model for mapping Korean medical information into a global standard terminology system, although a comprehensive mapping of official vocabulary remains to be done in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seong</LastName><ForeName>Yeonchan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sociology, Yonsei University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rho</LastName><ForeName>Yeunsook</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Deparment of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Deparment of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dymshyts</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Odysseus Data Services Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real Wolrd Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Yunjung</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Humanities and Social Medicine, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Health Insurance Review and Assessment Service</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological Ontologies</Keyword><Keyword MajorTopicYN="N">Controlled Vocabulary</Keyword><Keyword MajorTopicYN="N">Knowledge Bases</Keyword><Keyword MajorTopicYN="N">Medical Informatics</Keyword><Keyword MajorTopicYN="N">National Health Programs</Keyword></KeywordList><CoiStatement><b>Conflict of Interest</b>. Dr. Dymshyts is employed by Odysseus Data Services, Inc. Dr. Reich is an employee of IQVIA. There are no financial incentives related to the work described here. The other authors declare no competing financial interests. None of the sponsors or funders above, including Odysseus and IQVIA, had input in the design, execution, interpretation of results, or decision to publish.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>21</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33611874</ArticleId><ArticleId IdType="pmc">PMC7921574</ArticleId><ArticleId IdType="doi">10.4258/hir.2021.27.1.29</ArticleId><ArticleId IdType="pii">hir.2021.27.1.29</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park HA, Kim HY, Min YH. Use of clinical terminology for semantic interoperability of electronic health records. J Korean Am Med Assoc. 2012;55(8):720&#x2013;8.</Citation></Reference><Reference><Citation>Healthcare Information Standard [Internet] Seoul, Korea: Korea Health Information Service; 2017.  [cited at 2021 Jan 26]. Available from:  https://www.hins.or.kr/cmm/main/mainPage.do.</Citation></Reference><Reference><Citation>Kim M. A study on a comparison of diagnostic domain between SNOMED CT and Korea standard terminology of medicine. Int J Database Theory Appl. 2015;9(11):49&#x2013;60.</Citation></Reference><Reference><Citation>Jung BK, Kim J, Cho CH, Kim JY, Nam MH, Shin BK, et al. Report on the Project for Establishment of the Standardized Korean Laboratory Terminology Database, 2015. J Korean Med Sci. 2017;32(4):695&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334171</ArticleId><ArticleId IdType="pubmed">28244299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang EJ, Park HA, Sohn SK, Lee HB, Choi HK, Ha S, et al. Mapping Korean EDI medical procedure code to SNOMED CT. Stud Health Technol Inform. 2019;264:178&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino JJ. Desiderata for controlled medical vocabularies in the twenty-first century. Methods Inf Med. 1998;37(4&#x2013;5):394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415631</ArticleId><ArticleId IdType="pubmed">9865037</ArticleId></ArticleIdList></Reference><Reference><Citation>EdiToOmop: the package to convert Korean EDI code to the OMOP vocabulary [Internet] San Francisco (CA): GitHub Inc; 2020.  [cited at 2021 Jan 26]. Available from:  https://github.com/OHDSI/EdiToOmop.</Citation></Reference><Reference><Citation>Chute CG, Cohn SP, Campbell JR. A framework for comprehensive health terminology systems in the United States: development guidelines, criteria for selection, and public policy implications. ANSI Healthcare Informatics Standards Board Vocabulary Working Group and the Computer-Based Patient Records Institute Working Group on Codes and Structures. J Am Med Inform Assoc. 1998;5(6):503&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61331</ArticleId><ArticleId IdType="pubmed">9824798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom ST, Miller RA, Johnson KB, Elkin PL, Brown SH. Interface terminologies: facilitating direct entry of clinical data into electronic health record systems. J Am Med Inform Assoc. 2006;13(3):277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513664</ArticleId><ArticleId IdType="pubmed">16501181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KC. A study on enhancing terminology &amp; its major issues [dissertation] Seoul, Korea: Yonsei University; 2012.</Citation></Reference><Reference><Citation>ATHENA. OHDSI vocabularies repository [Internet] Bethesda (MD): Observational Health Data Sciences and Informatics; 2018.  [cited at 2021 Jan 26]. Available from:  http://athena.ohdsi.org.</Citation></Reference><Reference><Citation>Han SH, Lee MH, Kim SG, Jeong JY, Lee BN, Choi MS, et al. Implementation of medical information exchange system based on EHR standard. Health Inform Res. 2010;16(4):281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3092130</ArticleId><ArticleId IdType="pubmed">21818447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TG, Kwon O, Shin YS, Sung JH, Koh JS, Kim BT. Endovascular treatments performed collaboratively by the Society of Korean Endovascular Neurosurgeons members: a nationwide multicenter survey. J Korean Neurosurg Soc. 2019;62(5):502&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732345</ArticleId><ArticleId IdType="pubmed">31288507</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, An MH, Yoon D, Ban GY, Yang PS, Yu HT, et al. Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease. Heart Rhythm. 2018;15(12):1825&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">30509364</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahao MT, et al. Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study. medRxiv. 2020 doi: 10.1101/2020.04.22.20074336. [Epub].</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean OMOP Vocabulary [Internet] San Francisco (CA): GitHub Inc; 2019.  [cited at 2021 Jan 26]. Available from:  https://github.com/ohdsi-korea/OmopVocabularyKorea.</Citation></Reference><Reference><Citation>OHDSI-Korea [Internet] San Francisco (CA): GitHub Inc; 2019.  [cited at 2021 Jan 26]. Available from:  https://github.com/ohdsi-korea.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33661754</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Implementation of the COVID-19 Vulnerability Index Across an International Network of Health Care Data Sets: Collaborative External Validation Study.</ArticleTitle><Pagination><StartPage>e21547</StartPage><MedlinePgn>e21547</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e21547</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/21547</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 is straining health care systems globally. The burden on hospitals during the pandemic could be reduced by implementing prediction models that can discriminate patients who require hospitalization from those who do not. The COVID-19 vulnerability (C-19) index, a model that predicts which patients will be admitted to hospital for treatment of pneumonia or pneumonia proxies, has been developed and proposed as a valuable tool for decision-making during the pandemic. However, the model is at high risk of bias according to the "prediction model risk of bias assessment" criteria, and it has not been externally validated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to externally validate the C-19 index across a range of health care settings to determine how well it broadly predicts hospitalization due to pneumonia in COVID-19 cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We followed the Observational Health Data Sciences and Informatics (OHDSI) framework for external validation to assess the reliability of the C-19 index. We evaluated the model on two different target populations, 41,381 patients who presented with SARS-CoV-2 at an outpatient or emergency department visit and 9,429,285 patients who presented with influenza or related symptoms during an outpatient or emergency department visit, to predict their risk of hospitalization with pneumonia during the following 0-30 days. In total, we validated the model across a network of 14 databases spanning the United States, Europe, Australia, and Asia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The internal validation performance of the C-19 index had a C statistic of 0.73, and the calibration was not reported by the authors. When we externally validated it by transporting it to SARS-CoV-2 data, the model obtained C statistics of 0.36, 0.53 (0.473-0.584) and 0.56 (0.488-0.636) on Spanish, US, and South Korean data sets, respectively. The calibration was poor, with the model underestimating risk. When validated on 12 data sets containing influenza patients across the OHDSI network, the C statistics ranged between 0.40 and 0.68.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results show that the discriminative performance of the C-19 index model is low for influenza cohorts and even worse among patients with COVID-19 in the United States, Spain, and South Korea. These results suggest that C-19 should not be used to aid decision-making during the COVID-19 pandemic. Our findings highlight the importance of performing external validation across a range of settings, especially when a prediction model is being extrapolated to a different population. In the field of prediction, extensive validation is required to create appropriate trust in a model.</AbstractText><CopyrightInformation>&#xa9;Jenna M Reps, Chungsoo Kim, Ross D Williams, Aniek F Markus, Cynthia Yang, Talita Duarte-Salles, Thomas Falconer, Jitendra Jonnagaddala, Andrew Williams, Sergio Fern&#xe1;ndez-Bertol&#xed;n, Scott L DuVall, Kristin Kostka, Gowtham Rao, Azza Shoaibi, Anna Ostropolets, Matthew E Spotnitz, Lin Zhang, Paula Casajust, Ewout W Steyerberg, Fredrik Nyberg, Benjamin Skov Kaas-Hansen, Young Hwa Choi, Daniel Morales, Siaw-Teng Liaw, Maria Tereza Fernandes Abrah&#xe3;o, Carlos Areia, Michael E Matheny, Kristine E Lynch, Mar&#xed;a Arag&#xf3;n, Rae Woong Park, George Hripcsak, Christian G Reich, Marc A Suchard, Seng Chan You, Patrick B Ryan, Daniel Prieto-Alhambra, Peter R Rijnbeek. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 05.04.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1802-1777</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0001-7723-417X</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markus</LastName><ForeName>Aniek F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0001-5779-4794</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6769-3153</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6904-1394</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9912-2344</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0692-412X</Identifier><AffiliationInfo><Affiliation>Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0029-6564</Identifier><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-4898-3865</Identifier><AffiliationInfo><Affiliation>Department of Veterans Affairs, University of Utah, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4949-7236</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6976-2594</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0847-6682</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2064-8440</Identifier><AffiliationInfo><Affiliation>Melbourne School of Public Health, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2733-5436</Identifier><AffiliationInfo><Affiliation>Department of Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyerberg</LastName><ForeName>Ewout W</ForeName><Initials>EW</Initials><Identifier Source="ORCID">0000-0002-7787-0122</Identifier><AffiliationInfo><Affiliation>Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaas-Hansen</LastName><ForeName>Benjamin Skov</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0003-1023-0371</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NNF Centre for Protein Research, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Young Hwa</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0001-5254-3101</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liaw</LastName><ForeName>Siaw-Teng</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0001-5989-3614</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrah&#xe3;o</LastName><ForeName>Maria Tereza Fernandes</ForeName><Initials>MTF</Initials><Identifier Source="ORCID">0000-0003-2701-670X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-3217-4147</Identifier><AffiliationInfo><Affiliation>Department of Veterans Affairs, Vanderbilt University, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0002-2221-2421</Identifier><AffiliationInfo><Affiliation>Department of Veterans Affairs, University of Utah, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5990-6953</Identifier><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0002-3641-055X</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-9727-2138</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>INV-016201</GrantID><Acronym>GATES</Acronym><Agency>Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-19</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">bias</Keyword><Keyword MajorTopicYN="N">datasets</Keyword><Keyword MajorTopicYN="N">decision-making</Keyword><Keyword MajorTopicYN="N">external validation</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">modeling</Keyword><Keyword MajorTopicYN="N">observation</Keyword><Keyword MajorTopicYN="N">prediction</Keyword><Keyword MajorTopicYN="N">prognostic model</Keyword><Keyword MajorTopicYN="N">risk</Keyword><Keyword MajorTopicYN="N">transportability</Keyword></KeywordList><CoiStatement>Conflicts of Interest: DPA reports grants and other funding from AMGEN, grants, nonfinancial support and other from UCB Biopharma, and grants from Les Laboratoires Servier outside the submitted work; also, Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums and Synapse Management Partners, has supported training programs organized by DPA's department and open for external participants. PRR reports grants from Innovative Medicines Initiative and grants from Janssen Research and Development, during the conduct of the study. CGR and KK report that they are employees of IQVIA. JMR, PBR, AS, and GR are compensated employees of Janssen Research &amp; Development, JNJ. MAS reports receiving grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, personal fees from Private Health Management, during the conduct of the study. DM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from the Chief Scientist Office, Health Data Research UK, and NIHR outside the submitted work. GH reports receiving grants from the US National Institutes of Health National Library of Medicine during the conduct of the study and from Janssen Research outside the submitted work. BSKH reports receiving grants from Innovation Fund Denmark and Novo Nordisk Foundation outside the submitted work. SLD reports grants from Anolinx LLC, Astellas Pharma Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc, Janssen Pharmaceuticals Inc, Kantar Health, Myriad Genetic Laboratories Inc, Novartis International AG, Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33661754</ArticleId><ArticleId IdType="pmc">PMC8023380</ArticleId><ArticleId IdType="doi">10.2196/21547</ArticleId><ArticleId IdType="pii">v9i4e21547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr;395(10231):1225&#x2013;1228. doi: 10.1016/s0140-6736(20)30627-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30627-9</ArticleId><ArticleId IdType="pmc">PMC7102589</ArticleId><ArticleId IdType="pubmed">32178769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L, Van Calster Ben, Collins Gary S, Riley Richard D, Heinze Georg, Schuit Ewoud, Bonten Marc M J, Dahly Darren L, Damen Johanna A A, Debray Thomas P A, de Jong Valentijn M T, De Vos Maarten, Dhiman Paul, Haller Maria C, Harhay Michael O, Henckaerts Liesbet, Heus Pauline, Kammer Michael, Kreuzberger Nina, Lohmann Anna, Luijken Kim, Ma Jie, Martin Glen P, McLernon David J, Andaur Constanza L, Reitsma Johannes B, Sergeant Jamie C, Shi Chunhu, Skoetz Nicole, Smits Luc J M, Snell Kym I E, Sperrin Matthew, Spijker Ren&#xe9;, Steyerberg Ewout W, Takada Toshihiko, Tzoulaki Ioanna, van Kuijk Sander M J, van Bussel Bas, van Royen Florien S, Verbakel Jan Y, Wallisch Christine, Wilkinson Jack, Wolff Robert, Hooft Lotty, Moons Karel G M, van Smeden Maarten. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020 Apr 07;369:m1328. doi: 10.1136/bmj.m1328.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang X, Fu Z, Luo M, Zhang Z, Zhang K, He Y, Wan D, Zhang L, Wang J, Yan X. Potential factors for prediction of disease severity of COVID-19 patients. medRxiv. doi: 10.1101/2020.03.20.20039818. Preprint posted online on March 23, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.20.20039818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Hu S, Fan R, Liu Z, Yin X, Wang Q, Lv Q, Cai Z, Li H, Hu Y, Han Y, Hu H, Gao W, Feng S, Liu Q, Li H, Sun J, Peng J, Yi X, Zhou Z, Guo Y, Hou J. ACP Risk Grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan, China. SSRN Journal. doi: 10.2139/ssrn.3543603. Preprint posted online on February 28, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3543603</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCaprio D, Gartner J, McCall CJ, Burgess T, Garcia K, Kothari S, Sayed S. Building a COVID-19 vulnerability index. ArXiv.  Preprint posted online on March 16, 2020
 .</Citation></Reference><Reference><Citation>C-19 index.  [2021-03-05].   http://c19survey.closedloop.ai/</Citation></Reference><Reference><Citation>Wolff RF, Moons KG, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019 Jan 01;170(1):51. doi: 10.7326/m18-1376.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m18-1376</ArticleId><ArticleId IdType="pubmed">30596875</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster Ben, Wynants Laure, Timmerman Dirk, Steyerberg Ewout W, Collins Gary S. Predictive analytics in health care: how can we know it works? J Am Med Inform Assoc. 2019 Dec 01;26(12):1651&#x2013;1654. doi: 10.1093/jamia/ocz130.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz130</ArticleId><ArticleId IdType="pmc">PMC6857503</ArticleId><ArticleId IdType="pubmed">31373357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J, Shah N, Reich Christian G, Huser Vojtech, Schuemie Martijn J, Suchard Marc A, Park Rae Woong, Wong Ian Chi Kei, Rijnbeek Peter R, van der Lei Johan, Pratt Nicole, Nor&#xe9;n G Niklas, Li Yu-Chuan, Stang Paul E, Madigan David, Ryan Patrick B. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J, Williams RD, You SC, Falconer T, Minty E, Callahan A, Ryan PB, Park RW, Lim HS, Rijnbeek P. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. Research Square. doi: 10.21203/rs.2.11750/v3. Preprint posted online on May 06, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.2.11750/v3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins Gs, Reitsma Jb, Altman Dg, Moons Kg. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement. Br J Surg. 2015 Feb 07;102(3):148&#x2013;58. doi: 10.1002/bjs.9736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9736</ArticleId><ArticleId IdType="pubmed">25627261</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss Erica A, Makadia Rupa, Matcho Amy, Ma Qianli, Knoll Chris, Schuemie Martijn, DeFalco Frank J, Londhe Ajit, Zhu Vivienne, Ryan Patrick B. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;64. doi: 10.1093/jamia/ocu023.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>ohdsi-studies: Covid19 Prediction Studies. GitHub.  [2021-03-05].   https://github.com/ohdsi-studies/Covid19PredictionStudies/tree/master/CovidVulnerabilityIndex.</Citation></Reference><Reference><Citation>Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS One. 2015 Mar 4;10(3):e0118432. doi: 10.1371/journal.pone.0118432.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0118432</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0118432</ArticleId><ArticleId IdType="pmc">PMC4349800</ArticleId><ArticleId IdType="pubmed">25738806</ArticleId></ArticleIdList></Reference><Reference><Citation>Can we trust the prediction model? Demonstrating the importance of external validation by investigating the COVID-19 Vulnerability (C-19) Index across an international network of observational healthcare datasets. C-19 Validation.  [2021-03-05].   http://evidence.ohdsi.org/C19validation.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33674830</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>COVID-19 SignSym: a fast adaptation of a general clinical NLP tool to identify and normalize COVID-19 signs and symptoms to OMOP common data model.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1283</EndPage><MedlinePgn>1275-1283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab015</ELocationID><Abstract><AbstractText>The COVID-19 pandemic swept across the world rapidly, infecting millions of people. An efficient tool that can accurately recognize important clinical concepts of COVID-19 from free text in electronic health records (EHRs) will be valuable to accelerate COVID-19 clinical research. To this end, this study aims at adapting the existing CLAMP natural language processing tool to quickly build COVID-19 SignSym, which can extract COVID-19 signs/symptoms and their 8 attributes (body location, severity, temporal expression, subject, condition, uncertainty, negation, and course) from clinical text. The extracted information is also mapped to standard concepts in the Observational Medical Outcomes Partnership common data model. A hybrid approach of combining deep learning-based models, curated lexicons, and pattern-based rules was applied to quickly build the COVID-19 SignSym from CLAMP, with optimized performance. Our extensive evaluation using 3 external sites with clinical notes of COVID-19 patients, as well as the online medical dialogues of COVID-19, shows COVID-19 SignSym can achieve high performance across data sources. The workflow used for this study can be generalized to other use cases, where existing clinical natural language processing tools need to be customized for specific information needs within a short time. COVID-19 SignSym is freely accessible to the research community as a downloadable package (https://clamp.uth.edu/covid/nlp.php) and has been used by 16 healthcare organizations to support clinical research of COVID-19.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingqi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Melax Technologies, Inc, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu-El-Rub</LastName><ForeName>Noor</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Informatics, University of Kansas Medical Center, Kansas City, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Josh</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3388-5867</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Huy Anh</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Melax Technologies, Inc, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yujia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0889-2261</Identifier><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manion</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Melax Technologies, Inc, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8036-2110</Identifier><AffiliationInfo><Affiliation>Division of Medical Informatics, University of Kansas Medical Center, Kansas City, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>University of Missouri School of Medicine, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5274-4672</Identifier><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouhizadeh</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yaoyun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9220-3101</Identifier><AffiliationInfo><Affiliation>Melax Technologies, Inc, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R44 TR003254</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>ArXiv. 2020 Jul 13:arXiv:2007.10286v4.</RefSource><PMID Version="1">32908948</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="N">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33674830</ArticleId><ArticleId IdType="pmc">PMC7989301</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab015</ArticleId><ArticleId IdType="pii">6155732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/&#xa0;Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Coronavirus in the U.S.:Latest Map and Case Count., https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html&#xa0; Accessed February 23, 2021.</Citation></Reference><Reference><Citation>
Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science | AAAS; 2020. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Open science initiatives related to the COVID-19. OECD. https://community.oecd.org/docs/DOC-172520 Accessed January 10, 2020.</Citation></Reference><Reference><Citation>COVID-19 Datasets and Machine Learning Projects. https://www.kaggle.com/tags/covid19/ Accessed January 10, 2020.</Citation></Reference><Reference><Citation>COVID-19 Open Research Dataset Challenge (CORD-19). https://kaggle.com/allen-institute-for-ai/CORD-19-research-challenge Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Wang LL, Lo K, Chandrasekhar Y, et al. CORD-19: The Covid-19 Open Research Dataset. ArXiv200410706 Cs; 2020.</Citation></Reference><Reference><Citation>LitCovid. https://www.ncbi.nlm.nih.gov/research/coronavirus/ Accessed January 10, 2020.</Citation></Reference><Reference><Citation>AlRahman AlMomani A, Bollt E. Informative Ranking of Stand Out Collections of Symptoms: A New Data-Driven Approach to Identify the Strong Warning Signs of COVID 19. arXiv arXiv&#x2013;2004; 2020.</Citation></Reference><Reference><Citation>
Wagner T, Shweta FN, Murugadoss K, et al.Augmented Curation of Clinical Notes from a Massive EHR System Reveals Symptoms of Impending COVID-19 Diagnosis;2020. http://medrxiv.org/lookup/doi/10.1101/2020.04.19.20067660 Accessed January 10, 2020. doi: 10.1101/2020.04.19.20067660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.19.20067660</ArticleId><ArticleId IdType="pmc">PMC7410498</ArticleId><ArticleId IdType="pubmed">32633720</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. COVID-19 Updates Page. https://www.ohdsi.org/covid-19-updates/ Accessed January 10, 2020.</Citation></Reference><Reference><Citation>National COVID Cohort Collaborative (N3C). National Center for Advancing Translational Sciences; 2020. https://ncats.nih.gov/n3c Accessed January 10, 2020.</Citation></Reference><Reference><Citation>International Electronic Health Record-Derived COVID-19 Clinical Course Profiles: The 4CE Consortium medRxiv. https://www.medrxiv.org/content/10.1101/2020.04.13.20059691v5 Accessed January 10, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.13.20059691v5</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Li J, Soysal E, et al.COVID-19 TestNorm: a tool to normalize COVID-19 testing names to LOINC codes. J. Am. Med. Inform. Assoc 2020; 27 (9): 1437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337837</ArticleId><ArticleId IdType="pubmed">32569358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen A, Fu S, Moon S, et al.Desiderata for delivering NLP to accelerate healthcare AI advancement and a Mayo Clinic NLP-as-a-service implementation. NPJ Digit Med 2019; 2 (1): 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917754</ArticleId><ArticleId IdType="pubmed">31872069</ArticleId></ArticleIdList></Reference><Reference><Citation>OHNLP/MedTagger. GitHubhttps://github.com/OHNLP/MedTagger Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Soysal E, Wang J, Jiang M, et al.CLAMP&#x2014;a toolkit for efficiently building customized clinical natural language processing pipelines. J Am Med Inform Assoc 2018; 25 (3): 331&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378877</ArticleId><ArticleId IdType="pubmed">29186491</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, et al.Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation, and applications. J Am Med Inform Assoc 2010; 17 (5): 507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OMOP Common Data Model. https://www.ohdsi.org/data-standardization/the-common-data-model/ Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Garibaldi BT, Fiksel J, Muschelli J, &#xa0;et al.Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530643</ArticleId><ArticleId IdType="pubmed">32960645</ArticleId></ArticleIdList></Reference><Reference><Citation>iCliniq. Common &#x2018;Covid-19&#x2019; queries answered by top doctors. https://www.icliniq.com/qa/covid-19 Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Elhadad N, Pradhan S, Gorman S, et al. SemEval-2015 task 14: analysis of clinical text. In: proceedings of the 9th International Workshop on Semantic Evaluation (SemEval 2015); June 4&#x2013;5, 2015; Denver, CO.</Citation></Reference><Reference><Citation>World Health Organization. Case management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management Accessed January 10, 2020.</Citation></Reference><Reference><Citation>List of COVID-19 Signs and Symptoms; 2020. https://github.com/Medical-NLP/COVID-19-Sign-Symptom Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Uzuner &#xd6;, South BR, Shen S, DuVall SL.. 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text. J Am Med Inform Assoc 2011; 18 (5): 552&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168320</ArticleId><ArticleId IdType="pubmed">21685143</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Xu W, Yu K. Bidirectional LSTM-CRF Models for Sequence Tagging. ArXiv150801991 Cs; 2015.</Citation></Reference><Reference><Citation>Wei Q, Ji Z, Li Z, et al.A study of deep learning approaches for medication and adverse drug event extraction from clinical text. J Am Med Inform Assoc 2020; 27 (1): 13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913210</ArticleId><ArticleId IdType="pubmed">31135882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezen-Can A. A Comparison of LSTM and BERT for Small Corpus. ArXiv Prepr. ArXiv200905451; 2020.</Citation></Reference><Reference><Citation>Zhang Y, Wang J, Tang B, et al. UTH_CCB: A report for SemEval 2014 &#x2013; task 7 analysis of clinical text. In: proceedings of the 8th International Workshop on Semantic Evaluation (SemEval 2014). Association for Computational Linguistics; August 23&#x2013;24, 2014; Dublin, Ireland. doi: 10.3115/v1/S14-2142.</Citation></Reference><Reference><Citation>OHDSI. documentation:cdm:note_nlp. https://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:note_nlp Accessed January 10, 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33705440</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea.</ArticleTitle><Pagination><StartPage>e0248058</StartPage><MedlinePgn>e0248058</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0248058</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0248058</ELocationID><Abstract><AbstractText Label="BACKGROUND">The effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated the association between RAAS inhibitor use and outcomes of Covid-19.</AbstractText><AbstractText Label="METHODS">This study was a retrospective observational cohort study that used data based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19 tested cases and the history of medical service use in these patients for the past five years. The primary outcome was all-cause mortality, and the rate of ventilator care was compared between the groups.</AbstractText><AbstractText Label="RESULTS">From a total of 7,590 patients diagnosed with Covid-19, two distinct cohorts were generated based on RAAS inhibitors prescribed within 6 months before Covid-19 diagnosis. A total of 1,111 patients was prescribed RAAS inhibitors, and 794 patients were prescribed antihypertensive drugs, excluding RAAS inhibitors. In propensity-score matched analysis, 666 pairs of data set were generated, and all-cause mortality of the RAAS inhibitor group showed no significant difference compared with the non-RAAS inhibitor group (14.6% vs. 11.1%; hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.54-1.15; p = 0.22). The rate of ventilator care was not significantly different between the two groups (4.4% vs. 4.1%; HR, 1.04; 95%CI, 0.60-1.79; p = 0.89).</AbstractText><AbstractText Label="CONCLUSIONS">RAAS inhibitor treatment did not appear to increase the mortality of Covid-19 patients compared with other antihypertensive drugs, suggesting that they may be safely continued in Covid-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jungchan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7794-3547</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Hwa</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0001-5508-7519</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kwangmo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33705440</ArticleId><ArticleId IdType="pmc">PMC7951918</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0248058</ArticleId><ArticleId IdType="pii">PONE-D-20-27008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation> World Health Organization. Rolling updates on coronavirus disease (COVID-19) [Internet]. 2020 [cited 2020 Mar 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.</Citation></Reference><Reference><Citation>The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team China CDC. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronaviurs Diseases. Vital Surveillances. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020; 382:1653&#x2013;9. 10.1056/NEJMsr2005760 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr2005760</ArticleId><ArticleId IdType="pmc">PMC7121452</ArticleId><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 81:537&#x2013;40. 10.1002/ddr.21656 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21656</ArticleId><ArticleId IdType="pmc">PMC7228359</ArticleId><ArticleId IdType="pubmed">32129518</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1&#x2013;7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007; 3:125&#x2013;37. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994039</ArticleId><ArticleId IdType="pubmed">17583183</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al.. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436:112&#x2013;6. 10.1038/nature03712 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03712</ArticleId><ArticleId IdType="pmc">PMC7094998</ArticleId><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020; 75:1382&#x2013;5. 10.1161/HYPERTENSIONAHA.120.15082 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15082</ArticleId><ArticleId IdType="pmc">PMC7225046</ArticleId><ArticleId IdType="pubmed">32208987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al.. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020; 41:1801&#x2013;3. 10.1093/eurheartj/ehaa235 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa235</ArticleId><ArticleId IdType="pmc">PMC7184407</ArticleId><ArticleId IdType="pubmed">32196087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020; 5:745&#x2013;7. 10.1001/jamacardio.2020.1282 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1282</ArticleId><ArticleId IdType="pubmed">32242890</ArticleId></ArticleIdList></Reference><Reference><Citation>ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [Internet]. 2020 [cited 2020 Mar 31]. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.</Citation></Reference><Reference><Citation>You SC, Lee S, Cho SY, Park H, Jung S, Cho J, et al.. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM). Stud Health Technol Inform. 2017; 245:467&#x2013;70. .</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012; 19:54&#x2013;60. 10.1136/amiajnl-2011-000376 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al.. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348:1986&#x2013;94. 10.1056/NEJMoa030685 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030685</ArticleId><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426:450&#x2013;4. 10.1038/nature02145 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins J. Preventing a covid-19 pandemic. BMJ. 2020; 368:m810. 10.1136/bmj.m810 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m810</ArticleId><ArticleId IdType="pubmed">32111649</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifiro G, Crisafulli S, Ando G, Racagni G, Drago F, Italian Society of P. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf. 2020; 43:507&#x2013;9. 10.1007/s40264-020-00935-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00935-2</ArticleId><ArticleId IdType="pmc">PMC7164333</ArticleId><ArticleId IdType="pubmed">32303915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8:e21. 10.1016/S2213-2600(20)30116-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30116-8</ArticleId><ArticleId IdType="pmc">PMC7118626</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17:259&#x2013;60. 10.1038/s41569-020-0360-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0360-5</ArticleId><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004; 383:45&#x2013;51. 10.1042/BJ20040634 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20040634</ArticleId><ArticleId IdType="pmc">PMC1134042</ArticleId><ArticleId IdType="pubmed">15283675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al.. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111:2605&#x2013;10. 10.1161/CIRCULATIONAHA.104.510461 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.510461</ArticleId><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al.. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11:875&#x2013;9. 10.1038/nm1267 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al.. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension. 2020; 76:51&#x2013;8. 10.1161/HYPERTENSIONAHA.120.15143 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15143</ArticleId><ArticleId IdType="pubmed">32348166</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al.. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5:1020&#x2013;6. 10.1001/jamacardio.2020.1855 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1855</ArticleId><ArticleId IdType="pmc">PMC7201375</ArticleId><ArticleId IdType="pubmed">32936273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43:970&#x2013;6. 10.1161/01.HYP.0000124667.34652.1a .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000124667.34652.1a</ArticleId><ArticleId IdType="pubmed">15007027</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SC Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al.. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458&#x2013;73. 10.1161/CIR.0b013e318235eb4d .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e318235eb4d</ArticleId><ArticleId IdType="pubmed">22052934</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39:3021&#x2013;104. 10.1093/eurheartj/ehy339 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy339</ArticleId><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497&#x2013;506. 10.1016/S0140-6736(20)30183-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al.. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5:811&#x2013;8. 10.1001/jamacardio.2020.1017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al.. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015; 47:693&#x2013;705. 10.1007/s00726-014-1889-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-014-1889-6</ArticleId><ArticleId IdType="pubmed">25534429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebek S, Tafelmeier M, Messmann R, Provaznik Z, Schmid C, Maier LS, et al.. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. Eur J Heart Fail. 2020. 10.1002/ejhf.2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2020</ArticleId><ArticleId IdType="pmc">PMC7675329</ArticleId><ArticleId IdType="pubmed">33017071</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society Hypertension, Hypertension Epidemiology Research Working Group, Kim HC, Cho MC. Korea hypertension fact sheet 2018. Clin Hypertens. 2018; 24:13. 10.1186/s40885-018-0098-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-018-0098-0</ArticleId><ArticleId IdType="pmc">PMC6166277</ArticleId><ArticleId IdType="pubmed">30288297</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadegiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020; 7:453. 10.3389/fmed.2020.00453 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00453</ArticleId><ArticleId IdType="pmc">PMC7399048</ArticleId><ArticleId IdType="pubmed">32850920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33712854</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>ACE: the Advanced Cohort Engine for searching longitudinal patient records.</ArticleTitle><Pagination><StartPage>1468</StartPage><EndPage>1479</EndPage><MedlinePgn>1468-1479</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab027</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To propose a paradigm for a scalable time-aware clinical data search, and to describe the design, implementation and use of a search engine realizing this paradigm.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The Advanced Cohort Engine (ACE) uses a temporal query language and in-memory datastore of patient objects to provide a fast, scalable, and expressive time-aware search. ACE accepts data in the Observational Medicine Outcomes Partnership Common Data Model, and is configurable to balance performance with compute cost. ACE's temporal query language supports automatic query expansion using clinical knowledge graphs. The ACE API can be used with R, Python, Java, HTTP, and a Web UI.</AbstractText><AbstractText Label="RESULTS">ACE offers an expressive query language for complex temporal search across many clinical data types with multiple output options. ACE enables electronic phenotyping and cohort-building with subsecond response times in searching the data of millions of patients for a variety of use cases.</AbstractText><AbstractText Label="DISCUSSION">ACE enables fast, time-aware search using a patient object-centric datastore, thereby overcoming many technical and design shortcomings of relational algebra-based querying. Integrating electronic phenotype development with cohort-building enables a variety of high-value uses for a learning health system. Tradeoffs include the need to learn a new query language and the technical setup burden.</AbstractText><AbstractText Label="CONCLUSION">ACE is a tool that combines a unique query language for time-aware search of longitudinal patient records with a patient object datastore for rapid electronic phenotyping, cohort extraction, and exploratory data analyses.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polony</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jos&#xe9; D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-8499-824X</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Georgia State University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gombar</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="Y">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057386" MajorTopicYN="Y">Search Engine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">in-memory datastore, query language, search engine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33712854</ArticleId><ArticleId IdType="pmc">PMC8279796</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab027</ArticleId><ArticleId IdType="pii">6169466</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palmer RH. Process-based measures of quality: the need for detailed clinical data in large health care databases. Ann Intern Med 1997; 127 (8_Part_2): 733&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382389</ArticleId></ArticleIdList></Reference><Reference><Citation>Longhurst CA, Harrington RA, Shah NH.. A &#x2018;green button&#x2019; for using aggregate patient data at the point of care. Health Aff 2014; 33 (7): 1229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al.Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA 2016; 6: 7329&#x2013;36. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenes RA, Pappalardo AN, Marble CW, et al.Design and implementation of a clinical data management system. Comput Biomed Res 1969; 2 (5): 469&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11697375</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Porter D, Rury CD, et al.ClinQuery: searching a large clinical database. MD Comput 1990; 7 (3): 144&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanauer DA. EMERSE: the Electronic Medical Record Search Engine. AMIA Annu Symp Proc 2006; 2006: 941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839699</ArticleId><ArticleId IdType="pubmed">17238560</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Yates SN, Lovely JK, et al. Patient-like-mine: a real time, visual analytics tool for clinical decision support. In: proceedings of the 2015 IEEE International Conference on Big Data (Big Data); October 29&#x2013;November 1, 2015; Santa Clara.&#xa0;</Citation></Reference><Reference><Citation>Murphy SN, Barnett GO, Chueh HC.. Visual query tool for finding patient cohorts from a clinical data warehouse of the partners HealthCare system. Proc AMIA Symp 2000; 2000: 1174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243863</ArticleId><ArticleId IdType="pubmed">11080028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurdle JF, Haroldsen SC, Hammer A, et al.Identifying clinical/translational research cohorts: ascertainment via querying an integrated multi-source database. J Am Med Inform Assoc 2013; 20 (1): 164&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555332</ArticleId><ArticleId IdType="pubmed">23059733</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao S, Cui L, Wu X, et al.Facilitating cohort discovery by enhancing ontology exploration, query management and query sharing for large clinical data repositories. AMIA Annu Symp Proc 2017; 2017: 1685&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977665</ArticleId><ArticleId IdType="pubmed">29854239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui L, Zeng N, Kim M, et al.X-search: an open access interface for cross-cohort exploration of the National Sleep Research Resource. BMC Med Inform Decis Mak 2018; 18 (1): 99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234631</ArticleId><ArticleId IdType="pubmed">30424756</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt PS, Kiefer RC, Pacheco JA, et al.Toward cross&#x2010;platform electronic health record &#x2010;driven phenotyping using Clinical Quality Language. Learn Health Sys 2020; 2015: 147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556419</ArticleId><ArticleId IdType="pubmed">33083538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbins NJ, Spital CH, Black RA, et al.Leaf: an open-source, model-agnostic, data-driven web application for cohort discovery and translational biomedical research. J Am Med Inform Assoc 2020; 27 (1): 109&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913227</ArticleId><ArticleId IdType="pubmed">31592524</ArticleId></ArticleIdList></Reference><Reference><Citation>UC Research eXchange (UC ReX). https://www.ucbraid.org/ucrexAccessed September 10, 2020</Citation></Reference><Reference><Citation>Anderson N, Abend A, Mandel A, et al.Implementation of a deidentified federated data network for population-based cohort discovery. J Am Med Inform Assoc 2012; 19 (e1): e60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392860</ArticleId><ArticleId IdType="pubmed">21873473</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath MM, Rusincovitch SA, Brinson S, et al.Modular design, application architecture, and usage of a self-service model for enterprise data delivery: the Duke Enterprise Data Unified Content Explorer (DEDUCE). J Biomed Inform 2014; 52: 231&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335712</ArticleId><ArticleId IdType="pubmed">25051403</ArticleId></ArticleIdList></Reference><Reference><Citation>Badgeley MA, Shameer K, Glicksberg BS, et al.EHDViz: clinical dashboard development using open-source technologies. BMJ Open 2016; 6 (3): e010579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809078</ArticleId><ArticleId IdType="pubmed">27013597</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcelon N, Neuraz A, Salomon R, et al.A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse. J Biomed Inform 2018; 80: 52&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29501921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferranti JM, Gilbert W, McCall J, et al.The design and implementation of an open-source, data-driven cohort recruitment system: the Duke Integrated Subject Cohort and Enrollment Research Network (DISCERN). J Am Med Inform Assoc 2012; 19 (e1): e68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392865</ArticleId><ArticleId IdType="pubmed">21946237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bache R, Taweel A, Miles S, et al.An eligibility criteria query language for heterogeneous data warehouses. Methods Inf Med 2015; 54 (01): 41&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">24985949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe HJ, Ferris TA, Hernandez PM, et al.STRIDE&#x2013;An integrated standards-based translational research informatics platform. AMIA Annu Symp Proc 2009; 2009: 391&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815452</ArticleId><ArticleId IdType="pubmed">20351886</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, et al.Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc 2010; 17 (2): 124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shah NH, Polony V, Banda JM, et al. Systems and Methods for Cohort Analysis Using Compressed Data Objects Enabling Fast Memory Lookups. US Patent. 2020. https://patentimages.storage.googleapis.com/68/4d/0b/f0eb4750b68a43/US20200057767A1.pdfAccessed December 4, 2020</Citation></Reference><Reference><Citation>S&#xe1;nchez-de-Madariaga R, Mu&#xf1;oz A, Lozano-Rub&#xed; R, et al.Examining database persistence of ISO/EN 13606 standardized electronic health record extracts: relational vs. NoSQL approaches. BMC Med Inform Decis Mak 2017; 17 (1): 123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563027</ArticleId><ArticleId IdType="pubmed">28821246</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al.Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open 2018; 1 (4): e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLAS. http://www.ohdsi.org/web/atlas/Accessed September 10, 2020</Citation></Reference><Reference><Citation>Snodgrass RT, ed. The TSQL2 Temporal Query Language. Boston, MA: Springer; 1995.</Citation></Reference><Reference><Citation>Das AK, Musen MA.. A temporal query system for protocol-directed decision support. Methods Inf Med 1994; 33 (04): 358&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799812</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigrin DJ, Kohane IS.. Temporal expressiveness in querying a time-stamp&#x2013;based clinical database. J Am Med Inform Assoc 2000; 7 (2): 152&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61469</ArticleId><ArticleId IdType="pubmed">10730599</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor MJ, Tu SW, Musen MA.. The Chronus II temporal database mediator. Proc AMIA Symp 2002; 2002: 567&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244583</ArticleId><ArticleId IdType="pubmed">12474882</ArticleId></ArticleIdList></Reference><Reference><Citation>Post AR, Sovarel AN, Harrison JH Jr.. Abstraction-based temporal data retrieval for a Clinical Data Repository. AMIA Annu Symp Proc 2007; 2007: 603&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655874</ArticleId><ArticleId IdType="pubmed">18693907</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisant C, Lam S, Shneiderman B, et al.Searching electronic health records for temporal patterns in patient histories: a case study with microsoft amalga. AMIA Annu Symp Proc 2008; 2008: 601&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655947</ArticleId><ArticleId IdType="pubmed">18999158</ArticleId></ArticleIdList></Reference><Reference><Citation>Combi C, Cucchi G, Pinciroli F.. Applying object-oriented technologies in modeling and querying temporally oriented clinical databases dealing with temporal granularity and indeterminacy. IEEE Trans Inform Technol Biomed 1997; 1 (2): 100&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020814</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Du J, He Y, et al.Time event ontology (TEO): to support semantic representation and reasoning of complex temporal relations of clinical events. J Am Med Inform Assoc 2020; 27 (7): 1046&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647306</ArticleId><ArticleId IdType="pubmed">32626903</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fries JA, Steinberg E, Khattar S, et al. Trove: Ontology-driven weak supervision for medical entity classification. ArXiv. https://www.ncbi.nlm.nih.gov/pubmed/32793768Accessed August 5, 2020</Citation></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, et al.Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc 2010; 17 (5): 507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain NL, Knirsch CA, Friedman C, et al.Identification of suspected tuberculosis patients based on natural language processing of chest radiograph reports. Proc AMIA Annu Fall Symp 1996; 1996: 542&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233236</ArticleId><ArticleId IdType="pubmed">8947725</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B, Ceusters W, Klagges B, et al.Relations in biomedical ontologies. Genome Biol 2005; 6: 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1175958</ArticleId><ArticleId IdType="pubmed">15892874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn CE Jr. Transitive closure of subsumption and causal relations in a large ontology of radiological diagnosis. J Biomed Inform 2016; 61: 27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27005590</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NH, Jonquet C, Chiang AP, et al.Ontology-driven indexing of public datasets for translational bioinformatics. BMC Bioinformatics 2009; 10 (S2): S1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646250</ArticleId><ArticleId IdType="pubmed">19208184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lependu P, Dou D.. Using ontology databases for scalable query answering, inconsistency detection, and data integration. J Intell Inf Syst 2011; 37 (2): 217&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230227</ArticleId><ArticleId IdType="pubmed">22163378</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing X, Cimino JJ.. Graphical methods for reducing, visualizing and analyzing large data sets using hierarchical terminologies. AMIA Annu Symp Proc 2011; 2011: 635&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243153</ArticleId><ArticleId IdType="pubmed">22195119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Wang F, Lu J.. Enabling ontology based semantic queries in biomedical database systems. Int J Semant Comput 2014; 08 (01): 67&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275106</ArticleId><ArticleId IdType="pubmed">25541585</ArticleId></ArticleIdList></Reference><Reference><Citation>Munir K, Sheraz Anjum M.. The use of ontologies for effective knowledge modelling and information retrieval. Appl Comput Inform 2018; 14 (2): 116&#x2013;26.</Citation></Reference><Reference><Citation>Jing X, Emerson M, Masters D, et al.A visual interactive analytic tool for filtering and summarizing large health data sets coded with hierarchical terminologies (VIADS). BMC Med Inform Decis Mak 2019; 19 (1): 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376747</ArticleId><ArticleId IdType="pubmed">30764811</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, et al.Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc 2011; 18 (4): 441&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Contributors to Wikimedia projects. Object storage. 2013. https://en.wikipedia.org/wiki/Object_storageAccessed October 1, 2020</Citation></Reference><Reference><Citation>
Wang C, Ohe K.. 
A CORBA-based object framework with patient identification translation and dynamic linking. Methods for exchanging patient data. Methods Inf Med 1999; 38 (01): 56&#x2013;65. https://pubmed.ncbi.nlm.nih.gov/10339965/. Accessed October 1, 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">10339965</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ohe K.
A hospital information system based on Common Object Request Broker Architecture (CORBA) for exchanging distributed medical objects&#x2013;an approach to future environment of sharing healthcare information. Stud Health Technol Inform 1998; 52 (Pt 2). https://pubmed.ncbi.nlm.nih.gov/10384602/. Accessed October 1, 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">10384602</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisant C, Mushlin R, Snyder A, et al.LifeLines: using visualization to enhance navigation and analysis of patient records. Proc AMIA Symp 1998; 1998: 76&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2232192</ArticleId><ArticleId IdType="pubmed">9929185</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso DL, Rose A, Plaisant C, et al.Viewing personal history records: a comparison of tabular format and graphical presentation using LifeLines. Behav Inf Technol 1998; 17 (5): 249&#x2013;62.</Citation></Reference><Reference><Citation>Bui AAT, Aberle DR, Kangarloo H.. TimeLine: visualizing integrated patient records. IEEE Trans Inform Technol Biomed 2007; 11 (4): 462&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17674629</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller A, Scheinkestel C, Steele C.. The effects of clinical information presentation on physicians&#x2019; and nurses' decision-making in ICUs. Appl Ergon 2009; 40 (4): 753&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18834970</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill J, Chearman T, Carey M, et al.Presenting patient data in the electronic care record: the role of timelines. JRSM Short Rep 2010; 1 (4): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984360</ArticleId><ArticleId IdType="pubmed">21103121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledieu T, Bouzill&#xe9; G, Thiessard F, et al.Timeline representation of clinical data: usability and added value for pharmacovigilance. BMC Med Inform Decis Mak 2018; 18 (1): 86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6194681</ArticleId><ArticleId IdType="pubmed">30340483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma A, Bidargaddi N, Strobel J, et al.Health timeline: an insight-based study of a timeline visualization of clinical data. BMC Med Inform Decis Mak 2019; 19 (1): 170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704521</ArticleId><ArticleId IdType="pubmed">31438942</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, et al.Advances in electronic phenotyping: from rule-based definitions to machine learning models. Annu Rev Biomed Data Sci 2018; 1 (1): 53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombar S, Callahan A, Califf R, et al.It is time to learn from patients like mine. NPJ Digit Med 2019; 2 (1): 16. doi: 10.1038/s41746-019-0091-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-019-0091-3</ArticleId><ArticleId IdType="pmc">PMC6550176</ArticleId><ArticleId IdType="pubmed">31304364</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler A, Callahan A, Jung K, et al.Performing an informatics consult: methods and challenges. J Am Coll Radiol 2018; 15 (3): 563&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901653</ArticleId><ArticleId IdType="pubmed">29396125</ArticleId></ArticleIdList></Reference><Reference><Citation>Penberthy L, Brown R, Puma F, et al.Automated matching software for clinical trials eligibility: measuring efficiency and flexibility. Contemp Clin Trials 2010; 31 (3): 207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387843</ArticleId><ArticleId IdType="pubmed">20230913</ArticleId></ArticleIdList></Reference><Reference><Citation>Penberthy LT, Dahman BA, Petkov VI, et al.Effort required in eligibility screening for clinical trials. JOP 2012; 8 (6): 365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500483</ArticleId><ArticleId IdType="pubmed">23598846</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;pcke F, Prokosch H-U.. Employing computers for the recruitment into clinical trials: a comprehensive systematic review. J Med Internet Res 2014; 16 (7): e161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128959</ArticleId><ArticleId IdType="pubmed">24985568</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton GK, Shepherd J, Pickett K, et al.Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials 2020; 21 (1): 478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273688</ArticleId><ArticleId IdType="pubmed">32498690</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ratner A, Bach SH, Ehrenberg H, et al. Snorkel: Rapid Training Data Creation with Weak Supervision. arXiv [cs.LG]. 2017. http://arxiv.org/abs/1711.10160</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951191</ArticleId><ArticleId IdType="pubmed">29770249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner A, Hancock B, Dunnmon J, et al.Training complex models with multi-task weak supervision. AAAI 2019; 33: 4763&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6765366</ArticleId><ArticleId IdType="pubmed">31565535</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Halpern Y, Sontag D, et al.Electronic phenotyping with APHRODITE and the Observational Health Sciences and Informatics (OHDSI) data network. AMIA Jt Summits Transl Sci Proc 2017; 2017: 48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543379</ArticleId><ArticleId IdType="pubmed">28815104</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries JA, Varma P, Chen VS, et al.Weakly supervised classification of aortic valve malformations using unlabeled cardiac MRI sequences. Nat Commun 2019; 10 (1): 3111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629670</ArticleId><ArticleId IdType="pubmed">31308376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap M, Seneviratne M, Banda JM, et al.Development and validation of phenotype classifiers across multiple sites in the observational health data sciences and informatics network. J Am Med Inform Assoc 2020; 27 (6): 877&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309227</ArticleId><ArticleId IdType="pubmed">32374408</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan A, Fries JA, R&#xe9; C, et al.Medical device surveillance with electronic health records. NPJ Digit Med 2019; 2: 94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6761113</ArticleId><ArticleId IdType="pubmed">31583282</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd AD, Hosner C, Hunscher DA, et al.An &#x2018;honest broker&#x2019; mechanism to maintain privacy for patient care and academic medical research. Int J Med Inform 2007; 76: 407&#x2013;11. doi: 10.1016/j.ijmedinf.2006.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2006.09.004</ArticleId><ArticleId IdType="pubmed">17081800</ArticleId></ArticleIdList></Reference><Reference><Citation>
Datta S, Posada J, Olson G, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. arXiv [cs.CY]. 2020. http://arxiv.org/abs/2003.10534</Citation></Reference><Reference><Citation>Feinstein AR, Rubinstein JF, Ramshaw WA.. Estimating prognosis with the aid of a conversational-mode computer program. Ann Intern Med 1972; 76 (6): 911&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">4554880</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (US) Roundtable on Value &amp; Science-Driven Health Care. Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good. Washington, DC: National Academies Press; 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">21595112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Elhadad N, Chen Y-H, et al.Using empiric semantic correlation to interpret temporal assertions in clinical texts. J Am Med Inform Assoc 2009; 16 (2): 220&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649319</ArticleId><ArticleId IdType="pubmed">19074297</ArticleId></ArticleIdList></Reference><Reference><Citation>Getz KA, Wenger J, Campo RA, et al.Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15 (5): 450&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18806521</ArticleId></ArticleIdList></Reference><Reference><Citation>Getz KA, Zuckerman R, Cropp AB, et al.Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inform J 2011; 45 (3): 265&#x2013;75.</Citation></Reference><Reference><Citation>Boericke K, Gwinn B.. Planned to perfection. Int Clin Trials 2010; 17: 26&#x2013;30.</Citation></Reference><Reference><Citation>Getz K. Improving protocol design feasibility to drive drug development economics and performance. IJERPH 2014; 11 (5): 5069&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053871</ArticleId><ArticleId IdType="pubmed">24823665</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankovich J, Longhurst CA, Sutherland SM.. Evidence-based medicine in the EMR era. N Engl J Med 2011; 365 (19): 1758&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22047518</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, Bafna V, Boxwala AA, et al.; and the iDASH team. iDASH: integrating data for analysis, anonymization, and sharing. J Am Med Inform Assoc 2012; 19 (2): 196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277627</ArticleId><ArticleId IdType="pubmed">22081224</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie SL, Wyatt MC, Schuff R, et al.Practices and perspectives on building integrated data repositories: results from a 2010 CTSA survey. J Am Med Inform Assoc 2012; 19 (e1): e119&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392848</ArticleId><ArticleId IdType="pubmed">22437072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S, Kim S, Lee K-H, et al.Electronically implemented clinical indicators based on a data warehouse in a tertiary hospital: its clinical benefit and effectiveness. Int J Med Inform 2014; 83 (7): 507&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867195</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaloglu U, Palchuk MB.. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inform 2018; 2 (2): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816049</ArticleId><ArticleId IdType="pubmed">30652541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z, Huang X, Chang EI-C, et al.Constrained deep weak supervision for histopathology image segmentation. IEEE Trans Med Imaging 2017; 36 (11): 2376&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28692971</ArticleId></ArticleIdList></Reference><Reference><Citation>Saab K, Dunnmon J, Goldman R, et al.Doubly weak supervision of deep learning models for head CT. In: Medical Image Computing and Computer Assisted Intervention &#x2013; MICCAI 2019. Springer International Publishing; 2019: 811&#x2013;9.</Citation></Reference><Reference><Citation>Saab K, Dunnmon J, R&#xe9; C, et al.Weak supervision as an efficient approach for automated seizure detection in electroencephalography. NPJ Digit Med 2020; 3: 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170880</ArticleId><ArticleId IdType="pubmed">32352037</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33720842</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study.</ArticleTitle><Pagination><StartPage>e25035</StartPage><MedlinePgn>e25035</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/25035</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accurate and rapid clinical decisions based on real-world evidence are essential for patients with cancer. However, the complexity of chemotherapy regimens for cancer impedes retrospective research that uses observational health databases.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to compare the anticancer treatment trajectories and patterns of clinical events according to regimen type using the chemotherapy episodes determined by an algorithm.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed an algorithm to extract the regimen-level abstracted chemotherapy episodes from medication records in a conventional Observational Medical Outcomes Partnership (OMOP) common data model (CDM) database. The algorithm was validated on the Ajou University School Of Medicine (AUSOM) database by manual review of clinical notes. Using the algorithm, we extracted episodes of chemotherapy from patients in the EHR database and the claims database. We also developed an application software for visualizing the chemotherapy treatment patterns based on the treatment episodes in the OMOP-CDM database. Using this software, we generated the trends in the types of regimen used in the institutions, the patterns of the iterative chemotherapy use, and the trajectories of cancer treatment in two EHR-based OMOP-CDM databases. As a pilot study, the time of onset of chemotherapy-induced neutropenia according to regimen was measured using the AUSOM database. The anticancer treatment trajectories for patients with COVID-19 were also visualized based on the nationwide claims database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We generated 178,360 treatment episodes for patients with colorectal, breast, and lung cancer for 85 different regimens. The algorithm precisely identified the type of chemotherapy regimen in 400 patients (average positive predictive value &gt;98%). The trends in the use of routine clinical chemotherapy regimens from 2008-2018 were identified for 8236 patients. For a total of 12 regimens (those administered to the largest proportion of patients), the number of repeated treatments was concordant with the protocols for standard chemotherapy regimens for certain cases. In addition, the anticancer treatment trajectories for 8315 patients were shown, including 62 patients with COVID-19. A comparative analysis of neutropenia showed that its onset in colorectal cancer regimens tended to cluster between days 9-15, whereas it tended to cluster between days 2-8 for certain regimens for breast cancer or lung cancer.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We propose a method for generating chemotherapy episodes for introduction into the oncology extension module of the OMOP-CDM databases. These proof-of-concept studies demonstrated the usability, scalability, and interoperability of the proposed framework through a distributed research network.</AbstractText><CopyrightInformation>&#xa9;Hokyun Jeon, Seng Chan You, Seok Yun Kang, Seung In Seo, Jeremy L Warner, Rimma Belenkaya, Rae Woong Park. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 06.04.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jeon</LastName><ForeName>Hokyun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6220-4207</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Seok Yun</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-4995-9912</Identifier><AffiliationInfo><Affiliation>Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0003-4417-0135</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Jeremy L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-2851-7242</Identifier><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belenkaya</LastName><ForeName>Rimma</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7318-1541</Identifier><AffiliationInfo><Affiliation>Department of Health Informatics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA231840</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA194215</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA248010</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">algorithm</Keyword><Keyword MajorTopicYN="N">antineoplastic combined chemotherapy protocols</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">pattern</Keyword><Keyword MajorTopicYN="N">retrospective</Keyword><Keyword MajorTopicYN="N">scalability</Keyword></KeywordList><CoiStatement>Conflicts of Interest: JW has equity in HemOnc.org LLC; this equity has no financial value. JW is the chief software architect of the HemOnc ontology; this role is uncompensated. The development of HemOnc is partially supported by NIH grants U24 CA194215; U01 CA231840; and U24 CA248010. The funder had no role in the development or conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>15</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33720842</ArticleId><ArticleId IdType="pmc">PMC8058693</ArticleId><ArticleId IdType="doi">10.2196/25035</ArticleId><ArticleId IdType="pii">v9i4e25035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khozin S, Blumenthal GM, Pazdur R. Real-world Data for Clinical Evidence Generation in Oncology. J Natl Cancer Inst. 2017 Nov 01;109(11) doi: 10.1093/jnci/djx187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djx187</ArticleId><ArticleId IdType="pubmed">29059439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012;17(12):1486&#x2013;95. doi: 10.1634/theoncologist.2012-0190. doi: 10.1634/theoncologist.2012-0190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2012-0190</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2012-0190</ArticleId><ArticleId IdType="pmc">PMC3528380</ArticleId><ArticleId IdType="pubmed">23015662</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 Aug;24(8):1066&#x2013;1075. doi: 10.1634/theoncologist.2018-0520. doi: 10.1634/theoncologist.2018-0520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2018-0520</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2018-0520</ArticleId><ArticleId IdType="pmc">PMC6693720</ArticleId><ArticleId IdType="pubmed">30610008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler E, Espirito JL, Pavilack M, Boyd M, Vergara-Silva A, Fernandes A. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer&#xa0;Patients Treated in the Community Practice Setting. Clin Lung Cancer. 2018 Jul;19(4):360&#x2013;370. doi: 10.1016/j.cllc.2018.02.002.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cllc.2018.02.002</ArticleId><ArticleId IdType="pubmed">29576407</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikov KA, Mullins CD, Seal B, Onukwugha E, Hanna N. Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care. 2015 Aug;53(8):e58&#x2013;64. doi: 10.1097/MLR.0b013e31828fad9f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31828fad9f</ArticleId><ArticleId IdType="pubmed">23552436</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll NM, Burniece KM, Holzman J, McQuillan DB, Plata A, Ritzwoller DP. Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data. JCO Clin Cancer Inform. 2017 Nov;1:1&#x2013;9. doi: 10.1200/CCI.17.00002.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.17.00002?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.17.00002</ArticleId><ArticleId IdType="pmc">PMC7006900</ArticleId><ArticleId IdType="pubmed">30657379</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodel M, Lamarsalle L, Augusto V. ATLAS: a robust algorithm for temporal sequence alignment of treatment lines using claim databases. 2019 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB); July 9-11, 2019; Siena, Italy. 2019. pp. 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/cibcb.2019.8791467</ArticleId></ArticleIdList></Reference><Reference><Citation>Weymann D, Costa S, Regier DA. Validation of a Cyclic Algorithm to Proxy Number of Lines of Systemic Cancer Therapy Using Administrative Data. JCO Clin Cancer Inform. 2019 Aug;3:1&#x2013;10. doi: 10.1200/CCI.19.00022.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.19.00022?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.19.00022</ArticleId><ArticleId IdType="pubmed">31365273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van DLJ, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley M, Dymshyts D, Araujo S, Williams A, Chen R, Reich C. Standardized Observational Cancer Research Using the OMOP CDM Oncology Module. Stud Health Technol Inform. 2019 Aug 21;264:1831&#x2013;1832. doi: 10.3233/SHTI190670.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI190670</ArticleId><ArticleId IdType="pubmed">31438365</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner JL, Dymshyts D, Reich CG, Gurley MJ, Hochheiser H, Moldwin ZH, Belenkaya R, Williams AE, Yang PC. HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J Biomed Inform. 2019 Aug;96:103239. doi: 10.1016/j.jbi.2019.103239.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103239</ArticleId><ArticleId IdType="pmc">PMC6697579</ArticleId><ArticleId IdType="pubmed">31238109</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54.  </Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Gao W, Golozar A, Hardin J, Hripcsak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta P, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Park RW, Park J, Posada JD, Prats-Uribe A, Rao G, Reich C, Rho Y, Rijnbeek P, Sathappan SMK, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P. An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza. medRxiv. doi: 10.1101/2020.04.22.20074336. doi: 10.1101/2020.04.22.20074336. Preprint published online on April 25, 2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner JL, Cowan AJ, Hall AC, Yang PC. HemOnc.org: A Collaborative Online Knowledge Platform for Oncology Professionals. J Oncol Pract. 2015 May;11(3):e336&#x2013;50. doi: 10.1200/JOP.2014.001511.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JOP.2014.001511</ArticleId><ArticleId IdType="pmc">PMC5706141</ArticleId><ArticleId IdType="pubmed">25736385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon HK, You SC. CancerTxPathway. GitHub. 2020.  [2020-10-15].   https://github.com/ABMI/CancerTxPathway.</Citation></Reference><Reference><Citation>Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002 Aug;40(8 Suppl):IV&#x2013;19. doi: 10.1097/00005650-200208001-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-200208001-00003</ArticleId><ArticleId IdType="pubmed">12187164</ArticleId></ArticleIdList></Reference><Reference><Citation>Enewold L, Parsons H, Zhao L, Bott D, Rivera DR, Barrett MJ, Virnig BA, Warren JL. Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications. J Natl Cancer Inst Monogr. 2020 May 01;2020(55):3&#x2013;13. doi: 10.1093/jncimonographs/lgz029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncimonographs/lgz029</ArticleId><ArticleId IdType="pmc">PMC7225666</ArticleId><ArticleId IdType="pubmed">32412076</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002 Aug;40(8 Suppl):IV&#x2013;3. doi: 10.1097/01.MLR.0000020942.47004.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MLR.0000020942.47004.03</ArticleId><ArticleId IdType="pubmed">12187163</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K, Won Y, Kong H, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. Cancer Res Treat. 2019 Apr;51(2):417&#x2013;430. doi: 10.4143/crt.2019.138. doi: 10.4143/crt.2019.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2019.138</ArticleId><ArticleId IdType="doi">10.4143/crt.2019.138</ArticleId><ArticleId IdType="pmc">PMC6473271</ArticleId><ArticleId IdType="pubmed">30913865</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H, Won Y, Jung K, Kong H, Yim S, Lee J, Noh H, Lee J, Pisani P, Park J, Members of the Regional Cancer Registries Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005 Dec;37(6):325&#x2013;31. doi: 10.4143/crt.2005.37.6.325. doi: 10.4143/crt.2005.37.6.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2005.37.6.325</ArticleId><ArticleId IdType="doi">10.4143/crt.2005.37.6.325</ArticleId><ArticleId IdType="pmc">PMC2785938</ArticleId><ArticleId IdType="pubmed">19956367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Long L, Moon S, Adamson B, Baxi S. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR. MedRxiv. doi: 10.1101/2020.03.16.20037143. Preprint published online on May 30, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.16.20037143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu C, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 Cancer Consortium  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907&#x2013;1918. doi: 10.1016/S0140-6736(20)31187-9.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31187-9</ArticleId><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011;61(5):287&#x2013;314. doi: 10.3322/caac.20124. doi: 10.3322/caac.20124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20124</ArticleId><ArticleId IdType="doi">10.3322/caac.20124</ArticleId><ArticleId IdType="pubmed">21858793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 May 15;106(10):2258&#x2013;66. doi: 10.1002/cncr.21847. doi: 10.1002/cncr.21847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21847</ArticleId><ArticleId IdType="doi">10.1002/cncr.21847</ArticleId><ArticleId IdType="pubmed">16575919</ArticleId></ArticleIdList></Reference><Reference><Citation>Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, Crawford J, Lyman GH. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014 Apr;3(2):434&#x2013;44. doi: 10.1002/cam4.200. doi: 10.1002/cam4.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.200</ArticleId><ArticleId IdType="doi">10.1002/cam4.200</ArticleId><ArticleId IdType="pmc">PMC3987093</ArticleId><ArticleId IdType="pubmed">24706592</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008 Feb;6(2):109&#x2013;18. doi: 10.6004/jnccn.2008.0012.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2008.0012</ArticleId><ArticleId IdType="pubmed">18319047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalami Y, Paesmans M, Muanza F, Barette M, Plehiers B, Dubreucq L, Georgala A, Klastersky J. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol. 2006 Mar;17(3):507&#x2013;14. doi: 10.1093/annonc/mdj092.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdj092</ArticleId><ArticleId IdType="pubmed">16322116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33725121</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>SI</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.</ArticleTitle><Pagination><StartPage>SI37</StartPage><EndPage>SI50</EndPage><MedlinePgn>SI37-SI50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keab250</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.</AbstractText><AbstractText Label="METHODS">A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30&#x2009;days of hospitalization.</AbstractText><AbstractText Label="RESULTS">We studied 133&#x2009;589 patients diagnosed and 48&#x2009;418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged &#x2265;50&#x2009;years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70&#x2009;660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).</AbstractText><AbstractText Label="CONCLUSION">Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, OX3, 7LD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's, 2LU, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertolin</LastName><ForeName>Sergio Fernandez</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, 02114, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer C E</ForeName><Initials>JCE</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, OX3, 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Digital China Health Technologies Co., LTD, Beijing 100085, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, The University of Melbourne, Victoria 3015, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9912-2344</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, UNSW Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Engineering, The University of Arizona Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Sant Joan Despi, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Y H</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health Sciences, University of Dundee, Dundee, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Management Institute, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivekanantham</LastName><ForeName>Arani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, OX3, 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abend</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Autoimmune Registry Inc., Guilford, CT 06437, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>O'Brien School for Public Health, Faculty of Medicine, University of Calgary, Calgary, Alberta, T2N, 1N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>21605</GrantID><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2020 Nov 27:2020.11.24.20236802. doi: 10.1101/2020.11.24.20236802.</RefSource><PMID Version="1">33269355</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Observational Health Data Sciences and Informatics (OHDSI)</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership (OMOP)</Keyword><Keyword MajorTopicYN="N">autoimmune condition</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">open science</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>17</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33725121</ArticleId><ArticleId IdType="pmc">PMC7989171</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keab250</ArticleId><ArticleId IdType="pii">6174122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, updated 16 March 2021. https://coronavirus.jhu.edu/map.html (16 March 2021, date last accessed).</Citation></Reference><Reference><Citation>Kastritis E, Kitas GD, Vassilopoulos D. et al. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int 2020;40:1353&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7353833</ArticleId><ArticleId IdType="pubmed">32654078</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D, Campisi J, Verdin E. et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019;25:1822&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147972</ArticleId><ArticleId IdType="pubmed">31806905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollan I, Meroni PL, Ahearn JM. et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013;12:1004&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitia S, Atzeni F, Sarzi-Puttini P. et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:281&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18817899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf HR, Hooper WC, Beckman MG. et al. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 2014;38:306&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477705</ArticleId><ArticleId IdType="pubmed">24464552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ.. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011;9:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025873</ArticleId><ArticleId IdType="pubmed">21219637</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xf6;ller B, Li X, Sundquist J, Sundquist K.. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012;2:171&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427982</ArticleId><ArticleId IdType="pubmed">22937487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Int Med 2020;180:934&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Freites Nu&#xf1;ez DD, Leon L, Mucientes A. et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:1393&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32769150</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman R, Axelrad J, Chen A. et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med 2020;383:85&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204427</ArticleId><ArticleId IdType="pubmed">32348641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicola M, O'Neill N, Sohrabi C. et al. Evidence based management guideline for the COVID-19 pandemic - Review article. Int J Surg 2020;77:206&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151371</ArticleId><ArticleId IdType="pubmed">32289472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam L-S, Tanaka Y, Handa R. et al. Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR. Int J Rheum Dis 2020;23:717&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283887</ArticleId><ArticleId IdType="pubmed">32462761</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Chen Z, Wang Y. et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study. Ann Rheum Dis 2020;79:1163&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316114</ArticleId><ArticleId IdType="pubmed">32546598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mahevas M, Rohmer J. et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020;79:837&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32332072</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti S, Balduzzi S, Delvino P. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211079</ArticleId><ArticleId IdType="pubmed">32241793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthony S, Kristin K. Martijn Schuemie, jdposada. ohdsi-studies/Covid19CharacterizationCharybdis: Charybdis v1.1.1 - Publication Package (Version v1.1.1): Zenodo; 2020. updated 2020, September 16. 10.5281/zenodo.4033034 (16 September 2020, date last accessed).</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A. et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil Mdel M, Hermosilla E, Prieto-Alhambra D. et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-A, Yoon S, Kim L-Y, Kim D-S.. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of hira data. J Korean Med Sci 2017;32:718&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD. et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A 2016;113:7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat - Simul Comput 2009;38:1228&#x2013;34.</Citation></Reference><Reference><Citation>R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2013.</Citation></Reference><Reference><Citation>Argenziano MG, Bruce SL, Slater CL. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020;369:m1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256651</ArticleId><ArticleId IdType="pubmed">32471884</ArticleId></ArticleIdList></Reference><Reference><Citation>Jutzeler CR, Bourguignon L, Weis CV. et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;37:101825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402237</ArticleId><ArticleId IdType="pubmed">32763496</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnino MW, Moskowitz A, Thompson GS, Heydrick SJ, Pawar RD, Berg KM. et al. Comparison between influenza and COVID-19 at a Tertiary Care Center. medRxiv. 2020:2020.08.19.20163857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7971402</ArticleId><ArticleId IdType="pubmed">33738759</ArticleId></ArticleIdList></Reference><Reference><Citation>Marietta M, Coluccio V, Luppi M.. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Int Emerg Med 2020;15:1375&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352087</ArticleId><ArticleId IdType="pubmed">32653981</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Silva KM, Jorge A, Cohen A. et al. COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) compared to the general population: a US Multi-Center Comparative Cohort Study. Arthritis Rheumatol 2020; doi: 10.1002/art.41619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169514</ArticleId><ArticleId IdType="pubmed">33305544</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S, Hamdeh S, Micic D, Sakuraba A.. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2021;80:384&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M, Roel E, Pistillo A, Sena AG, Prats-Uribe A, Ahmed WU-R. et al. Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom. medRxiv. 2020:2020.09.02.20185173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8281807</ArticleId><ArticleId IdType="pubmed">34267326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai LYH, Golozar A, Sena A, Margulis AV, Haro N, Casajust P. et al. &#x201c;Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis&#x201d;. medRxiv. 2020:2020.10.13.20211821.</Citation></Reference><Reference><Citation>Burn E, You SC, Sena AG. et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun 2020;11:5009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33775125</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4563</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Hypertension (Dallas, Tex. : 1979)</Title><ISOAbbreviation>Hypertension</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Comparative Effectiveness and Safety of First-Line &#x3b2;-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.</ArticleTitle><Pagination><StartPage>1528</StartPage><EndPage>1538</EndPage><MedlinePgn>1528-1538</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.120.16402</ELocationID><Abstract><AbstractText>[Figure: see text].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan You</LastName><ForeName>Seng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (S.C.Y., R.W.P.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health (S.C.Y.), Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Yale University School of Medicine, New Haven, CT (H.M.K.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, CT (H.M.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health (M.A.S., M.J.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at University of California, Los Angeles (M.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health (M.A.S., M.J.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ (M.J.S., P.B.R.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY (G.H., R.C., S.S., P.B.R.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital (G.H.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY (G.H., R.C., S.S., P.B.R.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY (R.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY (G.H., R.C., S.S., P.B.R.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY (S.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Georgia Tech Research Institute, Georgia Tech College of Computing, Atlanta (J.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide (N.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA (C.G.R.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY (D.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ (M.J.S., P.B.R.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY (G.H., R.C., S.S., P.B.R.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woong Park</LastName><ForeName>Rae</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (S.C.Y., R.W.P.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea (R.W.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sungha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Cardiovascular Hospital and Integrated Research Center for Cerebrovascular and Cardiovascular Diseases (S.P.), Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine (S.P.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hypertension</MedlineTA><NlmUniqueID>7906255</NlmUniqueID><ISSNLinking>0194-911X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>030Y90569U</RegistryNumber><NameOfSubstance UI="D000068577">Nebivolol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0K47UL67F2</RegistryNumber><NameOfSubstance UI="D000077261">Carvedilol</NameOfSubstance></Chemical><Chemical><RegistryNumber>50VV3VW0TI</RegistryNumber><NameOfSubstance UI="D001262">Atenolol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2021 Oct;163(18):32. doi: 10.1007/s15006-021-0429-z.</RefSource><PMID Version="1">34652654</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001262" MajorTopicYN="N">Atenolol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077261" MajorTopicYN="N">Carvedilol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068577" MajorTopicYN="N">Nebivolol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antihypertensive agents</Keyword><Keyword MajorTopicYN="N">atenolol</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>29</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33775125</ArticleId><ArticleId IdType="mid">NIHMS1675253</ArticleId><ArticleId IdType="pmc">PMC8035236</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16402</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prichard BN, Gillam PM. Use of propranolol (Inderal) in treatment of hypertension. Br Med J. 1964;2:725&#x2013;727. doi: 10.1136/bmj.2.5411.725</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.5411.725</ArticleId><ArticleId IdType="pmc">PMC1815864</ArticleId><ArticleId IdType="pubmed">14172036</ArticleId></ArticleIdList></Reference><Reference><Citation>Report of the joint national committee on detection, evaluation, and treatment of high blood pressure: a cooperative study. JAMA. 1977;237:255&#x2013;261. doi: 10.1001/jama.1977.03270300059008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1977.03270300059008</ArticleId><ArticleId IdType="pubmed">576159</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560&#x2013;2572. doi: 10.1001/jama.289.19.2560</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.19.2560</ArticleId><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? a systematic review. JAMA. 1998;279:1903&#x2013;1907. doi: 10.1001/jama.279.23.1903</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.23.1903</ArticleId><ArticleId IdType="pubmed">9634263</ArticleId></ArticleIdList></Reference><Reference><Citation>Messerli FH, Beevers DG, Franklin SS, Pickering TG. &#x3b2;-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens. 2003;16:870&#x2013;873. doi: 10.1016/s0895-7061(03)01017-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-7061(03)01017-3</ArticleId><ArticleId IdType="pubmed">14553968</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684&#x2013;1689. doi: 10.1016/s0140-6736(04)17355-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(04)17355-8</ArticleId><ArticleId IdType="pubmed">15530629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? a meta-analysis. Lancet. 2005;366:1545&#x2013;1553. doi: 10.1016/s0140-6736(05)67573-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)67573-3</ArticleId><ArticleId IdType="pubmed">16257341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? systematic review and meta-analysis. J Hypertens. 2006;24:2131&#x2013;2141. doi: 10.1097/01.hjh.0000249685.58370.28</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.hjh.0000249685.58370.28</ArticleId><ArticleId IdType="pubmed">17053529</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174:1737&#x2013;1742. doi: 10.1503/cmaj.060110</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.060110</ArticleId><ArticleId IdType="pmc">PMC1471831</ArticleId><ArticleId IdType="pubmed">16754904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta&#x2010;blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003. doi: 10.1002/14651858.CD002003.pub5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002003.pub5</ArticleId><ArticleId IdType="pmc">PMC5369873</ArticleId><ArticleId IdType="pubmed">28107561</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e13&#x2013;e115. doi: 10.1161/hyp.0000000000000065</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hyp.0000000000000065</ArticleId><ArticleId IdType="pubmed">29133356</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235&#x2013;1481. doi: 10.1038/s41440-019-0284-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-019-0284-9</ArticleId><ArticleId IdType="pubmed">31375757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017;11:54&#x2013;65. doi: 10.1016/j.jash.2016.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jash.2016.11.007</ArticleId><ArticleId IdType="pubmed">28057444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther. 2009;31:447&#x2013;462. doi: 10.1016/j.clinthera.2009.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2009.03.007</ArticleId><ArticleId IdType="pubmed">19393838</ArticleId></ArticleIdList></Reference><Reference><Citation>Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich). 2009;11:369&#x2013;375. doi: 10.1111/j.1751-7176.2009.00140.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-7176.2009.00140.x</ArticleId><ArticleId IdType="pmc">PMC8672999</ArticleId><ArticleId IdType="pubmed">19583633</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/s0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180:542&#x2013;551. doi: 10.1001/jamainternmed.2019.7454</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Ryan P, Pratt N, Chen R, You S, Krumholz H, Madigan D, Hripcsak G, Suchard M. Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND). J Am Med Inform Assoc. 2020;0:1331&#x2013;1337. doi: 10.1093/jamia/ocaa103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Ryan P, Pratt N, Chen R, You S, Krumholz H, Madigan D, Hripcsak G, Suchard M. Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc. 2020;0:1268&#x2013;1277. doi: 10.1093/jamia/ocaa124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa124</ArticleId><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A, Chuang-Stein C, Roddam A, Jones B. Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases. Pharm Stat. 2019;18:65&#x2013;77. doi: 10.1002/pst.1908</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.1908</ArticleId><ArticleId IdType="pubmed">30362223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong IC, Rijnbeek PR, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578. doi: 10.3233/978-1-61499-564-7-574</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-564-7-574</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36:59&#x2013;72. doi: 10.1007/s40264-013-0099-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758&#x2013;764. doi: 10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR 3rd, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e116&#x2013;e135. doi: 10.1161/hyp.0000000000000067</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hyp.0000000000000067</ArticleId><ArticleId IdType="pubmed">29133355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005&#x2013;2014. doi: 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Patrick A, Lauer M, Hornbrook M, Marin M, Platt R, Roger V, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res (Auckl). 2013;3:11&#x2013;20. doi: 10.2147/CER.S40357</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CER.S40357</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81. doi: 10.1016/j.jbi.2016.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115:2571&#x2013;2577. doi: 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b1665</ArticleId><ArticleId IdType="pmc">PMC2684577</ArticleId><ArticleId IdType="pubmed">19454737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957&#x2013;967. doi: 10.1016/s0140-6736(15)01225-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(15)01225-8</ArticleId><ArticleId IdType="pubmed">26724178</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38(9):1669&#x2013;1681. doi:10.1097/HJH.0000000000002523</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002523</ArticleId><ArticleId IdType="pubmed">32649628</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S, Bourgault C, Barkun A, Sheehy O, Ernst P. Antihypertensive drugs and the risk of gastrointestinal bleeding. Am J Med. 1998;105(3):230&#x2013;235. doi:10.1016/s0002-9343(98)00239-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9343(98)00239-3</ArticleId><ArticleId IdType="pubmed">9753026</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O&#x2019;Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213&#x2013;1225. doi: 10.1161/circulationaha.105.595496</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.105.595496</ArticleId><ArticleId IdType="pubmed">16476843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122&#x2013;1128. doi: 10.1161/hypertensionaha.110.155507</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hypertensionaha.110.155507</ArticleId><ArticleId IdType="pubmed">21536983</ArticleId></ArticleIdList></Reference><Reference><Citation>Pucci G, Ranalli MG, Battista F, Schillaci G. Effects of &#x3b2;-blockers with and without vasodilating properties on central blood pressure: systematic review and meta-analysis of randomized trials in hypertension. Hypertension. 2016;67:316&#x2013;324. doi: 10.1161/hypertensionaha.115.06467</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hypertensionaha.115.06467</ArticleId><ArticleId IdType="pubmed">26628678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, Kim KI, Kim JH, Lee JH, Park JM, Pyun WB, Chae SC. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20. doi: 10.1186/s40885-019-0124-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0124-x</ArticleId><ArticleId IdType="pmc">PMC6670135</ArticleId><ArticleId IdType="pubmed">31388453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, et al. Hypertension Canada&#x2019;s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506&#x2013;525. doi: 10.1016/j.cjca.2018.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2018.02.022</ArticleId><ArticleId IdType="pubmed">29731013</ArticleId></ArticleIdList></Reference><Reference><Citation>Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005&#x2013;2016. Hypertension. 2020;75:973&#x2013;981. doi: 10.1161/hypertensionaha.119.14360</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hypertensionaha.119.14360</ArticleId><ArticleId IdType="pmc">PMC7398637</ArticleId><ArticleId IdType="pubmed">32148129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Shin DW, Kim S, Han K, Park SH, Kim YH, Jeon SA, Kwon YC. Prescribing patterns of antihypertensives for treatment-na&#xef;ve patients in South Korea: from Korean NHISS claim data. Int J Hypertens. 2019;2019:4735876. doi: 10.1155/2019/4735876</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/4735876</ArticleId><ArticleId IdType="pmc">PMC6732595</ArticleId><ArticleId IdType="pubmed">31534797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund JL, Richardson DB, St&#xfc;rmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221&#x2013;228. doi: 10.1007/s40471-015-0053-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-015-0053-5</ArticleId><ArticleId IdType="pmc">PMC4778958</ArticleId><ArticleId IdType="pubmed">26954351</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Patrick AR, St&#xfc;rmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131&#x2013;S142. doi: 10.1097/MLR.0b013e318070c08e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318070c08e</ArticleId><ArticleId IdType="pmc">PMC2905666</ArticleId><ArticleId IdType="pubmed">17909372</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97&#x2013;111. doi: 10.1002/jrsm.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.12</ArticleId><ArticleId IdType="pubmed">26061376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33782494</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Transforming electronic health record polysomnographic data into the Observational Medical Outcome Partnership's Common Data Model: a pilot feasibility study.</ArticleTitle><Pagination><StartPage>7013</StartPage><MedlinePgn>7013</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7013</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-86564-w</ELocationID><Abstract><AbstractText>Well-defined large-volume polysomnographic (PSG) data can identify subgroups and predict outcomes of obstructive sleep apnea (OSA). However, current PSG data are scattered across numerous sleep laboratories and have different formats in the electronic health record (EHR). Hence, this study aimed to convert EHR PSG into a standardized data format-the Observational Medical Outcome Partnership (OMOP) common data model (CDM). We extracted the PSG data of a university hospital for the period from 2004 to 2019. We designed and implemented an extract-transform-load (ETL) process to transform PSG data into the OMOP CDM format and verified the data quality through expert evaluation. We converted the data of 11,797 sleep studies into CDM and added 632,841 measurements and 9,535 observations to the existing CDM database. Among 86 PSG parameters, 20 were mapped to CDM standard vocabulary and 66 could not be mapped; thus, new custom standard concepts were created. We validated the conversion and usefulness of PSG data through patient-level prediction analyses for the CDM data. We believe that this study represents the first CDM conversion of PSG. In the future, CDM transformation will enable network research in sleep medicine and will contribute to presenting more relevant clinical evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong-Whun</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Borim</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wongeun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. yoosoo0@snubh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="Y">Health Information Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010317" MajorTopicYN="N">Partnership Practice</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020181" MajorTopicYN="N">Sleep Apnea, Obstructive</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>7</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33782494</ArticleId><ArticleId IdType="pmc">PMC8007756</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-86564-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-86564-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tietjens JR, et al. Obstructive sleep Apnea in cardiovascular disease: a review of the literature and proposed multidisciplinary clinical management strategy. J. Am. Heart Assoc. 2019;8:e010440. doi: 10.1161/jaha.118.010440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.118.010440</ArticleId><ArticleId IdType="pmc">PMC6405725</ArticleId><ArticleId IdType="pubmed">30590966</ArticleId></ArticleIdList></Reference><Reference><Citation>Strausz S, et al. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open. 2018;8:e022752. doi: 10.1136/bmjopen-2018-022752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-022752</ArticleId><ArticleId IdType="pmc">PMC6194468</ArticleId><ArticleId IdType="pubmed">30327404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadby G, et al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest. 2015;148:945&#x2013;952. doi: 10.1378/chest.15-0229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.15-0229</ArticleId><ArticleId IdType="pubmed">25927872</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyeux-Faure M, et al. Contribution of obstructive sleep apnoea to arterial stiffness: a meta-analysis using individual patient data. Thorax. 2018;73:1146&#x2013;1151. doi: 10.1136/thoraxjnl-2018-211513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2018-211513</ArticleId><ArticleId IdType="pubmed">30032122</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalan-Serra P, et al. Increased incidence of stroke, but not coronary heart disease, in elderly patients with sleep Apnea. Stroke. 2019;50:491&#x2013;494. doi: 10.1161/strokeaha.118.023353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/strokeaha.118.023353</ArticleId><ArticleId IdType="pubmed">30580706</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello-Branco RC, et al. Association between risk of obstructive sleep Apnea and cerebrovascular reactivity in stroke patients. J. Am. Heart Assoc. 2020;9:e015313. doi: 10.1161/jaha.119.015313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.119.015313</ArticleId><ArticleId IdType="pmc">PMC7335520</ArticleId><ArticleId IdType="pubmed">32164495</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Risk of incident obstructive sleep Apnea among patients with type 2 diabetes. Diabetes Care. 2019;42:954&#x2013;963. doi: 10.2337/dc18-2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-2004</ArticleId><ArticleId IdType="pubmed">30862657</ArticleId></ArticleIdList></Reference><Reference><Citation>Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: Systematic review and meta-analysis. Sleep Med. Rev. 2016;30:11&#x2013;24. doi: 10.1016/j.smrv.2015.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2015.10.002</ArticleId><ArticleId IdType="pubmed">26687279</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot M, et al. Association between severe obstructive sleep apnea and incident arterial hypertension in the older people population. Sleep Med. 2013;14:838&#x2013;842. doi: 10.1016/j.sleep.2013.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2013.05.002</ArticleId><ArticleId IdType="pubmed">23831239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendonca E, Tachinardi U. Personalized and Precision Medicine Informatics. Berlin: Springer; 2020. pp. 199&#x2013;213.</Citation></Reference><Reference><Citation>Hripcsak G, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inf. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl. Clin. Inf. 2015;6:536&#x2013;547. doi: 10.4338/aci-2014-12-cr-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/aci-2014-12-cr-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>The Report of an American Academy of Sleep Medicine Task Force Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667&#x2013;689. doi: 10.1093/sleep/22.5.667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/22.5.667</ArticleId><ArticleId IdType="pubmed">10450601</ArticleId></ArticleIdList></Reference><Reference><Citation>Group, O. O. W. OHDSI Oncology Working Group, https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg&amp;s%5B%5D=oncology</Citation></Reference><Reference><Citation>JM, R., MJ, S., MA, S., PB, R. &amp; PR, R. OHDSI Patient Level Prediction Package, https://github.com/OHDSI/PatientLevelPrediction</Citation></Reference><Reference><Citation>Zinchuk A, Yaggi HK. Phenotypic subtypes of OSA: a challenge and opportunity for precision medicine. Chest. 2020;157:403&#x2013;420. doi: 10.1016/j.chest.2019.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.09.002</ArticleId><ArticleId IdType="pmc">PMC7005379</ArticleId><ArticleId IdType="pubmed">31539538</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra A, Orr JE, Owens RL. On the cutting edge of obstructive sleep apnoea: where next? Lancet Respir. Med. 2015;3:397&#x2013;403. doi: 10.1016/s2213-2600(15)00051-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(15)00051-x</ArticleId><ArticleId IdType="pmc">PMC4431916</ArticleId><ArticleId IdType="pubmed">25887980</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, et al. Polysomnographic phenotype as a risk factor for cardiovascular diseases in patients with obstructive sleep apnea syndrome: a retrospective cohort study. J. Thorac. Dis. 2020;12:907&#x2013;915. doi: 10.21037/jtd.2019.12.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2019.12.66</ArticleId><ArticleId IdType="pmc">PMC7138968</ArticleId><ArticleId IdType="pubmed">32274158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinchuk AV, et al. Polysomnographic phenotypes and their cardiovascular implications in obstructive sleep apnoea. Thorax. 2018;73:472&#x2013;480. doi: 10.1136/thoraxjnl-2017-210431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2017-210431</ArticleId><ArticleId IdType="pmc">PMC6693344</ArticleId><ArticleId IdType="pubmed">28935698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-W, et al. Polysomnographic phenotyping of obstructive sleep apnea and its implications in mortality in Korea. Sci. Rep. 2020;10:1&#x2013;12. doi: 10.1038/s41598-019-56847-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56847-4</ArticleId><ArticleId IdType="pmc">PMC7411028</ArticleId><ArticleId IdType="pubmed">32764677</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SA, et al. Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model. Epilepsia. 2020;61:610&#x2013;616. doi: 10.1111/epi.16472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.16472</ArticleId><ArticleId IdType="pubmed">32162687</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SI, et al. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: a 15-year hospital cohort study using a common data model. J. Gastroenterol. Hepatol. 2020 doi: 10.1111/jgh.14983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14983</ArticleId><ArticleId IdType="pubmed">31970824</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YI, et al. Effect of age on the initiation of biologic agent therapy in patients with inflammatory bowel disease: Korean common data model cohort study. JMIR Med. Inform. 2020;8:e15124. doi: 10.2196/15124.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/15124</ArticleId><ArticleId IdType="pmc">PMC7191339</ArticleId><ArticleId IdType="pubmed">32293578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC, et al. Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges. Clin. Epidemiol. 2018;10:875&#x2013;885. doi: 10.2147/CLEP.S149961.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S149961</ArticleId><ArticleId IdType="pmc">PMC6067778</ArticleId><ArticleId IdType="pubmed">30100761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS ONE. 2020;15:e0226718. doi: 10.1371/journal.pone.0226718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N, et al. Preliminary exploration of survival analysis using the OHDSI common data model: a case study of intrahepatic cholangiocarcinoma. BMC Med. Inform. Decis. Mak. 2018;18:116. doi: 10.1186/s12911-018-0686-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0686-7</ArticleId><ArticleId IdType="pmc">PMC6284277</ArticleId><ArticleId IdType="pubmed">30526572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33783361</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>A Framework (SOCRATex) for Hierarchical Annotation of Unstructured Electronic Health Records and Integration Into a Standardized Medical Database: Development and Usability Study.</ArticleTitle><Pagination><StartPage>e23983</StartPage><MedlinePgn>e23983</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e23983</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/23983</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although electronic health records (EHRs) have been widely used in secondary assessments, clinical documents are relatively less utilized owing to the lack of standardized clinical text frameworks across different institutions.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to develop a framework for processing unstructured clinical documents of EHRs and integration with standardized structured data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed a framework known as Staged Optimization of Curation, Regularization, and Annotation of clinical text (SOCRATex). SOCRATex has the following four aspects: (1) extracting clinical notes for the target population and preprocessing the data, (2) defining the annotation schema with a hierarchical structure, (3) performing document-level hierarchical annotation using the annotation schema, and (4) indexing annotations for a search engine system. To test the usability of the proposed framework, proof-of-concept studies were performed on EHRs. We defined three distinctive patient groups and extracted their clinical documents (ie, pathology reports, radiology reports, and admission notes). The documents were annotated and integrated into the Observational Medical Outcomes Partnership (OMOP)-common data model (CDM) database. The annotations were used for creating Cox proportional hazard models with different settings of clinical analyses to measure (1) all-cause mortality, (2) thyroid cancer recurrence, and (3) 30-day hospital readmission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 1055 clinical documents of 953 patients were extracted and annotated using the defined annotation schemas. The generated annotations were indexed into an unstructured textual data repository. Using the annotations of pathology reports, we identified that node metastasis and lymphovascular tumor invasion were associated with all-cause mortality among colon and rectum cancer patients (both P=.02). The other analyses involving measuring thyroid cancer recurrence using radiology reports and 30-day hospital readmission using admission notes in depressive disorder patients also showed results consistent with previous findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We propose a framework for hierarchical annotation of textual data and integration into a standardized OMOP-CDM medical database. The proof-of-concept studies demonstrated that our framework can effectively process and integrate diverse clinical documents with standardized structured data for clinical research.</AbstractText><CopyrightInformation>&#xa9;Jimyung Park, Seng Chan You, Eugene Jeong, Chunhua Weng, Dongsu Park, Jin Roh, Dong Yun Lee, Jae Youn Cheong, Jin Wook Choi, Mira Kang, Rae Woong Park. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 30.03.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2655-5517</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8240-1198</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9624-0214</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dongsu</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5614-3145</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Jin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3995-355X</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Ajou University Hospital, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-3678-9862</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>Jae Youn</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0001-6246-1783</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jin Wook</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-2396-4705</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Mira</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7842-0035</Identifier><AffiliationInfo><Affiliation>Department of Digital Health, Samsung Advanced Institute for Health Sciences &amp; Technology, Sungkyunkwan University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data curation</Keyword><Keyword MajorTopicYN="N">data management</Keyword><Keyword MajorTopicYN="N">natural language processing</Keyword><Keyword MajorTopicYN="N">search engine</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33783361</ArticleId><ArticleId IdType="pmc">PMC8044740</ArticleId><ArticleId IdType="doi">10.2196/23983</ArticleId><ArticleId IdType="pii">v9i3e23983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blumenthal D. Launching HITECH. N Engl J Med. 2010 Feb 04;362(5):382&#x2013;5. doi: 10.1056/NEJMp0912825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp0912825</ArticleId><ArticleId IdType="pubmed">20042745</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C, Hripcsak G. Natural language processing and its future in medicine. Acad Med. 1999 Aug;74(8):890&#x2013;5. doi: 10.1097/00001888-199908000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001888-199908000-00012</ArticleId><ArticleId IdType="pubmed">10495728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gans D, Kralewski J, Hammons T, Dowd B. Medical groups' adoption of electronic health records and information systems. Health Aff (Millwood) 2005 Sep;24(5):1323&#x2013;33. doi: 10.1377/hlthaff.24.5.1323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.24.5.1323</ArticleId><ArticleId IdType="pubmed">16162580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet. 2019 Nov 16;394(10211):1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Shah NH, Hripcsak G. Deep phenotyping: Embracing complexity and temporality-Towards scalability, portability, and interoperability. J Biomed Inform. 2020 May;105:103433. doi: 10.1016/j.jbi.2020.103433.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103433</ArticleId><ArticleId IdType="pmc">PMC7179504</ArticleId><ArticleId IdType="pubmed">32335224</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018 Sep 13;376(2128):20170356. doi: 10.1098/rsta.2017.0356.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J, Schuemie M, Suchard M, Ryan P, Rijnbeek P. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018 Aug 01;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford E, Nicholson A, Koeling R, Tate AR, Carroll J, Axelrod L, Smith HE, Rait G, Davies KA, Petersen I, Williams T, Cassell JA. Optimising the use of electronic health records to estimate the incidence of rheumatoid arthritis in primary care: what information is hidden in free text? BMC Med Res Methodol. 2013 Aug 21;13(1):105. doi: 10.1186/1471-2288-13-105.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-13-105</ArticleId><ArticleId IdType="doi">10.1186/1471-2288-13-105</ArticleId><ArticleId IdType="pmc">PMC3765394</ArticleId><ArticleId IdType="pubmed">23964710</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom ST, Denny JC, Xu H, Lorenzi N, Stead WW, Johnson KB. Data from clinical notes: a perspective on the tension between structure and flexible documentation. J Am Med Inform Assoc. 2011 Mar 01;18(2):181&#x2013;6. doi: 10.1136/jamia.2010.007237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2010.007237</ArticleId><ArticleId IdType="pmc">PMC3116264</ArticleId><ArticleId IdType="pubmed">21233086</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzuner &#xd6;, Stubbs A, Lenert L. Advancing the state of the art in automatic extraction of adverse drug events from narratives. J Am Med Inform Assoc. 2020 Jan 01;27(1):1&#x2013;2. doi: 10.1093/jamia/ocz206.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz206</ArticleId><ArticleId IdType="pmc">PMC6913224</ArticleId><ArticleId IdType="pubmed">31841150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman WW, Nadkarni PM, Hirschman L, D'Avolio LW, Savova GK, Uzuner O. Overcoming barriers to NLP for clinical text: the role of shared tasks and the need for additional creative solutions. J Am Med Inform Assoc. 2011 Oct;18(5):540&#x2013;3. doi: 10.1136/amiajnl-2011-000465.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000465</ArticleId><ArticleId IdType="pmc">PMC3168329</ArticleId><ArticleId IdType="pubmed">21846785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury GG. Natural language processing. Ann. Rev. Info. Sci. Tech. 2005 Jan 31;37(1):51&#x2013;89. doi: 10.1002/aris.1440370103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aris.1440370103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang L, Rastegar-Mojarad M, Moon S, Shen F, Afzal N, Liu S, Zeng Y, Mehrabi S, Sohn S, Liu H. Clinical information extraction applications: A literature review. J Biomed Inform. 2018 Jan;77:34&#x2013;49. doi: 10.1016/j.jbi.2017.11.011.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.11.011</ArticleId><ArticleId IdType="pmc">PMC5771858</ArticleId><ArticleId IdType="pubmed">29162496</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs A, Kotfila C, Xu H, Uzuner &#xd6;. Identifying risk factors for heart disease over time: Overview of 2014 i2b2/UTHealth shared task Track 2. J Biomed Inform. 2015 Dec;58 Suppl:S67&#x2013;77. doi: 10.1016/j.jbi.2015.07.001.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4978189</ArticleId><ArticleId IdType="pubmed">26210362</ArticleId></ArticleIdList></Reference><Reference><Citation>Styler WF, Bethard S, Finan S, Palmer M, Pradhan S, de Groen PC, Erickson B, Miller T, Lin C, Savova G, Pustejovsky J. Temporal Annotation in the Clinical Domain. Trans Assoc Comput Linguist. 2014 Apr;2:143&#x2013;154.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657277</ArticleId><ArticleId IdType="pubmed">29082229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N, Wen A, Mojarad MR, Sohn S, Liu H, Jiang G. Standardizing Heterogeneous Annotation Corpora Using HL7 FHIR for Facilitating their Reuse and Integration in Clinical NLP. AMIA Annu Symp Proc. 2018;2018:574&#x2013;583.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371380</ArticleId><ArticleId IdType="pubmed">30815098</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart M, Liu W, Cardell-Oliver R. Redcoat: A Collaborative Annotation Tool for Hierarchical Entity Typing. Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP): System Demonstrations; 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP): System Demonstrations; November 3-7, 2019; Hong Kong, China. 2019. pp. 193&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="doi">10.18653/v1/d19-3033</ArticleId></ArticleIdList></Reference><Reference><Citation>Nye B, Li J, Patel R, Yang Y, Marshall I, Nenkova A, Wallace B. A Corpus with Multi-Level Annotations of Patients, Interventions and Outcomes to Support Language Processing for Medical Literature. Proceedings of the 56th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers); 56th Annual Meeting of the Association for Computational Linguistics; July 15-20, 2018; Melbourne, Australia. 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.18653/v1/p18-1019</ArticleId><ArticleId IdType="pmc">PMC6174533</ArticleId><ArticleId IdType="pubmed">30305770</ArticleId></ArticleIdList></Reference><Reference><Citation>Campillos L, Del&#xe9;ger L, Grouin C, Hamon T, Ligozat A, N&#xe9;v&#xe9;ol A. A French clinical corpus with comprehensive semantic annotations: development of the Medical Entity and Relation LIMSI annOtated Text corpus (MERLOT) Lang Resources &amp; Evaluation. 2017 Feb 15;52(2):571&#x2013;601. doi: 10.1007/s10579-017-9382-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10579-017-9382-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, Raebel MA, Beaulieu NU, Rosofsky R, Woodworth TS, Brown JS. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:23&#x2013;31. doi: 10.1002/pds.2336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2336</ArticleId><ArticleId IdType="pubmed">22262590</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016 Dec;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: A report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE) J Biomed Inform. 2015 Jun;55:290&#x2013;300. doi: 10.1016/j.jbi.2015.05.003.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.05.003</ArticleId><ArticleId IdType="pmc">PMC4527540</ArticleId><ArticleId IdType="pubmed">25979153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Toti G, Morley K, Ibrahim Z, Folarin A, Jackson R, Kartoglu I, Agrawal A, Stringer C, Gale D, Gorrell G, Roberts A, Broadbent M, Stewart R, Dobson RJB. SemEHR: A general-purpose semantic search system to surface semantic data from clinical notes for tailored care, trial recruitment, and clinical research. J Am Med Inform Assoc. 2018 May 01;25(5):530&#x2013;537. doi: 10.1093/jamia/ocx160.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx160</ArticleId><ArticleId IdType="pmc">PMC6019046</ArticleId><ArticleId IdType="pubmed">29361077</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, Zheng J, Sohn S, Kipper-Schuler KC, Chute CG. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc. 2010;17(5):507&#x2013;13. doi: 10.1136/jamia.2009.001560.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.001560</ArticleId><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Soysal E, Wang J, Jiang M, Wu Y, Pakhomov S, Liu H, Xu H. CLAMP - a toolkit for efficiently building customized clinical natural language processing pipelines. J Am Med Inform Assoc. 2018 Mar 01;25(3):331&#x2013;336. doi: 10.1093/jamia/ocx132.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx132</ArticleId><ArticleId IdType="pmc">PMC7378877</ArticleId><ArticleId IdType="pubmed">29186491</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang Y, Wen A, Wang L, Hong N, Shen F, Bedrick S, Hersh W, Liu H. Implementation of a Cohort Retrieval System for Clinical Data Repositories Using the Observational Medical Outcomes Partnership Common Data Model: Proof-of-Concept System Validation. JMIR Med Inform. 2020 Oct 06;8(10):e17376. doi: 10.2196/17376.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/17376</ArticleId><ArticleId IdType="pmc">PMC7576539</ArticleId><ArticleId IdType="pubmed">33021486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma H, Mao C, Zhang Y, Vatani H, Yao L, Zhong Y, Rasmussen L, Jiang G, Pathak J, Luo Y. Developing a portable natural language processing based phenotyping system. BMC Med Inform Decis Mak. 2019 Apr 04;19(Suppl 3):78. doi: 10.1186/s12911-019-0786-z.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0786-z</ArticleId><ArticleId IdType="doi">10.1186/s12911-019-0786-z</ArticleId><ArticleId IdType="pmc">PMC6448187</ArticleId><ArticleId IdType="pubmed">30943974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng K, Vydiswaran VGV, Liu Y, Wang Y, Stubbs A, Uzuner. Gururaj AE, Bayer S, Aberdeen J, Rumshisky A, Pakhomov S, Liu H, Xu H. Ease of adoption of clinical natural language processing software: An evaluation of five systems. J Biomed Inform. 2015 Dec;58 Suppl:S189&#x2013;96. doi: 10.1016/j.jbi.2015.07.008.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.07.008</ArticleId><ArticleId IdType="pmc">PMC4974203</ArticleId><ArticleId IdType="pubmed">26210361</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J. ABMI / SOCRATex. GitHub.  [2021-03-23].   https://github.com/ABMI/SOCRATex.</Citation></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, Rasmussen LV, Liu C, Benoit B, Carroll RJ, Carrell DS, Denny JC, Dikilitas O, Gainer VS, Howell KM, Klann JG, Kullo IJ, Lingren T, Mentch FD, Murphy SN, Natarajan K, Pacheco JA, Wei W, Wiley K, Weng C. Facilitating phenotype transfer using a common data model. J Biomed Inform. 2019 Aug;96:103253. doi: 10.1016/j.jbi.2019.103253.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103253</ArticleId><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;96. doi: 10.1016/j.jbi.2012.05.002.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Blei DM, Ng AY, Jordan MI. Latent dirichlet allocation. Journal of Machine Learning Research. 2003;3:993&#x2013;1022. doi: 10.5555/944919.944937.</Citation><ArticleIdList><ArticleId IdType="doi">10.5555/944919.944937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelodar H, Wang Y, Yuan C, Feng X, Jiang X, Li Y, Zhao L. Latent Dirichlet allocation (LDA) and topic modeling: models, applications, a survey. Multimed Tools Appl. 2018 Nov 28;78(11):15169&#x2013;15211. doi: 10.1007/s11042-018-6894-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11042-018-6894-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths TL, Steyvers M. Finding scientific topics. Proc Natl Acad Sci U S A. 2004 Apr 06;101 Suppl 1:5228&#x2013;35. doi: 10.1073/pnas.0307752101.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307752101</ArticleId><ArticleId IdType="pmc">PMC387300</ArticleId><ArticleId IdType="pubmed">14872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Xia T, Li J, Zhang Y, Tang S. A density-based method for adaptive LDA model selection. Neurocomputing. 2009 Mar;72(7-9):1775&#x2013;1781. doi: 10.1016/j.neucom.2008.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neucom.2008.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun R, Suresh V, Madhavan C, Murthy M. On Finding the Natural Number of Topics with Latent Dirichlet Allocation: Some Observations. PAKDD 2010: Advances in Knowledge Discovery and Data Mining; Pacific-Asia Conference on Knowledge Discovery and Data Mining; July 21-24, 2010; Hyderabad, India. 2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-13657-3_43</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveaud R, SanJuan E, Bellot P. Accurate and effective latent concept modeling for ad hoc information retrieval. Document num&#xe9;rique. 2014 Apr 30;17(1):61&#x2013;84. doi: 10.3166/dn.17.1.61-84.</Citation><ArticleIdList><ArticleId IdType="doi">10.3166/dn.17.1.61-84</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J, Boyd-Graber J, Gerrish S, Wang C, Blei D. Reading tea leaves: how humans interpret topic models. Proceedings of the 22nd International Conference on Neural Information Processing Systems; 22nd International Conference on Neural Information Processing Systems; December 2009; Vancouver. 2009. pp. 288&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="doi">10.5555/2984093.2984126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezoa F, Reutter J, Suarez F, Ugarte M, Vrgo&#x10d; D. Foundations of JSON Schema. Proceedings of the 25th International Conference on World Wide Web; 25th International Conference on World Wide Web; April 2016; Montr&#xe9;al. 2016. pp. 263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2872427.2883029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kononenko O, Baysal O, Holmes R, Godfrey M. Mining modern repositories with elasticsearch. Proceedings of the 11th Working Conference on Mining Software Repositories; 11th Working Conference on Mining Software Repositories; May 2014; Hyderabad, India. 2014. pp. 328&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2597073.2597091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54.  </Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Srigley JR, McGowan T, Maclean A, Raby M, Ross J, Kramer S, Sawka C. Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol. 2009 Jun 15;99(8):517&#x2013;24. doi: 10.1002/jso.21282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.21282</ArticleId><ArticleId IdType="pubmed">19466743</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt P, von dem Bussche A. The EU General Data Protection Regulation (GDPR) Cham: Springer; 2017. Practical Implementation of the Requirements Under the GDPR; pp. 245&#x2013;249.</Citation></Reference><Reference><Citation>Centers for Disease ControlPrevention (CDC)  HIPAA privacy rule and public health. Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Suppl. 2003 May 02;52:1&#x2013;17, 19.  </Citation><ArticleIdList><ArticleId IdType="pubmed">12741579</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, Lee M, Choi C, Kim W, Lee JH. A De-identification method for bilingual clinical texts of various note types. J Korean Med Sci. 2015 Jan;30(1):7&#x2013;15. doi: 10.3346/jkms.2015.30.1.7.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2015.30.1.7</ArticleId><ArticleId IdType="pmc">PMC4278030</ArticleId><ArticleId IdType="pubmed">25552878</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-5&#xae;) Washington, DC: American Psychiatric Association Publishing; 2013.</Citation></Reference><Reference><Citation>Shin JH, Baek JH, Chung J, Ha EJ, Kim J, Lee YH, Lim HK, Moon W, Na DG, Park JS, Choi YJ, Hahn SY, Jeon SJ, Jung SL, Kim DW, Kim E, Kwak JY, Lee CY, Lee HJ, Lee JH, Lee JH, Lee KH, Park S, Sung JY, Korean Society of Thyroid Radiology (KSThR)Korean Society of Radiology  Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2016;17(3):370&#x2013;95. doi: 10.3348/kjr.2016.17.3.370.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2016.17.3.370</ArticleId><ArticleId IdType="pmc">PMC4842857</ArticleId><ArticleId IdType="pubmed">27134526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic Significance of Lymphovascular Invasion in Sporadic Colorectal Cancer. Diseases of the Colon &amp; Rectum. 2010;53(4):377&#x2013;384. doi: 10.1007/dcr.0b013e3181cf8ae5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/dcr.0b013e3181cf8ae5</ArticleId><ArticleId IdType="pubmed">20305435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lykke J, Roikjaer O, Jess P, Danish Colorectal Cancer Group The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis. 2013 May 25;15(5):559&#x2013;65. doi: 10.1111/codi.12059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.12059</ArticleId><ArticleId IdType="pubmed">23061638</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin J, Chang M, Lee K, Toutanova K. Bert: Pre-training of deep bidirectional transformers for language understanding. Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers); 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies; June 2019; Minneapolis, MN. 2019. pp. 4171&#x2013;4186.</Citation><ArticleIdList><ArticleId IdType="doi">10.18653/v1/N19-1423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Dai Z, Yang Y, Carbonell J, Salakhutdinov R, Le Q. XLNet: Generalized Autoregressive Pretraining for Language Understanding. Advances in Neural Information Processing Systems 32 (NeurIPS 2019); 2019 Conference on Neural Information Processing Systems; December 8-14, 2019; Vancouver, Canada. 2019.</Citation></Reference><Reference><Citation>Brown T, Mann B, Ryder N, Subbiah M, Kaplan J, Dhariwal P, Neelakantan A, Shyam P, Sastry G, Askell A, Agarwal S, Herbert-Voss A, Krueger G, Henighan T, Child R, Ramesh A, Ziegler DM, Wu J, Winter C, Hesse C, Chen M, Sigler E, Litwin M, Gray S, Chess B, Clark J, Berner C, McCandlish S, Radford A, Sutskever I, Amodei D. Language Models are Few-Shot Learners. Advances in Neural Information Processing Systems 33 (NeurIPS 2020); 2020 Conference on Neural Information Processing Systems; December 6-12, 2020; Virtual. 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33813032</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>A knowledge base of clinical trial eligibility criteria.</ArticleTitle><Pagination><StartPage>103771</StartPage><MedlinePgn>103771</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2021.103771</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(21)00100-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We present the Clinical Trial Knowledge Base, a regularly updated knowledge base of discrete clinical trial eligibility criteria equipped with a web-based user interface for querying and aggregate analysis of common eligibility criteria.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We used a natural language processing (NLP) tool named Criteria2Query (Yuan et al., 2019) to transform free text clinical trial eligibility criteria from ClinicalTrials.gov into discrete criteria concepts and attributes encoded using the widely adopted Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) and stored in a relational SQL database. A web application accessible via RESTful APIs was implemented to enable queries and visual aggregate analyses. We demonstrate CTKB's potential role in EHR phenotype knowledge engineering using ten validated phenotyping algorithms.</AbstractText><AbstractText Label="RESULTS">At the time of writing, CTKB contained 87,504 distinctive OMOP CDM standard concepts, including Condition (47.82%), Drug (23.01%), Procedure (13.73%), Measurement (24.70%) and Observation (5.28%), with 34.78% for inclusion criteria and 65.22% for exclusion criteria, extracted from 352,110 clinical trials. The average hit rate of criteria concepts in eMERGE phenotype algorithms is 77.56%.</AbstractText><AbstractText Label="CONCLUSION">CTKB is a novel comprehensive knowledge base of discrete eligibility criteria concepts with the potential to enable knowledge engineering for clinical trial cohort definition, clinical trial population representativeness assessment, electronical phenotyping, and data gap analyses for using electronic health records to support clinical trial recruitment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA. Electronic address: chunhua@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 TR003434</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051188" MajorTopicYN="Y">Knowledge Bases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Trial</Keyword><Keyword MajorTopicYN="N">Eligibility Criteria</Keyword><Keyword MajorTopicYN="N">Knowledge Base</Keyword><Keyword MajorTopicYN="N">Natural Language Processing</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33813032</ArticleId><ArticleId IdType="mid">NIHMS1734312</ArticleId><ArticleId IdType="pmc">PMC8407851</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2021.103771</ArticleId><ArticleId IdType="pii">S1532-0464(21)00100-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yuan C, Ryan PB, Ta C, Guo Y, Li Z, Hardin J, et al., Criteria2Query: a natural language interface to clinical databases for cohort definition, J. Am. Med. Inform. Assoc 26 (4) (2019) 294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL, Recruitment for controlled clinical trials: literature summary and annotated bibliography, Control. Clin. Trials 18 (4) (1997) 328&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">9257072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel DB, Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review, Contemp. Clin. Trials Commun 11 (2018) 156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092479</ArticleId><ArticleId IdType="pubmed">30112460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins V, Farewell V, Farewell D, Darmanin J, Wagstaff J, Langridge C, et al., Drivers and barriers to patient participation in RCTs, Br. J. Cancer 108 (7) (2013) 1402&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629425</ArticleId><ArticleId IdType="pubmed">23511558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al., Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors, Lancet Oncol. 7 (2) (2006) 141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16455478</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, et al., A comparison of phenotype definitions for diabetes mellitus, J. Am. Med. Inform. Assoc 20 (e2) (2013) e319&#x2013;e326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861928</ArticleId><ArticleId IdType="pubmed">24026307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Rusanov A, Boland MR, Weng C, Clustering clinical trials with similar eligibility criteria features, J. Biomed. Inform 52 (2014) 112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119097</ArticleId><ArticleId IdType="pubmed">24496068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaman A, Chakrabarti S, Sen A, Weng C, How have cancer clinical trial eligibility criteria evolved over time?, in: AMIA Summits on Translational Science Proceedings, 2016, 2016, p. 269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001741</ArticleId><ArticleId IdType="pubmed">27570681</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Wei W, Yuan C, Kang T, Si Y, Weng C, The data gap in the EHR for clinical research eligibility screening, in: AMIA Summits on Translational Science Proceedings, 2018, 2018, p. 320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961795</ArticleId><ArticleId IdType="pubmed">29888090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DL, Gennari J, Musen MA, Knowledge representation and tool support for critiquing clinical trial protocols. Proceedings of the AMIA Symposium, American Medical Informatics Association, 2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243914</ArticleId><ArticleId IdType="pubmed">11079979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar RD, Martins SB, O&#x2019;Connor MJ, Parrish DB, Das AK, Epoch: an ontological framework to support clinical trials management. Proceedings of the International Workshop on Healthcare Information and Knowledge Management, 2006.</Citation></Reference><Reference><Citation>Sim I, Olasov B, Carini S, The Trial Bank system: capturing randomized trials for evidence-based medicine. AMIA Annual Symposium proceedings AMIA Symposium, American Medical Informatics Association, 2003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479965</ArticleId><ArticleId IdType="pubmed">14728579</ArticleId></ArticleIdList></Reference><Reference><Citation>Speedie SM, Taweel A, Sim I, Arvanitis TN, Delaney B, Peterson KA, The Primary Care Research Object Model (PCROM): a computable information model for practice-based primary care research, J. Am. Med. Inform. Assoc 15 (5) (2008) 661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528032</ArticleId><ArticleId IdType="pubmed">18579829</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldacre B, Gray J, OpenTrials: towards a collaborative open database of all available information on all clinical trials, Trials 17 (1) (2016) 164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825083</ArticleId><ArticleId IdType="pubmed">27056367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Loparo K, Information extraction from free text in clinical trials with knowledge-based distant supervision. 2019 IEEE 43rd Annual Computer Software and Applications Conference (COMPSAC), IEEE, 2019.</Citation></Reference><Reference><Citation>Sun Y, Loparo K, Knowledge-guided text structuring in clinical trials, arXiv preprint arXiv:191212380, 2019.</Citation></Reference><Reference><Citation>Si Y, Weng C, An OMOP CDM-based relational database of clinical research eligibility criteria, Stud. Health Technol. Inform 245 (2017) 950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893219</ArticleId><ArticleId IdType="pubmed">29295240</ArticleId></ArticleIdList></Reference><Reference><Citation>Carini S, Sim I, SysBank: a knowledge base for systematic reviews of randomized clinical trials. AMIA Annual Symposium Proceedings, American Medical Informatics Association, 2003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479927</ArticleId><ArticleId IdType="pubmed">14728309</ArticleId></ArticleIdList></Reference><Reference><Citation>Musen M, Rohn J, Fagan L, Shortliffe E, Knowledge engineering for a clinical trial advice system: uncovering errors in protocol specification, Bull. Cancer 74 (3) (1987) 291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">3620734</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu SW, Kemper CA, Lane NM, Carlson RW, Musen MA, A methodology for determining patients&#x2019; eligibility for clinical trials, Methods Inf. Med 32 (04) (1993) 317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">8412828</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Gennari JH, McDonald DW, A collaborative clinical trial protocol writing system, Medinfo (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15361061</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim I, Detmer DE, Beyond trial registration: a global trial bank for clinical trial reporting, PLoS Med. 2 (11) (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1255763</ArticleId><ArticleId IdType="pubmed">16220999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Chakrabarti S, Goldstein A, Wang S, Ryan PB, Weng CGIST, 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies, J. Biomed. Inform 63 (2016) 325&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077682</ArticleId><ArticleId IdType="pubmed">27600407</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Yuan C, Butler AM, Carvajal RD, Li ZR, Ta CN, et al., DQueST: dynamic questionnaire for search of clinical trials, J. Am. Med. Inform. Assoc 26 (11) (2019) 1333&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798577</ArticleId><ArticleId IdType="pubmed">31390010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC, The ClinicalTrials.gov results database&#x2014;update and key issues, N. Engl. J. Med 364 (9) (2011) 852&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066456</ArticleId><ArticleId IdType="pubmed">21366476</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al., The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies, BMC Med. Genomics 4 (1) (2011) 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al., The electronic medical records and genomics (eMERGE) network: past, present, and future, Genet. Med 15 (10) (2013) 761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, McCourt BJ, et al., The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty, PloS One 7 (3) (2012) e33677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306288</ArticleId><ArticleId IdType="pubmed">22438982</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Carini S, Sim I, Weng C, Visual aggregate analysis of eligibility features of clinical trials, J. Biomed. Inform 54 (2015) 241&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408222</ArticleId><ArticleId IdType="pubmed">25615940</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Carini S, Hao T, Sim I, Weng C, A method for analyzing commonalities in clinical trial target populations. AMIA Annual Symposium Proceedings, American Medical Informatics Association, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419878</ArticleId><ArticleId IdType="pubmed">25954450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MZ, Thompson CB, Yates B, Zimmerman L, Pullen CH, Implementing common data elements across studies to advance research, Nurs. Outlook 63 (2) (2015) 181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361774</ArticleId><ArticleId IdType="pubmed">25771192</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE, Validation of a common data model for active safety surveillance research, J. Am. Med. Inform. Assoc 19 (1) (2012) 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C, Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model, Drug Saf 37 (11) (2014) 945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Mikkelsen EM, Riis A, S&#xf8;rensen HT, Wise LA, Hatch EE, Randomized trial of questionnaire length, Epidemiology 20 (1) (2009) 154.</Citation><ArticleIdList><ArticleId IdType="pubmed">19234404</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Li Y, Ryan P, Zhang Y, Liu F, Gao J, et al., A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records, Appl. Clin. Inform 5 (2) (2014) 463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33825838</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Comparison of Clinical Characteristics Between Clinical Trial Participants and Nonparticipants Using Electronic Health Record Data.</ArticleTitle><Pagination><StartPage>e214732</StartPage><MedlinePgn>e214732</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e214732</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.4732</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Assessing generalizability of clinical trials is important to ensure appropriate application of interventions, but most assessments provide minimal granularity on comparisons of clinical characteristics.</AbstractText><AbstractText Label="OBJECTIVE">To assess the extent of underlying clinical differences between clinical trial participants and nonparticipants by using a combination of electronic health record and trial enrollment data.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study used data obtained from a single academic medical center between September 1996 and January 2019 to identify 1645 clinical trial participants from a diverse set of 202 available trials conducted at the center. Using an aggregated resampling procedure, nonparticipants were matched to participants 1:1 based on trial conditions, number of recent visits to a health care professional, and calendar time.</AbstractText><AbstractText Label="EXPOSURES">Clinical trial enrollment vs no enrollment.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was standardized differences in clinical characteristics between participants and nonparticipants in clinical trials stratified into the 4 most common disease domains.</AbstractText><AbstractText Label="RESULTS">This cross-sectional study included 1645 participants from 202 trials (929 [56.5%] male; mean [SD] age, 54.65 [21.38] years) and an aggregated set of 1645 nonparticipants (855 [52.0%] male; mean [SD] age, 57.24 [21.91] years). The most common disease domains for the selected trials were neoplastic disease (86 trials; 737 participants), disorders of the digestive system (31 trials; 321 participants), inflammatory disorders (28 trials; 276 participants), and disorders of the cardiovascular system (27 trials; 319 participants); trials could qualify for multiple disease domains. Among 31 conditions, the percentage of conditions for which the prevalence was lower among participants than among nonparticipants per standardized differences was 64.5% (20 conditions) for neoplastic disease trials, 61.3% (19) for digestive system trials, 58.1% (18) for inflammatory disorder trials, and 38.7% (12) for cardiovascular system trials. Among 17 medications, the percentage of medications for which use was less among participants than among nonparticipants per standardized differences was 64.7% (11) for neoplastic disease trials, 58.8% (10) for digestive system trials, 88.2% (15) for inflammatory disorder trials, and 52.9% (9) for cardiovascular system trials.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Using a combination of electronic health record and trial enrollment data, this study found that clinical trial participants had fewer comorbidities and less use of medication than nonparticipants across a variety of disease domains. Combining trial enrollment data with electronic health record data may be useful for better understanding of the generalizability of trial results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>James R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Ying Kuen</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Mr Rogers and Dr Weng reported receiving grants from the National Library of Medicine during the conduct of the study. Dr Hripcsak reported receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33825838</ArticleId><ArticleId IdType="pmc">PMC8027910</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.4732</ArticleId><ArticleId IdType="pii">2778202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothwell PM. External validity of randomised controlled trials: &#x201c;to whom do the results of this trial apply?&#x201d; Lancet. 2005;365(9453):82-93. doi:10.1016/S0140-6736(04)17670-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)17670-8</ArticleId><ArticleId IdType="pubmed">15639683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludmir EB, Mainwaring W, Lin TA, et al. . Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.2055</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.2055</ArticleId><ArticleId IdType="pmc">PMC6547133</ArticleId><ArticleId IdType="pubmed">31158272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. doi:10.1186/s13063-015-1023-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-015-1023-4</ArticleId><ArticleId IdType="pmc">PMC4632358</ArticleId><ArticleId IdType="pubmed">26530985</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Barlow WE, Martin DP, et al. . Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106(3):dju002. doi:10.1093/jnci/dju002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dju002</ArticleId><ArticleId IdType="pmc">PMC3982777</ArticleId><ArticleId IdType="pubmed">24627276</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726. doi:10.1001/jama.291.22.2720</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.22.2720</ArticleId><ArticleId IdType="pubmed">15187053</ArticleId></ArticleIdList></Reference><Reference><Citation>Steg PG, L&#xf3;pez-Send&#xf3;n J, Lopez de Sa E, et al. ; GRACE Investigators . External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167(1):68-73. doi:10.1001/archinte.167.1.68</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.1.68</ArticleId><ArticleId IdType="pubmed">17210880</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth B, Haber A, Trongtrakul K, et al. . Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis. JAMA Intern Med. 2019;179(10):1316-1324. doi:10.1001/jamainternmed.2019.1501</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.1501</ArticleId><ArticleId IdType="pmc">PMC6618769</ArticleId><ArticleId IdType="pubmed">31282924</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiu ZZN, Mason KJ, Barker JNWN, et al. ; BADBIR Study Group . A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019;181(6):1265-1271. doi:10.1111/bjd.17849</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.17849</ArticleId><ArticleId IdType="pmc">PMC6916305</ArticleId><ArticleId IdType="pubmed">30822358</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkeland KI, Bodegard J, Norhammar A, et al. . How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? a large European observational study. Diabetes Obes Metab. 2019;21(4):968-974. doi:10.1111/dom.13612</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13612</ArticleId><ArticleId IdType="pmc">PMC6590461</ArticleId><ArticleId IdType="pubmed">30537226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostev K, Schokker E, Jacob L. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings. Int J Clin Pharmacol Ther. 2018;56(9):411-416. doi:10.5414/CP203285</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CP203285</ArticleId><ArticleId IdType="pubmed">30049306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JR, Lee J, Zhou Z, Cheung YK, Hripcsak G, Weng C. Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review. J Am Med Inform Assoc. 2021;28(1):144-154. doi:10.1093/jamia/ocaa224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa224</ArticleId><ArticleId IdType="pmc">PMC7810452</ArticleId><ArticleId IdType="pubmed">33164065</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Tang X, Yang X, et al. . Clinical trial generalizability assessment in the big data era: a review. Clin Transl Sci. 2020;13(4):675-684. doi:10.1111/cts.12764</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12764</ArticleId><ArticleId IdType="pmc">PMC7359942</ArticleId><ArticleId IdType="pubmed">32058639</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. CommonDataModel: definition and DDLs for the OMOP Common Data Model (CDM). 2018. Accessed January 5, 2018. https://github.com/OHDSI/CommonDataModel</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578. doi:10.3233/978-1-61499-564-7-574</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-564-7-574</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasneem A, Aberle L, Ananth H, et al. . The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS One. 2012;7(3):e33677. doi:10.1371/journal.pone.0033677</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033677</ArticleId><ArticleId IdType="pmc">PMC3306288</ArticleId><ArticleId IdType="pubmed">22438982</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. Github: OHDSI/FeatureExtraction. 2020. Accessed December 30, 2020. https://github.com/OHDSI/FeatureExtraction</Citation></Reference><Reference><Citation>Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33(10):1685-1699. doi:10.1002/sim.6058</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6058</ArticleId><ArticleId IdType="pubmed">24323618</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Github. Tidyverse/Ggplot2: tidyverse. 2020. Accessed September 30, 2020. https://github.com/tidyverse/ggplot2</Citation></Reference><Reference><Citation>Bonsu J, Charles L, Guha A, et al. . Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation. 2019;139(22):2594-2596. doi:10.1161/CIRCULATIONAHA.118.039180</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.039180</ArticleId><ArticleId IdType="pmc">PMC8244729</ArticleId><ArticleId IdType="pubmed">30882246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457-1467. doi:10.1056/NEJMra1100265</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100265</ArticleId><ArticleId IdType="pubmed">27732808</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph PD, Craig JC, Tong A, Caldwell PHY. Researchers&#x2019;, regulators&#x2019;, and sponsors&#x2019; views on pediatric clinical trials: a multinational study. Pediatrics. 2016;138(4):e20161171. doi:10.1542/peds.2016-1171</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2016-1171</ArticleId><ArticleId IdType="pubmed">27940891</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357-369. doi:10.1111/bcp.12305</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12305</ArticleId><ArticleId IdType="pmc">PMC4345947</ArticleId><ArticleId IdType="pubmed">24325152</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy S, McIntyre J, Choonara I, Stephenson T. Drug trials in children: problems and the way forward. Br J Clin Pharmacol. 2000;49(2):93-97. doi:10.1046/j.1365-2125.2000.00125.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2000.00125.x</ArticleId><ArticleId IdType="pmc">PMC2014901</ArticleId><ArticleId IdType="pubmed">10671901</ArticleId></ArticleIdList></Reference><Reference><Citation>Doussau A, Geoerger B, Jim&#xe9;nez I, Paoletti X. Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp Clin Trials. 2016;47:217-227. doi:10.1016/j.cct.2016.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2016.01.009</ArticleId><ArticleId IdType="pmc">PMC4818190</ArticleId><ArticleId IdType="pubmed">26825023</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg SL. Ethical challenges in cancer research in children. Oncologist. 2007;12(11):1336-1343. doi:10.1634/theoncologist.12-11-1336</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.12-11-1336</ArticleId><ArticleId IdType="pubmed">18055854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177-1182. doi:10.1111/j.0006-341X.2000.01177.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.2000.01177.x</ArticleId><ArticleId IdType="pubmed">11129476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wages NA, Conaway MR. Phase I/II adaptive design for drug combination oncology trials. Stat Med. 2014;33(12):1990-2003. doi:10.1002/sim.6097</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6097</ArticleId><ArticleId IdType="pmc">PMC4258389</ArticleId><ArticleId IdType="pubmed">24470329</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144-1165. doi:10.1002/hep.26972</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26972</ArticleId><ArticleId IdType="pubmed">24716201</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton E, McLoughlin A, Williams DJ, et al. . Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J. 2019;4(2):160-171. doi:10.1177/2396987318825484</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2396987318825484</ArticleId><ArticleId IdType="pmc">PMC6591758</ArticleId><ArticleId IdType="pubmed">31259264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock A, Baer G, Campbell P, et al. . Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database Syst Rev. 2014;(4):CD001920. doi:10.1002/14651858.CD001920.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001920.pub3</ArticleId><ArticleId IdType="pmc">PMC6465059</ArticleId><ArticleId IdType="pubmed">24756870</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-1018. doi:10.1016/S1474-4422(09)70236-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70236-4</ArticleId><ArticleId IdType="pubmed">19782001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankey GJ. Secondary stroke prevention. Lancet Neurol. 2014;13(2):178-194. doi:10.1016/S1474-4422(13)70255-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70255-2</ArticleId><ArticleId IdType="pubmed">24361114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ay H, Gungor L, Arsava EM, et al. . A score to predict early risk of recurrence after ischemic stroke. Neurology. 2010;74(2):128-135. doi:10.1212/WNL.0b013e3181ca9cff</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ca9cff</ArticleId><ArticleId IdType="pmc">PMC2809031</ArticleId><ArticleId IdType="pubmed">20018608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women&#x2019;s participation in cardiovascular clinical trials from 2010 to 2017. Circulation. 2020;141(7):540-548. doi:10.1161/CIRCULATIONAHA.119.043594</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.043594</ArticleId><ArticleId IdType="pubmed">32065763</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman S, Ammar W, Lo K, Trepman E, van Zuylen M, Etzioni O. Quantifying sex bias in clinical studies at scale with automated data extraction. JAMA Netw Open. 2019;2(7):e196700. doi:10.1001/jamanetworkopen.2019.6700</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.6700</ArticleId><ArticleId IdType="pmc">PMC6613296</ArticleId><ArticleId IdType="pubmed">31268541</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott PE, Unger EF, Jenkins MR, et al. . Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71(18):1960-1969. doi:10.1016/j.jacc.2018.02.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.02.070</ArticleId><ArticleId IdType="pubmed">29724348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding EL, Powe NR, Manson JE, Sherber NS, Braunstein JB. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med. 2007;167(9):905-912. doi:10.1001/archinte.167.9.905</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.9.905</ArticleId><ArticleId IdType="pubmed">17502531</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013;20(1):144-151. doi:10.1136/amiajnl-2011-000681</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000681</ArticleId><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse T, Fain KM, Zarin DA. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ. 2018;361:k1452. doi:10.1136/bmj.k1452</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k1452</ArticleId><ArticleId IdType="pmc">PMC5968400</ArticleId><ArticleId IdType="pubmed">29802130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33830834</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1281</EndPage><MedlinePgn>1275-1281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03007995.2021.1913109</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study aimed to determine rates of hospitalization and in-hospital mortality in the first year following amyloidosis diagnosis with cardiac involvement using observational databases.</AbstractText><AbstractText Label="METHODS">Three administrative claims databases, IBM MarketScan<sup>&#xae;</sup> Commercial Claims and Encounters (CCAE), IBM MarketScan<sup>&#xae;</sup> Multi-State Medicare Database (MDCR), and Optum's de-identified Clinformatics<sup>&#xae;</sup> Data Mart Database (Optum) were analyzed. Adults &#x2265;18&#xa0;years old, with a diagnosis of amyloidosis and evidence of cardiac involvement (i.e. heart failure, heart block, or cardiomyopathy) but no hepatic/renal failure prior to amyloidosis diagnosis were included for analysis. The primary analyses identified patients between 01-01-2010 and 31-12-2017 period. We calculated the rates of hospitalization and in-hospital mortality within 1&#xa0;year after the initial diagnosis of amyloidosis. A sensitivity analysis was conducted for patients identified in Optum database during 2004-2011 period, which provided additional mortality information.</AbstractText><AbstractText Label="RESULTS">A total of 419, 654, and 922 patients from CCAE, MDCR, and Optum were identified during 2010-2017 period, with mean age of 55.6, 77.8, and 74.2&#xa0;years, respectively. Within 1&#xa0;year following initial amyloidosis diagnosis, incidence rates (95% confidence interval [CI]) of hospitalization were 78.4 (66.3, 90.4), 78.6 (69.2, 87.9), and 61.2 (54.4, 68.0) per 100 person-years, rates of in-hospital mortality were 16.5 (11.8, 21.3), 8.4 (5.7, 11.0), and 17.7 (14.5, 21.0) per 100 person-years, in CCAE, MDCR, and Optum, respectively. The mortality rate from the sensitivity analysis among patients identified in Optum 2004-2011 period was higher compared with Optum 2010-2017 period.</AbstractText><AbstractText Label="CONCLUSIONS">The results from this study indicate that amyloidosis with cardiac involvement is a condition with high rates of hospitalization and mortality in the first year after initial diagnosis. Future studies are needed to further evaluate the outcomes within the subtypes of amyloidosis and understand the risk factors associated with poor prognoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Guohua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiBattiste</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Curr Med Res Opin. 2022 Oct;38(10):1683. doi: 10.1080/03007995.2022.2108617.</RefSource><PMID Version="1">35916337</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="Y">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac amyloidosis</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33830834</ArticleId><ArticleId IdType="doi">10.1080/03007995.2021.1913109</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33841914</PMID><DateRevised><Year>2021</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2058-5241</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>EFORT open reviews</Title><ISOAbbreviation>EFORT Open Rev</ISOAbbreviation></Journal><ArticleTitle>The case for an academic discipline of medical device science.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>163</EndPage><MedlinePgn>160-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1302/2058-5241.6.200094</ELocationID><Abstract><AbstractText>Medical devices are a very important but largely under-recognized and fragmented component of healthcare.The limited regulation of the past and the lack of systematic rigorous evaluation of devices leading to numerous high-profile failures will now be replaced by stricter legal requirements and more transparent evaluation processes.This constitutes an unprecedented opportunity, but it also uncovers urgent needs in landscaping, methodology development, and independent comprehensive assessment of device risks and benefits for individual patients and society, especially in the context of increasingly complex devices.We argue that an academic discipline of 'medical device science' is well placed to lead and coordinate the efforts necessary to achieve much needed improvement in the medical device sector.Orthopaedics and traumatology could contribute and benefit considerably as one of the medical specialties with the highest use of medical devices. Cite this article: <i>EFORT Open Rev</i> 2021;6:160-163. DOI: 10.1302/2058-5241.6.200094.</AbstractText><CopyrightInformation>&#xa9; 2021 The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xfc;bbeke</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Orthopaedic Surgery and Traumatology, Geneva University Hospitals and University of Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EFORT Open Rev</MedlineTA><NlmUniqueID>101695674</NlmUniqueID><ISSNLinking>2058-5241</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">implants</Keyword><Keyword MajorTopicYN="N">medical device science</Keyword><Keyword MajorTopicYN="N">medical devices</Keyword></KeywordList><CoiStatement>ICMJE Conflict of interest statement: AL declares no conflict of interest relevant to this work. JAS reports consultancy for Biolacuna Ltd, outside the submitted work. DPA reports fees for speaker services and advisory board membership. AMGEN, fees for consultancy services from UCB Biopharma, grants from Les Laboratoires Servier, all outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. AJC reports consultancy for the Novartis musculoskeletal advisory board and patents with BioPatch, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33841914</ArticleId><ArticleId IdType="pmc">PMC8025702</ArticleId><ArticleId IdType="doi">10.1302/2058-5241.6.200094</ArticleId><ArticleId IdType="pii">10.1302_2058-5241.6.200094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackerman IN, Bohensky MA, de Steiger R, et al. . Substantial rise in the lifetime risk of primary total knee replacement surgery for osteoarthritis from 2003 to 2013: an international, population-level analysis. Osteoarthritis Cartilage 2017;25:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">27856293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrakyan A. Metal-on-metal failures&#x2014;in science, regulation, and policy. Lancet 2012;379:1174&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22417409</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand R, Graves SE, de Steiger RN, et al. . What is the benefit of introducing new hip and knee prostheses? J Bone Joint Surg Am 2011;93:51&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson C, Drummond M, Bhuiyan Khan B. Medical technology as a key driver of rising health expenditure: disentangling the relationship. Clinicoecon Outcomes Res 2013;5:223&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686328</ArticleId><ArticleId IdType="pubmed">23807855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser AG, Butchart EG, Szyma&#x144;ski P, et al. . The need for transparency of clinical evidence for medical devices in Europe. Lancet 2018;392:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">30017550</ArticleId></ArticleIdList></Reference><Reference><Citation>
US Food &amp; Drug Administration (FDA). Kefauver-Harris amendments revolutionized drug development. 9
October
2012. https://www.fda.gov/consumers/consumer-updates/kefauver-harris-amendments-revolutionized-drug-development (date last accessed 22 January 2021).</Citation></Reference><Reference><Citation>Huiskes R. Failed innovation in total hip replacement: diagnosis and proposals for a cure. Acta Orthop Scand 1993;64:699&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">8291421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sochart DH, Long AJ, Porter ML. Joint responsibility: the need for a national arthroplasty register. BMJ 1996;313:66&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2351469</ArticleId><ArticleId IdType="pubmed">8688749</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;bbeke A, Silman AJ, Barea C, Prieto-Alhambra D, Carr AJ. Mapping existing hip and knee replacement registries in Europe. Health Policy 2018;122:548&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598886</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrendt CA, Venermo M, Cronenwett JL, et al. ; VASCUNET, the Vascular Quality Initiative and the International Consortium of Vascular Registries. VASCUNET, VQI, and the International Consortium of Vascular Registries: unique collaborations for quality improvement in vascular surgery. Eur J Vasc Endovasc Surg 2019;58:792&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">31422049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi VK, Ross JS. Modernizing the FDA&#x2019;s 510(k) pathway. N Engl J Med 2019;381:1891&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">31644865</ArticleId></ArticleIdList></Reference><Reference><Citation>
Medical Device Epidemiology Network. http://mdepinet.org/ (date last accessed 22 January 2021).</Citation></Reference><Reference><Citation>
ICIJ. Implant files. 25
November
2018. https://www.icij.org/investigations/implant-files/ (date last accessed 22 January 2021).</Citation></Reference><Reference><Citation>National Assembly: Information report submitted in application of article 145 of the regulations by the social affairs committee in conclusion of the work of the information committee on medical devices.</Citation></Reference><Reference><Citation>
Law on the establishment of the implant register in Germany and on further amendments to the fifth book of the Social Security Code (Implantateregister-Errichtungsgesetz - EIRD). Federal Law Gazette
2019.  Part I No. 48, issued in Bonn on 17
December
2019. 6
March
2019. https://www.assemblee-nationale.fr/dyn/15/rapports/cion-soc/l15b1734_rapport-information (date last accessed 22 January 2021).</Citation></Reference><Reference><Citation>Niederl&#xe4;nder C, Wahlster P, Kriza C, Kolominsky-Rabas P. Registries of implantable medical devices in Europe. Health Policy 2013;113:20&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">24075007</ArticleId></ArticleIdList></Reference><Reference><Citation>Malchau H, Garellick G, Berry D, et al. . Arthroplasty implant registries over the past five decades: development, current, and future impact. J Orthop Res 2018;36:2319&#x2013;2330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29663575</ArticleId></ArticleIdList></Reference><Reference><Citation>
International Medical Device Regulators Forum. http://www.imdrf.org/ (date last accessed 22 January 2021).</Citation></Reference><Reference><Citation>Sedrakyan A, Marinac-Dabic D, Normand SL, Mushlin A, Gross T. A framework for evidence evaluation and methodological issues in implantable device studies. Med Care 2010;48:S121&#x2013;S128.</Citation><ArticleIdList><ArticleId IdType="pubmed">20421824</ArticleId></ArticleIdList></Reference><Reference><Citation>Krewski D, Westphal M, Andersen ME, et al. . A framework for the next generation of risk science. Environ Health Perspect 2014;122:796&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123023</ArticleId><ArticleId IdType="pubmed">24727499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P. IDEAL-D: a rational framework for evaluating and regulating the use of medical devices. BMJ 2016;353:i2372.</Citation><ArticleIdList><ArticleId IdType="pubmed">27283585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs S, Olberg B, Panteli D, Perleth M, Busse R. HTA of medical devices: challenges and ideas for the future from a European perspective. Health Policy 2017;121:215&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">27751533</ArticleId></ArticleIdList></Reference><Reference><Citation>Faris O, Shuren J. An FDA viewpoint on unique considerations for medical-device clinical trials. N Engl J Med 2017;376:1350&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">28379790</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin L. Early evaluation of new health technologies: the case for premarket studies that harmonize regulatory and coverage perspectives. Int J Technol Assess Health Care 2015;31:207&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">26560412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33882595</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2364-0502</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Yearbook of medical informatics</Title><ISOAbbreviation>Yearb Med Inform</ISOAbbreviation></Journal><ArticleTitle>Drawing Reproducible Conclusions from Observational Clinical Data with OHDSI.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>289</EndPage><MedlinePgn>283-289</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0041-1726481</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The current observational research literature shows extensive publication bias and contradiction. The Observational Health Data Sciences and Informatics (OHDSI) initiative seeks to improve research reproducibility through open science.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">OHDSI has created an international federated data source of electronic health records and administrative claims that covers nearly 10% of the world's population. Using a common data model with a practical schema and extensive vocabulary mappings, data from around the world follow the identical format. OHDSI's research methods emphasize reproducibility, with a large-scale approach to addressing confounding using propensity score adjustment with extensive diagnostics; negative and positive control hypotheses to test for residual systematic error; a variety of data sources to assess consistency and generalizability; a completely open approach including protocol, software, models, parameters, and raw results so that studies can be externally verified; and the study of many hypotheses in parallel so that the operating characteristics of the methods can be assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">OHDSI has already produced findings in areas like hypertension treatment that are being incorporated into practice, and it has produced rigorous studies of COVID-19 that have aided government agencies in their treatment decisions, that have characterized the disease extensively, that have estimated the comparative effects of treatments, and that the predict likelihood of advancing to serious complications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">OHDSI practices open science and incorporates a series of methods to address reproducibility. It has produced important results in several areas, including hypertension therapy and COVID-19 research.</AbstractText><CopyrightInformation>IMIA and Thieme. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fielding School of Public Health, Department of Biostatistics, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>David Geffen School of Medicine, Department of Biomathematics, University of California, Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Yearb Med Inform</MedlineTA><NlmUniqueID>9312666</NlmUniqueID><ISSNLinking>0943-4747</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017594" MajorTopicYN="Y">Publication Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>21</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33882595</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, Duke J, Shah N, Reich C, Huser V, Schuemie M. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardwell C R, Abnet C C, Cantwell M M, Murray L J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513370</ArticleId><ArticleId IdType="pubmed">20699457</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933354</ArticleId><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Ryan P B, Hripcsak G, Madigan D, Suchard M A.Improving reproducibility by using high-throughput observational studies with empirical calibration Philos Trans A Math Phys Eng Sci 2018376(2128):2.0170356E7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Suchard M A, Hripcsak G, Ryan P B, Madigan D. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115(11):2571&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J, Ryan P, Reich C, Hartzema A, Stang P. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Anh H, Manion F, Rouhizadeh M, Zhang Y.COVID-19 SignSym&#x2013;A fast adaptation of general clinical NLP tools to identify and normalize COVID-19 signs and symptoms to OMOP common data modelArXiv 2020;arXiv:2007.10286v3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989301</ArticleId><ArticleId IdType="pubmed">33674830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang Y, Wen A, Wang L, Hong N, Shen F, Bedrick S, Hersh W, Liu H.CREATE: Cohort retrieval enhanced by analysis of text from electronic health records using OMOP common data modelArXiv 2019;arXiv:1901.07601</Citation></Reference><Reference><Citation>Meystre S M, Heider P M, Kim Y, Aruch D B, Britten C D. Automatic trial eligibility surveillance based on unstructured clinical data. Int J Med Inform. 2019;129:13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717538</ArticleId><ArticleId IdType="pubmed">31445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma H, Mao C, Zhang Y, Vatani H, Yao L, Zhong Y, Rasmussen L, Jiang G, Pathak J, Luo Y.Developing a portable natural language processing based phenotyping system BMC Med Inform Decis Mak 201919(Suppl 3):78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448187</ArticleId><ArticleId IdType="pubmed">30943974</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics GitHub Library. Available from: https://github.com/OHDSI/ [Accessed 2021 Feb 7]</Citation></Reference><Reference><Citation>ATLAS &#x2013; A unified interface for the OHDSI tools. https://www.ohdsi.org/atlas-a-unified-interface-for-the-ohdsi-tools/ [Accessed 2020 Nov 18]</Citation></Reference><Reference><Citation>Suchard M, Simpson S, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. Transactions on Modeling and Computer Simulation. 2013;23:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan P B, Duke J D, Shah N H, Park R W, Huser V, Suchard M A, Schuemie M J, DeFalco F J, Perotte A, Banda J M, Reich C G, Schilling L M, Matheny M E, Meeker D, Pratt N, Madigan D. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113:7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Ryan P B, Pratt N, Chen R, You S C, Krumholz H M. Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND) J Am Med Inform Assoc. 2020;27:1331&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Ryan P B, Pratt N, Chen R, You S C, Krumholz H M. Large-scale evidence generation and evaluation across a network of databases (LEGEND): Assessing validity using hypertension as a case study. J Am Med Inform Assoc. 2020;27:1268&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum P R, Rubin D B. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55.</Citation></Reference><Reference><Citation>Tian Y, Schuemie M J, Suchard M A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein R B, Ryan P, Berlin J A, Berlin J A, Matcho A, Schuemie M. Channeling in the use of nonprescription paracetamol and ibuprofen in an electronic medical records database: evidence and implications. Drug Saf. 2017;40(12):1279&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688206</ArticleId><ArticleId IdType="pubmed">28780741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B. 1996;58(01):267&#x2013;88.</Citation></Reference><Reference><Citation>Walker A M, Patrick A R, Lauer M S, Hornbrook M C, Marin M G, Platt R. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effectiveness Research. 2013;3:11&#x2013;20.</Citation></Reference><Reference><Citation>Austin P C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham D J, Reichman M E, Wernecke M, Zhang R, RossSouthworth M, Levenson M. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard M A, Shea S, Chen R, You S C, Pratt N. Real-world evidence on the effectiveness and safety of chlorthalidone and hydrochlorothiazide. JAMA Intern Med. 2020;180(04):542&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Cepeda M S, Suchard M A, Yang J, Tian Y, Schuler A.How confident are we about observational findings in healthcare: a benchmark studyHarv Data Sci Rev 2020;2(01): 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E A, Boyce R D, Ryan P B, van der Lei J, Rijnbeek P R, Schuemie M J. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J D, Ryan P B, Suchard M A, Hripcsak G, Jin P, Reich C. Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. Epilepsia. 2017;58:e101&#x2013;e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M A, Schuemie M J, Krumholz H M, You S C, Chen R, Pratt N. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes. Lancet. 2019;394:1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton P K, Carey R M, Aronow W S, Casey Jr D E, Collins K J, DennisonHimmelfarb C. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(06):1269&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shea S, Schuemie M J. Chlorthalidone and hydrochlorothiazide for treatment of patients with hypertension-reply. JAMA Intern Med. 2020;180:1133&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32568364</ArticleId></ArticleIdList></Reference><Reference><Citation>The Medical Letter, Inc. Drugs for hypertension The Medical Letter on Drugs and Therapeutics 202062(1598):73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555118</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J M, Schuemie M J, Suchard M A, Ryan P B, Rijnbeekv P R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25:969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps J M, Kostka K F, Ryan P B, Zou Y, Voss E A. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PloS One. 2020;15(01):e0226718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J M, Rijnbeek P R, Ryan P B. Identifying the DEAD: development and validation of a patient-level model to predict death status in population-level claims data. Drug Saf. 2019;42(11):1377&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834730</ArticleId><ArticleId IdType="pubmed">31054141</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J M, Williams R D, You S C, Falconer T, Minty E, Callahan A. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R D, Markus A F, Yang C, DuarteSalles T, DuVall S L, Falconer T.Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international networkmedRxiv 2020. doi: https://doi.org/10.1101/2020.05.26.20112649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="pubmed">35094685</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You S C, Sena A, Kostka K, Abedtash H, Abrah&#xe3;o M TF.Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network studyNat Commun 2020;11(5009). doi: 10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales D R, Conover M M, You S C, Pratt N, Kostka K, Duarte-Salles T. Renin-angiotensin system blockers and susceptibility to COVID-19: an international open science cohort study. Lancet Digit Health. 2021;3(02):e98&#x2013;e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane J CE, Weaver J, Kostka K, Duarte-Salles T, Abrahao T, Alghoul H. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. Lancet Rheumatology. 2020;2(11):e698&#x2013;e711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine2020 April 28. Available from: https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine [cited 2021 Feb 7]</Citation></Reference><Reference><Citation>The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 8)EMA/95098/2010. Available from: http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf [Accessed 2021 Feb 7]</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI; 2020Available from: https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33887457</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials.</ArticleTitle><Pagination><StartPage>103790</StartPage><MedlinePgn>103790</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2021.103790</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(21)00119-2</ELocationID><Abstract><AbstractText>Clinical trials are essential for generating reliable medical evidence, but often suffer from expensive and delayed patient recruitment because the unstructured eligibility criteria description prevents automatic query generation for eligibility screening. In response to the COVID-19 pandemic, many trials have been created but their information is not computable. We included 700 COVID-19 trials available at the point of study and developed a semi-automatic approach to generate an annotated corpus for COVID-19 clinical trial eligibility criteria called COVIC. A hierarchical annotation schema based on the OMOP Common Data Model was developed to accommodate four levels of annotation granularity: i.e., study cohort, eligibility criteria, named entity and standard concept. In COVIC, 39 trials with more than one study cohorts were identified and labelled with an identifier for each cohort. 1,943 criteria for non-clinical characteristics such as "informed consent", "exclusivity of participation" were annotated. 9767 criteria were represented by 18,161 entities in 8 domains, 7,743 attributes of 7 attribute types and 16,443 relationships of 11 relationship types. 17,171 entities were mapped to standard medical concepts and 1,009 attributes were normalized into computable representations. COVIC can serve as a corpus indexed by semantic tags for COVID-19 trial search and analytics, and a benchmark for machine learning based criteria extraction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA; Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Latoya A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southard</LastName><ForeName>Christopher T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA. Electronic address: chunhua@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT3 TR002027</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR001579</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="Y">Eligibility Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Eligibility criteria</Keyword><Keyword MajorTopicYN="N">Machine readable dataset</Keyword><Keyword MajorTopicYN="N">Structured text corpus</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33887457</ArticleId><ArticleId IdType="mid">NIHMS1695446</ArticleId><ArticleId IdType="pmc">PMC8079156</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2021.103790</ArticleId><ArticleId IdType="pii">S1532-0464(21)00119-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zheng Q., Jones F.K., Leavitt S.V., Ung L., Labrique A.B., Peters D.H., Lee E.C., Azman A.S. HIT-COVID, a global database tracking public health interventions to COVID-19. Sci. Data. 2020;7(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453020</ArticleId><ArticleId IdType="pubmed">32855428</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Map - Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html Accessed September 31, 2020.</Citation></Reference><Reference><Citation>N.A. Sansa, Effects of the COVID-19 Pandemic on the World Population: Lessons to Adopt from Past Years Global Pandemics (2020). Available at SSRN 3565645.</Citation></Reference><Reference><Citation>Kang T., Zhang S., Tang Y., Hruby G.W., Rusanov A., Elhadad N., Weng C. EliIE: An open-source information extraction system for clinical trial eligibility criteria. J. Am. Med. Inform. Assoc. 2017;24(6):1062&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6259668</ArticleId><ArticleId IdType="pubmed">28379377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C., Ryan P.B., Ta C., Guo Y., Li Z., Hardin J., Makadia R., Jin P., Shang N., Kang T., Weng C. Criteria2Query: a natural language interface to clinical databases for cohort definition. J. Am. Med. Inform. Assoc. 2019;26(4):294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Butler A.M., Lin F., Liu H., Stewart L.A., Kim J.H., Idnay B.R.S., Ge Q., Wei X., Liu C., Yuan C., Weng C. The COVID-19 Trial Finder. J. Am. Med. Inform. Assoc. 2021;28(3):616&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717322</ArticleId><ArticleId IdType="pubmed">33216120</ArticleId></ArticleIdList></Reference><Reference><Citation>Desvars-Larrive, A., Dervic, E., Haug, N., Niederkrotenthaler, T., Chen, J., Di Natale, A., Lasser, J., Gliga, D.S., Roux, A., Chakraborty, A. and Ten, A., 2020. A structured open dataset of government interventions in response to COVID-19. medRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452888</ArticleId><ArticleId IdType="pubmed">32855430</ArticleId></ArticleIdList></Reference><Reference><Citation>Y. Sun, K. Loparo, Information extraction from free text in clinical trials with knowledge-based distant supervision. In 2019 IEEE 43rd Annual Computer Software and Applications Conference (COMPSAC), IEEE 2019, July, Vol. 1, pp. 954&#x2013;955.</Citation></Reference><Reference><Citation>Ross J., Tu S., Carini S., Sim I. Analysis of eligibility criteria complexity in clinical trials. Summit Transl. Bioinform. 2010;2010:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041539</ArticleId><ArticleId IdType="pubmed">21347148</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C., Wu X., Luo Z., Boland M.R., Theodoratos D., Johnson S.B. EliXR: an approach to eligibility criteria extraction and representation. J. Am. Med. Inform. Assoc. 2011;18(Supplement_1):i116&#x2013;i124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241167</ArticleId><ArticleId IdType="pubmed">21807647</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. Usagi, https://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:usagi (2018).</Citation></Reference><Reference><Citation>Kury F., Butler A., Yuan C., Fu L.H., Sun Y., Liu H., Sim I., Carini S., Weng C. Chia, a large annotated corpus of clinical trial eligibility criteria. Sci. Data. 2020;7(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452886</ArticleId><ArticleId IdType="pubmed">32855408</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Reich, P.B. Ryan, R. Belenkaya, K. Natarajan, C. Blacketer, OHDSI Common Data Model v6.0 Specifications, https://github.com/OHDSI/CommonDataModel/wiki (2019).</Citation></Reference><Reference><Citation>Ross J.S., Tse T., Zarin D.A., et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ. 2012;344 doi: 10.1136/bmj.d7292. d7292-d7292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d7292</ArticleId><ArticleId IdType="pmc">PMC3623605</ArticleId><ArticleId IdType="pubmed">22214755</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials Transformation Initiative. Aggregate Analysis of ClinicalTrials.gov, https://aact.ctti-clinicaltrials.org/ (2016).</Citation></Reference><Reference><Citation>i2b2 Common Data Model. https://i2b2.org/software/files/PDF/current/CRC_Design.pdf. Accessed 25 Aug 2020.</Citation></Reference><Reference><Citation>Sentinel Common Data Model. https://www.sentinelinitiative.org/sentinel/data/distributed-database-common-data-model. Accessed 25 Aug 2020.</Citation></Reference><Reference><Citation>S. Toh, L.J. Rasmussen-Torvik, E.E. Harmata, R. Pardee, R. Saizan, E. Malanga, J.L. Sturtevant, C.E. Horgan, J. Anau, C.D. Janning, R.D. Wellman, The National Patient-Centered Clinical Research Network (PCORnet) bariatric study cohort: rationale, methods, and baseline characteristics. JMIR research protocols, 6(12) (2017) p.e222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736875</ArticleId><ArticleId IdType="pubmed">29208590</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E.A., Makadia R., Matcho A., Ma Q., Knoll C., Schuemie M., DeFalco F.J., Londhe A., Zhu V., Ryan P.B. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. 2015;22(3):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenetorp P., Pyysalo S., Topi&#x107; G., Ohta T., Ananiadou S., Tsujii J.I. Proceedings of the Demonstrations at the 13th Conference of the European Chapter of the Association for Computational Linguistics. 2012. April. BRAT: a web-based tool for NLP-assisted text annotation; pp. 102&#x2013;107.</Citation></Reference><Reference><Citation>A.X. Chang, C.D. Manning, Sutime: A library for recognizing and normalizing time expressions, in Lrec, 2012, May ,Vol. 2012, pp. 3735&#x2013;3740.</Citation></Reference><Reference><Citation>T. Kolditz, C. Lohr, J. Hellrich, L. Modersohn, B. Betz, M. Kiehntopf, U. Hahn, August. Annotating German Clinical Documents for De-Identification. In MedInfo, 2019, pp. 203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437914</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova G.K., Masanz J.J., Ogren P.V., Zheng J., Sohn S., Kipper-Schuler K.C., Chute C.G. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J. Am. Med. Inform. Assoc. 2010;17(5):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>A.R. Aronson, Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. In Proceedings of the AMIA Symposium, 2001, p. 17. American Medical Informatics Association.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243666</ArticleId><ArticleId IdType="pubmed">11825149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Rothschild A.S. Agreement, the f-measure, and reliability in information retrieval. J. Am. Med. Inform. Assoc. 2005;12(3):296&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1090460</ArticleId><ArticleId IdType="pubmed">15684123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33963368</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2474-9842</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>BJS open</Title><ISOAbbreviation>BJS Open</ISOAbbreviation></Journal><ArticleTitle>Prediction of 90-day mortality after surgery for colorectal cancer using standardized nationwide quality-assurance data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">zrab023</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bjsopen/zrab023</ELocationID><Abstract><AbstractText Label="BACKGROUND">Personalized risk assessment provides opportunities for tailoring treatment, optimizing healthcare resources and improving outcome. The aim of this study was to develop a 90-day mortality-risk prediction model for identification of high- and low-risk patients undergoing surgery for colorectal cancer.</AbstractText><AbstractText Label="METHODS">This was a nationwide cohort study using records from the Danish Colorectal Cancer Group database that included all patients undergoing surgery for colorectal cancer between 1 January 2004 and 31 December 2015. A least absolute shrinkage and selection operator logistic regression prediction model was developed using 121 pre- and intraoperative variables and internally validated in a hold-out test data set. The accuracy of the model was assessed in terms of discrimination and calibration.</AbstractText><AbstractText Label="RESULTS">In total, 49&#x2009;607 patients were registered in the database. After exclusion of 16&#x2009;680 individuals, 32&#x2009;927 patients were included in the analysis. Overall, 1754 (5.3 per cent) deaths were recorded. Targeting high-risk individuals, the model identified 5.5 per cent of all patients facing a risk of 90-day mortality exceeding 35 per cent, corresponding to a 6.7 times greater risk than the average population. Targeting low-risk individuals, the model identified 20.9 per cent of patients facing a risk less than 0.3 per cent, corresponding to a 17.7 times lower risk compared with the average population. The model exhibited discriminatory power with an area under the receiver operating characteristics curve of 85.3 per cent (95 per cent c.i. 83.6 to 87.0) and excellent calibration with a Brier score of 0.04 and 32 per cent average precision.</AbstractText><AbstractText Label="CONCLUSION">Pre- and intraoperative data, as captured in national health registries, can be used to predict 90-day mortality accurately after colorectal cancer surgery.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vogelsang</LastName><ForeName>R P</ForeName><Initials>RP</Initials><Identifier Source="ORCID">0000-0003-0081-5093</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojesen</LastName><ForeName>R D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-3998-1160</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Slagelse Hospital, Slagelse, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoelmich</LastName><ForeName>E R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orhan</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buzquurz</LastName><ForeName>F</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4871-0891</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grube</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahid</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allakhverdiiev</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odysseus Data Services Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raskov</LastName><ForeName>H H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drakos</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derian</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Janssen Research &amp; Development LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJS Open</MedlineTA><NlmUniqueID>101722685</NlmUniqueID><ISSNLinking>2474-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="Y">Digestive System Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33963368</ArticleId><ArticleId IdType="pmc">PMC8105588</ArticleId><ArticleId IdType="doi">10.1093/bjsopen/zrab023</ArticleId><ArticleId IdType="pii">6272169</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Degett TH, Dalton SO, Christensen J, S&#xf8;gaard J, Iversen LH, G&#xf6;genur I &#xa0;et al. &#xa0;Mortality after emergency treatment of colorectal cancer and associated risk factors &#x2013; a nationwide cohort study. Int J Colorectal Dis &#xa0;2019;34:85&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pubmed">30327873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjo OH, Larsen S, Lunde OC, Nesbakken A. &#xa0;Short term outcome after emergency and elective surgery for colon cancer. Colorectal Dis &#xa0;2009;11:733&#x2013;739</Citation><ArticleIdList><ArticleId IdType="pubmed">18624817</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen LH, Ingeholm P, G&#xf6;genur I, Laurberg S. &#xa0;Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001&#x2013;2011. Ann Surg Oncol &#xa0;2014;21:2267&#x2013;2273</Citation><ArticleIdList><ArticleId IdType="pubmed">24585408</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen LH, Green A, Ingeholm P, &#xd8;sterlind K, G&#xf6;genur I. &#xa0;Improved survival of colorectal cancer in Denmark during 2001&#x2013;2012 &#x2013; the efforts of several national initiatives. Acta Oncol &#xa0;2016;55:10&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">26859340</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam MA, Turner MC, Sun Z, Kim J, Ezekian B, Migaly J &#xa0;et al. &#xa0;The appropriateness of 30-day mortality as a quality metric in colorectal cancer surgery. Am J Surg &#xa0;2018;215:66&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">28599835</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser BC, Keegan H, Martin M &#xa0;et al. &#xa0;Death after colectomy: it's later than we think. Arch Surg &#xa0;2009;144:1021&#x2013;1027</Citation><ArticleIdList><ArticleId IdType="pubmed">19917938</ArticleId></ArticleIdList></Reference><Reference><Citation>Damhuis RAM, Wijnhoven BPL, Plaisier PW, Kirkels WJ, Kranse R, van Lanschot JJ &#xa0;et al. &#xa0;Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer types. Br J Surg &#xa0;2012;99:1149&#x2013;1154</Citation><ArticleIdList><ArticleId IdType="pubmed">22718521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Dean J, Kohane I. &#xa0;Machine learning in medicine. N Engl J Med &#xa0;2019;380:1347&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pubmed">30943338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen AB, Thorsen-Meyer H-C, Belling K, Nielsen AP, Thomas CE, Chmura PJ &#xa0;et al. &#xa0;Survival prediction in intensive-care units based on aggregation of long-term disease history and acute physiology: a retrospective study of the Danish National Patient Registry and electronic patient records. Lancet Digit Heal &#xa0;2019;1:e78&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">33323232</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh RB, Schwartz JS, Navathe AS. &#xa0;Beyond genes and molecules &#x2013; a precision delivery initiative for precision medicine. N Engl J Med &#xa0;2017;376:1609&#x2013;1612</Citation><ArticleIdList><ArticleId IdType="pubmed">28445664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitka M. &#xa0;Data-based risk calculators becoming more sophisticated &#x2013; and more popular. JAMA &#xa0;2009;302:730&#x2013;731</Citation><ArticleIdList><ArticleId IdType="pubmed">19690297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ &#xa0;et al. &#xa0;Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform &#xa0;2015;216:574&#x2013;578</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V &#xa0;et al. &#xa0;Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A &#xa0;2016;113:7329&#x2013;7336</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. &#xa0;Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Informatics Assoc &#xa0;2018;25:969&#x2013;975</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, Ryan PB, Zou Y, Voss EA &#xa0;et al. &#xa0;Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS One &#xa0;2020;15:e0226718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>
Danish Colorectal Cancer Group (DCCG.dk). https://dccg.dk/. (accessed 20 August 2020)</Citation></Reference><Reference><Citation>Reps JM, Rijnbeek PR, Ryan PB. &#xa0;Identifying the DEAD: development and validation of a patient-level model to predict death status in population-level claims data. Drug Saf &#xa0;2019;42:1377&#x2013;1386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834730</ArticleId><ArticleId IdType="pubmed">31054141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gori M. &#xa0;Deep architectures. In: Katey Birtcher, Steve Merken, Peter Jardim (eds) Machine Learning: A Constraint-Based Approach &#xa0;(1st edn). Burlington, MA: Morgan Kaufmann Publishers, 2017, 236&#x2013;238</Citation></Reference><Reference><Citation>Bishop PM. In: Jordan M, Kleinberg J, Sch&#xf6;lkopf B (eds), Pattern Recognition and Machine Learning &#xa0;(1st edn). New York, NY: Springer Science+Buisness Media, 2006, 359&#x2013;418.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. &#xa0;Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul &#xa0;2013;23:1&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Guestrin C. &#xa0;XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD '16). New York, NY, USA: Association for Computing Machinery; &#xa0;2016: 785&#x2013;794.</Citation></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM. &#xa0;Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ &#xa0;2015;350:g7594.</Citation><ArticleIdList><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Comitee on Health Research Ethics
. What to Notify? &#xa0;https://en.nvk.dk/how-to-notify/what-to-notify (accessed 6 October 2020)</Citation></Reference><Reference><Citation>Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY &#xa0;et al. &#xa0;Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg &#xa0;2013;217:833&#x2013;842.e1-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805776</ArticleId><ArticleId IdType="pubmed">24055383</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani LC, Gutierrez CDS, Castro S. M D J, Zimmer RL, Diehl FP, Meyer LE &#xa0;et al. &#xa0;Derivation and validation of a preoperative risk model for postoperative mortality (SAMPE model): an approach to care stratification. PLoS One &#xa0;2017;12:e0187122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662221</ArticleId><ArticleId IdType="pubmed">29084236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawande AA, Kwaan MR, Regenbogen SE, Lipsitz SA, Zinner MJ. &#xa0;An Apgar score for surgery. J Am Coll Surg &#xa0;2007;204:201&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pubmed">17254923</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekkis PP, Prytherch DR, Kocher HM, Senapati A, Poloniecki JD, Stamatakis JD &#xa0;et al. &#xa0;Development of a dedicated risk-adjustment scoring system for colorectal surgery (colorectal POSSUM). Br J Surg &#xa0;2004;91:1174&#x2013;1182</Citation><ArticleIdList><ArticleId IdType="pubmed">15449270</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland GP, Jones D, Walters M. &#xa0;POSSUM: a scoring system for surgical audit. Br J Surg &#xa0;1991;78:355&#x2013;360</Citation><ArticleIdList><ArticleId IdType="pubmed">2021856</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries S, Jeffe DB, Davidson NO, Deshpande AD, Schootman M. &#xa0;Postoperative 30-day mortality in patients undergoing surgery for colorectal cancer: development of a prognostic model using administrative claims data. Cancer Causes Control &#xa0;2014;25:1503&#x2013;1512</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216620</ArticleId><ArticleId IdType="pubmed">25104569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazio VW, Tekkis PP, Remzi F, Lavery IC. &#xa0;Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum &#xa0;2004;47:2015&#x2013;2024</Citation><ArticleIdList><ArticleId IdType="pubmed">15657649</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. &#xa0;Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. JAMA &#xa0;2017;24:198&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi-Velez F, Perlis RH. &#xa0;Evaluating machine learning articles. JAMA &#xa0;2019;322:1777&#x2013;1779</Citation><ArticleIdList><ArticleId IdType="pubmed">31714974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappen TH, van Klei WA, van Wolfswinkel L, Kalkman CJ, Vergouwe Y, Moons KGM &#xa0;et al. &#xa0;Evaluating the impact of prediction models: lessons learned, challenges, and recommendations. Diagn Progn Res &#xa0;2018;2:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6460651</ArticleId><ArticleId IdType="pubmed">31093561</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker K, Finan PJ, Van Der Meulen JH. &#xa0;Model for risk adjustment of postoperative mortality in patients with colorectal cancer. Br J Surg &#xa0;2015;102:260&#x2013;280</Citation><ArticleIdList><ArticleId IdType="pubmed">25524216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingeholm P, G&#xf6;genur I, Iversen LH. &#xa0;Danish colorectal cancer group database. CLEP &#xa0;2016;8:465&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094575</ArticleId><ArticleId IdType="pubmed">27822086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33975825</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.</ArticleTitle><Pagination><StartPage>n1038</StartPage><MedlinePgn>n1038</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">n1038</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.n1038</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate the use of repurposed and adjuvant drugs in patients admitted to hospital with covid-19 across three continents.</AbstractText><AbstractText Label="DESIGN">Multinational network cohort study.</AbstractText><AbstractText Label="SETTING">Hospital electronic health records from the United States, Spain, and China, and nationwide claims data from South Korea.</AbstractText><AbstractText Label="PARTICIPANTS">303&#x2009;264 patients admitted to hospital with covid-19 from January 2020 to December 2020.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Prescriptions or dispensations of any drug on or 30 days after the date of hospital admission for covid-19.</AbstractText><AbstractText Label="RESULTS">Of the 303&#x2009;264 patients included, 290&#x2009;131 were from the US, 7599 from South Korea, 5230 from Spain, and 304 from China. 3455 drugs were identified. Common repurposed drugs were hydroxychloroquine (used in from &lt;5 (&lt;2%) patients in China to 2165 (85.1%) in Spain), azithromycin (from 15 (4.9%) in China to 1473 (57.9%) in Spain), combined lopinavir and ritonavir (from 156 (&lt;2%) in the VA-OMOP US to 2,652 (34.9%) in South Korea and 1285 (50.5%) in Spain), and umifenovir (0% in the US, South Korea, and Spain and 238 (78.3%) in China). Use of adjunctive drugs varied greatly, with the five most used treatments being enoxaparin, fluoroquinolones, ceftriaxone, vitamin D, and corticosteroids. Hydroxychloroquine use increased rapidly from March to April 2020 but declined steeply in May to June and remained low for the rest of the year. The use of dexamethasone and corticosteroids increased steadily during 2020.</AbstractText><AbstractText Label="CONCLUSIONS">Multiple drugs were used in the first few months of the covid-19 pandemic, with substantial geographical and temporal variation. Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir (in China only) were the most prescribed repurposed drugs. Antithrombotics, antibiotics, H2 receptor antagonists, and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of covid-19.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Yin Hui</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza City, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Excellence, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Tarrytown, NY, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Population Health, UNSW Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DHC Technologies, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Engineering, University of Arizona Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Sant Joan Desp&#xed;, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>DHC Technologies, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nanfang University, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nanfang University, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System, Salt Lake City, Utah, USA; Department&#x202f;of&#x202f;Internal&#x202f;Medicine, University of&#x202f;Utah&#x202f;School of&#x202f;Medicine, Salt&#x202f;Lake&#x202f;City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Tennessee&#x202f;Valley&#x202f;Healthcare&#x202f;System, VA&#x202f;Medical&#x202f;Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department&#x202f;of&#x202f;Biomedical&#x202f;Informatics,&#x202f;Vanderbilt&#x202f;University Medical&#x202f;Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department&#x202f;of&#x202f;Biomedical&#x202f;Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer Ce</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-9727-2138</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA ryan@ohdsi.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-16-2</RegistryNumber><NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>75J73V1629</RegistryNumber><NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>BMJ. 2021 May 21;373:n1277. doi: 10.1136/bmj.n1277.</RefSource><PMID Version="1">34020967</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000067575" MajorTopicYN="N">Administrative Claims, Healthcare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002443" MajorTopicYN="N">Ceftriaxone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="N">Fluoroquinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from Bill &amp; Melinda Gates Foundation for the submitted work; AP-U reports grants from Fundacion Alfonso Martin Escudero and the Medical Research Council, outside the submitted work; AGS reports personal fees from Janssen Research and Development, during the conduct of the study and personal fees from Janssen Research and Development, outside the submitted work; W-U-RA reports funding from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England; AG reports personal fees from Regeneron Pharmaceuticals and full time employment at Regeneron Pharmaceuticals, outside the submitted work; DRM reports funding support from the Wellcome Trust, NIHR, Scottish Chief Scientist Office, and Tenovus Scotland for research unrelated to this work; FN was an employee of AstraZeneca until 2019, before the conduct of this study, owns some AstraZeneca shares, and has other relationships or activities that could appear to have influenced the submitted work; VS reports funding from the US National Science Foundation, Agency for Healthcare Research and Quality through the University of Utah, and Arizona Board of Regents; DV reports personal fees from Bayer, outside the submitted work, and full time employment at Bayer; JC reports grants from the Korean Ministry of Health and Welfare and the Korean Ministry of Trade, Industry, and Energy, during the conduct of the study; SCY reports grants from the Korean Ministry of Health and Welfare and the Korean Ministry of Trade, Industry, and Energy, during the conduct of the study; PRR reports grants from Innovative Medicines Initiative and Janssen Research and Development, during the conduct of the study; GH reports grants from the US National Institutes of Health (NIH) National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work; CR is an employee of IQVIA; MAS reports grants from the US National Science Foundation, US NIH, and IQVIA, personal fees from Janssen Research and Development, during the conduct of the study; KK is an employee of IQVIA; PR is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson; DP-A reports grants and other from Amgen; grants, non-financial support, and other from UCB Biopharma; and grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of the Innovative Medicines Initiative (IMI) funded European Health Data and Evidence Network (EHDEN) and European Medical Information Framework (EMIF) consortiums, and Synapse Management Partners have supported training programmes organised by DP-A&#x2019;s department and are open for external participants.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33975825</ArticleId><ArticleId IdType="pmc">PMC8111167</ArticleId><ArticleId IdType="doi">10.1136/bmj.n1038</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University. 2020. https://coronavirus.jhu.edu/map.html.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. 10.1038/s41422-020-0282-0.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food &amp; Drug Administration (FDA). Coronavirus (COVID-19) update: FDA evokes emergency use authorization for chloroquine and hydroxychloroquine. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.</Citation></Reference><Reference><Citation>Horby P, Mafham M, Linsell L, et al. RECOVERY Collaborative Group . Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020;383:2030-40. 10.1056/NEJMoa2022926.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022926</ArticleId><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo AM, et al. WHO Solidarity Trial Consortium . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021;384:497-511. 10.1056/NEJMoa2023184.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 Study Group Members . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813-26. 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ 2020;370:m3379. 10.1136/bmj.m3379.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704. 10.1056/NEJMoa2021436.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Murthy S, Diaz JV, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020;324:1330-41. 10.1001/jama.2020.17023.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows. BMJ 2021;372:n433. 10.1136/bmj.n433.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n433</ArticleId><ArticleId IdType="pubmed">33574097</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea covid-19 Central Clinical Task Force 2020. Antimicrobial therapy recommendation.</Citation></Reference><Reference><Citation>Ministerio de Sanitarias (Madrid) 2020. Technical document on the clinical management of patients with novel coronavirus (COVID-19).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease. 2019 (COVID-19). 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.</Citation></Reference><Reference><Citation>World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: Interim guidance. 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.</Citation></Reference><Reference><Citation>National Health Commission of China. Diagnosis and treatment protocols for patients with novel coronavirus pneumonia. 2020. https://www.chinadaily.com.cn/pdf/2020/1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7.pdf.</Citation></Reference><Reference><Citation>Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ 2020;369:m1936. 10.1136/bmj.m1936.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1936</ArticleId><ArticleId IdType="pmc">PMC7249097</ArticleId><ArticleId IdType="pubmed">32457027</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553-64. 10.1093/jamia/ocu023.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>ohdsi-studies/Covid19CharacterizationCharybdis: Charybdis v1.1.1 - Publication Package [program]. 2020.</Citation></Reference><Reference><Citation>Prieto-Alhambra D, Kostka K, Duarte-Salles T, et al. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. <i>Res Sq</i> [preprint] 2021. 10.21203/rs.3.rs-279400/v1
</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-279400/v1</ArticleId><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. 2020.</Citation></Reference><Reference><Citation>Rho Y, Cho DY, Son Y, et al. COVID-19 International Collaborative Research by the Health Insurance Review and Assessment Service Using Its Nationwide Real-world Data: Database, Outcomes, and Implications. J Prev Med Public Health 2021;54:8-16. 10.3961/jpmph.20.616.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3961/jpmph.20.616</ArticleId><ArticleId IdType="pmc">PMC7939755</ArticleId><ArticleId IdType="pubmed">33618494</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health 2020;2:e286-7. 10.1016/S2589-7500(20)30086-8.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30086-8</ArticleId><ArticleId IdType="pmc">PMC7195288</ArticleId><ArticleId IdType="pubmed">32363333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;323:1824-36. 10.1001/jama.2020.6019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;395:1820. 10.1016/S0140-6736(20)31324-6.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31324-6</ArticleId><ArticleId IdType="pmc">PMC7274621</ArticleId><ArticleId IdType="pubmed">32511943</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. 10.1016/j.ijantimicag.2020.105949.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad S, Kilgore P, Chaudhry ZS, et al. Henry Ford COVID-19 Task Force . Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020;97:396-403. 10.1016/j.ijid.2020.06.099.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.06.099</ArticleId><ArticleId IdType="pmc">PMC7330574</ArticleId><ArticleId IdType="pubmed">32623082</ArticleId></ArticleIdList></Reference><Reference><Citation>
Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.
medRxiv [Preprint] https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.15.20151852v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Github. OHDSI/CommonDataModel - Drug Era (OMOP Common Data Model v6.0). 2018. <i>https://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:drug_era</i>
</Citation></Reference><Reference><Citation>Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Suissa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol Drug Saf 2019;29:3-7. 10.1002/pds.4722&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4722</ArticleId><ArticleId IdType="pubmed">30648307</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. &#x201c;Solidarity&#x201d; clinical trial for COVID-19 treatments. 2020. www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.</Citation></Reference><Reference><Citation>Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ 2020;369:m1936. 10.1136/bmj.m1936&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1936</ArticleId><ArticleId IdType="pmc">PMC7249097</ArticleId><ArticleId IdType="pubmed">32457027</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:605-12. 10.1016/S0140-6736(21)00149-5.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00149-5</ArticleId><ArticleId IdType="pmc">PMC7884931</ArticleId><ArticleId IdType="pubmed">33545096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x3b1;-ketoamide inhibitors. Science 2020;368:409-12. 10.1126/science.abb3405&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen FF, Zhong M, Liu Y, et al. The characteristics and outcomes of 681 severe cases with COVID-19 in China. J Crit Care 2020;60:32-7. 10.1016/j.jcrc.2020.07.003.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7340593</ArticleId><ArticleId IdType="pubmed">32736197</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Huang J, Fan Z, et al. Arbidol/IFN-&#x3b1;2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect 2020;22:200-5. 10.1016/j.micinf.2020.05.012.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7238991</ArticleId><ArticleId IdType="pubmed">32445881</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683-4. 10.1016/S0140-6736(20)30361-5&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30361-5</ArticleId><ArticleId IdType="pmc">PMC7159292</ArticleId><ArticleId IdType="pubmed">32122468</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5. 10.1016/S0140-6736(20)30317-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30317-2</ArticleId><ArticleId IdType="pmc">PMC7134694</ArticleId><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Societ&#xe0; Italiana di Malattie Infettive e Tropicali. 2020. [Therapeutic and supportive care guidelines for patients with COVID-19 coronavirus.] <i>h</i>
ttp://www.fvcalabria.unicz.it/COVID-19/LINEE-GUIDA/linee-guida-SIMIT-marzo-2020.pdf.</Citation></Reference><Reference><Citation>Horby P, Shen Lim W, Emberson J. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv [preprint] 2020. www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.22.20137273v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020;50:72-81. 10.1007/s11239-020-02138-z&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02138-z</ArticleId><ArticleId IdType="pmc">PMC7241581</ArticleId><ArticleId IdType="pubmed">32440883</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-6. 10.1111/jth.14810&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14810</ArticleId><ArticleId IdType="pmc">PMC9906133</ArticleId><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhopal R, Munro APS. Scholarly communications harmed by covid-19. BMJ 2021;372:n742. 10.1136/bmj.n742.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n742</ArticleId><ArticleId IdType="pubmed">33753356</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbian V, Solomonides A, Clarkson M, et al. Ethics and informatics in the age of COVID-19: challenges and recommendations for public health organization and public policy. J Am Med Inform Assoc 2021;28:184-9. 10.1093/jamia/ocaa188.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa188</ArticleId><ArticleId IdType="pmc">PMC7454584</ArticleId><ArticleId IdType="pubmed">32722749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33982938</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.</ArticleTitle><Pagination><StartPage>692</StartPage><EndPage>699</EndPage><MedlinePgn>692-699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000001153</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.</AbstractText><AbstractText Label="METHODS">We constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic health records. The study population was COVID-19 hospitalized patients aged 18 years or older. Famotidine, PPI, and hydroxychloroquine exposure groups were defined as patients dispensed any medication containing 1 of the 3 drugs on the day of admission. The famotidine nonuser group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient before or on the day of admission. Time at risk was defined based on the intention-to-treat principle starting 1 day after admission to 30 days after admission. For each study comparison group, we fit a propensity score model through large-scale regularized logistic regression. The outcome was modeled using a survival model.</AbstractText><AbstractText Label="RESULTS">We identified 2,193 users of PPI, 5,950 users of the hydroxychloroquine, 1,816 users of famotidine, and 26,820 nonfamotidine users. After propensity score stratification, the hazard ratios (HRs) for death were as follows: famotidine vs no famotidine HR 1.03 (0.89-1.18), vs PPIs: HR 1.14 (0.94-1.39), and vs hydroxychloroquine: 1.03 (0.85-1.24). Similar results were observed for the risk of death or intensive services use.</AbstractText><AbstractText Label="DISCUSSION">We found no evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used famotidine compared with those who did not or compared with PPI or hydroxychloroquine users.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1Janssen Research &amp; Development, LLC, Titusville, New Jersey, USA; 2Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen Patrick</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5QZO15J2Z8</RegistryNumber><NameOfSubstance UI="D015738">Famotidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015738" MajorTopicYN="N">Famotidine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>10</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33982938</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001153</ArticleId><ArticleId IdType="pii">00000434-202104000-00021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33987667</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Deep-learning-based automated terminology mapping in OMOP-CDM.</ArticleTitle><Pagination><StartPage>1489</StartPage><EndPage>1496</EndPage><MedlinePgn>1489-1496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab030</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Accessing medical data from multiple institutions is difficult owing to the interinstitutional diversity of vocabularies. Standardization schemes, such as the common data model, have been proposed as solutions to this problem, but such schemes require expensive human supervision. This study aims to construct a trainable system that can automate the process of semantic interinstitutional code mapping.</AbstractText><AbstractText Label="MATERIALS AND METHODS">To automate mapping between source and target codes, we compute the embedding-based semantic similarity between corresponding descriptive sentences. We also implement a systematic approach for preparing training data for similarity computation. Experimental results are compared to traditional word-based mappings.</AbstractText><AbstractText Label="RESULTS">The proposed model is compared against the state-of-the-art automated matching system, which is called Usagi, of the Observational Medical Outcomes Partnership common data model. By incorporating multiple negative training samples per positive sample, our semantic matching method significantly outperforms Usagi. Its matching accuracy is at least 10% greater than that of Usagi, and this trend is consistent across various top-k measurements.</AbstractText><AbstractText Label="DISCUSSION">The proposed deep learning-based mapping approach outperforms previous simple word-level matching algorithms because it can account for contextual and semantic information. Additionally, we demonstrate that the manner in which negative training samples are selected significantly affects the overall performance of the system.</AbstractText><AbstractText Label="CONCLUSION">Incorporating the semantics of code descriptions more significantly increases matching accuracy compared to traditional text co-occurrence-based approaches. The negative training sample collection methodology is also an important component of the proposed trainable system that can be adopted in both present and future related systems.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Byungkon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Computer Science, State University of New York, Incheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jisang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Graduate School of Information, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ha Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Graduate School of Information, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Sung Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Industrial and Management Engineering, Pohang University of Science and Technology, Pohang, North Gyeongsang,South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yourim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>RWE Analytics, EvidNet, Seongnam-si, Gyeonggi-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kam</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1522-4539</Identifier><AffiliationInfo><Affiliation>Healthcare, Life Solution Cluster, New Business Unit, Hanwha Life, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">automated mapping</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">deep-learning</Keyword><Keyword MajorTopicYN="N">embedding</Keyword><Keyword MajorTopicYN="N">terminology mapping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33987667</ArticleId><ArticleId IdType="pmc">PMC8279781</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab030</ArticleId><ArticleId IdType="pii">6275415</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMurry AJ, Murphy SN, MacFadden D, et al.SHRINE: enabling nationally scalable multi-site disease Studies. PLoS ONE 2013; 8 (3): e55811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591385</ArticleId><ArticleId IdType="pubmed">23533569</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrows EK, Razzaghi H, Utidjian L, et al.Standardizing clinical diagnoses: evaluating alternate terminology selection. AMIA Summits Transl Sci Proc 2020; 2020: 71&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233070</ArticleId><ArticleId IdType="pubmed">32477625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wermuth C, Verplaetse H. (2019). Medical terminology in the Western world: current situation. In: Alsulaiman A, Allaithy A, eds. Handbook of Terminology Volume2. Amsterdam, The Netherlands: John Benjamins Publishing; 2019: 84&#x2013;108.</Citation></Reference><Reference><Citation>Awaysheh A, Wilcke J, Elvinger F, et al.A review of medical terminology standards and structured reporting. J Vet Diagn Invest 2018; 30 (1): 17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6504145</ArticleId><ArticleId IdType="pubmed">29034813</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna D, Otero C, Gambarte ML, Frangella J. Terminology Services: Standard Terminologies to Control Medical Vocabulary. &#x201c;Words are Not What they Say but What they Mean.&#x201d; eHealth: Making Health Care Smarter, 2018. doi: 10.5772/intechopen.75781.</Citation></Reference><Reference><Citation>Klann JG, Phillips LC, Herrick C, et al.Web services for data warehouses: OMOP and PCORnet on i2b2. J Am Med Inform Associ 2018; 25 (10): 1331&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188504</ArticleId><ArticleId IdType="pubmed">30085008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabano DC, Cole E, Holve E, et al.Distributed data networks that support public health information needs. J Public Health Manag Pract 2017; 23 (6): 674&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28628584</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, et al.Evaluating common data models for use with a longitudinal community registry. Journal of Biomedical Informatics 2016; 64: 333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Joss MA, Embree K, et al.Data model harmonization for the All of Us Research Program: Transforming i2b2 data into the OMOP common data model. PloS One 2019; 14 (2): e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Candore G, Hedenmalm K, Slattery J, et al.Can we rely on results from IQVIA medical research data UK converted to the observational medical outcome partnership common data model? A validation study based on prescribing codeine in children. Clin Pharmacol Ther 2020; 107 (4): 915&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158210</ArticleId><ArticleId IdType="pubmed">31956997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Kim S, Yi S, et al.Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J Biomed Inform 2020; 107: 103459.</Citation><ArticleIdList><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>
https://www.ohdsi.org/data-standardization/the-common-data-model/Accessed July, 2020</Citation></Reference><Reference><Citation>Yoon D, Ahn EK, Park M, et al.Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res 2016; 22 (1): 54&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, et al.Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform 2020; 11 (01): 13&#x2013; 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch KE, Deppen SA, DuVall SL, et al.Incrementally transforming electronic medical records into the Observational Medical Outcomes Partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform 2019; 10 (05): 794&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>
https://www.ohdsi.org/software-tools/Accessed April, 2020</Citation></Reference><Reference><Citation>Mikolov T. Distributed representations of words and phrases and their compositionality. In proceedings of Advances in Neural Information Processing Systems2013.</Citation></Reference><Reference><Citation>Joulin A, Grave E, Bojanowski P, et al. Bag of tricks for efficient text classification. In proceedings of the Conference of the European Chapter of the Association for Computational Linguistics; April 3&#x2013;7, 2017; Valencia, Spain.</Citation></Reference><Reference><Citation>Peters M, Neumann M, Iyyer M, et al. Deep contextualized word representations. In proceedings of the Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies; June 1&#x2013;6, 2018; New Orleans.</Citation></Reference><Reference><Citation>Kiros R, Zhu Y, Salakhutdinov R, et al. Skip-thought vectors. In proceedings of Neural Information Processing Systems; December 7&#x2013;10, 2015; Montreal, Canada.</Citation></Reference><Reference><Citation>Devlin JC, Chang M-W, Lee K, et al. BERT: Pre-training of deep bidirectional transformers for language understanding. In Proceedings of the Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies; June 2&#x2013;7, 2019; Minneapolis.</Citation></Reference><Reference><Citation>Conneau A, Kiela D, Schwenk H, et al. Supervised learning of universal sentence representations from natural language inference data. In Proceedings of the Conference on Empirical Methods in Natural Language Processing;September 7&#x2013;11, 2017; Copenhagen, Denmark.</Citation></Reference><Reference><Citation>
https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html#fn20Accessed July, 2020</Citation></Reference><Reference><Citation>
https://athena.ohdsi.org/search-terms/startAccessed July, 2020</Citation></Reference><Reference><Citation>
Kim S, Park A, Cho S-Y, et al. Evaluation of a semi-automated code mapping and management system, OHDSI symposium 2019. https://www.ohdsi.org/2019-us-symposium-showcase-13/</Citation></Reference><Reference><Citation>Williams RJ, Hinton GE, Rumelhart DE.. Learning representations by back-propagating errors. Nature 1986; 323 (6088): 533&#x2013;6.</Citation></Reference><Reference><Citation>Hochreiter S, Schmidhuber J.. Long short-term memory. Neural Comput 1997; 9 (8): 1735&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9377276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington J, Socher R, Manning CD. GloVe: Global vectors for word representation. In proceedings of the Conference on Empirical Methods in Natural Language Processing; 2014; Doha, Qatar.</Citation></Reference><Reference><Citation>Bengio Y, Ducharme R, Vincent P, Janvin C.. A neural probabilistic language model. J Mach Learn Res 2003; 3: 1137&#x2013;55.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33993254</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Automated production of research data marts from a canonical fast healthcare interoperability resource data repository: applications to COVID-19 research.</ArticleTitle><Pagination><StartPage>1605</StartPage><EndPage>1611</EndPage><MedlinePgn>1605-1611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab108</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The rapidly evolving COVID-19 pandemic has created a need for timely data from the healthcare systems for research. To meet this need, several large new data consortia have been developed that require frequent updating and sharing of electronic health record (EHR) data in different common data models (CDMs) to create multi-institutional databases for research. Traditionally, each CDM has had a custom pipeline for extract, transform, and load operations for production and incremental updates of data feeds to the networks from raw EHR data. However, the demands of COVID-19 research for timely data are far higher, and the requirements for updating faster than previous collaborative research using national data networks have increased. New approaches need to be developed to address these demands.</AbstractText><AbstractText Label="METHODS">In this article, we describe the use of the Fast Healthcare Interoperability Resource (FHIR) data model as a canonical data model and the automated transformation of clinical data to the Patient-Centered Outcomes Research Network (PCORnet) and Observational Medical Outcomes Partnership (OMOP) CDMs for data sharing and research collaboration on COVID-19.</AbstractText><AbstractText Label="RESULTS">FHIR data resources could be transformed to operational PCORnet and OMOP CDMs with minimal production delays through a combination of real-time and postprocessing steps, leveraging the FHIR data subscription feature.</AbstractText><AbstractText Label="CONCLUSIONS">The approach leverages evolving standards for the availability of EHR data developed to facilitate data exchange under the 21st Century Cures Act and could greatly enhance the availability of standardized datasets for research.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lenert</LastName><ForeName>Leslie A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilatovskiy</LastName><ForeName>Andrey V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agnew</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Smile CDR, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudisill</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health Sciences South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weatherston</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Smile CDR, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deans</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Health Sciences South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Duke Endowment</Agency><Country/></Grant><Grant><Agency>Health Sciences South Carolina</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Mar 12:2021.03.11.21253384. doi: 10.1101/2021.03.11.21253384.</RefSource><PMID Version="1">33758877</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="N">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079803" MajorTopicYN="N">Data Management</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="Y">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">FHIR Subscription</Keyword><Keyword MajorTopicYN="N">Federated on FHIR architecture</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">PCORnet</Keyword><Keyword MajorTopicYN="N">data model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>16</Day><Hour>20</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33993254</ArticleId><ArticleId IdType="pmc">PMC8243354</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab108</ArticleId><ArticleId IdType="pii">6276433</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piller C. Disgraced COVID-19 studies are still routinely cited. Science 2021; 371: 331&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33479130</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al.; the N3C Consortium. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc 2021; 28 (3): 427&#x2013;43. doi:10.1093/jamia/ocaa196</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Visweswaran S, Becich MJ, D&#x2019;Itri VS, et al.Accrual to Clinical Trials (ACT): a clinical and translational science award consortium network. JAMIA Open 2018; 1: 147&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241502</ArticleId><ArticleId IdType="pubmed">30474072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Block JP, Marsolo KA, Nagavedu K, et al.Characteristics of 24,516 patients diagnosed with COVID-19 illness in a national clinical research network: results from PCORnet. bioRxiv 2020; doi:10.1101/2020.08.01.20163733.</Citation></Reference><Reference><Citation>PCORnet: Progress, challenges, and opportunities ahead. 2015. https://www.pcori.org/blog/pcornet-progress-challenges-and-opportunities-aheadAccessed November 24, 2019</Citation></Reference><Reference><Citation>TriNetX readies its real-world data platform and global network of healthcare organizations to support COVID-19 Clinical Research. 2020. https://trinetx.com/covid-19/Accessed January 31, 2021</Citation></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, et al.Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 2021; 8 (2): 130&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Sentinel System&#x2019;s Coronavirus (COVID-19) activities. 2020. https://www.sentinelinitiative.org/assessments/coronavirus-covid-19Accessed January 31, 2021</Citation></Reference><Reference><Citation>Brat GA, Weber GM, Gehlenborg N, et al.International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. NPJ Digit Med 2020; 3: 109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl KD, Gottlieb D, Mandel JC, et al.Push button population health: The SMART/HL7 FHIR bulk data access application programming interface. NPJ Digit Med 2020; 3 (1): 151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678833</ArticleId><ArticleId IdType="pubmed">33299056</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Core Data for Interoperability (USCDI) | Interoperability Standards Advisory (ISA). https://www.healthit.gov/isa/us-core-data-interoperability-uscdiAccessed November 24, 2019</Citation></Reference><Reference><Citation>Braunstein ML. SMART on FHIR. In: Health Informatics on FHIR: How HL7&#x2019;s New API is Transforming Healthcare. Cham, Switzerland: Springer; 2018: 205&#x2013;25. doi:10.1007/978-3-319-93414-3_10.</Citation></Reference><Reference><Citation>Braunstein ML. FHIR. In: Health Informatics on FHIR: How HL7&#x2019;s New API is Transforming Healthcare. Cham, Switzerland: Springer; 2018: 179&#x2013;203.</Citation></Reference><Reference><Citation>Azure API for FHIR. https://azure.microsoft.com/en-us/services/azure-api-for-fhir/Accessed February 14, 2021</Citation></Reference><Reference><Citation>Subscription - FHIR v4.0.1. https://www.hl7.org/fhir/subscription.htmlAccessed November 24, 2019.</Citation></Reference><Reference><Citation>Health Sciences South Carolina lights up a FHIR-based clinical data repository. 2018. https://www.healthcareitnews.com/news/health-sciences-south-carolina-lights-fhir-based-clinical-data-repositoryAccessed January 30, 2021</Citation></Reference><Reference><Citation>Mandel JC, Kreda DA, Mandl KD, et al.SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc 2016; 23: 899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997036</ArticleId><ArticleId IdType="pubmed">26911829</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Phillips LC, Herrick C, et al.Web services for data warehouses: OMOP and PCORnet on i2b2. J Am Med Inform Assoc 2018; 25: 1331&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188504</ArticleId><ArticleId IdType="pubmed">30085008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong TC, Kahn MG, Kwan BM, et al.Dynamic-ETL: a hybrid approach for health data extraction, transformation and loading. BMC Med Inform Decis Mak 2017; 17: 134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5598056</ArticleId><ArticleId IdType="pubmed">28903729</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M, Starr R, Duke J. . OMOP on FHIR as an enabler for analytics-as-a-service. Washington, DC: AMIA; 2017.</Citation></Reference><Reference><Citation>Pfaff ER, Champion J, Bradford RL, et al.Fast Healthcare Interoperability Resources (FHIR) as a meta model to integrate common data models: development of a tool and quantitative validation study. JMIR Med Inform 2019; 7: e15199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913576</ArticleId><ArticleId IdType="pubmed">31621639</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks J, Pardee R.. Learning to share health care data: a brief timeline of influential common data models and distributed health data networks in US Health Care Research. EGEMS (Wash DC) 2019; 7 (1): 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437693</ArticleId><ArticleId IdType="pubmed">30937326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34001114</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.</ArticleTitle><Pagination><StartPage>159</StartPage><MedlinePgn>159</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">159</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-021-01520-y</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adverse drug reactions (ADRs) are regarded as a major cause of death and a major contributor to public health costs. For the active surveillance of drug safety, the use of real-world data and real-world evidence as part of the overall pharmacovigilance process is important. In this regard, many studies apply the data-driven approaches to support pharmacovigilance. We developed a pharmacovigilance data-processing pipeline (PDP) that utilized electronic health records (EHR) and spontaneous reporting system (SRS) data to explore pharmacovigilance signals.</AbstractText><AbstractText Label="METHODS">To this end, we integrated two medical data sources: Konyang University Hospital (KYUH) EHR and the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). As part of the presented PDP, we converted EHR data on the Observation Medical Outcomes Partnership (OMOP) data model. To evaluate the ability of using the proposed PDP for pharmacovigilance purposes, we performed a statistical validation using drugs that induce ear disorders.</AbstractText><AbstractText Label="RESULTS">To validate the presented PDP, we extracted six drugs from the EHR that were significantly involved in ADRs causing ear disorders: nortriptyline, (hazard ratio [HR] 8.06, 95% CI 2.41-26.91); metoclopramide (HR 3.35, 95% CI 3.01-3.74); doxycycline (HR 1.73, 95% CI 1.14-2.62); digoxin (HR 1.60, 95% CI 1.08-2.38); acetaminophen (HR 1.59, 95% CI 1.47-1.72); and sucralfate (HR 1.21, 95% CI 1.06-1.38). In FAERS, the strongest associations were found for nortriptyline (reporting odds ratio [ROR] 1.94, 95% CI 1.73-2.16), sucralfate (ROR 1.22, 95% CI 1.01-1.45), doxycycline (ROR 1.30, 95% CI 1.20-1.40), and hydroxyzine (ROR 1.17, 95% CI 1.06-1.29). We confirmed the results in a meta-analysis using random and fixed models for doxycycline, hydroxyzine, metoclopramide, nortriptyline, and sucralfate.</AbstractText><AbstractText Label="CONCLUSIONS">The proposed PDP could support active surveillance and the strengthening of potential ADR signals via real-world data sources. In addition, the PDP was able to generate real-world evidence for drug safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Hyunah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Health Care Data Science Center, Konyang University Hospital, 158 Gwanjeo-dong-ro, Seo-gu, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suehyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0651-6481</Identifier><AffiliationInfo><Affiliation>Health Care Data Science Center, Konyang University Hospital, 158 Gwanjeo-dong-ro, Seo-gu, Daejeon, Republic of Korea. shleemedi@kyuh.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biomedical Informatics, Konyang University College of Medicine, 158 Gwanjeo-dong-ro, Seo-gu, Daejeon, Republic of Korea. shleemedi@kyuh.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADRs</Keyword><Keyword MajorTopicYN="N">CDM</Keyword><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">FAERS</Keyword><Keyword MajorTopicYN="N">PTA</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList><CoiStatement>The authors declare that they have no other competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34001114</ArticleId><ArticleId IdType="pmc">PMC8130307</ArticleId><ArticleId IdType="doi">10.1186/s12911-021-01520-y</ArticleId><ArticleId IdType="pii">10.1186/s12911-021-01520-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Intern Med. 2003;18:57&#x2013;60. doi: 10.1046/j.1525-1497.2003.20130.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2003.20130.x</ArticleId><ArticleId IdType="pmc">PMC1494803</ArticleId><ArticleId IdType="pubmed">12534765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med. 2008;358:637&#x2013;639. doi: 10.1056/nejme0708842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejme0708842</ArticleId><ArticleId IdType="pubmed">18256400</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidu MVS, Sushma DS, Jaiswal V, Asha S, Pal T. The role of advanced technologies supplemented with traditional methods in pharmacovigilance sciences. Recent Patents Biotechnol. 2020;14. https://doi.org/10.2174/1872208314666201021162704.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087036</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil JJ, Piccenna L, Ronaldson K, Ioannides-Demos LL. The value of patient-centred registries in phase IV drug surveillance. Pharmaceut Med. 2010;24:281&#x2013;288. doi: 10.1007/bf03256826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf03256826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-S, Kim JH. Proceed with caution when using real world data and real world evidence. J Korean Med Sci. 2019;34. https://doi.org/10.3346/jkms.2019.34.e28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345637</ArticleId><ArticleId IdType="pubmed">30686950</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2012;20:413&#x2013;419. doi: 10.1136/amiajnl-2012-000930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Suissa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol Drug Saf. 2019;29:3&#x2013;7. doi: 10.1002/pds.4722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4722</ArticleId><ArticleId IdType="pubmed">30648307</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, et al. A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015;38:749&#x2013;765. doi: 10.1007/s40264-015-0297-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0297-5</ArticleId><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho MJ, Kim SR, Park SH, Jang KS, Park BJ, Choi IY. Development common data model for adverse drug signal detection based on multi-center EMR systems. In: 2013 International conference on information science and applications (ICISA). IEEE; 2013. https://doi.org/10.1109/icisa.2013.6579355.</Citation></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119&#x2013;134. doi: 10.1007/s40264-012-0009-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho MJ, Kim SR, Park SH, Jang KS, Park BJ, Hong JY, et al. Common data model for decision support system of adverse drug reaction to extract knowledge from multi-center database. Inf Technol Manage. 2015;17:57&#x2013;66. doi: 10.1007/s10799-015-0240-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10799-015-0240-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990&#x2013;2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545&#x2013;1602. doi: 10.1016/s0140-6736(16)31678-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(16)31678-6</ArticleId><ArticleId IdType="pmc">PMC5055577</ArticleId><ArticleId IdType="pubmed">27733282</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, et al. Global costs of unaddressed hearing loss and cost-effectiveness of interventions: a WHO report, 2017. World Health Organization. 2017.</Citation></Reference><Reference><Citation>Shariff M. Analysis of hearing loss by pure tone audiometry in patients with chronic suppurative otitis media. Natl J Physiol Pharm Pharmacol. 2019;:1. https://doi.org/10.5455/njppp.2019.9.0308223032019.</Citation></Reference><Reference><Citation>Chow AHC, Cai T, McPherson B, Yang F. Otitis media with effusion in children: cross-frequency correlation in pure tone audiometry. PLoS ONE. 2019;14:e0221405. doi: 10.1371/journal.pone.0221405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0221405</ArticleId><ArticleId IdType="pmc">PMC6705822</ArticleId><ArticleId IdType="pubmed">31437206</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterloo BC, Homans NC, Baatenburg de Jong RJ, Ikram MA, Nagtegaal AP, Goedegebure A. Assessing hearing loss in older adults with a single question and person characteristics; Comparison with pure tone audiometry in the Rotterdam Study. PLOS ONE. 2020;15:e0228349. https://doi.org/10.1371/journal.pone.0228349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6984733</ArticleId><ArticleId IdType="pubmed">31986178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, et al. ADEpedia-on-OHDSI: a next generation pharmacovigilance signal detection platform using the OHDSI common data model. J Biomed Inform. 2019;91:103119. doi: 10.1016/j.jbi.2019.103119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103119</ArticleId><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796&#x2013;803. doi: 10.7150/ijms.6048.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.6048</ArticleId><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3. https://doi.org/10.1038/sdata.2016.26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015;14:248&#x2013;254. doi: 10.1016/j.jcf.2014.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2014.07.009</ArticleId><ArticleId IdType="pubmed">25127922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Choi J, Kim H-S, Kim GJ, Lee KH, Park CH, et al. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records. J Am Med Inform Assoc. 2017;24:697&#x2013;708. doi: 10.1093/jamia/ocw168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw168</ArticleId><ArticleId IdType="pmc">PMC7651894</ArticleId><ArticleId IdType="pubmed">28087585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med. 2003;163:2716. doi: 10.1001/archinte.163.22.2716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.22.2716</ArticleId><ArticleId IdType="pubmed">14662625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially inappropriate medication use in the community-dwelling elderly. JAMA. 2001;286:2823. doi: 10.1001/jama.286.22.2823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.22.2823</ArticleId><ArticleId IdType="pubmed">11735757</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH E. Clinical investigation of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). London, 2000;</Citation></Reference><Reference><Citation>Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 6. Hudson, OH: LexiComp, Inc; 1999.</Citation></Reference><Reference><Citation>Kliegman RM., et al. Nelson textbook of pediatrics e-book. Elsevier Health Sciences, 2007.</Citation></Reference><Reference><Citation>United Nations Department of Economic and Social Affairs. Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. [https://www.un.org/esa/coordination/CL-14-Final.for.Printing.pdf].</Citation></Reference><Reference><Citation>Ninan B, Wertheimer AI. Withdrawing drugs in the US versus other countries. 2012.</Citation></Reference><Reference><Citation>Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg. 2011;63:255&#x2013;259. doi: 10.1007/s12070-011-0151-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12070-011-0151-8</ArticleId><ArticleId IdType="pmc">PMC3138949</ArticleId><ArticleId IdType="pubmed">22754805</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3&#x2013;10. doi: 10.1002/pds.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res. 2007;226:221&#x2013;231. doi: 10.1016/j.heares.2006.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heares.2006.08.004</ArticleId><ArticleId IdType="pubmed">16973315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontopantelis E, Reeves D. Metaan: random-effects meta-analysis. Stata J: Promoting Commun Stat Stata. 2010;10:395&#x2013;407. doi: 10.1177/1536867x1001000307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867x1001000307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MD, Sakai CS, Dobie RA, Katon WJ. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol. 1989;98:867&#x2013;872. doi: 10.1177/000348948909801107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000348948909801107</ArticleId><ArticleId IdType="pubmed">2817678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan M. A randomized trial of nortriptyline for severe chronic tinnitus. Arch Intern Med. 1993;153:2251. doi: 10.1001/archinte.1993.00410190091011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1993.00410190091011</ArticleId><ArticleId IdType="pubmed">8215728</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldo P, Doree C, Molin P, McFerran D, Cecco S. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev. 2012 doi: 10.1002/14651858.cd003853.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.cd003853.pub3</ArticleId><ArticleId IdType="pmc">PMC7156891</ArticleId><ArticleId IdType="pubmed">22972065</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinnitus: http://www.health.kr/Menu.PharmReview/View.asp?PharmReview_IDX=2800</Citation></Reference><Reference><Citation>Zhang X, Duan R, Du J, Huang J, Chen Y, Tao C. Comparing pharmacovigilance outcomes between FAERS and EMR data for acute mania patients. In: 2018 IEEE international conference on healthcare informatics workshop (ICHI-W). IEEE; 2018. https://doi.org/10.1109/ichi-w.2018.00018.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34030640</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Applied comparison of large-scale propensity score matching and cardinality matching for causal inference in observational research.</ArticleTitle><Pagination><StartPage>109</StartPage><MedlinePgn>109</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-021-01282-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cardinality matching (CM), a novel matching technique, finds the largest matched sample meeting prespecified balance criteria thereby overcoming limitations of propensity score matching (PSM) associated with limited covariate overlap, which are especially pronounced in studies with small sample sizes. The current study proposes a framework for large-scale CM (LS-CM); and compares large-scale PSM (LS-PSM) and LS-CM in terms of post-match sample size, covariate balance and residual confounding at progressively smaller sample sizes.</AbstractText><AbstractText Label="METHODS">Evaluation of LS-PSM and LS-CM within a comparative cohort study of new users of angiotensin-converting enzyme inhibitor (ACEI) and thiazide or thiazide-like diuretic monotherapy identified from a U.S. insurance claims database. Candidate covariates included patient demographics, and all observed prior conditions, drug exposures and procedures. Propensity scores were calculated using LASSO regression, and candidate covariates with non-zero beta coefficients in the propensity model were defined as matching covariates for use in LS-CM. One-to-one matching was performed using progressively tighter parameter settings. Covariate balance was assessed using standardized mean differences. Hazard ratios for negative control outcomes perceived as unassociated with treatment (i.e., true hazard ratio of 1) were estimated using unconditional Cox models. Residual confounding was assessed using the expected systematic error of the empirical null distribution of negative control effect estimates compared to the ground truth. To simulate diverse research conditions, analyses were repeated within 10&#x2009;%, 1 and 0.5&#x2009;% subsample groups with increasingly limited covariate overlap.</AbstractText><AbstractText Label="RESULTS">A total of 172,117 patients (ACEI: 129,078; thiazide: 43,039) met the study criteria. As compared to LS-PSM, LS-CM was associated with increased sample retention. Although LS-PSM achieved balance across all matching covariates within the full study population, substantial matching covariate imbalance was observed within the 1 and 0.5&#x2009;% subsample groups. Meanwhile, LS-CM achieved matching covariate balance across all analyses. LS-PSM was associated with better candidate covariate balance within the full study population. Otherwise, both matching techniques achieved comparable candidate covariate balance and expected systematic error.</AbstractText><AbstractText Label="CONCLUSIONS">LS-CM found the largest matched sample meeting prespecified balance criteria while achieving comparable candidate covariate balance and residual confounding. We recommend LS-CM as an alternative to LS-PSM in studies with small sample sizes or limited covariate overlap.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Janssen R&amp;D, LLC, Raritan, NJ, USA. stephenfortin12@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen R&amp;D, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>BMC Med Res Methodol. 2021 Aug 21;21(1):174. doi: 10.1186/s12874-021-01365-z.</RefSource><PMID Version="1">34418962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACEI</Keyword><Keyword MajorTopicYN="N">Balance</Keyword><Keyword MajorTopicYN="N">Cardinality matching</Keyword><Keyword MajorTopicYN="N">Causal inference</Keyword><Keyword MajorTopicYN="N">Diuretic</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Propensity score matching</Keyword><Keyword MajorTopicYN="N">Residual bias</Keyword><Keyword MajorTopicYN="N">Sample size</Keyword><Keyword MajorTopicYN="N">Systematic error</Keyword></KeywordList><CoiStatement>SPF, SSJ and MS are employees of Johnson &amp; Johnson and Janssen R&amp;D, LLC, a subsidiary of Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34030640</ArticleId><ArticleId IdType="pmc">PMC8146256</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01282-1</ArticleId><ArticleId IdType="pii">10.1186/s12874-021-01282-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armitage P. The role of randomization in clinical trials. Stat Med. 1982;1(4):345&#x2013;52. doi: 10.1002/sim.4780010412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780010412</ArticleId><ArticleId IdType="pubmed">7187102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn HF. Philosophy of inferences from retrospective studies. Am J Public Health Nations Health. 1953;43(6 Pt 1):677&#x2013;83. doi: 10.2105/ajph.43.6_pt_1.677.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.43.6_pt_1.677</ArticleId><ArticleId IdType="pmc">PMC1620309</ArticleId><ArticleId IdType="pubmed">13040587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran WG, Rubin DB. Controlling bias in observational studies: A review. Sankhya Ser A. 1973;35:417&#x2013;46.</Citation></Reference><Reference><Citation>Visconti G, Zubizarreta J. Handling Limited Overlap in Observational Studies with Cardinality Matching. Observational Studies. 2018;4:217&#x2013;49. doi: 10.1353/obs.2018.0012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1353/obs.2018.0012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR. Design of observational studies. New York: Springer-Verlag; 2010.</Citation></Reference><Reference><Citation>Crump RK, Hotz VJ, Imbens GW, Mitnik OA. Dealing with limited overlap in estimation of average treatment effects. Biometrika. 2009;96(1):187&#x2013;99. doi: 10.1093/biomet/asn055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asn055</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothe C. Robust confidence intervals for average treatment effects under limited overlap. Econometrica. 2017;85:645&#x2013;60. doi: 10.3982/ECTA13141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3982/ECTA13141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. BMC Med Res Methodol. 2012;12:70. doi: 10.1186/1471-2288-12-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-12-70</ArticleId><ArticleId IdType="pmc">PMC3511219</ArticleId><ArticleId IdType="pubmed">22646911</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2013;14. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>De Los Angeles Resa M, Zubizarreta JR. Evaluation of subset matching methods and forms of covariate balance. Stat Med. 2016;35(27):4961&#x2013;79. doi: 10.1002/sim.7036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7036</ArticleId><ArticleId IdType="pubmed">27442072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;18. doi: 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35(22):3883&#x2013;8. doi: 10.1002/sim.6977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. (2019). The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI.</Citation></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;26. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426&#x2013;83. doi: 10.1161/CIR.0000000000000597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000597</ArticleId><ArticleId IdType="pubmed">30354655</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives, J Clin Epidemiol, 1993, vol.&#xa0;46 10(pg. 1075&#x2013;1079).</Citation><ArticleIdList><ArticleId IdType="pubmed">8410092</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810070</ArticleId><ArticleId IdType="pubmed">18197741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864&#x2013;70. doi: 10.1001/jama.285.22.2864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.285.22.2864</ArticleId><ArticleId IdType="pubmed">11401607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263&#x2013;72. doi: 10.1378/chest.09-1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-1584</ArticleId><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001 (165):1339&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC81628</ArticleId><ArticleId IdType="pubmed">11760981</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub HADES. Health analytics data-to-evidence suite. https://ohdsi.githu.io/Hades/. Accessed Aug 4, 2020.</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. The American Statistician. 1985;39(1):33&#x2013;8. doi: 10.1080/00031305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss AE, Boyce RD, Ryan PB, van der Lei J, Rijbbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81. doi: 10.1016/j.jbi.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115(11):2571&#x2013;7. doi: 10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34032695</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Seasonal variation of peptic ulcer disease, peptic ulcer bleeding, and acute pancreatitis: A nationwide population-based study using a common data model.</ArticleTitle><Pagination><StartPage>e25820</StartPage><MedlinePgn>e25820</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25820</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000025820</ELocationID><Abstract><AbstractText>Although gastrointestinal diseases are reported at various times throughout the year, some particular seasons are associated with a higher incidence of these diseases. This study aimed to identify the seasonal variations of peptic ulcer (PU), peptic ulcer bleeding (PUB), and acute pancreatitis (AP) in South Korea.We conducted a retrospective, observational cohort study of all subjects aged &gt;18 years between 2012 and 2016 using the Health Insurance Review and Assessment-National Patient Samples database, previously converted to the standardized Observational Medical Outcomes Partnership-Common Data Model. We assessed the overall seasonal variations of PU, PUB, and AP and further analyzed seasonal variations according to age and sex subgroups.In total, 14,626 patients with PU, 3575 with PUB, and 9023 with AP were analyzed for 5 years. A clear seasonal variation was noted in PU, with the highest incidence rate during winter, the second highest during spring, the third highest during summer, and the lowest incidence during autumn for 5 years (P&#x200a;&lt;&#x200a;.001). PUB also showed significant seasonal fluctuations, with winter peak for 4 years, except 1 year, which had a spring peak (P&#x200a;&lt;&#x200a;.001). However, AP showed no clear seasonal variations (P&#x200a;=&#x200a;.090). No significant differences in the seasonal variation of PU, PUB, and AP were observed according to sex and age subgroups (&lt;60 years vs &#x2265;60 years).Seasonal variation of PU and PUB should be considered when determining allocation of available health care resources.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jin Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology, Kyung Hee University Hospital at Gang Dong, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jae Myung</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ha Il</ForeName><Initials>HI</Initials></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Min Seob</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062665" MajorTopicYN="N">Epidemiological Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010437" MajorTopicYN="N">Peptic Ulcer</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010438" MajorTopicYN="N">Peptic Ulcer Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34032695</ArticleId><ArticleId IdType="pmc">PMC8154390</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000025820</ArticleId><ArticleId IdType="pii">00005792-202105280-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fares A. Global patterns of seasonal variation in gastrointestinal diseases. J Postgrad Med 2013;59:203&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24029198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangbar B, Rhee P, Pandit V, et al. . Seasonal variation in emergency general surgery. Ann Surg 2016;263:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">25876008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikaheimo TM. Cardiovascular diseases, cold exposure and exercise. Temperature (Austin) 2018;5:123&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204981</ArticleId><ArticleId IdType="pubmed">30377633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins CR, Celli B, Anderson JA, et al. . Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012;39:38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley DJ, Wolfe F, Lue FA, Moldofsky H. Seasonal symptom severity in patients with rheumatic diseases: a study of 1,424 patients. J Rheumatol 2001;28:1900&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11508598</ArticleId></ArticleIdList></Reference><Reference><Citation>Danai PA, Sinha S, Moss M, Haber MJ, Martin GS. Seasonal variation in the epidemiology of sepsis. Crit Care Med 2007;35:410&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanska DJ, Hoffmann RG. Seasonal variation in stroke mortality rates. Neurology 1999;52:984&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102417</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckova M, Fahrenbruch CE, Cobb LA, Hallstrom AP. Weekly and seasonal variation in the incidence of cardiac arrests. Am Heart J 1999;137:512&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Xirasagar S, Lin HC, Chen CS. Role of meteorological factors in duodenal ulcer seasonality: a nation-wide, population-based study. J Gen Intern Med 2007;22:1439&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2305852</ArticleId><ArticleId IdType="pubmed">17668271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanotra R, Ahmed M, Patel N, et al. . Seasonal variations and trends in hospitalization for peptic ulcer disease in the United States: a 12-year analysis of the nationwide inpatient sample. Cureus 2016;8:e854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5130352</ArticleId><ArticleId IdType="pubmed">27909642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Cepero JM, Lopez-Silva ME, Amaya-Vidal A, et al. . Influence of climatic factors on the incidence of upper gastrointestinal bleeding. Gastroenterol Hepatol 2005;28:540&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16277960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallerani M, Boari B, Salmi R, Manfredini R. Seasonal variation in the onset of acute pancreatitis. World J Gastroenterol 2004;10:3328&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4572305</ArticleId><ArticleId IdType="pubmed">15484310</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M, Bologna A, Ursini F, et al. . Chronobiology of acute pancreatitis in a single Italian centre. Eur Rev Med Pharmacol Sci 2020;24:1988&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">32141567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian JV, Somasundaram A, Ramalingam S, Jayanthi V. Peptic ulcer disease in India--a 16 year trend analysis. Trop Gastroenterol 2010;31:260&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21568140</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredini R, De Giorgio R, Smolensky MH, et al. . Seasonal pattern of peptic ulcer hospitalizations: analysis of the hospital discharge data of the Emilia-Romagna region of Italy. BMC Gastroenterol 2010;10:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873599</ArticleId><ArticleId IdType="pubmed">20398297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sezgin O, Altintas E, Tombak A. Effects of seasonal variations on acute upper gastrointestinal bleeding and its etiology. Turk J Gastroenterol 2007;18:172&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17891690</ArticleId></ArticleIdList></Reference><Reference><Citation>Du T, Lewin MR, Wang H, et al. . Circadian and seasonal rhythms of acute upper gastrointestinal bleeding in Beijing. Emerg Med J 2010;27:504&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20515908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzen H, Musmann E, Kottas M, et al. . Acute gastrointestinal bleeding cases presenting to the emergency department are associated with age, sex and seasonal and circadian factors. Eur J Gastroenterol Hepatol 2017;29:78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">27662496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan XG, Xie C, Chen J, Xie Y, Zhang KH, Lu NH. Seasonal changes in gastric mucosal factors associated with peptic ulcer bleeding. Exp Ther Med 2015;9:125&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4247295</ArticleId><ArticleId IdType="pubmed">25452787</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts SE, Akbari A, Thorne K, Atkinson M, Evans PA. The incidence of acute pancreatitis: impact of social deprivation, alcohol consumption, seasonal and demographic factors. Aliment Pharmacol Ther 2013;38:539&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489350</ArticleId><ArticleId IdType="pubmed">23859492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertilsson S, Hakansson A, Kalaitzakis E. Acute pancreatitis: impact of alcohol consumption and seasonal factors. Alcohol Alcohol 2017;52:383&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28430933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Tang M, Zhao Y, et al. . Impact of seasons and festivals on the onset of acute pancreatitis in Shanghai, China. Pancreas 2017;46:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">28196016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017;32:718&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med 2008;359:928&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18753649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermansson M, Ekedahl A, Ranstam J, et al. . Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol 2009;9:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679757</ArticleId><ArticleId IdType="pubmed">19379513</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CJ, Lin CY. Seasonal changes in symptomatic duodenal ulcer activity in Taiwan: a comparison between subjects with and without haemorrhage. J Intern Med 1998;244:405&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Pal LS. Seasonal behaviour of healed duodenal ulcer. J Indian Med Assoc 1998;96:106&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9844330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendahan J, Gilboa S, Paran H, et al. . Seasonal pattern in the incidence of bleeding caused by peptic ulcer in Israel. Am J Gastroenterol 1992;87:733&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590310</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino V, Mela GS, Zentilin P, et al. . Are duodenal ulcer seasonal fluctuations paralleled by seasonal changes in 24-hour gastric acidity and Helicobacter pylori infection? J Clin Gastroenterol 1996;22:178&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8724253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostensen H, Gudmundsen TE, Burhol PG, Bonnevie O. Seasonal periodicity of peptic ulcer disease. A prospective radiologic study. Scand J Gastroenterol 1985;20:1281&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">4095498</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008;22:209&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18346679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmann C, Imhof M, Ruppert C, et al. . Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005;40:914&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16165708</ArticleId></ArticleIdList></Reference><Reference><Citation>Loperfido S, Baldo V, Piovesana E, et al. . Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 2009;70:212&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19409558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. . Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;104:1633&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19574968</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015;30:559&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4578017</ArticleId><ArticleId IdType="pubmed">26354049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarnawski AS, Ahluwalia A, Jones MK. The mechanisms of gastric mucosal injury: focus on microvascular endothelium as a key target. Curr Med Chem 2012;19:04&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T, Ohkusa T, Araki A, et al. . Influence of climatic factors in the incidence of upper gastrointestinal bleeding. J Gastroenterol Hepatol 2001;16:619&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422613</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksson AE, Edman AC, Nilsson I, Bergqvist D, Wadstrom T. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol 1998;33:1030&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829355</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschka C, Schorr W, Koch HJ. Is there seasonal periodicity in the prevalence of Helicobacter pylori? Chronobiol Int 1999;16:811&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10584180</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshkowitz M, Konikoff FM, Arber N, et al. . Seasonal variation in the frequency of Helicobacter pylori infection: a possible cause of the seasonal occurrence of peptic ulcer disease. Am J Gastroenterol 1994;89:731&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8172147</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B, Xia HH, Ma CW, et al. . Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther 2005;22:243&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16091062</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillip V, Huber W, Hagemes F, et al. . Incidence of acute pancreatitis does not increase during Oktoberfest, but is higher than previously described in Germany. Clin Gastroenterol Hepatol 2011;9:995&#x2013;1000.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21723238</ArticleId></ArticleIdList></Reference><Reference><Citation>Raty S, Sand J, Alho H, Nordback I. Alcoholic, but not biliary, pancreatitis varies seasonally in occurrence. Scand J Gastroenterol 2003;38:794&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankisch PG, Assmus C, Pflichthofer D. The calendar and acute pancreatitis. Pancreas 1998;16:465&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9598805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, et al. . Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:542&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, et al. . Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS One 2020;15:e0226718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042637</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Pharmacovigilance and Clinical Environment: Utilizing OMOP-CDM and OHDSI Software Stack to Integrate EHR Data.</ArticleTitle><Pagination><StartPage>555</StartPage><EndPage>559</EndPage><MedlinePgn>555-559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210232</ELocationID><Abstract><AbstractText>Information Technology (IT) and specialized systems could have a prominent role towards the support of drug safety processes, both in the clinical context but also beyond that. PVClinical project aims to build an IT platform, enabling the investigation of potential Adverse Drug Reactions (ADRs). In this paper, we outline the utilization of Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM) and the openly available Observational Health Data Sciences and Informatics (OHDSI) software stack as part of PVClinical platform. OMOP-CDM offers the capacity to integrate data from Electronic Health Records (EHRs) (e.g., encounters, patients, providers, diagnoses, drugs, measurements and procedures) via an accepted data model. Furthermore, the OHDSI software stack provides valuable analytics tools which could be used to address important questions regarding drug safety quickly and efficiently, enabling the investigation of potential ADRs in the clinical environment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dimitriadis</LastName><ForeName>Vlasios K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research &amp; Technology Hellas, Thermi, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavriilidis</LastName><ForeName>George I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research &amp; Technology Hellas, Thermi, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natsiavas</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research &amp; Technology Hellas, Thermi, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse Drug Reactions</Keyword><Keyword MajorTopicYN="N">Drug Safety</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042637</ArticleId><ArticleId IdType="doi">10.3233/SHTI210232</ArticleId><ArticleId IdType="pii">SHTI210232</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042721</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Adaption of the OMOP CDM for Rare Diseases.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>142</EndPage><MedlinePgn>138-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210136</ELocationID><Abstract><AbstractText>The OMOP Common Data Model (OMOP CDM) is an option to store patient data and to use these in an international context. Up to now, rare diseases can only be partly described in OMOP CDM. Therefore, it is necessary to investigate which special features in the context of rare diseases (e.g. terminologies) have to be considered, how these can be included in OMOP CDM and how physicians can use the data. An interdisciplinary team developed (1) a Transition Database for Rare Diseases by mapping Orpha Code, Alpha ID, SNOMED, ICD-10-GM, ICD-10-WHO and OMOP-conform concepts; and (2) a Rare Diseases Dashboard for physicians of a German Center of Rare Diseases by using methods of user-centered design. This demonstrated how OMOP CDM can be flexibly extended for different medical issues by using independent tools for mappings and visualization. Thereby, the adaption of OMOP CDM allows for international collaboration, enables (distributed) analysis of patient data and thus it can improve the care of people with rare diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gierschner</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruhl</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leutner</LastName><ForeName>Liz A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="Y">Rare Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="Y">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dashboard</Keyword><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Rare Diseases</Keyword><Keyword MajorTopicYN="N">Secondary Data Use</Keyword><Keyword MajorTopicYN="N">Transition Database</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042721</ArticleId><ArticleId IdType="doi">10.3233/SHTI210136</ArticleId><ArticleId IdType="pii">SHTI210136</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042723</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Potential Role of Clinical Trial Eligibility Criteria in Electronic Phenotyping.</ArticleTitle><Pagination><StartPage>148</StartPage><EndPage>152</EndPage><MedlinePgn>148-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210138</ELocationID><Abstract><AbstractText>2,719 distinctive phenotyping variables from 176 electronic phenotypes were compared with 57,150 distinctive clinical trial eligibility criteria concepts to assess the phenotype knowledge overlap between them. We observed a high percentage (69.5%) of eMERGE phenotype features and a lower percentage (47.6%) of OHDSI phenotype features matched to clinical trial eligibility criteria, possibly due to the relative emphasis on specificity for eMERGE phenotypes and the relative emphasis on sensitivity for OHDSI phenotypes. The study results show the potential of reusing clinical trial eligibility criteria for phenotyping feature selection and moderate benefits of using them for local cohort query implementation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhehuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004581" MajorTopicYN="N">Electronics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Trial Eligibility Criteria</Keyword><Keyword MajorTopicYN="N">Electronic Phenotyping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042723</ArticleId><ArticleId IdType="doi">10.3233/SHTI210138</ArticleId><ArticleId IdType="pii">SHTI210138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042737</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Automated Generation of Individual and Population Clinical Pathways with the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>218</StartPage><EndPage>222</EndPage><MedlinePgn>218-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210152</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Clinical pathways represents the sequence of interventions from which the patients benefit during their encounters with health care structures. There are several complex issues which make it difficult to represent these pathways (e.g. high numbers of patients, heterogeneity of variables).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed a tool to automate the representation of clinical pathways, from an individual and population points of view, and based on the OMOP CDM. The tool implemented the Sankey diagram in three stages: (i) data extraction, (ii) generation of individual sequence of steps and (iii) aggregation of sequence to obtain the population-level diagram. We tested the tool with three surgery procedures: the total hip replacement, the coronary bypass and the transcatheter aortic valve implantation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The tool provided different ways of visualizing pathways depending on the question asked: a pathway before a surgery, the pathway of deceased patients or the complete pathway with different steps of interest.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">We proposed a tool automating the representation of the clinical pathways, and reducing complexity of visualization. Representations are detailed from an individual and population points of view. It has been tested with three surgical procedures. The tool functionalities will be extended to cover a greater number of use cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boudis</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Analyse et Traitement de l'information m&#xe9;dicale, F-59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Facult&#xe9; Ing&#xe9;nierie et Management de la Sant&#xe9;, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clement</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Analyse et Traitement de l'information m&#xe9;dicale, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruandet</LastName><ForeName>Amelie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Analyse et Traitement de l'information m&#xe9;dicale, F-59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des Pratiques m&#xe9;dicales, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Analyse et Traitement de l'information m&#xe9;dicale, F-59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Facult&#xe9; Ing&#xe9;nierie et Management de la Sant&#xe9;, F-59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des Pratiques m&#xe9;dicales, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D019091" MajorTopicYN="Y">Critical Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data reuse</Keyword><Keyword MajorTopicYN="N">Data visualization</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Pathway</Keyword><Keyword MajorTopicYN="N">Sankey diagram</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042737</ArticleId><ArticleId IdType="doi">10.3233/SHTI210152</ArticleId><ArticleId IdType="pii">SHTI210152</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042774</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>From OpenEHR to FHIR and OMOP Data Model for Microbiology Findings.</ArticleTitle><Pagination><StartPage>402</StartPage><EndPage>406</EndPage><MedlinePgn>402-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210189</ELocationID><Abstract><AbstractText>HiGHmed is a German Consortium where eight University Hospitals have agreed to the cross-institutional data exchange through novel medical informatics solutions. The HiGHmed Use Case Infection Control group has modelled a set of infection-related data in the openEHR format. In order to establish interoperability with the other German Consortia belonging to the same national initiative, we mapped the openEHR information to the Fast Healthcare Interoperability Resources (FHIR) format recommended within the initiative. FHIR enables fast exchange of data thanks to the discrete and independent data elements into which information is organized. Furthermore, to explore the possibility of maximizing analysis capabilities for our data set, we subsequently mapped the FHIR elements to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). The OMOP data model is designed to support the conduct of research to identify and evaluate associations between interventions and outcomes caused by these interventions. Mapping across standard allows to exploit their peculiarities while establishing and/or maintaining interoperability. This article provides an overview of our experience in mapping infection control related data across three different standards openEHR, FHIR and OMOP CDM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thun</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">mapping</Keyword><Keyword MajorTopicYN="N">microbiology</Keyword><Keyword MajorTopicYN="N">openEHR</Keyword><Keyword MajorTopicYN="N">standard</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042774</ArticleId><ArticleId IdType="doi">10.3233/SHTI210189</ArticleId><ArticleId IdType="pii">SHTI210189</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042878</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>278</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>HIStream-Import: A Generic ETL Framework for Processing Arbitrary Patient Data Collections or Hospital Information Systems into HL7 FHIR Bundles.</ArticleTitle><Pagination><StartPage>75</StartPage><EndPage>79</EndPage><MedlinePgn>75-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210053</ELocationID><Abstract><AbstractText>Data integration is a necessary and important step to perform translational research and improve the sample size beyond single data collections. For health information, the most recent established communication standards is HL7 FHIR. To bridge the concepts of "minimal invasive" data integration and open standards, we propose a generic ETL framework to process arbitrary patient related data collections into HL7 FHIR - which in turn can then be used for loading into target data warehouses. The proposed algorithm is able to read any relational delimited text exports and produce a standard HL7 FHIR bundle collection. We evaluated an implementation of the algorithm using different lung research registries and used the resulting FHIR resources to fill our i2b2 based data warehouse as well an OMOP common data model repository.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majeed</LastName><ForeName>Raphael W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Universities Gie&#xdf;en and Marburg Lung Center (UGMLC), Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Informatics, Medical Faculty of RWTH University Aachen, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;hr</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Universities Gie&#xdf;en and Marburg Lung Center (UGMLC), Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universities Gie&#xdf;en and Marburg Lung Center (UGMLC), Giessen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="N">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006751" MajorTopicYN="Y">Hospital Information Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data integration</Keyword><Keyword MajorTopicYN="N">factual databases</Keyword><Keyword MajorTopicYN="N">standardization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042878</ArticleId><ArticleId IdType="doi">10.3233/SHTI210053</ArticleId><ArticleId IdType="pii">SHTI210053</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34042902</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>278</Volume><PubDate><Year>2021</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Accessing OMOP Common Data Model Repositories with the i2b2 Webclient - Algorithm for Automatic Query Translation.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>259</EndPage><MedlinePgn>251-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210077</ELocationID><Abstract><AbstractText>In the era of translational research, data integration and clinical data warehouses are important enabling technologies for clinical researchers. The OMOP common data model is a wide-spread choice as a target for data integration in medical informatics. It's portability of queries and analyses across different institutions and data are ideal also from the viewpoint of the FAIR principles. Yet, the OMOP CDM lacks a simple and intuitive user interface for untrained users to run simple queries for feasibility analysis. Aim of this study is to provide an algorithm to translate any given i2b2 query to an equivalent query which can then be run on the OMOP CDM database. The provided algorithm is able to convert queries created in the i2b2 webclient to SQL statements which can be executed on a standard OMOP CDM database programmatically.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majeed</LastName><ForeName>Raphael W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Universities Giessen and Marburg Lung Center (UGMLC), German Centre For Lung Research (DZL), Justus-Liebig University Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Informatics, Medical Faculty of RWTH Aachen University, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Justus-Liebig University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universities Giessen and Marburg Lung Center (UGMLC), German Centre For Lung Research (DZL), Justus-Liebig University Giessen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="Y">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data integration</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">factual databases</Keyword><Keyword MajorTopicYN="N">i2b2</Keyword><Keyword MajorTopicYN="N">standardization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34042902</ArticleId><ArticleId IdType="doi">10.3233/SHTI210077</ArticleId><ArticleId IdType="pii">SHTI210077</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34049958</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2020042929</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2020-042929</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children and adolescents diagnosed or hospitalized with coronavirus disease 2019 (COVID-19) and to compare them in secondary analyses with patients diagnosed with previous seasonal influenza in 2017-2018.</AbstractText><AbstractText Label="METHODS">International network cohort using real-world data from European primary care records (France, Germany, and Spain), South Korean claims and US claims, and hospital databases. We included children and adolescents diagnosed and/or hospitalized with COVID-19 at age &lt;18 between January and June 2020. We described baseline demographics, comorbidities, symptoms, 30-day in-hospital treatments, and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome, multisystem inflammatory syndrome in children, and death.</AbstractText><AbstractText Label="RESULTS">A total of 242&#x2009;158 children and adolescents diagnosed and 9769 hospitalized with COVID-19 and 2&#x2009;084&#x2009;180 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were more common among those hospitalized with versus diagnosed with COVID-19. Dyspnea, bronchiolitis, anosmia, and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-19 included repurposed medications (&lt;10%) and adjunctive therapies: systemic corticosteroids (6.8%-7.6%), famotidine (9.0%-28.1%), and antithrombotics such as aspirin (2.0%-21.4%), heparin (2.2%-18.1%), and enoxaparin (2.8%-14.8%). Hospitalization was observed in 0.3% to 1.3% of the cohort diagnosed with COVID-19, with undetectable (<i>n</i> &lt; 5 per database) 30-day fatality. Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 than influenza.</AbstractText><AbstractText Label="CONCLUSIONS">Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza. Dyspnea, anosmia, and gastrointestinal symptoms could help differentiate diagnoses. A wide range of medications was used for the inpatient management of pediatric COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Sant Joan Despi, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Yin Hui</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, St Luke's Campus, University of Exeter, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Medication Safety Research, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, Ajou University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Salt Lake City, Utah.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Utah, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Tarrytown, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DHC Technologies, Co, Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lister Hill National Center for Biomedical Communications, National Library of Medicine, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iveli</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bayer AG, Wuppertal, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Data Science to Patient Value Program, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Sant Joan Despi, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Sant Joan Despi, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>DHC Technologies, Co, Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2020 Oct 30:2020.10.29.20222083. doi: 10.1101/2020.10.29.20222083.</RefSource><PMID Version="1">33140074</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34049958</ArticleId><ArticleId IdType="doi">10.1542/peds.2020-042929</ArticleId><ArticleId IdType="pii">peds.2020-042929</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34057426</PMID><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Privacy Risks of Personal Health Identifiers and Quasi-Identifiers in a Distributed Research Network: Development and Validation Study.</ArticleTitle><Pagination><StartPage>e24940</StartPage><MedlinePgn>e24940</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e24940</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/24940</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Privacy should be protected in medical data that include patient information. A distributed research network (DRN) is one of the challenges in privacy protection and in the encouragement of multi-institutional clinical research. A DRN standardizes multi-institutional data into a common structure and terminology called a common data model (CDM), and it only shares analysis results. It is necessary to measure how a DRN protects patient information privacy even without sharing data in practice.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to quantify the privacy risk of a DRN by comparing different deidentification levels focusing on personal health identifiers (PHIs) and quasi-identifiers (QIs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We detected PHIs and QIs in an Observational Medical Outcomes Partnership (OMOP) CDM as threatening privacy, based on 18 Health Insurance Portability and Accountability Act of 1996 (HIPPA) identifiers and previous studies. To compare the privacy risk according to the different privacy policies, we generated limited and safe harbor data sets based on 16 PHIs and 12 QIs as threatening privacy from the Synthetic Public Use File 5 Percent (SynPUF5PCT) data set, which is a public data set of the OMOP CDM. With minimum cell size and equivalence class methods, we measured the privacy risk reduction with a trust differential gap obtained by comparing the two data sets. We also measured the gap in randomly sampled records from the two data sets to adjust the number of PHI or QI records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The gaps averaged 31.448% and 73.798% for PHIs and QIs, respectively, with a minimum cell size of one, which represents a unique record in a data set. Among PHIs, the national provider identifier had the highest gap of 71.236% (71.244% and 0.007% in the limited and safe harbor data sets, respectively). The maximum size of the equivalence class, which has the largest size of an indistinguishable set of records, averaged 771. In 1000 random samples of PHIs, Device_exposure_start_date had the highest gap of 33.730% (87.705% and 53.975% in the data sets). Among QIs, Death had the highest gap of 99.212% (99.997% and 0.784% in the data sets). In 1000, 10,000, and 100,000 random samples of QIs, Device_treatment had the highest gaps of 12.980% (99.980% and 87.000% in the data sets), 60.118% (99.831% and 39.713%), and 93.597% (98.805% and 5.207%), respectively, and in 1 million random samples, Death had the highest gap of 99.063% (99.998% and 0.934% in the data sets).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study, we verified and quantified the privacy risk of PHIs and QIs in the DRN. Although this study used limited PHIs and QIs for verification, the privacy limitations found in this study could be used as a quality measurement index for deidentification of multi-institutional collaboration research, thereby increasing DRN safety.</AbstractText><CopyrightInformation>&#xa9;SeHee Oh, MinDong Sung, Yumie Rhee, Namki Hong, Yu Rang Park. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 31.05.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>SeHee</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0975-4709</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>MinDong</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5217-8877</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Yumie</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4227-5638</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Namki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8246-1956</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yu Rang</ForeName><Initials>YR</Initials><Identifier Source="ORCID">0000-0002-4210-2094</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership common data model</Keyword><Keyword MajorTopicYN="N">distributed research network</Keyword><Keyword MajorTopicYN="N">personal health identifier</Keyword><Keyword MajorTopicYN="N">privacy risk quantification</Keyword><Keyword MajorTopicYN="N">quasi-identifier</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>31</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34057426</ArticleId><ArticleId IdType="pmc">PMC8204238</ArticleId><ArticleId IdType="doi">10.2196/24940</ArticleId><ArticleId IdType="pii">v9i5e24940</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NIH Collaboratory Distributed Research Network (DRN) Rethinking Clinical Trials.  [2020-08-01].   https://rethinkingclinicaltrials.org/nih-collaboratory-drn/</Citation></Reference><Reference><Citation>Passerat-Palmbach J, Farnan T, McCoy M, Harris JD, Manion ST, Flannery HL, Gleim B. Blockchain-orchestrated machine learning for privacy preserving federated learning in electronic health data. 2020 IEEE International Conference on Blockchain (Blockchain); November 2-6, 2020; Rhodes, Greece. 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/Blockchain50366.2020.00080</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheu A, Smith A, Ullman J, Zeber D, Zhilyaev M. Distributed Differential Privacy via Shuffling. In: Ishai Y, Rijmen V, editors. Advances in Cryptology &#x2013; EUROCRYPT 2019. EUROCRYPT 2019. Lecture Notes in Computer Science, vol 11476. Cham: Springer; 2019. pp. 375&#x2013;403.</Citation></Reference><Reference><Citation>Kone&#x10d;n&#xfd; J, McMahan HB, Yu FX, Richt&#xe1;rik P, Suresh AT, Bacon D. Federated Learning: Strategies for Improving Communication Efficiency. arXiv. 2016.  [2021-05-22].   https://arxiv.org/abs/1610.05492.</Citation></Reference><Reference><Citation>Rieke N, Hancox J, Li W, Milletar&#xec; F, Roth HR, Albarqouni S, Bakas S, Galtier MN, Landman BA, Maier-Hein K, Ourselin S, Sheller M, Summers RM, Trask A, Xu D, Baust M, Cardoso MJ. The future of digital health with federated learning. NPJ Digit Med. 2020 Sep 14;3(1):119&#x2013;7. doi: 10.1038/s41746-020-00323-1. doi: 10.1038/s41746-020-00323-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="pmc">PMC7490367</ArticleId><ArticleId IdType="pubmed">33015372</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachenko O, Weinert C, Schneider T, Hamacher K. Large-Scale Privacy-Preserving Statistical Computations for Distributed Genome-Wide Association Studies. ASIACCS '18: Proceedings of the 2018 Asia Conference on Computer and Communications Security; 2018 Asia Conference on Computer and Communications Security; June 2018; Incheon, Republic of Korea. 2018. pp. 221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/3196494.3196541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomsett R, Chan K, Chakraborty S. Model poisoning attacks against distributed machine learning systems. Proceedings Volume 11006, Artificial Intelligence and Machine Learning for Multi-Domain Operations Applications; Artificial Intelligence and Machine Learning for Multi-Domain Operations Applications; 2019; Baltimore, MD. 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/12.2520275</ArticleId></ArticleIdList></Reference><Reference><Citation>Takabi D, Podschwadt R, Druce J, Wu C, Procopio K. Privacy preserving Neural Network Inference on Encrypted Data with GPUs. arXiv. 2019.  [2021-05-22].   https://arxiv.org/abs/1911.11377.</Citation></Reference><Reference><Citation>Dahl M, Mancuso J, Dupis Y, Decoste B, Giraud M, Livingstone I, Patriquin J, Uhma G. Private Machine Learning in TensorFlow using Secure Computation. arXiv. 2018.  [2021-05-22].   https://arxiv.org/abs/1810.08130.</Citation></Reference><Reference><Citation>Kaissis GA, Makowski MR, R&#xfc;ckert D, Braren RF. Secure, privacy-preserving and federated machine learning in medical imaging. Nat Mach Intell. 2020 Jun 8;2(6):305&#x2013;311. doi: 10.1038/s42256-020-0186-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-020-0186-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem M, Taheri S, Yuan J. Utilizing Transfer Learning and Homomorphic Encryption in a Privacy Preserving and Secure Biometric Recognition System. Computers. 2018 Dec 29;8(1):3&#x2013;24. doi: 10.3390/computers8010003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/computers8010003</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F, Robbins S, Denton J, Nookala L, Meeker D, Ohno-Machado L, Matheny M. Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform. 2017 Dec 19;06(03):536&#x2013;547. doi: 10.4338/aci-2014-12-cr-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/aci-2014-12-cr-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us Research Program: Transforming i2b2 data into the OMOP common data model. PLoS One. 2019 Feb 19;14(2):e0212463&#x2013;13. doi: 10.1371/journal.pone.0212463.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gujarathi G, Ma Y. Parametric CAD/CAE integration using a common data model. Journal of Manufacturing Systems. 2011 Aug;30(3):118&#x2013;132. doi: 10.1016/j.jmsy.2011.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmsy.2011.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Saver JL, Warach S, Janis S, Odenkirchen J, Becker K, Benavente O, Broderick J, Dromerick AW, Duncan P, Elkind MS, Johnston K, Kidwell CS, Meschia JF, Schwamm L. Standardizing the Structure of Stroke Clinical and Epidemiologic Research Data. Stroke. 2012 Apr;43(4):967&#x2013;973. doi: 10.1161/strokeaha.111.634352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/strokeaha.111.634352</ArticleId><ArticleId IdType="pmc">PMC3493110</ArticleId><ArticleId IdType="pubmed">22308239</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan 01;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamo L, Browe D, Logan H, Kim K. Patient informed governance of distributed research networks: results and discussion from six patient focus groups. AMIA Annu Symp Proc. 2013;2013:920&#x2013;9.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900224</ArticleId><ArticleId IdType="pubmed">24551383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Data. The National Patient-Centered Clinical Research Network.  [2020-08-01].   https://pcornet.org/data/</Citation></Reference><Reference><Citation>Ji H, Kim S, Yi S, Hwang H, Kim J, Yoo S. Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J Biomed Inform. 2020 Jul;107:103459&#x2013;7. doi: 10.1016/j.jbi.2020.103459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103459</ArticleId><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Timbie J, Rudin R, Towe V, Chen E, Hunter L, Case S, Kotzias V, Predmore Z, Moen S, Ridgely MS. National Patient-Centered Clinical Research Network (PCORnet) Phase I: Final Evaluation Report. RAND.  [2021-05-22].   https://www.rand.org/pubs/research_reports/RR1191.html.</Citation></Reference><Reference><Citation>Martin-Sanchez FJ, Aguiar-Pulido V, Lopez-Campos GH, Peek N, Sacchi L. Secondary Use and Analysis of Big Data Collected for Patient Care. Yearb Med Inform. 2017 Aug 19;26(01):28&#x2013;37. doi: 10.1055/s-0037-1606529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1606529</ArticleId><ArticleId IdType="pmc">PMC6239231</ArticleId><ArticleId IdType="pubmed">28480474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Steele A, Blanton M. PICCO: a general-purpose compiler for private distributed computation. CCS '13: Proceedings of the 2013 ACM SIGSAC Conference on Computer &amp; Communications Security; 2013 ACM SIGSAC Conference on Computer &amp; Communications Security; November 2013; Berlin, Germany. 2013. pp. 813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2508859.2516752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Blanton M, Almashaqbeh G. Secure distributed genome analysis for GWAS and sequence comparison computation. BMC Med Inform Decis Mak. 2015 Dec 21;15(S5):1&#x2013;12. doi: 10.1186/1472-6947-15-s5-s4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-15-s5-s4</ArticleId><ArticleId IdType="pmc">PMC4699166</ArticleId><ArticleId IdType="pubmed">26733307</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubovitskaya A, Urovi V, Vasirani M, Aberer K, Schumacher M. A Cloud-Based eHealth Architecture for Privacy Preserving Data Integration. In: Federrath H, Gollmann D, editors. ICT Systems Security and Privacy Protection. SEC 2015. IFIP Advances in Information and Communication Technology, vol 455. Cham: Springer; 2015. pp. 585&#x2013;598.</Citation></Reference><Reference><Citation>Kho A, Cashy J, Jackson K, Pah A, Goel S, Boehnke J, Humphries JE, Kominers SD, Hota BN, Sims SA, Malin BA, French DD, Walunas TL, Meltzer DO, Kaleba EO, Jones RC, Galanter WL. Design and implementation of a privacy preserving electronic health record linkage tool in Chicago. J Am Med Inform Assoc. 2015 Sep;22(5):1072&#x2013;80. doi: 10.1093/jamia/ocv038.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv038</ArticleId><ArticleId IdType="pmc">PMC5009931</ArticleId><ArticleId IdType="pubmed">26104741</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Chu H, Lien C, Hsiao C, Kao T. Privacy preservation and information security protection for patients' portable electronic health records. Comput Biol Med. 2009 Sep;39(9):743&#x2013;50. doi: 10.1016/j.compbiomed.2009.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2009.06.004</ArticleId><ArticleId IdType="pubmed">19589509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahi MA, Abbas H, Saleem K, Yang X, Derhab A, Orgun MA, Iqbal W, Rashid I, Yaseen A. Privacy Preservation in e-Healthcare Environments: State of the Art and Future Directions. IEEE Access. 2018 Oct;6:464&#x2013;478. doi: 10.1109/access.2017.2767561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/access.2017.2767561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol K, Kim Y, Lee E, Seo Y, Baik D. Privacy-Preserving Attribute-Based Access Control Model for XML-Based Electronic Health Record System. IEEE Access. 2018 Feb 5;6:9114&#x2013;9128. doi: 10.1109/access.2018.2800288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/access.2018.2800288</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C. Chapter 4 The Common Data Model. The Book of OHDSI.  [2020-08-01].   https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html.</Citation></Reference><Reference><Citation>Lee S, You SC, Park J, Cho J, Borel S, El Emam K, Park RW. OMOP-CDM Conversion and Anonymization of National Health Insurance Service-National Sample Cohort. Observational Health Data Sciences and Informatics. 2019.  [2021-05-22].   https://www.ohdsi.org/2019-us-symposium-showcase-17/</Citation></Reference><Reference><Citation>Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. U.S. Department of Health &amp; Human Services. 2015.  [2020-08-01].   https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html.</Citation></Reference><Reference><Citation>Wiley DC, Cory AC, editors. Encyclopedia of School Health. Thousand Oaks, CA: SAGE Publications, Inc; 2013. Health Insurance Portability and Accountability Act.</Citation></Reference><Reference><Citation>Murphy SN, Gainer V, Mendis M, Churchill S, Kohane I. Strategies for maintaining patient privacy in i2b2. J Am Med Inform Assoc. 2011 Dec 01;18 Suppl 1(Supplement 1):i103&#x2013;8. doi: 10.1136/amiajnl-2011-000316.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000316</ArticleId><ArticleId IdType="pmc">PMC3241166</ArticleId><ArticleId IdType="pubmed">21984588</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D. Data management system having a common database infrastructure. Google Patents. 2008.  [2021-05-22].   https://patents.google.com/patent/US20040054675.</Citation></Reference><Reference><Citation>Olivier MS. Database privacy. SIGKDD Explor. Newsl. 2002 Dec;4(2):20&#x2013;27. doi: 10.1145/772862.772866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/772862.772866</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum A, Ligett K, Roth A. A learning theory approach to noninteractive database privacy. J. ACM. 2013 Apr;60(2):1&#x2013;25. doi: 10.1145/2450142.2450148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2450142.2450148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist T, Brandt P. Prometheus: Differential Privacy in the OMOP CDM. University of Washington. 2018.  [2021-05-22].   https://courses.cs.washington.edu/courses/cse544/18wi/project/examples-successful-projects/psbrandt.pdf.</Citation></Reference><Reference><Citation>Slavic A, Cordeiro M. Sharing and re-use of classification systems: the need for a common data model. The University of Arizona Libraries. 2005.  [2021-05-22].   https://repository.arizona.edu/handle/10150/105132.</Citation></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Wash DC) 2014 Nov 11;2(1):1110&#x2013;10. doi: 10.13063/2327-9214.1110.  </Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1110</ArticleId><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganslandt T, Mate S, Helbing K, Sax U, Prokosch H. Unlocking Data for Clinical Research &#x2013; The German i2b2 Experience. Appl Clin Inform. 2017 Dec 16;02(01):116&#x2013;117. doi: 10.4338/aci-2010-09-cr-0051.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/aci-2010-09-cr-0051</ArticleId><ArticleId IdType="pmc">PMC3631913</ArticleId><ArticleId IdType="pubmed">23616864</ArticleId></ArticleIdList></Reference><Reference><Citation>Liyanage H, Liaw S, Jonnagaddala J, Hinton W, de Lusignan S. Common Data Models (CDMs) to Enhance International Big Data Analytics: A Diabetes Use Case to Compare Three CDMs. Stud Health Technol Inform. 2018;255:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30306907</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisaro JL, Choi G, Pradervand S, Colsenet R, Jacquemont N, Rosat N, Mooser V, Hubaux J. Protecting Privacy and Security of Genomic Data in i2b2 With Homomorphic Encryption and Differential Privacy. IEEE/ACM Trans. Comput. Biol. and Bioinf. 2018:1&#x2013;1. doi: 10.1109/tcbb.2018.2854782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/tcbb.2018.2854782</ArticleId><ArticleId IdType="pubmed">30004884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney L. k-anonymity: A model for protecting privacy. Int. J. Unc. Fuzz. Knowl. Based Syst. 2012 May 02;10(05):557&#x2013;570. doi: 10.1142/s0218488502001648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/s0218488502001648</ArticleId></ArticleIdList></Reference><Reference><Citation>Machanavajjhala A, Gehrke J, Kifer D, Venkitasubramaniam M. L-diversity: privacy beyond k-anonymity. 22nd International Conference on Data Engineering (ICDE'06); April 3-7, 2006; Atlanta, GA. 2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/icde.2006.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Li T, Venkatasubramanian S. t-Closeness: Privacy Beyond k-Anonymity and l-Diversity. 2007 IEEE 23rd International Conference on Data Engineering; April 15-20, 2007; Istanbul, Turkey. 2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/icde.2007.367856</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin SJ, You SC, Park YR, Roh J, Kim J, Haam S, Reich CG, Blacketer C, Son D, Oh S, Park RW. Genomic Common Data Model for Seamless Interoperation of Biomedical Data in Clinical Practice: Retrospective Study. J Med Internet Res. 2019 Mar 26;21(3):e13249. doi: 10.2196/13249.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13249</ArticleId><ArticleId IdType="pmc">PMC6454347</ArticleId><ArticleId IdType="pubmed">30912749</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/CommonDataModel. GitHub.  [2020-08-01].   https://github.com/OHDSI/CommonDataModel/wiki.</Citation></Reference><Reference><Citation>CMS 2008-2010 Data Entrepreneurs&#x2019; Synthetic Public Use File (DE-SynPUF) U.S. Centers for Medicare &amp; Medicaid Services.  [2020-08-01].   https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/DE_Syn_PUF.</Citation></Reference><Reference><Citation>Data Standardization. Observational Health Data Sciences and Informatics.  [2020-08-01].   https://ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>OHDSI Google Drive.  [2020-08-01].   https://drive.google.com/file/d/18EjMxyA6NsqBo9eed_Gab1ESHWPxJygz/view.</Citation></Reference><Reference><Citation>El Emam K, Arbuckle L, Koru G, Eze B, Gaudette L, Neri E, Rose S, Howard J, Gluck J. De-identification methods for open health data: the case of the Heritage Health Prize claims dataset. J Med Internet Res. 2012 Feb 27;14(1):e33. doi: 10.2196/jmir.2001.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.2001</ArticleId><ArticleId IdType="pmc">PMC3374547</ArticleId><ArticleId IdType="pubmed">22370452</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, Wang S, Wang L, Liu C, Wang J, Guo Q, Zheng H, Xie K, Wang C, Hui Z. Evaluation of Privacy Risks of Patients' Data in China: Case Study. JMIR Med Inform. 2020 Feb 05;8(2):e13046. doi: 10.2196/13046.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13046</ArticleId><ArticleId IdType="pmc">PMC7055805</ArticleId><ArticleId IdType="pubmed">32022691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez K, Malin K. Evaluating re-identification risks with respect to the HIPAA privacy rule. J Am Med Inform Assoc. 2010;17(2):169&#x2013;77. doi: 10.1136/jamia.2009.000026.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000026</ArticleId><ArticleId IdType="pmc">PMC3000773</ArticleId><ArticleId IdType="pubmed">20190059</ArticleId></ArticleIdList></Reference><Reference><Citation>Garfinkel SL. De-Identification of Personal Information. National Institute of Standards and Technology. 2015.  [2021-05-17].   https://nvlpubs.nist.gov/nistpubs/ir/2015/NIST.IR.8053.pdf.</Citation></Reference><Reference><Citation>Committee on Strategies for Responsible Sharing of Clinical Trial Data. Board on Health Sciences Policy. Institute of Medicine . Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: National Academies Press (US); 2015. Concepts and Methods for De-identifying Clinical Trial Data.</Citation><ArticleIdList><ArticleId IdType="pubmed">25590113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YJ, Lee KH. What are the optimum quasi-identifiers to re-identify medical records?. 20th International Conference on Advanced Communication Technology (ICACT); February 11-14, 2018; Chuncheon, Korea (South). 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.23919/icact.2018.8323926</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition and DDLs for the OMOP Common Data Model (CDM) GitHub.  [2020-08-01].   https://github.com/OHDSI/CommonDataModel/tree/v5.2.2.</Citation></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013 Feb 4;36(2):119&#x2013;34. doi: 10.1007/s40264-012-0009-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, Weng C. An OMOP CDM-Based Relational Database of Clinical Research Eligibility Criteria. Stud Health Technol Inform. 2017;245:950&#x2013;954.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893219</ArticleId><ArticleId IdType="pubmed">29295240</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksberg B, Oskotsky B, Thangaraj P, Giangreco N, Badgeley M, Johnson K, Datta D, Rudrapatna VA, Rappoport N, Shervey MM, Miotto R, Goldstein TC, Rutenberg E, Frazier R, Lee N, Israni S, Larsen R, Percha B, Li L, Dudley JT, Tatonetti NP, Butte AJ. PatientExploreR: an extensible application for dynamic visualization of patient clinical history from electronic health records in the OMOP common data model. Bioinformatics. 2019 Nov 01;35(21):4515&#x2013;4518. doi: 10.1093/bioinformatics/btz409.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz409</ArticleId><ArticleId IdType="pmc">PMC6821222</ArticleId><ArticleId IdType="pubmed">31214700</ArticleId></ArticleIdList></Reference><Reference><Citation>Karr AF, Feng J, Lin X, Sanil AP, Young SS, Reiter JP. Secure analysis of distributed chemical databases without data integration. J Comput Aided Mol Des. 2005 Nov 3;19(9-10):739&#x2013;47. doi: 10.1007/s10822-005-9011-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-005-9011-5</ArticleId><ArticleId IdType="pubmed">16267693</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo-Ferrer J. Microaggregation for Database and Location Privacy. In: Etzion O, Kuflik T, Motro A, editors. Next Generation Information Technologies and Systems. NGITS 2006. Lecture Notes in Computer Science, vol 4032. Berlin, Heidelberg: Springer; 2006. pp. 106&#x2013;116.</Citation></Reference><Reference><Citation>Raab M, Steger A. &#x201c;Balls into Bins&#x201d; &#x2014; A Simple and Tight Analysis. In: Luby M, Rolim JDP, Serna M, editors. Randomization and Approximation Techniques in Computer Science. RANDOM 1998. Lecture Notes in Computer Science, vol 1518. Berlin, Heidelberg: Springer; 1998. pp. 159&#x2013;170.</Citation></Reference><Reference><Citation>Shin S, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, Lee M, Choi C, Kim W, Lee JH. A De-identification method for bilingual clinical texts of various note types. J Korean Med Sci. 2015 Jan;30(1):7&#x2013;15. doi: 10.3346/jkms.2015.30.1.7.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2015.30.1.7</ArticleId><ArticleId IdType="pmc">PMC4278030</ArticleId><ArticleId IdType="pubmed">25552878</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdalla M, Abdalla M, Rudzicz F, Hirst G. Using word embeddings to improve the privacy of clinical notes. J Am Med Inform Assoc. 2020 Jun 01;27(6):901&#x2013;907. doi: 10.1093/jamia/ocaa038.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa038</ArticleId><ArticleId IdType="pmc">PMC7309261</ArticleId><ArticleId IdType="pubmed">32388549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34068814</PMID><DateRevised><Year>2021</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Risk of Osteoporosis and Osteoporotic Fracture Following the Use of Irritable Bowel Syndrome Medical Treatment: An Analysis Using the OMOP CDM Database.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2044</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm10092044</ELocationID><Abstract><AbstractText>Patients with irritable bowel syndrome (IBS) are at increased risk of osteoporosis and osteoporotic fracture. This study investigated whether IBS medication attenuated the rate of osteoporosis and osteoporotic fracture risk. We conducted a retrospective large-scale multicenter study across eight hospital databases encoded in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The primary outcome was the incidence of osteoporosis, whereas secondary outcomes were osteoporotic fractures. After 1:4 matching, 24,723 IBS patients, 78,318 non-IBS patients, 427,640 non-IBS patients with IBS medication, and 827,954 non-IBS patients without IBS medication were selected. The risk of osteoporosis was significantly increased in the IBS group compared to the non-IBS group (hazard ratio (HR) 1.33; confidence interval (CI) 1.17~1.51). Even in patients who were not diagnosed with IBS, the risk of osteoporosis was significantly increased in those with IBS medication compared to those without (HR 1.77, CI 1.62~1.93). The risk of osteoporotic fracture was significantly increased in the IBS medication group (HR 1.69, CI 1.55~1.84). Patients exposed to IBS treatment even without IBS diagnosis were at increased risk of osteoporosis and osteoporotic fracture. Early diagnosis and treatment of osteoporosis should be considered in patients who have received medication for IBS symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Gyu Lee</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0003-2825-0629</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yu Hyeon</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0002-1786-2737</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hye Rim</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinmi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6715-0447</Identifier><AffiliationInfo><Affiliation>Clinical Trial Center, Department of Biostatistics, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Youngmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yun Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeong Gyu</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tak</LastName><ForeName>Young Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung Hun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang Yeoup</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-3585-9910</Identifier><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Family Medicine Clinic, Obesity, Metabolism and Nutrition Center Pusan National University Yangsan Hospital, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Youn Hye</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0003-2176-6227</Identifier><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Family Medicine Clinic, Obesity, Metabolism and Nutrition Center Pusan National University Yangsan Hospital, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Eun Ju</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-2415-8243</Identifier><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Family Medicine Clinic, Obesity, Metabolism and Nutrition Center Pusan National University Yangsan Hospital, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Youngin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pusan National University School of Medicine, Yangsan 50612, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Family Medicine Clinic, Obesity, Metabolism and Nutrition Center Pusan National University Yangsan Hospital, Yangsan 50612, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Biomedical Research Institute Grant (2019B029)</GrantID><Agency>PUSAN NATIONAL UNIVERSITY HOSPITAL</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">osteoporosis</Keyword><Keyword MajorTopicYN="N">treatment for IBS</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34068814</ArticleId><ArticleId IdType="pmc">PMC8126251</ArticleId><ArticleId IdType="doi">10.3390/jcm10092044</ArticleId><ArticleId IdType="pii">jcm10092044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wongtrakul W., Charoenngam N., Ungprasert P. The association between irritable bowel syndrome and osteoporosis: A systematic review and meta-analysis. Osteoporos. Int. 2020;31:1049&#x2013;1057. doi: 10.1007/s00198-020-05318-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-020-05318-y</ArticleId><ArticleId IdType="pubmed">32008157</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen C.M., Muo C.H., Lin M.C., Chang S.N., Chang Y.J., Kao C.H. A nationwide population cohort study: Irritable bowel syndrome is a risk factor of osteoporosis. Eur. J. Intern. Med. 2014;25:87&#x2013;91. doi: 10.1016/j.ejim.2013.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2013.10.009</ArticleId><ArticleId IdType="pubmed">24183216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.Y., Lee K.J., Kim S.J., Cho S.W. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: A population-based study. Digestion. 2009;79:196&#x2013;201. doi: 10.1159/000211715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000211715</ArticleId><ArticleId IdType="pubmed">19342860</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zba&#x15f; H., Tutgun Onrat S., &#xd6;zdamar K. Genetic and environment factors in human osteoporosis. Mol. Biol. Rep. 2012;39:11289&#x2013;11296. doi: 10.1007/s11033-012-2038-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-012-2038-5</ArticleId><ArticleId IdType="pubmed">23065268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima C.A., Lyra A.C., Rocha R., Santana G.O. Risk factors for osteoporosis in inflammatory bowel disease patients. World J. Gastrointest. Pathophysiol. 2015;6:210&#x2013;218. doi: 10.4291/wjgp.v6.i4.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.4291/wjgp.v6.i4.210</ArticleId><ArticleId IdType="pmc">PMC4644885</ArticleId><ArticleId IdType="pubmed">26600979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N. Engl. J. Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Barau E., Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 1990;11:72&#x2013;77. doi: 10.1097/00005176-199007000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-199007000-00015</ArticleId><ArticleId IdType="pubmed">2117653</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693&#x2013;702. doi: 10.1053/j.gastro.2003.11.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2003.11.055</ArticleId><ArticleId IdType="pubmed">14988823</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P., Mearin F., Azpiroz F., Andresen V., Barbara G., Corsetti M., Emmanuel A., Hungin A.P.S., Layer P., Stanhellini V., et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United Eur. Gastroenterol. J. 2017;5:773&#x2013;788. doi: 10.1177/2050640617731968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617731968</ArticleId><ArticleId IdType="pmc">PMC5625880</ArticleId><ArticleId IdType="pubmed">29026591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cangemi D.J., Lacy B.E. Management of irritable bowel syndrome with diarrhea: A review of nonpharmacological and pharmacological interventions. Ther. Adv. Gastroenterol. 2019;12:1&#x2013;19. doi: 10.1177/1756284819878950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756284819878950</ArticleId><ArticleId IdType="pmc">PMC6778998</ArticleId><ArticleId IdType="pubmed">31632456</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.K., Kim Y.H., Park J.Y., Jang B.H., Park S.Y., Nam M.H., Choi M.G. Estimating the burden of irritable bowel syndrome: Analysis of a nationwide Korean database. J. Neurogastroenterol. Motil. 2014;20:242&#x2013;252. doi: 10.5056/jnm.2014.20.2.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2014.20.2.242</ArticleId><ArticleId IdType="pmc">PMC4015204</ArticleId><ArticleId IdType="pubmed">24840377</ArticleId></ArticleIdList></Reference><Reference><Citation>Panday K., Gona A., Humphrey M.B. Medication-induced osteoporosis: Screening and treatment strategies. Ther. Adv. Musculoskel. Dis. 2014;6:185&#x2013;202. doi: 10.1177/1759720X14546350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X14546350</ArticleId><ArticleId IdType="pmc">PMC4206646</ArticleId><ArticleId IdType="pubmed">25342997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wang L., Miao S., Xu H., Yin Y., Zhu Y., Dai Z., Shan T., Jing S., Wang J., et al. Analysis of treatment pathways for three chronic diseases using OMOP CDM. J. Med. Syst. 2018;42:260. doi: 10.1007/s10916-018-1076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-018-1076-5</ArticleId><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F., Resnic F.S., Robbins S.L., Denton J. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl. Clin. Inform. 2015;6:536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M.A., Schuemie M.J., Krumholz H.M., You S.C., Chen R., Pratt N., Reich C.G., Duke J., Madigan D., Hripcsak G., et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer A.D., Wood E., Ruffle J.K. An approach to the care of patients with irritable bowel syndrome. CMAJ. 2020;192:E275&#x2013;E282. doi: 10.1503/cmaj.190716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.190716</ArticleId><ArticleId IdType="pmc">PMC7083544</ArticleId><ArticleId IdType="pubmed">32179536</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C., Ha Y.C., Jang S., Jang S., Yoon H.K., Lee Y.K. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J. Bone Miner. Metab. 2011;29:744&#x2013;751. doi: 10.1007/s00774-011-0279-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00774-011-0279-3</ArticleId><ArticleId IdType="pubmed">21644058</ArticleId></ArticleIdList></Reference><Reference><Citation>Warriner A.H., Patkar N.M., Curtis J.R., Delzell E., Gary L., Kilgore M., Saag K. Which fractures are most attributable to osteoporosis? J. Clin. Epidemiol. 2011;64:46&#x2013;53. doi: 10.1016/j.jclinepi.2010.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.07.007</ArticleId><ArticleId IdType="pmc">PMC5030717</ArticleId><ArticleId IdType="pubmed">21130353</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model.  [(accessed on 10 January 2018)]; Available online:  https://www.ohdsi.org/data-standardization/the-common-data-model/</Citation></Reference><Reference><Citation>Shin D.W., Suh B., Lim H., Yun J.M., Song S.O., Park Y. J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: A retrospective cohort study. J. Bone Miner. Res. 2018;33:1037&#x2013;1043. doi: 10.1002/jbmr.3407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.3407</ArticleId><ArticleId IdType="pubmed">29447437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Schuemie M.J., Suchard M.A. Evaluating large-scale propensity score performance through realworld and synthetic data experiments. Int. J. Epidemiol. 2018;47:2005&#x2013;2014. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M.A., Simpson S.E., Zorych I., Ryan P., Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans. Model Comput. Simul. 2013;23 doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M., Tchetgen E., Cohen T. Negative controls: A tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383&#x2013;388. doi: 10.1097/EDE.0b013e3181d61eeb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E.A., Boyce R.D., Ryan P.B., van der Lei J., Rijnbeek P.R., Schuemie M.J. Accuracy of an automated knowledge base for identifying drug adverse reactions. J. Biomed. Inform. 2017;66:72&#x2013;81. doi: 10.1016/j.jbi.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., Hripcsak G., Ryan P.B., Madigan D., Suchard M.A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc. Natl. Acad. Sci. USA. 2018;115:2571&#x2013;2577. doi: 10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.S., Chen C.Y., Huang W.T., Chang L.J., Chen S.C.C., Yang H.Y. Risk of fractures at different anatomic sites in patients with irritable bowel syndrome: A nationwide population-based cohort study. Arch. Osteoporos. 2018;13:80. doi: 10.1007/s11657-018-0496-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-018-0496-7</ArticleId><ArticleId IdType="pubmed">30032473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.Y., Yi Y.H., Kim Y.J., Lee J.G., Tak Y.J., Hwang H.R., Lee S.H., Cho Y.H., Park E.J., Kim J.M. Irritable Bowel Syndrome Is a Risk of Osteoporosis: A Population Based Nationwide 1 Cohort Study (29 April 2019)  [(accessed on 24 September 2020)]; SSRN. Available online:  https://ssrn.com/abstract=3379819.</Citation></Reference><Reference><Citation>Stobaugh D.J., Deepak P., Ehrenpreis E.D. Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome. Osteoporos. Int. 2013;24:1169&#x2013;1175. doi: 10.1007/s00198-012-2141-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-012-2141-4</ArticleId><ArticleId IdType="pubmed">22993020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone R.A., Sansone L.A. SSRIs: Bad to the bone? Innov. Clin. Neurosci. 2012;9:42&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442753</ArticleId><ArticleId IdType="pubmed">22984652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruy&#xe8;re O., Reginster J.-Y. Osteoporosis in patients taking selective serotonin reuptake inhibitors: A focus on fracture outcome. Endocrine. 2015;48:65&#x2013;68. doi: 10.1007/s12020-014-0357-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-014-0357-0</ArticleId><ArticleId IdType="pubmed">25091520</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell M.D. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. 2004;141:1285&#x2013;1293. doi: 10.1038/sj.bjp.0705762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705762</ArticleId><ArticleId IdType="pmc">PMC1574906</ArticleId><ArticleId IdType="pubmed">15100164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwa R., Kumar M., Talegaonkar S., Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporos. Sarcopenia. 2017;3:75&#x2013;81. doi: 10.1016/j.afos.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.afos.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC6372777</ArticleId><ArticleId IdType="pubmed">30775508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Yu T., Tang Y., Xiong W., Shen X., Jiang L., Lin L. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2017;12:e0172846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349445</ArticleId><ArticleId IdType="pubmed">28291778</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.J., Kim N., Yoon H., Shin C.M., Park Y.S., Kim J.-W., Kim Y.S., Lee D.H., Jung H.C. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. J. Gastroenterol. Hepatol. 2017;32:1553&#x2013;1561. doi: 10.1111/jgh.13756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13756</ArticleId><ArticleId IdType="pubmed">28160607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M., Lembo A. Microbiome and its role in irritable bowel syndrome. Dig. Dis. Sci. 2020;65:829&#x2013;839. doi: 10.1007/s10620-020-06109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06109-5</ArticleId><ArticleId IdType="pubmed">32026278</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305&#x2013;1318. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Gkolfakis P., Dimitriadis G., Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis. Int. 2015;14:572&#x2013;581. doi: 10.1016/S1499-3872(15)60026-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1499-3872(15)60026-1</ArticleId><ArticleId IdType="pubmed">26663004</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobert A.P., Sagrestani G., Delmas E., Wilson K.T., Verriere T.G., Dapoigny M., Del&#x2019;homme C., Bernalier-Donadille A. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. Sci. Rep. 2016;6:39399. doi: 10.1038/srep39399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39399</ArticleId><ArticleId IdType="pmc">PMC5159846</ArticleId><ArticleId IdType="pubmed">27982124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson C., Sj&#xf6;gren K. Osteomicrobiology: A new cross-disciplinary research field. Calcif. Tissue Int. 2018;102:426&#x2013;432. doi: 10.1007/s00223-017-0336-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00223-017-0336-6</ArticleId><ArticleId IdType="pmc">PMC5851705</ArticleId><ArticleId IdType="pubmed">29079994</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaiss C.A., Zmora N., Levy M., Elinav E. The microbiome and innate immunity. Nature. 2016;535:65&#x2013;74. doi: 10.1038/nature18847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18847</ArticleId><ArticleId IdType="pubmed">27383981</ArticleId></ArticleIdList></Reference><Reference><Citation>Takiishi T., Fenero C.I.M., C&#xe2;mara N.O.S. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017;5:e1373208. doi: 10.1080/21688370.2017.1373208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21688370.2017.1373208</ArticleId><ArticleId IdType="pmc">PMC5788425</ArticleId><ArticleId IdType="pubmed">28956703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebregts T., Adam B., Bredack C., R&#xf6;th A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913&#x2013;920. doi: 10.1053/j.gastro.2007.01.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.01.046</ArticleId><ArticleId IdType="pubmed">17383420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaura H., Marahleh A., Ohori F., Noguchi T., Shen W.-R., Qi J., Nara Y., Pramusita A., Kinjo R., Mizoguchi I. Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int. J. Mol. Sci. 2020;21:5169. doi: 10.3390/ijms21145169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21145169</ArticleId><ArticleId IdType="pmc">PMC7404053</ArticleId><ArticleId IdType="pubmed">32708317</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S., Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol. Hepatol. 2010;6:506&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950667</ArticleId><ArticleId IdType="pubmed">20978554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wedlake L., A&#x2019;Hern R., Russell D., Thomas K., Walters J.R., Andreyev H.J. Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009;30:707&#x2013;717. doi: 10.1111/j.1365-2036.2009.04081.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04081.x</ArticleId><ArticleId IdType="pubmed">19570102</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasnezhad A., Amani R., Hasanvand A., Yousefi R.E., Alipour M., Saboori S., Choghakhori R. Association of serum vitamin D concentration with clinical symptoms and quality of life in patients with irritable bowel syndrome. J. Am. Coll. Nutr. 2019;38:327&#x2013;333. doi: 10.1080/07315724.2018.1510349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07315724.2018.1510349</ArticleId><ArticleId IdType="pubmed">30252633</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie Y.A., Bowyer R.K., Leach H., Gulia P., Horobin J., O&#x2019;Sullivan N.A., Pettitt C., Reeves L.B., Seamark L., Williams M., et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update) J. Hum. Nutr. Diet. 2016;29:549&#x2013;575. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes P., Corish C., O&#x2019;Mahony E., Quigley E.M. A dietary survey of patients with irritable bowel syndrome. J. Hum. Nutr. Diet. 2014;27:36&#x2013;47. doi: 10.1111/jhn.12114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12114</ArticleId><ArticleId IdType="pubmed">23659729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34079378</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1349</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Clinical epidemiology</Title><ISOAbbreviation>Clin Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Smoking and COVID-19 Infection and Related Mortality: A Prospective Cohort Analysis of UK Biobank Data.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>365</EndPage><MedlinePgn>357-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CLEP.S300597</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several papers have shown contradictory evidence about the relationship between smoking and COVID-19-related deaths. There is little evidence about smoking and risk of infection. We aim to examine association between smoking and COVID-19 infection and subsequent mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a prospective study with participants from the UK Biobank cohort. Participants who lived in England were followed up from 01/02/2020 to 28/06/2020 with data linked to hospital episode statistics, Office for National Statistics and Public Health England PCR tests. We compared current-smokers, previous-smokers with never-smokers and estimated risk ratio (RR) of COVID-19 infection and subsequent mortality using Poisson regression adjusting for age, sex, ethnicity, body mass index and socio-economic status. Interactions between smoking status and age and sex were tested for using multiplicative interactions, and analyses were stratified by median age (49-68 years, 69-86 years) and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 402,978 participants were included in the analyses. The majority were never smokers, 226,294 (56.2%), 140,090 (34.8%) were previous smokers, and 39,974 (9.9%) current smokers. COVID-19 infection was identified in 1591 (0.39%) people, and 372/1591 (23.4%) died. Amongst the younger participants, smokers were nearly twice as likely to become infected with COVID-19 than never smokers (RR 1.88 [1.49-2.38]) whereas there was no difference for those aged 69+ (RR 1.05 [0.82-1.34]). In contrast, amongst the older participants, smokers were twice as likely to die from COVID-19 compared to non-smokers (RR 2.15 [1.11-4.16]) whereas there was no difference for those under the age of 69 (RR 1.22[0.83-1.79]). Similar patterns were observed for previous smokers. The impact of smoking was similar in men and women.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The association between smoking and COVID-19 infection and subsequent death is modified by age. Smokers and previous smokers aged under 69 were at higher risk of COVID-19 infection, suggesting the risk is associated with increased exposure to SARS-COV-2 virus. Once infected, older smokers were twice as likely to die from COVID-19 than never smokers, possibly mediated by increased risk of chronic conditions/illnesses.</AbstractText><CopyrightInformation>&#xa9; 2021 Prats-Uribe et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0037-7524</Identifier><AffiliationInfo><Affiliation>Department of Primary Care and Population Health, UCL, London, NW3 2PF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Aarhus University, Aarhus N, 8200, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Epidemiol</MedlineTA><NlmUniqueID>101531700</NlmUniqueID><ISSNLinking>1179-1349</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">UK Biobank</Keyword><Keyword MajorTopicYN="N">smoking</Keyword></KeywordList><CoiStatement>Professor Daniel Prieto-Alhambra reports fees for speakers services and advisory board membership from Amgen and fees for consultancy services from UCB Biopharma and Les Laboratoires Servier, outside the submitted work. He reports HTA Funding Committee membership; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA&#x2019;s department and open for external participants. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34079378</ArticleId><ArticleId IdType="pmc">PMC8164669</ArticleId><ArticleId IdType="doi">10.2147/CLEP.S300597</ArticleId><ArticleId IdType="pii">300597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2013;436. doi:10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, Tubach F, Pourcher V, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios. 2020. doi:10.32388/WPP19W.3</Citation><ArticleIdList><ArticleId IdType="doi">10.32388/WPP19W.3</ArticleId></ArticleIdList></Reference><Reference><Citation>Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;ntaa082. doi:10.1093/ntr/ntaa082</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ntr/ntaa082</ArticleId><ArticleId IdType="pmc">PMC7239135</ArticleId><ArticleId IdType="pubmed">32399563</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1045&#x2013;1056. doi:10.1002/jmv.26389</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26389</ArticleId><ArticleId IdType="pmc">PMC7436545</ArticleId><ArticleId IdType="pubmed">32749705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkinson NS, Rossi N, El-Sayed_Moustafa J, et al. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax. 2021:thoraxjnl-2020-216422. doi:10.1136/thoraxjnl-2020-216422</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216422</ArticleId><ArticleId IdType="pubmed">33402392</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoking and COVID-19. Available from:
https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19. Accessed May
8, 2021.</Citation></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLOS Med. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R. What makes UK biobank special? Lancet. 2012;379(9822):1173&#x2013;1174. doi:10.1016/S0140-6736(12)60404-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60404-8</ArticleId><ArticleId IdType="pubmed">22463865</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong J, Rudkin JK, Allen N, et al. Dynamic linkage of COVID-19 test results between public health England&#x2019;s second generation surveillance system and UK biobank. Microb Genom. 2020;6(7). doi:10.1099/mgen.0.000397</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000397</ArticleId><ArticleId IdType="pmc">PMC7478634</ArticleId><ArticleId IdType="pubmed">32553051</ArticleId></ArticleIdList></Reference><Reference><Citation>Peto R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323&#x2013;329. doi:10.1136/bmj.321.7257.323</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.321.7257.323</ArticleId><ArticleId IdType="pmc">PMC27446</ArticleId><ArticleId IdType="pubmed">10926586</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson NC. Asthma and cigarette smoking. Eur Respir J. 2004;24(5):822&#x2013;833. doi:10.1183/09031936.04.00039004</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.04.00039004</ArticleId><ArticleId IdType="pubmed">15516679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu KK, Mishra AK, Goldman Y. A rare case of pneumopericardium secondary to COVID-19. Heart Lung. 2020;49:679&#x2013;680. doi:10.1016/j.hrtlng.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7441933</ArticleId><ArticleId IdType="pubmed">32861883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonnesen P, Marott J, Nordestgaard B, Bojesen S, Lange P. Secular trends in smoking in relation to prevalent and incident smoking-related disease: a prospective population-basedstudy. Tob Induc Dis. 2019;17. doi:10.18332/tid/112459</Citation><ArticleIdList><ArticleId IdType="doi">10.18332/tid/112459</ArticleId><ArticleId IdType="pmc">PMC6830353</ArticleId><ArticleId IdType="pubmed">31768164</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F, Liang C-L, Liu H, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017;8(1):268&#x2013;284. doi:10.18632/oncotarget.13613</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13613</ArticleId><ArticleId IdType="pmc">PMC5352117</ArticleId><ArticleId IdType="pubmed">27902485</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Wulan H, Song Z, et al. Regulatory B cell function is suppressed by smoking and obesity in H. pylori-infected subjects and is correlated with elevated risk of gastric cancer. PLoS One. 2015;10(7):e0134591. doi:10.1371/journal.pone.0134591</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134591</ArticleId><ArticleId IdType="pmc">PMC4520600</ArticleId><ArticleId IdType="pubmed">26226399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang S, Ordway D, Henao-Tamayo M, et al. Cigarette smoke increases susceptibility to tuberculosis&#x2014;evidence from in vivo and in vitro models. J Infect Dis. 2011;203(9):1240&#x2013;1248. doi:10.1093/infdis/jir009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir009</ArticleId><ArticleId IdType="pubmed">21357942</ArticleId></ArticleIdList></Reference><Reference><Citation>Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016;22(1):49&#x2013;55. doi:10.3201/eid2201.151340</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2201.151340</ArticleId><ArticleId IdType="pmc">PMC4696714</ArticleId><ArticleId IdType="pubmed">26692185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondi A, Castilletti C, Gagliardini R, et al. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021;105:532&#x2013;539. doi:10.1016/j.ijid.2021.02.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.117</ArticleId><ArticleId IdType="pmc">PMC7927669</ArticleId><ArticleId IdType="pubmed">33676001</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Kasper B, Petersen F, Yu X. Association of cigarette smoking, COPD, and lung cancer with expression of SARS-CoV-2 entry genes in human airway epithelial cells. Front Med. 2020;7:619453. doi:10.3389/fmed.2020.619453</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.619453</ArticleId><ArticleId IdType="pmc">PMC7793919</ArticleId><ArticleId IdType="pubmed">33425965</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Pizzol D, Cebola B, et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: a review. Tuberculosis. 2017;103:44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28237033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzol D, Veronese N, Marotta C, et al. Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. BMC Res Notes. 2018;11:99. doi:10.1186/s13104-018-3209-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-018-3209-9</ArticleId><ArticleId IdType="pmc">PMC5800087</ArticleId><ArticleId IdType="pubmed">29402317</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) infection survey - office for national statistics. Available from:
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata. Accessed May
8, 2021.</Citation></Reference><Reference><Citation>Age, male sex, obesity, and underlying illness emerge as risk factors for severe covid-19 or death
BMJ. Available from:
https://www.bmj.com/company/newsroom/age-male-sex-obesity-and-underlying-illness-emerge-as-risk-factors-for-severe-covid-19-or-death-finds-largest-cohort-study-to-date/. Accessed May
8, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34085538</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C).</ArticleTitle><Pagination><StartPage>2232</StartPage><EndPage>2246</EndPage><MedlinePgn>2232-2246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.21.01074</ELocationID><Abstract><AbstractText Label="PURPOSE">Variation in risk of adverse clinical outcomes in patients with cancer and COVID-19 has been reported from relatively small cohorts. The NCATS' National COVID Cohort Collaborative (N3C) is a centralized data resource representing the largest multicenter cohort of COVID-19 cases and controls nationwide. We aimed to construct and characterize the cancer cohort within N3C and identify risk factors for all-cause mortality from COVID-19.</AbstractText><AbstractText Label="METHODS">We used 4,382,085 patients from 50 US medical centers to construct a cohort of patients with cancer. We restricted analyses to adults &#x2265; 18 years old with a COVID-19-positive or COVID-19-negative diagnosis between January 1, 2020, and March 25, 2021. We followed N3C selection of an index encounter per patient for analyses. All analyses were performed in the N3C Data Enclave Palantir platform.</AbstractText><AbstractText Label="RESULTS">A total of 398,579 adult patients with cancer were identified from the N3C cohort; 63,413 (15.9%) were COVID-19-positive. Most common represented cancers were skin (13.8%), breast (13.7%), prostate (10.6%), hematologic (10.5%), and GI cancers (10%). COVID-19 positivity was significantly associated with increased risk of all-cause mortality (hazard ratio, 1.20; 95% CI, 1.15 to 1.24). Among COVID-19-positive patients, age &#x2265; 65 years, male gender, Southern or Western US residence, an adjusted Charlson Comorbidity Index score &#x2265; 4, hematologic malignancy, multitumor sites, and recent cytotoxic therapy were associated with increased risk of all-cause mortality. Patients who received recent immunotherapies or targeted therapies did not have higher risk of overall mortality.</AbstractText><AbstractText Label="CONCLUSION">Using N3C, we assembled the largest nationally representative cohort of patients with cancer and COVID-19 to date. We identified demographic and clinical factors associated with increased all-cause mortality in patients with cancer. Full characterization of the cohort will provide further insights into the effects of COVID-19 on cancer outcomes and the ability to continue specific cancer treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharafeldin</LastName><ForeName>Noha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8835-8899</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1221-4028</Identifier><AffiliationInfo><Affiliation>Rutgers University, New Brunswick, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-4455-5302</Identifier><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhira</LastName><ForeName>Vithal</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5359-1703</Identifier><AffiliationInfo><Affiliation>Palila Software LLC, Reno, NV.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6544-1478</Identifier><AffiliationInfo><Affiliation>University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Sharlene</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6983-6012</Identifier><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2316-2419</Identifier><AffiliationInfo><Affiliation>Rutgers University, New Brunswick, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhrt</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0117-8519</Identifier><AffiliationInfo><Affiliation>Rutgers University, New Brunswick, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Yu Raymond</ForeName><Initials>YR</Initials><Identifier Source="ORCID">0000-0002-1030-7765</Identifier><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feifan</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0881-6365</Identifier><AffiliationInfo><Affiliation>University of Massachusetts Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergquist</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5614-8977</Identifier><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinney</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1477-1888</Identifier><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4917-6173</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Umit</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-3241-8773</Identifier><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA012197</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2021 Dec 10;39(35):3997-3998. doi: 10.1200/JCO.21.02150.</RefSource><PMID Version="1">34623872</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2021 Dec 10;39(35):3996. doi: 10.1200/JCO.21.01561.</RefSource><PMID Version="1">34623886</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Benjamin Bates</b><b>Stock and Other Ownership Interests:</b> Pfizer <b>Eileen Lee</b><b>Employment:</b> Johnson &amp; Johnson/Janssen <b>Yu Raymond Shao</b><b>Employment:</b> GlaxoSmithKline, Suzhou Kintor Pharmaceuticals <b>Feifan Liu</b><b>Stock and Other Ownership Interests:</b> Pfizer <b>Timothy Bergquist</b><b>Research Funding:</b> Celgene <b>Justin Guinney</b><b>Consulting or Advisory Role:</b> AstraZeneca<b>Research Funding:</b> AstraZeneca, Bristol Meyers Squib, Roche/Genentech <b>Umit Topaloglu</b><b>Stock and Other Ownership Interests:</b> CareDirectionsNo other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>8</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34085538</ArticleId><ArticleId IdType="pmc">PMC8260918</ArticleId><ArticleId IdType="doi">10.1200/JCO.21.01074</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lima NT, Buss PM, Paes-Sousa R. COVID-19 pandemic: A health and humanitarian crisis. Cad Saude Publica. 2020;36:e00177020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32725086</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review Int J Surg 78185&#x2013;1932020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162753</ArticleId><ArticleId IdType="pubmed">32305533</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakoulis VG, Papoutsi E, Siempos II.Effect of cancer on clinical outcomes of patients with COVID-19: A meta-analysis of patient data JCO Glob Oncol 6799&#x2013;8082020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328119</ArticleId><ArticleId IdType="pubmed">32511066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunski MJ, Burton J, Tawagi K, et al. Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana Cancer 127266&#x2013;2742021</Citation><ArticleIdList><ArticleId IdType="pubmed">33112411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathania AS, Prathipati P, Abdul BA, et al. COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges Theranostics 11731&#x2013;7532021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738845</ArticleId><ArticleId IdType="pubmed">33391502</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies Eur J Cancer 13943&#x2013;502020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467090</ArticleId><ArticleId IdType="pubmed">32971510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachem RY, Datoguia T, Siddiqui B, et al. 372. Comparing the outcome of COVID-19 in cancer and non-cancer patients: An international multicenter study. Open Forum Infect Dis. 2020;7:S256.</Citation></Reference><Reference><Citation>Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China Lancet Oncol 21335&#x2013;3372020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China JAMA Oncol 61108&#x2013;11102020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097836</ArticleId><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker TJA.Risk of COVID-19 in patients with cancer JAMA Oncol 61470&#x2013;14712020</Citation><ArticleIdList><ArticleId IdType="pubmed">32614372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang J, Tu Y, et al. Cancer patients in SARS-CoV-2 infection: A single-center experience from Wuhan J Cancer 116243&#x2013;62472020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532501</ArticleId><ArticleId IdType="pubmed">33033507</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak Cancer Discov 10783&#x2013;7912020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York city Ann Oncol 311088&#x2013;10892020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172785</ArticleId><ArticleId IdType="pubmed">32330541</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;thrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: Clinical characteristics and outcome&#x2014;An analysis of the LEOSS registry Ann Hematol 100383&#x2013;3932021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648543</ArticleId><ArticleId IdType="pubmed">33159569</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anti-cancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium Ann Oncol 32787&#x2013;8002021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972830</ArticleId><ArticleId IdType="pubmed">33746047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier J-B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study Lancet 3951919&#x2013;19262020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Albiges L, Foulon S, Bayle A, et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: Results from the Gustave Roussy cohort Nat Cancer 1965&#x2013;9752020</Citation><ArticleIdList><ArticleId IdType="pubmed">35121871</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment J Am Med Inform Assoc 28427&#x2013;4432021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, et al. The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction. medRxiv; 2021.</Citation></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform. 2019;96:103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40373&#x2013;3831987</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Golestaneh L, Neugarten J, Fisher M, et al. The association of race and COVID-19 mortality. EClinicalMedicine. 2020;25:100455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361093</ArticleId><ArticleId IdType="pubmed">32838233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Berger NA, Xu R.Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection JAMA Oncol 7220&#x2013;2272021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7729584</ArticleId><ArticleId IdType="pubmed">33300956</ArticleId></ArticleIdList></Reference><Reference><Citation>Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among black patients and white patients with Covid-19 N Engl J Med 3822534&#x2013;25432020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269015</ArticleId><ArticleId IdType="pubmed">32459916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehia BR, Winegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020;3:e2018039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435340</ArticleId><ArticleId IdType="pubmed">32809033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med. 2020;17:e1003379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508372</ArticleId><ArticleId IdType="pubmed">32960880</ArticleId></ArticleIdList></Reference><Reference><Citation>Millett GA, Jones AT, Benkeser D, et al. Assessing differential impacts of COVID-19 on black communities Ann Epidemiol 4737&#x2013;442020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224670</ArticleId><ArticleId IdType="pubmed">32419766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J, Sullivan PS, Sanchez TH, et al. Similarities and differences in COVID-19 awareness, concern, and symptoms by race and ethnicity in the United States: Cross-sectional Survey. J Med Internet Res. 2020;22:e20001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357692</ArticleId><ArticleId IdType="pubmed">32614778</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar G, Pinheiro LC, Shusterman M, et al. COVID-19 severity and outcomes in patients with cancer: A matched cohort study J Clin Oncol 383914&#x2013;39242020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676890</ArticleId><ArticleId IdType="pubmed">32986528</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Scotti L, Gennari A, et al. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: A European study Eur J Cancer 150190&#x2013;2022021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023206</ArticleId><ArticleId IdType="pubmed">33932726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study Lancet 3951907&#x2013;19182020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: A perspective. J Glob Health. 2020;10:010367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296208</ArticleId><ArticleId IdType="pubmed">32566158</ArticleId></ArticleIdList></Reference><Reference><Citation>Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors JCO Clin Cancer Inform 41059&#x2013;10712020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713534</ArticleId><ArticleId IdType="pubmed">33253013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers Stud Health Technol Inform 216574&#x2013;5782015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34142015</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Comparative effectiveness of medical concept embedding for feature engineering in phenotyping.</ArticleTitle><Pagination><StartPage>ooab028</StartPage><MedlinePgn>ooab028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooab028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooab028</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Feature engineering is a major bottleneck in phenotyping. Properly learned medical concept embeddings (MCEs) capture the semantics of medical concepts, thus are useful for retrieving relevant medical features in phenotyping tasks. We compared the effectiveness of MCEs learned from knowledge graphs and electronic healthcare records (EHR) data in retrieving relevant medical features for phenotyping tasks.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We implemented 5 embedding methods including node2vec, singular value decomposition (SVD), LINE, skip-gram, and GloVe with 2 data sources: (1) knowledge graphs obtained from the observational medical outcomes partnership (OMOP) common data model; and (2) patient-level data obtained from the OMOP compatible electronic health records (EHR) from Columbia University Irving Medical Center (CUIMC). We used phenotypes with their relevant concepts developed and validated by the electronic medical records and genomics (eMERGE) network to evaluate the performance of learned MCEs in retrieving phenotype-relevant concepts. <i>Hits@k%</i> in retrieving phenotype-relevant concepts based on a single and multiple seed concept(s) was used to evaluate MCEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among all MCEs, MCEs learned by using node2vec with knowledge graphs showed the best performance. Of MCEs based on knowledge graphs and EHR data, MCEs learned by using node2vec with knowledge graphs and MCEs learned by using GloVe with EHR data outperforms other MCEs, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MCE enables scalable feature engineering tasks, thereby facilitating phenotyping. Based on current phenotyping practices, MCEs learned by using knowledge graphs constructed by hierarchical relationships among medical concepts outperformed MCEs learned by using EHR data.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Junghwan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1240-7655</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 TR003434</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012895</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013061</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">embedding</Keyword><Keyword MajorTopicYN="N">knowledge graph</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword><Keyword MajorTopicYN="N">representation learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34142015</ArticleId><ArticleId IdType="pmc">PMC8206403</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooab028</ArticleId><ArticleId IdType="pii">ooab028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, Shah NH.. Advances in electronic phenotyping: from rule-based definitions to machine learning models. Annu Rev Biomed Data Sci 2018; 1: 53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al.PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc 2016; 23 (6): 1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N, Liu C, Rasmussen LV, et al.Making work visible for electronic phenotype implementation: lessons learned from the eMERGE network. J Biomed Inform 2019; 99: 103293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894517</ArticleId><ArticleId IdType="pubmed">31542521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W-Q, Leibson CL, Ransom JE, et al.Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus. J Am Med Inform Assoc 2012; 19 (2): 219&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277630</ArticleId><ArticleId IdType="pubmed">22249968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho AN, Hayes MG, Rasmussen-Torvik L, et al.Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012; 19 (2): 212&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277617</ArticleId><ArticleId IdType="pubmed">22101970</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Liao KP, Shaw SY, et al.Toward high-throughput phenotyping: unbiased automated feature extraction and selection from knowledge sources. J Am Med Inform Assoc 2015; 22 (5): 993&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986664</ArticleId><ArticleId IdType="pubmed">25929596</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy TH Jr, Yu S, Hart KL, et al.High throughput phenotyping for dimensional psychopathology in electronic health records. Biol Psychiatry 2018; 83 (12): 997&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972065</ArticleId><ArticleId IdType="pubmed">29496195</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronsbell J, Minnier J, Yu S, Liao K, Cai T.. Automated feature selection of predictors in electronic medical records data. Biometrics 2019; 75 (1): 268&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30353541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cai T, Yu S, et al.High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). Nat Protoc 2019; 14 (12): 3426&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323894</ArticleId><ArticleId IdType="pubmed">31748751</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao KP, Sun J, Cai TA, et al.High-throughput multimodal automated phenotyping (MAP) with application to PheWAS. J Am Med Inform Assoc 2019; 26 (11): 1255&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798574</ArticleId><ArticleId IdType="pubmed">31613361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengio Y, Ducharme R, Vincent P, Janvin C.. A neural probabilistic language model. J Mach Learn Res 2003; 3: 1137&#x2013;55.</Citation></Reference><Reference><Citation>Mikolov T, Sutskever I, Chen K, Corrado GS, Dean J. Distributed representations of words and phrases and their compositionality. In: advances in neural information processing systems; arXiv preprint arXiv:1310.4546; 2013.</Citation></Reference><Reference><Citation>Xiao C, Choi E, Sun J.. Opportunities and challenges in developing deep learning models using electronic health records data: a systematic review. J Am Med Inform Assoc 2018; 25 (10): 1419&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188527</ArticleId><ArticleId IdType="pubmed">29893864</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng W-H, Szolovits P. Representation learning for electronic health records. arXiv preprint, arXiv:1909.09248; 2019.</Citation></Reference><Reference><Citation>Choi E, Bahadori MT, Searles E, et al. Multi-layer representation learning for medical concepts. In: proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining; San Francisco, CA; Aug 13&#x2013;17, 2016.</Citation></Reference><Reference><Citation>Xiao C, Ma T, Dieng AB, Blei DM, Wang F.. Readmission prediction via deep contextual embedding of clinical concepts. PloS One 2018; 13 (4): e0195024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890980</ArticleId><ArticleId IdType="pubmed">29630604</ArticleId></ArticleIdList></Reference><Reference><Citation>Miotto R, Li L, Kidd BA, Dudley JT.. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Sci Rep 2016; 6 (1): 26094&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869115</ArticleId><ArticleId IdType="pubmed">27185194</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue X, Wang Z, Huang J, et al.Graph embedding on biomedical networks: methods, applications and evaluations. Bioinformatics 2020; 36 (4): 1241&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703771</ArticleId><ArticleId IdType="pubmed">31584634</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal K, Eftimov T, Addanki R, Choudhury S, Tamang S, Rallo R. Snomed2Vec: random walk and poincar&#xe9; embeddings of a clinical knowledge base for healthcare analytics. arXiv preprint arXiv:1907.08650; 2019.</Citation></Reference><Reference><Citation>Shen F, Peng S, Fan Y, et al.HPO2Vec+: leveraging heterogeneous knowledge resources to enrich node embeddings for the human phenotype ontology. J Biomed Inform 2019; 96: 103246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710011</ArticleId><ArticleId IdType="pubmed">31255713</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington J, Socher R, Manning CD. Glove: global vectors for word representation. In: proceedings of the 2014 conference on empirical methods in natural language processing (EMNLP); Doha, Qatar; Oct 25&#x2013;29, 2014.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>The Observational Health Data Sciences and Informatics (OHDSI). The Book of OHDSI; 2019.</Citation></Reference><Reference><Citation>Ta CN, Dumontier M, Hripcsak G, Tatonetti NP, Weng C.. Columbia open health data, clinical concept prevalence and co-occurrence from electronic health records. Sci Data 2018; 5: 180273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6257042</ArticleId><ArticleId IdType="pubmed">30480666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta CN, Weng C.. Detecting systemic data quality issues in electronic health records. Stud Health Technol Inform 2019; 264: 383&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857180</ArticleId><ArticleId IdType="pubmed">31437950</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover A, Leskovec J. node2vec: scalable feature learning for networks. In: proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining; San Francisco, CA; Aug 13&#x2013;17, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108654</ArticleId><ArticleId IdType="pubmed">27853626</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Qu M, Wang M, Zhang M, Yan J, Mei Q. LINE: large-scale information network embedding. In: Proceedings of the 24th international conference on world wide web; Florence, Italy; May 20&#x2013;22, 2015.</Citation></Reference><Reference><Citation>Abadi M, Barham P, Chen J, et al. Tensorflow: a system for large-scale machine learning. In: 12th {USENIX} symposium on operating systems design and implementation ({OSDI} 16); Savannah, GA; Nov 2&#x2013;4, 2016.</Citation></Reference><Reference><Citation>
OpenNE: an open source toolkit for network embedding. https://github.com/thunlp/OpenNEAccessed February, 2021.</Citation></Reference><Reference><Citation>
The Phenotype Knowledgebase website. https://www.phekb.org/Accessed February, 2021.</Citation></Reference><Reference><Citation>Maaten L, Hinton G.. Visualizing data using t-SNE. J Mach Learn Res 2008; 9: 2579&#x2013;605.</Citation></Reference><Reference><Citation>Kipf TN, Welling M. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907; 2016.</Citation></Reference><Reference><Citation>Kipf TN, Welling M. Variational graph auto-encoders. arXiv preprint arXiv:1611.07308; 2016.</Citation></Reference><Reference><Citation>Perozzi B, Al-Rfou R, Skiena S. Deepwalk: online learning of social representations. In: proceedings of the 20th ACM SIGKDD international conference on knowledge discovery and data mining; New York, NY; Aug 24&#x2013;27, 2014.</Citation></Reference><Reference><Citation>Tsitsulin A, Mottin D, Karras P, M&#xfc;ller E. Verse: versatile graph embeddings from similarity measures. In: proceedings of the 2018 world wide web conference; Lyon, France; Apr 23&#x2013;27, 2018.</Citation></Reference><Reference><Citation>Peters ME, Neumann M, Iyyer M, et al. Deep contextualized word representations. arXiv preprint arXiv:1802.05365; 2018.</Citation></Reference><Reference><Citation>Devlin J, Chang M-W, Lee K, Toutanova K. Bert: pre-training of deep bidirectional transformers for language understanding. arXiv preprint arXiv:1810.04805; 2018.</Citation></Reference><Reference><Citation>Choi E, Bahadori MT, Song L, Stewart WF, Sun J. GRAM: graph-based attention model for healthcare representation learning. In: proceedings of the 23rd ACM SIGKDD international conference on knowledge discovery and data mining; Halifax, Canada; Aug 13&#x2013;17, 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7954122</ArticleId><ArticleId IdType="pubmed">33717639</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Cheong CW, Yin K, Cheung WK, Fung BC, Poon J. Medical concept embedding with multiple ontological representations. In: IJCAI; 2019.</Citation></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al.Facilitating phenotype transfer using a common data model. J Biomed Inform 2019; 96: 103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34151259</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2624-909X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in big data</Title><ISOAbbreviation>Front Big Data</ISOAbbreviation></Journal><ArticleTitle>Development of An Individualized Risk Prediction Model for COVID-19 Using Electronic Health Record Data.</ArticleTitle><Pagination><StartPage>675882</StartPage><MedlinePgn>675882</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">675882</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fdata.2021.675882</ELocationID><Abstract><AbstractText>Developing an accurate and interpretable model to predict an individual's risk for Coronavirus Disease 2019 (COVID-19) is a critical step to efficiently triage testing and other scarce preventative resources. To aid in this effort, we have developed an interpretable risk calculator that utilized de-identified electronic health records (EHR) from the University of Alabama at Birmingham Informatics for Integrating Biology and the Bedside (UAB-i2b2) COVID-19 repository under the U-BRITE framework. The generated risk scores are analogous to commonly used credit scores where higher scores indicate higher risks for COVID-19 infection. By design, these risk scores can easily be calculated in spreadsheets or even with pen and paper. To predict risk, we implemented a Credit Scorecard modeling approach on longitudinal EHR data from 7,262 patients enrolled in the UAB Health System who were evaluated and/or tested for COVID-19 between January and June 2020. In this cohort, 912 patients were positive for COVID-19. Our workflow considered the timing of symptoms and medical conditions and tested the effects by applying different variable selection techniques such as LASSO and Elastic-Net. Within the two weeks before a COVID-19 diagnosis, the most predictive features were respiratory symptoms such as cough, abnormalities of breathing, pain in the throat and chest as well as other chronic conditions including nicotine dependence and major depressive disorder. When extending the timeframe to include all medical conditions across all time, our models also uncovered several chronic conditions impacting the respiratory, cardiovascular, central nervous and urinary organ systems. The whole pipeline of data processing, risk modeling and web-based risk calculator can be applied to any EHR data following the OMOP common data format. The results can be employed to generate questionnaires to estimate COVID-19 risk for screening in building entries or to optimize hospital resources.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Mamidi, Tran-Nguyen, Melvin and Worthey.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mamidi</LastName><ForeName>Tarun Karthik Kumar</ForeName><Initials>TKK</Initials><AffiliationInfo><Affiliation>Center for Computational Genomics and Data Science, Departments of Pediatrics and Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran-Nguyen</LastName><ForeName>Thi K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melvin</LastName><ForeName>Ryan L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worthey</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Center for Computational Genomics and Data Science, Departments of Pediatrics and Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Big Data</MedlineTA><NlmUniqueID>101770603</NlmUniqueID><ISSNLinking>2624-909X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ICD-10</Keyword><Keyword MajorTopicYN="N">credit scorecard model</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">risk prediction</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34151259</ArticleId><ArticleId IdType="pmc">PMC8211871</ArticleId><ArticleId IdType="doi">10.3389/fdata.2021.675882</ArticleId><ArticleId IdType="pii">675882</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adapa S., Chenna A., Balla M., Merugu G. P., Koduri N. M., Daggubati S. R., et al. (2020). COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients with Chronic Kidney Disease and Renal Transplantation. J. Clin. Med. Res. 12 (6), 352&#x2013;361. 10.14740/jocmr4200</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4200</ArticleId><ArticleId IdType="pmc">PMC7295554</ArticleId><ArticleId IdType="pubmed">32587651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alballa N., Al-Turaiki I. (2021). Machine Learning Approaches in COVID-19 diagnosis, Mortality, and Severity Risk Prediction: A Review. Inform. Med. 24, 100564. 10.1016/j.imu.2021.100564</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2021.100564</ArticleId><ArticleId IdType="pmc">PMC8018906</ArticleId><ArticleId IdType="pubmed">33842685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey M. (2006). Practical Credit Scoring: Issues and Techniques. Bristol, United Kingdom: White Box Publishing.</Citation></Reference><Reference><Citation>Bishop C. M. (2016). Pattern Recognition and Machine Learning Springer.</Citation></Reference><Reference><Citation>
Blacketer C. (2021). Chapter 4. The Common Data Model [Online]. Available at: https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html
</Citation></Reference><Reference><Citation>
Bowman S. E. (2005). Coordination of SNOMED-CT and ICD-10: Getting the Most out of Electronic Health Record Systems. Perspectives in Health Information Management [Online]. http://library.ahima.org/doc?oid=106578#.YDXOMGNMEXx
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797550</ArticleId><ArticleId IdType="pubmed">24159271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox E., Martin B. C., Van Staa T., Garbe E., Siebert U., Johnson M. L. (2009). Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value in Health. 12 (8), 1053&#x2013;1061. 10.1111/j.1524-4733.2009.00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2009.00601.x</ArticleId><ArticleId IdType="pubmed">19744292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagliati A., Malovini A., Tibollo V., Bellazzi R. (2021). Health Informatics and EHR to Support Clinical Research in the COVID-19 PANDEMIc: An Overview. Brief Bioinform 22 (2), 812&#x2013;822. 10.1093/bib/bbaa418</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa418</ArticleId><ArticleId IdType="pmc">PMC7929411</ArticleId><ArticleId IdType="pubmed">33454728</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong E. R., DeLong D. M., Clarke-Pearson D. L. (1988). Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: a Nonparametric Approach. Biometrics 44 (3), 837&#x2013;845. 10.2307/2531595</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Estiri H., Strasser Z. H., Klann J. G., Naseri P., Wagholikar K. B., Murphy S. N. (2021). Predicting COVID-19 Mortality with Electronic Medical Records. Npj Digit. Med. 4 (1), 15. 10.1038/s41746-021-00383-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-021-00383-x</ArticleId><ArticleId IdType="pmc">PMC7862405</ArticleId><ArticleId IdType="pubmed">33542473</ArticleId></ArticleIdList></Reference><Reference><Citation>Filho A. C., de Moraes Batista A. F., dos Santos H. G. (2021). Data Leakage in Health Outcomes Prediction With Machine Learning. Comment on &#x201c;Prediction of Incident Hypertension Within the Next Year: Prospective Study Using Statewide Electronic Health Records and Machine Learning&#x201d;. J. Med. Internet. Res. 23, 1&#x2013;3. 10.2196/10969</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/10969</ArticleId><ArticleId IdType="pmc">PMC7880048</ArticleId><ArticleId IdType="pubmed">33570496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettman C. K., Abdalla S. M., Cohen G. H., Sampson L., Vivier P. M., Galea S. (2020). Prevalence of Depression Symptoms in US Adults before and during the COVID-19 Pandemic. JAMA Netw. Open 3 (9), e2019686. 10.1001/jamanetworkopen.2020.19686</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.19686</ArticleId><ArticleId IdType="pmc">PMC7489837</ArticleId><ArticleId IdType="pubmed">32876685</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng C., Wang L., Chen X., Zhai Y., Zhu F., Chen H., et al. (2021). A Novel Artificial Intelligence-Assisted Triage Tool to aid in the Diagnosis of Suspected COVID-19 Pneumonia Cases in Fever Clinics. Ann. Transl. Med. 9 (3), 201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940949</ArticleId><ArticleId IdType="pubmed">33708828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in China: A Systematic Review and Meta-Analysis. J. Infect. 80 (6), 656&#x2013;665. 10.1016/j.jinf.2020.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.041</ArticleId><ArticleId IdType="pmc">PMC7151416</ArticleId><ArticleId IdType="pubmed">32283155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong J., Ou J., Qiu X., Jie Y., Chen Y., Yuan L., et al. (2020). A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China. Clin. Infect. Dis. 71 (15), 833&#x2013;840. 10.1093/cid/ciaa443</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa443</ArticleId><ArticleId IdType="pmc">PMC7184338</ArticleId><ArticleId IdType="pubmed">32296824</ArticleId></ArticleIdList></Reference><Reference><Citation>Halalau A., Imam Z., Karabon P., Mankuzhy N., Shaheen A., Tu J., et al. (2021). External Validation of a Clinical Risk Score to Predict Hospital Admission and In-Hospital Mortality in COVID-19 Patients. Ann. Med. 53 (1), 78&#x2013;86. 10.1080/07853890.2020.1828616</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1828616</ArticleId><ArticleId IdType="pmc">PMC7877986</ArticleId><ArticleId IdType="pubmed">32997542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanratty B. (2019). ICD9CMtoICD10CM [Online] (Accessed March, 2, 2021)</Citation></Reference><Reference><Citation>Hastie T., Tibshirani R., Friedman J. (2001). The Elements of Statistical Learning. New York: Springer;</Citation></Reference><Reference><Citation>Heldt F. S., Vizcaychipi M. P., Peacock S., Cinelli M., McLachlan L., Andreotti F., et al. (2021). Early Risk Assessment for COVID-19 Patients From Emergency Department Data Using Machine Learning. Sci. Rep. 11 (1), 4200. 10.1038/s41598-021-83784-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83784-y</ArticleId><ArticleId IdType="pmc">PMC7892838</ArticleId><ArticleId IdType="pubmed">33603086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T., Hornik K., Zeileis A. (2006). Unbiased Recursive Partitioning: A Conditional Inference Framework. J. Comput. Graphic. Stat. 15 (3), 651&#x2013;674. 10.1198/106186006X133933</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/106186006X133933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Liu Z., Jiang Y., Shi O., Zhang X., Xu K., et al. (2021). Early Prediction of Mortality Risk Among Patients With Severe COVID-19, Using Machine Learning. Int. J. Epidemiol. 49 (6), 1918&#x2013;1929. 10.1093/ije/dyaa171</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa171</ArticleId><ArticleId IdType="pmc">PMC7543461</ArticleId><ArticleId IdType="pubmed">32997743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Radenkovic D., Perez K., Nadeau K., Verdin E., Furman D., et al. (2021). Modeling Predictive Age-Dependent and Age-Independent Symptoms and Comorbidities of Patients Seeking Treatment for COVID-19: Model Development and Validation Study. J. Med. Internet Res. 23 (3), e25696. 10.2196/25696</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/25696</ArticleId><ArticleId IdType="pmc">PMC7996196</ArticleId><ArticleId IdType="pubmed">33621185</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. (2020). Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 395 (10223), 497&#x2013;506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jehi L., Ji X., Milinovich A., Erzurum S., Merlino A., Gordon S., et al. (2020a). Development and Validation of a Model for Individualized Prediction of Hospitalization Risk in 4,536 Patients with COVID-19. PLoS One 15 (8), e0237419. 10.1371/journal.pone.0237419</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237419</ArticleId><ArticleId IdType="pmc">PMC7418996</ArticleId><ArticleId IdType="pubmed">32780765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jehi L., Ji X., Milinovich A., Erzurum S., Rubin B. P., Gordon S., et al. (2020b). Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing. Chest 158 (4), 1364&#x2013;1375. 10.1016/j.chest.2020.05.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.05.580</ArticleId><ArticleId IdType="pmc">PMC7286244</ArticleId><ArticleId IdType="pubmed">32533957</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi R. P., Pejaver V., Hammarlund N. E., Sung H., Lee S. K., Furmanchuk A., et al. (2020). A predictive Tool for Identification of SARS-CoV-2 PCR-Negative Emergency Department Patients Using Routine Test Results. J Clin. Virol. 129, 104502. 10.1016/j.jcv.2020.104502</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104502</ArticleId><ArticleId IdType="pmc">PMC7286235</ArticleId><ArticleId IdType="pubmed">32544861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohavi R., Brodley C., Frasca B. (2000). KDD-Cup 2000 Organizers&#x2019; Report: Peeling the Onion. ACM SIGKDD Explorations Newsletter 2 (2), 86&#x2013;98. 10.1145/380995.381033</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/380995.381033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman S., Rosset S., Perlich C., Stitelman O. (2012). Leakage in Data Mining: Formulation, Detection, and Avoidance. ACM Trans Knowl Discov Data 6, 563&#x2013;556. 10.1145/2382577.2382579</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2382577.2382579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullar R., Marcelin J. R., Swartz T. H., Piggott D. A., Macias Gil R., Mathew T. A., et al. (2020). Racial Disparity of Coronavirus Disease 2019 in African American Communities. J. Infect. Dis. 222 (6), 890&#x2013;893. 10.1093/infdis/jiaa372</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa372</ArticleId><ArticleId IdType="pmc">PMC7337812</ArticleId><ArticleId IdType="pubmed">32599614</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Liang H., Ou L., Chen B., Chen A., Li C., et al. (2020). Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients with COVID-19. JAMA Intern. Med. 180 (8), 1081&#x2013;1089. 10.1001/jamainternmed.2020.2033</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2033</ArticleId><ArticleId IdType="pmc">PMC7218676</ArticleId><ArticleId IdType="pubmed">32396163</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Chen S., Liu M., Nie H., Lu H. (2020). Comorbid Chronic Diseases Are Strongly Correlated with Disease Severity Among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging Dis. 11 (3), 668&#x2013;678. 10.14336/AD.2020.0502</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0502</ArticleId><ArticleId IdType="pmc">PMC7220287</ArticleId><ArticleId IdType="pubmed">32489711</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell T. (1997). Machine Learning. New York:McGraw Hill.</Citation></Reference><Reference><Citation>Nami M., Gadad B. S., Chong L., Ghumman U., Misra A., Gadad S. S., et al. (2020). The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies. J Clin Med. 9 (8), 2624. 10.3390/jcm9082624</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082624</ArticleId><ArticleId IdType="pmc">PMC7464612</ArticleId><ArticleId IdType="pubmed">32823540</ArticleId></ArticleIdList></Reference><Reference><Citation>NCATS (2020). COVID-19 Clinical Data Warehouse Data Dictionary Based on OMOP Common Data Model Specifications. Version 5.3.1</Citation></Reference><Reference><Citation>Nisbet R., Elder J., Miner J. (2009). Handbook of Statistical Analysis and Data Mining Applications Academic Press.</Citation></Reference><Reference><Citation>Nishiga M., Wang D. W., Han Y., Lewis D. B., Wu J. C. (2020). COVID-19 and Cardiovascular Disease: from Basic Mechanisms to Clinical Perspectives. Nat. Rev. Cardiol. 17 (9), 543&#x2013;558. 10.1038/s41569-020-0413-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Malley K. J., Cook K. F., Price M. D., Wildes K. R., Hurdle J. F., Ashton C. M. (2005). Measuring Diagnoses: ICD Code Accuracy. Health Serv. Res. 40 (5 Pt 2), 1620&#x2013;1639. 10.1111/j.1475-6773.2005.00444.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2005.00444.x</ArticleId><ArticleId IdType="pmc">PMC1361216</ArticleId><ArticleId IdType="pubmed">16178999</ArticleId></ArticleIdList></Reference><Reference><Citation>Oetjens M. T., Luo J. Z., Chang A., Leader J. B., Hartzel D. N., Moore B. S., et al. (2020). Electronic Health Record Analysis Identifies Kidney Disease as the Leading Risk Factor for Hospitalization in Confirmed COVID-19 Patients. PLoS One 15 (11), e0242182. 10.1371/journal.pone.0242182</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0242182</ArticleId><ArticleId IdType="pmc">PMC7660530</ArticleId><ArticleId IdType="pubmed">33180868</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne T. F., Veigulis Z. P., Arreola D. M., R&#xf6;&#xf6;sli E., Curtin C. M. (2020). Automated EHR Score to Predict COVID-19 Outcomes at US Department of Veterans Affairs. PLoS One 15 (7), e0236554. 10.1371/journal.pone.0236554</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236554</ArticleId><ArticleId IdType="pmc">PMC7384633</ArticleId><ArticleId IdType="pubmed">32716922</ArticleId></ArticleIdList></Reference><Reference><Citation>Polosa R., Caci G. (2020). COVID-19: Counter-intuitive Data on Smoking Prevalence and Therapeutic Implications for Nicotine. Intern. Emerg. Med. 15 (5), 853&#x2013;856. 10.1007/s11739-020-02361-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-020-02361-9</ArticleId><ArticleId IdType="pmc">PMC7236870</ArticleId><ArticleId IdType="pubmed">32430652</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkin B. M., Du S., Green W. D., Beck M. A., Algaith T., Herbst C. H., et al. (2020). Individuals with Obesity and COVID&#x2010;19: A Global Perspective on the Epidemiology and Biological Relationships. Obes. Rev. 21 (11), e13128. 10.1111/obr.13128</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13128</ArticleId><ArticleId IdType="pmc">PMC7461480</ArticleId><ArticleId IdType="pubmed">32845580</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashedi J., Mahdavi Poor B., Asgharzadeh V., Pourostadi M., Samadi Kafil H., Vegari A., et al. (2020). Risk Factors for COVID-19. Infez Med. 28 (4), 469&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab P., Mehrjou A., Parbhoo S., Celi L. A., Hetzel J., Hofer M., et al. (2021). Real-time Prediction of COVID-19 Related Mortality Using Electronic Health Records. Nat. Commun. 12 (1), 1058. 10.1038/s41467-020-20816-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20816-7</ArticleId><ArticleId IdType="pmc">PMC7886884</ArticleId><ArticleId IdType="pubmed">33594046</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoda E.-M., B&#xe4;uerle A., Schweda A., D&#xf6;rrie N., Musche V., Hetkamp M., et al. (2020). Severely Increased Generalized Anxiety, but Not COVID-19-Related Fear in Individuals with Mental Illnesses: A Population Based Cross-Sectional Study in Germany. Int. J. Soc. Psychiatry., 20764020960773. 10.1177/0020764020960773</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0020764020960773</ArticleId><ArticleId IdType="pubmed">33040668</ArticleId></ArticleIdList></Reference><Reference><Citation>Szepannek G. (2020). An Overview on the Landscape of R Packages for Credit Scoring. arXiv XX, 1&#x2013;25.</Citation></Reference><Reference><Citation>Tibshirani R. (1996). Regression Shrinkage and Selection via the Lasso. J. R. Stat. Soc. Ser. B (Methodological) 58 (1), 267&#x2013;288. 10.1111/j.2517-6161.1996.tb02080.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1996.tb02080.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaid A., Somani S., Russak A. J., De Freitas J. K., Chaudhry F. F., Paranjpe I., et al. (2020). Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients with COVID-19 in New York City: Model Development and Validation. J. Med. Internet Res. 22 (11), e24018. 10.2196/24018</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/24018</ArticleId><ArticleId IdType="pmc">PMC7652593</ArticleId><ArticleId IdType="pubmed">33027032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Davis P. B., Gurney M. E., Xu R. (2021a). COVID&#x2010;19 and Dementia: Analyses of Risk, Disparity, and Outcomes from Electronic Health Records in the US. Alzheimer's Demen. 10.1002/alz.12296</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12296</ArticleId><ArticleId IdType="pmc">PMC8014535</ArticleId><ArticleId IdType="pubmed">33559975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Davis P. B., Xu R. (2021b). COVID-19 Risk, Disparities and Outcomes in Patients with Chronic Liver Disease in the United States. EClinicalMedicine 31, 100688. 10.1016/j.eclinm.2020.100688</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100688</ArticleId><ArticleId IdType="pmc">PMC7834443</ArticleId><ArticleId IdType="pubmed">33521611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L., Van Calster B., Collins G. S., Riley R. D., Heinze G., Schuit E., et al. (2020). Prediction Models for Diagnosis and Prognosis of Covid-19: Systematic Review and Critical Appraisal. BMJ 369, m1328. 10.1136/bmj.m1328</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J. M., Koh H. Y., Moon S. Y., Yoo I. K., Ha E. K., You S., et al. (2020). Allergic Disorders and Susceptibility to and Severity of COVID-19: A Nationwide Cohort Study. J. Allergy Clin. Immunol. 146 (4), 790&#x2013;798. 10.1016/j.jaci.2020.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.08.008</ArticleId><ArticleId IdType="pmc">PMC7428784</ArticleId><ArticleId IdType="pubmed">32810517</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdravevski E., Lameski P., Kulakov A. (2011). Weight of Evidence as a tool for Attribute Transformation in the Preprocessing Stage of Supervised Learning Algorithms in: The 2011 International Joint Conference on Neural Networks, 181&#x2013;188.</Citation></Reference><Reference><Citation>Zhao Z., Chen A., Hou W., Graham J. M., Li H., Richman P. S., et al. (2020). Prediction Model and Risk Scores of ICU Admission and Mortality in COVID-19. PLoS One 15 (7), e0236618. 10.1371/journal.pone.0236618</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236618</ArticleId><ArticleId IdType="pmc">PMC7392248</ArticleId><ArticleId IdType="pubmed">32730358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H., Hastie T. (2005). Regularization and Variable Selection via the Elastic Net. J. R. Stat. Soc B 67 (2), 301&#x2013;320. 10.1111/j.1467-9868.2005.00503.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-9868.2005.00503.x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34174396</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Adaptation of an NLP system to a new healthcare environment to identify social determinants of health.</ArticleTitle><Pagination><StartPage>103851</StartPage><MedlinePgn>103851</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2021.103851</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(21)00180-5</ELocationID><Abstract><AbstractText>Social determinants of health (SDoH) are increasingly important factors for population health, healthcare outcomes, and care delivery. However, many of these factors are not reliably captured within structured electronic health record (EHR) data. In this work, we evaluated and adapted a previously published NLP tool to include additional social risk factors for deployment at Vanderbilt University Medical Center in an Acute Myocardial Infarction cohort. We developed a transformation of the SDoH outputs of the tool into the OMOP common data model (CDM) for re-use across many potential use cases, yielding performance measures across 8 SDoH classes of precision 0.83 recall 0.74 and F-measure of 0.78.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Ruth M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States; Geriatric Research Education and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville, TN, United States. Electronic address: ruth.reeves@vumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeremiah R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biomedical Data Science, Dartmouth Geisel School of Medicine, Hanover, NH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levis</LastName><ForeName>Maxwell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biomedical Data Science, Dartmouth Geisel School of Medicine, Hanover, NH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbel</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States; Division of General Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Geriatric Research Education and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Rashmee U</ForeName><Initials>RU</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodrich</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biomedical Data Science, Dartmouth Geisel School of Medicine, Hanover, NH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricket</LastName><ForeName>Iben</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biomedical Data Science, Dartmouth Geisel School of Medicine, Hanover, NH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minter</LastName><ForeName>Freneka</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohm</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biomedical Data Science, Dartmouth Geisel School of Medicine, Hanover, NH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bray</LastName><ForeName>Bruce E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States; Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States; Division of General Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Geriatric Research Education and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT, United States; Centre for Clinical and Public Health Informatics, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 HL136850</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL130828</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 LM012204</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000046" MajorTopicYN="N">Academic Medical Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064890" MajorTopicYN="Y">Social Determinants of Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>26</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34174396</ArticleId><ArticleId IdType="mid">NIHMS1720934</ArticleId><ArticleId IdType="pmc">PMC8386129</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2021.103851</ArticleId><ArticleId IdType="pii">S1532-0464(21)00180-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hatef ESK, Predmore Z, Lasser EC, et al.The Impact of Social Determinants of Health on Hospitalization in the Veterans Health Administration. American Journal of Preventative Medicine 2019;56:811&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31003812</ArticleId></ArticleIdList></Reference><Reference><Citation>Havranek EP, Mujahid MS, Barr DA, et al.Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2015;132:873&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26240271</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. World Health Organization Commission on Social Determinants of Health. Geneva: World Health Organization; 2008.</Citation></Reference><Reference><Citation>Conway M, Keyhani S, Christensen L, et al.Moonstone: a novel natural language processing system for inferring social risk from clinical narratives. J Biomed Semantics 2019;10:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6458709</ArticleId><ArticleId IdType="pubmed">30975223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SYTA, Claggett B, Chandra A, Khatana SAM, Lutsey PL, Kucharska-Newton A, Koton S, Solomon SD, Kawachi I. . Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. JAMA Cardiology 2019;4:1203&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802267</ArticleId><ArticleId IdType="pubmed">31596441</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfassy T, Swift SL, Glymour MM, et al.Associations of Income Volatility With Incident Cardiovascular Disease and All-Cause Mortality in a US Cohort. Circulation 2019;139:850&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6370510</ArticleId><ArticleId IdType="pubmed">30612448</ArticleId></ArticleIdList></Reference><Reference><Citation>Joynt KEMT. Looking Beyond the Hospital to Reduce Acute Myocardial Infarction: Progress and Potential. JAMA Cardiology 2016;1:251&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27438101</ArticleId></ArticleIdList></Reference><Reference><Citation>Manrique-Garcia ESA, Hallqvist J, et al.Socioeconomic position and incidence of acute myocardial infarction: a meta-analysis. Journal of Epidemiology &amp; Community Health Journal of Epidemiology and Community Health 2011;65:301&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20841371</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatz ESBA, Wang Y, Desai NR, Krumholz HM. . Geographic Variation in Trends and Disparities in Acute Myocardial Infarction Hospitalization and Mortality by Income Levels. JAMA Cardiology 2016;1:255&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5459393</ArticleId><ArticleId IdType="pubmed">27438103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood) 2014;33:778&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24799574</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett ML, Hsu J, McWilliams JM. Patient Characteristics and Differences in Hospital Readmission Rates. JAMA Intern Med 2015;175:1803&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991542</ArticleId><ArticleId IdType="pubmed">26368317</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academy of Medicine (formerly Institute of Medicine). Capturing Social and Behavioral Domains in Electronic Health Records: Phase 1. The National Academy Press; 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24757748</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academy of Medicine (formerly Institute of Medicine) Capturing Social and Behavioral Domains and Measures in Electronic Health Records: Phase 2. The National Academies Press; 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">25590118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejan CA, Angiolillo J, Conway D, Nash R, Shirey-Rice JK, Lipworth, et al.Mining 100 million notes to find homelessness and adverse childhood experiences: 2 case studies of rare and severe social determinants of health in electronic health records. Journal of American Medical Informatics Association 2018;25:61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080810</ArticleId><ArticleId IdType="pubmed">29016793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Tan X, Padman R. Social determinants of health in electronic health records and their impact on analysis and risk prediction: A systematic review. J Am Med Inform Assoc 2020;27:1764&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7671639</ArticleId><ArticleId IdType="pubmed">33202021</ArticleId></ArticleIdList></Reference><Reference><Citation>Freij M, Dullabh P, Lewis S, Smith SR, Hovey L, Dhopeshwarkar R. Incorporating Social Determinants of Health in Electronic Health Records: Qualitative Study of Current Practices Among Top Vendors. JMIR Med Inform 2019;7:e13849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592390</ArticleId><ArticleId IdType="pubmed">31199345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantor MN, Thorpe L. Integrating Data On Social Determinants Of Health Into Electronic Health Records. Health Aff (Millwood) 2018;37:585&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10995852</ArticleId><ArticleId IdType="pubmed">29608369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade G, Rosenbloom S. Experiences mapping a legacy interface terminology to SNOMED CT. BMC Medical Informatics and Decision Making 2008;8:S3 - S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582790</ArticleId><ArticleId IdType="pubmed">19007440</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom S, Miller R, Johnson K, Elkin P, Brown S. Interface Terminologies: Facilitating Direct Entry of Clinical Data into Electronic Health Record Systems. Journal of the American Medical Informatics Association 2006;13:277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513664</ArticleId><ArticleId IdType="pubmed">16501181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatef E, Rouhizadeh M, Tia I, et al.Assessing the Availability of Data on Social and Behavioral Determinants in Structured and Unstructured Electronic Health Records: A Retrospective Analysis of a Multilevel Health Care System. JMIR Med Inform 2019;7:e13802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696855</ArticleId><ArticleId IdType="pubmed">31376277</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundlapalli AV, Carter ME, Divita G, Shen S, Palmer M, South B, et al.Extracting Concepts Related to Homelessness from the Free Text of VA Electronic Medical Records. AMIA Symposium: AMIA Annual Symposium Proceedings Archives; 2014:589&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419940</ArticleId><ArticleId IdType="pubmed">25954364</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundlapalli AV, Carter ME, Palmer M, Ginter T, Redd A, Pickard S, et al.Using natural language processing on the free text of clinical documents to screen for evidence of homelessness among US veterans. AMIA Symposium: AMIA Annual Symposium Proceedings Archives; 2013:537&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900197</ArticleId><ArticleId IdType="pubmed">24551356</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea Wang. Automated Extraction of Substance Use Information from Clinical Texts. AMIA Annual Symposium proceedings 2015;20152121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765598</ArticleId><ArticleId IdType="pubmed">26958312</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald JL, Cronin PR, Carballo V, Danaei G, Choy G. A Novel Model for Predicting Rehospitalization Risk Incorporating Physical Function, Cognitive Status, and Psychosocial Support Using Natural Language Processing. Med Care 2017;55:261&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27632767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumshisky A, Ghassemi M, Naumann T, et al.Predicting early psychiatric readmission with natural language processing of narrative discharge summaries. Transl Psychiatry 2016;6:e921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315537</ArticleId><ArticleId IdType="pubmed">27754482</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. The Book of OHDSI: Observational Health Data Sciences and Informatics: OHSDI; 2019.</Citation></Reference><Reference><Citation>Dorr D, Bejan CA, Pizzimenti C, Singh S, Storer M, Quinones A. Identifying Patients with Significant Problems Related to Social Determinants of Health with Natural Language Processing. Stud Health Technol Inform 2019;264:1456&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438179</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Lakin J, Riley C, Korach Z, Frain LN, Zhou L. Disease Trajectories and End-of-Life Care for Dementias: Latent Topic Modeling and Trend Analysis Using Clinical Notes. AMIA Annu Symp Proc 2018;2018:1056&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371376</ArticleId><ArticleId IdType="pubmed">30815148</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheny ME, Ricket I, Goodrich CA, et al.Development of Electronic Health Record&#x2013;Based Prediction Models for 30-Day Readmission Risk Among Patients Hospitalized for Acute Myocardial Infarction. JAMA Network Open 2021;4:e2035782-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846941</ArticleId><ArticleId IdType="pubmed">33512518</ArticleId></ArticleIdList></Reference><Reference><Citation>South BR, Mowery D, Suo Y, et al.Evaluating the effects of machine pre-annotation and an interactive annotation interface on manual de-identification of clinical text. J Biomed Inform 2014;50:162&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627768</ArticleId><ArticleId IdType="pubmed">24859155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruth M. Reeves BS, Glenn Gobbel, Lee Christensen, Paul Thompson, Wendy Chapman, Michael Matheny, Jeremiah Brown. Annotating Social Determinants of Health and Functional Status Information Using Publicly Accessible Corpora. AMIA annual symposium. San Francisco, CA2018.</Citation></Reference><Reference><Citation>Winden TJ, Chen ES, Melton GB. Representing Residence, Living Situation, and Living Conditions: An Evaluation of Terminologies, Standards, Guidelines, and Measures/Surveys. AMIA Annu Symp Proc 2016;2016:2072&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333311</ArticleId><ArticleId IdType="pubmed">28269967</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academy of Medicine (formerly Institute of Medicine) Capturing Social and Behavioral Domains and Measures in Electronic Health Records: Phase 2. Washington (DC)2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">25590118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jani A, Liyanage H, Okusi C, et al.Using an Ontology to Facilitate More Accurate Coding of Social Prescriptions Addressing Social Determinants of Health: Feasibility Study. J Med Internet Res 2020;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7762682</ArticleId><ArticleId IdType="pubmed">33306032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasser EC, Kim JM, Hatef E, Kharrazi H, Marsteller JA, DeCamp LR. Social and Behavioral Variables in the Electronic Health Record: A Path Forward to Increase Data Quality and Utility. Acad Med 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243784</ArticleId><ArticleId IdType="pubmed">33735133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34185008</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>A National, Semantic-Driven, Three-Pillar Strategy to Enable Health Data Secondary Usage Interoperability for Research Within the Swiss Personalized Health Network: Methodological Study.</ArticleTitle><Pagination><StartPage>e27591</StartPage><MedlinePgn>e27591</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e27591</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/27591</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Interoperability is a well-known challenge in medical informatics. Current trends in interoperability have moved from a data model technocentric approach to sustainable semantics, formal descriptive languages, and processes. Despite many initiatives and investments for decades, the interoperability challenge remains crucial. The need for data sharing for most purposes ranging from patient care to secondary uses, such as public health, research, and quality assessment, faces unmet problems.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This work was performed in the context of a large Swiss Federal initiative aiming at building a national infrastructure for reusing consented data acquired in the health care and research system to enable research in the field of personalized medicine in Switzerland. The initiative is the Swiss Personalized Health Network (SPHN). This initiative is providing funding to foster use and exchange of health-related data for research. As part of the initiative, a national strategy to enable a semantically interoperable clinical data landscape was developed and implemented.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A deep analysis of various approaches to address interoperability was performed at the start, including large frameworks in health care, such as Health Level Seven (HL7) and Integrating Healthcare Enterprise (IHE), and in several domains, such as regulatory agencies (eg, Clinical Data Interchange Standards Consortium [CDISC]) and research communities (eg, Observational Medical Outcome Partnership [OMOP]), to identify bottlenecks and assess sustainability. Based on this research, a strategy composed of three pillars was designed. It has strong multidimensional semantics, descriptive formal language for exchanges, and as many data models as needed to comply with the needs of various communities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This strategy has been implemented stepwise in Switzerland since the middle of 2019 and has been adopted by all university hospitals and high research organizations. The initiative is coordinated by a central organization, the SPHN Data Coordination Center of the SIB Swiss Institute of Bioinformatics. The semantics is mapped by domain experts on various existing standards, such as Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), Logical Observation Identifiers Names and Codes (LOINC), and International Classification of Diseases (ICD). The resource description framework (RDF) is used for storing and transporting data, and to integrate information from different sources and standards. Data transformers based on SPARQL query language are implemented to convert RDF representations to the numerous data models required by the research community or bridge with other systems, such as electronic case report forms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The SPHN strategy successfully implemented existing standards in a pragmatic and applicable way. It did not try to build any new standards but used existing ones in a nondogmatic way. It has now been funded for another 4 years, bringing the Swiss landscape into a new dimension to support research in the field of personalized medicine and large interoperable clinical data.</AbstractText><CopyrightInformation>&#xa9;Christophe Gaudet-Blavignac, Jean Louis Raisaro, Vasundra Tour&#xe9;, Sabine &#xd6;sterle, Katrin Crameri, Christian Lovis. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 24.06.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaudet-Blavignac</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6527-5898</Identifier><AffiliationInfo><Affiliation>Division of Medical Information Sciences, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Medical Informatics, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raisaro</LastName><ForeName>Jean Louis</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-2052-6133</Identifier><AffiliationInfo><Affiliation>Data Science Group, Division of Information Systems, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Medicine Unit, Department of Laboratories, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tour&#xe9;</LastName><ForeName>Vasundra</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-4639-4431</Identifier><AffiliationInfo><Affiliation>Personalized Health Informatics Group, SIB Swiss Institute of Bioinformatics, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;sterle</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3248-7899</Identifier><AffiliationInfo><Affiliation>Personalized Health Informatics Group, SIB Swiss Institute of Bioinformatics, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crameri</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3656-3457</Identifier><AffiliationInfo><Affiliation>Personalized Health Informatics Group, SIB Swiss Institute of Bioinformatics, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovis</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2681-8076</Identifier><AffiliationInfo><Affiliation>Division of Medical Information Sciences, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Medical Informatics, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical data reuse</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword></KeywordList><CoiStatement>Conflicts of Interest: CL is the Editor-in-Chief of this journal (JMIR Medical Informatics).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34185008</ArticleId><ArticleId IdType="pmc">PMC8277320</ArticleId><ArticleId IdType="doi">10.2196/27591</ArticleId><ArticleId IdType="pii">v9i6e27591</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Classification of Diseases, 11th Revision (ICD-11) World Health Organization.  [2021-06-09].   http://www.who.int/classifications/icd/en/</Citation></Reference><Reference><Citation>Health Level Seven International-Homepage. HL7 International.  [2021-06-09].   http://www.hl7.org/</Citation></Reference><Reference><Citation>Bhattacharyya SB. Introduction to SNOMED CT. Singapore: Springer; 2016. SNOMED CT History and IHTSDO.</Citation></Reference><Reference><Citation>Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010 Aug 05;363(6):501&#x2013;4. doi: 10.1056/NEJMp1006114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1006114</ArticleId><ArticleId IdType="pubmed">20647183</ArticleId></ArticleIdList></Reference><Reference><Citation>Integrating the Healthcare Enterprise (IHE) IHE International.  [2021-06-09].   https://www.ihe.net/</Citation></Reference><Reference><Citation>Sternbach GL. The Glasgow Coma Scale. The Journal of Emergency Medicine. 2000 Jul;19(1):67&#x2013;71. doi: 10.1016/s0736-4679(00)00182-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0736-4679(00)00182-7</ArticleId><ArticleId IdType="pubmed">10863122</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics, Committee on Fetus and Newborn. American College of Obstetricians and Gynecologists and Committee on Obstetric Practice The Apgar score. Pediatrics. 2006 Apr;117(4):1444&#x2013;7. doi: 10.1542/peds.2006-0325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-0325</ArticleId><ArticleId IdType="pubmed">16585348</ArticleId></ArticleIdList></Reference><Reference><Citation>What Are the Classifications of Heart Failure? Heart Failure. 2019.  [2021-06-09].   https://heart-failure.net/classification.</Citation></Reference><Reference><Citation>Schoonjans F, Zalata A, Depuydt CE, Comhaire FH. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995 Dec;48(3):257&#x2013;62. doi: 10.1016/0169-2607(95)01703-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-2607(95)01703-8</ArticleId><ArticleId IdType="pubmed">8925653</ArticleId></ArticleIdList></Reference><Reference><Citation>Elovic A, Pourmand A. MDCalc Medical Calculator App Review. J Digit Imaging. 2019 Oct;32(5):682&#x2013;684. doi: 10.1007/s10278-019-00218-y.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-019-00218-y</ArticleId><ArticleId IdType="pmc">PMC6737202</ArticleId><ArticleId IdType="pubmed">31025219</ArticleId></ArticleIdList></Reference><Reference><Citation>ICD-10 Version:2019. World Health Organization.  [2021-06-09].   https://icd.who.int/browse10/2019/en.</Citation></Reference><Reference><Citation>McDonald CJ, Huff SM, Suico JG, Hill G, Leavelle D, Aller R, Forrey A, Mercer K, DeMoor G, Hook J, Williams W, Case J, Maloney P. LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem. 2003 Apr;49(4):624&#x2013;33. doi: 10.1373/49.4.624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/49.4.624</ArticleId><ArticleId IdType="pubmed">12651816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004 Jan 01;32(Database issue):D267&#x2013;70. doi: 10.1093/nar/gkh061.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh061</ArticleId><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>The Unified Medical Language System (UMLS) National Library of Medicine.  [2021-06-09].   https://www.nlm.nih.gov/research/umls/new_users/online_learning/OVR_001.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">10104531</ArticleId></ArticleIdList></Reference><Reference><Citation>GTIN Definition: Information. GTIN.  [2021-06-09].   https://www.gtin.info/</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology-Home. WHOCC.  [2021-06-09].   https://www.whocc.no/</Citation></Reference><Reference><Citation>MedDRA.  [2021-06-09].   https://www.meddra.org/</Citation></Reference><Reference><Citation>Planned transition to concrete domains. SNOMED. 2020.  [2021-06-09].   https://www.snomed.org/news-and-events/articles/planned-transition-concrete-domains.</Citation></Reference><Reference><Citation>Gaudet-Blavignac C, Foufi V, Bjelogrlic M, Lovis C. Use of the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) for Processing Free Text in Health Care: Systematic Scoping Review. J Med Internet Res. 2021 Jan 26;23(1):e24594. doi: 10.2196/24594.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/24594</ArticleId><ArticleId IdType="pmc">PMC7872838</ArticleId><ArticleId IdType="pubmed">33496673</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson T, Grieve G. Principles of Health Interoperability. Health Information Technology Standards. Cham: Springer; 2016. Implementing Terminologies; pp. 189&#x2013;219.</Citation></Reference><Reference><Citation>Benson T, Grieve G. Principles of Health Interoperability. Health Information Technology Standards. Cham: Springer; 2016. The HL7 v3 RIM; pp. 243&#x2013;264.</Citation></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us Research Program: Transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14(2):e0212463. doi: 10.1371/journal.pone.0212463.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model. OHDSI.  [2021-06-09].   https://www.ohdsi.org/data-standardization/the-common-data-model/</Citation></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, Kohane I. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010;17(2):124&#x2013;30. doi: 10.1136/jamia.2009.000893.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hume S, Aerts J, Sarnikar S, Huser V. Current applications and future directions for the CDISC Operational Data Model standard: A methodological review. J Biomed Inform. 2016 Apr;60:352&#x2013;62. doi: 10.1016/j.jbi.2016.02.016.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.02.016</ArticleId><ArticleId IdType="pmc">PMC4837012</ArticleId><ArticleId IdType="pubmed">26944737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra D, Beale T, Heard S. The openEHR Foundation. Stud Health Technol Inform. 2005;115:153&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160223</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas B. Archetypes: Constraint-based Domain Models for Futureproof Information Systems. CiteSeerX. 2000.  [2021-06-09].   http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.21.1158.</Citation></Reference><Reference><Citation>Swiss Personalized Health Network (SPHN)  [2021-06-09].   https://sphn.ch.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>First review report of the International Advisory Board. SPHN. 2019.  [2021-06-09].   https://sphn.ch/2019/12/20/iab-report/</Citation></Reference><Reference><Citation>Swiss Personalized Health Network  Report from the National Steering Board 2016&#x2013;2019. Zenodo.  [2021-06-09].   https://zenodo.org/record/4044123.</Citation></Reference><Reference><Citation>Resource Description Framework (RDF): Concepts and Abstract Syntax. W3C.  [2021-06-09].   https://www.w3.org/TR/rdf-concepts/</Citation></Reference><Reference><Citation>Samwald M, Fehre K, de Bruin J, Adlassnig K. The Arden Syntax standard for clinical decision support: experiences and directions. J Biomed Inform. 2012 Aug;45(4):711&#x2013;8. doi: 10.1016/j.jbi.2012.02.001.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.02.001</ArticleId><ArticleId IdType="pubmed">22342733</ArticleId></ArticleIdList></Reference><Reference><Citation>OWL Web Ontology Language Semantics and Abstract Syntax. W3C.  [2021-06-09].   https://www.w3.org/TR/2004/REC-owl-semantics-20040210/</Citation></Reference><Reference><Citation>Peleg M, Boxwala AA, Ogunyemi O, Zeng Q, Tu S, Lacson R, Bernstam E, Ash N, Mork P, Ohno-Machado L, Shortliffe EH, Greenes RA. GLIF3: the evolution of a guideline representation format. Proc AMIA Symp. 2000:645&#x2013;9.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243832</ArticleId><ArticleId IdType="pubmed">11079963</ArticleId></ArticleIdList></Reference><Reference><Citation>jBPM.  [2021-06-09].   https://www.jbpm.org/</Citation></Reference><Reference><Citation>Mate S, K&#xf6;pcke F, Toddenroth D, Martin M, Prokosch H, B&#xfc;rkle T, Ganslandt T. Ontology-based data integration between clinical and research systems. PLoS One. 2015;10(1):e0116656. doi: 10.1371/journal.pone.0116656.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116656</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0116656</ArticleId><ArticleId IdType="pmc">PMC4294641</ArticleId><ArticleId IdType="pubmed">25588043</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr MR, Majeed RW, G&#xfc;nther A. Metadata Import from RDF to i2b2. Stud Health Technol Inform. 2018;253:40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">30147037</ArticleId></ArticleIdList></Reference><Reference><Citation>Solbrig HR, Hong N, Murphy SN, Jiang G. Automated Population of an i2b2 Clinical Data Warehouse using FHIR. AMIA Annu Symp Proc. 2018;2018:979&#x2013;988.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371332</ArticleId><ArticleId IdType="pubmed">30815141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacaci A, Gonul S, Sinaci AA, Yuksel M, Laleci Erturkmen GB. A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies. Front Pharmacol. 2018 Apr 30;9:435. doi: 10.3389/fphar.2018.00435. doi: 10.3389/fphar.2018.00435.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00435</ArticleId><ArticleId IdType="doi">10.3389/fphar.2018.00435</ArticleId><ArticleId IdType="pmc">PMC5937227</ArticleId><ArticleId IdType="pubmed">29760661</ArticleId></ArticleIdList></Reference><Reference><Citation>Data Coordination Center (DCC) SPHN.  [2021-06-09].   https://sphn.ch/network/data-coordination-center/</Citation></Reference><Reference><Citation>SPHN Dataset Release. SPHN.  [2021-06-09].   https://sphn.ch/document/sphn-dataset/</Citation></Reference><Reference><Citation>Decker S, Melnik S, van Harmelen F, Fensel D, Klein M, Broekstra J, Erdmann M, Horrocks I. The Semantic Web: the roles of XML and RDF. IEEE Internet Comput. 2000 Sep;4(5):63&#x2013;73. doi: 10.1109/4236.877487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/4236.877487</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, Wu G, D'Eustachio P, Schaefer C, Luciano J, Schacherer F, Martinez-Flores I, Hu Z, Jimenez-Jacinto V, Joshi-Tope G, Kandasamy K, Lopez-Fuentes AC, Mi H, Pichler E, Rodchenkov I, Splendiani A, Tkachev S, Zucker J, Gopinath G, Rajasimha H, Ramakrishnan R, Shah I, Syed M, Anwar N, Babur O, Blinov M, Brauner E, Corwin D, Donaldson S, Gibbons F, Goldberg R, Hornbeck P, Luna A, Murray-Rust P, Neumann E, Ruebenacker O, Reubenacker O, Samwald M, van Iersel M, Wimalaratne S, Allen K, Braun B, Whirl-Carrillo M, Cheung K, Dahlquist K, Finney A, Gillespie M, Glass E, Gong L, Haw R, Honig M, Hubaut O, Kane D, Krupa S, Kutmon M, Leonard J, Marks D, Merberg D, Petri V, Pico A, Ravenscroft D, Ren L, Shah N, Sunshine M, Tang R, Whaley R, Letovksy S, Buetow KH, Rzhetsky A, Schachter V, Sobral BS, Dogrusoz U, McWeeney S, Aladjem M, Birney E, Collado-Vides J, Goto S, Hucka M, Le Nov&#xe8;re N, Maltsev N, Pandey A, Thomas P, Wingender E, Karp PD, Sander C, Bader GD. The BioPAX community standard for pathway data sharing. Nat Biotechnol. 2010 Sep;28(9):935&#x2013;42. doi: 10.1038/nbt.1666.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1666</ArticleId><ArticleId IdType="pmc">PMC3001121</ArticleId><ArticleId IdType="pubmed">20829833</ArticleId></ArticleIdList></Reference><Reference><Citation>Antezana E, Blond&#xe9; W, Ega&#xf1;a M, Rutherford A, Stevens R, De Baets B, Mironov V, Kuiper M. BioGateway: a semantic systems biology tool for the life sciences. BMC Bioinformatics. 2009 Oct 01;10 Suppl 10:S11. doi: 10.1186/1471-2105-10-S10-S11.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-10-S10-S11</ArticleId><ArticleId IdType="doi">10.1186/1471-2105-10-S10-S11</ArticleId><ArticleId IdType="pmc">PMC2755819</ArticleId><ArticleId IdType="pubmed">19796395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmann S, Link V, Marbach E, Negru S. WebVOWL: Web-based Visualization of Ontologies. In: Lambrix P, Hyv&#xf6;nen E, Blomqvist E, Presutti V, Qi G, Sattler U, Ding Y, Ghidini C, editors. Knowledge Engineering and Knowledge Management. EKAW 2014. Lecture Notes in Computer Science, vol 8982. Cham: Springer; 2015. pp. 154&#x2013;158.</Citation></Reference><Reference><Citation>Musen MA, Prot&#xe9;g&#xe9; Team  The Prot&#xe9;g&#xe9; Project: A Look Back and a Look Forward. AI Matters. 2015 Jun;1(4):4&#x2013;12. doi: 10.1145/2757001.2757003.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2757001.2757003</ArticleId><ArticleId IdType="pmc">PMC4883684</ArticleId><ArticleId IdType="pubmed">27239556</ArticleId></ArticleIdList></Reference><Reference><Citation>Prot&#xe9;g&#xe9;.  [2021-06-09].   https://protege.stanford.edu/</Citation></Reference><Reference><Citation>SPHN RDF Schema. SPHN.  [2021-06-09].   https://sphn-semantic-framework.readthedocs.io/en/latest/sphn_framework/sphnrdfschema.html#technical-specification.</Citation></Reference><Reference><Citation>SPHN RDF quality control. GitLab.  [2021-06-09].   https://git.dcc.sib.swiss/sphn-semantic-framework/sphn-rdf-quality-control.</Citation></Reference><Reference><Citation>SPHN Webinar Series. SPHN.  [2021-06-09].   https://sphn.ch/services/seminars-training/</Citation></Reference><Reference><Citation>Clinical Data Semantics Interoperability Working Group Strategy. SPHN.  [2021-06-09].   https://sphn.ch/document/csi_wg_strategy/</Citation></Reference><Reference><Citation>Fact sheet Semantic Strategy. SPHN.  [2021-06-09].   https://sphn.ch/document/fact-sheet-semantic-strategy/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34214696</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>A two-stage workflow to extract and harmonize drug mentions from clinical notes into observational databases.</ArticleTitle><Pagination><StartPage>103849</StartPage><MedlinePgn>103849</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2021.103849</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(21)00178-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">The content of the clinical notes that have been continuously collected along patients' health history has the potential to provide relevant information about treatments and diseases, and to increase the value of structured data available in Electronic Health Records (EHR) databases. EHR databases are currently being used in observational studies which lead to important findings in medical and biomedical sciences. However, the information present in clinical notes is not being used in those studies, since the computational analysis of this unstructured data is much complex in comparison to structured data.</AbstractText><AbstractText Label="METHODS">We propose a two-stage workflow for solving an existing gap in Extraction, Transformation and Loading (ETL) procedures regarding observational databases. The first stage of the workflow extracts prescriptions present in patient's clinical notes, while the second stage harmonises the extracted information into their standard definition and stores the resulting information in a common database schema used in observational studies.</AbstractText><AbstractText Label="RESULTS">We validated this methodology using two distinct data sets, in which the goal was to extract and store drug related information in a new Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) database. We analysed the performance of the used annotator as well as its limitations. Finally, we described some practical examples of how users can explore these datasets once migrated to OMOP CDM databases.</AbstractText><AbstractText Label="CONCLUSION">With this methodology, we were able to show a strategy for using the information extracted from the clinical notes in business intelligence tools, or for other applications such as data exploration through the use of SQL queries. Besides, the extracted information complements the data present in OMOP CDM databases which was not directly available in the EHR database.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Jo&#xe3;o Rafael</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Aveiro, Portugal; Department of Computation, University of A Coru&#xf1;a, A Coru&#xf1;a, Spain. Electronic address: joao.rafael.almeida@ua.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Jo&#xe3;o Figueira</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Aveiro, Portugal. Electronic address: joaofsilva@ua.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos</LastName><ForeName>S&#xe9;rgio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Aveiro, Portugal. Electronic address: aleixomatos@ua.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jos&#xe9; Lu&#xed;s</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Aveiro, Portugal. Electronic address: jlo@ua.pt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057188" MajorTopicYN="N">Workflow</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical NLP</Keyword><Keyword MajorTopicYN="N">Clinical notes</Keyword><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">Information extraction</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Observational studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34214696</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2021.103849</ArticleId><ArticleId IdType="pii">S1532-0464(21)00178-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34255046</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative.</ArticleTitle><Pagination><StartPage>e2116901</StartPage><MedlinePgn>e2116901</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2116901</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.16901</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The National COVID Cohort Collaborative (N3C) is a centralized, harmonized, high-granularity electronic health record repository that is the largest, most representative COVID-19 cohort to date. This multicenter data set can support robust evidence-based development of predictive and diagnostic tools and inform clinical care and policy.</AbstractText><AbstractText Label="OBJECTIVES">To evaluate COVID-19 severity and risk factors over time and assess the use of machine learning to predict clinical severity.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In a retrospective cohort study of 1&#x202f;926&#x202f;526 US adults with SARS-CoV-2 infection (polymerase chain reaction &gt;99% or antigen &lt;1%) and adult patients without SARS-CoV-2 infection who served as controls from 34 medical centers nationwide between January 1, 2020, and December 7, 2020, patients were stratified using a World Health Organization COVID-19 severity scale and demographic characteristics. Differences between groups over time were evaluated using multivariable logistic regression. Random forest and XGBoost models were used to predict severe clinical course (death, discharge to hospice, invasive ventilatory support, or extracorporeal membrane oxygenation).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Patient demographic characteristics and COVID-19 severity using the World Health Organization COVID-19 severity scale and differences between groups over time using multivariable logistic regression.</AbstractText><AbstractText Label="RESULTS">The cohort included 174&#x202f;568 adults who tested positive for SARS-CoV-2 (mean [SD] age, 44.4 [18.6] years; 53.2% female) and 1&#x202f;133&#x202f;848 adult controls who tested negative for SARS-CoV-2 (mean [SD] age, 49.5 [19.2] years; 57.1% female). Of the 174&#x202f;568 adults with SARS-CoV-2, 32&#x202f;472 (18.6%) were hospitalized, and 6565 (20.2%) of those had a severe clinical course (invasive ventilatory support, extracorporeal membrane oxygenation, death, or discharge to hospice). Of the hospitalized patients, mortality was 11.6% overall and decreased from 16.4% in March to April 2020 to 8.6% in September to October 2020 (P&#x2009;=&#x2009;.002 for monthly trend). Using 64 inputs available on the first hospital day, this study predicted a severe clinical course using random forest and XGBoost models (area under the receiver operating curve&#x2009;=&#x2009;0.87 for both) that were stable over time. The factor most strongly associated with clinical severity was pH; this result was consistent across machine learning methods. In a separate multivariable logistic regression model built for inference, age (odds ratio [OR], 1.03 per year; 95% CI, 1.03-1.04), male sex (OR, 1.60; 95% CI, 1.51-1.69), liver disease (OR, 1.20; 95% CI, 1.08-1.34), dementia (OR, 1.26; 95% CI, 1.13-1.41), African American (OR, 1.12; 95% CI, 1.05-1.20) and Asian (OR, 1.33; 95% CI, 1.12-1.57) race, and obesity (OR, 1.36; 95% CI, 1.27-1.46) were independently associated with higher clinical severity.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This cohort study found that COVID-19 mortality decreased over time during 2020 and that patient demographic characteristics and comorbidities were associated with higher clinical severity. The machine learning models accurately predicted ultimate clinical severity using commonly collected clinical data from the first 24 hours of a hospital admission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajagos</LastName><ForeName>Janos G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Adit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradwell</LastName><ForeName>Katie Rebecca</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bremer</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>James Brian</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Michigan at Ann Arbor, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denham</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeWitt</LastName><ForeName>Peter E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Translational Research, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garibaldi</LastName><ForeName>Brian T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinney</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Elaine L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Hunter</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavuluru</LastName><ForeName>Ramakanth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Internal Medicine, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Division of Health Science Informatics, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levitt</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallipattu</LastName><ForeName>Sandeep K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Translational and Integrative Sciences Center, Oregon State University, Corvallis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muschelli</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Translational and Integrative Sciences Center, Oregon State University, Corvallis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>TriNetX, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhenglong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of biomedical informatics, Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Texas Medical Branch, Galveston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Tufts Medical Center Clinical and Translational Science Institute, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wooldridge</LastName><ForeName>Jacob T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Yun Jae</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersing</LastName><ForeName>Ken R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>TriNetX, Cambridge, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National COVID Cohort Collaborative (N3C) Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK092926</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES001247</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Jan 23:2021.01.12.21249511. doi: 10.1101/2021.01.12.21249511.</RefSource><PMID Version="1">33469592</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Netw Open. 2021 Jul 1;4(7):e2117175. doi: 10.1001/jamanetworkopen.2021.17175.</RefSource><PMID Version="1">34255055</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="Y">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Bennett reported receiving grants from the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) during the conduct of the study and grants from the NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development and NIH/National Institute of Allergy and Infectious Diseases outside the submitted work. Dr Moffitt reported receiving grants from the NIH during the conduct of the study. Dr Hajagos reported receiving grants from the NIH/NCATS during the conduct of the study. Dr Amor reported receiving commercial payment from the NCATS during the conduct of the study. Mr Bissell reported being employed by Palantir Technologies during the conduct of the study. Dr Bradwell reported being employed by Palantir Technologies during the conduct of the study and outside the submitted work. Dr Byrd reported receiving grants from the NIH/National Heart, Lung, and Blood Institute during the conduct of the study. Ms Gabriel reported receiving grants from the NIH/NCATS during the conduct of the study. Dr Garibaldi reported receiving personal fees from Janssen Development LLC and from the US Food and Drug Administration Pulmonary-Asthma Drug Advisory Committee outside the submitted work. Dr Girvin reported being an employee of Palantir Technologies. Dr Kavuluru reported receiving grants from the NIH/NCATS during the conduct of the study. Ms Kostka reported receiving an N3C subaward from Johns Hopkins University during the conduct of the study and is an employee of IQVIA. Dr Lehmann reported receiving grants from the NIH during the conduct of the study. Mr Manna reported receiving personal fees from Palantir Technologies Inc during the conduct of the study. Ms McMurry reported being a cofounder of Pryzm Health outside the submitted work. Dr Pfaff reported receiving grants from NIH/NCATS during the conduct of the study. Mr Qureshi reported being an employee of Palantir Technologies during the conduct of the study. Dr Haendel reported receiving grants from the NIH during the conduct of the study. Dr Chute reported receiving grants from the NIH/NCATS during the conduct of the study. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Gagnier</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Siqing</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lota</LastName><ForeName>Kanchan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maidlow</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanauer</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weatherwax</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandrakota</LastName><ForeName>Nikhila</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamaleswaran</LastName><ForeName>Rishikesan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qian</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farley</LastName><ForeName>Jason E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiao</LastName><ForeName>Dazhi</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kharrazi</LastName><ForeName>Hadi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reese</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deacy</LastName><ForeName>Mariam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Usman</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patton</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsey</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Jasvinder</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cimino</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duong</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Islam</LastName><ForeName>Jessica Yasmine</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obeid</LastName><ForeName>Jihad S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meystre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patterson</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zemmel</LastName><ForeName>Misha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grider</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solway</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiu</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Gerald B</ForeName><Initials>GB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cui</LastName><ForeName>Jiafeng</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khanipov</LastName><ForeName>Kamil</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Jeremy Richard</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Embi</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichmann</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knosp</LastName><ForeName>Boyd M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hillegass</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chunlei</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aaron</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gul</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Tamela</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbert</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bahroos</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubinett</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathew</LastName><ForeName>Jomol</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMahan</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucchinetti</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sacco</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taghioff</LastName><ForeName>Peyman</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Angst</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marek</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueroa Castro</LastName><ForeName>Carlos E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blazar</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basford</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernard</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Rosalind</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finkelstein</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campion</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuld</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anzalone</LastName><ForeName>Alfred</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McClay</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Visweswaran</LastName><ForeName>Shyam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Connor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dest</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellison</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relevo</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volz</LastName><ForeName>Andrea M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chengda</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tenzer</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowers</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrell</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qin</LastName><ForeName>Qiuyuan</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zand</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holden-Wiltse</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gouripeddi</LastName><ForeName>Ramkiran</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Facelli</LastName><ForeName>Julio</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becerra</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>Yao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chae</LastName><ForeName>Yooree</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Rena C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zampino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Said</LastName><ForeName>Ahmed S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Philip R O</ForeName><Initials>PRO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawa</LastName><ForeName>Randeep</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elkin</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koraishy</LastName><ForeName>Farrukh M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golovko</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weisdorf</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinoway</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morizono</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crandall</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahnavard</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shara</LastName><ForeName>Nawar</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taxter</LastName><ForeName>Alysha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostasiewski</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Song</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vangala</LastName><ForeName>Uma Maheswara Reddy</ForeName><Initials>UMR</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Luzuriaga</LastName><ForeName>Katherine Ruiz</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khatib</LastName><ForeName>Rasha</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirwan</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Oehsen</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakhuja</LastName><ForeName>Ankit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutter</LastName><ForeName>Joni</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34255046</ArticleId><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.16901</ArticleId><ArticleId IdType="pii">2781923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt JH, Gerds TA, Schou M, et al. . Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open. 2020;10(12):e044421. doi:10.1136/bmjopen-2020-044421</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044421</ArticleId><ArticleId IdType="pmc">PMC7722358</ArticleId><ArticleId IdType="pubmed">33277291</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al. ; N3C Consortium . The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28(3):427-443. doi:10.1093/jamia/ocaa196</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Institutional Development Award Program Infrastructure for Clinical and Translational Research (IDeA-CTR). March 30, 2021. Accessed March 30, 2021. https://www.nigms.nih.gov/Research/DRCB/IDeA/Pages/IDeA-CTR.aspx</Citation></Reference><Reference><Citation>Phenotype_Data_Acquisition. Github. Accessed March 30, 2021. https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition</Citation></Reference><Reference><Citation>World Health Organization Working Group on the Clinical Characterisation and management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192&#x2013;e197. doi:10.1016/S1473-3099(20)30483-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, March to June 2020. Crit Care Med. 2021;49(2):209-214. doi:10.1097/CCM.0000000000004747</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004747</ArticleId><ArticleId IdType="pmc">PMC7803441</ArticleId><ArticleId IdType="pubmed">33105150</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar KMJ, Shen Z, Romanelli RJ, et al. . disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff (Millwood). 2020;39(7):1253-1262. doi:10.1377/hlthaff.2020.00598</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2020.00598</ArticleId><ArticleId IdType="pubmed">32437224</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz LI, Jones SA, Cerfolio RJ, et al. . Trends in COVID-19 risk-adjusted mortality rates. J Hosp Med. 2021;16(2):90-92. doi:10.12788/jhm.3552</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/jhm.3552</ArticleId><ArticleId IdType="pubmed">33147129</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik TJ, Mohiddin SA, Dimarco A, et al. . COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-1687. doi:10.1093/cvr/cvaa106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa106</ArticleId><ArticleId IdType="pmc">PMC7197627</ArticleId><ArticleId IdType="pubmed">32352535</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. ; RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid-19: preliminary report. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Derde L, Al-Beidh F, et al. ; Writing Committee for the REMAP-CAP Investigators . Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 Corticosteroid Domain randomized clinical trial. JAMA. 2020;324(13):1317-1329. doi:10.1001/jama.2020.17022</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17022</ArticleId><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36. doi:10.1148/radiology.143.1.7063747</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.143.1.7063747</ArticleId><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med. 2020;382(26):2534-2543. doi:10.1056/NEJMsa2011686</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa2011686</ArticleId><ArticleId IdType="pmc">PMC7269015</ArticleId><ArticleId IdType="pubmed">32459916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Qian L, Hong V, et al. . Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173(10):773-781. doi:10.7326/M20-3742</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3742</ArticleId><ArticleId IdType="pmc">PMC7429998</ArticleId><ArticleId IdType="pubmed">32783686</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters SAE, MacMahon S, Woodward M. Obesity as a risk factor for COVID-19 mortality in women and men in the UK Biobank: comparisons with influenza/pneumonia and coronary heart disease. Diabetes Obes Metab. 2021;23(1):258-262. doi:10.1111/dom.14199</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14199</ArticleId><ArticleId IdType="pmc">PMC7536945</ArticleId><ArticleId IdType="pubmed">32969132</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis. J Alzheimers Dis. 2020;78(4):1775-1782. doi:10.3233/JAD-201016</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201016</ArticleId><ArticleId IdType="pubmed">33285638</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon AM, Webb GJ, Aloman C, et al. . High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020;73(3):705-708. doi:10.1016/j.jhep.2020.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.05.013</ArticleId><ArticleId IdType="pmc">PMC7241346</ArticleId><ArticleId IdType="pubmed">32446714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71-72. doi:10.1038/s41584-020-00562-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00562-2</ArticleId><ArticleId IdType="pmc">PMC7747184</ArticleId><ArticleId IdType="pubmed">33339986</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz CA, DeCarlo C, Boitano L, et al. . Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(9):2113-2118. doi:10.1007/s00277-020-04169-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04169-1</ArticleId><ArticleId IdType="pmc">PMC7354354</ArticleId><ArticleId IdType="pubmed">32656591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11(1):5761. doi:10.1038/s41467-020-19623-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19623-x</ArticleId><ArticleId IdType="pmc">PMC7666188</ArticleId><ArticleId IdType="pubmed">33188185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study. Ann Intern Med. 2021;174(3):308-315. doi:10.7326/M20-4511</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4511</ArticleId><ArticleId IdType="pmc">PMC7711653</ArticleId><ArticleId IdType="pubmed">33226859</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal P, Choi JJ, Pinheiro LC, et al. . Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374. doi:10.1056/NEJMc2010419</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2010419</ArticleId><ArticleId IdType="pmc">PMC7182018</ArticleId><ArticleId IdType="pubmed">32302078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, et al. ; STOP-COVID Investigators . Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-1447. doi:10.1001/jamainternmed.2020.3596</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. ; the Northwell COVID-19 Research Consortium . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld SC, Caridi-Scheible M, Blum JM, et al. ; and the Emory COVID-19 Quality and Clinical Research Collaborative . ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48(9):e799-e804. doi:10.1097/CCM.0000000000004457</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004457</ArticleId><ArticleId IdType="pmc">PMC7255393</ArticleId><ArticleId IdType="pubmed">32452888</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat GA, Weber GM, Gehlenborg N, et al. . International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. NPJ Digit Med. 2020;3:109. doi:10.1038/s41746-020-00308-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett M, Schultz S, Lyall J, et al. . Clinical mortality in a large COVID-19 cohort: observational study. J Med internet Res. 2020;22(9):e23565. doi:10.2196/23565</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/23565</ArticleId><ArticleId IdType="pmc">PMC7537718</ArticleId><ArticleId IdType="pubmed">32930099</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Cui P, Zeng S, et al. . Risk factors for developing into critical COVID-19 patients in Wuhan, China: a multicenter, retrospective, cohort study. EClinicalMedicine. 2020;25:100471. doi:10.1016/j.eclinm.2020.100471</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100471</ArticleId><ArticleId IdType="pmc">PMC7391125</ArticleId><ArticleId IdType="pubmed">32840491</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi BT, Fiksel J, Muschelli J, et al. . Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med. 2021;174(1):33-41. doi:10.7326/M20-3905</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3905</ArticleId><ArticleId IdType="pmc">PMC7530643</ArticleId><ArticleId IdType="pubmed">32960645</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24(1):179. doi:10.1186/s13054-020-02902-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02902-w</ArticleId><ArticleId IdType="pmc">PMC7187660</ArticleId><ArticleId IdType="pubmed">32345311</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820. doi:10.1016/S0140-6736(20)31324-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31324-6</ArticleId><ArticleId IdType="pmc">PMC7274621</ArticleId><ArticleId IdType="pubmed">32511943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(25):e102. doi:10.1056/NEJMoa2007621</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007621</ArticleId><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sottile PD, Albers D, DeWitt PE, et al. . Real-time electronic health record mortality prediction during the COVID-19 pandemic: a prospective cohort study. Preprint. medRxiv. 2021. doi:10.1101/2021.01.14.21249793</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.14.21249793</ArticleId><ArticleId IdType="pmc">PMC8136054</ArticleId><ArticleId IdType="pubmed">33973011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34267326</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5497</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of obesity (2005)</Title><ISOAbbreviation>Int J Obes (Lond)</ISOAbbreviation></Journal><ArticleTitle>Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom.</ArticleTitle><Pagination><StartPage>2347</StartPage><EndPage>2357</EndPage><MedlinePgn>2347-2357</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41366-021-00893-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.</AbstractText><AbstractText Label="METHODS">We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.</AbstractText><AbstractText Label="RESULTS">We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.</AbstractText><AbstractText Label="CONCLUSION">We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1964-3546</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4467-0220</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5630-2468</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cairo University, Faculty of Pharmacy, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins School of Public, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacoepidemiology, Regeneron Pharmaceuticals, Tarrytown, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DHC Technologies co, Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Yin Hui</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer C E</ForeName><Initials>JCE</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>College of Medicine, The University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarjan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Engineering, The University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Health Management, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Obes (Lond)</MedlineTA><NlmUniqueID>101256108</NlmUniqueID><ISSNLinking>0307-0565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Mr. Sena reports personal fees from Janssen Research &amp; Development, outside the submitted work; Dr. DuVall reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research, outside the submitted work; Mr Ahmed reports funding from the NIHR Oxford Biomedical Research Center (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England; Dr. Golozar reports personal fees from Regeneron Pharmaceuticals, outside the submitted work. She is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Miss Lane is supported by a Medical Research Council Doctoral Research Fellowship (MR/K501256/1) and a Versus Arthritis Clinical Research Fellowship (21605). Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), outside the submitted work; Dr. Nyberg reports other from AstraZeneca, outside the submitted work; Dr. Subbian reports grants from National Science Foundation, grants from State of Arizona; Arizona Board of Regents, grants from Agency for Healthcare Research and Quality, outside the submitted work; Dr Prieto-Alhambra reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA&#x2019;s department and open for external participants. Ms. Kostka and Dr. Reich report being employees of IQVIA Inc at the time the analysis was conducted. Dr. Rijnbeek reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study. Dr. Ryan is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. No other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34267326</ArticleId><ArticleId IdType="pmc">PMC8281807</ArticleId><ArticleId IdType="doi">10.1038/s41366-021-00893-4</ArticleId><ArticleId IdType="pii">10.1038/s41366-021-00893-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776&#x2013;86. doi: 10.1016/S0140-6736(16)30175-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30175-1</ArticleId><ArticleId IdType="pmc">PMC4995441</ArticleId><ArticleId IdType="pubmed">27423262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB. Obesity Epidemiology. New York: Oxford University Press, 2009.</Citation></Reference><Reference><Citation>Moser JAS, Galindo-Fraga A, Ortiz-Hern&#xe1;ndez AA, Gu W, Hunsberger S, Gal&#xe1;n-Herrera JF, et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir Viruses. 2019;13:3&#x2013;9. doi: 10.1111/irv.12618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12618</ArticleId><ArticleId IdType="pmc">PMC6304312</ArticleId><ArticleId IdType="pubmed">30515985</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19&#x2014;11 March 2020. WHO. 2020. https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-oncovid-19---11-march-2020.</Citation></Reference><Reference><Citation>Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza a (H1N1) Clin Infect Dis. 2011;52:301&#x2013;12. doi: 10.1093/cid/ciq152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq152</ArticleId><ArticleId IdType="pubmed">21208911</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. New obesity strategy unveiled as country urged to lose weight to beat coronavirus (COVID-19) and protect the NHS. GOV.UK. 2020. https://www.gov.uk/government/news/new-obesity-strategy-unveiled-as-country-urged-to-lose-weight-to-beat-coronavirus-covid-19-and-protect-the-nhs.</Citation></Reference><Reference><Citation>Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128. doi: 10.1111/obr.13128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13128</ArticleId><ArticleId IdType="pmc">PMC7461480</ArticleId><ArticleId IdType="pubmed">32845580</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11:1&#x2013;12. doi: 10.1038/s41467-020-19478-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19478-2</ArticleId><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Informatics Assoc. 2015;22:553&#x2013;64. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xed;bar B, Fina Avil&#xe9;s F, Morros R, Del Mar Garcia-Gil M, Hermosilla E, Ramos R, et al. Base de datos SIDIAP: La historia cl&#xed;nica informatizada de Atenci&#xf3;n Primaria como fuente de informaci&#xf3;n para la investigaci&#xf3;n epidemiol&#xf3;gica. Med Clin. 2012;138:617&#x2013;21. doi: 10.1016/j.medcli.2012.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2012.01.020</ArticleId><ArticleId IdType="pubmed">22444996</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Staa Tvan, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;36. doi: 10.1093/ije/dyv098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G, Li W, O&#x2019;Reilly C, Balraj D, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. arXiv:2003.10534v1 [Preprint]. 2020 [cited 2020 Aug 20]. Available from: https://arxiv.org/abs/2003.10534v1</Citation></Reference><Reference><Citation>Burn E, Teb&#xe9; C, Fernandez-Bertolin S, Aragon M, Recalde M, Roel E, et al. The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat Commun. 2021;12:1&#x2013;12. doi: 10.1038/s41467-021-21100-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21100-y</ArticleId><ArticleId IdType="pmc">PMC7858639</ArticleId><ArticleId IdType="pubmed">33536436</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11:5009. doi: 10.1038/s41467-020-18849-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI (Independently published). 2019. https://ohdsi.github.io/TheBookOfOhdsi/.</Citation></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052&#x2013;9. doi: 10.1001/jama.2020.6775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228&#x2013;34. doi: 10.1080/03610910902859574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Overweight and obesity. World Health Organization. 2020. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-risk-factors.</Citation></Reference><Reference><Citation>Kelly SP, Lennon H, Sperrin M, Matthews C, Freedman ND, Albanes D, et al. Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP diet and health study. Int J Epidemiol. 2019;48:464&#x2013;73. doi: 10.1093/ije/dyy219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy219</ArticleId><ArticleId IdType="pmc">PMC6469294</ArticleId><ArticleId IdType="pubmed">30376043</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S, Kim L, Whitaker M, O&#x2019;Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019&#x2014;COVID-NET, 14 states, March 1&#x2013;30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458&#x2013;64. doi: 10.15585/mmwr.mm6915e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6915e3</ArticleId><ArticleId IdType="pmc">PMC7755063</ArticleId><ArticleId IdType="pubmed">32298251</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O&#x2019;Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436&#x2013;47. doi: 10.1001/jamainternmed.2020.3596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MR, Geleris J, Anderson DR, Zucker J, Nobel YR, Freedberg D, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Ann Intern Med. 2020;173:782&#x2013;90. doi: 10.7326/M20-3214.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3214</ArticleId><ArticleId IdType="pmc">PMC7397550</ArticleId><ArticleId IdType="pubmed">32726151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, et al. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes Metab Syndr Clin Res Rev. 2020;14:1149&#x2013;51. doi: 10.1016/j.dsx.2020.06.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.06.060</ArticleId><ArticleId IdType="pmc">PMC7326434</ArticleId><ArticleId IdType="pubmed">32668401</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173:773&#x2013;81. doi: 10.7326/M20-3742.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3742</ArticleId><ArticleId IdType="pmc">PMC7429998</ArticleId><ArticleId IdType="pubmed">32783686</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2021;117:154373. doi: 10.1016/j.metabol.2020.154373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154373</ArticleId><ArticleId IdType="pmc">PMC7493748</ArticleId><ArticleId IdType="pubmed">32949592</ArticleId></ArticleIdList></Reference><Reference><Citation>Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44:1055&#x2013;68. doi: 10.1183/09031936.00059814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00059814</ArticleId><ArticleId IdType="pmc">PMC4918092</ArticleId><ArticleId IdType="pubmed">25142482</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc R Soc B Biol Sci. 2015;282:20143085. doi: 10.1098/rspb.2014.3085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2014.3085</ArticleId><ArticleId IdType="pmc">PMC4707740</ArticleId><ArticleId IdType="pubmed">26702035</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscogiuri G, Pugliese G, Laudisio D, Castellucci B, Barrea L, Savastano S, et al. The impact of obesity on immune response to infection: plausible mechanisms and outcomes. Obes Rev. 2021;22:e13216. doi: 10.1111/obr.13216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13216</ArticleId><ArticleId IdType="pubmed">33719175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896&#x2013;7. doi: 10.1093/cid/ciaa415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa415</ArticleId><ArticleId IdType="pmc">PMC7184372</ArticleId><ArticleId IdType="pubmed">32271368</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;6. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilev M, Kristensen KB, Potteg&#xe5;rd A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468&#x2013;81. doi: 10.1093/ije/dyaa140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa140</ArticleId><ArticleId IdType="pmc">PMC7499657</ArticleId><ArticleId IdType="pubmed">32887982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34272262</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</Title><ISOAbbreviation>Cancer Epidemiol Biomarkers Prev</ISOAbbreviation></Journal><ArticleTitle>Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain.</ArticleTitle><Pagination><StartPage>1884</StartPage><EndPage>1894</EndPage><MedlinePgn>1884-1894</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1055-9965.EPI-21-0266</ELocationID><Abstract><AbstractText Label="BACKGROUND">We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.</AbstractText><AbstractText Label="METHODS">We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.</AbstractText><AbstractText Label="RESULTS">We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%-18% and 1%-14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (<i>n</i> = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events.</AbstractText><AbstractText Label="CONCLUSIONS">Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent.</AbstractText><AbstractText Label="IMPACT">This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.</AbstractText><CopyrightInformation>&#xa9;2021 The Authors; Published by the American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1964-3546</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4467-0220</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2256-618X</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puente</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><Identifier Source="ORCID">0000-0003-0880-0355</Identifier><AffiliationInfo><Affiliation>NDORMS, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8234-5843</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6743-803X</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5630-2468</Identifier><AffiliationInfo><Affiliation>Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2733-5436</Identifier><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culhane</LastName><ForeName>Aedin C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-1395-9734</Identifier><AffiliationInfo><Affiliation>Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2105-1937</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-4898-3865</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacoepidemiology, Regeneron Pharmaceuticals, Westchester County, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Health China Technologies Co., Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hester</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4593-1293</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0003-4470-2736</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Hokyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9912-2344</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, UNSW Sydney, Kensington, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Y H</ForeName><Initials>LYH</Initials><Identifier Source="ORCID">0000-0002-0485-0956</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0847-6682</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jos&#xe9; D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Redwood City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Donna R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-4565-4556</Identifier><AffiliationInfo><Affiliation>Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-6878-189X</Identifier><AffiliationInfo><Affiliation>Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soerjomataram</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6219-1653</Identifier><AffiliationInfo><Affiliation>NDORMS, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Redwood City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Digital Health China Technologies Co., Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotniz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Engineering, University of Arizona, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Fielding School of Public Health, University of California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trama</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8220-9833</Identifier><AffiliationInfo><Affiliation>Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population Health and Global Health, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Digital Health China Technologies Co., Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Epidemiol Biomarkers Prev</MedlineTA><NlmUniqueID>9200608</NlmUniqueID><ISSNLinking>1055-9965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.G. Sena reports employment with Janssen R&amp;D and Johnson &amp; Johnson stock ownership. C. Blacketer reports other support from Janssen Research &amp; Development during the conduct of the study, as well as other support from Janssen Research &amp; Development outside the submitted work. S.L. DuVall reports grants from Genomic Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation outside the submitted work. A. Golozar reports other support from Regeneron Pharmaceuticals outside the submitted work. L. Hester reports other support from Janssen R&amp;D, LLC outside the submitted work. G. Hripcsak reports grants from NIH during the conduct of the study, as well as grants from Janssen Research outside the submitted work. K. Natarajan reports grants from NIH during the conduct of the study. F. Nyberg reports other support from AstraZeneca outside the submitted work. J.D. Posada reports grants from National Library of Medicine during the conduct of the study. V. Subbian reports grants from National Science Foundation, State of Arizona, Arizona Board of Regents, Agency for Healthcare Research and Quality, and NIH outside the submitted work. M.A. Suchard reports grants from U.S. Department of Veterans Affairs during the conduct of the study, as well as grants from U.S. NIH and IQVIA and personal fees from Janssen Research and Development outside the submitted work. P.B. Ryan reports employment with Janssen Research and Development and ownership of Johnson &amp; Johnson stock. D. Prieto-Alhambra reports grants and other support from Amgen; grants, nonfinancial support, and other support from UCB Biopharma; and grants from Les Laboratoires Servier outside the submitted work; in addition, Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA's department and open for external participants. K. Kostka reports other support from IQVIA and grants from NIH outside the submitted work. No disclosures were reported by the other authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34272262</ArticleId><ArticleId IdType="pmc">PMC8974356</ArticleId><ArticleId IdType="doi">10.1158/1055-9965.EPI-21-0266</ArticleId><ArticleId IdType="pii">1055-9965.EPI-21-0266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020;6:1108&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097836</ArticleId><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolston KVI. Infections in cancer patients with solid tumors: a review. Infect Dis Ther 2017;6:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5336421</ArticleId><ArticleId IdType="pubmed">28160269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;6736:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21:1309&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7444972</ArticleId><ArticleId IdType="pubmed">32853557</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilev M, Kristensen KB, Potteg&#xe5;rd A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol 2020;49:1468&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499657</ArticleId><ArticleId IdType="pubmed">32887982</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Soroka O, et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol 2020;38:3914&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676890</ArticleId><ArticleId IdType="pubmed">32986528</ArticleId></ArticleIdList></Reference><Reference><Citation>Westreich D, van Smeden M, Edwards JK. (OpenSAFELY): the Table 2 fallacy in a study of COVID-19 mortality risk factors. Epidemiology 2021;32:e1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33065610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennant P, Murray EJ. The quest for timely insights into COVID-19 should not come at the cost of scientific rigor. Epidemiology 2021;32:e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33065609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Informatics Assoc 2015;22:553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Mar Garc&#xed;a-Gil M, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2012;19:135&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>
Datta S, Posada J, Olson G, Li W, O'Reilly C, Balraj D, et al. 
A new paradigm for accelerating clinical data science at Stanford Medicine.
arXiv [Internet] 2020[cited 2020 Aug 20]. Available from:
http://arxiv.org/abs/2003.10534.</Citation></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun 2020;11:5009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.
The Book of OHDSI [Internet].
2019. 
[cited 2020 Aug 20]. Available from:
https://ohdsi.github.io/TheBookOfOhdsi/.</Citation></Reference><Reference><Citation>World Health Organization. Cancer Today [Internet].
Int. Agency Res.
2018. 
[cited 2020 Oct 22]. Available from: https://gco.iarc.fr/today/home.</Citation></Reference><Reference><Citation>
Sena A, Kostka K, Schuemie M.
jdposada. ohdsi-studies/Covid19CharacterizationCharybdis: Charybdis v1.1.1 - Publication Package.
2020. 
[cited 2020 Dec 3]. Available from: https://zenodo.org/record/4033034.</Citation></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228&#x2013;34.</Citation></Reference><Reference><Citation>Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">31184787</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323:2052&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>de Azambuja E, Brand&#xe3;o M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open 2020;5:e000947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7520811</ArticleId><ArticleId IdType="pubmed">32978251</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 2020;369:m1985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, et al. Prevalence and outcome of COVID-19 infection in cancer patients: a national veterans affairs study. J Natl Cancer Inst 2020;00:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665587</ArticleId><ArticleId IdType="pubmed">33031532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2020;44106:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7729584</ArticleId><ArticleId IdType="pubmed">33300956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LYW, Cazier JB, Starkey T, Turnbull CD, UK Coronavirus Cancer Monitoring Project Team. Kerr R, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jutzeler CR, Bourguignon L, Weis CV, Tong B, Wong C, Rieck B, et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;37:101825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402237</ArticleId><ArticleId IdType="pubmed">32763496</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC - COVID-19.
Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 [Internet]. [cited 2020 Dec 3]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html.</Citation></Reference><Reference><Citation>World Health Organization.
Coronavirus disease (COVID-19): situation report, 162 [Internet].
WHO.
2020. Available from: https://apps.who.int/iris/handle/10665/332970.</Citation></Reference><Reference><Citation>Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer 2020;139:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467090</ArticleId><ArticleId IdType="pubmed">32971510</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun 2020;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34284037</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>161</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.</ArticleTitle><Pagination><StartPage>1487</StartPage><EndPage>1501.e5</EndPage><MedlinePgn>1487-1501.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2021.07.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(21)03244-3</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">In patients with chronic liver disease (CLD) with or without cirrhosis, existing studies on the outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have limited generalizability. We used the National COVID Cohort Collaborative (N3C), a harmonized electronic health record dataset of 6.4 million, to describe SARS-CoV-2 outcomes in patients with CLD and cirrhosis.</AbstractText><AbstractText Label="METHODS">We identified all patients with CLD with or without cirrhosis who had SARS-CoV-2 testing in the N3C Data Enclave as of July 1, 2021. We used survival analyses to associate SARS-CoV-2 infection, presence of cirrhosis, and clinical factors with the primary outcome of 30-day mortality.</AbstractText><AbstractText Label="RESULTS">We isolated 220,727 patients with CLD and SARS-CoV-2 test status: 128,864 (58%) were noncirrhosis/negative, 29,446 (13%) were noncirrhosis/positive, 53,476 (24%) were cirrhosis/negative, and 8941 (4%) were cirrhosis/positive patients. Thirty-day all-cause mortality rates were 3.9% in cirrhosis/negative and 8.9% in cirrhosis/positive patients. Compared to cirrhosis/negative patients, cirrhosis/positive patients had 2.38 times adjusted hazard of death at 30 days. Compared to noncirrhosis/positive patients, cirrhosis/positive patients had 3.31 times adjusted hazard of death at 30 days. In stratified analyses among patients with cirrhosis with increased age, obesity, and comorbid conditions (ie, diabetes, heart failure, and pulmonary disease), SARS-CoV-2 infection was associated with increased adjusted hazard of death.</AbstractText><AbstractText Label="CONCLUSIONS">In this study of approximately 221,000 nationally representative, diverse, and sex-balanced patients with CLD; we found SARS-CoV-2 infection in patients with cirrhosis was associated with 2.38 times mortality hazard, and the presence of cirrhosis among patients with CLD infected with SARS-CoV-2 was associated with 3.31 times mortality hazard. These results provide an additional impetus for increasing vaccination uptake and further research regarding immune responses to vaccines in patients with severe liver disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California. Electronic address: jin.ge@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletcher</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California; Division of General Internal Medicine, Department of Medicine, University of California-San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK026743</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK060414</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Jun 07:2021.06.03.21258312. doi: 10.1101/2021.06.03.21258312.</RefSource><PMID Version="1">34127981</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2021 Nov;161(5):1371-1373. doi: 10.1053/j.gastro.2021.08.037.</RefSource><PMID Version="1">34453892</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2021 Nov;161(5):1373-1376. doi: 10.1053/j.gastro.2021.08.040.</RefSource><PMID Version="1">34454917</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cirrhosis</Keyword><Keyword MajorTopicYN="N">N3C</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Jeremy R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34284037</ArticleId><ArticleId IdType="pmc">PMC8286237</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2021.07.010</ArticleId><ArticleId IdType="pii">S0016-5085(21)03244-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang Y., Liu S., Liu H., Li W., et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J&#xa0;Hepatol. 2020;73:807&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211738</ArticleId><ArticleId IdType="pubmed">32437830</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer E.A.K., Arvind A., Bloom P.P., et al. Interrelationship between coronavirus infection and liver disease. Clin Liver Dis (Hoboken) 2020;15:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242011</ArticleId><ArticleId IdType="pubmed">32489653</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D., Du B., Li L., Zeng G., Yuen K., et al. Clinical characteristics of coronavirus disease 2019 in China. N&#xa0;Engl J Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel&#xa0;coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Moon A.M., Cook J.A., et al. Barnes E., Barritt A.S., Webb G.J. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J&#xa0;Hepatol. 2021;74:567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536538</ArticleId><ArticleId IdType="pubmed">33035628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Adeniji N., Latt N., et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol. 2021;19:1469&#x2013;1479.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497795</ArticleId><ArticleId IdType="pubmed">32950749</ArticleId></ArticleIdList></Reference><Reference><Citation>Iavarone M., D&#x2019;Ambrosio R., Soria A., et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J&#xa0;Hepatol. 2020;73:1063&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280108</ArticleId><ArticleId IdType="pubmed">32526252</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the united states: a multicenter research network study. Gastroenterology. 2020;159:768&#x2013;771.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196546</ArticleId><ArticleId IdType="pubmed">32376408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj J.S., Garcia-Tsao G., Biggins S.W., et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371484</ArticleId><ArticleId IdType="pubmed">32660964</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon A.M., Webb G.J., Aloman C., et al. Barnes E., Barritt A.S., Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J&#xa0;Hepatol. 2020;73:705&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241346</ArticleId><ArticleId IdType="pubmed">32446714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Liang PS, Locke E, et&#xa0;al. Cirrhosis and SARS-CoV-2 infection in US veterans: risk of infection, hospitalization, ventilation and mortality [published online ahead of print November 21, 2020. Hepatology 10.1002/hep.31649</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31649</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel M.A., Chute C.G., Bennett T.D., et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J&#xa0;Am Med Inform Assoc. 2021;28:427&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>National COVID Cohort Collaborative. Accessed April 8, 2021. Available at: https://covid.cd2h.org</Citation></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, et&#xa0;al. The national COVID cohort collaborative: clinical characterization and early severity prediction. Preprint. Posted online January 13, 2021. medRxiv 2021.01.12.21249511. 10.1101/2021.01.12.21249511</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.12.21249511</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model&#x2013;OHDSI. https://www.ohdsi.org/data-standardization/the-common-data-model/ Accessed February 17, 2021. Available at:</Citation></Reference><Reference><Citation>National COVID Cohort Collaborative. COVID-19 Clinical Data Warehouse Data Dictionary Based on OMOP Common Data Model Specifications, Version 5.3.1.</Citation></Reference><Reference><Citation>Documentation:vocabulary:mapping. Observational Health Data Sciences and Informatics. https://www.ohdsi.org/web/wiki/doku.php?id&#xa0;= documentation:vocabulary:mapping Accessed April 15, 2021. Available at:</Citation></Reference><Reference><Citation>Pintus R., Yang Y., Rushmeier H. ATHENA. J Comput Cult Herit. 2015;8:1&#x2013;25.</Citation></Reference><Reference><Citation>Kim D., Li A.A., Gadiparthi C., et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology. 2018;155:1154&#x2013;1163.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467699</ArticleId><ArticleId IdType="pubmed">30009816</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedeli U., Avossa F., Guzzinati S., et al. Trends in mortality from chronic liver disease. Ann Epidemiol. 2014;24:522&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">24861431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes F.D., Kim W.R., Pedersen R., et al. Mortality attributable to cholestatic liver disease in the United States. Hepatology. 2008;47:1241&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">18318437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf8;nbaek L., Otete H., Ban L., et al. Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study. Liver Int. 2020;40:1634&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pubmed">32304617</ArticleId></ArticleIdList></Reference><Reference><Citation>Global status report on alcohol and health. https://www.who.int/publications/i/item/9789241565639 2018. Accessed April 8, 2021. Available at:</Citation></Reference><Reference><Citation>Yoon Y.-H., Yi H., Thomson P.C. Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res. 2011;35:240&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059250</ArticleId><ArticleId IdType="pubmed">21121934</ArticleId></ArticleIdList></Reference><Reference><Citation>Surveillance Report #93. National Institute on Alcohol Abuse and Alcoholism. https://pubs.niaaa.nih.gov/publications/Surveillance93/cirr09.htm Accessed April 8, 2021. Available&#xa0;at:</Citation></Reference><Reference><Citation>Fialoke S., Malarstig A., Miller M.R., et al. Application of machine learning methods to predict non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver (NAFL) patients. AMIA Annu Symp Proc. 2018;2018:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371264</ArticleId><ArticleId IdType="pubmed">30815083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin J.B., Lai J.C., Shui A.M., et al. Patterns of inpatient opioid use and related adverse events among patients with cirrhosis: a propensity-matched analysis. Hepatol Commun. 2021;5:1081&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183179</ArticleId><ArticleId IdType="pubmed">34141991</ArticleId></ArticleIdList></Reference><Reference><Citation>RSV Regional Trends. Centers for Disease Control and Prevention. National Respiratory and Enteric Virus Surveillance System. https://www.cdc.gov/surveillance/nrevss/rsv/region.html Accessed April 8, 2021. Available at:</Citation></Reference><Reference><Citation>Charlson M.E., Pompei P., Ales K.L., et al. A&#xa0;new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J.&#xa0;Chronic Dis. 1987;40:373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H., Li B., Couris C.M., et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 2011;173:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>ICD: comorbidity calculations and tools for ICD-9 and ICD-10 codes version 4.0.9 from CRAN. https://rdrr.io/cran/icd/ Accessed July 6, 2021. Available at:</Citation></Reference><Reference><Citation>R: A Language and Environment For Statistical Computing. R Foundation,&#xa0;2013.</Citation></Reference><Reference><Citation>Ravani P., Saxinger L., Chandran U., et al. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. CMAJ Open. 2020;8:E887&#x2013;E894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759116</ArticleId><ArticleId IdType="pubmed">33355274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai A.D., Li X.X., Alsalem M., et al. Utility of asymptomatic inpatient testing for COVID-19 in a low-prevalence setting: a multicenter point-prevalence study. Infect Control Hosp Epidemiol. 2020;41:1233&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390710</ArticleId><ArticleId IdType="pubmed">32693864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey K., Ayers C.K., Kondo K.K., et al. Racial and ethnic&#xa0;disparities in COVID-19-related infections, hospitalizations, and deaths&#x202f;: a systematic review. Ann Intern Med. 2021;174:362&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772883</ArticleId><ArticleId IdType="pubmed">33253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb Hooper M., N&#xe1;poles A.M., P&#xe9;rez-Stable E.J. COVID-19 and racial/ethnic disparities. JAMA. 2020;323:2466&#x2013;2467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310097</ArticleId><ArticleId IdType="pubmed">32391864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E.J., Kim T., Conigliaro J., et al. Racial and ethnic disparities in diagnosis of chronic medical conditions in the USA. J&#xa0;Gen Intern Med. 2018;33:1116&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6025658</ArticleId><ArticleId IdType="pubmed">29736755</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiawan V.W., Stram D.O., Porcel J., et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64:1969&#x2013;1977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5115980</ArticleId><ArticleId IdType="pubmed">27301913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzler H.L., Peters J., O&#x2019;Sullivan D.M., et al. Disparities in end-organ care for Hispanic patients with kidney and liver disease: implications for access to transplantation. Curr Surg Rep. 2020;8:3.</Citation></Reference><Reference><Citation>Gupta S., Hayek S.S., Wang W., et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra M.R., Desai S.S., Kuy S., et al. cardiovascular disease, drug therapy, and mortality in Covid-19. N&#xa0;Engl J Med. 2020;382:e102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle M.C., Buse J.B., Franks P.W., et al. COVID-19 in people with diabetes: urgently needed lessons from early reports. Diabetes Care. 2020;43:1378&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305002</ArticleId><ArticleId IdType="pubmed">32409505</ArticleId></ArticleIdList></Reference><Reference><Citation>Signes-Costa J., N&#xfa;&#xf1;ez-Gil I.J., Soriano J.B., et al. prevalence and 30-day mortality in hospitalized patients with Covid-19 and prior lung diseases. Arch Bronconeumol. 2021;57(Suppl 2):13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744014</ArticleId><ArticleId IdType="pubmed">34629634</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V., Moinat M., Payralbe S., et al. Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423424</ArticleId><ArticleId IdType="pubmed">34514354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix OK, Blumberg EA, Chang K-M, et&#xa0;al, Fontana RJ. AASLD Expert Panel Consensus Statement: vaccines to prevent COVID-19 infection in patients with liver disease [published online ahead of print February 12, 2021. Hepatology 10.1002/hep.31751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31751</ArticleId><ArticleId IdType="pmc">PMC8014184</ArticleId><ArticleId IdType="pubmed">33577086</ArticleId></ArticleIdList></Reference><Reference><Citation>McCashland T.M., Preheim L.C., Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J&#xa0;Infect Dis. 2000;181:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669371</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rm&#xe4;l&#xe4; S., Parisinos C.A., Shallcross L., et al. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open. 2019;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731888</ArticleId><ArticleId IdType="pubmed">31494620</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggeletopoulou I., Davoulou P., Konstantakis C., et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27</Citation><ArticleIdList><ArticleId IdType="pubmed">28905444</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Webb G.J., Barritt A.S., et al. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021;6:156&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832019</ArticleId><ArticleId IdType="pubmed">33444545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper E.B., Asrani S.K. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J&#xa0;Hepatol. 2020;73:441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194911</ArticleId><ArticleId IdType="pubmed">32298769</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. ARDI Alcohol-Related ICD Codes - Alcohol. Available at: https://www.cdc.gov/alcohol/ardi/alcohol-related-icd-codes.html. Accessed April 8, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34287211</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Three Feasibility Tools for Identifying Patient Data and Biospecimen Availability: Comparative Usability Study.</ArticleTitle><Pagination><StartPage>e25531</StartPage><MedlinePgn>e25531</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25531</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/25531</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To meet the growing importance of real-word data analysis, clinical data and biosamples must be timely made available. Feasibility platforms are often the first contact point for determining the availability of such data for specific research questions. Therefore, a user-friendly interface should be provided to enable access to this information easily. The German Medical Informatics Initiative also aims to establish such a platform for its infrastructure. Although some of these platforms are actively used, their tools still have limitations. Consequently, the Medical Informatics Initiative consortium MIRACUM (Medical Informatics in Research and Care in University Medicine) committed itself to analyzing the pros and cons of existing solutions and to designing an optimized graphical feasibility user interface.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to identify the system that is most user-friendly and thus forms the best basis for developing a harmonized tool. To achieve this goal, we carried out a comparative usability evaluation of existing tools used by researchers acting as end users.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The evaluation included three preselected search tools and was conducted as a qualitative exploratory study with a randomized design over a period of 6 weeks. The tools in question were the MIRACUM i2b2 (Informatics for Integrating Biology and the Bedside) feasibility platform, OHDSI's (Observational Health Data Sciences and Informatics) ATLAS, and the Sample Locator of the German Biobank Alliance. The evaluation was conducted in the form of a web-based usability test (usability walkthrough combined with a web-based questionnaire) with participants aged between 26 and 63 years who work as medical doctors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 17 study participants evaluated the three tools. The overall evaluation of usability, which was based on the System Usability Scale, showed that the Sample Locator, with a mean System Usability Scale score of 77.03 (SD 20.62), was significantly superior to the other two tools (Wilcoxon test; Sample Locator vs i2b2: P=.047; Sample Locator vs ATLAS: P=.001). i2b2, with a score of 59.83 (SD 25.36), performed significantly better than ATLAS, which had a score of 27.81 (SD 21.79; Wilcoxon test; i2b2 vs ATLAS: P=.005). The analysis of the material generated by the usability walkthrough method confirmed these findings. ATLAS caused the most usability problems (n=66), followed by i2b2 (n=48) and the Sample Locator (n=22). Moreover, the Sample Locator achieved the highest ratings with respect to additional questions regarding satisfaction with the tools.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides data to develop a suitable basis for the selection of a harmonized tool for feasibility studies via concrete evaluation and a comparison of the usability of three different types of query builders. The feedback obtained from the participants during the usability test made it possible to identify user problems and positive design aspects of the individual tools and compare them qualitatively.</AbstractText><CopyrightInformation>&#xa9;Christina Sch&#xfc;ttler, Hans-Ulrich Prokosch, Martin Sedlmayr, Brita Sedlmayr. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 21.07.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sch&#xfc;ttler</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9008-1868</Identifier><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><Identifier Source="ORCID">0000-0001-6200-753X</Identifier><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9888-8460</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Brita</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6159-7822</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JMIR Med Inform. 2021 Oct 8;9(10):e33105. doi: 10.2196/33105.</RefSource><PMID Version="1">34623958</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">evaluation</Keyword><Keyword MajorTopicYN="N">feasibility</Keyword><Keyword MajorTopicYN="N">research</Keyword><Keyword MajorTopicYN="N">software tools</Keyword><Keyword MajorTopicYN="N">user interface</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34287211</ArticleId><ArticleId IdType="pmc">PMC8339981</ArticleId><ArticleId IdType="doi">10.2196/25531</ArticleId><ArticleId IdType="pii">v9i7e25531</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maissenhaelter BE, Woolmore AL, Schlag PM. Real-world evidence research based on big data: motivation-challenges-success factors. Onkologe (Berl) 2018 Jun 7;24(Suppl 2):91&#x2013;8. doi: 10.1007/s00761-018-0358-3. 
 
358</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00761-018-0358-3</ArticleId><ArticleId IdType="pmc">PMC6224010</ArticleId><ArticleId IdType="pubmed">30464373</ArticleId></ArticleIdList></Reference><Reference><Citation>Makady A, de Boer A, Hillege H, Klungel O, Goettsch W, (on behalf of GetReal Work Package 1)  What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017 Jul;20(7):858&#x2013;65. doi: 10.1016/j.jval.2017.03.008. 
 
S1098-3015(17)30171-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2017.03.008</ArticleId><ArticleId IdType="pubmed">28712614</ArticleId></ArticleIdList></Reference><Reference><Citation>European Health Data &amp; Evidence Network (EHDEN)  [2020-10-23].  
 https://www.ehden.eu/
</Citation></Reference><Reference><Citation>Swiss Personalized Health Network (SPHN)  [2020-10-23].  
 https://sphn.ch/
</Citation><ArticleIdList><ArticleId IdType="pubmed">32570562</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Research Infrastructure (Health RI)  [2020-10-23].  
 https://www.health-ri.nl/
</Citation></Reference><Reference><Citation>Semler SC, Wissing F, Heyder R. German medical informatics initiative. Methods Inf Med. 2018 Jul;57(S 01):50&#x2013;6. doi: 10.3414/ME18-03-0003. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-03-0003</ArticleId><ArticleId IdType="pmc">PMC6178199</ArticleId><ArticleId IdType="pubmed">30016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bache R, Miles S, Taweel A. An adaptable architecture for patient cohort identification from diverse data sources. J Am Med Inform Assoc. 2013 Dec;20(e2):327&#x2013;33. doi: 10.1136/amiajnl-2013-001858. 
 
amiajnl-2013-001858</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001858</ArticleId><ArticleId IdType="pmc">PMC3861920</ArticleId><ArticleId IdType="pubmed">24064442</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Rey I, N'Dja A, Cunningham J, Newe A, Trinczek B, Lafitte C, Sedlmayr B, Fritz F. User satisfaction evaluation of the EHR4CR query builder: a multisite patient count cohort system. Biomed Res Int. 2015;2015:801436. doi: 10.1155/2015/801436. doi: 10.1155/2015/801436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/801436</ArticleId><ArticleId IdType="doi">10.1155/2015/801436</ArticleId><ArticleId IdType="pmc">PMC4619869</ArticleId><ArticleId IdType="pubmed">26539525</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokosch HU, Acker T, Bernarding J, Binder H, Boeker M, Boerries M, Daumke P, Ganslandt T, Hesser J, H&#xf6;ning G, Neumaier M, Marquardt K, Renz H, Rothk&#xf6;tter H, Schade-Brittinger C, Schm&#xfc;cker P, Sch&#xfc;ttler J, Sedlmayr M, Serve H, Sohrabi K, Storf H. MIRACUM: Medical Informatics in Research and Care in University Medicine. Methods Inf Med. 2018 Jul;57(S 01):82&#x2013;91. doi: 10.3414/ME17-02-0025. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME17-02-0025</ArticleId><ArticleId IdType="pmc">PMC6178200</ArticleId><ArticleId IdType="pubmed">30016814</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, Kohane I. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010;17(2):124&#x2013;30. doi: 10.1136/jamia.2009.000893. 
 
17/2/124</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong IC, Rijnbeek PR, van DL, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) ATLAS.  [2020-10-23].  
 https://atlas.ohdsi.org/
</Citation></Reference><Reference><Citation>German Biobank Alliance (GBA) Sample Locator.  [2020-10-23].  
 https://samplelocator.bbmri.de/search
.</Citation></Reference><Reference><Citation>Baber R, Hummel M, Jahns R, von Jagwitz-Biegnitz M, Kirsten R, Klingler C, Nussbeck SY, Specht C. Position statement from the German biobank alliance on the cooperation between academic biobanks and industry partners. Biopreserv Biobank. 2019 Aug;17(4):372&#x2013;4. doi: 10.1089/bio.2019.0042. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/bio.2019.0042</ArticleId><ArticleId IdType="pmc">PMC6703240</ArticleId><ArticleId IdType="pubmed">31314575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;ttler C, Buschh&#xfc;ter N, D&#xf6;llinger C, Ebert L, Hummel M, Linde J, Prokosch HU, Proynova R, Lablans M. [Requirements for a&#xa0;cross-location biobank IT infrastructure : survey of stakeholder input on the establishment of a&#xa0;biobank network of the German Biobank Alliance (GBA)] Pathologe. 2018 Jul;39(4):289&#x2013;96. doi: 10.1007/s00292-018-0435-9.10.1007/s00292-018-0435-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00292-018-0435-9</ArticleId><ArticleId IdType="pubmed">29691676</ArticleId></ArticleIdList></Reference><Reference><Citation>Alroobaea R, Mayhew PJ. How many participants are really enough for usability studies?. Proceedings of the Science and Information Conference; Science and Information Conference; August 27-29, 2014; IEEE, London. 2014. pp. 27&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/SAI.2014.6918171</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat GA, Weber GM, Gehlenborg N, Avillach P, Palmer NP, Chiovato L, Cimino J, Waitman LR, Omenn GS, Malovini A, Moore JH, Beaulieu-Jones BK, Tibollo V, Murphy SN, Yi SL, Keller MS, Bellazzi R, Hanauer DA, Serret-Larmande A, Gutierrez-Sacristan A, Holmes JJ, Bell DS, Mandl KD, Follett RW, Klann JG, Murad DA, Scudeller L, Bucalo M, Kirchoff K, Craig J, Obeid J, Jouhet V, Griffier R, Cossin S, Moal B, Patel LP, Bellasi A, Prokosch HU, Kraska D, Sliz P, Tan AL, Ngiam KY, Zambelli A, Mowery DL, Schiver E, Devkota B, Bradford RL, Daniar M, Daniel C, Benoit V, Bey R, Paris N, Serre P, Orlova N, Dubiel J, Hilka M, Jannot AS, Breant S, Leblanc J, Griffon N, Burgun A, Bernaux M, Sandrin A, Salamanca E, Cormont S, Ganslandt T, Gradinger T, Champ J, Boeker M, Martel P, Esteve L, Gramfort A, Grisel O, Leprovost D, Moreau T, Varoquaux G, Vie J, Wassermann D, Mensch A, Caucheteux C, Haverkamp C, Lemaitre G, Bosari S, Krantz ID, South A, Cai T, Kohane IS. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. NPJ Digit Med. 2020;3:109. doi: 10.1038/s41746-020-00308-0. doi: 10.1038/s41746-020-00308-0.308</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaspers MW, Steen T, van den Bos C, Geenen M. The think aloud method: a guide to user interface design. Int J Med Inform. 2004 Nov;73(11-12):781&#x2013;95. doi: 10.1016/j.ijmedinf.2004.08.003.S1386-5056(04)00182-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2004.08.003</ArticleId><ArticleId IdType="pubmed">15491929</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooke J. SUS: A 'Quick and Dirty' usability scale. In: Jordan PW, Thomas B, Weerdmeester BA, McClelland IL, editors. Usability Evaluation in Industry. London, England: Taylor and Francis; 1996.</Citation></Reference><Reference><Citation>Nielsen J, Mack RL. Usability Inspection Methods. New York, United States: John Wiley &amp; Sons; 1994. pp. 1&#x2013;448.</Citation></Reference><Reference><Citation>Zapf D, Brodbeck FC, Pr&#xfc;mper J. Handlungsorientierte Fehlertaxonomie in der Mensch - Computer - Interaktion. Zeitschrift f&#xfc;r Arbeits- und Organisationspsychologie. 1989.  [2021-06-26].  
 https://people.f3.htw-berlin.de/Professoren/Pruemper/publikation/1989/Zapf%20_Brodbeck_Pruemper(1989).pdf
.</Citation></Reference><Reference><Citation>Bastien JM. Usability testing: a review of some methodological and technical aspects of the method. Int J Med Inform. 2010 Apr;79(4):18&#x2013;23. doi: 10.1016/j.ijmedinf.2008.12.004.S1386-5056(08)00209-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2008.12.004</ArticleId><ArticleId IdType="pubmed">19345139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tullis T, Fleischman S, McNulty M, Cianchette C, Bergel M. An empirical comparison of lab and remote usability testing of web sites. Usability Professional Association Conference, Orlando. 2002.  [2021-06-26].  
 https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.457.3080&amp;rep=rep1&amp;type=pdf
.</Citation></Reference><Reference><Citation>Andreasen M, Nielsen H, Schr&#xf8;der SO, Stage J. What happened to remote usability testing? An empirical study of three methods. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems; CHI07: CHI Conference on Human Factors in Computing Systems; April 28-May 3, 2007; San Jose California USA. 2007. pp. 1405&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1240624.1240838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen J, Clemmensen T, Yssing C. Getting access to what goes on in people's heads? - Reflections on the think-aloud technique. Proceedings of the Second Nordic Conference on Human-computer Interaction; NORDICHI02: NORDICHI 2002, The second Nordic conference on Human-Computer Interaction; October 19-23, 2002; Aarhus Denmark. 2002. pp. 101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/572020.572033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauro J, Lewis JR. Standardized usability questionnaires. In: Sauro J, Lewis JR, editors. Quantifying the User Experience. New York: Morgan Kaufmann; 2012. pp. 185&#x2013;240.</Citation></Reference><Reference><Citation>Bangor A, Kortum PT, Miller JT. An empirical evaluation of the system usability scale. Int J Hum-Comput Int. 2008 Jul 30;24(6):574&#x2013;94. doi: 10.1080/10447310802205776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10447310802205776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarodnick F, Brau H. Methoden Der Usability Evaluation: Wissenschaftliche Grundlagen und Praktische Anwendung. Bern: Hogrefe; 2016.</Citation></Reference><Reference><Citation>Sch&#xfc;ttler C, Huth V, von Jagwitz-Biegnitz M, Lablans M, Prokosch HU, Griebel L. A federated online search tool for biospecimens (sample locator): usability study. J Med Internet Res. 2020 Aug 18;22(8):e17739. doi: 10.2196/17739. 
 
v22i8e17739</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/17739</ArticleId><ArticleId IdType="pmc">PMC7463387</ArticleId><ArticleId IdType="pubmed">32663150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ryan PB, Ta C, Guo Y, Li Z, Hardin J, Makadia R, Jin P, Shang N, Kang T, Weng C. Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc. 2019 Apr 01;26(4):294&#x2013;305. doi: 10.1093/jamia/ocy178.5308980</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy178</ArticleId><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath MM, Winfield S, Evans S, Slopek S, Shang H, Ferranti J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. J Biomed Inform. 2011 Apr;44(2):266&#x2013;76. doi: 10.1016/j.jbi.2010.11.008. 
 
S1532-0464(10)00174-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2010.11.008</ArticleId><ArticleId IdType="pmc">PMC3063322</ArticleId><ArticleId IdType="pubmed">21130181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuric E, Fern&#xe1;ndez JD, Drozd O. Knowledge graph exploration: a usability evaluation of query builders for laypeople. In: Acosta M, Cudr&#xe9;-Mauroux P, Maleshkova M, Pellegrini T, Sack H, Sure-Vetter Y, editors. Semantic Systems. The Power of AI and Knowledge Graphs. Switzerland: Springer; 2019. pp. 326&#x2013;42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34291033</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Risk Diagrams Based on Primary Care Electronic Medical Records and Linked Real-Time PCR Data to Monitor Local COVID-19 Outbreaks During the Summer 2020: A Prospective Study Including 7,671,862 People in Catalonia.</ArticleTitle><Pagination><StartPage>693956</StartPage><MedlinePgn>693956</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">693956</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2021.693956</ELocationID><Abstract><AbstractText>Monitoring transmission is a prerequisite for containing COVID-19. We report on effective potential growth (EPG) as a novel measure for the early identification of local outbreaks based on primary care electronic medical records (EMR) and PCR-confirmed cases. Secondly, we studied whether increasing EPG precedes local hospital and intensive care (ICU) admissions and mortality. Population-based cohort including all Catalan citizens' PCR tests, hospitalization, intensive care (ICU) and mortality between 1/07/2020 and 13/09/2020; linked EMR covering 88.6% of the Catalan population was obtained. Nursing home residents were excluded. COVID-19 counts were ascertained based on EMR and PCRs separately. Weekly empirical propagation (&#x3c1;<sub>7</sub>) and 14-day cumulative incidence (A<sub>14</sub>) and 95% confidence intervals were estimated at care management area (CMA) level, and combined as EPG = &#x3c1;<sub>7</sub> &#xd7; A<sub>14</sub>. Overall, 7,607,201 and 6,798,994 people in 43 CMAs were included for PCR and EMR measures, respectively. A14, &#x3c1;<sub>7</sub>, and EPG increased in numerous CMAs during summer 2020. EMR identified 2.70-fold more cases than PCRs, with similar trends, a median (interquartile range) 2 (1) days earlier, and better precision. Upticks in EPG preceded increases in local hospital admissions, ICU occupancy, and mortality. Increasing EPG identified localized outbreaks in Catalonia, and preceded local hospital and ICU admissions and subsequent mortality. EMRs provided similar estimates to PCR, but some days earlier and with better precision. EPG is a useful tool for the monitoring of community transmission and for the early identification of COVID-19 local outbreaks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Catala, Coma, Alonso, &#xc1;lvarez-Lacalle, Cordomi, L&#xf3;pez, Fina, Medina-Peralta, Prats and Prieto-Alhambra.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catala</LastName><ForeName>Marti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Computational Biology and Complex Systems (BIOCOM-SC), Department of Physics, Universitat Polit&#xe8;cnica de Catalunya, Castelldefels, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coma</LastName><ForeName>Ermengol</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sistemes d'Informaci&#xf3; dels Serveis d'Atenci&#xf3; Prim&#xe0;ria (SISAP), Institut Catal&#xe0; de la Salut (ICS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Computational Biology and Complex Systems (BIOCOM-SC), Department of Physics, Universitat Polit&#xe8;cnica de Catalunya, Castelldefels, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-Lacalle</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Computational Biology and Complex Systems (BIOCOM-SC), Department of Physics, Universitat Polit&#xe8;cnica de Catalunya, Castelldefels, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordomi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Direcci&#xf3; d'Estrat&#xe8;gia i Qualitat, Institut Catal&#xe0; de la Salut, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Computational Biology and Complex Systems (BIOCOM-SC), Department of Physics, Universitat Polit&#xe8;cnica de Catalunya, Castelldefels, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fina</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sistemes d'Informaci&#xf3; dels Serveis d'Atenci&#xf3; Prim&#xe0;ria (SISAP), Institut Catal&#xe0; de la Salut (ICS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina-Peralta</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sistemes d'Informaci&#xf3; dels Serveis d'Atenci&#xf3; Prim&#xe0;ria (SISAP), Institut Catal&#xe0; de la Salut (ICS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Computational Biology and Complex Systems (BIOCOM-SC), Department of Physics, Universitat Polit&#xe8;cnica de Catalunya, Castelldefels, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">outbreak detection</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">sentinel</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword></KeywordList><CoiStatement>DP-A department has received consultancy fees from UCB Biopharma. DP-A department has received speaker fees from AMGEN. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DP-A department and open for external participants. CP has received consultancy fees from Janssen. None of these relationships has directly funded this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34291033</ArticleId><ArticleId IdType="pmc">PMC8287173</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2021.693956</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stoecklin SB, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. . First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Eurosurveillance. (2020) 25:2000094. 10.2807/1560-7917.ES.2020.25.6.2000094</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.6.2000094</ArticleId><ArticleId IdType="pmc">PMC7029452</ArticleId><ArticleId IdType="pubmed">32070465</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Basteiro A, Alvarez-Dardet C, Arenas A, Bengoa R, Borrell C, Del Val M, et al. . The need for an independent evaluation of the COVID-19 response in Spain. Lancet. (2020) 396:529&#x2013;30. 10.1016/S0140-6736(20)31713-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31713-X</ArticleId><ArticleId IdType="pmc">PMC7831872</ArticleId><ArticleId IdType="pubmed">32771082</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Ball&#xf3; E, Coma E, Mora N, Arag&#xf3;n M, Prats-Uribe A, et al. . Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain. Int J Epidemiol. (2020) 49:1930&#x2013;9. 10.1093/ije/dyaa190</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa190</ArticleId><ArticleId IdType="pmc">PMC7665572</ArticleId><ArticleId IdType="pubmed">33118037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dades COVID. Generalitat de Catalunya. Available online at: https://www.dadescovid.cat (accessed Nov 12, 2020).</Citation></Reference><Reference><Citation>Evoluci&#xf3; dels casos i taxa reproducci&#xf3; efectiva (Rt) dels SARS-CoV-2 . Departament de Salut Generalitat de Catalunya. Available online at: https://app.powerbi.com/view?r=eyJrIjoiZTE2OTAwYzctMzQ3ZC00ZjY5L WExNDctYWIzODFmMDQxMjRmIiwidCI6IjNiOTQyN2RjLWQzMGUt NDNiYy04YzA2LWZmNzI1MzY3NmZlYyIsImMiOjh9. Accessed 12 Nov 2020.</Citation></Reference><Reference><Citation>Closas P, Coma E, M&#xe9;ndez L. Sequential detection of influenza epidemics by the Kolmogorov-Smirnov test. BMC Med Inform Decis Mak. (2012) 12:112. 10.1186/1472-6947-12-112</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-12-112</ArticleId><ArticleId IdType="pmc">PMC3557152</ArticleId><ArticleId IdType="pubmed">23031321</ArticleId></ArticleIdList></Reference><Reference><Citation>Coma E, Mora N, Prats-Uribe A, Avil&#xe9;s FF, Prieto-Alhambra D, Medina M. Excess cases of influenza and the coronavirus epidemic in Catalonia: a time-series analysis of primary-care electronic medical records covering over 6 million people. BMJ Open. (2020) 10:e039369. 10.1136/bmjopen-2020-039369</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-039369</ArticleId><ArticleId IdType="pmc">PMC7431772</ArticleId><ArticleId IdType="pubmed">32727740</ArticleId></ArticleIdList></Reference><Reference><Citation>Han E, Tan MMJ, Turk E, Sridhar D, Leung GM, Shibuya K, et al. . Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe. Lancet. (2020) 396:1525&#x2013;34. 10.1016/S0140-6736(20)32007-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32007-9</ArticleId><ArticleId IdType="pmc">PMC7515628</ArticleId><ArticleId IdType="pubmed">32979936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Boston-Fisher N, Luo Y, Verma A, Buckeridge DL. A systematic review of aberration detection algorithms used in public health surveillance. J Biomed Inform. (2019) 94:103181. 10.1016/j.jbi.2019.103181</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103181</ArticleId><ArticleId IdType="pubmed">31014979</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Cardona P-J, Prats C, et al. . Analysis and Prediction of COVID-19 for EU-EFTA-UK and Other Countries. Reports collection (2020). Available online at: https://upcommons.upc.edu/handle/2117/110978</Citation></Reference><Reference><Citation>Prats C, L&#xf3;pez-Codina D, Vilella A, Trilla A. How Should We Deal With New Outbreaks of Covid-19? ISGlobal. 2020. Available online at: https://www.isglobal.org/en_GB/-/-como-hacer-frente-a-los-nuevos-brotes-de-la-covid-19-</Citation></Reference><Reference><Citation>Gesti&#xf3; de la infecci&#xf3; pel coronavirus SARS-CoV-2 en l'&#xe0;mbit residencial . Pla sectorial. Departament de Salut Generalitat de Catalunya. Available online at: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-divulgatiu/gestio-infeccio-coronavirus-ambit-residencial.pdf (accessed Nov 12, 2020).</Citation></Reference><Reference><Citation>Ramos R, Ball&#xf3; E, Marrugat J, Elosua R, Sala J, Grau M, et al. . Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol. (2012) 65:29&#x2013;37. 10.1016/j.rec.2011.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2011.07.016</ArticleId><ArticleId IdType="pubmed">22036238</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gil M, Elorza JM, Banque M, Comas-Cuf&#xed; M, Blanch J, Ramos R, et al. . Linking of primary care records to census data to study the association between socioeconomic status and cancer incidence in Southern Europe: a nation-wide ecological study. PLoS ONE. (2014) 9:e109706. 10.1371/journal.pone.0109706</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0109706</ArticleId><ArticleId IdType="pmc">PMC4203762</ArticleId><ArticleId IdType="pubmed">25329578</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, et al. . Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat commun. (2020) 11:5009. 10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Cardona P-J, Prats C. Risk diagrams colour-code and the ability to do contact tracing. In: Analysis and prediction of COVID-19 for EU-EFTA-UK and other countries. Report 52. Reports collection (2020). Available online at: https://upcommons.upc.edu/handle/2117/186911</Citation></Reference><Reference><Citation>Johnson NL, Kemp AW, Kotz S. Univariate Discrete Distributions. John Wiley &amp; Sons. Hoboken: New Jersey. (2005). 10.1002/0471715816</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471715816</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Pino D, Marchena M, Palacios P, Urdiales T, Cardona P-J, et al. . Robust estimation of diagnostic rate and real incidence of COVID-19 for European policymakers. PLoS ONE. (2021) 16:e0243701. 10.1371/journal.pone.0243701</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243701</ArticleId><ArticleId IdType="pmc">PMC7790392</ArticleId><ArticleId IdType="pubmed">33411737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawaf S, Quezada Yamamoto H, Rawaf D. Unlocking towns and cities: COVID-19 exit strategy. East Mediterr Health J. (2020) 26:499&#x2013;502. 10.26719/emhj.20.028</Citation><ArticleIdList><ArticleId IdType="doi">10.26719/emhj.20.028</ArticleId><ArticleId IdType="pubmed">32538441</ArticleId></ArticleIdList></Reference><Reference><Citation>Normativa d'inter&#xe8;s per a la Salut P&#xfa;blica . Departament de Salut Generalitat de Catalunya. Available online at: https://www.diba.cat/es/web/salutpublica/coronavirus-normativa (accessed at: Nov 12, 2020).</Citation></Reference><Reference><Citation>Eddy M. Flare-Up in Virus Cases Sets Back Germany's Efforts to Reopen. New York, NY: The New York Times;  (2020). Available online at: https://www.nytimes.com/2020/06/25/world/europe/germany-coronavirusreopening.html (accessed June 29, 2020).</Citation></Reference><Reference><Citation>Information Services Department the Government of Hong Kong Special Administrative Region . Some Anti-Epidemic Measures Eased. Available online at: https://www.news.gov.hk/eng/2020/05/20200505/20200505_170734_576.html (accessed June 19, 2020).</Citation></Reference><Reference><Citation>Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. . Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. (2020) 584:257&#x2013;61. 10.1038/s41586-020-2405-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2405-7</ArticleId><ArticleId IdType="pubmed">32512579</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddy M. Flare-Up in Virus Cases Sets Back Germany's Efforts to Reopen. New York, NY: The New York Times;  (2020). Available online at: https://www.nytimes.com/2020/06/25/world/europe/germany-coronavirusreopening.html (accessed June 29, 2020).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34294093</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1756-0381</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>BioData mining</Title><ISOAbbreviation>BioData Min</ISOAbbreviation></Journal><ArticleTitle>Evaluating risk detection methods to uncover ontogenic-mediated adverse drug effect mechanisms in children.</ArticleTitle><Pagination><StartPage>34</StartPage><MedlinePgn>34</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">34</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13040-021-00264-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Identifying adverse drugs effects (ADEs) in children, overall and within pediatric age groups, is essential for preventing disability and death from marketed drugs. At the same time, however, detection is challenging due to dynamic biological processes during growth and maturation, called ontogeny, that alter pharmacokinetics and pharmacodynamics. As a result, methodologies in pediatric drug safety have been limited to event surveillance and have not focused on investigating adverse event mechanisms. There is an opportunity to identify drug event patterns within observational databases for evaluating ontogenic-mediated adverse event mechanisms. The first step of which is to establish statistical models that can identify temporal trends of adverse effects across childhood.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using simulation, we evaluated a population stratification method (the proportional reporting ratio or PRR) and a population modeling method (the generalized additive model or GAM) to identify and quantify ADE risk at varying reporting rates and dynamics. We found that GAMs showed improved performance over the PRR in detecting dynamic drug event reporting across child development stages. Moreover, GAMs exhibited normally distributed and robust ADE risk estimation at all development stages by sharing information across child development stages.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study underscores the opportunity for using population modeling techniques, which leverage drug event reporting across development stages, as biologically-inspired detection methods for evaluating ontogenic mechanisms.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giangreco</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0001-8138-4947</Identifier><AffiliationInfo><Affiliation>Departments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168th Street, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-2700-2597</Identifier><AffiliationInfo><Affiliation>Departments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168th Street, New York, NY, 10032, USA. npt2105@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM131905</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008224</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35GM131905</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BioData Min</MedlineTA><NlmUniqueID>101319161</NlmUniqueID><ISSNLinking>1756-0381</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Child development</Keyword><Keyword MajorTopicYN="N">Dynamics</Keyword><Keyword MajorTopicYN="N">Modeling</Keyword><Keyword MajorTopicYN="N">Pediatrics</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34294093</ArticleId><ArticleId IdType="pmc">PMC8296590</ArticleId><ArticleId IdType="doi">10.1186/s13040-021-00264-9</ArticleId><ArticleId IdType="pii">10.1186/s13040-021-00264-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77&#x2013;83. doi: 10.1046/j.0306-5251.2001.01407.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0306-5251.2001.01407.x</ArticleId><ArticleId IdType="pmc">PMC2014499</ArticleId><ArticleId IdType="pubmed">11453893</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P. Adverse drug reactions in children--a systematic review. PLoS One. 2012;7(3):e24061. doi: 10.1371/journal.pone.0024061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024061</ArticleId><ArticleId IdType="pmc">PMC3293884</ArticleId><ArticleId IdType="pubmed">22403604</ArticleId></ArticleIdList></Reference><Reference><Citation>Giangreco NP, Elias JE, Tatonetti NP. No population left behind: Improving paediatric drug safety using informatics and systems biology. Br J Clin Pharmacol. 2020:bcp.14705 Available from: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14705. Cited 2021 Jan 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14705</ArticleId><ArticleId IdType="pmc">PMC8209126</ArticleId><ArticleId IdType="pubmed">33332641</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin DK, Smith PB, Sun MJM, Murphy MD, Avant D, Mathis L, Rodriguez W, Califf RM, Li JS. Safety and transparency of pediatric drug trials. Arch Pediatr Adolesc Med. 2009;163(12):1080&#x2013;1086. doi: 10.1001/archpediatrics.2009.229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpediatrics.2009.229</ArticleId><ArticleId IdType="pmc">PMC2792563</ArticleId><ArticleId IdType="pubmed">19996043</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bie S, Ferrajolo C, Straus SMJM, Verhamme KMC, Bonhoeffer J, Wong ICK, Sturkenboom MCJM. Pediatric drug safety surveillance in FDA-AERS: a description of adverse events from GRiP project. PLoS One. 2015;10(6):e0130399. doi: 10.1371/journal.pone.0130399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130399</ArticleId><ArticleId IdType="pmc">PMC4474891</ArticleId><ArticleId IdType="pubmed">26090678</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol. 2011;18(2):e76&#x2013;e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">21467599</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi B. The evolutionary biology of child health. Proc R Soc B Biol Sci. 2011;278(1711):1441&#x2013;1449. doi: 10.1098/rspb.2010.2627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2010.2627</ArticleId><ArticleId IdType="pmc">PMC3081756</ArticleId><ArticleId IdType="pubmed">21288946</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe S, Estabrook RW, Pitluck S, Davis JR. Rational therapeutics for infants and children. 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">25077267</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003;192(1):37&#x2013;48. doi: 10.1016/S0300-483X(03)00249-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0300-483X(03)00249-X</ArticleId><ArticleId IdType="pubmed">14511902</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010;11(11):1591&#x2013;1602. doi: 10.2217/pgs.10.146.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs.10.146</ArticleId><ArticleId IdType="pmc">PMC3044438</ArticleId><ArticleId IdType="pubmed">21121777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf-Peters VB, Hadders-Algra M. Ontogeny of the human central nervous system: what is happening when? Early Hum Dev. 2006;82(4):257&#x2013;266. doi: 10.1016/j.earlhumdev.2005.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.earlhumdev.2005.10.013</ArticleId><ArticleId IdType="pubmed">16360292</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707740</ArticleId><ArticleId IdType="pubmed">26702035</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106&#x2013;135. doi: 10.1002/med.21280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21280</ArticleId><ArticleId IdType="pubmed">23494977</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H-L, Jing X, Sun J-Y, Hu Y, Xu Z-J, Ni M-M, Chen F, Lu X-P, Qiu J-C, Wang T. Valproic acid and the liver injury in patients with epilepsy: an update. Curr Pharm Des. 2019;25(3):343&#x2013;351. doi: 10.2174/1381612825666190329145428.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666190329145428</ArticleId><ArticleId IdType="pubmed">30931853</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon YE. Paradoxical reaction to midazolam in children. Korean J Anesthesiol. 2013;65(1):2&#x2013;3. doi: 10.4097/kjae.2013.65.1.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.4097/kjae.2013.65.1.2</ArticleId><ArticleId IdType="pmc">PMC3726842</ArticleId><ArticleId IdType="pubmed">23904931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami Y, Fujii S, Ishikawa G, Sekiguchi A, Nakai A, Takase M. Valproate-induced polycystic ovary syndrome in a girl with epilepsy: a case study. J Nippon Med Sch. 2018;85(5):287&#x2013;290. doi: 10.1272/jnms.JNMS.2018_85-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1272/jnms.JNMS.2018_85-46</ArticleId><ArticleId IdType="pubmed">30464147</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui N, Wu F, Lu W, Bai R, Ke B, Liu T, Li L, Lan F, Cui M. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase II&#x3b1; to II&#x3b2; in human stem cell derived cardiomyocytes. N. 2019;23(7):4627&#x2013;4639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584544</ArticleId><ArticleId IdType="pubmed">31106979</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SO, Wamsley HL, Bae K, Hu Z, Li X, Choe S, Slayton WB, Oh SP, Wagner KU, Sayeski PP. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One. 2013;8(3):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609865</ArticleId><ArticleId IdType="pubmed">23544085</ArticleId></ArticleIdList></Reference><Reference><Citation>Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate on brain development: An excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol. 1995;54:358&#x2013;370. doi: 10.1097/00005072-199505000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199505000-00009</ArticleId><ArticleId IdType="pubmed">7745435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X-L, Zhao P, Barrett J, Lesko L, Schmidt S. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):80. doi: 10.1038/psp.2013.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.55</ArticleId><ArticleId IdType="pmc">PMC3817375</ArticleId><ArticleId IdType="pubmed">24132164</ArticleId></ArticleIdList></Reference><Reference><Citation>Krekels EHJ, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CAJ. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012;1(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603431</ArticleId><ArticleId IdType="pubmed">23887364</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldrick P. Juvenile animal testing in drug development - is it useful? Regul Toxicol Pharmacol. 2010;57(2&#x2013;3):291&#x2013;299. doi: 10.1016/j.yrtph.2010.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yrtph.2010.03.009</ArticleId><ArticleId IdType="pubmed">20350578</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulooze SC, Zwep LB, Vogt JE, Krekels EHJ, Hankemeier T, Anker JN, Knibbe CAJ. Beyond the randomized clinical trial: innovative data science to close the pediatric evidence gap. Clin Pharmacol Ther. 2020;107(4):786&#x2013;795. doi: 10.1002/cpt.1744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1744</ArticleId><ArticleId IdType="pubmed">31863465</ArticleId></ArticleIdList></Reference><Reference><Citation>Brussee JM, Calvier EAM, Krekels EHJ, V&#xe4;litalo PAJ, Tibboel D, Allegaert K, Knibbe CAJ. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol. 2016;9(9):1235&#x2013;1244. doi: 10.1080/17512433.2016.1198256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2016.1198256</ArticleId><ArticleId IdType="pubmed">27269200</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen ML, Davis RL. Identifying the &#x201c;blip on the radar screen&#x201d;: leveraging big data in defining drug safety and efficacy in pediatric practice. J Clin Pharmacol. 2018;58(January):S86&#x2013;S93. doi: 10.1002/jcph.1141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1141</ArticleId><ArticleId IdType="pubmed">30248191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP. Translational medicine in the Age of Big Data. Brief Bioinform. 2019;20(2):457&#x2013;462. doi: 10.1093/bib/bbx116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbx116</ArticleId><ArticleId IdType="pmc">PMC6433900</ArticleId><ArticleId IdType="pubmed">29040418</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366&#x2013;1371. doi: 10.2105/AJPH.2007.124537.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.124537</ArticleId><ArticleId IdType="pmc">PMC2446471</ArticleId><ArticleId IdType="pubmed">18556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Etwel FA, Rieder MJ, Bend JR, Koren G. A surveillance method for the early identification of idiosyncratic Adverse drug reactions. Drug Saf. 2008;31(2):169&#x2013;180. doi: 10.2165/00002018-200831020-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200831020-00006</ArticleId><ArticleId IdType="pubmed">18217792</ArticleId></ArticleIdList></Reference><Reference><Citation>Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards IR. Paediatric safety signals identified in VigiBase: methods and results from Uppsala monitoring Centre. Pharmacoepidemiol Drug Saf. 2019;28(5):680&#x2013;689. doi: 10.1002/pds.4734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4734</ArticleId><ArticleId IdType="pmc">PMC6594230</ArticleId><ArticleId IdType="pubmed">30767342</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483&#x2013;486. doi: 10.1002/pds.677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokogu OU, Dodd C, Pacurariu A, Kaguelidou F, Weibel D, Sturkenboom MCJM. Drug safety monitoring in children: performance of signal detection algorithms and impact of age stratification. Drug Saf. 2016;39(9):873&#x2013;881. doi: 10.1007/s40264-016-0433-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-016-0433-x</ArticleId><ArticleId IdType="pmc">PMC4982893</ArticleId><ArticleId IdType="pubmed">27255487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie T, Tibshirani R, Friedman J. Elements of statistical learning. 2nd ed. New York: Springer; 2008. p. 764. Available from: http://web.stanford.edu/~hastie/pub.htm</Citation></Reference><Reference><Citation>Guisan A, Edwards TC, Hastie T. Generalized linear and generalized additive models in studies of species distributions: setting the scene. Ecol Model. 2002;157(2&#x2013;3):89&#x2013;100. doi: 10.1016/S0304-3800(02)00204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3800(02)00204-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Q, Wang J. The association between consecutive days&#x2019; heat wave and cardiovascular disease mortality in Beijing, China. BMC Public Health. 2017;17(1):1&#x2013;10. doi: 10.1186/s12889-017-4129-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-017-4129-7</ArticleId><ArticleId IdType="pmc">PMC5322604</ArticleId><ArticleId IdType="pubmed">28228117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayo-Uria I, Mateu J, Escobar F, Mughini-Gras L. Risk factors and spatial distribution of urban rat infestations. J Pest Sci (2004) 2014;87(1):107&#x2013;115. doi: 10.1007/s10340-013-0530-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10340-013-0530-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf. 2012;11(1):95&#x2013;105. doi: 10.1517/14740338.2011.584531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.2011.584531</ArticleId><ArticleId IdType="pubmed">21548838</ArticleId></ArticleIdList></Reference><Reference><Citation>Saghir SA, Khan SA, McCoy AT. Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. Crit Rev Toxicol. 2012;42(5):323&#x2013;357. doi: 10.3109/10408444.2012.674100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408444.2012.674100</ArticleId><ArticleId IdType="pubmed">22512665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunewardena SS, Yoo B, Peng L, Lu H, Zhong X, Klaassen CD, Cui JY. Deciphering the developmental dynamics of the mouse liver transcriptome. PLoS One. 2015;10(10):e0141220. doi: 10.1371/journal.pone.0141220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141220</ArticleId><ArticleId IdType="pmc">PMC4619800</ArticleId><ArticleId IdType="pubmed">26496202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn J, Kortepeter C, Mu&#xf1;oz M, Simms K, Montenegro S, Dal PG. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508&#x2013;517. doi: 10.1002/cpt.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.81</ArticleId><ArticleId IdType="pubmed">25670505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagattini F, Karlsson I, Rebane J, Papapetrou P. A classification framework for exploiting sparse multi-variate temporal features with application to adverse drug event detection in medical records. BMC Med Inform Decis Mak. 2019;19(1):1&#x2013;21. doi: 10.1186/s12911-018-0717-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0717-4</ArticleId><ArticleId IdType="pmc">PMC6327495</ArticleId><ArticleId IdType="pubmed">30630486</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Papapetrou P, Asker L, Bostr&#xf6;m H. Learning from heterogeneous temporal data in electronic health records. J Biomed Inform. 2017;65:105&#x2013;119. doi: 10.1016/j.jbi.2016.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.11.006</ArticleId><ArticleId IdType="pubmed">27919732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SN. Generalized additive models: an introduction with R. 2. 2017. pp. 1&#x2013;476.</Citation></Reference><Reference><Citation>Helwig NE. Regression with ordered predictors via ordinal smoothing splines. Front Appl Math Stat. 2017;3(July):1&#x2013;13.</Citation></Reference><Reference><Citation>Simpson D, Rue H, Riebler A, Martins TG, S&#xf8;rbye SH. Penalising model component complexity: a principled, practical approach to constructing priors. Stat Sci. 2017;32(1):1&#x2013;28.</Citation></Reference><Reference><Citation>Williams K, Thomson D, Seto I, Contopoulos-Ioannidis DG, JPA I, Curtis S, Constantin E, Batmanabane G, Hartling L, Klassen T, Offringa M, K. W, D. T, I. S, D.G. C-I, J.P.A. I, S. C, E. C, G. B, L. H, T. K, M. O. Williams K, Thomson D, Seto I, Contopoulos-Ioannidis DG, Ioannidis JPA, Curtis S, Constantin E, Batmanabane G, Hartling L, Klassen T. Standard 6: Age groups for pediatric trials. Pediatrics. 2012;129(SUPPL. 3):S153&#x2013;S160. doi: 10.1542/peds.2012-0055I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2012-0055I</ArticleId><ArticleId IdType="pubmed">22661762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, Johanson E, Bright RA. OpenFDA: an innovative platform providing access to a wealth of FDA&#x2019;s publicly available data. J Am Med Inform Assoc. 2016;23(3):596&#x2013;600. doi: 10.1093/jamia/ocv153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv153</ArticleId><ArticleId IdType="pmc">PMC4901374</ArticleId><ArticleId IdType="pubmed">26644398</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Athena. Available from: https://athena.ohdsi.org/search-terms/start. Cited 2021 Jan 17.</Citation></Reference><Reference><Citation>Buja BYA, Hastie T, Tibshirani R. Linear Smoothers Additive Models. 2016;17(2):453&#x2013;510.</Citation></Reference><Reference><Citation>Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res. 1995;4(3):187&#x2013;196. doi: 10.1177/096228029500400302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096228029500400302</ArticleId><ArticleId IdType="pubmed">8548102</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokogu OU, Fregonese F, Ferrajolo C, Verhamme K, de Bie S, Jong G, Catapano M, Weibel D, Kaguelidou F, Bramer WM, Hsia Y, ICK W, Gazarian M, Bonhoeffer J, Sturkenboom M. Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems. Drug Saf. 2015;38(2):207&#x2013;217. doi: 10.1007/s40264-015-0265-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0265-0</ArticleId><ArticleId IdType="pmc">PMC4328124</ArticleId><ArticleId IdType="pubmed">25663078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34304580</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4563</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Hypertension (Dallas, Tex. : 1979)</Title><ISOAbbreviation>Hypertension</ISOAbbreviation></Journal><ArticleTitle>Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>603</EndPage><MedlinePgn>591-603</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.120.16667</ELocationID><Abstract><AbstractText>[Figure: see text].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Data Science and Informatics, Geisinger, Danville, PA (R.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (M.A.S., M.J.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles (M.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT (H.M.K.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, CT (H.M.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (M.A.S., M.J.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, NJ (M.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine (S.S.), Columbia University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Georgia Tech Research Institute, Georgia Tech College of Computing, Atlanta (J.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia (N.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA (C.G.R.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics (D.M.), Columbia University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (S.C.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York (R.C., P.B.R., G.H.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital (G.H.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI135995</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hypertension</MedlineTA><NlmUniqueID>7906255</NlmUniqueID><ISSNLinking>0194-911X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2022 Feb 8;145(6):413-415. doi: 10.1161/CIRCULATIONAHA.121.057835.</RefSource><PMID Version="1">35130055</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiotensin receptor</Keyword><Keyword MajorTopicYN="N">angiotensin receptor blocker</Keyword><Keyword MajorTopicYN="N">cardiovascular outcomes</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34304580</ArticleId><ArticleId IdType="mid">NIHMS1700171</ArticleId><ArticleId IdType="pmc">PMC8363588</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2018;71:e127&#x2013;e248. doi:10.1016/j.jacc.2017.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.11.006</ArticleId><ArticleId IdType="pubmed">29146535</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021&#x2013;3104. doi:10.1093/eurheartj/ehy339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy339</ArticleId><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboussin David M, Allen Norrina B, Griswold Michael E, Eliseo Guallar, Yuling Hong, Lackland Daniel T., et al.Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e116&#x2013;e135. doi:10.1161/HYP.0000000000000067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000067</ArticleId><ArticleId IdType="pubmed">29133355</ArticleId></ArticleIdList></Reference><Reference><Citation>The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting&#x2013;Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine 2000;342:145&#x2013;153. doi:10.1056/NEJM200001203420301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200001203420301</ArticleId><ArticleId IdType="pubmed">10639539</ArticleId></ArticleIdList></Reference><Reference><Citation>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981&#x2013;2997. doi:10.1001/jama.288.23.2981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.288.23.2981</ArticleId><ArticleId IdType="pubmed">12479763</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl&#xf6;f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002;359:995&#x2013;1003. doi:10.1016/S0140-6736(02)08089-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)08089-3</ArticleId><ArticleId IdType="pubmed">11937178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al.The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 2003;21:875.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714861</ArticleId></ArticleIdList></Reference><Reference><Citation>The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine 2008;358:1547&#x2013;1559. doi:10.1056/NEJMoa0801317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0801317</ArticleId><ArticleId IdType="pubmed">18378520</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al.Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents: A Network Meta-analysis. JAMA 2003;289:2534&#x2013;2544. doi:10.1001/jama.289.19.2534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.19.2534</ArticleId><ArticleId IdType="pubmed">12759325</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J, et al.Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin&#x2013;angiotensin&#x2013;aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012;33:2088&#x2013;2097. doi:10.1093/eurheartj/ehs075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs075</ArticleId><ArticleId IdType="pmc">PMC3418510</ArticleId><ArticleId IdType="pubmed">22511654</ArticleId></ArticleIdList></Reference><Reference><Citation>Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2014. doi:10.1002/14651858.CD009096.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009096.pub2</ArticleId><ArticleId IdType="pmc">PMC6486121</ArticleId><ArticleId IdType="pubmed">25148386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, et al.Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Agency for Healthcare Research and Quality (US); 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">21977520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997;19:1263&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9385475</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al.Angiotensin-Receptor Blockade versus Converting&#x2013;Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 2004;351:1952&#x2013;1961. doi:10.1056/NEJMoa042274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042274</ArticleId><ArticleId IdType="pubmed">15516696</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;pinar J, V&#xed;tovec J, Sou&#x10d;ek M, Du&#x161;ek L, Pavl&#xed;k T. CORD: COmparison of Recommended Doses of ace inhibitors and angiotensin II receptor blockers. International Journal of Cardiology 2010;144:293&#x2013;294. doi:10.1016/j.ijcard.2009.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2009.02.022</ArticleId><ArticleId IdType="pubmed">19297039</ArticleId></ArticleIdList></Reference><Reference><Citation>Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, et al.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 2017;103:1339&#x2013;1346. doi:10.1136/heartjnl-2016-310705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2016-310705</ArticleId><ArticleId IdType="pubmed">28285267</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss Martin H, Hall Alistair S Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Circulation 2006;114:838&#x2013;854. doi:10.1161/CIRCULATIONAHA.105.594986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.594986</ArticleId><ArticleId IdType="pubmed">16923768</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al.Characterizing treatment pathways at scale using the OHDSI network. PNAS 2016;113:7329&#x2013;7336. doi:10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiuping Gu, Burt Vicki L., Dillon Charles F., Yoon Sarah. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension. Circulation 2012;126:2105&#x2013;2114. doi:10.1161/CIRCULATIONAHA.112.096156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.096156</ArticleId><ArticleId IdType="pubmed">23091084</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 2019;394:1816&#x2013;1826. doi:10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, et al.Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med 2020;180:542&#x2013;551. doi:10.1001/jamainternmed.2019.7454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, Hripcsak G, Jin P, Reich C, et al.Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. Epilepsia 2017;58:e101&#x2013;e106. doi:10.1111/epi.13828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.13828</ArticleId><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, et al.Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Network Open 2018;1:e181755&#x2013;e181755. doi:10.1001/jamanetworkopen.2018.1755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1755</ArticleId><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Ryan P, Natarajan K, Falconer T, Crew KD, Reich CG, et al.Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network. JCO Clinical Cancer Informatics 2020:171&#x2013;183. doi:10.1200/CCI.19.00107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.19.00107</ArticleId><ArticleId IdType="pmc">PMC7113074</ArticleId><ArticleId IdType="pubmed">32134687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf 2013;36Suppl 1:S59&#x2013;72. doi:10.1007/s40264-013-0099-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine 2015;373:2103&#x2013;2116. doi:10.1056/NEJMoa1511939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1511939</ArticleId><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41&#x2013;55. doi:10.1093/biomet/70.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018;47:2005&#x2013;2014. doi:10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013;23. doi:10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177&#x2013;188. doi:10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E, Boyce R, Ryan P, van der Lei J, Rijnbeek P, Schuemie M. Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions. J Biomed Inform 2017;66:72&#x2013;81. doi:10.1016/j.jbi.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Phil Trans R Soc A 2018;376:20170356. doi:10.1098/rsta.2017.0356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. PNAS 2018;115:2571&#x2013;2577. doi:10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Statistics in Medicine 2016;35:3883&#x2013;3888. doi:10.1002/sim.6977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al.Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. Int J Cardiol 2016;217:128&#x2013;134. doi:10.1016/j.ijcard.2016.04.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.04.132</ArticleId><ArticleId IdType="pubmed">27179902</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Pressure Lowering Treatment Trialists&#x2019; Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet 2003;362:1527&#x2013;1535. doi:10.1016/S0140-6736(03)14739-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14739-3</ArticleId><ArticleId IdType="pubmed">14615107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342. doi:10.1136/bmj.d2234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d2234</ArticleId><ArticleId IdType="pmc">PMC3082637</ArticleId><ArticleId IdType="pubmed">21521728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-Induced Acute Pancreatitis: A Review. Ochsner J 2015;15:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365846</ArticleId><ArticleId IdType="pubmed">25829880</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaurich T Drug-Induced Acute Pancreatitis. Baylor University Medical Center Proceedings 2008;21:77&#x2013;81. doi:10.1080/08998280.2008.11928366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2008.11928366</ArticleId><ArticleId IdType="pmc">PMC2190558</ArticleId><ArticleId IdType="pubmed">18209761</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesbacher T Kallikrein-Kinin System in Acute Pancreatitis: Potential of B2-Bradykinin Antagonists and Kallikrein Inhibitors. PHA 2000;60:113&#x2013;120. doi:10.1159/000028355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000028355</ArticleId><ArticleId IdType="pubmed">10754447</ArticleId></ArticleIdList></Reference><Reference><Citation>Eland IA, Sundstr&#xf6;m A, Velo GP, Andersen M, Sturkenboom MCJM, Langman MJS, et al.Antihypertensive medication and the risk of acute pancreatitis: The European case-control study on drug-induced acute pancreatitis (EDIP). Scandinavian Journal of Gastroenterology 2006;41:1484&#x2013;1490. doi:10.1080/00365520600761676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520600761676</ArticleId><ArticleId IdType="pubmed">17101581</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S, Bourgault C, Barkun A, Sheehy O, Ernst P. Antihypertensive drugs and the risk of gastrointestinal bleeding. The American Journal of Medicine 1998;105:230&#x2013;235. doi:10.1016/S0002-9343(98)00239-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(98)00239-3</ArticleId><ArticleId IdType="pubmed">9753026</ArticleId></ArticleIdList></Reference><Reference><Citation>Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol 2018;71:1474&#x2013;1482. doi:10.1016/j.jacc.2018.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.01.058</ArticleId><ArticleId IdType="pubmed">29598869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H- Y, Shin J, Kim G- H, Park S, Ihm S- H, Kim HC, et al.2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens 2019;25. doi:10.1186/s40885-019-0124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0124-x</ArticleId><ArticleId IdType="pmc">PMC6670135</ArticleId><ArticleId IdType="pubmed">31388453</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34313749</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Increasing trust in real-world evidence through evaluation of observational data quality.</ArticleTitle><Pagination><StartPage>2251</StartPage><EndPage>2257</EndPage><MedlinePgn>2251-2257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab132</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Advances in standardization of observational healthcare data have enabled methodological breakthroughs, rapid global collaboration, and generation of real-world evidence to improve patient outcomes. Standardizations in data structure, such as use of common data models, need to be coupled with standardized approaches for data quality assessment. To ensure confidence in real-world evidence generated from the analysis of real-world data, one must first have confidence in the data itself.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We describe the implementation of check types across a data quality framework of conformance, completeness, plausibility, with both verification and validation. We illustrate how data quality checks, paired with decision thresholds, can be configured to customize data quality reporting across a range of observational health data sources. We discuss how data quality reporting can become part of the overall real-world evidence generation and dissemination process to promote transparency and build confidence in the resulting output.</AbstractText><AbstractText Label="RESULTS">The Data Quality Dashboard is an open-source R package that reports potential quality issues in an OMOP CDM instance through the systematic execution and summarization of over 3300 configurable data quality checks.</AbstractText><AbstractText Label="DISCUSSION">Transparently communicating how well common data model-standardized databases adhere to a set of quality measures adds a crucial piece that is currently missing from observational research.</AbstractText><AbstractText Label="CONCLUSION">Assessing and improving the quality of our data will inherently improve the quality of the evidence we generate.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035502" MajorTopicYN="Y">Trust</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Data Quality</Keyword><Keyword MajorTopicYN="N">Data Standardization</Keyword><Keyword MajorTopicYN="N">Real World Evidence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34313749</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pii">6328963</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Food and Drug Administration. Framework for FDA&#x2019;s Real-World Evidence Program. 2018. https://www.fda.gov/media/120060/download. Accessed January 10, 2020.</Citation></Reference><Reference><Citation>Heads of Medicines Agency, European Medicines Agency. HMA-EMA Joint Big Data Taskforce Summary Report. 2019. https://www.hma.eu/fileadmin/dateien/HMA_joint/00-_About_HMA/03-Working_Groups/Big_Data/2019_02_HMAEMA_Joint_Big_DataTaskforce_summary_report.pdf. Accessed January 10, 2020.</Citation></Reference><Reference><Citation>OMOP Common Data Model. http://ohdsi.github.io/CommonDataModel/. Accessed January 14, 2021.</Citation></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al.Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 2018; 25 (8): 969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, et al.Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf 2013; 36 (Suppl 1): S59&#x2013;72. doi:10.1007/s40264-013-0099-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al.Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA 2016; 113 (27): 7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019; 394 (10211): 1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Botsis T, Hartvigsen G, Chen F, et al.Secondary use of EHR: data quality issues and informatics opportunities. Summit Transl Bioinform 2010; 2010: 1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041534</ArticleId><ArticleId IdType="pubmed">21347133</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lucadou M, Ganslandt T, Prokosch H-U, et al.Feasibility analysis of conducting observational studies with the electronic health record. BMC Med Inform Decis Mak 2019; 19 (1): 202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819452</ArticleId><ArticleId IdType="pubmed">31660955</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokosch HU, Ganslandt T.. Perspectives for medical informatics. reusing the electronic medical record for clinical research. Methods Inf Med 2009; 48 (1): 38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151882</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero Varela L, Wiebe N, Niven DJ, et al.Evaluation of interventions to improve electronic health record documentation within the inpatient setting: a protocol for a systematic review. Syst Rev 2019; 8 (1): 54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373133</ArticleId><ArticleId IdType="pubmed">30760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Alla F, Rosilio M, Funck-Brentano C, et al. Participants of round table N&#xb0; 2 of Giens Workshops XXVIII (th). How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed? Therapie 2013; 68 (4): 209&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23981258</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan A, Shah NH, Chen JH.. Research and reporting considerations for observational studies using electronic health record data. Ann Intern Med 2020; 172 (Suppl 11): S79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413106</ArticleId><ArticleId IdType="pubmed">32479175</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrman RE, Benner JS, Brown JS, et al.Developing the Sentinel System&#x2013;a national resource for evidence development. N Engl J Med 2011; 364 (6): 498&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball R, Robb M, Anderson SA, et al.The FDA&#x2019;s sentinel initiative&#x2013;a comprehensive approach to medical product surveillance. Clin Pharmacol Ther 2016; 99 (3): 265&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667601</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Hudson KL, Briggs JP, et al.PCORnet: turning a dream into reality. J Am Med Inform Assoc 2014; 21 (4): 576&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Qualls LG, Phillips TA, Hammill BG, et al.Evaluating foundational data quality in the national patient-centered clinical research network (PCORnet&#xae;). EGEMS (Wash DC) 2018; 6 (1): 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983028</ArticleId><ArticleId IdType="pubmed">29881761</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, Margolis PA, Bailey LC, et al.PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 2014; 21 (4): 602&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Utidjian LH. Identifying and Understanding Data Quality Issues in a Pediatric Distributed Research Network. American Academy of Pediatrics, 2015. https://aap.confex.com/aap/2015/webprogrampress/Paper30131.html. Accessed January 13, 2021.</Citation></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, et al.Multisite evaluation of a data quality tool for patient-level clinical data sets. EGEMS (Wash DC) 2016; 4 (1): 1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan TJ, Bauck AE, Bertoch D, et al.A comparison of data quality assessment checks in six data sharing networks. EGEMS (Wash DC) 2017; 5 (1): 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5982846</ArticleId><ArticleId IdType="pubmed">29881733</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales DR, Conover MM, You SC, et al.Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health 2020: 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al.Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc 2020; 27 (8): 1268&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Golozar A, Lai LY, Sena AG, et al.Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including &gt;3.32 million people tested with real-time PCR and &gt;219,000 tested positive for SARS-CoV-2 in South Korea, Spain, and the United States. MedRxiv Prepr Serv Health Sci 2020: 27. doi:10.1101/2020.10.25.20218875</Citation></Reference><Reference><Citation>Schuemie M, Suchard M, Ryan P.. CohortMethod: New-User Cohort Method with Large Scale Propensity and Outcome Models. 2020. https://ohdsi.github.io/CohortMethod/index.html. Accessed January 21, 2021.</Citation></Reference><Reference><Citation>SNOMED CT.https://www.nlm.nih.gov/healthit/snomedct/index.html. Accessed March 4, 2021.</Citation></Reference><Reference><Citation>UMLS Metathesaurus - RXNORM (RXNORM) - Synopsis. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/RXNORM/index.html. Accessed March 4, 2021.</Citation></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al.A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC) 2016; 4 (1): 1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Suchard M.. SqlRender: Rendering Parameterized SQL and Translation to Dialects. 2020. https://ohdsi.github.io/SqlRender/. Accessed January 21, 2021.</Citation></Reference><Reference><Citation>Chang W, Cheng J, Allaire JJ, et al.Shiny: Web Application Framework for R. 2020. https://CRAN.R-project.org/package=shiny. Accessed January 10, 2021.</Citation></Reference><Reference><Citation>Blacketer C, DeFalco F, Londhe A, et al. DataQualityDashboard. https://ohdsi.github.io/DataQualityDashboard/. Accessed January 21, 2021.</Citation></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org/</Citation></Reference><Reference><Citation>Brainard J.Scientists are drowning in COVID-19 articles. Can new tools keep them afloat? Sci AAAS 2020. https://www.sciencemag.org/news/2020/05/scientists-are-drowning-covid-19-papers-can-new-tools-keep-them-afloat. Accessed January 21, 2021.</Citation></Reference><Reference><Citation>European Health Data Evidence Network. ehden.eu. https://www.ehden.eu/. Accessed March 12, 2021.</Citation></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al.; N3C Consortium. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc 2021; 28 (3): 427&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare R, Utidjian LH, Razzaghi H, et al.Design and refinement of a data quality assessment workflow for a large pediatric research network. EGEMS (Wash DC) 2019; 7 (1): 36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676917</ArticleId><ArticleId IdType="pubmed">31531382</ArticleId></ArticleIdList></Reference><Reference><Citation>How Sentinel Gets Its Data. Sentin. Initiat. 2019. https://www.sentinelinitiative.org/about/how-sentinel-gets-its-data. Accessed February 9, 2021.</Citation></Reference><Reference><Citation>Bailey LC, Razzaghi H, Burrows EK, et al.Assessment of 135&#x202f;794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr 2021; 175 (2): 176&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684518</ArticleId><ArticleId IdType="pubmed">33226415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann KN, Roumie CL, Wiese AD, et al.Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacol Res Perspect 2020; 8 (5): e00637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507366</ArticleId><ArticleId IdType="pubmed">32881317</ArticleId></ArticleIdList></Reference><Reference><Citation>Eworuke E, Haug N, Bradley M, et al.Risk of non-melanoma skin cancer in association with use of hydrochlorothiazide-containing products in the United States. JNCI Cancer Spectr 2021; 5 (2). doi:10.1093/jncics/pkab009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7947823</ArticleId><ArticleId IdType="pubmed">33733052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34315156</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9786</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cerebrovascular diseases (Basel, Switzerland)</Title><ISOAbbreviation>Cerebrovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Evolution of Evidence-Based Medicine in Stroke.</ArticleTitle><Pagination><StartPage>644</StartPage><EndPage>655</EndPage><MedlinePgn>644-655</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000517679</ELocationID><Abstract><AbstractText>The introduction and evolution of evidence-based stroke medicine has realized major advances in our knowledge about stroke, methods of medical research, and patient outcomes that continue to complement traditional individual patient care. It is humbling to recall the state of knowledge and scientific endeavour of our forebears who were unaware of what we know now and yet pursued the highest standards for evaluating and delivering effective stroke care. The science of stroke medicine has evolved from pathophysiological theory to empirical testing. Progress has been steady, despite inevitable disappointments and cul-de-sacs, and has occasionally been punctuated by sensational breakthroughs, such as the advent of reperfusion therapies guided by imaging.</AbstractText><CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hankey</LastName><ForeName>Graeme J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Washington, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sir Charles Gairdner Hospital, Perth, Washington, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cerebrovasc Dis</MedlineTA><NlmUniqueID>9100851</NlmUniqueID><ISSNLinking>1015-9770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>20</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34315156</ArticleId><ArticleId IdType="doi">10.1159/000517679</ArticleId><ArticleId IdType="pii">000517679</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34329583</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>398</Volume><Issue>10300</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.</ArticleTitle><Pagination><StartPage>577</StartPage><EndPage>578</EndPage><MedlinePgn>577-578</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(21)01693-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(21)01693-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhuyan</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Global Clinical Development Late R&amp;I, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medin</LastName><ForeName>Jennie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Medical BioPharmaceuticals, AstraZeneca, Gothenberg SE431 83, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Hugo Gomes</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Global Medical BioPharmaceuticals, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadavalli</LastName><ForeName>Madhavi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Patient Safety BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Nirmal Kumar</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Global Patient Safety BioPharmaceuticals, AstraZeneca, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullerova</LastName><ForeName>Hana</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Global Medical BioPharmaceuticals, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Medical BioPharmaceuticals, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nord</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenberg SE431 83, Sweden. Electronic address: magnus.nord@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2021 Nov 13;398(10313):1801. doi: 10.1016/S0140-6736(21)02285-6.</RefSource><PMID Version="1">34774143</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005062" MajorTopicYN="N">European Union</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>We are employees of AstraZeneca and might have stock or options, or both. Details of contributions are shown in the appendix.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34329583</ArticleId><ArticleId IdType="pmc">PMC9753120</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)01693-7</ArticleId><ArticleId IdType="pii">S0140-6736(21)01693-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brighton Collaboration  Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS) May 18, 2021. https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf</Citation></Reference><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New Engl J Med. 2021;384:2092&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Li X, Kostka K, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20&#xb7;6 million people in six European countries. medRxiv. 2021 doi: 10.1101/2021.05.12.21257083. published online May 13. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.12.21257083</ArticleId><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="pubmed">35191114</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslamifar Z, Behzadifard M, Soleimani M, Behzadifard S. Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor. Thromb J. 2020;18:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737414</ArticleId><ArticleId IdType="pubmed">33323111</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca  Vaxzevria, COVID-19 Vaccine (ChAdOx1-S [recombinant]). Summary of Product Characteristics. June, 2021. https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009612</ArticleId><ArticleId IdType="pubmed">33798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34333606</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Data Consult Service: Can we use observational data to address immediate clinical needs?</ArticleTitle><Pagination><StartPage>2139</StartPage><EndPage>2146</EndPage><MedlinePgn>2139-2146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab122</ELocationID><Abstract><AbstractText Label="OBJECTIVE">A number of clinical decision support tools aim to use observational data to address immediate clinical needs, but few of them address challenges and biases inherent in such data. The goal of this article is to describe the experience of running a data consult service that generates clinical evidence in real time and characterize the challenges related to its use of observational data.</AbstractText><AbstractText Label="MATERIALS AND METHODS">In 2019, we launched the Data Consult Service pilot with clinicians affiliated with Columbia University Irving Medical Center. We created and implemented a pipeline (question gathering, data exploration, iterative patient phenotyping, study execution, and assessing validity of results) for generating new evidence in real time. We collected user feedback and assessed issues related to producing reliable evidence.</AbstractText><AbstractText Label="RESULTS">We collected 29 questions from 22 clinicians through clinical rounds, emails, and in-person communication. We used validated practices to ensure reliability of evidence and answered 24 of them. Questions differed depending on the collection method, with clinical rounds supporting proactive team involvement and gathering more patient characterization questions and questions related to a current patient. The main challenges we encountered included missing and incomplete data, underreported conditions, and nonspecific coding and accurate identification of drug regimens.</AbstractText><AbstractText Label="CONCLUSIONS">While the Data Consult Service has the potential to generate evidence and facilitate decision making, only a portion of questions can be answered in real time. Recognizing challenges in patient phenotyping and designing studies along with using validated practices for observational research are mandatory to produce reliable evidence.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachariah</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ruijun</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5281-4143</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Data Science and Informatics, Geisinger, Danville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000046" MajorTopicYN="N">Academic Medical Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="Y">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="Y">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical decision support system</Keyword><Keyword MajorTopicYN="N">evidence-based medicine</Keyword><Keyword MajorTopicYN="N">information needs</Keyword><Keyword MajorTopicYN="N">observational studies</Keyword><Keyword MajorTopicYN="N">quality of healthcare</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>1</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34333606</ArticleId><ArticleId IdType="pmc">PMC8449613</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab122</ArticleId><ArticleId IdType="pii">6333393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Del Fiol G, Workman TE, Gorman PN.. Clinical questions raised by clinicians at the point of care: a systematic review. JAMA Intern Med 2014; 174 (5): 710&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24663331</ArticleId></ArticleIdList></Reference><Reference><Citation>Daei A, Soleymani MR, Ashrafi RH, et al.Personal, technical and organisational factors affect whether physicians seek answers to clinical questions during patient care: a literature review. Health Inf Libraries J 2020. Jul 20 [E-pub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">32686897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy-Martin T, Curtis S, Faries D, et al.A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015; 16 (1): 495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632358</ArticleId><ArticleId IdType="pubmed">26530985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Chen R, Zhang L, et al.Characterizing physicians&#x2019; information needs related to a gap in knowledge unmet by current evidence. JAMIA Open 2020; 3 (2): 281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382620</ArticleId><ArticleId IdType="pubmed">32734169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely JW, Osheroff JA, Ebell MH, et al.Analysis of questions asked by family doctors regarding patient care. BMJ 1999; 319 (7206): 358&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28191</ArticleId><ArticleId IdType="pubmed">10435959</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.What clinical information do doctors need? BMJ 1996; 313 (7064): 1062&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2352351</ArticleId><ArticleId IdType="pubmed">8898602</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnon J, Partington A, Horsfall M, et al.Variation in clinical practice: a priority setting approach to the staged funding of quality improvement. Appl Health Econ Health Policy 2016; 14 (1): 21&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25724919</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, Ge L, et al.Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ 2020; 370: m2980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390912</ArticleId><ArticleId IdType="pubmed">32732190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow N, Gallo L, Busse JW.. Evidence-based medicine and precision medicine: complementary approaches to clinical decision-making. Precis Clin Med 2018; 1 (2): 60&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985809</ArticleId><ArticleId IdType="pubmed">35693200</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown PJ, Borowitz SM, Novicoff W.. Information exchange in the NICU: what sources of patient data do physicians prefer to use? Int J Med Inform 2004; 73: 349&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15135753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DA, Sorensen KJ, Wilkinson JM, et al.Barriers and decisions when answering clinical questions at the point of care: a grounded theory study. JAMA Intern Med 2013; 173 (21): 1962&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23979118</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns PB, Rohrich RJ, Chung KC.. The Levels of Evidence and Their Role in Evidence-Based Medicine. Plast Reconstr Surg 2011; 128 (1): 305&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124652</ArticleId><ArticleId IdType="pubmed">21701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Shah NR, Selna MJ, et al.Bridging the inferential gap: the electronic health record and clinical evidence. Health Aff (Millwood) 2007; 26 (2): w181&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670472</ArticleId><ArticleId IdType="pubmed">17259202</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart EA, Bradshaw CP, Leaf PJ.. Assessing the generalizability of randomized trial results to target populations. Prev Sci 2015; 16 (3): 475&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359056</ArticleId><ArticleId IdType="pubmed">25307417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Zhang L, Hripcsak G.. A scoping review of clinical decision support tools that generate new knowledge to support decision making in real time. J Am Med Inform Assoc 2020; 27 (12): 1968&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824048</ArticleId><ArticleId IdType="pubmed">33120430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ.. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc 2013; 20 (1): 117&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombar S, Callahan A, Califf R, et al.It is time to learn from patients like mine. NPJ Digit Med 2019; 2 (1): 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6550176</ArticleId><ArticleId IdType="pubmed">31304364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman S, Pattison P, Steinley D.. Social networks. In: Balakrishnan N, Colton T, Everitt B, et al., eds. Wiley StatsRef: Statistics Reference Online. Chichester, United Kingdom: Wiley; 2014.</Citation></Reference><Reference><Citation>Riva JJ, Malik KMP, Burnie SJ, et al.What is your research question? An introduction to the PICOT format for clinicians. J Can Chiropr Assoc 2012; 56 (3): 167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3430448</ArticleId><ArticleId IdType="pubmed">22997465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al.Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). J Am Med Inform Assoc 2020; 27 (8): 1331&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB.. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79 (387): 516&#x2013;24.</Citation></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA.. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018; 47 (6): 2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, et al.Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2014; 33 (2): 209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al.Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A 2016; 113 (27): 7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, et al.Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS One 2020; 15 (1): e0226718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al.Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open 2018; 1 (4): e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019; 394 (10211): 1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, et al.Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. Epilepsia 2017; 58 (8): e101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al.Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc 2020; 27 (8): 1268&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena A, et al.Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study. medRxiv, doi: 10.1101/2020.04.22.20074336, 28 Jun 2020, preprint: not peer reviewed.</Citation></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, et al.Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. Lancet Rheumatol 2020; 2 (11): E698&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, Kahn MG, Brown JS, et al. Methods for examining data quality in healthcare integrated data repositories. In: Biocomputing 2018. Kohala Coast, HI: World Scientific; 2018: 628&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29218922</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, et al.Multisite evaluation of a data quality tool for patient-level clinical datasets. EGEMS (Wash DC) 2016; 4 (1): 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Informatics OHDS and Chapter 15 Data Quality. The Book of OHDSI. https://ohdsi.github.io/TheBookOfOhdsi/. Accessed October 8, 2020.</Citation></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, et al.How confident are we about observational findings in health care: a benchmark study. Harvard Data Sci Rev 2020; 2 (1): 10.1162/99608f92.147cc28e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Stang PE, Berlin JA, et al.A systematic statistical approach to evaluating evidence from observational studies. Annu Rev Stat Appl 2014; 1 (1): 11&#x2013;39.</Citation></Reference><Reference><Citation>Cuschieri S.The STROBE guidelines. Saudi J Anaesth 2019; 13 (Suppl 1): S31&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398292</ArticleId><ArticleId IdType="pubmed">30930717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Elias PA, Reyes MV, et al.Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol 2021; 14 (3): e009115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969445</ArticleId><ArticleId IdType="pubmed">33554609</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert A, Griffith G, Hemani G, et al.The spectre of Berkson&#x2019;s paradox: Collider bias in Covid&#x2010;19 research. Significance 2020; 17 (4): 6&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10016947</ArticleId><ArticleId IdType="pubmed">37250182</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglis JM, Caughey GE, Smith W, et al.Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels: Penicillin adverse drug reactions. Intern Med J 2017; 47 (11): 1292&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28742226</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly PC, Sutich RM, Easton R, et al.Ceftriaxone-associated biliary and cardiopulmonary adverse events in neonates: a systematic review of the literature. Paediatr Drugs 2017; 19 (1): 21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">27718120</ArticleId></ArticleIdList></Reference><Reference><Citation>Croskerry P.Individual variability in clinical decision making and diagnosis. In: P Croskerry, K Cosby, ML Graber, H Singh, eds. Diagnosis: Interpreting the Shadows. Oxford, United Kingdom: CRC Press, Taylor Francis Group; 2017.</Citation></Reference><Reference><Citation>Giuse NB, Kafantaris SR, Miller MD, et al.Clinical medical librarianship: the Vanderbilt experience. Bull Med Libr Assoc 1998; 86 (3): 412&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC226391</ArticleId><ArticleId IdType="pubmed">9681179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego B, Walter SR, Day RO, et al.Bringing cohort studies to the bedside: framework for a &#x2018;green button&#x2019; to support clinical decision-making. J Comp Eff Res 2015; 4 (3): 191&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25959863</ArticleId></ArticleIdList></Reference><Reference><Citation>Longhurst CA, Harrington RA, Shah NH.. A &#x2018;Green Button&#x2019; for using aggregate patient data at the point of care. Health Aff (Millwood) 2014; 33 (7): 1229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayley KB, Belnap T, Savitz L, et al.Challenges in using electronic health record data for CER: experience of 4 learning organizations and solutions applied. Med Care 2013; 51 (8 Suppl 3): S80&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford M, Stevens P, Coulton S, et al.Development of Risk Models for the Prediction of New or Worsening Acute Kidney Injury on or During Hospital Admission: A Cohort and Nested Study. Southampton, United Kingdom: NIHR Journals Library; 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">26937542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleet JL, Dixon SN, Shariff SZ, et al.Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol 2013; 14 (1): 81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637099</ArticleId><ArticleId IdType="pubmed">23560464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Reich C, Ryan P, et al.Adapting electronic health records-derived phenotypes to claims data: Lessons learned in using limited clinical data for phenotyping. J Biomed Inform 2020; 102: 103363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390483</ArticleId><ArticleId IdType="pubmed">31866433</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH, Garcia M, Sadeghi B, et al.Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010; 126 (1): 61&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430419</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Fouayzi H, Anzuoni K, et al.Diagnostic algorithms for cardiovascular death in administrative claims databases: a systematic review. Drug Saf 2019; 42 (4): 515&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471046</ArticleId></ArticleIdList></Reference><Reference><Citation>De Smedt T, Merrall E, Macina D, et al.Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness. PLoS One 2018; 13 (6): e0199180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003693</ArticleId><ArticleId IdType="pubmed">29906276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma H, Mao C, Zhang Y, et al.Developing a portable natural language processing based phenotyping system. BMC Med Inform Decis Mak 2019; 19 (S3): 78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448187</ArticleId><ArticleId IdType="pubmed">30943974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemingway H, Asselbergs FW, Danesh J, et al.; Innovative Medicines Initiative 2nd programme, Big Data for Better Outcomes, BigData@Heart Consortium of 20 academic and industry partners including ESC. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. Eur Heart J 2018; 39 (16): 1481&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019015</ArticleId><ArticleId IdType="pubmed">29370377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al.PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc 2016; 23 (6): 1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets AA. Investigating concept heterogeneity and granularity in the OHDSI network. 2020. https://www.ohdsi.org/wp-content/uploads/2020/10/Ostropolets_Plenary.pdf. Accessed October 28, 2020.</Citation></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al.Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc 2013; 20 (e1): e147&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan P, Berlin JA, et al.Channeling in the use of nonprescription paracetamol and ibuprofen in an electronic medical records database: evidence and implications. Drug Saf 2017; 40 (12): 1279&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688206</ArticleId><ArticleId IdType="pubmed">28780741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K, Schneeweiss S.. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clin Pharmacol Ther 2016; 100 (2): 147&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">26916672</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzer PR.Evidence&#x2010;based medicine&#x2019;s curious path: from clinical epidemiology to patient&#x2010;centered care through decision analysis. J Eval Clin Pract 2020; 27 (3): 631&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32844571</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB.. PheValuator: development and evaluation of a phenotype algorithm evaluator. J Biomed Inform 2019; 97: 103258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34380168</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Transformation of Electronic Health Records and Questionnaire Data to OMOP CDM: A Feasibility Study Using SG_T2DM Dataset.</ArticleTitle><Pagination><StartPage>757</StartPage><EndPage>767</EndPage><MedlinePgn>757-767</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0041-1732301</ELocationID><Abstract><AbstractText Label="BACKGROUND">Diabetes mellitus (DM) is an important public health concern in Singapore and places a massive burden on health care spending. Tackling chronic diseases such as DM requires innovative strategies to integrate patients' data from diverse sources and use scientific discovery to inform clinical practice that can help better manage the disease. The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) was chosen as the framework for integrating data with disparate formats.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to evaluate the feasibility of converting Singapore based data source, comprising of electronic health records (EHR), cognitive and depression assessment questionnaire data to OMOP CDM standard. Additionally, we also validate whether our OMOP CDM instance is fit for the purpose of research by executing a simple treatment pathways study using Atlas, a graphical user interface tool to conduct analysis on OMOP CDM data as a proof of concept.</AbstractText><AbstractText Label="METHODS">We used de-identified EHR, cognitive, and depression assessment questionnaires data from a tertiary care hospital in Singapore to convert it to version 5.3.1 of OMOP CDM standard. We evaluate the OMOP CDM conversion by (1) assessing the mapping coverage (that is the percentage of source terms mapped to OMOP CDM standard); (2) local raw dataset versus CDM dataset analysis; and (3) Implementing Harmonized Intrinsic Data Quality Framework using an open-source R package called Data Quality Dashboard.</AbstractText><AbstractText Label="RESULTS">The content coverage of OMOP CDM vocabularies is more than 90% for clinical data, but only around 11% for questionnaire data. The comparison of characteristics between source and target data returned consistent results and our transformed data did not pass 38 (1.4%) out of 2,622 quality checks.</AbstractText><AbstractText Label="CONCLUSION">Adoption of OMOP CDM at our site demonstrated that EHR data are feasible for standardization with minimal information loss, whereas challenges remain for standardizing cognitive and depression assessment questionnaire data that requires further work.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sathappan</LastName><ForeName>Selva Muthu Kumaran</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University Health System and National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Young Seok</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University Health System and National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Trung Kien</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University Health System and National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Su Chi</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Yi-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>E Shyong</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, National University Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Mengling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University Health System and National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Data Science, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34380168</ArticleId><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="doi">10.1055/s-0041-1732301</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Lawati J A. Diabetes mellitus: a local and global public health emergency! Oman Med J. 2017;32(03):177&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447787</ArticleId><ArticleId IdType="pubmed">28584596</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes  Who.intAccessed April 6, 2021 at:https://www.who.int/news-room/fact-sheets/detail/diabetes#:~:text=WHO%20estimates%20that%20diabetes%20was,onset%20of%20type%202%20diabetes</Citation></Reference><Reference><Citation>MOH | News Highlights  Moh.gov.sgAccessed April 6, 2021 at:https://www.moh.gov.sg/news-highlights/details/diabetes-the-war-continues</Citation></Reference><Reference><Citation>Luo M, Tan L WL, Sim X. Cohort profile: the Singapore diabetic cohort study. BMJ Open. 2020;10(05):e036443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264641</ArticleId><ArticleId IdType="pubmed">32474429</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi M N. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care. 2017;40(04):461&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">28325796</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus M N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Data Standardization &#x2013; OHDSI  Ohdsi.orgAccessed April 6, 2021 at:https://ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl A, Gall W. Feasibility of mapping austrian health claims data to the OMOP common data model. J Med Syst. 2019;43(10):314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H. Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan P B. Transforming the premier perspective hospital database into the observational medical outcomes partnership (OMOP) common data model. EGEMS (Wash DC) 2014;2(01):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M. Transforming French Electronic Health Records into the observational medical outcome partnership's common data model: a feasibility study. Appl Clin Inform. 2020;11(01):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013;36(02):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D. Content coverage evaluation of the OMOP vocabulary on the transplant domain focusing on concepts relevant for kidney transplant outcomes analysis. Appl Clin Inform. 2020;11(04):650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="pubmed">33027834</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick Ryan, Martijn Schuemie, Vojtech Huser, Chris Knoll, Ajit Londhe and Taha Abdul-Basser (2019). Achilles: Creates Descriptive Statistics Summary for an Entire OMOP CDM Instance. R package version. Accessed 2019 at:https://ohdsi.github.io/Achilles/1.6.7</Citation></Reference><Reference><Citation>OHDSI/DataQualityDashboard  GitHubPublished 2021. Accessed April 6, 2021 at:https://github.com/OHDSI/DataQualityDashboard</Citation></Reference><Reference><Citation>Kahn M G, Callahan T J, Barnard J. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC) 2016;4(01):1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/CommonDataModel  GitHubPublished 2021. Accessed April 6, 2021 at:https://github.com/OHDSI/CommonDataModel/</Citation></Reference><Reference><Citation>Glyburide DrugBank Online  Go.drugbank.comPublished 2021. Accessed April 6, 2021 at:https://go.drugbank.com/drugs/DB01016</Citation></Reference><Reference><Citation>Recommendations to avoid use of glibenclamide in the elderly and renal-impaired. HSAPublished 2021. Accessed April 6, 2021 at:https://www.hsa.gov.sg/announcements/safety-alert/recommendations-to-avoid-use-of-glibenclamide-in-the-elderly-and-renal-impaired</Citation></Reference><Reference><Citation>Athena  Athena.ohdsi.orgPublished 2021. Accessed April 6, 2021 at:https://athena.ohdsi.org/search-terms/start</Citation></Reference><Reference><Citation>OHDSI/Usagi  GitHubPublished 2021. Accessed April 6, 2021 at:https://github.com/OHDSI/Usagi</Citation></Reference><Reference><Citation>ATLAS  Atlas.ohdsi.orgPublished 2021. Accessed April 6, 2021 at:https://atlas.ohdsi.org/</Citation></Reference><Reference><Citation>Hripcsak G, Ryan P B, Duke J D. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/DataQualityDashboard  GitHubAccessed April 6, 2021 at:https://github.com/OHDSI/DataQualityDashboard/tree/master/inst/csv</Citation></Reference><Reference><Citation>Observational Health Data Sciences  Informatics. The book of OHDSI. Github.ioAccessed April 6, 2021 at:https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>AACE/ACE Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan - &#xa9; 2015Accessed April 6, 2021 at: pro.aace.com.https://pro.aace.com/disease-state-resources/diabetes/clinical-practice-guidelines/aaceace-clinical-practice-guidelines</Citation></Reference><Reference><Citation>Huser V.Data quality assessment of laboratory dataAccessed 2021 at:https://knowledge.amia.org/72332-amia-1.4602255/t005-1.4604904/t005-1.4604905/3413748-1.4605506/3413748-1.4605507?qr=1</Citation></Reference><Reference><Citation>Jonnagaddala J.External validation of type II diabetes electronic phenotyping algorithmsAccessed 2021 at: Presented at the:https://www.ohdsi.org/wp-content/uploads/2020/05/OHDI_symposium_2020_T2DM_poster_JJ.pdf</Citation></Reference><Reference><Citation>Report S.Data protection in the internet Springer; Cham: 2019https://www.springer.com/gp/book/9783030280482. Accessed January 18, 2021</Citation></Reference><Reference><Citation>Rodrigues J J, de la Torre I, Fern&#xe1;ndez G, L&#xf3;pez-Coronado M. Analysis of the security and privacy requirements of cloud-based electronic health records systems. J Med Internet Res. 2013;15(08):e186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757992</ArticleId><ArticleId IdType="pubmed">23965254</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway M K, Deng X, Ning Y.A de-identification tool for users in medical operations and public health2016 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI). Accessed 2021 at:10.1109/bhi.2016.7455951</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/bhi.2016.7455951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Mirhaji P, Low A F, Malin B A. Preserving temporal relations in clinical data while maintaining privacy. J Am Med Inform Assoc. 2016;23(06):1040&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070517</ArticleId><ArticleId IdType="pubmed">27013522</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A E, Pollard T J, Shen L. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3(01):160035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34389867</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>From clinical trials to clinical practice: How long are drugs tested and then used by patients?</ArticleTitle><Pagination><StartPage>2456</StartPage><EndPage>2460</EndPage><MedlinePgn>2456-2460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab164</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Evidence is scarce regarding the safety of long-term drug use, especially for drugs treating chronic diseases. To bridge this knowledge gap, this research investigated the differences in drug exposure between clinical trials and clinical practice.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We extracted drug follow-up times from clinical trials in ClinicalTrials.gov and compared the difference between clinical trials and real-world usage data for 914 drugs taken by 96&#xa0;645&#xa0;927 patients.</AbstractText><AbstractText Label="RESULTS">A total of 17.5% of drugs had longer median exposure in practice than in trials, 6% of patients had extended exposure to at least 1 drug, and drugs treating nervous system disorders and cardiovascular diseases were the most common among drugs with high rates of extended exposure.</AbstractText><AbstractText Label="CONCLUSIONS">For most of patients, the drug use length is shorter than the tested length in clinical trials. Still, a remarkable number of patients experienced extended drug exposure, particularly for drugs treating nervous system disorders or cardiovascular disorders.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ziran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9624-0214</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01LM009886-11</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>grant UL1TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">evidence-based medicine</Keyword><Keyword MajorTopicYN="N">follow-up studies</Keyword><Keyword MajorTopicYN="N">prescription drug overuse</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">validation study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34389867</ArticleId><ArticleId IdType="pmc">PMC8510283</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab164</ArticleId><ArticleId IdType="pii">6352182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Averitt AJ, Weng C, Ryan P, Perotte A.. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med 2020; 3: 67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214444</ArticleId><ArticleId IdType="pubmed">32411828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Goldstein A, Chakrabarti S, et al.The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0. J Am Med Inform Assoc 2018; 25 (3): 239&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378875</ArticleId><ArticleId IdType="pubmed">29025047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Ryan PB, Goldstein A, et al.Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials. Ann NY Acad Sci 2017; 1387 (1): 34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266625</ArticleId><ArticleId IdType="pubmed">27598694</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ.. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2014; 35 (7): 448&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25180895</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmoldt A, Benthe HF, Haberland G.. Human neutrophils show decreased survival upon long-term exposure to clozapine. Biochem Pharmacol 1975; 24 (17): 1639&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH.. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology 2009; 72 (20): 1727&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19228584</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg C, Lofmark S, Edlund C, Jansson JK.. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology (Reading) 2010; 156 (Pt 11): 3216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20705661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitahara CM, Berrington de Gonzalez A, Bouville A, et al.Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med 2019; 179 (8): 1034&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6604114</ArticleId><ArticleId IdType="pubmed">31260066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR.. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33 (6): 1304&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875444</ArticleId><ArticleId IdType="pubmed">20299480</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossello X, Pocock SJ, Julian DG.. Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol 2015; 66 (11): 1273&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361160</ArticleId></ArticleIdList></Reference><Reference><Citation>Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS.. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014; 311 (4): 368&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4144867</ArticleId><ArticleId IdType="pubmed">24449315</ArticleId></ArticleIdList></Reference><Reference><Citation>The Truven MarketScan Commercial Claims and Encounters (CCAE) database. http://truvenhealth.com/portals/0/assets/HP_11517_0912_MarketScanResearchDatabasesForHP_SS_WEB.pdf. Accessed September 30, 2019.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Manning C. SUTime: a library for recognizing and normalizing time expressions. In: Proceedings of the Eighth International Conference on Language Resources and Evaluation (LREC); 2012: 3735&#x2013;40.</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Medication Statistics Methodology, Guidelines for ATC Classification and DDD Assignment. https://www.whocc.no/atc/structure_and_principles/. Accessed January 14, 2021.</Citation></Reference><Reference><Citation>American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. 2010. http://psychiatryonline.org/guidelines.aspx. Accessed June 16, 2021.</Citation></Reference><Reference><Citation>Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J.. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Med 2018; 16 (1): 36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5842559</ArticleId><ArticleId IdType="pubmed">29514662</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Kataoka Y, Ostinelli EG, Cipriani A, Furukawa TA.. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis. Front Psychiatry 2020; 11: 35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033625</ArticleId><ArticleId IdType="pubmed">32116850</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Postauthorization safety studies (PASS). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/post-authorisation-safety-studies-pass-0. Accessed April 1, 2021.</Citation></Reference><Reference><Citation>Cesana BM, Biganzoli EM.. Phase IV studies: some insights, clarifications, and issues. Curr Clin Pharmacol 2018; 13 (1): 14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29651962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34397515</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of plastic surgery</Title><ISOAbbreviation>Ann Plast Surg</ISOAbbreviation></Journal><ArticleTitle>Temporal Trends and Geographical Variation in Dupuytren Disease Surgery in England: A Population-Based Cohort Study.</ArticleTitle><Pagination><StartPage>265</StartPage><EndPage>270</EndPage><MedlinePgn>265-270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SAP.0000000000002734</ELocationID><Abstract><AbstractText Label="BACKGROUND">Dupuytren disease (DD) is a common fibroproliferative disease of the palmar fascia. The mainstay of DD treatment in England is surgery with either percutaneous needle fasciotomy, limited fasciectomy, or dermofasciectomy. This study aimed to investigate the temporal trends and geographical variation of primary DD surgery in England.</AbstractText><AbstractText Label="METHODS">A longitudinal population-based cohort study was perfomed using the Hospital Episode Statistics database from April 1, 2007, to March 31, 2017. Directly standarized rates were estimated over time (between financial years 2007-2008 and 2016-2017) and by geographic region (by clinical commissioning groups [CCGs]; financial years 2010-2011, 2013-2014, and 2016-2017). The Office for National Statistics midyear population estimates were used as the reference population.</AbstractText><AbstractText Label="MAIN FINDINGS">Primary DD surgery was undertaken at a steadily increasing rate from financial year 2007 to 2008, to 2016 to 2017 in England. There was a striking 3.6-fold variation in the rates of primary DD surgery among National Health Service CCGs in England place of residence.</AbstractText><AbstractText Label="CONCLUSIONS">This significant variation in DD surgical treatment in England suggests a need for the development of standardized surgical practice across all CCGs and National Health Service hospitals, promoting equality of access to cost-effective health care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abram</LastName><ForeName>Simon G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer C E</ForeName><Initials>JCE</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Abigail V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Nuffield Orthopaedic Centre, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furniss</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03573765</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Plast Surg</MedlineTA><NlmUniqueID>7805336</NlmUniqueID><ISSNLinking>0148-7043</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004387" MajorTopicYN="Y">Dupuytren Contracture</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071938" MajorTopicYN="N">Fasciotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest and sources of funding: There are no conflicting interests with respect to the research, authorship, and/or publication of this article except D.P.-A reports grants and other from AMGEN; grants, nonfinancial support, and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by D.P.-A's department and open for external participants. O.A. is funded by the Oxford Centre for Islamic Studies Scholarship. S.G.F.A. is funded by the Oxford National Institute of Health Research-Biomedical Research Centre (NIHR-BRC). R.S.C. was a funded Royal College of Surgeons England/National Joint Registry research fellow and is also funded by the NIHR-BRC. J.C.E.L. is a clinical research fellow funded by Versus Arthritis and the Oxford Medical Research Council Doctoral Training Partnership. A.P.-U. is funded by Fundacion Alfonso Martin Escudero and by the Medical Research Council (grant numbers, MR/K501256/1 and MR/N013468/1). J.L.R. is funded by the Oxford NIHR BRC. D.P.-A. is an NIHR Clinician Scientist (project number, CS-2013-13-012). D.F. is funded by the Oxford NIHR-BRC. Funding bodies had no role in study design, data collection, data analysis, data interpretation, or article preparation. The views expressed are those of the authors and not necessarily those of any of the funding bodies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34397515</ArticleId><ArticleId IdType="doi">10.1097/SAP.0000000000002734</ArticleId><ArticleId IdType="pii">00000637-202109000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soreide E, Murad MH, Denbeigh JM, et al. Treatment of Dupuytren's contracture. Bone Joint J . 2018;100-B:1138&#x2013;1145.</Citation></Reference><Reference><Citation>Khan AA, Yeates DGR, Goodacre TE, et al. Trends over time and geographical variation in admission rates for plastic surgery in England. J Plast Reconstr Aesthetic Surg . 2010;63:1962&#x2013;1969.</Citation></Reference><Reference><Citation>Gerber RA, Perry R, Thompson R, et al. Dupuytren's contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Musculoskelet Disord . 2011;12:73.</Citation></Reference><Reference><Citation>Lipman MD, Carstensen SE, Deal DN. Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand . 2017;12:13&#x2013;20.</Citation></Reference><Reference><Citation>NHS Digital. Hospital Episode Statistics. Available at: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Office for National Statistics (ONS). Population estimates. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>NHS Clinical Commissioners, England. About Clinical Commissioning Groups (CCGs). Available at: https://www.nhscc.org/ccgs/#:~:text=Clinical Commissioning Groups (CCGs) were, services for their local area. Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Health and Social Care Act 2012 fact sheets. Available at: https://www.gov.uk/government/publications/health-and-social-care-act-2012-fact-sheets . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Office for National Statistics (ONS), England. Clinical Commissioning Groups (CCGs) boundaries April 2017. Available at: https://geoportal.statistics.gov.uk/datasets/de108fe659f2430d9558c20fe172638f_4 . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Office for National Statistics, England. Clinical Commissioning Groups (CCGs) mid-year population estimates. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>NHS Digital. Hospital Episode Statistics (HES) analysis guide. 2015. Available at: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Bebbington E, Furniss D. Linear regression analysis of Hospital Episode Statistics predicts a large increase in demand for elective hand surgery in England. J Plast Reconstr Aesthet Surg . 2015;68:243&#x2013;251.</Citation></Reference><Reference><Citation>Kuo RYL, Ng M, Prieto-Alhambra D, et al. Dupuytren's disease predicts increased all-cause and cancer-specific mortality: analysis of a large cohort from the U.K. Clinical Practice Research Datalink. Plast Reconstr Surg . 2020;145. Available at: https://journals.lww.com/plasreconsurg/Fulltext/2020/03000/Dupuytren_s_Disease_Predicts_Increased_All_Cause.30.aspx .</Citation></Reference><Reference><Citation>Procedures of Limited Clinical Effectiveness: Barnet, Camden, Enfield, Haringey and Islington CCGs 2015&#x2013;2016. Available at: https://www.barnetccg.nhs.uk/Downloads/Publications/Archive/NCL-Procedures-of-Limited-Clinical-Effectiveness-PoLCE-Policy-June-2015-2016.pdf . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Procedures of Limited Clinical Effectiveness and Referral Criteria: Luton CCG. Available at: https://www.blmkccg.nhs.uk/procedures-of-limited-clinical-value-polcv-mk-ccg/ . Accessed January 11, 2021.</Citation></Reference><Reference><Citation>Procedures of Limited Clinical Value Commissioning Policy: Dupuytren's Contracture, Sandwell and West Birmingham CCG Available at: https://www.birminghamandsolihullccg.nhs.uk/about-us/publications/policies/2276-policy-for-dupuytren/file . Accessed January 11, 2021.</Citation></Reference><Reference><Citation>NHS, England. Evidence-Based Interventions: Guidance for CCGs. 2018. Available at: https://www.england.nhs.uk/publication/evidence-based-interventions-guidance-for-clinical-commissioning-groups-ccgs/#:~:text=Evidence-Based Interventions%3A Guidance for Clinical Commissioning Groups (CCGs),-Document first published&amp;text=This guidance doc . Accessed November 5, 2020.</Citation></Reference><Reference><Citation>Iacobucci G. NHS proposes to stop funding 17 &#x201c;unnecessary&#x201d; procedures. BMJ . 2018;362:k2903.</Citation></Reference><Reference><Citation>Wilkinson DJ, Green PA, Beglinger S, et al. Hypospadias surgery in England: higher volume centres have lower complication rates. J Pediatr Urol . 2017;13:481.e1&#x2013;481.e6.</Citation></Reference><Reference><Citation>Paul JC, Lonner BS, Goz V, et al. Complication rates are reduced for revision adult spine deformity surgery among high-volume hospitals and surgeons. Spine J . 2015;15:1963&#x2013;1972.</Citation></Reference><Reference><Citation>Williams JG, Mann RY. Hospital episode statistics: time for clinicians to get involved? Clin Med . 2002;2:34&#x2013;37.</Citation></Reference><Reference><Citation>Herbert A, Wijlaars L, Zylbersztejn A, et al. Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol . 2017;46:1093&#x2013;1093i.</Citation></Reference><Reference><Citation>Burns EM, Rigby E, Mamidanna R, et al. Systematic review of discharge coding accuracy. J Public Health (Oxf) . 2012;34:138&#x2013;148.</Citation></Reference><Reference><Citation>Wright FL, Green J, Canoy D, et al. Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol . 2012;12:161.</Citation></Reference><Reference><Citation>Davis KAS, Bashford O, Jewell A, et al. Using data linkage to electronic patient records to assess the validity of selected mental health diagnoses in English Hospital Episode Statistics (HES). PLoS One . 2018;13:e0195002&#x2013;e0195002.</Citation></Reference><Reference><Citation>Atroshi I, Strandberg E, Lauritzson A, et al. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren's contracture: a retrospective cohort study. BMJ Open . 2014;4:e004166.</Citation></Reference><Reference><Citation>Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture. J Hand Surg Am . 2011;36:1826&#x2013;1834.e32.</Citation></Reference><Reference><Citation>Baltzer H, Binhammer PA. Cost-effectiveness in the management of Dupuytren's contracture. A Canadian cost-utility analysis of current and future management strategies. Bone Joint J . 2013;95-B:1094&#x2013;1100.</Citation></Reference><Reference><Citation>NICE. National Institute for Health and Care Excellence. Final appraisal determination. Collagenase clostridium histolyticum for treating Dupuytren's contracture. 2015. Available at: https://www.nice.org.uk/guidance/ta459/documents/dupuytrens-contracture-collagenase-clostridium-histolyticum-final-appraisal-determination-document-superseded2 . Accessed November 5, 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34454423</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the impact of covariate lookback times on performance of patient-level prediction models.</ArticleTitle><Pagination><StartPage>180</StartPage><MedlinePgn>180</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-021-01370-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">The goal of our study is to examine the impact of the lookback length when engineering features to use in developing predictive models using observational healthcare data. Using a longer lookback for feature engineering gives more insight about patients but increases the issue of left-censoring.</AbstractText><AbstractText Label="METHODS">We used five US observational databases to develop patient-level prediction models. A target cohort of subjects with hypertensive drug exposures and outcome cohorts of subjects with acute (stroke and gastrointestinal bleeding) and chronic outcomes (diabetes and chronic kidney disease) were developed. Candidate predictors that exist on or prior to the target index date were derived within the following lookback periods: 14, 30, 90, 180, 365, 730, and all days prior to index were evaluated. We predicted the risk of outcomes occurring 1&#xa0;day until 365 days after index. Ten lasso logistic models for each lookback period were generated to create a distribution of area under the curve (AUC) metrics to evaluate the discriminative performance of the models. Calibration intercept and slope were also calculated. Impact on external validation performance was investigated across five databases.</AbstractText><AbstractText Label="RESULTS">The maximum differences in AUCs for the models developed using different lookback periods within a database was &lt;&#x2009;0.04 for diabetes (in MDCR AUC of 0.593 with 14-day lookback vs. AUC of 0.631 with all-time lookback) and 0.012 for renal impairment (in MDCR AUC of 0.675 with 30-day lookback vs. AUC of 0.687 with 365-day lookback ). For the acute outcomes, the max difference in AUC across lookbacks within a database was 0.015 (in MDCD AUC of 0.767 with 14-day lookback vs. AUC 0.782 with 365-day lookback) for stroke and &lt;&#x2009;0.03 for gastrointestinal bleeding (in CCAE AUC of 0.631 with 14-day lookback vs. AUC of 0.660 with 730-day lookback).</AbstractText><AbstractText Label="CONCLUSIONS">In general the choice of covariate lookback had only a small impact on discrimination and calibration, with a short lookback (&lt;&#x2009;180 days) occasionally decreasing discrimination. Based on the&#xa0;results, if training a logistic regression model for prediction then using covariates with a 365&#xa0;day lookback appear to be a good tradeoff between performance and interpretation.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, NY, USA. jhardi10@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA. jhardi10@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Feature extraction lookback periods</Keyword><Keyword MajorTopicYN="N">Patient-level prediction</Keyword></KeywordList><CoiStatement>Both authors are employees of Janssen Research &amp; Development, LLC, and may own stock and/or stock options. The work on this study was part of their employment.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>29</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34454423</ArticleId><ArticleId IdType="pmc">PMC8403343</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01370-2</ArticleId><ArticleId IdType="pii">10.1186/s12874-021-01370-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moskovitch R, et al. Temporal biomedical data analytics. J Biomed Inform. 2019;90:103092. doi: 10.1016/j.jbi.2018.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC9745669</ArticleId><ArticleId IdType="pubmed">30654029</ArticleId></ArticleIdList></Reference><Reference><Citation>Conover MM, et al. Classifying medical histories in US Medicare beneficiaries using fixed vs all-available look-back approaches. Pharmacoepidemiol Drug Saf. 2018;27(7):771&#x2013;780. doi: 10.1002/pds.4435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4435</ArticleId><ArticleId IdType="pmc">PMC6417795</ArticleId><ArticleId IdType="pubmed">29655187</ArticleId></ArticleIdList></Reference><Reference><Citation>Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. BMC Med Res Methodol. 2017;17(1):122. doi: 10.1186/s12874-017-0407-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-017-0407-4</ArticleId><ArticleId IdType="pmc">PMC5556662</ArticleId><ArticleId IdType="pubmed">28806932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, et al. The effect of the look-back period for estimating incidence using administrative data. BMC Health Serv Res. 2020;20(1):166. doi: 10.1186/s12913-020-5016-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-5016-y</ArticleId><ArticleId IdType="pmc">PMC7057623</ArticleId><ArticleId IdType="pubmed">32131818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, et al. Use of hospitalisation history (lookback) to determine prevalence of chronic diseases: impact on modelling of risk factors for haemorrhage in pregnancy. BMC Med Res Methodol. 2011;11:68. doi: 10.1186/1471-2288-11-68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-68</ArticleId><ArticleId IdType="pmc">PMC3120808</ArticleId><ArticleId IdType="pubmed">21575257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Ahn LS. [A comparative study on comorbidity measurements with Lookback period using health insurance database: focused on patients who underwent percutaneous coronary intervention] J Prev Med Public Health. 2009;42(4):267&#x2013;73. doi: 10.3961/jpmph.2009.42.4.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3961/jpmph.2009.42.4.267</ArticleId><ArticleId IdType="pubmed">19675404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. Med Care. 1999;37(11):1128&#x2013;39. doi: 10.1097/00005650-199911000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199911000-00005</ArticleId><ArticleId IdType="pubmed">10549615</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136. doi: 10.1136/bmj.39261.471806.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39261.471806.55</ArticleId><ArticleId IdType="pmc">PMC1925200</ArticleId><ArticleId IdType="pubmed">17615182</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Reich RP, Hartzema CG, Stang AG. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2011;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, et al. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai M, et al. The use of complete-case and multiple imputation-based analyses in molecular epidemiology studies that assess interaction effects. Epidemiol Perspect Innov. 2011;8(1):5. doi: 10.1186/1742-5573-8-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-5573-8-5</ArticleId><ArticleId IdType="pmc">PMC3217865</ArticleId><ArticleId IdType="pubmed">21978450</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg GD, Gurley VF. Development and validation of 15-month mortality prediction models: a retrospective observational comparison of machine-learning techniques in a national sample of Medicare recipients. BMJ Open. 2019;9(7):e022935. doi: 10.1136/bmjopen-2018-022935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-022935</ArticleId><ArticleId IdType="pmc">PMC6661632</ArticleId><ArticleId IdType="pubmed">31315852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkura Y, et al. Development of a model predicting the risk of eight major postoperative complications after esophagectomy based on 10 826 cases in the Japan National Clinical Database. J Surg Oncol. 2019;121:313&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31823377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisk R, et al. Informative presence and observation in routine health data: a review of methodology for clinical risk prediction. J Am Med Inform Assoc. 2021;28(1):155&#x2013;166. doi: 10.1093/jamia/ocaa242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa242</ArticleId><ArticleId IdType="pmc">PMC7810439</ArticleId><ArticleId IdType="pubmed">33164082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, G., Schuemie, M., Ryan, P., Weaver, J. CohortDiagnostics. 2020; Available from: https://ohdsi.github.io/CohortDiagnostics/.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34457154</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2153-4063</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>A Comparison between Human and NLP-based Annotation of Clinical Trial Eligibility Criteria Text Using The OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>394</StartPage><EndPage>403</EndPage><MedlinePgn>394-403</MedlinePgn></Pagination><Abstract><AbstractText>Human annotations are the established gold standard for evaluating natural language processing (NLP) methods. The goals of this study are to quantify and qualify the disagreement between human and NLP. We developed an NLP system for annotating clinical trial eligibility criteria text and constructed a manually annotated corpus, both following the OMOP Common Data Model (CDM). We analyzed the discrepancies between the human and NLP annotations and their causes (e.g., ambiguities in concept categorization and tacit decisions on inclusion of qualifiers and temporal attributes during concept annotation). This study initially reported complexities in clinical trial eligibility criteria text that complicate NLP and the limitations of the OMOP CDM. The disagreement between and human and NLP annotations may be generalizable. We discuss implications for NLP evaluation.</AbstractText><CopyrightInformation>&#xa9;2021 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinhang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>equal-contribution first authors.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>equal-contribution first authors.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kury</LastName><ForeName>Fabr&#xed;cio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>30</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34457154</ArticleId><ArticleId IdType="pmc">PMC8378608</ArticleId><ArticleId IdType="pii">3478001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marrero M, Urbano J, S&#xe1;nchez-Cuadrado S, Morato J, G&#xf3;mez-Berb&#xed;s JM. Named entity recognition: fallacies, challenges and opportunities. Computer Standards &amp; Interfaces. 2013;35(5):482&#x2013;9.</Citation></Reference><Reference><Citation>Tsai RT-H, Wu S-H, Chou W-C, Lin Y-C, He D, Hsiang J, et al. Various criteria in the evaluation of biomedical named entity recognition. BMC bioinformatics. 2006;7(1):92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1402329</ArticleId><ArticleId IdType="pubmed">16504116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lasko TA, Mei Q, Denny JC, Xu H. A study of active learning methods for named entity recognition in clinical text. Journal of biomedical informatics. 2015;58:11&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934373</ArticleId><ArticleId IdType="pubmed">26385377</ArticleId></ArticleIdList></Reference><Reference><Citation>Galibert O, Rosset S, Grouin C, Zweigenbaum P, Quintard L. Structured and extended named entity evaluation in automatic speech transcriptions. Proceedings of 5th International Joint Conference on Natural Language Processing. 2011.</Citation></Reference><Reference><Citation>Atda&#x11f; S, Labatut V. 2nd International conference on systems and computer science. IEEE; 2013. A comparison of named entity recognition tools applied to biographical texts.</Citation></Reference><Reference><Citation>Marrero M, S&#xe1;nchez-Cuadrado S, Lara JM, Andreadakis G. Evaluation of named entity extraction systems. Advances in Computational Linguistics, Research in Computing Science. 2009;41:47&#x2013;58.</Citation></Reference><Reference><Citation>Jiang R, Banchs RE, Li H. Evaluating and combining name entity recognition systems. Proceedings of the Sixth Named Entity Workshop. 2016</Citation></Reference><Reference><Citation>Chinchor N. MUC-4 evaluation metrics. Proceedings of the 4th conference on Message understanding; McLean, Virginia. Association for Computational Linguistics; 1992. pp. 22&#x2013;9.</Citation></Reference><Reference><Citation>Chinchor N, Sundheim BM. MUC-5 evaluation metrics. Fifth Message Understanding Conference (MUC-5): Proceedings of a Conference Held in Baltimore; Maryland, August 25-27. 1993 1993.</Citation></Reference><Reference><Citation>Jannet MB, Adda-Decker M, Galibert O, Kahn J, Rosset S. Eter: a new metric for the evaluation of hierarchical named entity recognition. 2014.</Citation></Reference><Reference><Citation>Makhoul J, Kubala F, Schwartz R, Weischedel R. Proceedings of DARPA broadcast news workshop. VA: Herndon; 1999. Performance measures for information extraction.</Citation></Reference><Reference><Citation>SNOMED   Available from: http://www.snomed.org/ </Citation></Reference><Reference><Citation>Medical Subject Headings   Available from: https://www.nlm.nih.gov/mesh/meshhome.html .</Citation></Reference><Reference><Citation>Roberts A, Gaizauskas R, Hepple M, Demetriou G, Guo Y, Setzer A, et al. Semantic annotation of clinical text: The CLEF corpus. Proceedings of the LREC 2008 workshop on building and evaluating resources for biomedical text mining. 2008.</Citation></Reference><Reference><Citation>Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic acids research. 2004;32(suppl_1):D267&#x2013;D70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;uster S, Daelemans W. CliCR: a dataset of clinical case reports for machine reading comprehension. arXiv preprint arXiv. 2018;180309720</Citation></Reference><Reference><Citation>OMOP Common Data Model &#x2013; OHDSI   Available from: https://www.ohdsi.org/data-standardization/the-common-data-model/ </Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Studies in health technology and informatics. 2015;216:574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino JJ, Shortliffe EH. Biomedical Informatics: Computer Applications in Health Care and Biomedicine (Health Informatics) Springer-Verlag; 2006.</Citation></Reference><Reference><Citation>Kury F, Butler A, Yuan C, Fu L-h, Sun Y, Liu H, et al. Chia, a large annotated corpus of clinical trial eligibility criteria. Scientific data; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452886</ArticleId><ArticleId IdType="pubmed">32855408</ArticleId></ArticleIdList></Reference><Reference><Citation>Alex B, Haddow B, Grover C. Recognising nested named entities in biomedical text. Biological, translational, and clinical language processing. 2007.</Citation></Reference><Reference><Citation>Kim J-D, Ohta T, Tateisi Y, Tsujii Ji. GENIA corpus&#x2014;a semantically annotated corpus for bio-textmining. Bioinformatics. 2003;19(suppl_1):i180&#x2013;i2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ryan PB, Ta C, Guo Y, Li Z, Hardin J, et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. Journal of the American Medical Informatics Association. 2019;26(4):294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLAS   Available from: http://www.ohdsi.org/web/atlas/#/home .</Citation></Reference><Reference><Citation>Yuan C, Wang Y, Shang N, Li Z, Zhao R, Weng C. A graph-based method for reconstructing entities from coordination ellipsis in medical text. Journal of the American Medical Informatics Association. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647336</ArticleId><ArticleId IdType="pubmed">32719840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J-W, Friedman C. Semantic classification of biomedical concepts using distributional similarity. Journal of the American Medical Informatics Association. 2007;14(4):467&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244895</ArticleId><ArticleId IdType="pubmed">17460124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Anderson K, Grann VR, Friedman C. Facilitating cancer research using natural language processing of pathology reports. Studies in health technology and informatics. 2004;107(Pt 1):565.</Citation><ArticleIdList><ArticleId IdType="pubmed">15360876</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne K. International Conference on Semantic Computing (ICSC 2007) IEEE; 2007. Nested named entity recognition in historical archive text.</Citation></Reference><Reference><Citation>Finkel JR, Manning CD. Nested named entity recognition. Proceedings of the 2009 conference on empirical methods in natural language processing. 2009.</Citation></Reference><Reference><Citation>Buyko E, Tomanek K, Hahn U. PACLING 2007-Proceedings of the 10th Conference of the Pacific Association for Computational Linguistics. Citeseer; 2007. Resolution of coordination ellipses in biological named entities using Conditional Random Fields.</Citation></Reference><Reference><Citation>Wei C-H, Leaman R, Lu Z. SimConcept: a hybrid approach for simplifying composite named entities in biomedical text. IEEE journal of biomedical and health informatics. 2015;19(4):1385&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543296</ArticleId><ArticleId IdType="pubmed">25879978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34496418</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>A Framework for Systematic Assessment of Clinical Trial Population Representativeness Using Electronic Health Records Data.</ArticleTitle><Pagination><StartPage>816</StartPage><EndPage>825</EndPage><MedlinePgn>816-825</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0041-1733846</ELocationID><Abstract><AbstractText Label="BACKGROUND">Clinical trials are the gold standard for generating robust medical evidence, but clinical trial results often raise generalizability concerns, which can be attributed to the lack of population representativeness. The electronic health records (EHRs) data are useful for estimating the population representativeness of clinical trial study population.</AbstractText><AbstractText Label="OBJECTIVES">This research aims to estimate the population representativeness of clinical trials systematically using EHR data during the early design stage.</AbstractText><AbstractText Label="METHODS">We present an end-to-end analytical framework for transforming free-text clinical trial eligibility criteria into executable database queries conformant with the Observational Medical Outcomes Partnership Common Data Model and for systematically quantifying the population representativeness for each clinical trial.</AbstractText><AbstractText Label="RESULTS">We calculated the population representativeness of 782 novel coronavirus disease 2019 (COVID-19) trials and 3,827 type 2 diabetes mellitus (T2DM) trials in the United States respectively using this framework. With the use of overly restrictive eligibility criteria, 85.7% of the COVID-19 trials and 30.1% of T2DM trials had poor population representativeness.</AbstractText><AbstractText Label="CONCLUSION">This research demonstrates the potential of using the EHR data to assess the clinical trials population representativeness, providing data-driven metrics to inform the selection and optimization of eligibility criteria.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diallo</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>James R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>National Library of Medicine</GrantID><Agency>R01LM009886-11</Agency><Country/></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR001579</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>National Center for Advancing Clinical and Translational Science</GrantID><Agency>UL1TR001873</Agency><Country/></Grant><Grant><GrantID>National Center for Advancing Clinical and Translational Science</GrantID><Agency>3U24TR001579</Agency><Country/></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>8</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34496418</ArticleId><ArticleId IdType="pmc">PMC8426045</ArticleId><ArticleId IdType="doi">10.1055/s-0041-1733846</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piantadosi S. John Wiley &amp; Sons; 2017. Clinical Trials: A Methodologic Perspective.</Citation></Reference><Reference><Citation>Fogel D B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092479</ArticleId><ArticleId IdType="pubmed">30112460</ArticleId></ArticleIdList></Reference><Reference><Citation>Naceanceno K S, House S L, Asaro P V. Shared-task worklists improve clinical trial recruitment workflow in an academic emergency department. Appl Clin Inform. 2021;12(02):293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026258</ArticleId><ArticleId IdType="pubmed">33827142</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Ryan P, Goldstein A.Assessing eligibility criteria generalizability and their correlations with adverse events using big data for EHRS and clinical trialsIn Proceedings of the Data Science Learning and Applications to Biomedical and Health Sciences Conference (Big Data Workshop organized by New York Academy of Sciences; 74&#x2013;79</Citation></Reference><Reference><Citation>Thadani S R, Weng C, Bigger J T.Electronic screening improves efficiency in clinical trial recruitment J Am Med Inform Assoc 200916(6):869&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002129</ArticleId><ArticleId IdType="pubmed">19717797</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C.Optimizing clinical research participant selection with informatics Trends in pharmacological sciences 201536(11):706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686428</ArticleId><ArticleId IdType="pubmed">26549161</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Spall H G, Toren A, Kiss A, Fowler R A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374817</ArticleId></ArticleIdList></Reference><Reference><Citation>Janson M, Edlund G, Kressner U. Analysis of patient selection and external validity in the Swedish contribution to the COLOR trial. Surg Endosc. 2009;23(08):1764&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pubmed">19057955</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Aalst C M, van Iersel C A, van Klaveren R J. Generalisability of the results of the Dutch-Belgian randomised controlled lung cancer CT screening trial (NELSON): does self-selection play a role? Lung Cancer. 2012;77(01):51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22459203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bress A P, Tanner R M, Hess R, Colantonio L D, Shimbo D, Muntner P. Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol. 2016;67(05):463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237387</ArticleId><ArticleId IdType="pubmed">26562046</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Li Y, Ryan P. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Appl Clin Inform. 2014;5(02):463&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Ryan P, Goldstein A. Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials. Annals of the New York Academy of Sciences. 2017;1387(01):34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266625</ArticleId><ArticleId IdType="pubmed">27598694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Chakrabarti S, Goldstein A, Wang S, Ryan P B, Weng C. GIST 2.0: a scalable multi-trait metric for quantifying population representativeness of individual clinical studies. J Biomed Inform. 2016;63:325&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077682</ArticleId><ArticleId IdType="pubmed">27600407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahan A, Cahan S, Cimino J J. Computer-aided assessment of the generalizability of clinical trial results. Int J Med Inform. 2017;99:60&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28118923</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan P B, Belenkaya R.OHDSI Common Data Model v6.0 SpecificationsAccessed 2019 at:https://github.com/OHDSI/CommonDataModel/wiki</Citation></Reference><Reference><Citation>Tu S W, Peleg M, Carini S. A practical method for transforming free-text eligibility criteria into computable criteria. J Biomed Inform. 2011;44(02):239&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129371</ArticleId><ArticleId IdType="pubmed">20851207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ryan P B, Ta C. Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc. 2019;26(04):294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova G K, Masanz J J, Ogren P V. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc. 2010;17(05):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson A R.2001Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap programIn Proceedings of the AMIA Symposium (p. 17). American Medical Informatics Association. Accessed 2021 at:https://pubmed.ncbi.nlm.nih.gov/11825149/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243666</ArticleId><ArticleId IdType="pubmed">11825149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kury F, Butler A, Yuan C. Chia, a large annotated corpus of clinical trial eligibility criteria. Sci Data. 2020;7(01):281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452886</ArticleId><ArticleId IdType="pubmed">32855408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A X, Manning C D.2012, May. Sutime: a library for recognizing and normalizing time expressions. In: LREC. European Language Resources Association (ELRA); vol. 2012;3735&#x2013;3740. Accessed 2021 at:http://www.lrec-conf.org/proceedings/lrec2012/pdf/284_Paper.pdf</Citation></Reference><Reference><Citation>Laffin L J, Besser S A, Alenghat F J. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients. Eur J Prev Cardiol. 2019;26(06):569&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459598</ArticleId><ArticleId IdType="pubmed">30477321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Cymberknop L J, Armentano R L.Nonlinear systems in healthcare towards intelligent disease predictionIn: Nonlinear Systems-Theoretical Aspects and Recent Applications.IntechOpen; 2019</Citation></Reference><Reference><Citation>Awad M, Khanna R. Apress, Berkeley; CA: Support vector regression. In: Efficient Learning Machines; pp. 67&#x2013;80.</Citation></Reference><Reference><Citation>Steele A J, Denaxas S C, Shah A D, Hemingway H, Luscombe N M. Machine learning models in electronic health records can outperform conventional survival models for predicting patient mortality in coronary artery disease. PLoS One. 2018;13(08):e0202344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6118376</ArticleId><ArticleId IdType="pubmed">30169498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Butler A, Lin F. The COVID-19 trial finder. J Am Med Inform Assoc. 2021;28(03):616&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717322</ArticleId><ArticleId IdType="pubmed">33216120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J H, Ta C N, Liu C. Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. J Am Med Inform Assoc. 2021;28(01):14&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798960</ArticleId><ArticleId IdType="pubmed">33260201</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Lawati J A. Diabetes mellitus: a local and global public health emergency! Oman medical journal. 2017;32(03):177&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447787</ArticleId><ArticleId IdType="pubmed">28584596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Butler A, Stewart L A. Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials. J Biomed Inform. 2021;118:103790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079156</ArticleId><ArticleId IdType="pubmed">33887457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Goldstein A, Chakrabarti S. The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0. J Am Med Inform Assoc. 2018;25(03):239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378875</ArticleId><ArticleId IdType="pubmed">29025047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Loparo K.Information extraction from free text in clinical trials with knowledge-based distant supervisionIn 2019 IEEE 43rd Annual Computer Software and Applications Conference (COMPSAC) (Vol. 1, pp. 954&#x2013;955). IEEE</Citation></Reference><Reference><Citation>Li X, Liu H, Kury F.A Comparison between Human and NLP-based Annotation of Clinical Trial Eligibility Criteria Text Using The OMOP Common Data ModelIn AMIA 2021 Virtual Informatics Summit; 394-403</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378608</ArticleId><ArticleId IdType="pubmed">34457154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34514354</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure.</ArticleTitle><Pagination><StartPage>ooab001</StartPage><MedlinePgn>ooab001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooab001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooab001</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to transform a resource of linked electronic health records (EHR) to the OMOP common data model (CDM) and evaluate the process in terms of syntactic and semantic consistency and quality when implementing disease and risk factor phenotyping algorithms.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Using heart failure (HF) as an exemplar, we represented three national EHR sources (Clinical Practice Research Datalink, Hospital Episode Statistics Admitted Patient Care, Office for National Statistics) into the OMOP CDM 5.2. We compared the original and CDM HF patient population by calculating and presenting descriptive statistics of demographics, related comorbidities, and relevant clinical biomarkers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified a cohort of 502 536 patients with the incident and prevalent HF and converted 1 099 195 384 rows of data from 216 581 914 encounters across three EHR sources to the OMOP CDM. The largest percentage (65%) of unmapped events was related to medication prescriptions in primary care. The average coverage of source vocabularies was &gt;98% with the exception of laboratory tests recorded in primary care. The raw and transformed data were similar in terms of demographics and comorbidities with the largest difference observed being 3.78% in the prevalence of chronic obstructive pulmonary disease (COPD).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study demonstrated that the OMOP CDM can successfully be applied to convert EHR linked across multiple healthcare settings and represent phenotyping algorithms spanning multiple sources. Similar to previous research, challenges mapping primary care prescriptions and laboratory measurements still persist and require further work. The use of OMOP CDM in national UK EHR is a valuable research tool that can enable large-scale reproducible observational research.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papez</LastName><ForeName>Vaclav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinat</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Hyve, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payralbe</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Hyve, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asselbergs</LastName><ForeName>Folkert W</ForeName><Initials>FW</Initials><Identifier Source="ORCID">0000-0002-1692-8669</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Division Heart &amp; Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbers</LastName><ForeName>R Thomas</ForeName><Initials>RT</Initials><Identifier Source="ORCID">0000-0002-9077-4741</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemingway</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2279-0624</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4224-9245</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9612-7791</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Alan Turing Institute, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_13041</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K006584/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S003754/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">algorithms</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>13</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34514354</ArticleId><ArticleId IdType="pmc">PMC8423424</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooab001</ArticleId><ArticleId IdType="pii">ooab001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sudlow C, Gallacher J, Allen N, et al.UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12 (3): e1001779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al.Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc 2013; 20 (e1): e147&#x2013;54&#x2013;e154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Bastarache L, Roden DM.. Phenome-wide association studies as a tool to advance precision medicine. Annu Rev Genom Hum Genet 2016; 17 (1): 353&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480096</ArticleId><ArticleId IdType="pubmed">27147087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ.. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc 2013; 20 (1): 117&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom ST, Carroll RJ, Warner JL, Matheny ME, Denny JC.. Representing knowledge consistently across health systems. Yearb Med Inform 2017; 26 (01): 139&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6239235</ArticleId><ArticleId IdType="pubmed">29063555</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB.. Transforming the premier perspective hospital database into the observational medical outcomes partnership (OMOP) common data model. EGEMS (Wash DC) 2014; 2 (1): 1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al.Facilitating phenotype transfer using a common data model. J Biomed Inform 2019; 96: 103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C.. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf 2014; 37 (11): 945&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, et al.An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf 2013; 36 (2): 119&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan V, Denaxas S, Gonzalez-Izquierdo A, et al.A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lancet Digit Health 2019; 1 (2): e63&#x2013;e77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798263</ArticleId><ArticleId IdType="pubmed">31650125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiratunga N, Coenen F, Sani S. International Workshop on Knowledge Discovery in Healthcare Data. In: International Joint Conference on Artificial Intelligence (IJCAI 2019) CEUR Workshop Proceedings vol 2429; CEUR; August 10, 2019: 6&#x2013;14; Macao, China.</Citation></Reference><Reference><Citation>Hemingway H, Asselbergs FW, Danesh J, Innovative Medicines Initiative 2nd programme, Big Data for Better Outcomes, BigData@Heart Consortium of 20 academic and industry partners including ESC, et al.Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. Eur Heart J 2018; 39 (16): 1481&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019015</ArticleId><ArticleId IdType="pubmed">29370377</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI OMOP CMD 5.2.0. https://github.com/OHDSI/CommonDataModel/releases/tag/v5.2.0. Accessed November 11, 2020.</Citation></Reference><Reference><Citation>Athena. https://athena.ohdsi.org/search-terms/start. Accessed November 11, 2020.</Citation></Reference><Reference><Citation>Denaxas S, Gonzalez-Izquierdo A, Direk K, et al.UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc 2019; 26 (12): 1545&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857510</ArticleId><ArticleId IdType="pubmed">31329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas SC, George J, Herrett E, et al.Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol 2012; 41 (6): 1625&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535749</ArticleId><ArticleId IdType="pubmed">23220717</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AD, Denaxas S, Nicholas O, Hingorani AD, Hemingway H.. Neutrophil counts and initial presentation of 12 cardiovascular diseases: a CALIBER cohort study. J Am Coll Cardiol 2017; 69 (9): 1160&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5332591</ArticleId><ArticleId IdType="pubmed">28254179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapsomaniki E, Timmis A, George J, et al.Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1&#xb7;25 million people. Lancet 2014; 383 (9932): 1899&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042017</ArticleId><ArticleId IdType="pubmed">24881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoulis M, 
DeStavola B, 
Diaz-Ordaz K, 
Gomes M. Weight change and the incidence of cardiovascular diseases in adults with normal weight, overweight and obesity without chronic diseases; emulating trials using &#x2026;. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.05.14.20102129v3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.14.20102129v1.abstract</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujades-Rodriguez M, George J, Shah AD, et al.Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1 937 360 people in England: lifetime risks and &#x2026;. Aquat Microb Ecol 2015; 44 (1): 129&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339760</ArticleId><ArticleId IdType="pubmed">25416721</ArticleId></ArticleIdList></Reference><Reference><Citation>George J, Mathur R, Shah AD, et al.Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: Associations in a linked electronic health record cohort of 1 million patients. PLoS One 2017; 12 (6): e0178945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466321</ArticleId><ArticleId IdType="pubmed">28598987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell S, Daskalopoulou M, Rapsomaniki E, et al.Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. BMJ 2017; 356: j909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5594422</ArticleId><ArticleId IdType="pubmed">28331015</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S, Direk K, Gonzalez-Izquierdo A, et al.Methods for enhancing the reproducibility of biomedical research findings using electronic health records. BioData Min 2017; 10: 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5594436</ArticleId><ArticleId IdType="pubmed">28912836</ArticleId></ArticleIdList></Reference><Reference><Citation>Phenotype Library. HDR UK Phenotype Library. https://portal.caliberresearch.org/. Accessed November 11, 2020.</Citation></Reference><Reference><Citation>Lai AG, Pasea L, Banerjee A, et al.. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open 2020; 10 (11): e043828. doi: 10.1136/bmjopen-2020-043828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674020</ArticleId><ArticleId IdType="pubmed">33203640</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Pasea L, Harris S, et al.Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet 2020; 395 (10238): 1715&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217641</ArticleId><ArticleId IdType="pubmed">32405103</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al.Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 2015; 44 (3): 827&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neil M, Payne C, Read J.. Read codes version 3: a user led terminology. Methods Inf Med 2018; 34: 187&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9082130</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta-Nemdharry P, Thomson A, Beynon J.. Opportunities and challenges in developing a cohort of patients with type 2 diabetes mellitus using electronic primary care data. PLoS One 2016; 11 (11): e0162236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5115653</ArticleId><ArticleId IdType="pubmed">27861488</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ.. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69 (1): 4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805870</ArticleId><ArticleId IdType="pubmed">20078607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur R, Bhaskaran K, Chaturvedi N, et al.Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health 2014; 36 (4): 684&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245896</ArticleId><ArticleId IdType="pubmed">24323951</ArticleId></ArticleIdList></Reference><Reference><Citation>George J, Rapsomaniki E, Pujades-Rodriguez M, et al.How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1,937,360 people. Circulation 2015; 132 (14): 1320&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4590518</ArticleId><ArticleId IdType="pubmed">26330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P.. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol 2017; 46 (4): 1093&#x2013;1093i.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837677</ArticleId><ArticleId IdType="pubmed">28338941</ArticleId></ArticleIdList></Reference><Reference><Citation>American Medical Association. Current procedural terminology: CPT. American Medical Association; 2007. https://www.aapc.com/resources/medical-coding/cpt.aspx. Accessed January 27, 2021.</Citation></Reference><Reference><Citation>Jordan H, Roderick P, Martin D.. The index of multiple deprivation 2000 and accessibility effects on health. J Epidemiol Community Health 2004; 58 (3): 250&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1732697</ArticleId><ArticleId IdType="pubmed">14966241</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadow G, 
McDonald CJ.. The unified code for units of measure. Regenstrief Institute and UCUM Organization: Indianapolis, IN, USA. 2009. https://ucum.org/. Accessed January 27, 2021.</Citation></Reference><Reference><Citation>CALIBER OMOP ETL. https://github.com/thehyve/ohdsi-etl-caliber. Accessed November 11, 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34519186</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>36</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019.</ArticleTitle><Pagination><StartPage>e230</StartPage><MedlinePgn>e230</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e230</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2021.36.e230</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Real-world data analysis is useful for identifying treatment patterns. Understanding drug prescription patterns of type 2 diabetes mellitus may facilitate diabetes management. We aimed to analyze treatment patterns of type 2 diabetes mellitus using Observational Medical Outcomes Partnership Common Data Model based on electronic health records.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective, observational study employed electronic health records of patients who visited Jeonbuk National University Hospital in Korea during January 2000-December 2019. Data were transformed into the Observational Medical Outcomes Partnership Common Data Model and analyzed using R version 4.0.3 and ATLAS ver. 2.7.6. Prescription frequency for each anti-diabetic drug, combination therapy pattern, and prescription pattern according to age, renal function, and glycated hemoglobin were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of adults treated for type 2 diabetes mellitus increased from 1,867 (2.0%) in 2000 to 9,972 (5.9%) in 2019. In the early 2000s, sulfonylurea was most commonly prescribed (73%), and in the recent years, metformin has been most commonly prescribed (64%). Prescription rates for DPP4 and SGLT2 inhibitors have increased gradually over the past few years. Monotherapy prescription rates decreased, whereas triple and quadruple combination prescription rates increased steadily. Different drug prescription patterns according to age, renal function, and glycated hemoglobin were observed. The proportion of patients with HbA1c &#x2264; 7% increased from 31.1% in 2000 to 45.6% in 2019, but that of patients visiting the emergency room for severe hypoglycemia did not change over time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Medication utilization patterns have changed significantly over the past 20 years with an increase in the use of newer drugs and a shift to combination therapies. In addition, various prescription patterns were demonstrated according to the patient characteristics in actual practice. Although glycemic control has improved, the proportion within the target is still low, underscoring the need to improve diabetes management.</AbstractText><CopyrightInformation>&#xa9; 2021 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung Ae</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-3700-8279</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Heung Yong</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0002-1841-2092</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yu Ji</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0003-4100-5839</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Yong-Jin</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0003-4304-9747</Identifier><AffiliationInfo><Affiliation>Center for Clinical Pharmacology, Biochemical Research Institute, Jeonbuk National University Hospital, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun-Young</ForeName><Initials>EY</Initials><Identifier Source="ORCID">0000-0001-5885-9473</Identifier><AffiliationInfo><Affiliation>Center for Clinical Pharmacology, Biochemical Research Institute, Jeonbuk National University Hospital, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Tae Sun</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0001-7216-8468</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea. pts@jbnu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI19C0543</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Diabetes Mellitus Type 2</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Hypoglycemic Agents</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34519186</ArticleId><ArticleId IdType="pmc">PMC8438187</ArticleId><ArticleId IdType="doi">10.3346/jkms.2021.36.e230</ArticleId><ArticleId IdType="pii">36.e230</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021;45(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850879</ArticleId><ArticleId IdType="pubmed">33434426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, et al. Diabetes fact sheets in Korea, 2018: an appraisal of current status. Diabetes Metab J. 2019;43(4):487&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712228</ArticleId><ArticleId IdType="pubmed">31339012</ArticleId></ArticleIdList></Reference><Reference><Citation>White JR., Jr A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27(2):82&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522877</ArticleId><ArticleId IdType="pubmed">26246763</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract. 2020;162:108114.</Citation><ArticleIdList><ArticleId IdType="pubmed">32165164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen SL, R&#xf8;rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">31422062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, et al. 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712226</ArticleId><ArticleId IdType="pubmed">31441247</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111&#x2013;S124.</Citation><ArticleIdList><ArticleId IdType="pubmed">33298420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang C, Mortensen MB, Lauridsen KG, Bruun JM. Trends in antidiabetic drug utilization and expenditure in Denmark: a 22-year nationwide study. Diabetes Obes Metab. 2020;22(2):167&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">31486269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002&#x2013;2013: nationwide population-based cohort study. Medicine (Baltimore) 2016;95(27):e4018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058811</ArticleId><ArticleId IdType="pubmed">27399082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon Y, Choi Y, Kim EH, Oh S, Lee H. Common data model-based real-world data for practical clinical practice guidelines: clinical pharmacology perspectives. Transl Clin Pharmacol. 2020;28(2):67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327188</ArticleId><ArticleId IdType="pubmed">32656157</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Yoo S, Jeon Y, Yi S, Kim S, Choi SA, et al. Characterization of anti-seizure medication treatment pathways in pediatric epilepsy using the electronic health record-based common data model. Front Neurol. 2020;11:409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235379</ArticleId><ArticleId IdType="pubmed">32477256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang L, Miao S, Xu H, Yin Y, Zhu Y, et al. Analysis of treatment pathways for three chronic diseases using OMOP CDM. J Med Syst. 2018;42(12):260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(1):54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Won JC, Lee JH, Kim JH, Kang ES, Won KC, Kim DJ, et al. Diabetes fact sheet in Korea, 2016: an appraisal of current status. Diabetes Metab J. 2018;42(5):415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202557</ArticleId><ArticleId IdType="pubmed">30113146</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Suppl 2):S137&#x2013;S145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023033</ArticleId><ArticleId IdType="pubmed">27440826</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Diabetes Association. Diabetes fact sheet in Korea 2018.  [Updated 2020].  [Accessed May 12, 2021].   https://www.diabetes.or.kr/pro/news/admin.php?category=A&amp;code=admin&amp;mode=view&amp;number=1615.</Citation></Reference><Reference><Citation>Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845015</ArticleId><ArticleId IdType="pubmed">20086256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho YK, Lee J, Kim HS, Park JY, Jung CH, Lee WJ. Clinical efficacy of quadruple oral therapy for type 2 diabetes in real-world practice: a retrospective observational study. Diabetes Ther. 2020;11(9):2029&#x2013;2039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435139</ArticleId><ArticleId IdType="pubmed">32696268</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, et al. Efficacy and safety of treatment with quadruple oral hypoglycemic agents in uncontrolled type 2 diabetes mellitus: a multi-center, retrospective, observational study. Diabetes Metab J. 2020 doi: 10.4093/dmj.2020.0107. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2020.0107</ArticleId><ArticleId IdType="pmc">PMC8497923</ArticleId><ArticleId IdType="pubmed">32794385</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care. 2007;30(6):1448&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829641</ArticleId><ArticleId IdType="pubmed">17337497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J. 2011;35(5):431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221016</ArticleId><ArticleId IdType="pubmed">22111032</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther. 2012;29(3):218&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">22411425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med. 2021;121(2):229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">33567084</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352(9131):854&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">9742977</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function.  [Updated 2017].  [Accessed May 12, 2021].   http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm.</Citation></Reference><Reference><Citation>Hur KY, Kim MK, Ko SH, Han M, Lee DW, Kwon HS, et al. Metformin treatment for patients with diabetes and chronic kidney disease: a Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes Metab J. 2020;44(1):3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043977</ArticleId><ArticleId IdType="pubmed">32097995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillett MJ International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699715</ArticleId><ArticleId IdType="pubmed">19502545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34524714</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Timing of elective tracheotomy and duration of mechanical ventilation among patients admitted to intensive care with severe COVID-19: A multicenter prospective cohort study.</ArticleTitle><Pagination><StartPage>3743</StartPage><EndPage>3756</EndPage><MedlinePgn>3743-3756</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.26863</ELocationID><Abstract><AbstractText Label="BACKGROUND">Optimal timing for tracheotomy for critically ill COVID-19 patients requiring invasive mechanical ventilation (IMV) is not established.</AbstractText><AbstractText Label="METHODS">Multicenter prospective cohort including all COVID-19 patients admitted to intensive care units (ICUs) in 36 hospitals who required tracheotomy during first pandemic wave. With a target emulation trial framework, we studied the causal effects of early (7-10&#x2009;days) versus late (&gt;10&#x2009;days) tracheotomy (LT) on time from tracheotomy to weaning, postoperative mortality, and tracheotomy complications.</AbstractText><AbstractText Label="RESULTS">Of 696 patients, 20.4% received early tracheotomy (ET). ET was associated with faster weaning (hazard ratio [HR] [95% confidence interval, CI]: 1.25 [1.00-1.56]) without differences in mortality (HR [95% CI]: 0.85 [0.60-1.21]) or complications (adjusted rate ratio [95%&#xa0;CI]: 0.56 [0.23-1.33]).</AbstractText><AbstractText Label="CONCLUSIONS">ET had a similar or lower post-tracheotomy weaning time than LT, potentially shortening IMV and ICU stays, without changing complication or mortality rates in COVID-19 patients.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Pharmaco and Device Epidemiology, Centre for Statistics in Medicine - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobed</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Josep Trueta, Girona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villacampa</LastName><ForeName>Jos&#xe9; Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ag&#xfc;ero</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital General de Catalunya, Sant Cugat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Bastida</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tato</LastName><ForeName>Jos&#xe9; Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Pr&#xed;ncipe de Asturias, Alcal&#xe1; de Henares, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrig&#xe1;&#xf1;ez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Universitario de La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holguera</LastName><ForeName>Victoria Duque</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Cl&#xed;nico de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Garc&#xed;a</LastName><ForeName>Estefan&#xed;a</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6291-3249</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, M&#xfa;tua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villarraga</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Fundaci&#xf3; Althaia, Manresa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meler-Claramonte</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez Barrueco</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><Identifier Source="ORCID">0000-0002-7919-5765</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Universitario General de Villalba, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiesa-Estomba</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9454-9464</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital de Donosti, Donosti, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casasayas</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4183-5832</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parente-Arias</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mata-Castro</LastName><ForeName>Nieves</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital de Torrej&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rello</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clin Research/epidemiol In Pneumonia &amp; Sepsis (CRIPS)- Vall d'Hebr&#xf3;n Institute of Research (VHIR), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, Hospital Cl&#xed;nic de Barcelona, UB, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pharmaco and Device Epidemiology, Centre for Statistics in Medicine - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilaseca</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4399-5522</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Cl&#xed;nic de Barcelona, UB, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head Neck Cl&#xed;nic, Ag&#xe8;ncia de Gesti&#xf3; d'Ajuts Universitaris i de Recerca AGAUR, 2017-SGR-01581, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Respiratorias (CIBERes), Bunyola, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avil&#xe9;s-Jurado</LastName><ForeName>Francesc Xavier</ForeName><Initials>FX</Initials><Identifier Source="ORCID">0000-0001-5560-8097</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Hospital Cl&#xed;nic de Barcelona, UB, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head Neck Cl&#xed;nic, Ag&#xe8;ncia de Gesti&#xf3; d'Ajuts Universitaris i de Recerca AGAUR, 2017-SGR-01581, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>TraqueoCOVID SEORL Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017-SGR-01581</GrantID><Agency>Ag&#xe8;ncia de Gesti&#xf3; d'Ajuts Universitaris i de Recerca AGAUR</Agency><Country/></Grant><Grant><GrantID>MR/N013468/1</GrantID><Agency>Fundaci&#xf3;n Alfonso Mart&#xed;n Escudero and the Medical Research Council</Agency><Country/></Grant><Grant><GrantID>MR/K501256/1</GrantID><Agency>Fundaci&#xf3;n Alfonso Mart&#xed;n Escudero and the Medical Research Council</Agency><Country/></Grant><Grant><GrantID>SRF-2018-11-ST2-004</GrantID><Agency>NIHR Senior Research Fellowship</Agency><Country/></Grant><Grant><Agency>National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014140" MajorTopicYN="N">Tracheotomy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">respiratory failure</Keyword><Keyword MajorTopicYN="N">weaning</Keyword></KeywordList><CoiStatement>All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Daniel Prieto&#x2010;Alhambra reports grants and other from AMGEN; grants, nonfinancial support, and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI&#x2010;funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by Daniel Prieto&#x2010;Alhambra's department and open for external participants. Albert Prats&#x2010;Uribe reports grants from Fundaci&#xf3;n Alfonso Martin Escudero and the Medical Research Council. Pedro Castro reports honoraria received for talks on behalf of Merck Sharp and Dohme, Pfizer, Gilead, and Alexion. Isabel Vilaseca reports honoraria received for talks on behalf of Merck Sharp and Dohme and Lumenis outside the submitted work. The authors confirm that there are no other relationships or activities that could appear to have influenced the submitted work. The authors declare no conflict of interest related to the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34524714</ArticleId><ArticleId IdType="pmc">PMC8652734</ArticleId><ArticleId IdType="doi">10.1002/hed.26863</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esteban A, Anzueto A, Alia I, et al. How is mechanical ventilation employed in the intensive care unit: an international utilization review. Am J Respir Crit Care Med. 2000;161:1450&#x2010;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AB, Cooke CR, Wiener RS, et al. Hospital variation in early tracheotomy in the United States: a population&#x2010;based study. Crit Care Med. 2016;44:1506&#x2010;1514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4949074</ArticleId><ArticleId IdType="pubmed">27031382</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriolo BN, Andriolo RB, Saconato H, Atallah AN, Valente O. Early versus late tracheotomy for critically ill patients. Cochrane Database Syst Rev. 2015;1:CD007271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517297</ArticleId><ArticleId IdType="pubmed">25581416</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Li Y, Ariani F, Chen X, et al. Timing of tracheotomy in critically ill patients: a meta&#x2010;analysis. PLoS One. 2014;9:e92981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965497</ArticleId><ArticleId IdType="pubmed">24667875</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Qiu H, Wan L, et al. Intubation and ventilation amid the COVID&#x2010;19 outbreak: Wuhan's experience. Anesthesiology. 2020;132:1317&#x2010;1332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155908</ArticleId><ArticleId IdType="pubmed">32195705</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W&#x2010;j, Ni Z&#x2010;y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2010;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>
Burn E, Sena AG, Prats&#x2010;Uribe A, et al. Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 240,392 patients hospitalized with COVID&#x2010;19 in the United States. February 12, 2021. Accessed February 15, 2021. https://www.medrxiv.org/content/10.1101/2020.11.25.20229088v2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.25.20229088v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza C, Filauro M, Dikkers FG, et al. Long&#x2010;term intubation and high rate of tracheostomy in COVID&#x2010;19 patients might determine an unprecedented increase of airway stenoses: a call to action from the European Laryngological Society. Eur Arch Otorhinolaryngol. 2020;6:1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275663</ArticleId><ArticleId IdType="pubmed">32506145</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D, Montagne J, Raices M, et al. Tracheostomy in the intensive care unit: guidelines during COVID&#x2010;19 worldwide pandemic. Am J Otolaryngol. 2020;41:102578. 10.1016/j.amjoto.2020.102578</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102578</ArticleId><ArticleId IdType="pmc">PMC7832100</ArticleId><ArticleId IdType="pubmed">32505993</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba T, Ghazizadeh S, Chhetri D, St. John M, Long J. Tracheostomy considerations during the COVID&#x2010;19 pandemic. OTO Open. 2020;4:2473974X20922528. 10.1177/2473974X20922528</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2473974X20922528</ArticleId><ArticleId IdType="pmc">PMC7175063</ArticleId><ArticleId IdType="pubmed">32342026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer DD, Engels PT, Weitzel EK, et al. Recommendations from the CSO&#x2010;HNS taskforce on performance of tracheotomy during the COVID&#x2010;19 pandemic. J Otolaryngol Head Neck Surg. 2020;49:23. 10.1186/s40463-020-00414-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40463-020-00414-9</ArticleId><ArticleId IdType="pmc">PMC7184547</ArticleId><ArticleId IdType="pubmed">32340627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao TN, Braslow BM, Martin ND, et al. Tracheotomy in ventilated patients with COVID&#x2010;19. Ann Surg. 2020;272:e30&#x2010;e32. 10.1097/SLA.0000000000003956</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003956</ArticleId><ArticleId IdType="pmc">PMC7224612</ArticleId><ArticleId IdType="pubmed">32379079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay JK, Khoo ML, Loh WS. Surgical considerations for tracheostomy during the COVID&#x2010;19 pandemic: lessons learned from the severe acute respiratory syndrome outbreak. JAMA Otolaryngol Head Neck Surg. 2020;146:517&#x2010;518. 10.1001/jamaoto.2020.0764</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.0764</ArticleId><ArticleId IdType="pubmed">32232426</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath BA, Brenner MJ, Warrillow SJ, et al. Tracheostomy in the COVID&#x2010;19 era: global and multidisciplinary guidance. Lancet Respir Med. 2020;8:717&#x2010;725. 10.1016/S2213-2600(20)30230-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30230-7</ArticleId><ArticleId IdType="pmc">PMC7228735</ArticleId><ArticleId IdType="pubmed">32422180</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SM, Chern A, Feit NZ, et al. Percutaneous and open tracheostomy in patients with COVID&#x2010;19: comparison and outcomes of an institutional series in New York City. Ann Surg. 2021;273:403&#x2010;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">32889885</ArticleId></ArticleIdList></Reference><Reference><Citation>Takhar A, Walker A, Tricklebank S, et al. Recommendation of a practical guideline for safe tracheotomy during the COVID&#x2010;19 pandemic. Eur Arch Otorhinolaryngol. 2020;277:2173&#x2010;2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170707</ArticleId><ArticleId IdType="pubmed">32314050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal&#x2010;Sprekelsen M, Avil&#xe9;s&#x2010;Jurado FX, &#xc1;lvarez&#x2010;Escudero J, et al. Consensus document of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC), the Spanish Society of Otorhinolaryngology and Head and Neck Surgery (SEORL&#x2010;CCC) and the Spanish Society of Anesthesiology and Resuscitation (SEDAR) on tracheotomy in patients with COVID&#x2010;19 infection. Acta Otorrinolaringol Esp. 2020;71:386&#x2010;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211599</ArticleId><ArticleId IdType="pubmed">32513456</ArticleId></ArticleIdList></Reference><Reference><Citation>Avil&#xe9;s&#x2010;Jurado FX, Prieto&#x2010;Alhambra D, Gonz&#xe1;lez&#x2010;S&#xe1;nchez N, et al. Timing, complications, and safety of tracheotomy in critically ill patients with COVID&#x2010;19. JAMA Otolaryngol Head Neck Surg. 2020;8:e203641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545345</ArticleId><ArticleId IdType="pubmed">33034625</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med Res Methodol. 2014;14:75. 10.1186/1471-2288-14-75</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-75</ArticleId><ArticleId IdType="pmc">PMC4051964</ArticleId><ArticleId IdType="pubmed">24903709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley; 1987.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2010;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Picetti E, Fornaciari A, Taccone FS, et al. Safety of bedside surgical tracheostomy during COVID&#x2010;19 pandemic: a retrospective observational study. PLoS One. 2020;15:e0240014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526872</ArticleId><ArticleId IdType="pubmed">32997704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bier&#x2010;Laning C, Cramer JD, Roy S, et al. Tracheostomy during the COVID&#x2010;19 pandemic: comparison of international perioperative care protocols and practices in 26 countries. Otolaryngol Head Neck Surg. 2021;164(6):1136&#x2010;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">33138722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornari C, Surda P, Takhar A, et al. Tracheostomy, ventilatory wean, and decannulation in COVID&#x2010;19 patients. Eur Arch Otorhinolaryngol. 2020;1:1&#x2010;10. 10.1007/s00405-020-06187-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-020-06187-1</ArticleId><ArticleId IdType="pmc">PMC7395208</ArticleId><ArticleId IdType="pubmed">32740720</ArticleId></ArticleIdList></Reference><Reference><Citation>Terragni PP, Antonelli M, Fumagalli R, et al. Early vs late tracheostomy for prevention of pneumonia in mechanically ventilated adult ICU: a randomized controlled trial. JAMA. 2010;303:1483&#x2010;1489. 10.1001/jama.2010.447</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.447</ArticleId><ArticleId IdType="pubmed">20407057</ArticleId></ArticleIdList></Reference><Reference><Citation>Young D, Harrison D, Cuthbertson B, et al. Early vs late tracheostomy for prevention of pneumonia in mechanically ventilated adult ICU. The tracman randomized trial. JAMA. 2013;309:2121&#x2010;2129. 10.1001/jama.2013.5154</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.5154</ArticleId><ArticleId IdType="pubmed">23695482</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver ER, Gist A, Gillespie MB. Percutaneous versus surgical tracheotomy: an updated meta&#x2010;analysis. Laryngoscope. 2007;117:1570&#x2010;1575. 10.1097/MLG.0b013e318093edae</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLG.0b013e318093edae</ArticleId><ArticleId IdType="pubmed">17667139</ArticleId></ArticleIdList></Reference><Reference><Citation>Halum SL, Ting JY, Plowman EK, et al. A multi&#x2010;institutional analysis of tracheotomy complications. Laryngoscope. 2012;122:38&#x2010;45. 10.1002/lary.22364</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.22364</ArticleId><ArticleId IdType="pubmed">22183627</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;lk&#xfc;men B, Eskiizmir G, Tok D, &#xc7;ivi M, &#xc7;elik O. Our experience with percutaneous and surgical tracheotomy in intubated critically ill patients. Turk Arch Otorhinolaryngol. 2018;56:199&#x2010;205. 10.5152/tao.2018.3603</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tao.2018.3603</ArticleId><ArticleId IdType="pmc">PMC6340328</ArticleId><ArticleId IdType="pubmed">30701114</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S. Immortal time bias in pharmaco&#x2010;epidemiology. Am J Epidemiol. 2008;167:492&#x2010;499. 10.1093/aje/kwm324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwm324</ArticleId><ArticleId IdType="pubmed">18056625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758&#x2010;764. 10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34535723</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea.</ArticleTitle><Pagination><StartPage>18576</StartPage><MedlinePgn>18576</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18576</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-97989-8</ELocationID><Abstract><AbstractText>Contradictory findings exist about association of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) with lung cancer development. This was a retrospective observational cohort study that used data from 7 hospitals in Korea, converted to the Observational Medical Outcomes Partnership Common Data Model. The primary outcome was occurrence of lung cancer. A total of 207,794 patients across the 7 databases was included in the final analysis; 33,230 (16%) were prescribed ACEi and 174,564 (84%) were prescribed ARB. Crude analysis adjusted for sex and age showed higher incidence of lung cancer in the ACEi group compared to the ARB group (hazard ratio [HR], 1.46; 95% confidence rate [CI], 1.08-1.97). After propensity-score matching, 30,445 pairs were generated, and there was no difference in incidence of lung cancer between the two groups (HR, 0.93; 95% CI, 0.64-1.35). Patients prescribed ACEi showed no difference in incidence of lung cancer development compared to those using ARB. This finding provides evidence on the association between ACEi and occurrence of lung cancer.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Seung-Hwa</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Rehabilitation &amp; Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chun</LastName><ForeName>Kwang Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, College of Medicine, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jungchan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Ji Dong</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Rehabilitation &amp; Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jinwook</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kwangmo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea. kmhi.yang@samsung.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. kmhi.yang@samsung.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34535723</ArticleId><ArticleId IdType="pmc">PMC8448874</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-97989-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-97989-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627&#x2013;636. doi: 10.1016/S1470-2045(10)70106-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(10)70106-6</ArticleId><ArticleId IdType="pmc">PMC4070221</ArticleId><ArticleId IdType="pubmed">20542468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: Some old and new implications of ACE inhibition. Hypertens. Res. 2010;33:11&#x2013;21. doi: 10.1038/hr.2009.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2009.184</ArticleId><ArticleId IdType="pubmed">19911001</ArticleId></ArticleIdList></Reference><Reference><Citation>Song T, et al. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur. J. Cancer Prev. 2017;26:78&#x2013;85. doi: 10.1097/CEJ.0000000000000269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CEJ.0000000000000269</ArticleId><ArticleId IdType="pubmed">27158979</ArticleId></ArticleIdList></Reference><Reference><Citation>George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer. 2010;10:745&#x2013;759. doi: 10.1038/nrc2945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2945</ArticleId><ArticleId IdType="pubmed">20966920</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J. Clin. Oncol. 2011;29:3001&#x2013;3007. doi: 10.1200/JCO.2011.35.1908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.35.1908</ArticleId><ArticleId IdType="pubmed">21690476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang YY, Chen KB, Tsai TH, Tsai WC. Lowered cancer risk with ACE inhibitors/ARBs: A population-based cohort study. J. Clin. Hypertens. (Greenwich) 2014;16:27&#x2013;33. doi: 10.1111/jch.12228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.12228</ArticleId><ArticleId IdType="pmc">PMC8031532</ArticleId><ArticleId IdType="pubmed">24304931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic M, Cuspidi C, Belyavskiy E, Grassi G. Intriguing relationship between antihypertensive therapy and cancer. Pharmacol. Res. 2019;141:501&#x2013;511. doi: 10.1016/j.phrs.2019.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.01.037</ArticleId><ArticleId IdType="pubmed">30682424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks BM, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study. BMJ. 2018;363:k4209. doi: 10.1136/bmj.k4209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k4209</ArticleId><ArticleId IdType="pmc">PMC6199558</ArticleId><ArticleId IdType="pubmed">30355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY, et al. Association between angiotensin-converting enzyme inhibitors and lung cancer-a nationwide, population-based propensity score-matched cohort study. Cancers. 2020 doi: 10.3390/cancers12030747.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12030747</ArticleId><ArticleId IdType="pmc">PMC7140054</ArticleId><ArticleId IdType="pubmed">32245239</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177&#x2013;1181. doi: 10.1136/bmj.38803.528113.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38803.528113.55</ArticleId><ArticleId IdType="pmc">PMC1463974</ArticleId><ArticleId IdType="pubmed">16679330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, et al. Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65&#x2013;82. doi: 10.1016/S1470-2045(10)70260-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(10)70260-6</ArticleId><ArticleId IdType="pubmed">21123111</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, et al. Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM) Stud. Health Technol. Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Intern. Med. 2007;147:573&#x2013;577. doi: 10.7326/0003-4819-147-8-200710160-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam A, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088&#x2013;2089. doi: 10.1016/S0140-6736(02)08914-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)08914-6</ArticleId><ArticleId IdType="pubmed">12086766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahaj W, et al. Angiotensin converting enzyme inhibitors use and development of lung cancer: A systematic review and meta-analysis. J. Clin. Oncol. 2019;37:e13093. doi: 10.1200/JCO.2019.37.15_suppl.e13093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.e13093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorgel F, et al. The contamination of valsartan and other sartans, part 1: New findings. J. Pharm. Biomed. Anal. 2019;172:395&#x2013;405. doi: 10.1016/j.jpba.2019.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2019.05.022</ArticleId><ArticleId IdType="pubmed">31122801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int. J. Epidemiol. 2018;47:2005&#x2013;2014. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society Hypertension, Hypertension Epidemiology Research Working Group, Kim, H. C. &amp; Cho, M. C. Korea hypertension fact sheet 2018. Clin. Hypertens.24, 13, doi: 10.1186/s40885-018-0098-0 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166277</ArticleId><ArticleId IdType="pubmed">30288297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009&#x2013;2014. JAMA. 2017;318:1241&#x2013;1249. doi: 10.1001/jama.2017.13836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.13836</ArticleId><ArticleId IdType="pmc">PMC5710396</ArticleId><ArticleId IdType="pubmed">28903154</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640&#x2013;1650. doi: 10.1001/jama.2020.16167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16167</ArticleId><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34545823</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>283</Volume><PubDate><Year>2021</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Towards the Representation of Genomic Data in HL7 FHIR and OMOP CDM.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>94</EndPage><MedlinePgn>86-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210545</ELocationID><Abstract><AbstractText>High throughput sequencing technologies have facilitated an outburst in biological knowledge over the past decades and thus enables improvements in personalized medicine. In order to support (international) medical research with the combination of genomic and clinical patient data, a standardization and harmonization of these data sources is highly desirable. To support this increasing importance of genomic data, we have created semantic mapping from raw genomic data to both FHIR (Fast Healthcare Interoperability Resources) and OMOP (Observational Medical Outcomes Partnership) CDM (Common Data Model) and analyzed the data coverage of both models. For this, we calculated the mapping score for different data categories and the relative data coverage in both FHIR and OMOP CDM. Our results show, that the patients genomic data can be mapped to OMOP CDM directly from VCF (Variant Call Format) file with a coverage of slightly over 50%. However, using FHIR as intermediate representation does not lead to further information loss as the already stored data in FHIR can be further transformed into OMOP CDM format with almost 100% success. Our findings are in favor of extending OMOP CDM with patient genomic data using ETL to enable the researchers to apply different analysis methods including machine learning algorithms on genomic data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassirian</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Najia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Genomic data</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">VCF</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34545823</ArticleId><ArticleId IdType="doi">10.3233/SHTI210545</ArticleId><ArticleId IdType="pii">SHTI210545</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34545824</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>283</Volume><PubDate><Year>2021</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>The Usage of OHDSI OMOP - A Scoping Review.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>103</EndPage><MedlinePgn>95-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210546</ELocationID><Abstract><AbstractText>OHDSI, a fast growing open-science research community seeks to enable researchers from around the globe to conduct network studies based on standardized data and vocabularies. There is no comprehensive review of publications about OHDSI's standard: the OMOP Common Data Model and its usage available. In this work we aim to close this gap and provide a summary of existing publications including the analysis of its meta information such as the choice of journals, journal types, countries, as well as an analysis by topics based on a title and abstract screening. Since 2016, the number of publications has been constantly growing and the relevance of the OMOP CDM is increasing in terms of multi-country studies based on observational patient data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Mich&#xe9;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000098583">Scoping Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">scoping review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId><ArticleId IdType="doi">10.3233/SHTI210546</ArticleId><ArticleId IdType="pii">SHTI210546</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34552139</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model.</ArticleTitle><Pagination><StartPage>18812</StartPage><MedlinePgn>18812</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18812</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-98216-0</ELocationID><Abstract><AbstractText>Different strategies have been used to maximise the effect of COVID-19 vaccination campaigns in Europe. We modelled the impact of different prioritisation choices and dose intervals on infections, hospitalisations, mortality, and public health restrictions. An agent-based model was built to quantify the impact of different vaccination strategies over 6&#xa0;months. Input parameters were derived from published phase 3 trials and official European figures. We explored the effect of prioritising vulnerable people, care-home staff and residents, versus contagious groups; and the impact of dose intervals ranging from 3 to 12&#xa0;weeks. Prioritising vulnerable people, rather than the most contagious, led to higher numbers of COVID-19 infections, whilst reducing mortality, hospital admissions, and public health restrictions. At a realistic vaccination speed of&#x2009;&#x2264;&#x2009;0&#xb7;1% population/day, separating doses by 12&#xa0;weeks (vs a baseline scenario of 3&#xa0;weeks) reduced hospitalisations, mortality, and restrictions for vaccines with similar first- and second-dose efficacy (e.g., the Oxford-AstraZeneca and Moderna vaccines), but not for those with lower first vs second-dose efficacy (e.g., the Pfizer/BioNTech vaccine). Mass vaccination will dramatically reduce the effect of COVID-19 on Europe's health and economy. Early vaccination of vulnerable populations will reduce mortality, hospitalisations, and public health restrictions compared to prioritisation of the most contagious people. The choice of interval between doses should be based on expected vaccine availability and first-dose efficacy, with 12-week intervals preferred over shorter intervals in most realistic scenarios.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Comparative Medicine and Bioimage (CMCiB), Gemans Trias i Pujol Research Institute (IGTP), Badalona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physics Department, Computational Biology and Complex Systems (BIOCOM-SC), Universitat Polit&#xe8;cnica de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Physics Department, Computational Biology and Complex Systems (BIOCOM-SC), Universitat Polit&#xe8;cnica de Catalunya, Barcelona, Spain. clara.prats@upc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SRF-2018-11-ST2-004</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PGC2018-095456-B-I00</GrantID><Agency>Ministerio de Ciencia e Innovaci&#xf3;n, Gobierno de Espa&#xf1;a</Agency><Country/></Grant><Grant><GrantID>SRF-2018-11-ST2-004</GrantID><Agency>National Institute for Health Research (NIHR)</Agency><Country/></Grant><Grant><GrantID>LCF/PR/GN17/50300003</GrantID><Agency>La Caixa Foundation (ID 100010434)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035862" MajorTopicYN="N">Vulnerable Populations</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Prats reports Grants from Ministerio de Ciencia e Innovaci&#xf3;n, Gobierno de Espa&#xf1;a (PGC2018-095456-B-I00), during the conduct of the study; other from European Commission, DG-CONNECT (CNECT/LUX/2020/LVP/0085, LC-01591965) and Janssen, outside the submitted work. Dr. Prieto-Alhambra reports Grants and other from AMGEN, Grants, non-financial support and other from UCB Biopharma, Grants from Les Laboratoires Servier, outside the submitted work; and HTA Funding Committee membership. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. Dr. CATAL&#xc0; reports Grants from Ministerio de Ciencia e Innovaci&#xf3;n, Gobierno de Espa&#xf1;a (PGC2018-095456-B-I00), Grants from La Caixa Foundation (ID 100010434), under agreement LCF/PR/GN17/50300003, during the conduct of the study; other from European Commission, DG-CONNECT (CNECT/LUX/2020/LVP/0085, LC-01591965), outside the submitted work. Ms. Li has nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34552139</ArticleId><ArticleId IdType="pmc">PMC8458447</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-98216-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-98216-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus disease (COVID-19) dashboard. COVID 19 Special Issue, Vol. 10 (2020).</Citation></Reference><Reference><Citation>COVID-19 vaccine tracker. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker.</Citation></Reference><Reference><Citation>Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA FDA authorizes Moderna COVID-19 vaccine. Med. Lett. Drugs Ther. 2021;63:9&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33512345</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Committee on Vaccination and Immunisation: Advice on Priority Groups for COVID-19 Vaccination, 30 December 2020. https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020.</Citation></Reference><Reference><Citation>Thomson Reuters Foundation. Why Indonesia is vaccinating its working population first. https://news.trust.org/item/20210104063432-yquaj/.</Citation></Reference><Reference><Citation>Optimising the COVID-19 vaccination programme for maximum short-term impact. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact.</Citation></Reference><Reference><Citation>Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979&#x2013;1993. doi: 10.1016/S0140-6736(20)32466-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris, C. Supply-chain obstacles led to last month&#x2019;s cut to Pfizer&#x2019;s covid-19 vaccine-rollout target. Wall Street J. (Eastern ed.) (2020).</Citation></Reference><Reference><Citation>Wise J. Covid-19: New coronavirus variant is identified in UK. BMJ. 2020;371:m4857. doi: 10.1136/bmj.m4857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4857</ArticleId><ArticleId IdType="pubmed">33328153</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, et al. Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern 202012/01 in England. bioRxiv. 2020 doi: 10.1101/2020.12.24.20248822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.24.20248822</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. New variants of the virus that causes COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html (2021).</Citation></Reference><Reference><Citation>Hoertel N, et al. A stochastic agent-based model of the SARS-CoV-2 epidemic in France. Nat. Med. 2020;26:1417&#x2013;1421. doi: 10.1038/s41591-020-1001-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1001-6</ArticleId><ArticleId IdType="pubmed">32665655</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatramanan S, et al. Using data-driven agent-based models for forecasting emerging infectious diseases. Epidemics. 2018;22:43&#x2013;49. doi: 10.1016/j.epidem.2017.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2017.02.010</ArticleId><ArticleId IdType="pmc">PMC5568513</ArticleId><ArticleId IdType="pubmed">28256420</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, et al. Robust estimation of diagnostic rate and real incidence of COVID-19 for European policymakers. PLoS ONE. 2021;16:e0243701. doi: 10.1371/journal.pone.0243701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243701</ArticleId><ArticleId IdType="pmc">PMC7790392</ArticleId><ArticleId IdType="pubmed">33411737</ArticleId></ArticleIdList></Reference><Reference><Citation>Official UK Coronavirus Dashboard. https://coronavirus.data.gov.uk/.</Citation></Reference><Reference><Citation>Report 34&#x2014;COVID-19 infection fatality ratio estimates from seroprevalence. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/.</Citation></Reference><Reference><Citation>Riley S, et al. REACT-1 round 8 final report: High average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021. bioRxiv. 2021 doi: 10.1101/2021.01.28.21250606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.28.21250606</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, et al. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain. Int. J. Epidemiol. 2021;49:1930&#x2013;1939. doi: 10.1093/ije/dyaa190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa190</ArticleId><ArticleId IdType="pmc">PMC7665572</ArticleId><ArticleId IdType="pubmed">33118037</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus Pandemic Data Explorer. https://ourworldindata.org/coronavirus-data-explorer?zoomToSelection=true&amp;time=2020-03-01..latest&amp;country=IND~USA~GBR~CAN~DEU~FRA&amp;region=World&amp;vaccinationsMetric=true&amp;interval=smoothed&amp;perCapita=true&amp;smoothing=7&amp;pickerMetric=total_cases&amp;pickerSort=desc.</Citation></Reference><Reference><Citation>Catala M, et al. Risk diagrams based on primary care electronic medical records and linked real-time PCR data to monitor local COVID-19 outbreaks during the summer 2020: A prospective study including 7,671,862 people in Catalonia. Front. Public Health. 2021;9:890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287173</ArticleId><ArticleId IdType="pubmed">34291033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr CC, et al. Covasim: An agent-based model of COVID-19 dynamics and interventions. PLoS Comput. Biol. 2021;2:3&#x2013;9. doi: 10.1101/2020.05.10.20097469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.10.20097469</ArticleId><ArticleId IdType="pmc">PMC8341708</ArticleId><ArticleId IdType="pubmed">34310589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuite AR, Zhu L, Fisman DN, Salomon JA. Alternative dose allocation strategies to increase benefits from constrained COVID-19 vaccine supply. Ann. Intern. Med. 2021 doi: 10.7326/M20-8137.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-8137</ArticleId><ArticleId IdType="pmc">PMC7808325</ArticleId><ArticleId IdType="pubmed">33395334</ArticleId></ArticleIdList></Reference><Reference><Citation>Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of a COVID-19 vaccine: Implementation over efficacy. Health Aff. 2021;40:42&#x2013;52. doi: 10.1377/hlthaff.2020.02054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2020.02054</ArticleId><ArticleId IdType="pmc">PMC7931245</ArticleId><ArticleId IdType="pubmed">33211536</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: A modelling study. Lancet Public Health. 2020;5:e375&#x2013;e385. doi: 10.1016/S2468-2667(20)30133-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30133-X</ArticleId><ArticleId IdType="pmc">PMC7266572</ArticleId><ArticleId IdType="pubmed">32502389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinch R, et al. OpenABM-Covid19-an agent-based model for non-pharmaceutical interventions against COVID-19 including contact tracing. medRxiv. 2020;17:e1009146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8328312</ArticleId><ArticleId IdType="pubmed">34252083</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 vaccination and prioritisation strategies in the EU/EEA. https://www.ecdc.europa.eu/en/publications-data/covid-19-vaccination-and-prioritisation-strategies-eueea (2020).</Citation></Reference><Reference><Citation>Report 33&#x2014;Modelling the allocation and impact of a COVID-19 vaccine. http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-33-vaccine/.</Citation></Reference><Reference><Citation>Jentsch P, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes. bioRxiv. 2020 doi: 10.1101/2020.09.25.20201889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.25.20201889</ArticleId><ArticleId IdType="pmc">PMC8012029</ArticleId><ArticleId IdType="pubmed">33811817</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Hill EM, Dyson L, Tildesley M, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.09.22.20194183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.22.20194183</ArticleId><ArticleId IdType="pmc">PMC8101958</ArticleId><ArticleId IdType="pubmed">33956791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandmann F, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: Transmission model-based future scenario analysis and economic evaluation. bioRxiv. 2020 doi: 10.1101/2020.09.24.20200857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.24.20200857</ArticleId><ArticleId IdType="pmc">PMC7972313</ArticleId><ArticleId IdType="pubmed">33743846</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, et al. Multi-organ impairment in low-risk individuals with long COVID. bioRxiv. 2020 doi: 10.1101/2020.10.14.20212555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212555</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid, P.-B. Vaccine (BNT162, PF-07302048) Vaccines and related biological products advisory committee briefing document-FDA. gov (19AD).</Citation></Reference><Reference><Citation>Barnabas RV, Wald A. A public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose. Ann. Intern. Med. 2021 doi: 10.7326/M20-8060.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-8060</ArticleId><ArticleId IdType="pmc">PMC7808326</ArticleId><ArticleId IdType="pubmed">33395339</ArticleId></ArticleIdList></Reference><Reference><Citation>Paltiel AD, David Paltiel A, Zheng A, Schwartz JL. Speed versus efficacy: Quantifying potential tradeoffs in COVID-19 vaccine deployment. Ann. Intern. Med. 2021 doi: 10.7326/m20-7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-7866</ArticleId><ArticleId IdType="pmc">PMC7787166</ArticleId><ArticleId IdType="pubmed">33395345</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguas, R. et al. An analysis of the potential global impact of dosing regimen and roll out options for the ChAdOx1 n-CoV-19 vaccine (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569205</ArticleId><ArticleId IdType="pubmed">34737262</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrajt L, et al. Optimizing vaccine allocation for COVID-19 vaccines: Critical role of single-dose vaccination. medRxiv. 2021 doi: 10.1101/2020.12.31.20249099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.31.20249099</ArticleId><ArticleId IdType="pmc">PMC8187351</ArticleId><ArticleId IdType="pubmed">34103510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of &#x2018;real-world&#x2019; vaccination outcomes from Israel. bioRxiv. 2021 doi: 10.1101/2021.02.01.21250957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.01.21250957</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. Lancet. 2021;397:881&#x2013;891. doi: 10.1016/S0140-6736(21)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00432-3</ArticleId><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Social Care. Vivaldi 1: Coronavirus (COVID-19) Care Homes Study Report (2020).</Citation></Reference><Reference><Citation>Ladhani SN, et al. Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. EClinicalMedicine. 2020;26:100533. doi: 10.1016/j.eclinm.2020.100533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100533</ArticleId><ArticleId IdType="pmc">PMC7480335</ArticleId><ArticleId IdType="pubmed">32923993</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34560604</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7565</ISSN><JournalIssue CitedMedium="Internet"><Volume>211</Volume><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Computer methods and programs in biomedicine</Title><ISOAbbreviation>Comput Methods Programs Biomed</ISOAbbreviation></Journal><ArticleTitle>A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data.</ArticleTitle><Pagination><StartPage>106394</StartPage><MedlinePgn>106394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmpb.2021.106394</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0169-2607(21)00468-5</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">As a response to the ongoing COVID-19 pandemic, several prediction models in the existing literature were rapidly developed, with the aim of providing evidence-based guidance. However, none of these COVID-19 prediction models have been found to be reliable. Models are commonly assessed to have a risk of bias, often due to insufficient reporting, use of non-representative data, and lack of large-scale external validation. In this paper, we present the Observational Health Data Sciences and Informatics (OHDSI) analytics pipeline for patient-level prediction modeling as a standardized approach for rapid yet reliable development and validation of prediction models. We demonstrate how our analytics pipeline and open-source software tools can be used to answer important prediction questions while limiting potential causes of bias (e.g., by validating phenotypes, specifying the target population, performing large-scale external validation, and publicly providing all analytical source code).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We show step-by-step how to implement the analytics pipeline for the question: 'In patients hospitalized with COVID-19, what is the risk of death 0 to 30 days after hospitalization?'. We develop models using six different machine learning methods in a USA claims database containing over 20,000 COVID-19 hospitalizations and externally validate the models using data containing over 45,000 COVID-19 hospitalizations from South Korea, Spain, and the USA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our open-source software tools enabled us to efficiently go end-to-end from problem design to reliable Model Development and evaluation. When predicting death in patients hospitalized with COVID-19, AdaBoost, random forest, gradient boosting machine, and decision tree yielded similar or lower internal and external validation discrimination performance compared to L1-regularized logistic regression, whereas the MLP neural network consistently resulted in lower discrimination. L1-regularized logistic regression models were well calibrated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results show that following the OHDSI analytics pipeline for patient-level prediction modelling can enable the rapid development towards reliable prediction models. The OHDSI software tools and pipeline are open source and available to researchers from all around the world.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Botnar Research Centre, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a &#x13e;Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a &#x13e;Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands; Observational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Departments of Biomathematics, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA. Electronic address: jreps@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Comput Methods Programs Biomed</MedlineTA><NlmUniqueID>8506513</NlmUniqueID><ISSNLinking>0169-2607</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Data harmonization</Keyword><Keyword MajorTopicYN="N">Data quality control</Keyword><Keyword MajorTopicYN="N">Distributed data network</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Risk prediction</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest CB, MJS, AGS, JMR are employees of Janssen Research &amp; Development and shareholders of Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34560604</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pii">S0169-2607(21)00468-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . COVID-19 weekly epidemiological update, edition 45, 22 June 2021. World Health Organization [Online]; 2021. https://apps.who.int/iris/handle/10665/342009 [Online]. Available:</Citation></Reference><Reference><Citation>Collins G.S., Reitsma J.B., Altman D.G., Moons K.G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Circulation. 2015;131(2):211&#x2013;219. doi: 10.1186/s12916-014-0241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0241-z</ArticleId><ArticleId IdType="pmc">PMC4297220</ArticleId><ArticleId IdType="pubmed">25561516</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Najjar H., Al-Rousan N. A classifier prediction model to predict the status of coronavirus COVID-19 patients in South Korea. Eur. Rev. Med. Pharmacol. Sci. 2020;24(6):3400&#x2013;3403. doi: 10.26355/eurrev_202003_20709.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202003_20709</ArticleId><ArticleId IdType="pubmed">32271458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yu X., Zhao H., Wang H., Zhao R., Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit. Care. 2020;24(1):108. doi: 10.1186/s13054-020-2833-7. Mar 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-2833-7</ArticleId><ArticleId IdType="pmc">PMC7081524</ArticleId><ArticleId IdType="pubmed">32188484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L., et al. Prediction models for diagnosis and prognosis of COVID-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328. Apr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Yin W., Tao Z., Tan W., Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One. 2020;15(3) doi: 10.1371/journal.pone.0230548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0230548</ArticleId><ArticleId IdType="pmc">PMC7082074</ArticleId><ArticleId IdType="pubmed">32191764</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics . The Book of OHDSI. Observational Health Data Sciences and Informatics [Online]; 2020. https://ohdsi.github.io/TheBookOfOhdsi/ Available:</Citation></Reference><Reference><Citation>Burn E., et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat. Commun. 2020;11(1):5009. doi: 10.1038/s41467-020-18849-z. Oct.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Salles T., Vizcaya D., Pistillo A. 30-day outcomes of children and adolescents with COVID-19: an international experience. Pediatrics. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34049958</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency; Amsterdam, The Netherlands: 2020. COVID-19: Reminder of Risk of Serious Side Effects with Chloroquine and Hydroxychloroquine.https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine Apr. 23, [Online]. Available:</Citation></Reference><Reference><Citation>Golozar A., et al. Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including &gt;3.32 million people tested with real-time PCR and &gt;219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States. medRxiv [Preprint] 2020 doi: 10.1101/2020.10.25.20218875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.25.20218875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai L.Y.H., et al. Clinical characteristics, symptoms, management and health outcomes in 8598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis. medRxiv [Preprint] 2020 doi: 10.1101/2020.10.13.20211821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.13.20211821</ArticleId></ArticleIdList></Reference><Reference><Citation>J.C.E. Lane et&#xa0;al., Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology. 60 (7) (2021) 3222-3234, doi:10.1093/rheumatology/keaa771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa771</ArticleId><ArticleId IdType="pmc">PMC7798671</ArticleId><ArticleId IdType="pubmed">33367863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane J.C.E., et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020;2(11):e698&#x2013;e711. doi: 10.1016/S2665-9913(20)30276-9. Nov.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30276-9</ArticleId><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., et al. Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435. doi: 10.1136/bmj.n1435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales D.R., et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit. Health. 2020 doi: 10.1016/S2589-7500(20)30289-2. Dec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30289-2</ArticleId><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference><Reference><Citation>Prats-Uribe A., et al. Use of repurposed and adjuvant drugs in hospital patients with COVID-19: multinational network cohort study. BMJ. 2021;373:n1038. doi: 10.1136/bmj.n1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1038</ArticleId><ArticleId IdType="pmc">PMC8111167</ArticleId><ArticleId IdType="pubmed">33975825</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M., et al. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Int. J. Obes. 2021:1&#x2013;11. doi: 10.1038/s41366-021-00893-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-021-00893-4</ArticleId><ArticleId IdType="pmc">PMC8281807</ArticleId><ArticleId IdType="pubmed">34267326</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J.M., et al. Implementation of the COVID-19 vulnerability index across an international network of health care data sets: collaborative external validation study. JMIR Med. Inform. 2021;9(4):e21547. doi: 10.2196/21547. (in eng) Apr 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/21547</ArticleId><ArticleId IdType="pmc">PMC8023380</ArticleId><ArticleId IdType="pubmed">33661754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoaibi A., Fortin S.P., Weinstein R., Berlin J.A., Ryan P. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. Off. J. Am. Coll. Gastroenterol.| ACG. 2021;116(4):692&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">33982938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E.H., et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology. 2021 doi: 10.1093/rheumatology/keab250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab250</ArticleId><ArticleId IdType="pmc">PMC7989171</ArticleId><ArticleId IdType="pubmed">33725121</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R.D., et al. Seek COVER: development and validation of a personalized risk calculator for COVID-19 outcomes in an international network. medRxiv [Preprint] 2020 doi: 10.1101/2020.05.26.20112649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.26.20112649</ArticleId><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="pubmed">35094685</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R.W., Platt R., Brown J.S., Henry D.A., Klungel O.H., Suissa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol. Drug Saf. 2019 doi: 10.1002/pds.4722. Jan.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4722</ArticleId><ArticleId IdType="pubmed">30648307</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E., et al. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study. Lancet Rheumatol. 2019;1(4):e229&#x2013;e236. doi: 10.1016/S2665-9913(19)30075-X. Dec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30075-X</ArticleId><ArticleId IdType="pubmed">38229379</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E., et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nature communications. 2020;11(1):1&#x2013;11. doi: 10.1038/s41467-020-18849-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics OMOP Common Data Model. GitHub repository [Online] 2020 http://ohdsi.github.io/CommonDataModel/ (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics WhiteRabbit. GitHub repository [Online] 2020 https://ohdsi.github.io/WhiteRabbit/WhiteRabbit.html (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics Rabbit in a Hat. GitHub repository [Online] 2020 https://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics Usagi. GitHub repository [Online] 2020 https://github.com/ohdsi/usagi (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics DataQualityDashboard. GitHub repository [Online] 2020 https://ohdsi.github.io/DataQualityDashboard/ (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>Huser V., et al. Multisite evaluation of a data quality tool for patient-level clinical data sets. EGEMS. 2016;4(1):1239. doi: 10.13063/2327-9214.1239. (Wash DC)Nov.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1239</ArticleId><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J.M., Schuemie M.J., Suchard M.A., Ryan P.B., Rijnbeek P.R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J. Am. Med. Inform. Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics CohortDiagnostics. GitHub repository [Online] 2020 https://ohdsi.github.io/CohortDiagnostics/ (Accessed 7 December 2020)</Citation></Reference><Reference><Citation>L.H. John, J.A. Kors, J.M. Reps, P.B. Ryan, and P.R. Rijnbeek, How little data do we need for patient-level prediction?, arXiv [Preprint] (2020), doi: arXiv:2008.07361.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins G.S., Ogundimu E.O., Altman D.G. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat. Med. 2016;35(2):214&#x2013;226. doi: 10.1002/sim.6787. Jan.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6787</ArticleId><ArticleId IdType="pmc">PMC4738418</ArticleId><ArticleId IdType="pubmed">26553135</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M.A., Simpson S.E., Zorych I., Ryan P., Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans. Model. Comput. Simul. 2013;23(1) doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J.M., et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med. Res. Methodol. 2020;20(1):102. doi: 10.1186/s12874-020-00991-3. May.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M., et al. Building predictive models in R using the caret package. J. Stat. Softw. 2008;28(1):1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Zhou N., Shrivastava S., Kalagnanam J. Proceedings of the IEEE International Conference on Big Data. IEEE; 2020. Doctor for machines: a failure pattern analysis solution for industry 4.0; pp. 1614&#x2013;1623. 2020. (Big Data)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34583416</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2511-705X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>S 02</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Methods of information in medicine</Title><ISOAbbreviation>Methods Inf Med</ISOAbbreviation></Journal><ArticleTitle>Development of Prediction Models for Unplanned Hospital Readmission within 30 Days Based on Common Data Model: A Feasibility Study.</ArticleTitle><Pagination><StartPage>e65</StartPage><EndPage>e75</EndPage><MedlinePgn>e65-e75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0041-1735166</ELocationID><Abstract><AbstractText Label="BACKGROUND">Unplanned hospital readmission after discharge reflects low satisfaction and reliability in care and the possibility of potential medical accidents, and is thus indicative of the quality of patient care and the appropriateness of discharge plans.</AbstractText><AbstractText Label="OBJECTIVES">The purpose of this study was to develop and validate prediction models for all-cause unplanned hospital readmissions within 30 days of discharge, based on a common data model (CDM), which can be applied to multiple institutions for efficient readmission management.</AbstractText><AbstractText Label="METHODS">Retrospective patient-level prediction models were developed based on clinical data of two tertiary general university hospitals converted into a CDM developed by Observational Medical Outcomes Partnership. Machine learning classification models based on the LASSO logistic regression model, decision tree, AdaBoost, random forest, and gradient boosting machine (GBM) were developed and tested by manipulating a set of CDM variables. An internal 10-fold cross-validation was performed on the target data of the model. To examine its transportability, the model was externally validated. Verification indicators helped evaluate the model performance based on the values of area under the curve (AUC).</AbstractText><AbstractText Label="RESULTS">Based on the time interval for outcome prediction, it was confirmed that the prediction model targeting the variables obtained within 30 days of discharge was the most efficient (AUC of 82.75). The external validation showed that the model is transferable, with the combination of various clinical covariates. Above all, the prediction model based on the GBM showed the highest AUC performance of 84.14&#x2009;&#xb1;&#x2009;0.015 for the Seoul National University Hospital cohort, yielding in 78.33 in external validation.</AbstractText><AbstractText Label="CONCLUSIONS">This study showed that readmission prediction models developed using machine-learning techniques and CDM can be a useful tool to compare two hospitals in terms of patient-data features.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Borim</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, College of Medicine, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Choi</LastName><ForeName>Jinwook</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, College of Medicine, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Korea's Ministry of Trade, Industry, and Energy</GrantID><Agency>20004927</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Methods Inf Med</MedlineTA><NlmUniqueID>0210453</NlmUniqueID><ISSNLinking>0026-1270</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="Y">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34583416</ArticleId><ArticleId IdType="pmc">PMC8714301</ArticleId><ArticleId IdType="doi">10.1055/s-0041-1735166</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Toomey S L, Peltz A, Loren S. Potentially preventable 30-day hospital readmissions at a children's hospital. Pediatrics. 2016;138(02):e20154182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557411</ArticleId><ArticleId IdType="pubmed">27449421</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlvennan C K, Eapen Z J, Allen L A. Hospital readmissions reduction program. Circulation. 2015;131(20):1796&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439931</ArticleId><ArticleId IdType="pubmed">25986448</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Choi K, Lee J, Lee E. A study on the factors related to the readmission and ambulatory visit in an university hospital: using patient care information DB. J Korean Soc Med Informatics. 2000;6(04):23&#x2013;33.</Citation></Reference><Reference><Citation>Zuckerman R B, Sheingold S H, Orav E J, Ruhter J, Epstein A M. Readmissions, observation, and the hospital readmissions reduction program. N Engl J Med. 2016;374(16):1543&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910198</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M P, Waters T M, Kaplan C M, Cao Y, Bazzoli G J. Most hospitals received annual penalties for excess readmissions, but some fared better than others. Health Aff (Millwood) 2017;36(05):893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">28461357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan O, Meltzer D O, Shaykevich S A. Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med. 2010;25(03):211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839332</ArticleId><ArticleId IdType="pubmed">20013068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen O K, Makam A N, Clark C. Predicting all-cause readmissions using electronic health record data from the entire hospitalization: model development and comparison. J Hosp Med. 2016;11(07):473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5365027</ArticleId><ArticleId IdType="pubmed">26929062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kansagara D, Englander H, Salanitro A. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306(15):1688&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603349</ArticleId><ArticleId IdType="pubmed">22009101</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry S A, Li J, Davis D, Erdmann C, Sikka R, Sutariya B. A public-private partnership develops and externally validates a 30-day hospital readmission risk prediction model. Online J Public Health Inform. 2013;5(02):219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812998</ArticleId><ArticleId IdType="pubmed">24224068</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein M D, Qin H, Mercer S Q, Fong J, Haydar Z. Risk factors for 30-day hospital readmission in patients &#x2265;65 years of age. Proc (Bayl Univ Med Cent) 2008;21(04):363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566906</ArticleId><ArticleId IdType="pubmed">18982076</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain M J, Kharrazi H. Feasibility of 30-day hospital readmission prediction modeling based on health information exchange data. Int J Med Inform. 2015;84(12):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">26412010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Oren E, Chen K. Scalable and accurate deep learning with electronic health records. npj. Digit Med. 2018;1(01):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6550175</ArticleId><ArticleId IdType="pubmed">31304302</ArticleId></ArticleIdList></Reference><Reference><Citation>Frizzell J D, Liang L, Schulte P J. Prediction of 30-day all-cause readmissions in patients hospitalized for heart failure: comparison of machine learning and other statistical approaches. JAMA Cardiol. 2017;2(02):204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784047</ArticleId></ArticleIdList></Reference><Reference><Citation>Maali Y, Perez-Concha O, Coiera E, Roffe D, Day R O, Gallego B. Predicting 7-day, 30-day and 60-day all-cause unplanned readmission: a case study of a Sydney hospital. BMC Med Inform Decis Mak. 2018;18(01):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755362</ArticleId><ArticleId IdType="pubmed">29301576</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R, Hudali T. The HOSPITAL score and LACE index as predictors of 30 day readmission in a retrospective study at a university-affiliated community hospital. PeerJ. 2017;5(03):e3137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374974</ArticleId><ArticleId IdType="pubmed">28367375</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller W D, Nguyen K, Vangala S, Dowling E. Clinicians can independently predict 30-day hospital readmissions as well as the LACE index. BMC Health Serv Res. 2018;18(01):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5778655</ArticleId><ArticleId IdType="pubmed">29357864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shameer K, Johnson K W, Yahi A. Predictive modeling of hospital readmission rates using electronic medical record-wide machine learning: A case-study using Mount Sinai Heart Failure Cohort. Pac Symp Biocomput. 2017;22:276&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5362124</ArticleId><ArticleId IdType="pubmed">27896982</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C.Chapter 4: The Common Data Model Observational Health Data Sciences and Informatics; Accessed May 31, 2021 at:https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html</Citation></Reference><Reference><Citation>Williams R, Kontopantelis E, Buchan I, Peek N. Clinical code set engineering for reusing EHR data for research: a review. J Biomed Inform. 2017;70:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28442434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentinel Initiative. HomepageAccessed May 31, 2021 at:http://www.mini-sentinel.org/</Citation></Reference><Reference><Citation>The National Patient-Centered Clinical Research Network  DataAccessed May 31, 2021 at:https://pcornet.org/data/</Citation></Reference><Reference><Citation>Ross T R, Ng D, Brown J S. The HMO research network virtual data warehouse: a public data model to support collaboration. EGMS (Wash DC) 2014;2(01):1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP CDM v6.0. Accessed May 21, 2021 at:https://ohdsi.github.io/CommonDataModel/cdm60.html#OMOP_CDM_v60</Citation></Reference><Reference><Citation>CDISC. SDTM. Accessed May 31, 2021 at:https://www.cdisc.org/standards/foundational/sdtm</Citation></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus M N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J M, Ryan P B, Reich C G, Hartzema A G, Stang P E. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(01):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F S, Robbins S L. Creating a common data model for comparative effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform. 2015;6(03):536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI &#x2013; Observational Health Data Sciences and InformaticsAccessed December 29, 2020 at:https://www.ohdsi.org/</Citation></Reference><Reference><Citation>Park R W. Sharing clinical big data while protecting confidentiality and security: observational health data sciences and informatics. Healthc Inform Res. 2017;23(01):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334126</ArticleId><ArticleId IdType="pubmed">28261525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP CDM SpecificationsAccessed June 29, 2021 at:https://ohdsi.github.io/CommonDataModel/</Citation></Reference><Reference><Citation>Dreiseitl S, Ohno-Machado L.Logistic regression and artificial neural network classification models: a methodology review J Biomed Inform 200235(5&#x2013;6):352&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">12968784</ArticleId></ArticleIdList></Reference><Reference><Citation>Podgorelec V, Kokol P, Stiglic B, Rozman I. Decision trees: an overview and their use in medicine. J Med Syst. 2002;26(05):445&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182209</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random forests. Mach Learn. 2001;45(01):5&#x2013;32.</Citation></Reference><Reference><Citation>Freund Y, Schapire R E. A decision-theoretic generalization of on-line learning and an application to boosting. J Comput Syst Sci. 1997;55(01):119&#x2013;139.</Citation></Reference><Reference><Citation>Ke G, Meng Q, Finley T. Lightgbm: A highly efficient gradient boosting decision tree. Advances in Neural Information Processing Systems. 2017;30:3146&#x2013;3154.</Citation></Reference><Reference><Citation>Zhou H, Della P R, Roberts P, Goh L, Dhaliwal S S. Utility of models to predict 28-day or 30-day unplanned hospital readmissions: an updated systematic review. BMJ Open. 2016;6(06):e011060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932323</ArticleId><ArticleId IdType="pubmed">27354072</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions . Smith D M, Giobbie-Hurder A, Weinberger M. Predicting non-elective hospital readmissions: a multi-site study. J Clin Epidemiol. 2000;53(11):1113&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11106884</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R. The HOSPITAL score as a predictor of 30 day readmission in a retrospective study at a university affiliated community hospital. PeerJ. 2016;4(09):e2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018668</ArticleId><ArticleId IdType="pubmed">27651999</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Chin K S, Qu G, Tsui K L. An integrated machine learning framework for hospital readmission prediction. Knowl Base Syst. 2018;146:73&#x2013;90.</Citation></Reference><Reference><Citation>Jamei M, Nisnevich A, Wetchler E, Sudat S, Liu E. Predicting all-cause risk of 30-day hospital readmission using artificial neural networks. PLoS One. 2017;12(07):e0181173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510858</ArticleId><ArticleId IdType="pubmed">28708848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34609454</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>326</Volume><Issue>13</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Choose ARBs Over ACE Inhibitors for First-line Hypertension Treatment, Large New Analysis Suggests.</ArticleTitle><Pagination><StartPage>1244</StartPage><EndPage>1245</EndPage><MedlinePgn>1244-1245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.14017</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abbasi</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8TIM42R2W</RegistryNumber><NameOfSubstance UI="D001920">Bradykinin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000799" MajorTopicYN="N">Angioedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001920" MajorTopicYN="N">Bradykinin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34609454</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.14017</ArticleId><ArticleId IdType="pii">2784663</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34640472</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Assessment of Inter-Institutional Post-Operative Hypoparathyroidism Status Using a Common Data Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4454</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm10194454</ELocationID><Abstract><AbstractText>Post-thyroidectomy hypoparathyroidism may result in various transient or permanent symptoms, ranging from tingling sensation to severe breathing difficulties. Its incidence varies among surgeons and institutions, making it difficult to determine its actual incidence and associated factors. This study attempted to estimate the incidence of post-operative hypoparathyroidism in patients at two tertiary institutions that share a common data model, the Observational Health Data Sciences and Informatics. This study used the Common Data Model to extract explicitly specified encoding and relationships among concepts using standardized vocabularies. The EDI-codes of various thyroid disorders and thyroid operations were extracted from two separate tertiary hospitals between January 2013 and December 2018. Patients were grouped into no evidence of/transient/permanent hypoparathyroidism groups to analyze the likelihood of hypoparathyroidism occurrence related to operation types and diagnosis. Of the 4848 eligible patients at the two institutions who underwent thyroidectomy, 1370 (28.26%) experienced transient hypoparathyroidism and 251 (5.18%) experienced persistent hypoparathyroidism. Univariate logistic regression analysis predicted that, relative to total bilateral thyroidectomy, radical tumor resection was associated with a 48% greater likelihood of transient hypoparathyroidism and a 102% greater likelihood of persistent hypoparathyroidism. Moreover, multivariate logistic analysis found that radical tumor resection was associated with a 50% greater likelihood of transient hypoparathyroidism and a 97% greater likelihood of persistent hypoparathyroidism than total bilateral thyroidectomy. These findings, by integrating and analyzing two databases, suggest that this analysis could be expanded to include other large databases that share the same Observational Health Data Sciences and Informatics protocol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joon-Hyop</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-0470-7719</Identifier><AffiliationInfo><Affiliation>Gil Medical Center, Department of Surgery, Gachon University College of Medicine, Incheon 21565, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Suhyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Applied Statistics, Chung-Ang University, Seoul 06974, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4586-5062</Identifier><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine &amp; Advanced Technology, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Young Jun</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0001-8830-3433</Identifier><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine &amp; Advanced Technology, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hyeong Won</ForeName><Initials>HW</Initials><Identifier Source="ORCID">0000-0001-7338-5157</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Seoul National University Bundang Hospital, Seongnam 13620, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Su-Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>June Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0001-9990-607X</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Seoul National University Bundang Hospital, Seongnam 13620, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yoo Seung</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Gil Medical Center, Department of Surgery, Gachon University College of Medicine, Incheon 21565, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyu Eun</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0002-2354-3599</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Ka Hee</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.2019R1C1C1008384</GrantID><Agency>National Research Foundation of Korea</Agency><Country/></Grant><Grant><GrantID>800-20190517</GrantID><Agency>Seoul National University College of Medicine Research Foundation Research Program 2019</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">hypoparathyroidism</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">thyroidectomy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34640472</ArticleId><ArticleId IdType="pmc">PMC8509408</ArticleId><ArticleId IdType="doi">10.3390/jcm10194454</ArticleId><ArticleId IdType="pii">jcm10194454</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lazzara S., Barbera A., Zangh&#xec; G., Freni F., Pagano G., Cogliandolo A., Makay O., Dionigi G. Prevention, Identification and Management of Postoperative Hypoparathyroidism. J. Endocr. Surg. 2018;18:121&#x2013;131. doi: 10.16956/jes.2018.18.2.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.16956/jes.2018.18.2.121</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough M., Weber C., Leong C., Sharma J. Safety, efficacy, and cost savings of single parathyroid hormone measurement for risk stratification after total thyroidectomy. Am. Surg. 2013;79:768&#x2013;774. doi: 10.1177/000313481307900816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313481307900816</ArticleId><ArticleId IdType="pubmed">23896242</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomusch O., Machens A., Sekulla C., Ukkat J., Brauckhoff M., Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: A multivariate analysis of 5846 consecutive patients. Surgery. 2003;133:180&#x2013;185. doi: 10.1067/msy.2003.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/msy.2003.61</ArticleId><ArticleId IdType="pubmed">12605179</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Information Center.  [(accessed on 15 January 2021)].  Available online:  https://www.cancer.go.kr/</Citation></Reference><Reference><Citation>Healthcare Bigdata Hub.  [(accessed on 15 January 2021)].  Available online:  http://opendata.hira.or.kr/op/opc/olapMfrnIntrsIlnsBhvInfo.do.</Citation></Reference><Reference><Citation>Rubin D.L., Desser T.S. A data warehouse for integrating radiologic and pathologic data. J. Am. Coll. Radiol. 2008;5:210&#x2013;217. doi: 10.1016/j.jacr.2007.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacr.2007.09.004</ArticleId><ArticleId IdType="pubmed">18312970</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.Y., Kim W.S., Lee J.H. Characteristics desired in clinical data warehouse for biomedical research. Healthc. Inform. Res. 2014;20:109&#x2013;116. doi: 10.4258/hir.2014.20.2.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2014.20.2.109</ArticleId><ArticleId IdType="pmc">PMC4030054</ArticleId><ArticleId IdType="pubmed">24872909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagalova K.K., Leon Elizalde M.A., Portales-Casamar E., Gorges M. What You Need to Know Before Implementing a Clinical Research Data Warehouse: Comparative Review of Integrated Data Repositories in Health Care Institutions. JMIR Form. Res. 2020;4:e17687. doi: 10.2196/17687.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/17687</ArticleId><ArticleId IdType="pmc">PMC7484778</ArticleId><ArticleId IdType="pubmed">32852280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter K., Elfenbein D., Schneider D.F., Chen H., Sippel R.S. Hypoparathyroidism after total thyroidectomy: Incidence and resolution. J. Surg. Res. 2015;197:348&#x2013;353. doi: 10.1016/j.jss.2015.04.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2015.04.059</ArticleId><ArticleId IdType="pmc">PMC4466142</ArticleId><ArticleId IdType="pubmed">25982044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobore I., Li J., Yuhang L., Al-Handarish Y., Kandwal A., Nie Z., Wang L. Deep Learning Intervention for Health Care Challenges: Some Biomedical Domain Considerations. JMIR Mhealth Uhealth. 2019;7:e11966. doi: 10.2196/11966.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/11966</ArticleId><ArticleId IdType="pmc">PMC6696854</ArticleId><ArticleId IdType="pubmed">31376272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani A., Ochoa G. Google Trends in Infodemiology and Infoveillance: Methodology Framework. JMIR Public Health Surveill. 2019;5:e13439. doi: 10.2196/13439.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13439</ArticleId><ArticleId IdType="pmc">PMC6660120</ArticleId><ArticleId IdType="pubmed">31144671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.H., Kim B., Joo S., Shin S.Y., Cha H.S., Park Y.R. Why Do Data Users Say Health Care Data Are Difficult to Use? A Cross-Sectional Survey Study. J. Med. Internet Res. 2019;21:e14126. doi: 10.2196/14126.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14126</ArticleId><ArticleId IdType="pmc">PMC6701164</ArticleId><ArticleId IdType="pubmed">31389335</ArticleId></ArticleIdList></Reference><Reference><Citation>McPadden J., Durant T.J., Bunch D.R., Coppi A., Price N., Rodgerson K., Torre C.J., Jr., Byron W., Hsiao A.L., Krumholz H.M., et al. Health Care and Precision Medicine Research: Analysis of a Scalable Data Science Platform. J. Med Internet Res. 2019;21:e13043. doi: 10.2196/13043.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13043</ArticleId><ArticleId IdType="pmc">PMC6477571</ArticleId><ArticleId IdType="pubmed">30964441</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.I., Kim Y.J., Chung J.W., Kim K.O., Kim H., Park R.W., Park D.K. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform. 2020;8:e15124. doi: 10.2196/15124.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/15124</ArticleId><ArticleId IdType="pmc">PMC7191339</ArticleId><ArticleId IdType="pubmed">32293578</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue J.K., Vassar M.J., Lingsma H.F., Cooper S.R., Okonkwo D.O., Valadka A.B., Gordon W.A., Maas A.I., Mukherjee P., Yuh E.L., et al. Transforming research and clinical knowledge in traumatic brain injury pilot: Multicenter implementation of the common data elements for traumatic brain injury. J. Neurotrauma. 2013;30:1831&#x2013;1844. doi: 10.1089/neu.2013.2970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2013.2970</ArticleId><ArticleId IdType="pmc">PMC3814815</ArticleId><ArticleId IdType="pubmed">23815563</ArticleId></ArticleIdList></Reference><Reference><Citation>Amre D.K., Lambrette P., Law L., Krupoves A., Chotard V., Costea F., Grimard G., Israel D., Mack D., Seidman E.G. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn&#x2019;s Disease: A case-control study. Am. J. Gastroenterol. 2006;101:1005&#x2013;1011. doi: 10.1111/j.1572-0241.2006.00526.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00526.x</ArticleId><ArticleId IdType="pubmed">16573775</ArticleId></ArticleIdList></Reference><Reference><Citation>Panaccio M.P., Cummins G., Wentworth C., Lanes S., Reynolds S.L., Reynolds M.W., Miao R., Koren A. A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. Clin. Epidemiol. 2015;7:77&#x2013;90. doi: 10.2147/CLEP.S64936.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S64936</ArticleId><ArticleId IdType="pmc">PMC4296911</ArticleId><ArticleId IdType="pubmed">25624771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S.V., Lee J.H., Bove-Fenderson E.A., Park S.Y., Mannstadt M., Lee S. Incidence of Hypoparathyroidism After Thyroid Cancer Surgery in South Korea, 2007-2016. JAMA. 2019;322:2441&#x2013;2443. doi: 10.1001/jama.2019.19641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.19641</ArticleId><ArticleId IdType="pmc">PMC6990661</ArticleId><ArticleId IdType="pubmed">31860036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34673922</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-9537</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>23</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Blood advances</Title><ISOAbbreviation>Blood Adv</ISOAbbreviation></Journal><ArticleTitle>ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology.</ArticleTitle><Pagination><StartPage>5429</StartPage><EndPage>5438</EndPage><MedlinePgn>5429-5438</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2021005902</ELocationID><Abstract><AbstractText>The ASH Research Collaborative is a nonprofit organization established through the American Society of Hematology's commitment to patients with hematologic conditions and the science that informs clinical care and future therapies. The ASH Research Collaborative houses 2 major initiatives: (1) the Data Hub and (2) the Clinical Trials Network (CTN). The Data Hub is a program for hematologic diseases in which networks of clinical care delivery sites are developed in specific disease areas, with individual patient data contributed through electronic health record (EHR) integration, direct data entry through electronic data capture, and external data sources. Disease-specific data models are constructed so that data can be assembled into analytic datasets and used to enhance clinical care through dashboards and other mechanisms. Initial models have been built in multiple myeloma (MM) and sickle cell disease (SCD) using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) and Fast Healthcare Interoperability Resources (FHIR) standards. The Data Hub also provides a framework for development of disease-specific learning communities (LC) and testing of health care delivery strategies. The ASH Research Collaborative SCD CTN&#xa0;is a clinical trials accelerator that creates efficiencies in the execution of multicenter clinical trials and has been initially developed for SCD. Both components are operational, with the Data Hub actively aggregating source data and the SCD CTN&#xa0;reviewing study candidates. This manuscript describes processes involved in developing core features of the ASH Research Collaborative to inform the stakeholder community in preparation for expansion to additional disease areas.</AbstractText><CopyrightInformation>&#xa9; 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>U.S. Food and Drug Administration, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plovnick</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>The American Society of Hematology, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ASH Research Collaborative, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuberg</LastName><ForeName>Donna S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Breakthrough Healthcare, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Brendan K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>The University of Wisconsin School of Medicine and Public Health, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>ASH Research Collaborative, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrams</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexis A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-4961-8103</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University, Chicago, IL; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kluetz</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>U.S. Food and Drug Administration, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>U.S. Food and Drug Administration, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Donna</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4565-4556</Identifier><AffiliationInfo><Affiliation>U.S. Food and Drug Administration, Silver Spring, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gertzog</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The American Society of Hematology, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappas</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>U.S. Food and Drug Administration, Silver Spring, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Adv</MedlineTA><NlmUniqueID>101698425</NlmUniqueID><ISSNLinking>2473-9529</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006405" MajorTopicYN="Y">Hematology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080891" MajorTopicYN="Y">Learning Health System</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34673922</ArticleId><ArticleId IdType="pmc">PMC9153041</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021005902</ArticleId><ArticleId IdType="pii">477421</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Califf RM, Robb MA, Bindman AB, et al. . Transforming evidence generation to support health and health care decisions. N Engl J Med. 2016; 375(24):2395-2400.</Citation><ArticleIdList><ArticleId IdType="pubmed">27974039</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration. Real World Evidence. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>National Institutes of Health. All of Us Research Program. Available at: https://allofus.nih.gov. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127(7):810-819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4760087</ArticleId><ArticleId IdType="pubmed">26758919</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo A, Avet-Loiseau H, Oliva S, et al. . Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846284</ArticleId><ArticleId IdType="pubmed">26240224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.</Citation><ArticleIdList><ArticleId IdType="pubmed">27511158</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph NS, Kaufman JL, Dhodapkar MV, et al. . Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928-1937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587409</ArticleId><ArticleId IdType="pubmed">32298201</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR.. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10(2):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7026439</ArticleId><ArticleId IdType="pubmed">32066732</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala MA, Wildes TM.. Racial disparities in treatment use for multiple myeloma. Cancer. 2017;123(9):1590-1596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400674</ArticleId><ArticleId IdType="pubmed">28085188</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Medical Technology Policy (CMTP), Green Park Collaborative. Core Outcomes in Sickle Cell Disease. Available at: http://www.cmtpnet.org/green-park-collaborative/core-outcome-set-initiatives/corescd/. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>Bodenreider O, Nguyen D, Chiang P, et al. . The NLM value set authority center. Stud Health Technol Inform. 2013;192(1):1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300102</ArticleId><ArticleId IdType="pubmed">23920998</ArticleId></ArticleIdList></Reference><Reference><Citation>Phenotype Knowledge Base (PheKB). A knowledge base for discovering phenotypes from electronic medical records. Available at: https://phekb.org/. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>HealthIT.gov. United States Core Data for Interoperability (USCDI). Available at: https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>Lehne M, Sass J, Essenwanger A, Schepers J, Thun S.. Why digital medicine depends on interoperability. NPJ Digit Med. 2019;2(1):79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6702215</ArticleId><ArticleId IdType="pubmed">31453374</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterman TJ, Terry M, Miller RS.. Improving cancer data interoperability: the promise of the Minimal Common Oncology Data Elements (mCODE) initiative. JCO Clin Cancer Inform. 2020;4(4):993-1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713551</ArticleId><ArticleId IdType="pubmed">33136433</ArticleId></ArticleIdList></Reference><Reference><Citation>Krucoff MW, Sedrakyan A, Normand S-LT.. Bridging unmet medical device ecosystem needs with strategically coordinated registries networks. JAMA. 2015;314(16):1691-1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">26302152</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality. Inventory and prioritization of measures to support the growing effort in transparency using all-payer claims databases. Available at: https://www.ahrq.gov/data/apcd/backgroundrpt/intro.html#uses. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>The Commonwealth Fund. What can be done to improve all-payer claims databases? Available at: https://www.commonwealthfund.org/blog/2020/what-can-be-done-improve-all-payer-claims-databases. Accessed 18 November 2021.</Citation></Reference><Reference><Citation>Peters A, Sachs J, Porter J, Love D, Costello A.. The value of all-payer claims databases to states. N C Med J. 2014;75(3):211-213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24830498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack C, Christian J, Brinkley E, Warren EJ, Hall M, Dreyer N.. When context is hard to come by: external comparators and how to use them. Ther Innov Regul Sci. 2020;54(4):932-938.</Citation><ArticleIdList><ArticleId IdType="pubmed">32557316</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen LA, Aisner D, McGinnis JM, eds. Institute of Medicine Roundtable on Evidence-Based Medicine. The Learning Healthcare System: Workshop Summary. Washington, DC: National Academies Press; 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">21452449</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan-Curay J, Sacks L, Woodcock J.. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867-868.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook G, John Ashcroft A, Pratt G, et al. ; United Kingdom Myeloma Forum . Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190(2):e83-e86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280609</ArticleId><ArticleId IdType="pubmed">32438482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood WA, Neuberg DS, Thompson JC, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4(23):5966-5975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724912</ArticleId><ArticleId IdType="pubmed">33278301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34714250</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Transforming Anesthesia Data Into the Observational Medical Outcomes Partnership Common Data Model: Development and Usability Study.</ArticleTitle><Pagination><StartPage>e29259</StartPage><MedlinePgn>e29259</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e29259</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/29259</ELocationID><Abstract><AbstractText Label="BACKGROUND">Electronic health records (EHRs, such as those created by an anesthesia management system) generate a large amount of data that can notably be reused for clinical audits and scientific research. The sharing of these data and tools is generally affected by the lack of system interoperability. To overcome these issues, Observational Health Data Sciences and Informatics (OHDSI) developed the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) to standardize EHR data and promote large-scale observational and longitudinal research. Anesthesia data have not previously been mapped into the OMOP CDM.</AbstractText><AbstractText Label="OBJECTIVE">The primary objective was to transform anesthesia data into the OMOP CDM. The secondary objective was to provide vocabularies, queries, and dashboards that might promote the exploitation and sharing of anesthesia data through the CDM.</AbstractText><AbstractText Label="METHODS">Using our local anesthesia data warehouse, a group of 5 experts from 5 different medical centers identified local concepts related to anesthesia. The concepts were then matched with standard concepts in the OHDSI vocabularies. We performed structural mapping between the design of our local anesthesia data warehouse and the OMOP CDM tables and fields. To validate the implementation of anesthesia data into the OMOP CDM, we developed a set of queries and dashboards.</AbstractText><AbstractText Label="RESULTS">We identified 522 concepts related to anesthesia care. They were classified as demographics, units, measurements, operating room steps, drugs, periods of interest, and features. After semantic mapping, 353 (67.7%) of these anesthesia concepts were mapped to OHDSI concepts. Further, 169 (32.3%) concepts related to periods and features were added to the OHDSI vocabularies. Then, 8 OMOP CDM tables were implemented with anesthesia data and 2 new tables (EPISODE and FEATURE) were added to store secondarily computed data. We integrated data from 5,72,609 operations and provided the code for a set of 8 queries and 4 dashboards related to anesthesia care.</AbstractText><AbstractText Label="CONCLUSIONS">Generic data concerning demographics, drugs, units, measurements, and operating room steps were already available in OHDSI vocabularies. However, most of the intraoperative concepts (the duration of specific steps, an episode of hypotension, etc) were not present in OHDSI vocabularies. The OMOP mapping provided here enables anesthesia data reuse.</AbstractText><CopyrightInformation>&#xa9;Antoine Lamer, Osama Abou-Arab, Alexandre Bourgeois, Adrien Parrot, Benjamin Popoff, Jean-Baptiste Beuscart, Beno&#xee;t Tavernier, Mouhamed Djahoum Moussa. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 29.10.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9546-1808</Identifier><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Facult&#xe9; Ing&#xe9;nierie et Management de la Sant&#xe9;, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Arab</LastName><ForeName>Osama</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-3766-716X</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Amiens Picardie University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7877-3191</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Regional University Hospital of Nancy, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9862-1408</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popoff</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2854-0909</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuscart</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-0734-8371</Identifier><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavernier</LastName><ForeName>Beno&#xee;t</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8792-2865</Identifier><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Mouhamed Djahoum</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0003-3189-8119</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="Y">Anesthesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">anesthesia</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data reuse</Keyword><Keyword MajorTopicYN="N">data warehouse</Keyword><Keyword MajorTopicYN="N">reproducible research</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34714250</ArticleId><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="doi">10.2196/29259</ArticleId><ArticleId IdType="pii">v23i10e29259</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 Apr;58(4):323&#x2013;337. doi: 10.1016/j.jclinepi.2004.10.012.S0895-4356(04)00298-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.10.012</ArticleId><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart M, St&#xfc;rmer T, Glynn R, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010 Jun;48(6):S114&#x2013;S120. doi: 10.1097/MLR.0b013e3181dbebe3. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181dbebe3</ArticleId><ArticleId IdType="pmc">PMC4024462</ArticleId><ArticleId IdType="pubmed">20473199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayes LC, Horwitz RI, Feinstein AR. A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol. 1988 Sep;17(3):680&#x2013;685. doi: 10.1093/ije/17.3.680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/17.3.680</ArticleId><ArticleId IdType="pubmed">3272133</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Mallett S, Omar O, Yu L. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011 Sep 08;9:103. doi: 10.1186/1741-7015-9-103. 
 
1741-7015-9-103</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-9-103</ArticleId><ArticleId IdType="doi">10.1186/1741-7015-9-103</ArticleId><ArticleId IdType="pmc">PMC3180398</ArticleId><ArticleId IdType="pubmed">21902820</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Omar O, Shanyinde M, Yu L. A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods. J Clin Epidemiol. 2013 Mar;66(3):268&#x2013;277. doi: 10.1016/j.jclinepi.2012.06.020.S0895-4356(12)00263-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2012.06.020</ArticleId><ArticleId IdType="pubmed">23116690</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, Detmer DE. Toward a national framework for the secondary use of health data: an American Medical Informatics Association white paper. J Am Med Inform Assoc. 2007 Jan;14(1):1&#x2013;9. doi: 10.1197/jamia.M2273. 
 
M2273</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M2273</ArticleId><ArticleId IdType="pmc">PMC2329823</ArticleId><ArticleId IdType="pubmed">17077452</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 02;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.153/9/600</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376. 
 
amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J, Shah N, Reich C, Huser V, Schuemie M, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y-C, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F, Robbins S, Denton J, Nookala L, Meeker D, Ohno-Machado L, Matheny M. Creating a common Ddata model for comparative effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform. 2015;6(3):536&#x2013;547. doi: 10.4338/ACI-2014-12-CR-0121. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco FJ, Londhe A, Zhu V, Ryan PB. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;564. doi: 10.1093/jamia/ocu023. 
 
ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.  [2019-05-03].  
 https://www.ohdsi.org/
</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014 Jan;33(2):209&#x2013;218. doi: 10.1002/sim.5925. doi: 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J, Schuemie M, Suchard M, Ryan P, Rijnbeek P. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018 Aug;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032. 
 
4989437</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston SS, Morton JM, Kalsekar I, Ammann EM, Hsiao C, Reps J. Using machine learning applied to real-world healthcare data for predictive analytics: an applied example in bariatric surgery. Value Health. 2019 May;22(5):580&#x2013;586. doi: 10.1016/j.jval.2019.01.011.S1098-3015(19)30073-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.01.011</ArticleId><ArticleId IdType="pubmed">31104738</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition and DDLs for the OMOP common data model. OHDSI/CommonDataModel.  [2019-05-03].  
 https://github.com/OHDSI/CommonDataModel
.</Citation></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;696. doi: 10.1016/j.jbi.2012.05.002. 
 
S1532-0464(12)00069-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Schuemie M, Ryan P, Stang P. Seasonality in acute liver injury? findings in two health care claims databases. Drug Healthc Patient Saf. 2016 Mar;8:39&#x2013;48. doi: 10.2147/DHPS.S95399. doi: 10.2147/DHPS.S95399.dhps-8-039</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DHPS.S95399</ArticleId><ArticleId IdType="doi">10.2147/DHPS.S95399</ArticleId><ArticleId IdType="pmc">PMC4824282</ArticleId><ArticleId IdType="pubmed">27099532</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl A, Gall W. Feasibility of mapping Austrian health claims data to the OMOP common data model. J Med Syst. 2019 Sep;43(10):314. doi: 10.1007/s10916-019-1436-9. 
 
10.1007/s10916-019-1436-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M, Ficheur G, Chazard E, Beuscart J. Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform. 2020 Jan;11(1):13&#x2013;22. doi: 10.1055/s-0039-3402754. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurin NH, Lassalle R, Schuemie M, P&#xe9;nichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz-Perroteau C. Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): methodology of the ALCAPONE project. Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):993&#x2013;1000. doi: 10.1002/pds.4983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4983</ArticleId><ArticleId IdType="pubmed">32133717</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, Herrmann T, Haverkamp C, Horki P, Laufer J, Berger F, H&#xf6;ning G, Fritsch H, Sch&#xfc;ttler J, Ganslandt T, Prokosch H, Sedlmayr M. Towards Implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018 Jan;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang L, Miao S, Xu H, Yin Y, Zhu Y, Dai Z, Shan T, Jing S, Wang J, Zhang X, Huang Z, Wang Z, Guo J, Liu Y. Analysis of treatment pathways for three chronic diseases using OMOP CDM. J Med Syst. 2018 Nov;42(12):260. doi: 10.1007/s10916-018-1076-5. 
 
10.1007/s10916-018-1076-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-018-1076-5</ArticleId><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;58. doi: 10.4258/hir.2016.22.1.54. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec;31(30):4401&#x2013;4415. doi: 10.1002/sim.5620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5620</ArticleId><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, Reich CG, Schuemie MJ, Madigan D. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36 Suppl 1:S143&#x2013;S158. doi: 10.1007/s40264-013-0108-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0108-9</ArticleId><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, Suchard MA, Schuemie MJ, DeFalco FJ, Perotte A, Banda JM, Reich CG, Schilling LM, Matheny ME, Meeker D, Pratt N, Madigan D. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA. 2016 Jul;113(27):7329&#x2013;7336. doi: 10.1073/pnas.1510502113. 
 
1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fi&#x161;ter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D, OHDSI-COVID-19 consortium  Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020 Nov;2(11):e698&#x2013;e711. doi: 10.1016/S2665-9913(20)30276-9. 
 
S2665-9913(20)30276-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30276-9</ArticleId><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D, Dale L, Husain SA, Mohan S, Natarajan K. Content coverage evaluation of the OMOP vocabulary on the transplant domain focusing on concepts relevant for kidney transplant outcomes analysis. Appl Clin Inform. 2020 Aug;11(4):650&#x2013;658. doi: 10.1055/s-0040-1716528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1716528</ArticleId><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="pubmed">33027834</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael C, Sholle E, Wulff R, Roboz G, Campion T. Mapping local biospecimen records to the OMOP common data model. AMIA Jt Summits Transl Sci Proc. 2020 May;2020:422&#x2013;429. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233045</ArticleId><ArticleId IdType="pubmed">32477663</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner JL, Dymshyts D, Reich CG, Gurley MJ, Hochheiser H, Moldwin ZH, Belenkaya R, Williams AE, Yang PC. HemOnc: a new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J Biomed Inform. 2019 Aug;96:103239. doi: 10.1016/j.jbi.2019.103239. 
 
S1532-0464(19)30158-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103239</ArticleId><ArticleId IdType="pmc">PMC6697579</ArticleId><ArticleId IdType="pubmed">31238109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessler D, Sigl J, Kelley S, Chamoun N, Manberg P, Saager L, Kurz A, Greenwald S. Hospital stay and mortality are increased in patients having a "triple low" of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology. 2012 Jun;116(6):1195&#x2013;1203. doi: 10.1097/ALN.0b013e31825683dc. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e31825683dc</ArticleId><ArticleId IdType="doi">10.1097/ALN.0b013e31825683dc</ArticleId><ArticleId IdType="pubmed">22546967</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Devereaux P, Garg A, Kurz A, Turan A, Rodseth R, Cywinski J, Thabane LC, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507&#x2013;515. doi: 10.1097/ALN.0b013e3182a10e26. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3182a10e26</ArticleId><ArticleId IdType="doi">10.1097/ALN.0b013e3182a10e26</ArticleId><ArticleId IdType="pubmed">23835589</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu R, You J, Mascha E, Sessler D, Kasuya Y, Turan A. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg. 2013 Dec;117(6):1329&#x2013;1337. doi: 10.1213/ANE.0b013e318299a516.00000539-201312000-00012</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e318299a516</ArticleId><ArticleId IdType="pubmed">24257383</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MA, McCormick PJ, Lin HM, Hosseinian L, Fischer GW. Low intraoperative tidal volume ventilation with minimal PEEP is associated with increased mortality. Br J Anaesth. 2014 Jul;113(1):97&#x2013;108. doi: 10.1093/bja/aeu054. 
 
S0007-0912(17)31550-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu054</ArticleId><ArticleId IdType="pmc">PMC9585620</ArticleId><ArticleId IdType="pubmed">24623057</ArticleId></ArticleIdList></Reference><Reference><Citation>Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, Marret E, Beaussier M, Gutton C, Lefrant J, Allaouchiche B, Verzilli D, Leone M, De Jong A, Bazin JE, Pereira B, Jaber S. IMPROVE Study Group. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med. 2013 Aug;369(4):428&#x2013;37. doi: 10.1056/NEJMoa1301082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1301082</ArticleId><ArticleId IdType="pubmed">23902482</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden A, Grach M, Schneider I, Lazarovici H, Goldik Z, Pizov R. Implementation of an anesthesia information management system (AIMS) Eur J Anaesthesiol. 2005;22(Supplement 34):39&#x2013;40. doi: 10.1097/00003643-200505001-00138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003643-200505001-00138</ArticleId><ArticleId IdType="pubmed">16780614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Jeanne M, Marcilly R, Kipnis E, Schiro J, Logier R, Tavernier B. Methodology to automatically detect abnormal values of vital parameters in anesthesia time-series: proposal for an adaptable algorithm. Comput Methods Programs Biomed. 2016 Jun;129:160&#x2013;171. doi: 10.1016/j.cmpb.2016.01.004.S0169-2607(16)00005-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2016.01.004</ArticleId><ArticleId IdType="pubmed">26817405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Jeanne M, Ficheur G, Marcilly R. Automated data aggregation for time-series analysis: study case on anaesthesia data warehouse. Stud Health Technol Inform. 2016;221:102&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Jeanne M, Vallet B, Ditilyeu G, Delaby F, Tavernier B, Logier R. Development of an anesthesia data warehouse: preliminary results. IRBM. 2013 Dec;34(6):376&#x2013;378. doi: 10.1016/j.irbm.2013.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.irbm.2013.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapter 4 The common data model. The Book of OHDSI.  [2021-09-27].  
 https://ohdsi.github.io/TheBookOfOhdsi/
</Citation></Reference><Reference><Citation>Laurent G, Moussa MD, Cirenei C, Tavernier B, Marcilly R, Lamer A. Development, implementation and preliminary evaluation of clinical dashboards in a department of anesthesia. J Clin Monit Comput. 2020 May;35:617&#x2013;626. doi: 10.1007/s10877-020-00522-x. 
 
10.1007/s10877-020-00522-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10877-020-00522-x</ArticleId><ArticleId IdType="pmc">PMC7229430</ArticleId><ArticleId IdType="pubmed">32418147</ArticleId></ArticleIdList></Reference><Reference><Citation>WITH Queries (common table expressions) PostgreSQL Documentation.  [2021-09-27].  
 https://www.postgresql.org/docs/13/queries-with.html
.</Citation></Reference><Reference><Citation>Larmer A. omop_anesthesia. 2021.  [2021-09-29].  
 https://gitlab.com/antoinelamer/omop_anesthesia
.</Citation></Reference><Reference><Citation>Blaisure JC, Ceusters WM. Improving the 'fitness for purpose' of common data models through realism based ontology. AMIA Annu Symp Proc. 2017;2017:440&#x2013;447. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977618</ArticleId><ArticleId IdType="pubmed">29854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu B, Yoon E, Kim S, Lee S, Baek H, Yi S, Na HY, Kim J, Baek R, Hwang H, Yoo S. Transformation of pathology reports into the common data model with oncology module: use case for colon cancer. J Med Internet Res. 2020 Dec;22(12):e18526. doi: 10.2196/18526. 
 
v22i12e18526</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/18526</ArticleId><ArticleId IdType="pmc">PMC7758167</ArticleId><ArticleId IdType="pubmed">33295294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold P, Filiot A, Moussa M, Sobanski V, Ficheur G, Andrey P, Lamer A. A decentralized framework for biostatistics and privacy concerns. Stud Health Technol Inform. 2020 Nov;275:137&#x2013;141. doi: 10.3233/SHTI200710.SHTI200710</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200710</ArticleId><ArticleId IdType="pubmed">33227756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34727871</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases.</ArticleTitle><Pagination><StartPage>238</StartPage><MedlinePgn>238</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">238</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-021-01434-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) can be used to transform observational health data to a common format. CDM transformation allows for analysis across disparate databases for the generation of new, real-word evidence, which is especially important in rare disease where data are limited. Pulmonary hypertension (PH) is a progressive, life-threatening disease, with rare subgroups such as pulmonary arterial hypertension (PAH), for which generating real-world evidence is challenging. Our objective is to document the process and outcomes of transforming registry data in PH to the OMOP CDM, and highlight challenges and our potential solutions.</AbstractText><AbstractText Label="METHODS">Three observational studies were transformed from the Clinical Data Interchange Standards Consortium study data tabulation model (SDTM) to OMOP CDM format. OPUS was a prospective, multi-centre registry (2014-2020) and OrPHeUS was a retrospective, multi-centre chart review (2013-2017); both enrolled patients newly treated with macitentan in the US. EXPOSURE is a prospective, multi-centre cohort study (2017-ongoing) of patients newly treated with selexipag or any PAH-specific therapy in Europe and Canada. OMOP CDM version 5.3.1 with recent OMOP CDM vocabulary was used. Imputation rules were defined and applied for missing dates to avoid exclusion of data. Custom target concepts were introduced when existing concepts did not provide sufficient granularity.</AbstractText><AbstractText Label="RESULTS">Of the 6622 patients in the three registry studies, records were mapped for 6457. Custom target concepts were introduced for PAH subgroups (by combining SNOMED concepts or creating custom concepts) and World Health Organization functional class. Per the OMOP CDM convention, records about the absence of an event, or the lack of information, were not mapped. Excluding these non-event records, 4% (OPUS), 2% (OrPHeUS) and 1% (EXPOSURE) of records were not mapped.</AbstractText><AbstractText Label="CONCLUSIONS">SDTM data from three registries were transformed to the OMOP CDM with limited exclusion of data and deviation from the SDTM database content. Future researchers can apply our strategy and methods in different disease areas, with tailoring as necessary. Mapping registry data to the OMOP CDM facilitates more efficient collaborations between researchers and establishment of federated data networks, which is an unmet need in rare diseases.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biedermann</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlova</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solovyev</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetherill</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen-Cilag Ltd, High Wycombe, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didden</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland. edidden@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Data mapping</Keyword><Keyword MajorTopicYN="N">Observational data</Keyword><Keyword MajorTopicYN="N">Pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">Registry</Keyword></KeywordList><CoiStatement>PB was contracted by Actelion Pharmaceuticals Ltd., a Janssen Pharmaceutical Company of Johnson &amp; Johnson. RO, HS, MB, and EMD are employees of Actelion Pharmaceuticals Ltd., a Janssen Pharmaceutical Company of Johnson &amp; Johnson. GW is an employee of Janssen-Cilag Ltd. AD, AO, and PS are employees of Odysseus Data Services, Inc., a contract research organisation that performed the OMOP CDM ETL work as part of a commercial engagement with Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34727871</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pii">10.1186/s12874-021-01434-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases.&#xa0;Circ Cardiovasc Qual Outcomes.&#xa0;2019;12(5):e005095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665498</ArticleId><ArticleId IdType="pubmed">31109190</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ, Thompson L, O&#x2019;Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review.&#xa0;BMJ.&#xa0;2014;349:g6802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4242670</ArticleId><ArticleId IdType="pubmed">25422272</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikinheimo O, Bitzer J, Garc&#xed;a Rodr&#xed;guez L. Real-world research and the role of observational data in the field of gynaecology &#x2013; a practical review. Eur J Contracept Reprod Health Care. 2017;22(4):250&#x2013;259. doi: 10.1080/13625187.2017.1361528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13625187.2017.1361528</ArticleId><ArticleId IdType="pubmed">28817972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395&#x2013;405. doi: 10.1038/nrg3208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3208</ArticleId><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR. Adding value to the electronic health record through secondary use of data for quality assurance, research, and surveillance. Am J Managed Care. 2007;13(6 Part 1):277&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567224</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36(2):119&#x2013;134. doi: 10.1007/s40264-012-0009-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay M. 21st century cures Act. Hosp Pharm. 2017;52(4):264&#x2013;265. doi: 10.1310/hpx5204-264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/hpx5204-264</ArticleId><ArticleId IdType="pmc">PMC5424829</ArticleId><ArticleId IdType="pubmed">28515504</ArticleId></ArticleIdList></Reference><Reference><Citation>21st Century Cures Act, 2016. Available at: https://www.govinfo.gov/content/pkg/BILLS-114hr34enr/pdf/BILLS-114hr34enr.pdf [Last accessed November 2020]. In. United States of America.</Citation></Reference><Reference><Citation>21st Centry Cures 2.0: Concept Paper, 2020. Available at: https://degette.house.gov/sites/degette.house.gov/files/Cures%202.0%20Concept%20Paper_0.pdf [Last accessed November 2020]. In.</Citation></Reference><Reference><Citation>Cheng HG, Phillips MR. Secondary analysis of existing data: opportunities and implementation. Shanghai Arch Psychiatry. 2014;26(6):371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311114</ArticleId><ArticleId IdType="pubmed">25642115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration: FDA's Sentinel Initiative: Transforming how we monitor the safety of FDA-regulated products. 2019.</Citation></Reference><Reference><Citation>Food and Drug Administration, Sentinel Initiative. Available at: https://www.sentinelinitiative.org/ [Last accessed November 2020].</Citation></Reference><Reference><Citation>Oliveira JL, Lopes P, Nunes T, Campos D, Boyer S, Ahlberg E, van Mulligen EM, Kors JA, Singh B, Furlong LI, et al. The EU-ADR web platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf. 2013;22(5):459&#x2013;467. doi: 10.1002/pds.3375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3375</ArticleId><ArticleId IdType="pubmed">23208789</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Patient-Centered Clinical Research Network. PCORnet. Available at: https://pcornet.org/ [Last accessed November 2020].</Citation></Reference><Reference><Citation>Health Care Systems Research Network, HCSRN. Available at: http://www.hcsrn.org/en/ [Last accessed November 2020].</Citation></Reference><Reference><Citation>The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP): Guide on Methodological Standards in Pharmacoepidemiology (Revision 8). 2020.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics, OHDSI program. Available at: https://ohdsi.org/ [Last accessed November 2020].</Citation></Reference><Reference><Citation>Foundation for the National Institutes of Health, Observational Medical Outcomes Partnership (OMOP). Available at: https://fnih.org/what-we-do/major-completed-programs/omop [Last accessed November 2020].</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics, The Book of OHDSI, 2020. Available at: https://ohdsi.github.io/TheBookOfOhdsi/ [Last accessed November 2020]. In.</Citation></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Liyanage H, Liaw ST, Jonnagaddala J, Hinton W, de Lusignan S. Common data models (CDMs) to enhance international big data analytics: a diabetes use case to compare three CDMs. Stud Health Technol Inform. 2018;255:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30306907</ArticleId></ArticleIdList></Reference><Reference><Citation>SDTM [https://www.cdisc.org/standards/foundational/sdtm].</Citation></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945&#x2013;959. doi: 10.1007/s40264-014-0214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0214-3</ArticleId><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali&#xe8; N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2015;37(1):67&#x2013;119. doi: 10.1093/eurheartj/ehv317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv317</ArticleId><ArticleId IdType="pubmed">26320113</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen-van der Weide MC, CMW G, KCB R, Pontes C, Vives R, Sancho A, Nikolakopoulos S, Vermeulen E, van der Lee JH. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018;13(1):154. doi: 10.1186/s13023-018-0836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0836-0</ArticleId><ArticleId IdType="pmc">PMC6126025</ArticleId><ArticleId IdType="pubmed">30185208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacaze P, Millis N, Fookes M, Zurynski Y, Jaffe A, Bellgard M, et al. Rare disease registries: a call to action.&#xa0;Intern Med J.&#xa0;2017;47(9):1075&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco FJ, Londhe A, Zhu V, Ryan PB. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Washington, DC) 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer P, St&#xf6;hr MR, Gall H, Michel-Backofen A, Majeed RW. Data integration into OMOP CDM for heterogeneous clinical data collections via HL7 FHIR bundles and XSLT. Stud Health Technol Inform. 2020;270:138&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">32570362</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen ET, Dabelea DA, Praveen PA, Amutha A, Hockett CW, Isom SP, et al. Comparison of the incidence of diabetes in United States and Indian youth: an international harmonization of youth diabetes registries. Pediatr Diabetes. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748376</ArticleId><ArticleId IdType="pubmed">32196874</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley MJ, Golozar A, Dymshyts D, Miller RT, Williams AE, Ratwani S, Siapos A, Korsik V, Warner J, et al. Extending the OMOP common data model and standardized vocabularies to support observational Cancer research. JCO Clin Cancer Informatics. 2021;5:12&#x2013;20. doi: 10.1200/CCI.20.00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.20.00079</ArticleId><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(1):54&#x2013;58. doi: 10.4258/hir.2016.22.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Lee S, Cho SY, Park H, Jung S, Cho J, Yoon D, Park RW. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM) Stud Health Technol Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim HE, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care. 2013;51(8 Suppl 3):S45&#x2013;S52. doi: 10.1097/MLR.0b013e31829b1e0b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31829b1e0b</ArticleId><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>European Health Data Evidence Network. Available at: https://www.ehden.eu/ [Last Accessed June 2021].</Citation></Reference><Reference><Citation>OHDSI: Chapter 4. The Common Data Model. In: The Book of OHDSI: Observational Health Data Sciences and Informatics. edn.: OHDSI; 2020.</Citation></Reference><Reference><Citation>Belenkaya R, Gurley M, Dymshyts D, Araujo S, Williams A, Chen R, Reich C. Standardized observational Cancer research using the OMOP CDM oncology module. Stud Health Technol Inform. 2019;264:1831&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438365</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner JL, Dymshyts D, Reich CG, Gurley MJ, Hochheiser H, Moldwin ZH, Belenkaya R, Williams AE, Yang PC. HemOnc: a new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J Biomed Inform. 2019;96:103239. doi: 10.1016/j.jbi.2019.103239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103239</ArticleId><ArticleId IdType="pmc">PMC6697579</ArticleId><ArticleId IdType="pubmed">31238109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashkin DP, Amin AN, Kerwin EM. Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. Int J Chron Obstruct Pulmon Dis. 2020;15:1225&#x2013;1243. doi: 10.2147/COPD.S244942.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S244942</ArticleId><ArticleId IdType="pmc">PMC7276323</ArticleId><ArticleId IdType="pubmed">32581529</ArticleId></ArticleIdList></Reference><Reference><Citation>Negative information in OMOP CDM [https://forums.ohdsi.org/t/negative-information-in-omop-cdm/4923].</Citation></Reference><Reference><Citation>Proposal: Clinical trial data conventions for the OMOP Common Data Model [https://github.com/OHDSI/CommonDataModel/files/4948633/OMOP.clinical.trial.data.conventions.v1.0.July.2020.pdf].</Citation></Reference><Reference><Citation>ATLAS &#x2013; A unified interface for the OHDSI tools [https://www.ohdsi.org/atlas-a-unified-interface-for-the-ohdsi-tools/].</Citation></Reference><Reference><Citation>PHederation (Pulmonary Hypertension federated network of real-world assets) [https://portal.phederation.org/].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34773936</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2092-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Epidemiology and health</Title><ISOAbbreviation>Epidemiol Health</ISOAbbreviation></Journal><ArticleTitle>Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology.</ArticleTitle><Pagination><StartPage>e2021097</StartPage><MedlinePgn>e2021097</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2021097</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4178/epih.e2021097</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injections using data from the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with endophthalmitis that developed within 6 weeks after intravitreal anti-VEGF injections were identified in 3 large OMOP CDM databases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.64, 1.39, and 0.76, respectively. The annual incidence has remained below 5.00 per 10,000 injections since 2011 despite the increasing number of intravitreal anti-VEGF injections. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio, 3.17; p=0.021).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incidence of endophthalmitis after intravitreal anti-VEGF injections has stabilized since 2011 despite the explosive increase in anti-VEGF injections. The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mun</LastName><ForeName>Yongseok</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Da Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare Information &amp; Communications Technology (ICT) Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yoo-Ri</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kihwang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ji Hun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Young Gun</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Young Hoon</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Young-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Eye Hospital, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Se Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyu Hyung</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare Information &amp; Communications Technology (ICT) Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Dong-Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Eye Hospital, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Jun</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Korea Health Industry Development Institute</Agency><Country/></Grant><Grant><GrantID>HI19C0373</GrantID><Agency>Ministry of Health and Welfare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Epidemiol Health</MedlineTA><NlmUniqueID>101519472</NlmUniqueID><ISSNLinking>2092-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009885" MajorTopicYN="Y">Ophthalmology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-vascular endothelial growth factor</Keyword><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Endophthalmitis</Keyword><Keyword MajorTopicYN="N">Intravitreal injections</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare for this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>18</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34773936</ArticleId><ArticleId IdType="pmc">PMC8864106</ArticleId><ArticleId IdType="doi">10.4178/epih.e2021097</ArticleId><ArticleId IdType="pii">epih.e2021097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221&#x2013;e1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">29032195</ArticleId></ArticleIdList></Reference><Reference><Citation>Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye (Lond) 2010;24:717&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazari H, Modarres M, Parvaresh MM, Ghasemi Falavarjani K. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;248:1713&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">20582706</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) Br J Ophthalmol. 2014;98:1144&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145443</ArticleId><ArticleId IdType="pubmed">25136079</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA) Ophthalmologica. 2017;237:185&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">28423385</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA) Ophthalmologica. 2019;242:123&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">31412332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyall DA, Tey A, Foot B, Roxburgh ST, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522835</ArticleId><ArticleId IdType="pubmed">23060022</ArticleId></ArticleIdList></Reference><Reference><Citation>Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709385</ArticleId><ArticleId IdType="pubmed">23722722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018;12:1625&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124467</ArticleId><ArticleId IdType="pubmed">30214147</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudin F, Benzenine E, Mariet AS, Bron AM, Daien V, Korobelnik JF, et al. Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France. JAMA Ophthalmol. 2018;136:1352&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583044</ArticleId><ArticleId IdType="pubmed">30242325</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) The book of OHDSI.  [cited 2020 Sep 22]. Available from:  https://ohdsi.github.io/TheBookOfOhdsi.</Citation></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED International. SNOMED CT.  [cited 2020 Sep 23]. Available from:  https://www.snomed.org/snomed-ct/get-snomed.</Citation></Reference><Reference><Citation>Regenstrief Institute. LOINC.  [cited 2020 Sep 23]. Available from:  https://loinc.org.</Citation></Reference><Reference><Citation>National Library of Medicine. RxNorm.  [cited 2020 Sep 23]. Available from:  https://www.nlm.nih.gov/research/umls/rxnorm/index.html.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) OHDSI THEMIS.  [cited 2020 Sep 23]. Available from:  https://github.com/OHDSI/Themis.</Citation></Reference><Reference><Citation>Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET, Jr, D&#x2bc;Amico DJ, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34 Suppl 12:S1&#x2013;S18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25489719</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth DB, Flynn HW., Jr Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy. Surv Ophthalmol. 1997;41:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">9163836</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: management and visual outcomes. Ophthalmology. 2018;125:1279&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">29477689</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossarps D, Bron AM, Koehrer P, Aho-Gl&#xe9;l&#xe9; LS, Creuzot-Garcher C; FRCR net (FRenCh Retina specialists net) Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892127</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderBeek BL, Bonaffini SG, Ma L. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol. 2015;133:1159&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600036</ArticleId><ArticleId IdType="pubmed">26270251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Woo SJ, Park KH, Kim JH, Song JH, Park KU, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond) 2010;24:226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407833</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020;55:286&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">32204888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293&#x2013;2297.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics Initiative. JAMA Netw Open. 2018;1:e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SA, Kim H, Kim S, Yoo S, Yi S, Jeon Y, et al. Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model. Epilepsia. 2020;61:610&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">32162687</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad R, Zhang W, Bjarnd&#xf3;ttir M, Proa&#xf1;o R. Key considerations when using health insurance claims data in advanced data analyses: an experience report. Health Syst (Basingstoke) 2019;9:317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738306</ArticleId><ArticleId IdType="pubmed">33354323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795073</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Development of a FHIR Layer on Top of the OMOP Common Data Model for the CAPABLE Project.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>29</EndPage><MedlinePgn>28-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210804</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gabetta</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloni</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polce</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzola</LastName><ForeName>Giordano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parimbelli</LastName><ForeName>Enea</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbarini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="Y">Health Information Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="Y">Health Level Seven</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">API</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">HL7 FHIR</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795073</ArticleId><ArticleId IdType="doi">10.3233/SHTI210804</ArticleId><ArticleId IdType="pii">SHTI210804</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795074</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Automatic Data Transfer from OMOP-CDM to REDCap: A Semantically-Enriched Framework.</ArticleTitle><Pagination><StartPage>30</StartPage><EndPage>31</EndPage><MedlinePgn>30-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210805</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girani</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabetta</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloni</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuppia</LastName><ForeName>Morena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchi</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbarini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EDC</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">REDCap</Keyword><Keyword MajorTopicYN="N">Real World Data</Keyword><Keyword MajorTopicYN="N">eCRF</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795074</ArticleId><ArticleId IdType="doi">10.3233/SHTI210805</ArticleId><ArticleId IdType="pii">SHTI210805</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795082</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Transfer of Clinical Drug Data to a Research Infrastructure on OMOP - A FAIR Concept.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>67</EndPage><MedlinePgn>63-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210815</ELocationID><Abstract><AbstractText>Generating evidence based on real-world data is gaining importance in research not least since the COVID-19 pandemic. The Common Data Model of Observational Medical Outcomes Partnership (OMOP) is a research infrastructure that implements FAIR principles. Although the transfer of German claim data to OMOP is already implemented, drug data is an open issue. This paper provides a concept to prepare electronic health record (EHR) drug data for the transfer to OMOP based on requirements analysis and descriptive statistics for profiling EHR data developed by an interdisciplinary team and also covers data quality issues. The concept not only ensures FAIR principles for research, but provides the foundation for German drug data to OMOP transfer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Mich&#xe9;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">FAIR</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">drug administration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795082</ArticleId><ArticleId IdType="doi">10.3233/SHTI210815</ArticleId><ArticleId IdType="pii">SHTI210815</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795096</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Making EHRs Reusable: A Common Framework of Data Operations.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>133</EndPage><MedlinePgn>129-133</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210831</ELocationID><Abstract><AbstractText>Reuse of EHRs requires data extraction and transformation processes are based on homogeneous and formalized operations in order to make them understandable, reproducible and auditable. This work aims to define a common framework of data operations for obtaining EHR-derived datasets for secondary use. Thus, 21 operations were identified from different data-driven projects of a 1,300-beds tertiary Hospital. Then, ISO 13606 standard was used to formalize them. This work is the starting point to homogenize ETL processes for the reuse of EHRs, applicable to any condition and organization. In future studies, defined data operations will be implemented and validated in projects of different purposes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pedrera</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ETSI Telecomunicaci&#xf3;n, Universidad Polit&#xe9;cnica de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Noelia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernal</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Data reusability</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">FAIR</Keyword><Keyword MajorTopicYN="N">ISARIC</Keyword><Keyword MajorTopicYN="N">ISO 13606</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Real World Data</Keyword><Keyword MajorTopicYN="N">Semantics</Keyword><Keyword MajorTopicYN="N">Standards</Keyword><Keyword MajorTopicYN="N">i2b2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795096</ArticleId><ArticleId IdType="doi">10.3233/SHTI210831</ArticleId><ArticleId IdType="pii">SHTI210831</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34831777</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>The Prescription of Drug Ontology 2.0 (PDRO): More Than the Sum of Its Parts.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12025</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph182212025</ELocationID><Abstract><AbstractText>While drugs and related products have profoundly changed the lives of people around the world, ongoing challenges remain, including inappropriate use of a drug product. Inappropriate uses can be explained in part by ambiguous or incomplete information, for example, missing reasons for treatments, ambiguous information on how to take a medication, or lack of information on medication-related events outside the health care system. In order to fully assess the situation, data from multiple systems (electronic medical records, pharmacy and radiology information systems, laboratory management systems, etc.) from multiple organizations (outpatient clinics, hospitals, long-term care facilities, laboratories, pharmacies, registries, governments) on a large geographical scale is needed. Formal knowledge models like ontologies can help address such an information integration challenge. Existing approaches like the Observational Medical Outcomes Partnership are discussed and contrasted with the use of ontologies and systems using them for data integration. The PRescription Drug Ontology 2.0 (PDRO 2.0) is then presented and entities that are paramount in addressing this problematic are described. Finally, the benefits of using PDRO are discussed through a series of exemplar situation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ethier</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0001-9408-0109</Identifier><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyer</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabry</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRIT-Institut de Recherche en Informatique de Toulouse (CNRS), 31400 Toulouse, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010594" MajorTopicYN="Y">Pharmacies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="Y">Prescription Drugs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data annotation</Keyword><Keyword MajorTopicYN="N">drug ontology</Keyword><Keyword MajorTopicYN="N">drug prescription</Keyword><Keyword MajorTopicYN="N">medication management</Keyword><Keyword MajorTopicYN="N">ontology development</Keyword><Keyword MajorTopicYN="N">optimization of prescription</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34831777</ArticleId><ArticleId IdType="pmc">PMC8619589</ArticleId><ArticleId IdType="doi">10.3390/ijerph182212025</ArticleId><ArticleId IdType="pii">ijerph182212025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M., Perazella M.A. NSAIDs in CKD: Are They Safe? Am. J. Kidney Dis. 2020;76:546&#x2013;557. doi: 10.1053/j.ajkd.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2020.03.023</ArticleId><ArticleId IdType="pubmed">32479922</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara N., Ibrahim A., Satti Z., Ibrahim M., Kiernan T.J. Acute Pericarditis: A Review of Current Diagnostic and Management Guidelines. Future Cardiol. 2019;15:119&#x2013;126. doi: 10.2217/fca-2017-0102.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca-2017-0102</ArticleId><ArticleId IdType="pubmed">30848669</ArticleId></ArticleIdList></Reference><Reference><Citation>Codes Justificatifs|RAMQ.  [(accessed on 29 September 2021)]; Available online:  https://www.ramq.gouv.qc.ca/fr/professionnels/optometristes/medicaments/nps/Pages/modalites-application-codes-justificatifs.aspx.</Citation></Reference><Reference><Citation>Wittich C.M., Burkle C.M., Lanier W.L. Medication Errors: An Overview for Clinicians. Mayo Clin. Proc. 2014;89:1116&#x2013;1125. doi: 10.1016/j.mayocp.2014.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2014.05.007</ArticleId><ArticleId IdType="pubmed">24981217</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws M.B., Lee Y., Taubin T., Rogers W.H., Wilson I.B. Factors Associated with Patient Recall of Key Information in Ambulatory Specialty Care Visits: Results of an Innovative Methodology. PLoS ONE. 2018;13:e0191940. doi: 10.1371/journal.pone.0191940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191940</ArticleId><ArticleId IdType="pmc">PMC5794108</ArticleId><ArticleId IdType="pubmed">29389994</ArticleId></ArticleIdList></Reference><Reference><Citation>Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, Predictors, and Outcome of Thrombosis after Successful Implantation of Drug-Eluting Stents. JAMA. 2005;293:2126&#x2013;2130. doi: 10.1001/jama.293.17.2126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.293.17.2126</ArticleId><ArticleId IdType="pubmed">15870416</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacio S., Hart R.G., Pearce L.A., Benavente O.R. Effect of Addition of Clopidogrel to Aspirin on Mortality Systematic Review of Randomized Trials. Stroke J. Cereb. Circ. 2012;43:2157&#x2013;2162. doi: 10.1161/STROKEAHA.112.656173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.656173</ArticleId><ArticleId IdType="pmc">PMC3970708</ArticleId><ArticleId IdType="pubmed">22826359</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP  CDM v5.4.  [(accessed on 30 September 2021)].  Available online:  http://ohdsi.github.io/CommonDataModel/cdm54.html#DEVICE_EXPOSURE.</Citation></Reference><Reference><Citation>Arp R., Smith B., Spear A.D. Building Ontologies with Basic Formal Ontology. MIT Press; Cambridge, CA, USA: 2015.</Citation></Reference><Reference><Citation>Klann J.G., Joss M.A.H., Embree K., Murphy S.N. Data Model Harmonization for the All of Us Research Program: Transforming I2b2 Data into the OMOP Common Data Model. PLoS ONE. 2019;14:e0212463. doi: 10.1371/journal.pone.0212463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S.N., Mendis M.E., Berkowitz D.A., Kohane I., Chueh H.C. AMIA Annual Symposium Proceedings. American Medical Informatics Association; Bethesda, MD, USA: 2006. Integration of Clinical and Genetic Data in the I2b2 Architecture; p. 1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839291</ArticleId><ArticleId IdType="pubmed">17238659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceusters W., Blaisure J. A Realism-Based View on Counts in OMOP&#x2019;s Common Data Model. Stud. Health Technol. Inform. 2017;237:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479543</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7 HL7 Standards Product Brief&#x2014;FHIR&#xae; R4 (HL7 Fast Healthcare Interoperability Resources, Release 4)|HL7 International.  [(accessed on 7 January 2020)].  Available online:  https://www.hl7.org/implement/standards/product_brief.cfm?product_id=491.</Citation></Reference><Reference><Citation>Patient&#x2014;FHIR v1.0.2.  [(accessed on 29 September 2021)].  Available online:  http://hl7.org/fhir/dstu2/patient-definitions.html.</Citation></Reference><Reference><Citation>Lau F., Antonio M., Davison K., Queen R., Devor A. A Rapid Review of Gender, Sex, and Sexual Orientation Documentation in Electronic Health Records. J. Am. Med. Inform. Assoc. JAMIA. 2020;27:1774&#x2013;1783. doi: 10.1093/jamia/ocaa158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa158</ArticleId><ArticleId IdType="pmc">PMC7671624</ArticleId><ArticleId IdType="pubmed">32935124</ArticleId></ArticleIdList></Reference><Reference><Citation>OWL  2 Web Ontology Language Document Overview (Second Edition)  [(accessed on 29 September 2021)].  Available online:  https://www.w3.org/TR/owl-overview/</Citation></Reference><Reference><Citation>Smith B., Ashburner M., Rosse C., Bard J., Bug W., Ceusters W., Goldberg L.J., Eilbeck K., Ireland A., Mungall C.J., et al. The OBO Foundry: Coordinated Evolution of Ontologies to Support Biomedical Data Integration. Nat. Biotechnol. 2007;25:1251. doi: 10.1038/nbt1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1346</ArticleId><ArticleId IdType="pmc">PMC2814061</ArticleId><ArticleId IdType="pubmed">17989687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene Ontology: Tool for the Unification of Biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider T., &#x160;imkus M. Ontologies and Data Management: A Brief Survey. KI-K&#xfc;nstl. Intell. 2020;34:329&#x2013;353. doi: 10.1007/s13218-020-00686-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13218-020-00686-3</ArticleId><ArticleId IdType="pmc">PMC7497697</ArticleId><ArticleId IdType="pubmed">32999532</ArticleId></ArticleIdList></Reference><Reference><Citation>Towards a New Generation of Ontology Based Data Access|Www.Semantic-Web-Journal.Net.  [(accessed on 30 September 2021)].  Available online:  http://semantic-web-journal.net/content/towards-new-generation-ontology-based-data-access.</Citation></Reference><Reference><Citation>Ethier J.-F., Dameron O., Curcin V., McGilchrist M.M., Verheij R.A., Arvanitis T.N., Taweel A., Delaney B.C., Burgun A. A Unified Structural/Terminological Interoperability Framework Based on LexEVS: Application to TRANSFoRm. J. Am. Med. Inform. Assoc. 2013;20:986&#x2013;994. doi: 10.1136/amiajnl-2012-001312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001312</ArticleId><ArticleId IdType="pmc">PMC3756256</ArticleId><ArticleId IdType="pubmed">23571850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethier J.-F., Curcin V., Barton A., McGilchrist M.M., Bastiaens H., Andreasson A., Rossiter J., Zhao L., Arvanitis T.N., Taweel A., et al. Clinical Data Integration Model. Core Interoperability Ontology for Research Using Primary Care Data. Methods Inf. Med. 2015;54:16&#x2013;23. doi: 10.3414/ME13-02-0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME13-02-0024</ArticleId><ArticleId IdType="pubmed">24954896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecarot T., Fraikin B., Lavoie L., McGilchrist M., Ethier J.-F. A Sensitive Data Access Model in Support of Learning Health Systems. Computers. 2021;10:25. doi: 10.3390/computers10030025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/computers10030025</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton A., Fabry P., Ethier J.-F. A Classification of Instructions in Drug Prescriptions and Pharmacist Documents; Proceedings of the 10th International Conference on Biomedical Ontology (ICBO 2019); Buffalo, NY, USA. 30 July&#x2013;2 August 2019; pp. 1&#x2013;7.</Citation></Reference><Reference><Citation>Ethier J.-F., Taseen R., Lavoie L., Barton A. Improving the Semantics of Drug Prescriptions with a Realist Ontology; Proceedings of the International Conference on Biomedical Ontology and BioCreative (ICBO BioCreative 2016); Corvallis, OR, USA. 1&#x2013;4 August 2016;  [(accessed on 30 September 2021)].  Available online:  CEUR-ws.org.</Citation></Reference><Reference><Citation>Barton A., Fabry P., Lavoie L., Ethier J.-F. LABO: An Ontology for Laboratory Test Prescription and Reporting; Proceedings of the Joint Ontology Workshops 2019 Episode V: The Styrian Autumn of Ontology; Graz, Austria. 23&#x2013;25 September 2019.</Citation></Reference><Reference><Citation>Smith B. Basic Formal Ontology 2.0: Specification and User&#x2019;s Guide. 2015.  [(accessed on 30 September 2021)]. p. 100. Available online:  https://github.com/BFO-ontology/BFO/raw/master/docs/bfo2-reference/BFO2-Reference.pdf.</Citation></Reference><Reference><Citation>Ceusters W., Smith B. Aboutness: Towards Foundations for the Information Artifact Ontology; Proceedings of the Sixth International Conference on Biomedical Ontology (ICBO); Lisbon, Portugal. 27&#x2013;30 July 2015; pp. 1&#x2013;5.</Citation></Reference><Reference><Citation>Bandrowski A., Brinkman R., Brochhausen M., Brush M.H., Bug B., Chibucos M.C., Clancy K., Courtot M., Derom D., Dumontier M., et al. The Ontology for Biomedical Investigations. PLoS ONE. 2016;11:e0154556. doi: 10.1371/journal.pone.0154556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154556</ArticleId><ArticleId IdType="pmc">PMC4851331</ArticleId><ArticleId IdType="pubmed">27128319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq R.A., Vashisht R., Sinha A., Scherbak Y. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2021. Medication Dispensing Errors And Prevention.</Citation><ArticleIdList><ArticleId IdType="pubmed">30085607</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabry P., Barton A., Ethier J.-F. QUESTO&#x2014;An Ontology for Questionnaires; Proceedings of the 11th International Conference on Biomedical Ontologies, ICBO 2020; Bolzano, Italy. 17 September 2020; Bolzano, Italy: CEUR-WS.org; 2020.</Citation></Reference><Reference><Citation>Scheuermann R.H., Ceusters W., Smith B. Toward an Ontological Treatment of Disease and Diagnosis. Summit Transl. Bioinform. 2009;2009:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041577</ArticleId><ArticleId IdType="pubmed">21347182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Combs K., Downs J., Tillman F., III Medication Adherence: The Elephant in the Room.  [(accessed on 30 September 2021)].  Available online:  https://www.uspharmacist.com/article/medication-adherence-the-elephant-in-the-room.</Citation></Reference><Reference><Citation>Prescribed and Dispensed Drugs in the DRUG_EXPOSURE Tabl&#x2014;Implementers.  [(accessed on 30 September 2021)].  Available online:  https://forums.ohdsi.org/t/prescribed-and-dispensed-drugs-in-the-drug-exposure-table/10997/2.</Citation></Reference><Reference><Citation>Cossette B., Taseen R., Roy-Petit J., Villemure M.-P., Grondin M., Ricard G., Goyer F., Blanchard C., Joly-Mischlich T., &#xc9;thier J.-F. A Pharmacist-Physician Intervention Model Using a Computerized Alert System to Reduce High-Risk Medication Use in Primary Care. Eur. J. Clin. Pharmacol. 2019;75:1017&#x2013;1023. doi: 10.1007/s00228-019-02660-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-019-02660-x</ArticleId><ArticleId IdType="pubmed">30899989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau W.C., Welch T.D., Shields T., Rubenfire M., Tantry U.S., Gurbel P.A. The Effect of St John&#x2019;s Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. J. Cardiovasc. Pharmacol. 2011;57:86&#x2013;93. doi: 10.1097/FJC.0b013e3181ffe8d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0b013e3181ffe8d0</ArticleId><ArticleId IdType="pubmed">20980920</ArticleId></ArticleIdList></Reference><Reference><Citation>Claire Van Hout M. &#x201c;Doctor Shopping and Pharmacy Hopping&#x201d;: Practice Innovations Relating to Codeine. Drugs Alcohol Today. 2014;14:219&#x2013;234. doi: 10.1108/DAT-03-2014-0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1108/DAT-03-2014-0014</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcher C., Harris D.R., Park C., Strickler G.K., Talbert J., Freeman P.R. &#x201c;Doctor and Pharmacy Shopping&#x201d;: A Fading Signal for Prescription Opioid Use Monitoring? Drug Alcohol Depend. 2021;221:108618. doi: 10.1016/j.drugalcdep.2021.108618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2021.108618</ArticleId><ArticleId IdType="pmc">PMC8026641</ArticleId><ArticleId IdType="pubmed">33677354</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttigieg P.L., Pafilis E., Lewis S.E., Schildhauer M.P., Walls R.L., Mungall C.J. The Environment Ontology in 2016: Bridging Domains with Increased Scope, Semantic Density, and Interoperation. J. Biomed. Semant. 2016;7:57. doi: 10.1186/s13326-016-0097-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-016-0097-6</ArticleId><ArticleId IdType="pmc">PMC5035502</ArticleId><ArticleId IdType="pubmed">27664130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34860667</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Open-source Software Sustainability Models: Initial White Paper From the Informatics Technology for Cancer Research Sustainability and Industry Partnership Working Group.</ArticleTitle><Pagination><StartPage>e20028</StartPage><MedlinePgn>e20028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/20028</ELocationID><Abstract><AbstractText Label="BACKGROUND">The National Cancer Institute Informatics Technology for Cancer Research (ITCR) program provides a series of funding mechanisms to create an ecosystem of open-source software (OSS) that serves the needs of cancer research. As the ITCR ecosystem substantially grows, it faces the challenge of the long-term sustainability of the software being developed by ITCR grantees. To address this challenge, the ITCR sustainability and industry partnership working group (SIP-WG) was convened in 2019.</AbstractText><AbstractText Label="OBJECTIVE">The charter of the SIP-WG is to investigate options to enhance the long-term sustainability of the OSS being developed by ITCR, in part by developing a collection of business model archetypes that can serve as sustainability plans for ITCR OSS development initiatives. The working group assembled models from the ITCR program, from other studies, and from the engagement of its extensive network of relationships with other organizations (eg, Chan Zuckerberg Initiative, Open Source Initiative, and Software Sustainability Institute) in support of this objective.</AbstractText><AbstractText Label="METHODS">This paper reviews the existing sustainability models and describes 10 OSS use cases disseminated by the SIP-WG and others, including 3D Slicer, Bioconductor, Cytoscape, Globus, i2b2 (Informatics for Integrating Biology and the Bedside) and tranSMART, Insight Toolkit, Linux, Observational Health Data Sciences and Informatics tools, R, and REDCap (Research Electronic Data Capture), in 10 sustainability aspects: governance, documentation, code quality, support, ecosystem collaboration, security, legal, finance, marketing, and dependency hygiene.</AbstractText><AbstractText Label="RESULTS">Information available to the public reveals that all 10 OSS have effective governance, comprehensive documentation, high code quality, reliable dependency hygiene, strong user and developer support, and active marketing. These OSS include a variety of licensing models (eg, general public license version 2, general public license version 3, Berkeley Software Distribution, and Apache 3) and financial models (eg, federal research funding, industry and membership support, and commercial support). However, detailed information on ecosystem collaboration and security is not publicly provided by most OSS.</AbstractText><AbstractText Label="CONCLUSIONS">We recommend 6 essential attributes for research software: alignment with unmet scientific needs, a dedicated development team, a vibrant user community, a feasible licensing model, a sustainable financial model, and effective product management. We also stress important actions to be considered in future ITCR activities that involve the discussion of the sustainability and licensing models for ITCR OSS, the establishment of a central library, the allocation of consulting resources to code quality control, ecosystem collaboration, security, and dependency hygiene.</AbstractText><CopyrightInformation>&#xa9;Ye Ye, Seemran Barapatre, Michael K Davis, Keith O Elliston, Christos Davatzikos, Andrey Fedorov, Jean-Christophe Fillion-Robin, Ian Foster, John R Gilbertson, Andras Lasso, James V Miller, Martin Morgan, Steve Pieper, Brigitte E Raumann, Brion D Sarachan, Guergana Savova, Jonathan C Silverstein, Donald P Taylor, Joyce B Zelnis, Guo-Qiang Zhang, Jamie Cuticchia, Michael J Becich. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 02.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1138-9846</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barapatre</LastName><ForeName>Seemran</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8112-6147</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-7754-3957</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliston</LastName><ForeName>Keith O</ForeName><Initials>KO</Initials><Identifier Source="ORCID">0000-0002-9110-9233</Identifier><AffiliationInfo><Affiliation>Axiomedix, Inc., Bedford, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PHEMI Systems Corp., Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>tranSMART foundation, Wakefield, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1025-8561</Identifier><AffiliationInfo><Affiliation>Department of Radiology, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedorov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4806-9413</Identifier><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fillion-Robin</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-9688-8950</Identifier><AffiliationInfo><Affiliation>Kitware Inc., Clifton Park, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Ian</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2129-5269</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, University of Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbertson</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-9679-8261</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasso</LastName><ForeName>Andras</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4220-7064</Identifier><AffiliationInfo><Affiliation>The Perk Lab for Percutaneous Surgery, School of Computing, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>James V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0003-1877-7881</Identifier><AffiliationInfo><Affiliation>GE Global Research, Niskayuna, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5874-8148</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieper</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4193-9578</Identifier><AffiliationInfo><Affiliation>Isomics Inc., Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raumann</LastName><ForeName>Brigitte E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-3067-0366</Identifier><AffiliationInfo><Affiliation>Globus, University of Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarachan</LastName><ForeName>Brion D</ForeName><Initials>BD</Initials><Identifier Source="ORCID">0000-0002-6266-799X</Identifier><AffiliationInfo><Affiliation>GE Global Research, Niskayuna, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savova</LastName><ForeName>Guergana</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5887-200X</Identifier><AffiliationInfo><Affiliation>Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-9252-6039</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Donald P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0002-2146-8804</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelnis</LastName><ForeName>Joyce B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5785-968X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guo-Qiang</ForeName><Initials>GQ</Initials><Identifier Source="ORCID">0000-0002-3663-1109</Identifier><AffiliationInfo><Affiliation>The University of Texas Health Science Center at Houston, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuticchia</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2447-5161</Identifier><AffiliationInfo><Affiliation>Axiomedix, Inc., Bedford, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5998-8074</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 CA180918</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR002383</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 LM013383</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA180996</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OH009077</GrantID><Acronym>OH</Acronym><Agency>NIOSH CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA231904</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA204826</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015902</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA248010</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017753" MajorTopicYN="Y">Ecosystem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048088" MajorTopicYN="N">Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer informatics</Keyword><Keyword MajorTopicYN="N">financial model</Keyword><Keyword MajorTopicYN="N">licensing model</Keyword><Keyword MajorTopicYN="N">open-source software</Keyword><Keyword MajorTopicYN="N">product management</Keyword><Keyword MajorTopicYN="N">sustainability</Keyword></KeywordList><CoiStatement>Conflicts of Interest: KOE is a shareholder or investor in Ingentium, Inc; Axiomedix, Inc; Seneca Creek Research LLC; and Trazend, Inc; KOE holds advisory roles with Open-Source Pharma Foundation nongovernmental organization and i2b2 tranSMART Foundation and currently serves as the chief executive officer of PHEMI Systems Corp. MJB is a founder and has equity (stock) in SpIntellx, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>3</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34860667</ArticleId><ArticleId IdType="pmc">PMC8686402</ArticleId><ArticleId IdType="doi">10.2196/20028</ArticleId><ArticleId IdType="pii">v23i12e20028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>About ITCR. National Cancer Institute Informatics Technology for Cancer Research. 2019.  [2021-11-09].  
 https://itcr.cancer.gov/about-itcr
.</Citation></Reference><Reference><Citation>Funding opportunities. National Cancer Institute Informatics Technology for Cancer Research. 2019.  [2021-11-09].  
 https://itcr.cancer.gov/funding-opportunities
.</Citation></Reference><Reference><Citation>Pratt D, Chen J, Pillich R, Rynkov V, Gary A, Demchak B, Ideker T. NDEx 2.0: a clearinghouse for research on cancer pathways. Cancer Res. 2017 Nov 01;77(21):e58&#x2013;61. doi: 10.1158/0008-5472.CAN-17-0606. 
 
77/21/e58</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0606</ArticleId><ArticleId IdType="pmc">PMC5679399</ArticleId><ArticleId IdType="pubmed">29092941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillich R. ITCR Connectivity Map.  [2020-10-22].  
 http://www.ndexbio.org/#/network/04c0a7e8-af92-11e7-94d3-0ac135e8bacf
.</Citation></Reference><Reference><Citation>Information Technology for Cancer Research (ITCR) initiative. NCI Hub. 2019.  [2021-11-09].  
 https://ncihub.org/groups/itcr/sustainability_and_industry_partnership_wg
.</Citation></Reference><Reference><Citation>Kuchinke W, Ohmann C, Stenzhorn H, Anguista A, Sfakianakis S, Graf N, Demotes J. Ensuring sustainability of software tools and services by cooperation with a research infrastructure. Per Med. 2016 Jan;13(1):43&#x2013;55. doi: 10.2217/pme.15.43. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pme.15.43?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.2217/pme.15.43</ArticleId><ArticleId IdType="pubmed">29749867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang V, Mills H, Newhouse S. Form open source to long term sustainability: review of business models and case studies. Proceedings of the UK e-Science All Hands Meeting 2007; Proceedings of the UK e-Science All Hands Meeting 2007; Sep 10-13, 2007; Nottingham UK. 2007.</Citation></Reference><Reference><Citation>Aartsen W, Peeters P, Wagers S, Williams-Jones B. Getting digital assets from public-private partnership research projects through "the valley of death," and making them sustainable. Front Med (Lausanne) 2018;5:65. doi: 10.3389/fmed.2018.00065. doi: 10.3389/fmed.2018.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00065</ArticleId><ArticleId IdType="doi">10.3389/fmed.2018.00065</ArticleId><ArticleId IdType="pmc">PMC5855043</ArticleId><ArticleId IdType="pubmed">29594123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabella C, Durinx C, Appel R. Funding knowledgebases: towards a sustainable funding model for the UniProt use case. F1000Res. 2017;6:ELIXIR-2051. doi: 10.12688/f1000research.12989.2. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.12989.2/doi</ArticleId><ArticleId IdType="doi">10.12688/f1000research.12989.2</ArticleId><ArticleId IdType="pmc">PMC5747334</ArticleId><ArticleId IdType="pubmed">29333230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia  Business Models for Open-Source Software. 2019.  [2019-02-11].  
 https://en.wikipedia.org/wiki/Business_models_for_open-source_software
.</Citation></Reference><Reference><Citation>Iaffaldano G, Steinmacher I, Calefato F, Gerosa M, Lanubile F. Why do developers take breaks from contributing to OSS projects?: a preliminary analysis. Proceedings of the 2nd International Workshop on Software Health; 2nd International Workshop on Software Health; May 28, 2019; Montreal, Quebec, Canada. 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/SoHeal.2019.00009</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiq A, Tripathi A. Impact of financial benefits on open source software sustainability. Proceedings of the Thirty Seventh International Conference on Information Systems; Thirty Seventh International Conference on Information Systems; Dec 11-14, 2016; Dublin. 2016.</Citation></Reference><Reference><Citation>Jim&#xe9;nez RC, Kuzak M, Alhamdoosh M, Barker M, Batut B, Borg M, Capella-Gutierrez S, Chue Hong N, Cook M, Corpas M, Flannery M, Garcia L, Gelp&#xed; JL, Gladman S, Goble C, Gonz&#xe1;lez Ferreiro M, Gonzalez-Beltran A, Griffin PC, Gr&#xfc;ning B, Hagberg J, Holub P, Hooft R, Ison J, Katz DS, Lesko&#x161;ek B, L&#xf3;pez G&#xf3;mez F, Oliveira LJ, Mellor D, Mosbergen R, Mulder N, Perez-Riverol Y, Pergl R, Pichler H, Pope B, Sanz F, Schneider MV, Stodden V, Suchecki R, Svobodov&#xe1; Va&#x159;ekov&#xe1; R, Talvik H, Todorov I, Treloar A, Tyagi S, van Gompel M, Vaughan D, Via A, Wang X, Watson-Haigh NS, Crouch S. Four simple recommendations to encourage best practices in research software. F1000Res. 2017;6:ELIXIR-876. doi: 10.12688/f1000research.11407.1. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.11407.1/doi</ArticleId><ArticleId IdType="doi">10.12688/f1000research.11407.1</ArticleId><ArticleId IdType="pmc">PMC5490478</ArticleId><ArticleId IdType="pubmed">28751965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyman L, Lindman J. Code forking, governance, and sustainability in open source software. Technol Innov Manag Rev. 2013;3(1):7&#x2013;12. doi: 10.22215/timreview/644.</Citation><ArticleIdList><ArticleId IdType="doi">10.22215/timreview/644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyman L, Mikkonen T, Lindman J, Foug&#xe8;re M. IFIP International Conference on Open Source Systems. Berlin, Heidelberg: Springer; 2012. Perspectives on code forking and sustainability in open source software; pp. 274&#x2013;9.</Citation></Reference><Reference><Citation>Prins P, de Ligt J, Tarasov A, Jansen RC, Cuppen E, Bourne PE. Toward effective software solutions for big biology. Nat Biotechnol. 2015 Jul;33(7):686&#x2013;7. doi: 10.1038/nbt.3240.nbt.3240</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3240</ArticleId><ArticleId IdType="pubmed">26154002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R. 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012 Nov;30(9):1323&#x2013;41. doi: 10.1016/j.mri.2012.05.001. 
 
S0730-725X(12)00181-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mri.2012.05.001</ArticleId><ArticleId IdType="pmc">PMC3466397</ArticleId><ArticleId IdType="pubmed">22770690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. doi: 10.1186/gb-2004-5-10-r80. 
 
gb-2004-5-10-r80</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-10-r80</ArticleId><ArticleId IdType="doi">10.1186/gb-2004-5-10-r80</ArticleId><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003 Nov;13(11):2498&#x2013;504. doi: 10.1101/gr.1239303. 
 
13/11/2498</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard K, Tuecke S, Foster I. Globus: recent enhancements and future plans. Proceedings of the XSEDE16 Conference on Diversity, Big Data, and Science at Scale; XSEDE16 Conference on Diversity, Big Data, and Science at Scale; Jul 17 - 21, 2016; Miami, USA. 2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2949550.2949554</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, Kohane I. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010 Feb 26;17(2):124&#x2013;30. doi: 10.1136/jamia.2009.000893. 
 
17/2/124</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheufele E, Aronzon D, Coopersmith R, McDuffie MT, Kapoor M, Uhrich CA, Avitabile JE, Liu J, Housman D, Palchuk MB. tranSMART: an open source knowledge management and high content data analytics platform. AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:96&#x2013;101. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333702</ArticleId><ArticleId IdType="pubmed">25717408</ArticleId></ArticleIdList></Reference><Reference><Citation>About ITK. ITK.  [2021-10-01].  
 https://itk.org/
</Citation></Reference><Reference><Citation>About Linux. Linux.  [2021-11-09].  
 https://www.linux.org/
</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong IC, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y-C, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>The R Project for Statistical Computing. 2021.  [2021-10-01].  
 https://www.r-project.org/
</Citation></Reference><Reference><Citation>Obeid JS, McGraw CA, Minor BL, Conde JG, Pawluk R, Lin M, Wang J, Banks SR, Hemphill SA, Taylor R, Harris PA. Procurement of shared data instruments for Research Electronic Data Capture (REDCap) J Biomed Inform. 2013 Apr;46(2):259&#x2013;65. doi: 10.1016/j.jbi.2012.10.006. 
 
S1532-0464(12)00160-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.10.006</ArticleId><ArticleId IdType="pmc">PMC3600393</ArticleId><ArticleId IdType="pubmed">23149159</ArticleId></ArticleIdList></Reference><Reference><Citation>What Does A Sustainable Open Source Project Look Like? Libraries.io. 2017.  [2021-11-09].  
 https://medium.com/libraries-io/what-does-a-sustainable-open-source-project-look-like-bf9b8cf824f8
.</Citation></Reference><Reference><Citation>A handy guide to financial support for open source. GitHub. 2019.  [2021-10-01].  
 https://github.com/nayafia/lemonade-stand
.</Citation></Reference><Reference><Citation>i2b2 tranSMART foundation amended and restated by-laws.  [2017-04-25].  
 https://drive.google.com/file/d/0B8lizkKDeaKhTUF3QmNTTFk0ZnM/view
.</Citation></Reference><Reference><Citation>Amended and restated by-laws of i2b2 transmart foundation. i2b2 tranSMART. 2017.  [2021-11-09].  
 http://roadmap-i2b2-transmart-pmc.hms.harvard.edu
.</Citation></Reference><Reference><Citation>Documentation/Labs/Slicer5-roadmap. 3D Slicer Roadmap.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/Labs/Slicer5-roadmap
.</Citation></Reference><Reference><Citation>Cytoscape product roadmap. Cytoscape Consortium.  [2021-11-09].  
 https://cytoscape.org/roadmap.htm
.</Citation></Reference><Reference><Citation>Product roadmap. Globus Online.  [2021-11-09].  
 https://www.globusworld.org/files/2010/02/120412-GW2012_Tuecke_Roadmap.pdf
.</Citation></Reference><Reference><Citation>ITK  ITK Roadmap 2005-2006.  [2020-09-01].  
 https://itk.org/Wiki/ITK/Roadmap_2005_2006
.</Citation></Reference><Reference><Citation>ITK Roadmap 2008-2009. ITK.  [2021-11-09].  
 https://itk.org/Wiki/ITK_Roadmap_2008_2009
.</Citation></Reference><Reference><Citation>ITK/Release 4/DICOM/Meeting Roadmap. ITK.  [2021-11-09].  
 https://itk.org/Wiki/ITK/Release_4/DICOM/Meeting_2011.09.01_Roadmap
.</Citation></Reference><Reference><Citation>OHDSI architecture roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://www.ohdsi.org/web/wiki/doku.php?id=development:roadmap
.</Citation></Reference><Reference><Citation>CDM v6.0 Roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://forums.ohdsi.org/t/cdm-v6-0-roadmap/4809
.</Citation></Reference><Reference><Citation>OHDSI WebAPI Roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://github.com/OHDSI/WebAPI/wiki/Roadmap
.</Citation></Reference><Reference><Citation>The Linux roadmap. Corbet.  [2021-11-09].  
 https://lwn.net/Articles/114804/
</Citation></Reference><Reference><Citation>The ITK Software Guide. ITK. 2021.  [2021-11-09].  
 https://itk.org/ItkSoftwareGuide.pdf
.</Citation></Reference><Reference><Citation>Linux guide. Wikibooks.  [2021-11-09].  
 https://en.wikibooks.org/wiki/Linux_Guide
.</Citation></Reference><Reference><Citation>An Introduction to R. R-project. 2009.  [2021-10-26].  
 https://cran.r-project.org/doc/manuals/r-release/R-intro.pdf
.</Citation></Reference><Reference><Citation>Welcome to 3D Slicer&#x2019;s Documentation. 3D Slicer.  [2021-10-01].  
 https://slicer.readthedocs.io
.</Citation></Reference><Reference><Citation>3D Slicer Wiki. GitHub.  [2021-11-09].  
 https://github.com/Slicer/Slicer/wiki
.</Citation></Reference><Reference><Citation>Welcome to the i2b2 Community Wiki. i2b2 Community Wiki.  [2021-11-09].  
 https://community.i2b2.org/wiki/pages/viewpage.action?pageId=342684
.</Citation></Reference><Reference><Citation>Bioconductor Tutorial Part I. Bioconductor. 2003.  [2021-11-09].  
 https://bioconductor.org/help/course-materials/2003/MGED6/MGED6I.pdf
.</Citation></Reference><Reference><Citation>Harness the power of the Globus research data management cloud. Globus Docs.  [2021-11-09].  
 https://docs.globus.org/
</Citation></Reference><Reference><Citation>Cytoscape tutorials. GitHub.  [2021-11-09].  
 https://github.com/cytoscape/cytoscape-tutorials/wiki
.</Citation></Reference><Reference><Citation>tranSMART Platform Tutorials. i2b2 tranSMART Foundation.  [2021-11-09].  
 https://transmartfoundation.org/transmart-platform-tutorials/
</Citation></Reference><Reference><Citation>3D Slicer Nightly Tutorials.  [2020-03-12].  
 https://www.slicer.org/wiki/Documentation/Nightly/Training
.</Citation></Reference><Reference><Citation>OHDSI  2019 Tutorials &#x2013; OMOP Common Data Model and Standardized Vocabularies. Observational Health Data Sciences and Informatics. 2019.  [2021-11-09].  
 https://www.ohdsi.org/2019-tutorials-omop-common-data-model-and-standardized-vocabularies/
</Citation></Reference><Reference><Citation>REDCap Tutorial. YouTube.  [2021-11-09].  
 https://www.youtube.com/playlist?list=PLrnf34ZtZ9FohXnuD6KmwVb1xgbGDu3rY
.</Citation></Reference><Reference><Citation>3D Slicer YouTube Tutorials. YouTube.  [2021-11-09].  
 https://www.youtube.com/channel/UC8vxI0-dEWrw0_tBF-v8xGA
.</Citation></Reference><Reference><Citation>Cytoscape YouTube Channel. YouTube.  [2021-11-09].  
 https://www.youtube.com/channel/UCv6auk9FK4NgXiXiqrDLccw
.</Citation></Reference><Reference><Citation>Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, Irizarry RA, Lawrence M, Love MI, MacDonald J, Obenchain V, Ole&#x15b; AK, Pag&#xe8;s H, Reyes A, Shannon P, Smyth GK, Tenenbaum D, Waldron L, Morgan M. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015 Feb;12(2):115&#x2013;21. doi: 10.1038/nmeth.3252. 
 
nmeth.3252</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3252</ArticleId><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytoscape app ladder. GitHub. 2019.  [2021-11-09].  
 https://github.com/cytoscape/cytoscape/wiki/Cytoscape-App-Ladder
.</Citation></Reference><Reference><Citation>The R Manuals. CRAN.  [2021-11-09].  
 https://cran.r-project.org/manuals.html
.</Citation></Reference><Reference><Citation>3D Slicer Preview. CDash.  [2021-11-09].  
 http://slicer.cdash.org/index.php?project=SlicerPreview
.</Citation></Reference><Reference><Citation>Releasing a package. R Packages.  [2021-11-09].  
 http://r-pkgs.had.co.nz/release.html
.</Citation></Reference><Reference><Citation>Documentation/Nightly/Developers/Style Guide. 3D Slicer.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/Nightly/Developers/Style_Guide
.</Citation></Reference><Reference><Citation>R Internals for R Version 3.6.3. 2020.  [2020-03-12].  
 https://cran.r-project.org/doc/manuals/R-ints.html
.</Citation></Reference><Reference><Citation>OHDSI  OHDSI Forums. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://forums.ohdsi.org/
</Citation></Reference><Reference><Citation>OHDSI Github Repository. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://github.com/ohdsi/
</Citation></Reference><Reference><Citation>Linux Help Center. Linux Foundation.  [2021-11-09].  
 https://support.linuxfoundation.org/
</Citation></Reference><Reference><Citation>Cytoscape Helpdesk homepage. Cytoscape Helpdesk.  [2021-11-09].  
 https://groups.google.com/forum/#!forum/cytoscape-helpdesk
.</Citation></Reference><Reference><Citation>ITK discussion forum. ITK.  [2021-11-09].  
 https://discourse.itk.org
.</Citation></Reference><Reference><Citation>Connect with Globus on social media. Globus.  [2021-11-09].  
 https://www.globus.org/contact-us
.</Citation></Reference><Reference><Citation>Mookhey K, Burghate N. Linux: Security, Audit and Control Features. East Golf Road, Schaumburg, Illinois: ISACA; 2005.</Citation></Reference><Reference><Citation>UNIX/LINUX Security Features. Winsock.  [2021-11-09].  
 https://www.tenouk.com/linuxunixsecurityfeatures.html
.</Citation></Reference><Reference><Citation>How R Packages on bioconductor are licensed. CRAN.  [2021-11-09].  
 http://seankross.com/2016/08/02/How-R-Packages-are-Licensed.html
.</Citation></Reference><Reference><Citation>The i2b2 MPL 2.0 License with Healthcare Disclaimer Addendum. i2b2 Web Client.  [2021-11-09].  
 https://community.i2b2.org/wiki/display/webclient/The+i2b2+MPL+2.0+License+with+Healthcare+Disclaimer+Addendum
.</Citation></Reference><Reference><Citation>Documentation/4.x/Acknowledgments. 3D Slicer.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/4.x/Acknowledgments
.</Citation></Reference><Reference><Citation>Linux Foundation Membership. The Linux Foundation.  [2021-11-09].  
 https://www.linuxfoundation.org/membership/
</Citation></Reference><Reference><Citation>i2b2 tranSMART Foundation Sponsorship Programs.  [2021-11-09].  
 https://transmartfoundation.org/contributing-sponsors-program/
</Citation></Reference><Reference><Citation>Wagholikar KB, Dessai P, Sanz J, Mendis ME, Bell DS, Murphy SN. Implementation of informatics for integrating biology and the bedside (i2b2) platform as Docker containers. BMC Med Inform Decis Mak. 2018 Jul 16;18(1):66. doi: 10.1186/s12911-018-0646-2. 
 
10.1186/s12911-018-0646-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0646-2</ArticleId><ArticleId IdType="doi">10.1186/s12911-018-0646-2</ArticleId><ArticleId IdType="pmc">PMC6048900</ArticleId><ArticleId IdType="pubmed">30012140</ArticleId></ArticleIdList></Reference><Reference><Citation>Open source sustainability. Tech Crunch. 2018.  [2021-11-09].  
 https://techcrunch.com/2018/06/23/open-source-sustainability/
</Citation></Reference><Reference><Citation>Masys DR, Harris PA, Fearn PA, Kohane IS. Designing a public square for research computing. Sci Transl Med. 2012 Aug 29;4(149):149fs32. doi: 10.1126/scitranslmed.3004032. 
 
4/149/149fs32</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004032</ArticleId><ArticleId IdType="pmc">PMC3725749</ArticleId><ArticleId IdType="pubmed">22932220</ArticleId></ArticleIdList></Reference><Reference><Citation>Software for science: some personal reflections. arXiv. 2013.  [2021-11-09].  
 https://arxiv.org/abs/1309.2357
.</Citation></Reference><Reference><Citation>Open source licenses: trends and predictions. White Source. 2021.  [2021-11-09].  
 https://resources.whitesourcesoftware.com/blog-whitesource/open-source-licenses-trends-and-predictions
.</Citation></Reference><Reference><Citation>Guest Blog: Globus and the Path to Sustainability. Science Gateways. 2019.  [2021-11-09].  
 https://sciencegateways.org/-/guest-blog-globus-and-the-path-to-sustainability?inheritRedirect=true&amp;redirect=/community/blog
.</Citation></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 2: getting started.</Citation></Reference><Reference><Citation>Teixeira J Release early, release often and release on time. An empirical case study of release management. Proceedings of the IFIP International Conference on Open Source Systems; IFIP International Conference on Open Source Systems; May 22-23, 2017; Buenos Aires, Argentina. 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-57735-7_16</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 5: participating as a business, non-profit, or government agency.</Citation></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 3: techinical infrastructure.</Citation></Reference><Reference><Citation>Eghbal N. Roads and Bridges: The Unseen Labor Behind Our Digital Infrastructure. New York, NY: Ford Foundation; 2016.</Citation></Reference><Reference><Citation>Rougier N, Hinsen K, Alexandre F, Arildsen T, Barba LA, Benureau FC, Brown CT, de Buyl P, Caglayan O, Davison AP, Delsuc M-A, Detorakis G, Diem AK, Drix D, Enel P, Girard B, Guest O, Hall MG, Henriques RN, Hinaut X, Jaron KS, Khamassi M, Klein A, Manninen T, Marchesi P, McGlinn D, Metzner C, Petchey O, Plesser HE, Poisot T, Ram K, Ram Y, Roesch E, Rossant C, Rostami V, Shifman A, Stachelek J, Stimberg M, Stollmeier F, Vaggi F, Viejo G, Vitay J, Vostinar AE, Yurchak R, Zito T. Sustainable computational science: the ReScience initiative. PeerJ Comput Sci. 2017;3:e142. doi: 10.7717/peerj-cs.142. 
 
cs-142</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj-cs.142</ArticleId><ArticleId IdType="pmc">PMC8530091</ArticleId><ArticleId IdType="pubmed">34722870</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck S. Solving reproducibility. Science. 2015 Jun 25;348(6242):1403. doi: 10.1126/science.aac8041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac8041</ArticleId><ArticleId IdType="pubmed">26113692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoettle H. Open source license compliance-why and how? Computer. 2019 Aug;52(8):63&#x2013;7. doi: 10.1109/mc.2019.2915690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/mc.2019.2915690</ArticleId></ArticleIdList></Reference><Reference><Citation>Big Data to Knowledge. National Institutes of Health Office of Strategic Coordination The Common Fund.  [2021-11-09].  
 https://commonfund.nih.gov/bd2k
.</Citation></Reference><Reference><Citation>Bourne PE, Bonazzi V, Dunn M, Green ED, Guyer M, Komatsoulis G, Larkin J, Russell B. The NIH Big Data to Knowledge (BD2K) initiative. J Am Med Inform Assoc. 2015 Nov;22(6):1114. doi: 10.1093/jamia/ocv136. 
 
ocv136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv136</ArticleId><ArticleId IdType="pmc">PMC5009910</ArticleId><ArticleId IdType="pubmed">26555016</ArticleId></ArticleIdList></Reference><Reference><Citation>Data science at NIH. National Institutes of Health Office of Data Science Strategy.  [2021-11-09].  
 https://datascience.nih.gov/
</Citation></Reference><Reference><Citation>The precision medicine initiative cohort program &#x2013; building a research foundation for 21st century medicine. NIH. 2015.  [2021-11-09].  
 https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf
.</Citation></Reference><Reference><Citation>UK research and development roadmap. Gov.UK. 2020.  [2021-11-09].  
 https://www.gov.uk/government/publications/uk-research-and-development-roadmap
.</Citation></Reference><Reference><Citation>Reynolds CJ, Wyatt JC. Open source, open standards, and health care information systems. J Med Internet Res. 2011 Feb 17;13(1):e24. doi: 10.2196/jmir.1521. 
 
v13i1e24</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.1521</ArticleId><ArticleId IdType="pmc">PMC3221346</ArticleId><ArticleId IdType="pubmed">21447469</ArticleId></ArticleIdList></Reference><Reference><Citation>Recommendations on the Development, Use and Provision of Research Software. Zenodo. 2018.  [2021-11-09].  
 https://zenodo.org/record/1172988#.X9Q1UdhKiF
.</Citation></Reference><Reference><Citation>Katz D, Choi S, Lapp H, Maheshwari K, L&#xf6;ffler F, Turk M. Summary of the first Workshop on Sustainable Software for Science: Practice and Experiences (WSSSPE1) J Open Res Softw. 2014;2(1):e6. doi: 10.5334/jors.an.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/jors.an</ArticleId></ArticleIdList></Reference><Reference><Citation>Science Gateways Community Institute.  [2021-11-09].  
 https://sciencegateways.org/gateway-support/consulting-services
.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34899334</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis.</ArticleTitle><Pagination><StartPage>773875</StartPage><MedlinePgn>773875</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">773875</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2021.773875</ELocationID><Abstract><AbstractText>Using real-world data and past vaccination data, we conducted a large-scale experiment to quantify bias, precision and timeliness of different study designs to estimate historical background (expected) compared to post-vaccination (observed) rates of safety events for several vaccines. We used negative (not causally related) and positive control outcomes. The latter were synthetically generated true safety signals with incident rate ratios ranging from 1.5 to 4. Observed vs. expected analysis using within-database historical background rates is a sensitive but unspecific method for the identification of potential vaccine safety signals. Despite good discrimination, most analyses showed a tendency to overestimate risks, with 20%-100% type 1 error, but low (0% to 20%) type 2 error in the large databases included in our study. Efforts to improve the comparability of background and post-vaccine rates, including age-sex adjustment and anchoring background rates around a visit, reduced type 1 error and improved precision but residual systematic error persisted. Additionally, empirical calibration dramatically reduced type 1 to nominal but came at the cost of increasing type 2 error.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Li, Lai, Ostropolets, Arshad, Tan, Casajust, Alshammari, Duarte-Salles, Minty, Areia, Pratt, Ryan, Hripcsak, Suchard, Schuemie and Prieto-Alhambra.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Yh</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Faaizah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut Universitari D'Investigaci&#xf3; en Atenci&#xf3; Prim&#xe0;ria Jordi Gol (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, NewYork-Presbyterian Hospital, NewYork, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Sciences, Medical Informatics, Erasmus Medical Center University, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">background rate</Keyword><Keyword MajorTopicYN="N">empirical - comparison</Keyword><Keyword MajorTopicYN="N">incidence rate</Keyword><Keyword MajorTopicYN="N">real world data</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>DP's research group has received grants for unrelated work from Amgen, Chiesi-Taylor, and UCB Biopharma SRL; and his department has received speaker/consultancy fees from Amgen, Astra-Zeneca, Astellas, Janssen, and UCB Bioparhma SRL. Authors PR and MJS were employed by Janssen R&amp;D. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>13</Day><Hour>17</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34899334</ArticleId><ArticleId IdType="pmc">PMC8652333</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.773875</ArticleId><ArticleId IdType="pii">773875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barker C. I., Snape M. D. (2014). Pandemic Influenza A H1N1 Vaccines and Narcolepsy: Vaccine Safety Surveillance in Action. Lancet Infect. Dis. 14 (3), 227&#x2013;238. 10.1016/S1473-3099(13)70238-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70238-X</ArticleId><ArticleId IdType="pubmed">24360892</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia E. A., Irving S. A., Shui I. M., Kulldorff M., Lewis E., Yin R., et al. (2010). Real-time Surveillance to Assess Risk of Intussusception and Other Adverse Events after Pentavalent, Bovine-Derived Rotavirus Vaccine. Pediatr. Infect. Dis. J. 29 (1), 1&#x2013;5. 10.1097/INF.0b013e3181af8605</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181af8605</ArticleId><ArticleId IdType="pubmed">19907356</ArticleId></ArticleIdList></Reference><Reference><Citation>Benecke O., DeYoung S. E. (2019). Anti-Vaccine Decision-Making and Measles Resurgence in the United States. Glob. Pediatr. Health 6, 2333794X19862949&#x2013;2333794X. 10.1177/2333794X19862949</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2333794X19862949</ArticleId><ArticleId IdType="pmc">PMC6657116</ArticleId><ArticleId IdType="pubmed">31384629</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S., Eskola J., Siegrist C. A., Halsey N., MacDonald N., Law B., et al. (2009). Importance of Background Rates of Disease in Assessment of Vaccine Safety during Mass Immunisation with Pandemic H1N1 Influenza Vaccines. Lancet 374 (9707), 2115&#x2013;2122. 10.1016/S0140-6736(09)61877-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttery J. P., Danchin M. H., Lee K. J., Carlin J. B., McIntyre P. B., Elliott E. J., et al. (2011). Intussusception Following Rotavirus Vaccine Administration: post-marketing Surveillance in the National Immunization Program in Australia. Vaccine 29 (16), 3061&#x2013;3066. 10.1016/j.vaccine.2011.01.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.088</ArticleId><ArticleId IdType="pubmed">21316503</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Network of Centres of Pharmacoepidemiology and Pharmacovigilance (2021). EUMAEUS: Evaluating Use of Methods for Adverse Event under Surveillance (For Vaccines). 2021 [updated 15 April 2021. Available at: http://www.encepp.eu/encepp/viewResource.htm?id=40341
. </Citation></Reference><Reference><Citation>Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. (2011). Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine: Findings from the Vaccine Safety Datalink. Vaccine 29 (46), 8279&#x2013;8284. 10.1016/j.vaccine.2011.08.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.08.106</ArticleId><ArticleId IdType="pubmed">21907257</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlee F., Smith J., Marcovitch H. (2011). Wakefield's Article Linking MMR Vaccine and Autism Was Fraudulent. BMJ 342, c7452. 10.1136/bmj.c7452</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c7452</ArticleId><ArticleId IdType="pubmed">21209060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolley D., Douglas K. M. (2014). The Effects of Anti-vaccine Conspiracy Theories on Vaccination Intentions. PLOS ONE 9 (2), e89177. 10.1371/journal.pone.0089177</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089177</ArticleId><ArticleId IdType="pmc">PMC3930676</ArticleId><ArticleId IdType="pubmed">24586574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ostropolets A., Makadia R., Shaoibi A., Rao G., Sena A. G., et al. (2021). Characterizing the Incidence of Adverse Events of Special Interest for COVID-19 Vaccines across Eight Countries: a Multinational Network Cohort Study. medRxiv, 2021. 10.1101/2021.03.25.21254315</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.25.21254315</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieu T. A., Kulldorff M., Davis R. L., Lewis E. M., Weintraub E., Yih K., et al. (2007). Real-time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Med. Care 45 (10 Suppl. 2), S89&#x2013;S95. 10.1097/MLR.0b013e3180616c0a</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3180616c0a</ArticleId><ArticleId IdType="pubmed">17909389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaux O., Bauchau V., Van Holle L. (2016). Pharmacoepidemiological Considerations in Observed-To-Expected Analyses for Vaccines. Pharmacoepidemiol. Drug Saf. 25 (2), 215&#x2013;222. 10.1002/pds.3918</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3918</ArticleId><ArticleId IdType="pmc">PMC5063172</ArticleId><ArticleId IdType="pubmed">26602179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin Y. M., Cheng A., Lawrie J., Buttery J. (2019). Use of Routinely Collected Electronic Healthcare Data for Postlicensure Vaccine Safety Signal Detection: a Systematic Review. BMJ Glob. Health 4 (4), e001065. 10.1136/bmjgh-2018-001065</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2018-001065</ArticleId><ArticleId IdType="pmc">PMC6615875</ArticleId><ArticleId IdType="pubmed">31354969</ArticleId></ArticleIdList></Reference><Reference><Citation>
OHDSI (2019). The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI. Available at: https://ohdsi.github.io/TheBookOfOhdsi/TheBookOfOhdsi.pdf

</Citation></Reference><Reference><Citation>Remschmidt C., Wichmann O., Harder T. (2015). Frequency and Impact of Confounding by Indication and Healthy Vaccinee Bias in Observational Studies Assessing Influenza Vaccine Effectiveness: a Systematic Review. BMC Infect. Dis. 15, 429. 10.1186/s12879-015-1154-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1154-y</ArticleId><ArticleId IdType="pmc">PMC4609091</ArticleId><ArticleId IdType="pubmed">26474974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Cepeda M. S., Suchard M. A., Yang J., Tian Y., Schuler A., et al. (2020). How Confident Are We about Observational Findings in Healthcare: A Benchmark Study. Harv. Data Sci. Rev. 2 (1). 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., Suchard M. A. (2018). Empirical Confidence Interval Calibration for Population-Level Effect Estimation Studies in Observational Healthcare Data. Proc. Natl. Acad. Sci. U S A. 115 (11), 2571&#x2013;2577. 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., Suchard M. A. (2016). Robust Empirical Calibration of P-Values Using Observational Data. Stat. Med. 35 (22), 3883&#x2013;3888. 10.1002/sim.6977</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnans L., Lecomte C., de Vries C., Weibel D., Sammon C., Hviid A., et al. (2013). The Incidence of Narcolepsy in Europe: before, during, and after the Influenza A(H1N1)pdm09 Pandemic and Vaccination Campaigns. Vaccine 31 (8), 1246&#x2013;1254. 10.1016/j.vaccine.2012.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.015</ArticleId><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>
Winton Centre for Risk and Evidence Communication (2021). Communicating the Potential Benefits and Harms of the Astra-Zeneca COVID-19 Vaccine. 2021 [updated 7 April 2021. Available at: https://wintoncentre.maths.cam.ac.uk/news/communicating-potential-benefits-and-harms-astra-zeneca-covid-19-vaccine/
. </Citation></Reference><Reference><Citation>Yih W. K., Kulldorff M., Fireman B. H., Shui I. M., Lewis E. M., Klein N. P., et al. (2011). Active Surveillance for Adverse Events: the Experience of the Vaccine Safety Datalink Project. Pediatrics 127 (Suppl. 1), S54&#x2013;S64. 10.1542/peds.2010-1722I</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-1722I</ArticleId><ArticleId IdType="pubmed">21502252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih W. K., Nordin J. D., Kulldorff M., Lewis E., Lieu T. A., Shi P., et al. (2009). An Assessment of the Safety of Adolescent and Adult Tetanus-Diphtheria-Acellular Pertussis (Tdap) Vaccine, Using Active Surveillance for Adverse Events in the Vaccine Safety Datalink. Vaccine 27 (32), 4257&#x2013;4262. 10.1016/j.vaccine.2009.05.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.05.036</ArticleId><ArticleId IdType="pubmed">19486957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34904958</PMID><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Transformation and Evaluation of the MIMIC Database in the OMOP Common Data Model: Development and Usability Study.</ArticleTitle><Pagination><StartPage>e30970</StartPage><MedlinePgn>e30970</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30970</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/30970</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the era of big data, the intensive care unit (ICU) is likely to benefit from real-time computer analysis and modeling based on close patient monitoring and electronic health record data. The Medical Information Mart for Intensive Care (MIMIC) is the first open access database in the ICU domain. Many studies have shown that common data models (CDMs) improve database searching by allowing code, tools, and experience to be shared. The Observational Medical Outcomes Partnership (OMOP) CDM is spreading all over the world.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective was to transform MIMIC into an OMOP database and to evaluate the benefits of this transformation for analysts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We transformed MIMIC (version 1.4.21) into OMOP format (version 5.3.3.1) through semantic and structural mapping. The structural mapping aimed at moving the MIMIC data into the right place in OMOP, with some data transformations. The mapping was divided into 3 phases: conception, implementation, and evaluation. The conceptual mapping aimed at aligning the MIMIC local terminologies to OMOP's standard ones. It consisted of 3 phases: integration, alignment, and evaluation. A documented, tested, versioned, exemplified, and open repository was set up to support the transformation and improvement of the MIMIC community's source code. The resulting data set was evaluated over a 48-hour datathon.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With an investment of 2 people for 500 hours, 64% of the data items of the 26 MIMIC tables were standardized into the OMOP CDM and 78% of the source concepts mapped to reference terminologies. The model proved its ability to support community contributions and was well received during the datathon, with 160 participants and 15,000 requests executed with a maximum duration of 1 minute.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The resulting MIMIC-OMOP data set is the first MIMIC-OMOP data set available free of charge with real disidentified data ready for replicable intensive care research. This approach can be generalized to any medical field.</AbstractText><CopyrightInformation>&#xa9;Nicolas Paris, Antoine Lamer, Adrien Parrot. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 14.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Paris</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1533-5087</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9546-1808</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des Pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9862-1408</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">big data</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">data reuse</Keyword><Keyword MajorTopicYN="N">digital health</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">health care</Keyword><Keyword MajorTopicYN="N">health data</Keyword><Keyword MajorTopicYN="N">health database</Keyword><Keyword MajorTopicYN="N">health informatics</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">open access database</Keyword><Keyword MajorTopicYN="N">open data</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34904958</ArticleId><ArticleId IdType="pmc">PMC8715361</ArticleId><ArticleId IdType="doi">10.2196/30970</ArticleId><ArticleId IdType="pii">v9i12e30970</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus DC, Kelley MA, Schmitz RJ, White A, Popovich J, Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS) Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: can we meet the requirements of an aging population? JAMA. 2000 Dec 06;284(21):2762&#x2013;70. doi: 10.1001/jama.284.21.2762.jce00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.284.21.2762</ArticleId><ArticleId IdType="pubmed">11105183</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay E, Alberti C, Legendre I, Buisson CB, Le Gall JR, European Sepsis Group Post-ICU mortality in critically ill infected patients: an international study. Intensive Care Med. 2005 Jan;31(1):56&#x2013;63. doi: 10.1007/s00134-004-2484-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-004-2484-1</ArticleId><ArticleId IdType="pubmed">15526186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. Is the current management of severe sepsis and septic shock really evidence based? PLoS Med. 2006 Sep;3(9):e346. doi: 10.1371/journal.pmed.0030346. 
 
06-PLME-PF-0080R2</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030346</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0030346</ArticleId><ArticleId IdType="pmc">PMC1550732</ArticleId><ArticleId IdType="pubmed">16933970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross MK, Wei W, Ohno-Machado L. "Big data" and the electronic health record. Yearb Med Inform. 2014 Aug 15;9:97&#x2013;104. doi: 10.15265/IY-2014-0003. 
 
me2014-0003</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2014-0003</ArticleId><ArticleId IdType="pmc">PMC4287068</ArticleId><ArticleId IdType="pubmed">25123728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Guo S, Han L, Li T. Application and exploration of big data mining in clinical medicine. Chin Med J (Engl) 2016 Mar 20;129(6):731&#x2013;8. doi: 10.4103/0366-6999.178019. 
 
ChinMedJ_2016_129_6_731_178019</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.178019</ArticleId><ArticleId IdType="pmc">PMC4804421</ArticleId><ArticleId IdType="pubmed">26960378</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C. Reuse of clinical data. Yearb Med Inform. 2014 Aug 15;9:52&#x2013;4. doi: 10.15265/IY-2014-0013. 
 
me2014-0013</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2014-0013</ArticleId><ArticleId IdType="pmc">PMC4287069</ArticleId><ArticleId IdType="pubmed">25123722</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre SM, Lovis C, B&#xfc;rkle T, Tognola G, Budrionis A, Lehmann CU. Clinical data reuse or secondary use: current status and potential future progress. Yearb Med Inform. 2017 Aug;26(1):38&#x2013;52. doi: 10.15265/IY-2017-007. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2017-007</ArticleId><ArticleId IdType="pmc">PMC6239225</ArticleId><ArticleId IdType="pubmed">28480475</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M, Moody B, Szolovits P, Celi LA, Mark RG. MIMIC-III, a freely accessible critical care database. Sci Data. 2016 May 24;3:160035. doi: 10.1038/sdata.2016.35. doi: 10.1038/sdata.2016.35.sdata201635</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012 Jul;50 Suppl:S60&#x2013;7. doi: 10.1097/MLR.0b013e318259bff4. 
 
00005650-201207001-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318259bff4</ArticleId><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ. Common models, different approaches. Drug Saf. 2015 Aug;38(8):683&#x2013;6. doi: 10.1007/s40264-015-0313-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0313-9</ArticleId><ArticleId IdType="pubmed">26088718</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Lieu T. Data enclaves for sharing information derived from clinical and administrative data. JAMA. 2018 Aug 28;320(8):753&#x2013;754. doi: 10.1001/jama.2018.9342. 
 
2696616</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.9342</ArticleId><ArticleId IdType="pubmed">30083726</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015 Aug;38(8):749&#x2013;65. doi: 10.1007/s40264-015-0297-5.10.1007/s40264-015-0297-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0297-5</ArticleId><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645&#x2013;51. doi: 10.1093/aje/kwt010. 
 
kwt010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenstern H, Rafaely B. Spatial reverberation and dereverberation using an acoustic multiple-input multiple-output system. J Audio Eng Soc. 2017 Feb 17;65(1/2):42&#x2013;55. doi: 10.17743/jaes.2016.0063.</Citation><ArticleIdList><ArticleId IdType="doi">10.17743/jaes.2016.0063</ArticleId></ArticleIdList></Reference><Reference><Citation>Klungel O, Kurz X, de Groot MCH, Schlienger R, Tcherny-Lessenot S, Grimaldi L, Ib&#xe1;&#xf1;ez L, Groenwold R, Reynolds R. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:156&#x2013;65. doi: 10.1002/pds.3968. doi: 10.1002/pds.3968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3968</ArticleId><ArticleId IdType="doi">10.1002/pds.3968</ArticleId><ArticleId IdType="pubmed">27038361</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, Herrmann T, Haverkamp C, Horki P, Laufer J, Berger F, H&#xf6;ning G, Fritsch HW, Sch&#xfc;ttler J, Ganslandt T, Prokosch HU, Sedlmayr M. Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018 Jan;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic FS, Robbins SL, Denton J, Nookala L, Meeker D, Ohno-Machado L, Matheny ME. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(3):536&#x2013;47. doi: 10.4338/ACI-2014-12-CR-0121. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M, Ficheur G, Chazard E, Beuscart J. Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform. 2020 Jan;11(1):13&#x2013;22. doi: 10.1055/s-0039-3402754. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI: Observational Health Data Sciences and Informatics. 2021. Dec 01,  [2019-05-03].  
 https://www.ohdsi.org/
</Citation></Reference><Reference><Citation>Karwin B. Keeping It Simple: Rendering Trees with Closure Tables.  [2021-11-01].  
 https://karwin.blogspot.com/2010/03/rendering-trees-with-closure-tables.html
.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376. 
 
amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;96. doi: 10.1016/j.jbi.2012.05.002. 
 
S1532-0464(12)00069-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamsuzzoha B, Vojtech H, Joydeep G. Conversion of MIMIC to OHDSI CDM.  [2021-12-01].  
 https://www.ohdsi.org/web/wiki/lib/exe/fetch.php?media=resources:2016_ohdsi_paper_mimic_bayzid.pdf
.</Citation></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016 Dec;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016. 
 
S1532-0464(16)30153-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronaki C, Shahin A, Mark R. Designing reliable cohorts of cardiac patients across MIMIC and eICU. Comput Cardiol (2010) 2015;42:189&#x2013;192. doi: 10.1109/CIC.2015.7408618. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIC.2015.7408618</ArticleId><ArticleId IdType="pmc">PMC5072526</ArticleId><ArticleId IdType="pubmed">27774488</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7  Welcome to FHIR&#xae;.  [2021-12-01].  
 https://www.hl7.org/fhir/
</Citation></Reference><Reference><Citation>Athena.  [2019-01-03].  
 http://athena.ohdsi.org/search-terms/terms
.</Citation></Reference><Reference><Citation>MIT Laboratory for Computational Physiology  MIT-LCP/mimic-code.  [2021-12-01].  
 https://github.com/MIT-LCP/mimic-code
.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI Forums.  [2021-12-01].  
 https://forums.ohdsi.org/
</Citation></Reference><Reference><Citation>MIT Laboratory for Computational Physiology  MIT-LCP/mimic-omop.  [2021-12-01].  
 https://github.com/MIT-LCP/mimic-omop
.</Citation></Reference><Reference><Citation>Moody DL, Shanks GG. Improving the quality of data models: empirical validation of a quality management framework. Inf Syst. 2003 Sep;28(6):619&#x2013;650. doi: 10.1016/s0306-4379(02)00043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0306-4379(02)00043-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI/Achilles.  [2019-10-17].  
 https://github.com/OHDSI/Achilles
.</Citation></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine  ICD-9-CM Diagnostic Codes to SNOMED CT Map Internet.  [2021-12-01].  
 https://www.nlm.nih.gov/research/umls/mapping_projects/icd9cm_to_snomedct.html
.</Citation></Reference><Reference><Citation>Logical Observation Identifiers Names and Codes  LOINC Version 2.63 and RELMA Version 6.22 Are Now Available.  [2021-12-01].  
 https://loinc.org/news/loinc-version-2-63-and-relma-version-6-22-are-now-available/
</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI/Usagi.  [2021-12-01].  
 https://github.com/OHDSI/Usagi
.</Citation></Reference><Reference><Citation>Denny JC, Spickard A, Johnson KB, Peterson NB, Peterson JF, Miller RA. Evaluation of a method to identify and categorize section headers in clinical documents. J Am Med Inform Assoc. 2009;16(6):806&#x2013;15. doi: 10.1197/jamia.M3037. 
 
M3037</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3037</ArticleId><ArticleId IdType="pmc">PMC3002123</ArticleId><ArticleId IdType="pubmed">19717800</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOPonFHIR  The FHIR Project at Georgia Tech Internet.  [2021-12-01].  
 http://omoponfhir.org/
</Citation></Reference><Reference><Citation>Aboab J, Celi LA, Charlton P, Feng M, Ghassemi M, Marshall DC, Mayaud L, Naumann T, McCague N, Paik KE, Pollard TJ, Resche-Rigon M, Salciccioli JD, Stone DJ. A "datathon" model to support cross-disciplinary collaboration. Sci Transl Med. 2016 Apr 06;8(333):333ps8. doi: 10.1126/scitranslmed.aad9072. 
 
8/333/333ps8</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9072</ArticleId><ArticleId IdType="pmc">PMC5679209</ArticleId><ArticleId IdType="pubmed">27053770</ArticleId></ArticleIdList></Reference><Reference><Citation>Celi LA, Lokhandwala S, Montgomery R, Moses C, Naumann T, Pollard T, Spitz D, Stretch R. Datathons and software to promote reproducible research. J Med Internet Res. 2016 Aug 24;18(8):e230. doi: 10.2196/jmir.6365. 
 
v18i8e230</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.6365</ArticleId><ArticleId IdType="pmc">PMC5014984</ArticleId><ArticleId IdType="pubmed">27558834</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo EM, Newman S, Amat M, Charpignon M, Duralde ER, Jain S, Kaufman AR, Korolev I, Lai Y, Lam BD, Lipcsey M, Martinez A, Mechanic OJ, Mlabasati J, McCoy LG, Nguyen FT, Samuel M, Yang E, Celi LA. MIT COVID-19 datathon: data without boundaries. BMJ Innov. 2021 Jan 31;7(1):231&#x2013;234. doi: 10.1136/bmjinnov-2020-000492. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjinnov-2020-000492</ArticleId><ArticleId IdType="pmc">PMC7799368</ArticleId><ArticleId IdType="pubmed">33437494</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Xie C, Pollard T, Johnson AEW, Cao D, Kang H, Liang H, Zhang Y, Liu X, Fan Y, Zhang Y, Xue W, Xie L, Celi LA, Zhang Z. Promoting secondary analysis of electronic medical records in China: summary of the PLAGH-MIT Critical Data Conference and Health Datathon. JMIR Med Inform. 2017 Nov 14;5(4):e43. doi: 10.2196/medinform.7380. 
 
v5i4e43</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.7380</ArticleId><ArticleId IdType="pmc">PMC5705855</ArticleId><ArticleId IdType="pubmed">29138126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34911976</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Preliminary feasibility assessment of CDM-based active surveillance using current status of medical device data in medical records and OMOP-CDM.</ArticleTitle><Pagination><StartPage>24070</StartPage><MedlinePgn>24070</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24070</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-03332-6</ELocationID><Abstract><AbstractText>In recent years, there has been an emerging interest in the use of claims and electronic health record (EHR) data for evaluation of medical device safety and effectiveness. In Korea, national insurance electronic data interchange (EDI) code has been used as a medical device data source for common data model (CDM). This study performed a preliminary feasibility assessment of CDM-based vigilance. A cross-sectional study of target medical device data in EHR and CDM was conducted. A total of 155 medical devices were finally enrolled, with 58.7% of them having EDI codes. Femoral head prosthesis was selected as a focus group. It was registered in our institute with 11 EDI codes. However, only three EDI codes were converted to systematized nomenclature of medicine clinical terms concept. EDI code was matched in one-to-many (up to 104) with unique device identifier (UDI), including devices classified as different global medical device nomenclature. The use of UDI rather than EDI code as a medical device data source is recommended. We hope that this study will share the current state of medical device data recorded in the EHR and contribute to the introduction of CDM-based medical device vigilance by selecting appropriate medical device data sources.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sooin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Soo Jeong</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Kuk</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Ki Chang</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Medical Engineering, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suehyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, 35365, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju Han</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Seoul National University Biomedical Informatics (SNUBI), Seoul National University College of Medicine, Seoul, 08826, Republic of Korea. juhan@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea. cecilia@schmc.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34911976</ArticleId><ArticleId IdType="pmc">PMC8674329</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-03332-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-03332-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter&#x2013;defibrillator lead. Heart Rhythm. 2007;4:892&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599673</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel WH. Semper fidelis&#x2014;Consumer protection for patients with implanted medical devices. N. Engl. J. Med. 2008;358:985&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon C, et al. Differences in perspectives of medical device adverse events: Observational results in training program using virtual cases. J. Korean Med. Sci. 2019;34:e255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786964</ArticleId><ArticleId IdType="pubmed">31602825</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Shea JC, Kramer JM, Califf RM, Peterson ED. Part I: Identifying holes in the safety net. Am. Heart J. 2004;147:977&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15199343</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnic FS. Postmarketing surveillance of medical devices&#x2014;Filling in the gaps. N. Engl. J. Med. 2012;366:875.</Citation><ArticleIdList><ArticleId IdType="pubmed">22332950</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidi VD, Matheny ME, Resnic FS. Post-marketing device safety surveillance. Contemp. Clin. Trials. 2011;32:307&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371573</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand S-LT, Hatfield L, Drozda J, Resnic FS. Postmarket surveillance for medical devices: America&#x2019;s new strategy. Br. Med. J. 2012;345:e8648.</Citation><ArticleIdList><ArticleId IdType="pubmed">23060660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, et al. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model. J. Biomed. Inform. 2019;91:103&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M-F, et al. Web-based experience sharing platform on medical device incidents for clinical engineers in hospitals. J. Med. Biol. Eng. 2018;38:835&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132694</ArticleId><ArticleId IdType="pubmed">30220902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidi VD, Matheny ME, Donnelly S, Resnic FS. An evaluation of a distributed medical device safety surveillance system: The DELTA network study. Contemp. Clin. Trials. 2011;32:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070041</ArticleId><ArticleId IdType="pubmed">21356331</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat. Commun. 2020;11:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Park RW. The distributied research network, observational health data sciences and informatics, and the South Korea research network. Korean J. Med. 2019;94:309&#x2013;114.</Citation></Reference><Reference><Citation>Evidnet, FeederNet, https://feedernet.com/resource (2021).</Citation></Reference><Reference><Citation>White J, Carolan-Rees G. Current state of medical device nomenclature and taxonomy systems in the UK: Spotlight on GMDN and SNOMED CT. JRSM Short Rep. 2013;4:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704061</ArticleId><ArticleId IdType="pubmed">23885299</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig A, O&#x2019;Meley P, Carter P. The need for greater reporting of medical device incidents. Innovations. 2019;3:56&#x2013;63.</Citation></Reference><Reference><Citation>Krupka DC, et al. Transmitting device identifiers of implants from the point of care to insurers: A demonstration project. J. Patient Saf. 2021;17:223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984755</ArticleId><ArticleId IdType="pubmed">33734207</ArticleId></ArticleIdList></Reference><Reference><Citation>Seong Y, et al. Incorporation of Korean Electronic data interchange vocabulary into observational medical outcomes partnership vocabulary. Healthc. Inform. Res. 2021;27:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921574</ArticleId><ArticleId IdType="pubmed">33611874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang, E. J. et al. Mapping Korean EDI medical procedure code to SNOMED CT. In MEDINFO 2019: Health and Wellbeing e-Networks for All 178&#x2013;182 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31437909</ArticleId></ArticleIdList></Reference><Reference><Citation>You, S. C. et al. Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM). In MEDINFO 2017:Precision Healthcare Through Informatics 467&#x2013;470 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Health Information Service. Healthcare information standard, https://hins.or.kr (2021).</Citation></Reference><Reference><Citation>Paxton EW, Inacio MCS, Khatod M, Yue EJ, Namba RS. Kaiser Permanente national total joint replacement registry: Aligning operations with information technology. Clin. Orthop. Relat. Res. 2010;468:2646&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049637</ArticleId><ArticleId IdType="pubmed">20652461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom ST, et al. Data from clinical notes: A perspective on the tension between structure and flexible documentation. J. Am. Med. Inform. Assoc. 2011;18:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116264</ArticleId><ArticleId IdType="pubmed">21233086</ArticleId></ArticleIdList></Reference><Reference><Citation>Nancy AM, Maheswari R. A review on unstructured data in medical data. J. Crit. Rev. 2020;7:2202&#x2013;2208.</Citation></Reference><Reference><Citation>Campion TR, Jr, Johnson SB, Paxton EW, Mushlin AI, Sedrakyan A. Implementing unique device identification in electronic health record systems: Organizational, workflow, and technological challenges. Med. Care. 2014;52:26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24322986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrakyan A, et al. The international consortium of orthopaedic registries: Overview and summary. JBJS. 2011;93:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262417</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertsson O, Mendenhall S, Paxton EW, Inacio MCS, Graves S. Challenges in prosthesis classification. JBJS. 2011;93:72&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262428</ArticleId></ArticleIdList></Reference><Reference><Citation>IMDRF UDI Working Group. Unique Device Identification (UDI) of Medical Devices, http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-131209-udi-guidance (2013).</Citation></Reference><Reference><Citation>Barlas S. New FDA medical device rule imposes minimal burden on hospitals: Facilities able to scan unique device identifiers will benefit. Pharm. Ther. 2013;38:720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875269</ArticleId><ArticleId IdType="pubmed">24391393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross TP, Crowley J. Unique device identification in the service of public health. N. Engl. J. Med. 2012;367:1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">23013051</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston JW, Howarth AL, Wilson NA, Mahabir RC. The value of unique device identifiers in plastic surgery. Aesthet. Surg. J. 2018;38:1264&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">30202871</ArticleId></ArticleIdList></Reference><Reference><Citation>Camus D, et al. New European medical device regulation: How the French ecosystem should seize the opportunity of the EUDAMED and the UDI system, while overcoming the constraints thereof. Therapies. 2019;74:73&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30598315</ArticleId></ArticleIdList></Reference><Reference><Citation>Melvin T, Torre M. New medical device regulations: The regulator&#x2019;s view. EFORT Open Rev. 2019;4:351&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598613</ArticleId><ArticleId IdType="pubmed">31312522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety. Medical devices act, https://elaw.klri.re.kr/kor_service/lawView.do?hseq=50798&amp;lang=ENG (2019).</Citation></Reference><Reference><Citation>Wilson NA, Drozda J. Value of unique device identification in the digital health infrastructure. JAMA. 2013;309:2107&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">23695480</ArticleId></ArticleIdList></Reference><Reference><Citation>Drozda JP, Jr, Dudley C, Helmering P, Roach J, Hutchison L. The Mercy unique device identifier demonstration project: Implementing point of use product identification in the cardiac catheterization laboratories of a regional health system. Healthcare. 2016;4:116&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">27343161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Ross JS, Schulz WL, Krumholz HM. Fulfilling the promise of unique device identifiers. Ann. Intern. Med. 2018;7:183&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">29868760</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon EG, et al. Effect of bar-code technology on the safety of medication administration. N. Engl. J. Med. 2010;362:1698&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">20445181</ArticleId></ArticleIdList></Reference><Reference><Citation>Senders JW. On the complexity of medical devices and systems. BMJ Qual. Saf. 2006;15:i41&#x2013;i43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2464875</ArticleId><ArticleId IdType="pubmed">17142608</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnic FS, et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. JACC Cardiovasc. Interv. 2012;5:82&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11992667</ArticleId><ArticleId IdType="pubmed">22230153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, et al. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ. Cardiovasc. Qual. Outcomes. 2015;8:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5130285</ArticleId><ArticleId IdType="pubmed">25491915</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah JS, Maisel WH. Recalls and safety alerts affecting automated external defibrillators. JAMA. 2006;296:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen CJJ. The rosiglitazone story&#x2014;Lessons from an FDA Advisory Committee meeting. N. Engl. J. Med. 2007;357:844&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">17687124</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Yu Y, Kingsbury PR, Shah N. Augmenting medical device evaluation using a reusable unique device identifier interoperability solution based on the OHDSI common data model. Stud. Health Technol. Inform. 2019;264:1502&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438202</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K, Veermaram C, Saini SK, Singh BK. Global medical device nomenclature: The concept for reducing device-related medical errors. J. Young Pharm. 2010;2:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019382</ArticleId><ArticleId IdType="pubmed">21264103</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;yrinen K, Saranto K, Nyk&#xe4;nen P. Definition, structure, content, use and impacts of electronic health records: A review of the research literature. Int. J. Med. Inform. 2008;77:291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health and Welfare, Ministry of Health and Welfare notice 2021-174, Medical device price list, https://www.hira.or.kr/rd/insuadtcrtr/bbsView.do?pgmid=HIRAA030069000400&amp;brdScnBltNo=4&amp;brdBltNo=51884&amp;isPopupYn=Y (2021).</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety. Medical device information portal https://udiportal.mfds.go.kr (2021).</Citation></Reference><Reference><Citation>U.S. National library of medicine, Access GUDID, https://accessgudid.nlm.nih.gov (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34930903</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Predictors of diagnostic transition from major depressive disorder to bipolar disorder: a retrospective observational network study.</ArticleTitle><Pagination><StartPage>642</StartPage><MedlinePgn>642</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">642</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-021-01760-6</ELocationID><Abstract><AbstractText>Many patients with bipolar disorder (BD) are initially misdiagnosed with major depressive disorder (MDD) and are treated with antidepressants, whose potential iatrogenic effects are widely discussed. It is unknown whether MDD is a comorbidity of BD or its earlier stage, and no consensus exists on individual conversion predictors, delaying BD's timely recognition and treatment. We aimed to build a predictive model of MDD to BD conversion and to validate it across a multi-national network of patient databases using the standardization afforded by the Observational Medical Outcomes Partnership (OMOP) common data model. Five "training" US databases were retrospectively analyzed: IBM MarketScan CCAE, MDCR, MDCD, Optum EHR, and Optum Claims. Cyclops regularized logistic regression models were developed on one-year MDD-BD conversion with all standard covariates from the HADES PatientLevelPrediction package. Time-to-conversion Kaplan-Meier analysis was performed up to a decade after MDD, stratified by model-estimated risk. External validation of the final prediction model was performed across 9 patient record databases within the Observational Health Data Sciences and Informatics (OHDSI) network internationally. The model's area under the curve (AUC) varied 0.633-0.745 (&#xb5; = 0.689) across the five US training databases. Nine variables predicted one-year MDD-BD transition. Factors that increased risk were: younger age, severe depression, psychosis, anxiety, substance misuse, self-harm thoughts/actions, and prior mental disorder. AUCs of the validation datasets ranged 0.570-0.785 (&#xb5; = 0.664). An assessment algorithm was built for MDD to BD conversion that allows distinguishing as much as 100-fold risk differences among patients and validates well across multiple international data sources.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nestsiarovich</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-3217-4147</Identifier><AffiliationInfo><Affiliation>Vanderbilt University, Department of Biomedical Informatics, Department of Medicine, Department of Biostatistics, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System VA, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaton</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xinzhuo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfohl</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Stanford University, Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Carmen Olga</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-3678-9862</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Psychiatry, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Sang Joon</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-7434-7996</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Psychiatry, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Biomedical Informatics, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Biomedical Informatics, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0003-1994-2893</Identifier><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Albuquerque, NM, USA. cglambert@unm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Division of Translational Informatics, Albuquerque, NM, USA. cglambert@unm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 MH120826</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH018399</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.M.R. and P.B.R. are employees of Janssen Research &amp; Development and shareholders of Johnson &amp; Johnson. C.G.R. and C.O.T. are employees of IQVIA. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34930903</ArticleId><ArticleId IdType="pmc">PMC8688463</ArticleId><ArticleId IdType="doi">10.1038/s41398-021-01760-6</ArticleId><ArticleId IdType="pii">10.1038/s41398-021-01760-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789&#x2013;858. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Mental Health. NIMH &#xbb; Major Depression. https://www.nimh.nih.gov/health/statistics/major-depression.shtml (accessed 11 Feb 2020).</Citation></Reference><Reference><Citation>National Alliance on Mental Illness. Mental Health By the Numbers. https://www.nami.org/learn-more/mental-health-by-the-numbers (accessed 11 Feb 2020).</Citation></Reference><Reference><Citation>WHO, World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization; 1993.</Citation></Reference><Reference><Citation>Fagiolini A, Cuomo A. On the centrality of mixed features in mood disorders: listening to Kraepelin and Weygandt and moving forward. Bipolar Disord. 2017;19:704&#x2013;5. doi: 10.1111/bdi.12537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12537</ArticleId><ArticleId IdType="pubmed">28833966</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Merikangas KR, Cui L, Van Meter A, Ajdacic-Gross V, R&#xf6;ssler W. Bipolar spectrum in major depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2018;268:741&#x2013;8. doi: 10.1007/s00406-018-0927-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-018-0927-x</ArticleId><ArticleId IdType="pubmed">30032467</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi GS, Bell E. Mixed states: an early warning sign of profound problems in our taxonomy? Acta Psychiatr Scand. 2019;139:489&#x2013;92. doi: 10.1111/acps.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.13037</ArticleId><ArticleId IdType="pubmed">31093974</ArticleId></ArticleIdList></Reference><Reference><Citation>Musliner KL, &#xd8;stergaard SD. Patterns and predictors of conversion to bipolar disorder in 91 587 individuals diagnosed with unipolar depression. Acta Psychiatr Scand. 2018;137:422&#x2013;32. doi: 10.1111/acps.12869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.12869</ArticleId><ArticleId IdType="pubmed">29498031</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord. 2005;84:149&#x2013;57. doi: 10.1016/S0165-0327(03)00195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(03)00195-2</ArticleId><ArticleId IdType="pubmed">15708412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, Willer I, Andersen PK, Bukh JD. Rate and predictors of conversion from unipolar to bipolar disorder: A systematic review and meta-analysis. Bipolar Disord. 2017;19:324&#x2013;35. doi: 10.1111/bdi.12513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12513</ArticleId><ArticleId IdType="pubmed">28714575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen T-J, Cheng J-Y, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200:45&#x2013;51. doi: 10.1192/bjp.bp.110.086983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.110.086983</ArticleId><ArticleId IdType="pubmed">22016435</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno C, Hasin DS, Arango C, Oquendo MA, Vieta E, Liu S, et al. Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 2012;14:271&#x2013;82. doi: 10.1111/j.1399-5618.2012.01009.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5618.2012.01009.x</ArticleId><ArticleId IdType="pmc">PMC3349442</ArticleId><ArticleId IdType="pubmed">22548900</ArticleId></ArticleIdList></Reference><Reference><Citation>Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) J Clin Psychiatry. 2007;68:1472&#x2013;9. doi: 10.4088/JCP.v68n1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v68n1002</ArticleId><ArticleId IdType="pubmed">17960960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y-H, Chen K, Chang I-C, Shen C-C. Critical predictors for the early detection of conversion from unipolar major depressive disorder to bipolar disorder: nationwide population-based retrospective cohort study. JMIR Med Inf. 2020;8:e14278. doi: 10.2196/14278.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14278</ArticleId><ArticleId IdType="pmc">PMC7165312</ArticleId><ArticleId IdType="pubmed">32242821</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland A, Roberts G, Holmes-Preston E, Perich T, Levy F, Lenroot R, et al. Clinical predictors of conversion to bipolar disorder in a prospective longitudinal familial high-risk sample: focus on depressive features. Psychol Med. 2018;48:1713&#x2013;21. doi: 10.1017/S0033291717003233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291717003233</ArticleId><ArticleId IdType="pubmed">29108524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kim Y, Baek JH, Fava M, Mischoulon D, Nierenberg AA, et al. Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea. J Affect Disord. 2020;265:52&#x2013;58. doi: 10.1016/j.jad.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.01.009</ArticleId><ArticleId IdType="pubmed">31957692</ArticleId></ArticleIdList></Reference><Reference><Citation>James A, Wotton CJ, Duffy A, Hoang U, Goldacre M. Conversion from depression to bipolar disorder in a cohort of young people in England, 1999-2011: a national record linkage study. J Affect Disord. 2015;185:123&#x2013;8. doi: 10.1016/j.jad.2015.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2015.06.018</ArticleId><ArticleId IdType="pubmed">26172983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EY, Kim NW, Kim MJ, Yang BR, Rhee SJ, Park CHK, et al. Rate of diagnostic conversion to bipolar disorder in adults with unipolar depression and psychopharmacological treatment in the republic of Korea: A nationwide register-based study. J Affect Disord. 2020;273:240&#x2013;6. doi: 10.1016/j.jad.2020.03.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.03.159</ArticleId><ArticleId IdType="pubmed">32421610</ArticleId></ArticleIdList></Reference><Reference><Citation>McPadden J, Durant TJ, Bunch DR, Coppi A, Price N, Rodgerson K, et al. Health care and precision medicine research: analysis of a scalable data science platform. J Med Internet Res. 2019;21:e13043. doi: 10.2196/13043.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13043</ArticleId><ArticleId IdType="pmc">PMC6477571</ArticleId><ArticleId IdType="pubmed">30964441</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167&#x2013;76. doi: 10.1016/j.jclinepi.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.12.005</ArticleId><ArticleId IdType="pubmed">26772608</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G, Li W, O&#x2019;Reilly C, Balraj D, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. Preprint at http://arxiv.org/abs/2003.10534 (2020).</Citation></Reference><Reference><Citation>Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord. 2005;84:117&#x2013;25. doi: 10.1016/S0165-0327(03)00194-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(03)00194-0</ArticleId><ArticleId IdType="pubmed">15708408</ArticleId></ArticleIdList></Reference><Reference><Citation>Othmer E, Desouza CM, Penick EC, Nickel EJ, Hunter EE, Othmer SC, et al. Indicators of mania in depressed outpatients: a retrospective analysis of data from the Kansas 1500 study. J Clin Psychiatry. 2007;68:47&#x2013;51. doi: 10.4088/JCP.v68n0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v68n0106</ArticleId><ArticleId IdType="pubmed">17284129</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry. 2001;158:1265&#x2013;70. doi: 10.1176/appi.ajp.158.8.1265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.158.8.1265</ArticleId><ArticleId IdType="pubmed">11481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Holma KM, Melartin TK, Holma IAK, Isomets&#xe4; ET. Predictors for switch from unipolar major depressive disorder to bipolar disorder type I or II: a 5-year prospective study. J Clin Psychiatry. 2008;69:1267&#x2013;75. doi: 10.4088/JCP.v69n0809.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v69n0809</ArticleId><ArticleId IdType="pubmed">18681753</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Kimura T, Inagaki Y, Shirakawa O. Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder. Neuropsychiatr Dis Treat. 2020;16:1695&#x2013;704. doi: 10.2147/NDT.S246294.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S246294</ArticleId><ArticleId IdType="pmc">PMC7369363</ArticleId><ArticleId IdType="pubmed">32764945</ArticleId></ArticleIdList></Reference><Reference><Citation>Goes FS, McCusker MG, Bienvenu OJ, Mackinnon DF, Mondimore FM, Schweizer B, et al. Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychol Med. 2012;42:1449&#x2013;59. doi: 10.1017/S0033291711002637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291711002637</ArticleId><ArticleId IdType="pmc">PMC3643205</ArticleId><ArticleId IdType="pubmed">22099954</ArticleId></ArticleIdList></Reference><Reference><Citation>Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord. 2001;67:45&#x2013;59. doi: 10.1016/S0165-0327(01)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(01)00432-3</ArticleId><ArticleId IdType="pubmed">11869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161&#x2013;74. doi: 10.4088/JCP.v64n0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v64n0209</ArticleId><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985&#x2013;91. doi: 10.4088/JCP.v63n1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v63n1105</ArticleId><ArticleId IdType="pubmed">12444811</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pr. 2008;14:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18677197</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, Andreazza AC, et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord. 2009;114:1&#x2013;13. doi: 10.1016/j.jad.2008.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2008.08.011</ArticleId><ArticleId IdType="pubmed">18819715</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe PJ, Christopher PP, Pinals DA, Fisher WH. Predictors of criminal justice involvement in severe mania. J Affect Disord. 2013;149:367&#x2013;74. doi: 10.1016/j.jad.2013.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.02.015</ArticleId><ArticleId IdType="pubmed">23477847</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Abekawa T, Nakagawa S, Suzuki K, Tanaka T, Kitaichi Y, et al. Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity. J Affect Disord. 2011;129:64&#x2013;67. doi: 10.1016/j.jad.2010.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.08.022</ArticleId><ArticleId IdType="pubmed">20837361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34937726</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study.</ArticleTitle><Pagination><StartPage>e057632</StartPage><MedlinePgn>e057632</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e057632</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-057632</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To characterise patients with and without prevalent hypertension and COVID-19 and to assess adverse outcomes in both inpatients and outpatients.</AbstractText><AbstractText Label="DESIGN AND SETTING">This is a retrospective cohort study using 15 healthcare databases (primary and secondary electronic healthcare records, insurance and national claims data) from the USA, Europe and South Korea, standardised to the Observational Medical Outcomes Partnership common data model. Data were gathered from 1 March to 31 October 2020.</AbstractText><AbstractText Label="PARTICIPANTS">Two non-mutually exclusive cohorts were defined: (1) individuals diagnosed with COVID-19 (diagnosed cohort) and (2) individuals hospitalised with COVID-19 (hospitalised cohort), and stratified by hypertension status. Follow-up was from COVID-19 diagnosis/hospitalisation to death, end of the study period or 30 days.</AbstractText><AbstractText Label="OUTCOMES">Demographics, comorbidities and 30-day outcomes (hospitalisation and death for the 'diagnosed' cohort and adverse events and death for the 'hospitalised' cohort) were reported.</AbstractText><AbstractText Label="RESULTS">We identified 2&#x2009;851&#x2009;035 diagnosed and 563&#x2009;708 hospitalised patients with COVID-19. Hypertension was more prevalent in the latter (ranging across databases from 17.4% (95% CI 17.2 to 17.6) to 61.4% (95% CI 61.0 to 61.8) and from 25.6% (95% CI 24.6 to 26.6) to 85.9% (95% CI 85.2 to 86.6)). Patients in both cohorts with hypertension were predominantly &gt;50 years old and female. Patients with hypertension were frequently diagnosed with obesity, heart disease, dyslipidaemia and diabetes. Compared with patients without hypertension, patients with hypertension in the COVID-19 diagnosed cohort had more hospitalisations (ranging from 1.3% (95% CI 0.4 to 2.2) to 41.1% (95% CI 39.5 to 42.7) vs from 1.4% (95% CI 0.9 to 1.9) to 15.9% (95% CI 14.9 to 16.9)) and increased mortality (ranging from 0.3% (95% CI 0.1 to 0.5) to 18.5% (95% CI 15.7 to 21.3) vs from 0.2% (95% CI 0.2 to 0.2) to 11.8% (95% CI 10.8 to 12.8)). Patients in the COVID-19 hospitalised cohort with hypertension were more likely to have acute respiratory distress syndrome (ranging from 0.1% (95% CI 0.0 to 0.2) to 65.6% (95% CI 62.5 to 68.7) vs from 0.1% (95% CI 0.0 to 0.2) to 54.7% (95% CI 50.5 to 58.9)), arrhythmia (ranging from 0.5% (95% CI 0.3 to 0.7) to 45.8% (95% CI 42.6 to 49.0) vs from 0.4% (95% CI 0.3 to 0.5) to 36.8% (95% CI 32.7 to 40.9)) and increased mortality (ranging from 1.8% (95% CI 0.4 to 3.2) to 25.1% (95% CI 23.0 to 27.2) vs from 0.7% (95% CI 0.5 to 0.9) to 10.9% (95% CI 10.4 to 11.4)) than patients without hypertension.</AbstractText><AbstractText Label="CONCLUSIONS">COVID-19 patients with hypertension were more likely to suffer severe outcomes, hospitalisations and deaths compared with those without hypertension.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8486-3265</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puente</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ui-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6743-803X</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8234-5843</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Institute for Health and Care Excellence (NICE), London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Center for Statistics in Medicine, NDORMS, University of Oxford, Botnar Research Center, Nuffield Orthopaedic Center, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valveny</LastName><ForeName>Neus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Real-World Evidence, TFS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Maeztu</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IOMED, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorl&#xed; Red&#xf3;</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigaci&#xf3; M&#xe8;dica (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez Roldan</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Director of Innovation and Digital Transformation, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Montesinos</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigaci&#xf3; M&#xe8;dica (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Tarrytown, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterial Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Publich Health, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-016201</GrantID><Acronym>GATES</Acronym><Agency>Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-019257</GrantID><Acronym>GATES</Acronym><Agency>Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword></KeywordList><CoiStatement>Competing interests: SLD reports grants from Anolinx. MAS reports grants from US National Institutes of Health, grants from Department of Veterans Affairs, during the conduct of the study; grants from IQVIA, personal fees from Janssen Research and Development, grants from US Food and Drug Administration, personal fees from Private Health Management, outside the submitted work. GH reports grants from NIH, during the conduct of the study; and grants from Janssen Research, outside the submitted work. FN reports being an employee of AstraZeneca until 2019 and holds some AstraZeneca shares, outside the submitted work. KK reports personal fees from the National Institutes of Health, outside the submitted work, and at the time of data analysis and initial drafting of the manuscript. KK was an employee of IQVIA. CRei reports he is an employee of IQVIA. GdM is an employee of IOMED. NV is an employee of TFS. AGS reports personal fees from Janssen R&amp;D, outside the submitted work, and is a full-time employee of Janssen R&amp;D and a Johnson and Johnson shareholder. CB reports personal fees from Janssen R&amp;D, outside the submitted work, and is a full-time employee of Janssen R&amp;D and a Johnson and Johnson shareholder. JDP reports grants from the National Library of Medicine, during the conduct of the study. AG is an employee of Regeneron Pharmaceuticals and reports stocks from Regeneron Pharmaceuticals. PRR reports having received research group grants from Innovative Medicine Initiative and Janssen Research and Development. PR reports being an employee of Janssen Research and Development and a shareholder of Johnson &amp; Johnson. ER, SF-B, NS, LMS, DP, SCY, MR, AP-U, HA, KEL, MEM, AO, CA, CRey, TD-S, TMA, OA, W-U-RA, ILM, JMR, LSR, DD, LL and AP have nothing to declare. No other relationships or activities could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34937726</ArticleId><ArticleId IdType="pmc">PMC8704062</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-057632</ArticleId><ArticleId IdType="pii">bmjopen-2021-057632</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weekly Operational Update on COVID-19-6 Sep 2021 [internet] . WHO. Available: https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---6-september-2021</Citation></Reference><Reference><Citation>Unger T, Borghi C, Charchar F. 2020 International Society of hypertension global hypertension practice guidelines. J Hypertens 2020;75:982&#x2013;1004. 10.1161/HYPERTENSIONAHA.120.1502</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.1502</ArticleId><ArticleId IdType="pubmed">32371787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook TM. The importance of hypertension as a risk factor for severe illness and mortality in COVID-19. Anaesthesia 2020;75:976&#x2013;7. 10.1111/anae.15103</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15103</ArticleId><ArticleId IdType="pmc">PMC7267452</ArticleId><ArticleId IdType="pubmed">32339251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, et al. . Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436&#x2013;12. 10.1001/jamainternmed.2020.3596</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez E, Font&#xe1;n-Vela M, Valencia J, et al. . Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study. BMJ Open 2020;10:e042398. 10.1136/bmjopen-2020-042398</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-042398</ArticleId><ArticleId IdType="pmc">PMC7656887</ArticleId><ArticleId IdType="pubmed">33172949</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Wang J, Liu F, et al. . COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020;43:824&#x2013;31. 10.1038/s41440-020-0485-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0485-2</ArticleId><ArticleId IdType="pmc">PMC7261650</ArticleId><ArticleId IdType="pubmed">32483311</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BE, Lee JH, Park HK, et al. . Impact of cardiovascular risk factors and cardiovascular diseases on outcomes in patients hospitalized with COVID-19 in Daegu metropolitan City. J Korean Med Sci 2021;36:e15. 10.3346/jkms.2021.36.e15</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e15</ArticleId><ArticleId IdType="pmc">PMC7801150</ArticleId><ArticleId IdType="pubmed">33429474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Q, Ni J, Hu T-T, et al. . Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med 2020;21:615&#x2013;25. 10.31083/j.rcm.2020.04.113</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2020.04.113</ArticleId><ArticleId IdType="pubmed">33388007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054&#x2013;62. 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Lu X, Li Y, et al. . Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201:1430&#x2013;4. 10.1164/rccm.202003-0736LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0736LE</ArticleId><ArticleId IdType="pmc">PMC7258632</ArticleId><ArticleId IdType="pubmed">32267160</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574&#x2013;81. 10.1001/jama.2020.5394</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Cai Y, Zhang K, et al. . Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020;41:2058&#x2013;66. 10.1093/eurheartj/ehaa433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa433</ArticleId><ArticleId IdType="pmc">PMC7314067</ArticleId><ArticleId IdType="pubmed">32498076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-J, Liang W-H, Zhao Y, et al. . Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. 10.1183/13993003.00547-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00547-2020</ArticleId><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Huh K, Kang M, et al. . Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci 2020;35:e237. 10.3346/jkms.2020.35.e237</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e237</ArticleId><ArticleId IdType="pmc">PMC7324262</ArticleId><ArticleId IdType="pubmed">32597048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilimuri S, Sun H, Alemam A, et al. . Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City. West J Emerg Med 2020;21:779&#x2013;84. 10.5811/westjem.2020.6.47919</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/westjem.2020.6.47919</ArticleId><ArticleId IdType="pmc">PMC7390589</ArticleId><ArticleId IdType="pubmed">32726241</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA 2020;323:2052&#x2013;9. 10.1001/jama.2020.6775</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorjee K, Kim H, Bonomo E, et al. . Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: a comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One 2020;15:e0243191. 10.1371/journal.pone.0243191</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243191</ArticleId><ArticleId IdType="pmc">PMC7721151</ArticleId><ArticleId IdType="pubmed">33284825</ArticleId></ArticleIdList></Reference><Reference><Citation>Javanmardi F, Keshavarzi A, Akbari A, et al. . Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One 2020;15:e0241265. 10.1371/journal.pone.0241265</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241265</ArticleId><ArticleId IdType="pmc">PMC7584167</ArticleId><ArticleId IdType="pubmed">33095835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R, Lim MA, Huang I, et al. . Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst 2020;21:147032032092689. 10.1177/1470320320926899</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320320926899</ArticleId><ArticleId IdType="pmc">PMC7231906</ArticleId><ArticleId IdType="pubmed">32408793</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverio A, Di Maio M, Citro R, et al. . Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc Disord 2021;21:23. 10.1186/s12872-020-01816-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01816-3</ArticleId><ArticleId IdType="pmc">PMC7789083</ArticleId><ArticleId IdType="pubmed">33413093</ArticleId></ArticleIdList></Reference><Reference><Citation>Moazzami B, Chaichian S, Kasaeian A, et al. . Metabolic risk factors and risk of Covid-19: a systematic review and meta-analysis. PLoS One 2020;15:e0243600. 10.1371/journal.pone.0243600</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243600</ArticleId><ArticleId IdType="pmc">PMC7737901</ArticleId><ArticleId IdType="pubmed">33320875</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj J, Karaku&#x142;a-Juchnowicz H, Teresi&#x144;ski G, et al. . COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9:1753. 10.3390/jcm9061753</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061753</ArticleId><ArticleId IdType="pmc">PMC7356953</ArticleId><ArticleId IdType="pubmed">32516940</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Kostka K, Duarte-Salles T. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using Charybdis. Res Sq [Preprint] 2021:rs.3.rs-279400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MDM, Hermosilla E, Prieto-Alhambra D, et al. . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135&#x2013;45. 10.14236/jhi.v19i3.806</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v19i3.806</ArticleId><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G. A new paradigm for accelerating clinical data science at Stanford medicine. arXiv 2003;10534.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. . Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553&#x2013;64. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. . Hypertension and diabetes mellitus: Coprediction and time trajectories. Hypertension 2018;71:422&#x2013;8. 10.1161/HYPERTENSIONAHA.117.10546</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10546</ArticleId><ArticleId IdType="pmc">PMC5877818</ArticleId><ArticleId IdType="pubmed">29335249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34952871</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Investigating the impact of development and internal validation design when training prognostic models using a retrospective cohort in big US observational healthcare data.</ArticleTitle><Pagination><StartPage>e050146</StartPage><MedlinePgn>e050146</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e050146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-050146</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The internal validation of prediction models aims to quantify the generalisability of a model. We aim to determine the impact, if any, that the choice of development and internal validation design has on the internal performance bias and model generalisability in big data (n~500&#x2009;000).</AbstractText><AbstractText Label="DESIGN">Retrospective cohort.</AbstractText><AbstractText Label="SETTING">Primary and secondary care; three US claims databases.</AbstractText><AbstractText Label="PARTICIPANTS">1 200 769 patients pharmaceutically treated for their first occurrence of depression.</AbstractText><AbstractText Label="METHODS">We investigated the impact of the development/validation design across 21 real-world prediction questions. Model discrimination and calibration were assessed. We trained LASSO logistic regression models using US claims data and internally validated the models using eight different designs: 'no test/validation set', 'test/validation set' and cross validation with 3-fold, 5-fold or 10-fold with and without a test set. We then externally validated each model in two new US claims databases. We estimated the internal validation bias per design by empirically comparing the differences between the estimated internal performance and external performance.</AbstractText><AbstractText Label="RESULTS">The differences between the models' internal estimated performances and external performances were largest for the 'no test/validation set' design. This indicates even with large data the 'no test/validation set' design causes models to overfit. The seven alternative designs included some validation process to select the hyperparameters and a fair testing process to estimate internal performance. These designs had similar internal performance estimates and performed similarly when externally validated in the two external databases.</AbstractText><AbstractText Label="CONCLUSIONS">Even with big data, it is important to use some validation process to select the optimal hyperparameters and fairly assess internal validation using a test set or cross-validation.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA jreps@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">health informatics</Keyword><Keyword MajorTopicYN="N">preventive medicine</Keyword><Keyword MajorTopicYN="N">statistics &amp; research methods</Keyword></KeywordList><CoiStatement>Competing interests: JMR and PR report and are employees of Janssen Research and Development and are shareholders of Johnson &amp; Johnson. PRR reports grants from Innovative Medicines Initiative, grants from Janssen Research and development, during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34952871</ArticleId><ArticleId IdType="pmc">PMC8710861</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-050146</ArticleId><ArticleId IdType="pii">bmjopen-2021-050146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steyerberg EW, Moons KGM, van der Windt DA, et al. . Prognosis research strategy (progress) 3: prognostic model research. PLoS Med 2013;10:e1001381. 10.1371/journal.pmed.1001381</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001381</ArticleId><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Navar AM, Pencina MJ, et al. . Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc 2017;24:198&#x2013;208. 10.1093/jamia/ocw042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying X. An overview of overfitting and its solutions. Journal of Physics: Conference Series 2019;1168:022022. 10.1088/1742-6596/1168/2/022022</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1742-6596/1168/2/022022</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B, Tibshirani RJ. An introduction to the bootstrap. CRC Press, 1994.</Citation></Reference><Reference><Citation>Steyerberg EW, Harrell FE, Borsboom GJ, et al. . Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774&#x2013;81. 10.1016/s0895-4356(01)00341-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(01)00341-9</ArticleId><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol 2016;69:245&#x2013;7. 10.1016/j.jclinepi.2015.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.04.005</ArticleId><ArticleId IdType="pmc">PMC5578404</ArticleId><ArticleId IdType="pubmed">25981519</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al. . Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 2018;25:969&#x2013;75. 10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. . Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013;23:1&#x2013;17. 10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer-Verlag, 2001.</Citation></Reference><Reference><Citation>John LH, Kors JA, Reps JM. How little data do we need for patient-level prediction? arXiv preprint 2020:2008.07361.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35046809</PMID><DateRevised><Year>2022</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events.</ArticleTitle><Pagination><StartPage>773135</StartPage><MedlinePgn>773135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">773135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2021.773135</ELocationID><Abstract><AbstractText><b>Introduction:</b> Improving adverse drug event (ADE) detection is important for post-marketing drug safety surveillance. Existing statistical approaches can be further optimized owing to their high efficiency and low cost. <b>Objective:</b> The objective of this study was to evaluate the proposed approach for use in pharmacovigilance, the early detection of potential ADEs, and the improvement of drug safety. <b>Methods:</b> We developed a novel integrated approach, the Bayesian signal detection algorithm, based on the pharmacological network model (IC<sub>PNM</sub>) using the FDA Adverse Event Reporting System (FAERS) data published from 2004 to 2009 and from 2014 to 2019Q2, PubChem, and DrugBank database. First, we used a pharmacological network model to generate the probabilities for drug-ADE associations, which comprised the proper prior information component (IC). We then defined the probability of the propensity score adjustment based on a logistic regression model to control for the confounding bias. Finally, we chose the Side Effect Resource (SIDER) and the Observational Medical Outcomes Partnership (OMOP) data to evaluate the detection performance and robustness of the IC<sub>PNM</sub> compared with the statistical approaches [disproportionality analysis (DPA)] by using the area under the receiver operator characteristics curve (AUC) and Youden's index. <b>Results:</b> Of the statistical approaches implemented, the IC<sub>PNM</sub> showed the best performance (AUC, 0.8291; Youden's index, 0.5836). Meanwhile, the AUCs of the IC, EBGM, ROR, and PRR were 0.7343, 0.7231, 0.6828, and 0.6721, respectively. <b>Conclusion:</b> The proposed IC<sub>PNM</sub> combined the strengths of the pharmacological network model and the Bayesian signal detection algorithm and performed better in detecting true drug-ADE associations. It also detected newer ADE signals than a DPA and may be complementary to the existing statistical approaches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Ji, Cui, Xu, Hou, Zhang and Ren.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Xiangmin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Guimei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chengzhen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Computer Science and Technology, Huaibei Normal University, Huaibei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Computer Engineering, Ordos Institute of Technology, Ordos, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FDA adverse event reporting system</Keyword><Keyword MajorTopicYN="N">adverse drug events</Keyword><Keyword MajorTopicYN="N">pharmacological network model</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">signal detection algorithm</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35046809</ArticleId><ArticleId IdType="pmc">PMC8762263</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.773135</ArticleId><ArticleId IdType="pii">773135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banda J. M., Evans L., Vanguri R. S., Tatonetti N. P., Ryan P. B., Shah N. H. (2016). A Curated and Standardized Adverse Drug Event Resource to Accelerate Drug Safety Research. Sci. Data 3, 160026. 10.1038/sdata.2016.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.26</ArticleId><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A., Lindquist M., Edwards I. R., Olsson S., Orre R., Lansner A., et al. (1998). A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation. Eur. J. Clin. Pharmacol. 54, 315&#x2013;321. 10.1007/s002280050466</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050466</ArticleId><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A., Arnold A., Manzi S., Reis B. (2011). Predicting Adverse Drug Events Using Pharmacological Network Models. Sci. Transl Med. 3, 114ra127&#x2013;127. 10.1126/scitranslmed.3002774</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002774</ArticleId><ArticleId IdType="pubmed">22190238</ArticleId></ArticleIdList></Reference><Reference><Citation>Candore G., Juhlin K., Manlik K., Thakrar B., Quarcoo N., Seabroke S., et al. (2015). Comparison of Statistical Signal Detection Methods within and across Spontaneous Reporting Databases. Drug Saf. 38, 577&#x2013;587. 10.1007/s40264-015-0289-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0289-5</ArticleId><ArticleId IdType="pubmed">25899605</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster O., Nor&#xe9;n G. N., Madigan D., Bate A. (2010). Large-scale Regression-Based Pattern Discovery: The Example of Screening the WHO Global Drug Safety Database. Stat. Analy Data Mining 3, 197&#x2013;208. 10.1002/sam.10078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sam.10078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F., Li W., Wang X., Zhou Y., Wu Z., Shen J., et al. (2013). Adverse Drug Events: Database Construction and In Silico Prediction. J. Chem. Inf. Model. 53, 744&#x2013;752. 10.1021/ci4000079</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci4000079</ArticleId><ArticleId IdType="pubmed">23521697</ArticleId></ArticleIdList></Reference><Reference><Citation>Davazdahemami B., Delen D. (2018). A Chronological Pharmacovigilance Network Analytics Approach for Predicting Adverse Drug Events. J. Am. Med. Inform. Assoc. 25, 1311&#x2013;1321. 10.1093/jamia/ocy097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy097</ArticleId><ArticleId IdType="pmc">PMC7646912</ArticleId><ArticleId IdType="pubmed">30085102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Markatou M., Ball R. (2020). An Evaluation of Statistical Approaches to Postmarketing Surveillance. Stat. Med. 39, 845&#x2013;874. 10.1002/sim.8447</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8447</ArticleId><ArticleId IdType="pubmed">31912927</ArticleId></ArticleIdList></Reference><Reference><Citation>
DrugBank (2020). Available From: https://go.drugbank.com
.</Citation></Reference><Reference><Citation>DuMouchel W., Ryan P. B., Schuemie M. J., Madigan D. (2013). Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases. Drug Saf. 36, S123&#x2013;S132. 10.1007/s40264-013-0106-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0106-y</ArticleId><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W. (1999). Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System. The Am. Statistician 53, 177&#x2013;190. 10.1080/00031305.1999.10474456</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305.1999.10474456</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S. J., Waller P. C., Davis S. (2001). Use of Proportional Reporting Ratios (PRRs) for Signal Generation from Spontaneous Adverse Drug Reaction Reports. Pharmacoepidemiol. Drug Saf. 10, 483&#x2013;486. 10.1002/pds.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomini K. M., Krauss R. M., Roden D. M., Eichelbaum M., Hayden M. R., Nakamura Y. (2007). When Good Drugs Go Bad. Nature 446, 975&#x2013;977. 10.1038/446975a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/446975a</ArticleId><ArticleId IdType="pubmed">17460642</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B. A., Navar A. M., Pencina M. J., Ioannidis J. P. (2017). Opportunities and Challenges in Developing Risk Prediction Models with Electronic Health Records Data: a Systematic Review. J. Am. Med. Inform. Assoc. 24, 198&#x2013;208. 10.1093/jamia/ocw042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Lependu P., Bauer-Mehren A., Ryan P., Shah N. H. (2013a). Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. Clin. Pharmacol. Ther. 93, 539&#x2013;546. 10.1038/clpt.2013.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.24</ArticleId><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Schuemie M., Bodenreider O., Friedman C., Horvitz E., et al. (2017). Toward Multimodal Signal Detection of Adverse Drug Reactions. J. Biomed. Inform. 76, 41&#x2013;49. 10.1016/j.jbi.2017.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.10.013</ArticleId><ArticleId IdType="pmc">PMC8502488</ArticleId><ArticleId IdType="pubmed">29081385</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Shah N. H., Madigan D., Ryan P., Friedman C. (2012). Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis. Clin. Pharmacol. Ther. 91, 1010&#x2013;1021. 10.1038/clpt.2012.50</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Vilar S., DuMouchel W., Salmasian H., Haerian K., Shah N. H., et al. (2013b). Combing Signals from Spontaneous Reports and Electronic Health Records for Detection of Adverse Drug Reactions. J. Am. Med. Inform. Assoc. 20, 413&#x2013;419. 10.1136/amiajnl-2012-000930</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Zalkikar J., Tiwari R. C. (2011). A Likelihood Ratio Test Based Method for Signal Detection with Application to FDA's Drug Safety Data. J. Am. Stat. Assoc. 106, 1230&#x2013;1241. 10.1198/jasa.2011.ap10243</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/jasa.2011.ap10243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal S., Ali W., Nagpal P., Grover S., Grover A. (2019). Computational Models for the Prediction of Adverse Cardiovascular Drug Reactions. J. Transl Med. 17, 171. 10.1186/s12967-019-1918-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-1918-z</ArticleId><ArticleId IdType="pmc">PMC6530172</ArticleId><ArticleId IdType="pubmed">31118067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X., Wang L., Hua L., Wang X., Zhang P., Shendre A., et al. (2021). Improved Adverse Drug Event Prediction through Information Component Guided Pharmacological Network Model (IC-PNM). Ieee/acm Trans. Comput. Biol. Bioinf. 18, 1113&#x2013;1121. 10.1109/TCBB.2019.2928305</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TCBB.2019.2928305</ArticleId><ArticleId IdType="pubmed">31443040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou J., Pomeranz B. H., Corey P. N. (1998). Incidence of Adverse Drug Reactions in Hospitalized Patients: a Meta-Analysis of Prospective Studies. JAMA 279, 1200&#x2013;1205. 10.1001/jama.279.15.1200</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.15.1200</ArticleId><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jimeno Yepes A., Xiao C. (2020). Combining Social media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions. Drug Saf. 43, 893&#x2013;903. 10.1007/s40264-020-00943-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00943-2</ArticleId><ArticleId IdType="pmc">PMC7434724</ArticleId><ArticleId IdType="pubmed">32385840</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ryan P. B., Wei Y., Friedman C. (2015). A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. Drug Saf. 38, 895&#x2013;908. 10.1007/s40264-015-0314-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0314-8</ArticleId><ArticleId IdType="pmc">PMC4579260</ArticleId><ArticleId IdType="pubmed">26153397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Kuang Q., Li Y., Zhang Y., Sun J., Ding Z., et al. (2013). Prediction of Adverse Drug Reactions by a Network Based External Link Prediction Method. Anal. Methods 5, 6120&#x2013;6127. 10.1039/c3ay41290c</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3ay41290c</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Wu Y., Chen Y., Sun J., Zhao Z., Chen X. W., et al. (2012). Large-scale Prediction of Adverse Drug Reactions Using Chemical, Biological, and Phenotypic Properties of Drugs. J. Am. Med. Inform. Assoc. 19, e28&#x2013;35. 10.1136/amiajnl-2011-000699</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000699</ArticleId><ArticleId IdType="pmc">PMC3392844</ArticleId><ArticleId IdType="pubmed">22718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Zhang P. (2019). Towards Early Detection of Adverse Drug Reactions: Combining Pre-clinical Drug Structures and post-market Safety Reports. BMC Med. Inform. Decis. Mak 19, 279. 10.1186/s12911-019-0999-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0999-1</ArticleId><ArticleId IdType="pmc">PMC6918608</ArticleId><ArticleId IdType="pubmed">31849321</ArticleId></ArticleIdList></Reference><Reference><Citation>
MedDRA (2020). Available From: http://www.meddramsso.com/index.asp
.</Citation></Reference><Reference><Citation>Pham M., Cheng F., Ramachandran K. (2019). A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches. Drug Saf. 42, 743&#x2013;750. 10.1007/s40264-018-00792-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-018-00792-0</ArticleId><ArticleId IdType="pubmed">30762164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P. B., Schuemie M. J., Welebob E., Duke J., Valentine S., Hartzema A. G. (2013). Defining a Reference Set to Support Methodological Research in Drug Safety. Drug Saf. 36, S33&#x2013;S47. 10.1007/s40264-013-0097-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0097-8</ArticleId><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>
Side Effect Resource (2020). Available From: http://sideeffects.embl.de/

</Citation></Reference><Reference><Citation>Tatonetti N. P., Denny J. C., Murphy S. N., Fernald G. H., Krishnan G., Castro V., et al. (2011). Detecting Drug Interactions from Adverse-Event Reports: Interaction between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clin. Pharmacol. Ther. 90, 133&#x2013;142. 10.1038/clpt.2011.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.83</ArticleId><ArticleId IdType="pmc">PMC3216673</ArticleId><ArticleId IdType="pubmed">21613990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N. P., Ye P. P., Daneshjou R., Altman R. B. (2012). Data-driven Prediction of Drug Effects and Interactions. Sci. Transl. Med. 4, 125ra31&#x2013;131. 10.1126/scitranslmed.3003377</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003377</ArticleId><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>
Us Food and Drug Administration (2020). Adverse Event Reporting System (FAERS). Available From: https://www.fda.gov/Drugs/InformationOnDrugs/ucm135151.htm
. </Citation></Reference><Reference><Citation>Van Puijenbroek E. P., Bate A., Leufkens H. G., Lindquist M., Orre R., Egberts A. C. (2002). A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions. Pharmacoepidemiol. Drug Saf. 11, 3&#x2013;10. 10.1002/pds.668</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R., Wang Q. (2014). Large-scale Combining Signals from Both Biomedical Literature and the FDA Adverse Event Reporting System (FAERS) to Improve post-marketing Drug Safety Signal Detection. BMC Bioinformatics 15, 17. 10.1186/1471-2105-15-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-17</ArticleId><ArticleId IdType="pmc">PMC3906761</ArticleId><ArticleId IdType="pubmed">24428898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Li M., Chiang C. W., Wang L., Xiang Y., Cheng L., et al. (2018). Three-Component Mixture Model-Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System. CPT Pharmacometrics Syst. Pharmacol. 7, 499&#x2013;506. 10.1002/psp4.12294</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12294</ArticleId><ArticleId IdType="pmc">PMC6118321</ArticleId><ArticleId IdType="pubmed">30091855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35308947</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Extracting Patient-level Social Determinants of Health into the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>998</EndPage><MedlinePgn>989-998</MedlinePgn></Pagination><Abstract><AbstractText>Deficiencies in data sharing capabilities limit Social Determinants of Health (SDoH) analysis as part of COVID-19 research. The National COVID Cohort Collaborative (N3C) is an example of an Electronic Health Record (EHR) database of patients tested for COVID-19 that could benefit from a SDoH elements framework that captures various screening instruments in EHR data warehouse systems. This paper uses the University of Washington Enterprise Data Warehouse (a data contributor to N3C) to demonstrate how SDoH can be represented and managed to be made available within an OMOP common data model. We found that these data varied by type of social determinants data and where it was collected, in the time period that it was collected, and in how it was represented.</AbstractText><CopyrightInformation>&#xa9;2021 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zampino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobbins</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinoza</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Preventative Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madlock-Brown</LastName><ForeName>Charisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dept of Health Informatics and Information Management, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, OHSU, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064890" MajorTopicYN="Y">Social Determinants of Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35308947</ArticleId><ArticleId IdType="pmc">PMC8861735</ArticleId><ArticleId IdType="pii">3577690</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rollston R, Galea S. COVID-19 and the Social Determinants of Health. Am J Health Promot [Internet] 2020 [cited 2021 Jun 6];34:687&#x2013;9. Available at:  http://journals.sagepub.com/doi/10.1177/0890117120930536b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0890117120930536b</ArticleId><ArticleId IdType="pubmed">32551932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez IJ, Lee J. COVID-19 Emergence and Social and Health Determinants in Colorado: A Rapid Spatial Analysis. International Journal of Environmental Research and Public Health [Internet] 2020[cited 2020 Nov 9];17:3856. doi: 10.3390/ijerph17113856. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17113856</ArticleId><ArticleId IdType="pmc">PMC7312929</ArticleId><ArticleId IdType="pubmed">32485854</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Gersing K. The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment. Journal of the American Medical Informatics Association [Internet] 2020. [cited 2020 Nov 9]; Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al.  The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction [Internet] Health Informatics. 2021.  Jan [cited 2021 Jul 6]. Available at:  http://medrxiv.org/lookup/doi/10.1101/2021.01.12.21249511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.12.21249511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatef E, Rouhizadeh M, Tia I, Lasser E, Hill-Briggs F, Marsteller J, et al.  Assessing the Availability of Data on Social and Behavioral Determinants in Structured and Unstructured Electronic Health Records: A Retrospective Analysis of a Multilevel Health Care System. JMIR Med Inform [Internet] 2019[cited 2021 Feb 18];7:e13802. Available at:  http://medinform.jmir.org/2019/3/e13802/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696855</ArticleId><ArticleId IdType="pubmed">31376277</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M, Joynt Maddox KE. Utilization of Social Determinants of Health ICD-10 Z-Codes Among Hospitalized Patients in the United States, 2016-2017. Medical Care [Internet] 2020 [cited 2021 Feb 18];58:1037&#x2013;43. Available at:  https://journals.lww.com/10.1097/MLR.0000000000001418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000001418</ArticleId><ArticleId IdType="pmc">PMC7666017</ArticleId><ArticleId IdType="pubmed">32925453</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscrop A, Ziebland S, Bloch G, Iraola JR. If social determinants of health are so important, shouldn&#x2019;t we ask patients about them? BMJ [Internet] 2020.  [cited 2021 Feb 18];m4150. Available at:  https://www.bmj.com/lookup/doi/10.1136/bmj.m4150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4150</ArticleId><ArticleId IdType="pubmed">33234506</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroir BP. Healthy People 2030: A Call to Action to Lead America to Healthier Lives. Journal of Public Health Management and Practice [Internet] 2020.  [cited 2021 Jun 6];Publish Ahead of Print. Available at:  https://journals.lww.com/10.1097/PHH.0000000000001266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHH.0000000000001266</ArticleId><ArticleId IdType="pmc">PMC8478292</ArticleId><ArticleId IdType="pubmed">33278185</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels&#x2010;Kalow ME, Ciccolo GE, Lin MP, Schoenfeld EM, Camargo CA. The terminology of social emergency medicine: Measuring social determinants of health, social risk, and social need. Journal of the American College of Emergency Physicians Open [Internet] 2020 [cited 2021 Feb 18];1:852&#x2013;6. Available at:  https://onlinelibrary.wiley.com/doi/10.1002/emp2.12191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emp2.12191</ArticleId><ArticleId IdType="pmc">PMC7593464</ArticleId><ArticleId IdType="pubmed">33145531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr D, Bejan CA, Pizzimenti C, Singh S, Storer M, Quinones A. Identifying Patients with Significant Problems Related to Social Determinants of Health with Natural Language Processing. 264:1456&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lybarger K, Ostendorf M, Yetisgen M. Annotating Social Determinants of Health Using Active Learning, and Characterizing Determinants Using Neural Event Extraction.  Available at:  https://arxiv.org/abs/2004.05438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856628</ArticleId><ArticleId IdType="pubmed">33290878</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng A, Wilcox A. A Simplified Framework to Extract Social Determinants: A Data Science Approach. Submitted for publication.</Citation></Reference><Reference><Citation>Winden TJ, Chen ES, Monsen KA, Melton GB. Evaluation of Flowsheet Documentation in the Electronic Health Record for Residence, Living Situation, and Living Conditions. 2018:236&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961798</ArticleId><ArticleId IdType="pubmed">29888079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Bunce A, Cowburn S, Dambrun K, Dearing M, Middendorf M, et al.  Adoption of Social Determinants of Health EHR Tools by Community Health Centers. Ann Fam Med [Internet] 2018 [cited 2021 Feb 18];16:399&#x2013;407. Available at:  http://www.annfammed.org/lookup/doi/10.1370/afm.2275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2275</ArticleId><ArticleId IdType="pmc">PMC6131002</ArticleId><ArticleId IdType="pubmed">30201636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell EK, Dambrun K, Cowburn S, Mossman N, Bunce AE, Marino M, et al.  Variation in Electronic Health Record Documentation of Social Determinants of Health Across a National Network of Community Health Centers. American Journal of Preventive Medicine [Internet] 2019.  [cited 2020 Dec 17];57:S65-73. Available at:  https://linkinghub.elsevier.com/retrieve/pii/S0749379719303228.</Citation><ArticleIdList><ArticleId IdType="pubmed">31753281</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Boynton-Jarrett R, Dworkin PH. Avoiding the Unintended Consequences of Screening for Social Determinants of Health. JAMA [Internet] 2016.  [cited 2021 Jul 6];316:813. Available at:  http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.9282.</Citation><ArticleIdList><ArticleId IdType="pubmed">27367226</ArticleId></ArticleIdList></Reference><Reference><Citation>Page-Reeves J, Kaufman W, Bleecker M, Norris J, McCalmont K, Ianakieva V, et al.  Addressing Social Determinants of Health in a Clinic Setting: The WellRx Pilot in Albuquerque, New Mexico. The Journal of the American Board of Family Medicine [Internet] 2016 [cited 2021 Jul 6];29:414&#x2013;8. Available at:  http://www.jabfm.org/cgi/doi/10.3122/jabfm.2016.03.150272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2016.03.150272</ArticleId><ArticleId IdType="pubmed">27170801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb L. Uses and Misuses of Patient-and Neighborhood-level Social Determinants of Health Data. The Permanente Journal [Internet] 2018 [cited 2020 Dec 17]. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.7812/TPP/18-078</ArticleId><ArticleId IdType="pmc">PMC6141653</ArticleId><ArticleId IdType="pubmed">30227912</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrikson NB, Blasi PR, Dorsey CN, Mettert KD, Nguyen MB, Walsh-Bailey C, et al. Psychometric and Pragmatic Properties of Social Risk Screening Tools: A Systematic Review. American Journal of Preventive Medicine [Internet] 2019 [cited 2020 Dec 17];57:S13&#x2013;24. doi: 10.1016/j.amepre.2019.07.012. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2019.07.012</ArticleId><ArticleId IdType="pubmed">31753276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Bunce A, Cottrell E, Marino M, Middendorf M, Cowburn S, et al. Study protocol: a pragmatic, stepped-wedge trial of tailored support for implementing social determinants of health documentation/action in community health centers, with realist evaluation. Implementation Science. 2019. [cited 2020 Dec 17];14. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13012-019-0855-9</ArticleId><ArticleId IdType="pmc">PMC6348649</ArticleId><ArticleId IdType="pubmed">30691480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindig DA. A Population Health Framework for Setting National and State Health Goals. JAMA [Internet] 2008 [cited 2019 Dec 20];299:2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">18460667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H, Gamache R, Weiner J.  Cham: Springer International Publishing; 2020 [cited 2020 Nov 9]. Role of Informatics in Bridging Public and Population Health. In: Magnuson JA, Dixon BE, editors. Public Health Informatics and Information Systems [Internet] pp. 59&#x2013;79. (Health Informatics). Available at:  http://link.springer.com/10.1007/978-3-030-41215-9_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-41215-9_5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HN, Lan KF, Nkyekyer E, Neme S, Pierre-Louis M, Chew L, et al. Assessment of Disparities in COVID-19 Testing and Infection Across Language Groups in Seattle, Washington. JAMA Network Open [Internet] 2020 [cited 2020 Oct 2];3:1&#x2013;4. doi: 10.1001/jamanetworkopen.2020.21213. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.21213</ArticleId><ArticleId IdType="pmc">PMC7516622</ArticleId><ArticleId IdType="pubmed">32970156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt-Groh&#xe9; S, Teoh K, Uribe M.  Cambridge, MA: National Bureau of Economic Research; 2020. Covid-19: Testing Inequality in New York City [Internet] Apr [cited 2020 Nov 9]. Report No.: w27019. Available at:  http://www.nber.org/papers/w27019.</Citation></Reference><Reference><Citation>Seto E, Min E, Ingram C, Cummings B, Farquhar SA. Community-Level Factors Associated with COVID-19 Cases and Testing Equity in King County, Washington. International Journal of Environmental Research and Public Health [Internet] 2020.  [cited 2021 Jan 6];17:9516. Available at:  https://www.mdpi.com/1660-4601/17/24/9516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767300</ArticleId><ArticleId IdType="pubmed">33353095</ArticleId></ArticleIdList></Reference><Reference><Citation>McClung N, Chamberland M, Kinlaw K, Matthew DB, Wallace M, Bell B, et al.  The Advisory Committee on Immunization Practices&#x2019; Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine &#x2014; United States, 2020 [Internet] U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. 2012 Oct [cited 2021 Jan 21].  (Morbidity and Mortality Weekly Report). Available at:  https://www.cdc.gov/niosh/docs/2012-161/</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association [Internet] 2015 [cited 2020 May 28];22:553&#x2013;64. doi: 10.1093/jamia/ocu023. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M, Roel E, Pistillo A, Sena AG, Prats-Uribe A, Ahmed W-U-R, et al.  Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom [Internet] Epidemiology. 2020 Sep [cited 2021 Jul 6].  Available at:  http://medrxiv.org/lookup/doi/10.1101/2020.09.02.20185173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.02.20185173</ArticleId><ArticleId IdType="pmc">PMC8281807</ArticleId><ArticleId IdType="pubmed">34267326</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Kostka K, Duarte-Salles T, Prats-Uribe A, Sena A, Pistillo A, et al.  Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS [Internet]. In Review; 2021 Mar [cited 2021 Jul 6]  Available at:  https://www.researchsquare.com/article/rs-279400/v1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena A, Kostka K, Abedtash H, Abrahao MTF, et al.  Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study. 2020.  [cited 2020 Nov 9]; Available at:  http://medrxiv.org/lookup/doi/10.1101/2020.04.22.20074336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>UCSF Social Interventions Research &amp; Evaluation Network (SIREN) [Internet] Social Needs Screening Tool Comparison Table [Internet] 2020.  [cited 2021 Mar 10]. Available at:  https://sirenetwork.ucsf.edu/SocialNeedsScreeningToolComparisonTable.</Citation></Reference><Reference><Citation>OHDSI ATHENA standardized vocabularies [Internet]. [cited 2021 Jul 2]  Available at:  https://athena.ohdsi.org/</Citation></Reference><Reference><Citation>2018 Census Occupation Code List with Crosswalk. US Census Bureau. 2019.  [cited 2020 Aug 3]. Available at:  https://www2.census.gov/programs-surveys/demo/guidance/industry-occupation/2018-occupation-code-list-and-crosswalk.xlsx.</Citation></Reference><Reference><Citation>Espinoza J, Meeker D, Bahroos N. Social and Environmental Determinants of Health (SEDoH) in Clinical Informatics. Presented at: CD2H Informatics Maturity And Best Practices Community Meeting; 2020 May 21.</Citation></Reference><Reference><Citation>Thornton RLJ, Glover CM, Cen&#xe9; CW, Glik DC, Henderson JA, Williams DR. Evaluating Strategies For Reducing Health Disparities By Addressing The Social Determinants Of Health. Health Affairs [Internet] 2016 [cited 2021 Jul 6];35:1416&#x2013;23. Available at:  http://www.healthaffairs.org/doi/10.1377/hlthaff.2015.1357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2015.1357</ArticleId><ArticleId IdType="pmc">PMC5524193</ArticleId><ArticleId IdType="pubmed">27503966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lofters AK, Schuler A, Slater M, Baxter NN, Persaud N, Pinto AD, et al.  Using self-reported data on the social determinants of health in primary care to identify cancer screening disparities: opportunities and challenges. BMC Fam Pract [Internet] 2017.  [cited 2021 Jul 6];18:31. Available at:  http://bmcfampract.biomedcentral.com/articles/10.1186/s12875-017-0599-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-017-0599-z</ArticleId><ArticleId IdType="pmc">PMC5330155</ArticleId><ArticleId IdType="pubmed">28241787</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham K, Crutcher TD, Karp SM. Screening for Social Determinants of Health at Well-Child Appointments: A Quality Improvement Project. Nursing Clinics of North America [Internet] 2019;54:141&#x2013;8. doi: 10.1016/j.cnur.2018.10.009. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnur.2018.10.009</ArticleId><ArticleId IdType="pubmed">30712540</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Toy S, Tripodis Y, Silverstein M, Freeman E. Addressing Social Determinants of Health at Well Child Care Visits: A Cluster RCT. PEDIATRICS [Internet] 2015.  [cited 2021 Jul 6];135:e296-304. Available at:  http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-2888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-2888</ArticleId><ArticleId IdType="pmc">PMC4306802</ArticleId><ArticleId IdType="pubmed">25560448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35727911</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><PubDate><Year>2021</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.</ArticleTitle><Pagination><StartPage>n1435</StartPage><MedlinePgn>n1435</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">n1435</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.n1435</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines.</AbstractText><AbstractText Label="DESIGN">Multinational network cohort study.</AbstractText><AbstractText Label="SETTING">Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model.</AbstractText><AbstractText Label="PARTICIPANTS">126&#x2009;661&#x2009;070 people observed for at least 365 days before 1 January 2017, 2018, or 2019 from 13 databases.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Events of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylaxis, Bell's palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocytopenia, disseminated intravascular coagulation, encephalomyelitis (including acute disseminated encephalomyelitis), Guillain-Barr&#xe9; syndrome, and transverse myelitis). Incidence rates of AESIs were stratified by age, sex, and database. Rates were pooled across databases using random effects meta-analyses and classified according to the frequency categories of the Council for International Organizations of Medical Sciences.</AbstractText><AbstractText Label="RESULTS">Background rates varied greatly between databases. Deep vein thrombosis ranged from 387 (95% confidence interval 370 to 404) per 100&#x2009;000 person years in UK CPRD GOLD data to 1443 (1416 to 1470) per 100&#x2009;000 person years in US IBM MarketScan Multi-State Medicaid data among women aged 65 to 74 years. Some AESIs increased with age. For example, myocardial infarction rates in men increased from 28 (27 to 29) per 100&#x2009;000 person years among those aged 18-34 years to 1400 (1374 to 1427) per 100&#x2009;000 person years in those older than 85 years in US Optum electronic health record data. Other AESIs were more common in young people. For example, rates of anaphylaxis among boys and men were 78 (75 to 80) per 100&#x2009;000 person years in those aged 6-17 years and 8 (6 to 10) per 100&#x2009;000 person years in those older than 85 years in Optum electronic health record data. Meta-analytic estimates of AESI rates were classified according to age and sex.</AbstractText><AbstractText Label="CONCLUSION">This study found large variations in the observed rates of AESIs by age group and sex, showing the need for stratification or standardisation before using background rates for safety surveillance. Considerable population level heterogeneity in AESI rates was found between databases.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6872-5804</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Hernandez</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8317-7068</Identifier><AffiliationInfo><Affiliation>Neurology Department, Hospital Clinic de Barcelona and University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio-Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg, Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the following interests: DPA receives funding from the UK National Institute for Health Research (NIHR) in the form of a senior research fellowship and the Oxford NIHR Biomedical Research Centre. XL receives the Clarendon Fund and Brasenose College Scholarship (University of Oxford) to support her DPhil study. DPA&#x2019;s research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, and UCB Biopharma. GH and AO receive funding from the US National Institutes of Health (NIH) and the US Food and Drug Administration. KV and PR work for a research group that receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Amgen, and Chiesi, none of which relates to the content of this paper. PBR, RM, AS, GR, and AGS are employees of Janssen Research and Development and shareholders in Johnson and Johnson. MAS receives grants and contracts from the FDA and the US Department of Veterans Affairs within the scope of this research, and grants and contracts from NIH, IQVIA, and Private Health Management outside the scope of this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727911</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO COVID-19 Dashboard. Geneva: World Health Organization 
2020; Available at https://covid19.who.int/ (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>Black S, Eskola J, Siegrist C-A, et al. . Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. 10.1016/S0140-6736(09)61877-8&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnans L, Lecomte C, de Vries C, et al. . The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013;31:1246-54. 10.1016/j.vaccine.2012.12.015&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.015</ArticleId><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>ACCESS. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines. 2020. http://www.encepp.eu/encepp/viewResource.htm?id=37274 (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>Report of CIOMS Working Group on Vaccine Safety. CIOMS Guide to Active Vaccine Safety Surveillance. https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf (accessed 11 Mar 2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">28645716</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AE, van der Lei J, Mosseveld BM, et al. . Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-44. 10.1055/s-0038-1634402&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1634402</ArticleId><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouaville SL, Miotti H, Coffin G, et al. . Validity and limitations of the longitudinal patient database France for use in pharmacoepidemiological and pharmacoeconomics studies. Value Health 2015;18:A18 10.1016/j.jval.2015.03.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.03.115</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MdelM, Hermosilla E, Prieto-Alhambra D, et al. . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. . Data resource profile: Clinical practice research datalink (CPRD). Int J Epidemiol 2015;44:827-36. 10.1093/ije/dyv098&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187-94. 10.1377/hlthaff.2014.0038&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2014.0038</ArticleId><ArticleId IdType="pubmed">25006145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims databases sourced from Medical Institutions. J Gen Fam Med 2020;21:211-8. 10.1002/jgf2.367&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgf2.367</ArticleId><ArticleId IdType="pmc">PMC7689231</ArticleId><ArticleId IdType="pubmed">33304714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L. The Truven health MarketScan databases for life sciences researchers. 2017. https://www.ibm.com/uk-en/products/marketscan-research-databases</Citation></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform 2021. 10.1055/s-0041-1726481.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. . Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553-64. 10.1093/jamia/ocu023&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform 2015;216:574-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>bc-coordinator. Priority list of adverse events of special interest: COVID-19. 2020. https://brightoncollaboration.us/priority-list-aesi-covid/ (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 10.1016/0197-2456(86)90046-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Balduzzi S, R&#xfc;cker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153-60. 10.1136/ebmental-2019-300117&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebmental-2019-300117</ArticleId><ArticleId IdType="pmc">PMC10231495</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549. 10.1136/bmj.d549&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d549</ArticleId><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>The Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs Second Edition &#x2013; Report of CIOMS Working Groups III and V. Geneva: 1999.</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https://www.R-project.org/.</Citation></Reference><Reference><Citation>Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021;372:n699. 10.1136/bmj.n699&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n699</ArticleId><ArticleId IdType="pubmed">33707182</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus vaccine - weekly summary of Yellow Card reporting. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>CoViD Vaccines and thrombotic events: Possibility of mRNA translation and spike protein synthesis by platelets? Published Online First: 15 March 2021. https://www.bmj.com/content/372/bmj.n699/rr-6 (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>Black S, Eskola J, Siegrist C-A, et al. . Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. 10.1016/S0140-6736(09)61877-8&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih WK, Kulldorff M, Fireman BH, et al. . Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics 2011;127(Suppl 1):S54-64. 10.1542/peds.2010-1722I&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-1722I</ArticleId><ArticleId IdType="pubmed">21502252</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, Ray P, Carpenter D, et al. . Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010;28:1062-8. 10.1016/j.vaccine.2009.10.115&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.10.115</ArticleId><ArticleId IdType="pubmed">19896453</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Vaccine 2013;31(Suppl 10):K98-112. 10.1016/j.vaccine.2013.04.088&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.04.088</ArticleId><ArticleId IdType="pubmed">24331080</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen TA, J&#xf8;rgensen MRS, Bjerrum S, et al. . Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012;345:e5823. 10.1136/bmj.e5823&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e5823</ArticleId><ArticleId IdType="pmc">PMC3444137</ArticleId><ArticleId IdType="pubmed">22988304</ArticleId></ArticleIdList></Reference><Reference><Citation>Willame C, Dodd C, van der Aa L, et al. . Incidence rates of autoimmune diseases in European healthcare databases: A contribution of the ADVANCE project. Drug Saf 2021;44:383-95. 10.1007/s40264-020-01031-1&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-01031-1</ArticleId><ArticleId IdType="pmc">PMC7892524</ArticleId><ArticleId IdType="pubmed">33462778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hense S, Schink T, Kreisel SH, et al. . Estimation of background incidence rates of Guillain-Barr&#xe9; syndrome in Germany - a retrospective cohort study with electronic healthcare data. Neuroepidemiology 2014;43:244-52. 10.1159/000369344&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369344</ArticleId><ArticleId IdType="pubmed">25531827</ArticleId></ArticleIdList></Reference><Reference><Citation>Granieri E, Andreasi NG, De Martin P, et al. . Incidence study of Guillain-Barr&#xe9; syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 2019;40:603-9. 10.1007/s10072-018-3688-4&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3688-4</ArticleId><ArticleId IdType="pubmed">30617450</ArticleId></ArticleIdList></Reference><Reference><Citation>Black SB, Law B, Chen RT, et al. . The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine 2021;39:2712-8. 10.1016/j.vaccine.2021.03.016&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId><ArticleId IdType="pmc">PMC7936550</ArticleId><ArticleId IdType="pubmed">33846042</ArticleId></ArticleIdList></Reference><Reference><Citation>Levison LS, Thomsen RW, Christensen DH, Mellemkj&#xe6;r T, Sindrup SH, Andersen H. Guillain-Barr&#xe9; syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period. Clin Epidemiol 2019;11:275-83. 10.2147/CLEP.S199839&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S199839</ArticleId><ArticleId IdType="pmc">PMC6497480</ArticleId><ArticleId IdType="pubmed">31114387</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maas NAT, Kramer MA, Jacobs BC, et al. . Guillain-Barr&#xe9; syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst 2011;16:243-9. 10.1111/j.1529-8027.2011.00356.x&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1529-8027.2011.00356.x</ArticleId><ArticleId IdType="pubmed">22003939</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54-60. 10.1136/amiajnl-2011-000376&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. . Principles of Large-scale Evidence Generation and Evaluation across a network of databases (LEGEND). J Am Med Inform Assoc 2020;27:1331-7. 10.1093/jamia/ocaa103&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:1816-26. 10.1016/S0140-6736(19)32317-7&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, et al. . Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:542-51. 10.1001/jamainternmed.2019.7454&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, et al. OHDSI-COVID-19 consortium . Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol 2020;2:e698-711. 10.1016/S2665-9913(20)30276-9&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30276-9</ArticleId><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales DR, Conover MM, You SC, et al. . Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health 2021;3:e98-114. 10.1016/S2589-7500(20)30289-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30289-2</ArticleId><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37674813</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2813-0626</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in nephrology</Title><ISOAbbreviation>Front Nephrol</ISOAbbreviation></Journal><ArticleTitle>The Effect of Statins on Mortality of Patients With Chronic Kidney Disease Based on Data of the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) and Korea National Health Insurance Claims Database.</ArticleTitle><Pagination><StartPage>821585</StartPage><MedlinePgn>821585</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">821585</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneph.2021.821585</ELocationID><Abstract><AbstractText>The role of statins in chronic kidney disease (CKD) has been extensively evaluated, but it remains controversial in specific population such as dialysis-dependent CKD. This study examined the effect of statins on mortality in CKD patients using two large databases. In data from the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) from two hospitals, CKD was defined as an estimated glomerular filtration rate &lt; 60 mL/min/m<sup>2</sup>; we compared survival between patients with or without statin treatment. As a sensitivity analysis, the results were validated with the Korea National Health Insurance (KNHI) claims database. In the analysis of CDM datasets, statin users showed significantly lower risks of all-cause and cardiovascular mortality in both hospitals, compared to non-users. Similar results were observed in CKD patients from the KNHI claims database. Lower mortality in the statin group was consistently evident in all subgroup analyses, including patients on dialysis and low-risk young patients. In conclusion, we found that statins were associated with lower mortality in CKD patients, regardless of dialysis status or other risk factors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Kim, Choi, Oh, Kim, Jo, Cho, Ahn, Kwon and Ko.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yun Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Korea University Guro Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Se Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Myung Gyu</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Sang Kyung</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Won Yong</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Shin Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Young Joo</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Gang-Jee</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nephrol</MedlineTA><NlmUniqueID>9918469487906676</NlmUniqueID><ISSNLinking>2813-0626</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">all-cause mortality</Keyword><Keyword MajorTopicYN="N">cardiovascular mortality</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">population-based study</Keyword><Keyword MajorTopicYN="N">statins</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>4</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37674813</ArticleId><ArticleId IdType="pmc">PMC10479676</ArticleId><ArticleId IdType="doi">10.3389/fneph.2021.821585</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collaboration GBDCKD . Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet (2020) 395(10225):709&#x2013;33. doi:&#xa0;10.1016/S0140-6736(20)30045-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30045-3</ArticleId><ArticleId IdType="pmc">PMC7049905</ArticleId><ArticleId IdType="pubmed">32061315</ArticleId></ArticleIdList></Reference><Reference><Citation>Carracedo J, Alique M, Vida C, Bodega G, Ceprian N, Morales E, et al. . Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence. Front Cell Dev Biol (2020) 8:185. doi:&#xa0;10.3389/fcell.2020.00185</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00185</ArticleId><ArticleId IdType="pmc">PMC7099607</ArticleId><ArticleId IdType="pubmed">32266265</ArticleId></ArticleIdList></Reference><Reference><Citation>Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med (2004) 351(13):1296&#x2013;305. doi:&#xa0;10.1056/NEJMoa041031</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa041031</ArticleId><ArticleId IdType="pubmed">15385656</ArticleId></ArticleIdList></Reference><Reference><Citation>Drueke TB, Massy ZA. Atherosclerosis in CKD: Differences From the General Population. Nat Rev Nephrol (2010) 6(12):723&#x2013;35. doi:&#xa0;10.1038/nrneph.2010.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2010.143</ArticleId><ArticleId IdType="pubmed">20978469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: Summary of Recommendation Statements and Clinical Approach to the Patient. Kidney Int (2014) 85(6):1303&#x2013;9. doi:&#xa0;10.1038/ki.2014.31</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.31</ArticleId><ArticleId IdType="pubmed">24552851</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu C, Sima A. Statins: Mechanism of Action and Effects. J Cell Mol Med (2001) 5(4):378&#x2013;87. doi:&#xa0;10.1111/j.1582-4934.2001.tb00172.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2001.tb00172.x</ArticleId><ArticleId IdType="pmc">PMC6740083</ArticleId><ArticleId IdType="pubmed">12067471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain MK, Ridker PM. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nat. Rev. Drug Discov (2005) 4(12):977&#x2013;87. doi:&#xa0;10.1038/nrd1901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1901</ArticleId><ArticleId IdType="pubmed">16341063</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons From the Recent Clinical Trials. Curr Pharm Des (2012) 18(11):1519&#x2013;30. doi:&#xa0;10.2174/138161212799504803</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799504803</ArticleId><ArticleId IdType="pmc">PMC3394171</ArticleId><ArticleId IdType="pubmed">22364136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. . Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform (2015) 216:574&#x2013;8. doi: 10.3233/978-1-61499-564-7-574</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-564-7-574</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong M, Gardner HL, Dieterle N, Rentko V. Optimization of Electronic Medical Records for Data Mining Using a Common Data Model. Top Companion Anim Med (2019) 37:100364. doi:&#xa0;10.1016/j.tcam.2019.100364</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcam.2019.100364</ArticleId><ArticleId IdType="pmc">PMC7874511</ArticleId><ArticleId IdType="pubmed">31837755</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. . A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med (2009) 150(9):604&#x2013;12. doi:&#xa0;10.7326/0003-4819-150-9-200905050-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. . Cause of Death in Patients With Reduced Kidney Function. J Am Soc Nephrol (2015) 26(10):2504&#x2013;11. doi:&#xa0;10.1681/ASN.2014070714</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2014070714</ArticleId><ArticleId IdType="pmc">PMC4587695</ArticleId><ArticleId IdType="pubmed">25733525</ArticleId></ArticleIdList></Reference><Reference><Citation>Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in Chronic Kidney Disease: From Bench to Bedside. Eur Heart J (2021) 42(22):2170&#x2013;85. doi:&#xa0;10.1093/eurheartj/ehaa1050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa1050</ArticleId><ArticleId IdType="pubmed">33393990</ArticleId></ArticleIdList></Reference><Reference><Citation>Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, et al. . Carbamylated Low-Density Lipoprotein Induces Endothelial Dysfunction. Eur Heart J (2014) 35(43):3021&#x2013;32. doi:&#xa0;10.1093/eurheartj/ehu111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu111</ArticleId><ArticleId IdType="pubmed">24658767</ArticleId></ArticleIdList></Reference><Reference><Citation>Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and Fatty Acids in Chronic Kidney Disease: Molecular and Metabolic Alterations. Nat Rev Nephrol (2021) 17(8):528&#x2013;42. doi:&#xa0;10.1038/s41581-021-00423-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-021-00423-5</ArticleId><ArticleId IdType="pubmed">33972752</ArticleId></ArticleIdList></Reference><Reference><Citation>Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. . Relation Between Renal Dysfunction and Cardiovascular Outcomes After Myocardial Infarction. N Engl J Med (2004) 351(13):1285&#x2013;95. doi:&#xa0;10.1056/NEJMoa041365</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa041365</ArticleId><ArticleId IdType="pubmed">15385655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, et al. . Proteinuria, Impaired Kidney Function, and Adverse Outcomes in People With Coronary Disease: Analysis of a Previously Conducted Randomised Trial. BMJ (2006) 332(7555):1426. doi:&#xa0;10.1136/bmj.38814.566019.2F</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38814.566019.2F</ArticleId><ArticleId IdType="pmc">PMC1479622</ArticleId><ArticleId IdType="pubmed">16714328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. . Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease. Circulation (2004) 110(12):1557&#x2013;63. doi:&#xa0;10.1161/01.CIR.0000143892.84582.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000143892.84582.60</ArticleId><ArticleId IdType="pubmed">15364796</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. . Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol (2008) 51(15):1448&#x2013;54. doi:&#xa0;10.1016/j.jacc.2007.11.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2007.11.072</ArticleId><ArticleId IdType="pubmed">18402899</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. . The Effects of Lowering LDL Cholesterol With Simvastatin Plus Ezetimibe in Patients With Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. Lancet (2011) 377(9784):2181&#x2013;92. doi:&#xa0;10.1016/S0140-6736(11)60739-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60739-3</ArticleId><ArticleId IdType="pmc">PMC3145073</ArticleId><ArticleId IdType="pubmed">21663949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. . Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med (2005) 353(3):238&#x2013;48. doi:&#xa0;10.1056/NEJMoa043545</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043545</ArticleId><ArticleId IdType="pubmed">16034009</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. . Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med (2009) 360(14):1395&#x2013;407. doi:&#xa0;10.1056/NEJMoa0810177</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810177</ArticleId><ArticleId IdType="pubmed">19332456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. . HMG-Coenzyme a Reductase Inhibitor Use is Associated With Mortality Reduction in Hemodialysis Patients. Am J Kidney Dis (2005) 45(1):119&#x2013;26. doi:&#xa0;10.1053/j.ajkd.2004.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2004.09.025</ArticleId><ArticleId IdType="pubmed">15696451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Park S, Kim MS, Kang SJ, Lee JW, Kim KS, et al. . Statin Initiation and All-Cause Mortality in Incident Statin-Naive Dialysis Patients. Atherosclerosis (2021) 337:59&#x2013;65. doi:&#xa0;10.1016/j.atherosclerosis.2021.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.08.026</ArticleId><ArticleId IdType="pubmed">34429195</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, Bae GH, Kang M, Kim SW, Lee DH. Statins and All-Cause Mortality in Patients Undergoing Hemodialysis. J Am Heart Assoc (2020) 9(5):e014840. doi:&#xa0;10.1161/JAHA.119.014840</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.014840</ArticleId><ArticleId IdType="pmc">PMC7335561</ArticleId><ArticleId IdType="pubmed">32089045</ArticleId></ArticleIdList></Reference><Reference><Citation>Shurraw S, Tonelli M. AURORA: Is There a Role for Statin Therapy in Dialysis Patients? Am J Kidney Dis (2010) 55(2):237&#x2013;40. doi:&#xa0;10.1053/j.ajkd.2009.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2009.09.018</ArticleId><ArticleId IdType="pubmed">19926372</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. . Guidelines for the Management of Dyslipidemia. Korean J Intern Med (2019) 34(4):723&#x2013;71. doi:&#xa0;10.3904/kjim.2019.188</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2019.188</ArticleId><ArticleId IdType="pmc">PMC6610190</ArticleId><ArticleId IdType="pubmed">31272142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. . Comparison of the Efficacy and Tolerability of Pitavastatin and Atorvastatin: An 8-Week, Multicenter, Randomized, Open-Label, Dose-Titration Study in Korean Patients With Hypercholesterolemia. Clin Ther (2007) 29(11):2365&#x2013;73. doi:&#xa0;10.1016/j.clinthera.2007.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2007.11.002</ArticleId><ArticleId IdType="pubmed">18158077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, et al. . Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis. Circ J (2011) 75(2):398&#x2013;406. doi:&#xa0;10.1253/circj.cj-10-0658</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.cj-10-0658</ArticleId><ArticleId IdType="pubmed">21157106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Kang HJ, Kim HS, Sohn DW, Oh BH, Park YB. Effects of Ezetimibe/Simvastatin 10/20 Mg vs. Atorvastatin 20 Mg on Apolipoprotein B/apolipoprotein A1 in Korean Patients With Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial. Am J Cardiovasc Drugs (2013) 13(5):343&#x2013;51. doi:&#xa0;10.1007/s40256-013-0031-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-013-0031-6</ArticleId><ArticleId IdType="pubmed">23728830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, et al. . Comparison of Effects of Atorvastatin (20 Mg) Versus Rosuvastatin (10 Mg) Therapy on Mild Coronary Atherosclerotic Plaques (From the ARTMAP Trial). Am J Cardiol (2012) 109(12):1700&#x2013;4. doi:&#xa0;10.1016/j.amjcard.2012.01.399</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2012.01.399</ArticleId><ArticleId IdType="pubmed">22440123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Seo MK, Yoon MH, Choi DH, Hong TJ, Kim HS. Assessment of the Efficacy and Tolerability of 2 Formulations of Atorvastatin in Korean Adults With Hypercholesterolemia: A Multicenter, Prospective, Open-Label, Randomized Trial. Clin Ther (2013) 35(1):77&#x2013;86. doi:&#xa0;10.1016/j.clinthera.2012.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2012.11.009</ArticleId><ArticleId IdType="pubmed">23274145</ArticleId></ArticleIdList></Reference><Reference><Citation>Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. . Effects of Atorvastatin 20 Mg, Rosuvastatin 10 Mg, and Atorvastatin/Ezetimibe 5 Mg/5 Mg on Lipoproteins and Glucose Metabolism. J Cardiovasc Pharmacol Ther (2010) 15(2):167&#x2013;74. doi:&#xa0;10.1177/1074248409357922</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248409357922</ArticleId><ArticleId IdType="pubmed">20147603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Park K, Hong SJ, Cho YS, Sung JD, Moon GW, et al. . Efficacy and Tolerability of a Generic and a Branded Formulation of Atorvastatin 20 Mg/D in Hypercholesterolemic Korean Adults at High Risk for Cardiovascular Disease: A Multicenter, Prospective, Randomized, Double-Blind, Double-Dummy Clinical Trial. Clin Ther (2010) 32(11):1896&#x2013;905. doi:&#xa0;10.1016/j.clinthera.2010.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2010.10.004</ArticleId><ArticleId IdType="pubmed">21095484</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi ZJ, Lu Y, Ji N, Kapke A, Selewski DT, Dietrich X, et al. . Risk of Cardiovascular Disease and Mortality in Young Adults With End-Stage Renal Disease: An Analysis of the US Renal Data System. JAMA Cardiol (2019) 4(4):353&#x2013;62. doi:&#xa0;10.1001/jamacardio.2019.0375</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2019.0375</ArticleId><ArticleId IdType="pmc">PMC6484951</ArticleId><ArticleId IdType="pubmed">30892557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33735862</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9832</ISSN><JournalIssue CitedMedium="Internet"><Volume>238</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Dermatology (Basel, Switzerland)</Title><ISOAbbreviation>Dermatology</ISOAbbreviation></Journal><ArticleTitle>Dermatologic Research Potential of the Observational Health Data Sciences and Informatics (OHDSI) Network.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>52</EndPage><MedlinePgn>44-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000514536</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Health Data Sciences and Informatics (OHDSI) network enables access to billions of deidentified, standardized health records and built-in analytics software for observational health research, with numerous potential applications to dermatology. While the use of the OHDSI has increased steadily over the past several years, review of the literature reveals few studies utilizing OHDSI in dermatology. To our knowledge, the University of Colorado School of Medicine is unique in its use of OHDSI for dermatology big data research.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">A PubMed search was conducted in August 2020, followed by a literature review, with 24 of the 72 screened articles selected for inclusion. In this review, we discuss the ways OHDSI has been used to compile and analyze data, improve prediction and estimation capabilities, and inform treatment guidelines across specialties. We also discuss the potential for OHDSI in dermatology - specifically, ways that it could reveal adherence to available guidelines, establish standardized protocols, and ensure health equity. Key Messages: OHDSI has demonstrated broad utility in medicine. Adoption of OHDSI by the field of dermatology would facilitate big data research, allow for examination of current prescribing and treatment patterns without clear best practice guidelines, improve the dermatologic knowledge base and, by extension, improve patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sivesind</LastName><ForeName>Torunn Elise</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado, USA, torunn.sivesind@cuanschutz.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runion</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rocky Vista University College of Osteopathic Medicine, Parker, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Branda</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Data Science to Patient Value Program Aurora, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dellavalle</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dermatology</MedlineTA><NlmUniqueID>9203244</NlmUniqueID><ISSNLinking>1018-8665</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000077558" MajorTopicYN="N">Big Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="Y">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003880" MajorTopicYN="N">Dermatology</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Analytics</Keyword><Keyword MajorTopicYN="N">Data standardization</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Networks</Keyword><Keyword MajorTopicYN="N">Observational research</Keyword><Keyword MajorTopicYN="N">Treatment guidelines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>20</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33735862</ArticleId><ArticleId IdType="doi">10.1159/000514536</ArticleId><ArticleId IdType="pii">000514536</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34392386</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-2965</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</Title><ISOAbbreviation>Osteoporos Int</ISOAbbreviation></Journal><ArticleTitle>One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>137</EndPage><MedlinePgn>123-137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00198-021-06077-0</ELocationID><Abstract><AbstractText Label="UNLABELLED">We estimated and characterized the imminent fracture risk (1-2&#xa0;years) of high-risk fracture patients through a multinational (UK, Spain, Denmark) cohort study. Older individuals with newly diagnosed osteoporosis and individuals who had a fracture while on treatment with a bisphosphonate were at a high risk of imminent fracture.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To characterize and estimate 1- to 2-year fracture risk in high-risk fracture patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multi-cohort study in (database/study period) UK (CPRD/1995-2017), Spain (SIDIAP/2006-2016) and Denmark (DHR/1995-2016) including individuals &#x2265;&#x2009;50&#xa0;years old in NDO (newly diagnosed osteoporosis), OFx (incident osteoporotic fracture), BP (incident oral bisphosphonates use) or FWOT (fracture while on treatment with bisphosphonates). Outcomes (ICD-10/READ): hip, clinical spine, non-hip, non-spine and hip/humerus/distal forearm fracture.</AbstractText><AbstractText Label="FOLLOW-UP" NlmCategory="RESULTS">from cohort entry until death, migration/transfer or end of the study.</AbstractText><AbstractText Label="STATISTICS" NlmCategory="METHODS">baseline characteristics and incidence rate (IR per 1000 persons). RESULTS (1-YEAR IR): NDO included 69,899 (UK), 37,901 (Spain) and 158,191 (Denmark) individuals. Spanish-IR was lowest for hip (4.7), clinical spine (2.5) and major osteoporotic fracture (MOF) (17.3) and highest in Denmark (74.2, 26.0 and 120.1, respectively). OFx included 83,514 (UK), 51,044 (Spain) and 509,551 (Denmark) individuals. IR in Denmark was highest for hip (24.1) and MOF (47.2), in Spain was highest for the clinical spine (9.4) and lowest for hip (9.5) and in the UK was lowest for the clinical spine (2.8) and MOF (20.7). BP included 148,507 (UK), 52,037 (Spain) and 204,010 (Denmark) individuals. Spanish-IR was lowest for hip (5.0) and MOF (21.1) and highest in Denmark (20.3 and 48.6, respectively). FWOT included 28,930 (UK), 1,865 (Spain) and 31,882 (Denmark) individuals. Clinical spine-IR was highest for Spain (12.0). Hip-IR was lowest for Spain (7.6) and highest for Denmark (33.6). Comparing young subjects, those who have FWOT started with an increased fracture rate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">OFx and FWOT individuals experience higher re-fracture incidence rates than those with osteoporosis with or without treatment.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, Nuffield Orthopaedic Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a &#xcd;Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gorina (IDIAPJ Gol), CIBERFES, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health, Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, Nuffield Orthopaedic Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Emese</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UCB Biopharma Sprl, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libanati</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UCB Biopharma Sprl, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahamsen</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, Nuffield Orthopaedic Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Open Patient Data Explorative Network, University of Southern Denmark and Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Holb&#xe6;k Hospital, Holb&#xe6;k, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, Nuffield Orthopaedic Centre, Oxford, UK. Daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a &#xcd;Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gorina (IDIAPJ Gol), CIBERFES, Barcelona, Spain. Daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Barcelona, Spain. Daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK. Daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Osteoporos Int</MedlineTA><NlmUniqueID>9100105</NlmUniqueID><ISSNLinking>0937-941X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="Y">Osteoporosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058866" MajorTopicYN="Y">Osteoporotic Fractures</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-resorptive</Keyword><Keyword MajorTopicYN="N">Fracture prevention</Keyword><Keyword MajorTopicYN="N">General population studies</Keyword><Keyword MajorTopicYN="N">Osteoporosis</Keyword></KeywordList><CoiStatement>BA reports grants from UCB, during the conduct of the study, personal fees from UCB, grants from Novartis, personal fees from Amgen, personal fees from Eli-Lilly and personal fees from Pharmacosmos, outside the submitted work. ME reports institutional grants from UCB, during the conduct of the study. CL reports being an employee and stockholder of UCB Pharma. DPA reports grants and others from AMGEN; grants, non-financial support and others from UCB Biopharma; and grants from Les Laboratoires Servier, outside the submitted work; Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organized by DPA&#x2019;s department and open for external participants. ET is an employee of UCB Pharma, who sponsored the study. AD, SK and CR have no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>15</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34392386</ArticleId><ArticleId IdType="pmc">PMC8758600</ArticleId><ArticleId IdType="doi">10.1007/s00198-021-06077-0</ArticleId><ArticleId IdType="pii">10.1007/s00198-021-06077-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dyer SM, Crotty M, Fairhall N, Magaziner JS, Beaupre LA, Cameron I, Sherrington C. A critical review of the long-term disability outcomes following hip fracture. Innov Aging. 2017;1(1):736. doi: 10.1093/geroni/igx004.2656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geroni/igx004.2656</ArticleId><ArticleId IdType="pmc">PMC5010762</ArticleId><ArticleId IdType="pubmed">27590604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernlund E, Svedbom A, Iverg&#xe5;rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, J&#xf6;nsson B, Kanis JA. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2013;8(1&#x2013;2):136. doi: 10.1007/s11657-013-0136-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-013-0136-1</ArticleId><ArticleId IdType="pmc">PMC3880487</ArticleId><ArticleId IdType="pubmed">24113837</ArticleId></ArticleIdList></Reference><Reference><Citation>Banefelt J, &#xc5;kesson KE, Sp&#xe5;ng&#xe9;us A, Ljunggren O, Karlsson L, Str&#xf6;m O, Orts&#xe4;ter G, Libanati C, Toth E. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int. 2019;30(3):601&#x2013;609. doi: 10.1007/s00198-019-04852-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-019-04852-8</ArticleId><ArticleId IdType="pmc">PMC6422949</ArticleId><ArticleId IdType="pubmed">30680431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos. 2016;11(1):26. doi: 10.1007/s11657-016-0280-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-016-0280-5</ArticleId><ArticleId IdType="pmc">PMC4967418</ArticleId><ArticleId IdType="pubmed">27475642</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79&#x2013;92. doi: 10.1007/s00198-018-4732-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-018-4732-1</ArticleId><ArticleId IdType="pmc">PMC6332293</ArticleId><ArticleId IdType="pubmed">30456571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Johansson H, Od&#xe9;n A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgstr&#xf6;m F, McCloskey EV. Characteristics of recurrent fractures. Osteoporos Int. 2018;29(8):1747&#x2013;1757. doi: 10.1007/s00198-018-4502-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-018-4502-0</ArticleId><ArticleId IdType="pmc">PMC6076437</ArticleId><ArticleId IdType="pubmed">29947869</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson H, Siggeirsd&#xf3;ttir K, Harvey NC, Od&#xe9;n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775&#x2013;780. doi: 10.1007/s00198-016-3868-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-016-3868-0</ArticleId><ArticleId IdType="pmc">PMC5338733</ArticleId><ArticleId IdType="pubmed">28028554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan MT, Weycker D, McLean RR, Sahni S, Bornheimer R, Barron R, Travison TG, Kiel DP. Predictors of imminent risk of nonvertebral fracture in older, high-risk women: the Framingham Osteoporosis Study. JBMR Plus. 2019;3(6):e10129. doi: 10.1002/jbm4.10129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm4.10129</ArticleId><ArticleId IdType="pmc">PMC6636767</ArticleId><ArticleId IdType="pubmed">31346561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliuc D, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 2015;30(4):637&#x2013;646. doi: 10.1002/jbmr.2393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.2393</ArticleId><ArticleId IdType="pubmed">25359586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375&#x2013;382. doi: 10.1016/j.bone.2004.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2004.03.024</ArticleId><ArticleId IdType="pubmed">15268886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385&#x2013;397. doi: 10.1007/s00198-007-0543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-007-0543-5</ArticleId><ArticleId IdType="pmc">PMC2267485</ArticleId><ArticleId IdType="pubmed">18292978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427. doi: 10.1136/bmj.e3427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e3427</ArticleId><ArticleId IdType="pubmed">22619194</ArticleId></ArticleIdList></Reference><Reference><Citation>van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99&#x2013;102. doi: 10.1136/ard.2008.092775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.092775</ArticleId><ArticleId IdType="pubmed">18677009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open. 2014;4(8):e005809. doi: 10.1136/bmjopen-2014-005809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-005809</ArticleId><ArticleId IdType="pmc">PMC4156807</ArticleId><ArticleId IdType="pubmed">25168040</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil Mdel M, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, Rodriguez J, Williams T, Van Staa T, Bol&#xed;bar B. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP) Inform Prim Care. 2011;19(3):135&#x2013;145. doi: 10.14236/jhi.v19i3.806.</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v19i3.806</ArticleId><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, Schmidt SAJ, Wallach-Kildemoes H, S&#xf8;rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798&#x2013;798f. doi: 10.1093/ije/dyw213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw213</ArticleId><ArticleId IdType="pmc">PMC5837522</ArticleId><ArticleId IdType="pubmed">27789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;490. doi: 10.2147/CLEP.S91125.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S91125</ArticleId><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Imel EA, Eckert G, Modi A, Li Z, Martin J, de Papp A, Allen K, Johnston CC, Hui SL, Liu Z. Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates. Bone. 2016;83:267&#x2013;275. doi: 10.1016/j.bone.2015.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2015.11.021</ArticleId><ArticleId IdType="pubmed">26657827</ArticleId></ArticleIdList></Reference><Reference><Citation>Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial: FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118&#x2013;4124. doi: 10.1210/jcem.85.11.6953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.85.11.6953</ArticleId><ArticleId IdType="pubmed">11095442</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial: Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344&#x2013;1352. doi: 10.1001/jama.282.14.1344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.14.1344</ArticleId><ArticleId IdType="pubmed">10527181</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Pag&#xe8;s-Castell&#xe0; A, Wallace G, Javaid MK, Judge A, Nogu&#xe9;s X, Arden NK, Cooper C, Diez-Perez A. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268&#x2013;274. doi: 10.1002/jbmr.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.2011</ArticleId><ArticleId IdType="pmc">PMC3867340</ArticleId><ArticleId IdType="pubmed">23761350</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ. 2016;353:i3365. doi: 10.1136/bmj.i3365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i3365</ArticleId><ArticleId IdType="pmc">PMC4924596</ArticleId><ArticleId IdType="pubmed">27353596</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanwal DK, Dennison EM, Harvey NC, Cooper C. Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop. 2011;45(1):15&#x2013;22. doi: 10.4103/0019-5413.73656.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5413.73656</ArticleId><ArticleId IdType="pmc">PMC3004072</ArticleId><ArticleId IdType="pubmed">21221218</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis EM, Moon RJ, Harvey NC, Cooper C. Reprint of the impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs. 2017;26:7&#x2013;17. doi: 10.1016/j.ijotn.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijotn.2017.04.004</ArticleId><ArticleId IdType="pmc">PMC5480618</ArticleId><ArticleId IdType="pubmed">28578992</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte SD, Vilaplana L, G&#xfc;erri R, Nogu&#xe9;s X, Wang-Fagerland M, Diez-Perez A, Eriksen FE. Are the high hip fracture rates among Norwegian women explained by impaired bone material properties? J Bone Miner Res. 2015;30(10):1784&#x2013;1789. doi: 10.1002/jbmr.2537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.2537</ArticleId><ArticleId IdType="pubmed">25900016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajar JK, Taufan T, Syarif M, Azharuddin A. Hip geometry and femoral neck fractures: a meta-analysis. J Orthop Translat. 2018;13:1&#x2013;6. doi: 10.1016/j.jot.2017.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jot.2017.12.002</ArticleId><ArticleId IdType="pmc">PMC5892388</ArticleId><ArticleId IdType="pubmed">29662785</ArticleId></ArticleIdList></Reference><Reference><Citation>Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int. 2016;27(1):387&#x2013;396. doi: 10.1007/s00198-015-3415-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-015-3415-4</ArticleId><ArticleId IdType="pubmed">26576544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed LA, Center JR, Bj&#xf8;rnerem A, Bluic D, Joakimsen RM, J&#xf8;rgensen L, Meyer HE, Nguyen ND, Nguyen TV, Omsland TK, St&#xf8;rmer J, Tell GS, van Geel TA, Eisman JA, Emaus N. Progressively increasing fracture risk with advancing age after initial incident fragility fracture: the Troms&#xf8; study. J Bone Miner Res. 2013;28(10):2214&#x2013;2221. doi: 10.1002/jbmr.1952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.1952</ArticleId><ArticleId IdType="pubmed">23572401</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032&#x2013;1045. doi: 10.4065/83.9.1032.</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/83.9.1032</ArticleId><ArticleId IdType="pmc">PMC2667901</ArticleId><ArticleId IdType="pubmed">18775204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34571200</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2201</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The journal of allergy and clinical immunology. In practice</Title><ISOAbbreviation>J Allergy Clin Immunol Pract</ISOAbbreviation></Journal><ArticleTitle>Atopic Eczema-Associated Fracture Risk and Oral Corticosteroids: A Population-Based Cohort Study.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>266.e8</EndPage><MedlinePgn>257-266.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaip.2021.09.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2198(21)01018-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evidence suggests adults with atopic eczema have increased fracture risk. However, it is unclear whether oral corticosteroids explain the association.</AbstractText><AbstractText Label="OBJECTIVE">To assess to what extent oral corticosteroids mediate the relationship between atopic eczema and fractures.</AbstractText><AbstractText Label="METHODS">We conducted a cohort study using English primary care (Clinical Practice Research Datalink) and hospital admissions (Hospital Episode Statistics) records (1998-2016) including adults (18 years old and older) with atopic eczema matched (age, sex, and general practice) with up to 5 adults without atopic eczema. We used Cox regression to estimate hazard ratios (HRs) for specific major osteoporotic fractures (hip, spine, pelvis, or wrist) and for any-site fracture comparing individuals with atopic eczema with those without, adjusting for 6 different definitions of time-updated oral corticosteroid use (ever any prescription, ever high-dose, and recent, cumulative, current, or peak dose).</AbstractText><AbstractText Label="RESULTS">We identified 526,808 individuals with atopic eczema and 2,569,030 without. We saw evidence of an association between atopic eczema and major osteoporotic fractures (eg, spine HR 1.15, 99% CI 1.08-1.22; hip HR 1.11, 99% CI 1.08-1.15) that remained after additionally adjusting for oral corticosteroids (eg, cumulative corticosteroid dose: spine HR 1.09, 99% CI 1.03-1.16; hip HR 1.09, 99% CI 1.06-1.12). Fracture rates were higher in people with severe atopic eczema than in people without even after adjusting for oral corticosteroids (eg, spine HR [99% CI]: confounder-adjusted 2.31 [1.91-2.81]; additionally adjusted for cumulative dose 1.71 [1.40-2.09]).</AbstractText><AbstractText Label="CONCLUSIONS">Our findings suggest that little of the association between atopic eczema and major osteoporotic fractures is explained by oral corticosteroid use.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matthewman</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: julian.matthewman1@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansfield</LastName><ForeName>Kathryn E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulick</LastName><ForeName>Amy R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeeth</LastName><ForeName>Liam</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lerner College of Medicine of Case Western Reserve School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverwood</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Centre for Longitudinal Studies, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langan</LastName><ForeName>Sin&#xe9;ad M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>205039</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V005146/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol Pract</MedlineTA><NlmUniqueID>101597220</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003876" MajorTopicYN="Y">Dermatitis, Atopic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atopic dermatitis</Keyword><Keyword MajorTopicYN="N">Atopic eczema</Keyword><Keyword MajorTopicYN="N">Fracture</Keyword><Keyword MajorTopicYN="N">Oral corticosteroids</Keyword><Keyword MajorTopicYN="N">Osteoporotic fracture</Keyword></KeywordList><CoiStatement>Competing interests. JM, KEM, ARM, KEL, RS have nothing to disclose. DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and HTA Funding Committee membership. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA&#x2019;s department and open for external participants. LS reports grants from Wellcome, grants from MRC, grants from NIHR, grants from GSK, grants from BHF, grants from Diabetes UK, outside the submitted work. SML is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (205039/Z/16/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders. SML is also supported by Health Data Research UK (Grant number: LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. SML is an investigator on the European Union Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>27</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34571200</ArticleId><ArticleId IdType="mid">EMS136900</ArticleId><ArticleId IdType="pmc">PMC7612204</ArticleId><ArticleId IdType="doi">10.1016/j.jaip.2021.09.026</ArticleId><ArticleId IdType="pii">S2213-2198(21)01018-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population&#x2013;based study. Journal of Allergy and Clinical Immunology. 2013;132:1132&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24094544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-Y, Lu Y-Y, Lu C-C, Su Y-F, Tsai T-H, Wu C-H. Osteoporosis in adult patients with atopic dermatitis: A nationwide population-based study. Nguyen TV, editor. Plos One. 2017;12:e0171667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313211</ArticleId><ArticleId IdType="pubmed">28207767</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg NK, Silverberg JI. Eczema is associated with osteoporosis and fractures in adults: A US population-based study. Journal of Allergy and Clinical Immunology. 2015;135:1085&#x2013;1087.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">25512080</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N, Silverberg JI. Association Between Eczema and Increased Fracture and Bone or Joint Injury in Adults: A US Population-Based Study. JAMA Dermatology. 2015;151:33.</Citation><ArticleIdList><ArticleId IdType="pubmed">25353616</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukovozov IM, Morra DE, Giustini D, Tadrous M, Cheung AM, Drucker AM. Atopic dermatitis and bone health: a systematic review.  [cited 2020 Dec 22];Journal of the European Academy of Dermatology and Venereology [Internet] 2020  Available from:  https://onlinelibrary.wiley.com/doi/10.1111/jdv.16895
.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.16895</ArticleId><ArticleId IdType="pubmed">32853421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe KE, Mansfield KE, Delmestri A, Smeeth L, Roberts A, Abuabara K, et al. Atopic eczema and fracture risk in adults: A population-based cohort study. Journal of Allergy and Clinical Immunology. 2020;145:563&#x2013;571.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014587</ArticleId><ArticleId IdType="pubmed">31757515</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuid AN, Khaithir TMN, Mokhtar SA, Mohamed IN. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Therapeutics and Clinical Risk Management. 2014;937</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4242696</ArticleId><ArticleId IdType="pubmed">25429224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology. 2018;32:657&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29676534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Journal of the European Academy of Dermatology and Venereology. 2018;32:850&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">29878606</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology. 2018;178:768&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901393</ArticleId><ArticleId IdType="pubmed">28865094</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. Journal of the American Academy of Dermatology. 2018;78:733&#x2013;740.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29032119</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69:46&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">24354911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II: Guidelines for treatment of atopic eczema. Journal of the European Academy of Dermatology and Venereology. 2012;26:1176&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22813359</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Maxim E, Cardwell LA, Chawla A, Feldman SR. Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace. Journal of Dermatological Treatment. 2018;29:238&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28789575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaga M, Zervas E. Oral steroids in asthma: a double-edged sword. European Respiratory Journal. 2019;54:1902034</Citation><ArticleIdList><ArticleId IdType="pubmed">31780458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for severe asthma.  [cited 2020 Jul 26];Medical Journal of Australia. 2018 209 [Internet]. Available from:  https://onlinelibrary.wiley.com/doi/abs/10.5694/mja18.00134
.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja18.00134</ArticleId><ArticleId IdType="pubmed">30453868</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson DE, van Staa TP, Dennison EM, Cooper C, Dixon WG. The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study. Bone. 2018;117:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173307</ArticleId><ArticleId IdType="pubmed">30218790</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) International Journal of Epidemiology. 2015;44:827&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hospital Episode Statistics (HES)  [Internet]. Available from:  https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics#hes-publications
.</Citation></Reference><Reference><Citation>Vandenbroucke J, Pearce N. Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed From First Exposure Onward Damage Epidemiology? American Journal of Epidemiology. 2015;182:826&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634310</ArticleId><ArticleId IdType="pubmed">26507305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe KE, Mansfield KE, Delmestri A, Smeeth L, Roberts A, Abuabara K, et al.  Code lists for &#x201c;Atopic eczema and fracture risk in adults: a population-based cohort study&#x201d;. 2019.  [cited 2020 Aug 13].  Available from:  https://datacompass.lshtm.ac.uk/1156/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014587</ArticleId><ArticleId IdType="pubmed">31757515</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuabara K, Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, et al. Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK. Journal of Investigative Dermatology. 2017;137:1655&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5883318</ArticleId><ArticleId IdType="pubmed">28428130</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverwood RJ, Forbes HJ, Abuabara K, Ascott A, Schmidt M, Schmidt SAJ, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018:k1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190010</ArticleId><ArticleId IdType="pubmed">29792314</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE Clinical guidance. Tacrolimus and pimecrolimus for atopic eczema. 2004.  [Internet]. Available from:  https://www.nice.org.uk/guidance/ta82
.</Citation></Reference><Reference><Citation>Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. Journal of Bone and Mineral Research. 2012;27:645&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881741</ArticleId><ArticleId IdType="pubmed">22113888</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan H. The Index of Multiple Deprivation 2000 and accessibility effects on health. Journal of Epidemiology &amp; Community Health. 2004;58:250&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1732697</ArticleId><ArticleId IdType="pubmed">14966241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5&#xb7;24 million UK adults. The Lancet. 2014;384:755&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151483</ArticleId><ArticleId IdType="pubmed">25129328</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61:7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997116</ArticleId><ArticleId IdType="pubmed">29691807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer-Helmich L, Linneberg A, Thomsen SF, Gl&#xfc;mer C. Association between parental socioeconomic position and prevalence of asthma, atopic eczema and hay fever in children. Scandinavian Journal of Public Health. 2014;42:120&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24089102</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaniec UT, Turner RT. Influence of body weight on bone mass, architecture and turnover. Journal of Endocrinology. 2016;230:R115&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980254</ArticleId><ArticleId IdType="pubmed">27352896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcified Tissue International. 2001;68:259&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5352985</ArticleId><ArticleId IdType="pubmed">11683532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2016;75:1119&#x2013;1125.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216172</ArticleId><ArticleId IdType="pubmed">27542586</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg KM, Kunins HV, Jackson JL, Nahvi S, Chaudhry A, Harris KA, et al. Association Between Alcohol Consumption and Both Osteoporotic Fracture and Bone Density. The American Journal of Medicine. 2008;121:406&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692368</ArticleId><ArticleId IdType="pubmed">18456037</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jefri K, Newbury-Birch D, Muirhead CR, Gilvarry E, Ara&#xfa;jo-Soares V, Reynolds NJ, et al. High prevalence of alcohol use disorders in patients with inflammatory skin diseases. British Journal of Dermatology. 2017;177:837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28346655</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing [Internet] Vienna, Austria: 2018.  Available from:  https://www.R-project.org/
</Citation></Reference><Reference><Citation>Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000. p. 350. (Statistics for biology and health)</Citation></Reference><Reference><Citation>Egeberg A, Schwarz P, Harsl&#xf8;f T, Andersen YMF, Potteg&#xe5;rd A, Hallas J, et al. Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970335</ArticleId><ArticleId IdType="pubmed">33471030</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrendt H, Ring J. Histamine, antihistamines and atopic eczema. Clinical &amp; Experimental Allergy. 1990;20:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1980856</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28485036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association Between Atopic Eczema and Cancer in England and Denmark. JAMA Dermatol. 2020;156:1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315391</ArticleId><ArticleId IdType="pubmed">32579178</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, et al. Atopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8:248&#x2013;257.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947493</ArticleId><ArticleId IdType="pubmed">31479767</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, et al. Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study. Journal of Bone and Mineral Research. 2004;20:557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15765173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatgis J, Granville M, Jacobson RE. Delayed Recognition of Thoracic and Lumbar Vertebral Compression Fractures in Minor Accident Cases.  [cited 2020 Aug 13];Cureus. 2017  [Internet]. Available from:  http://www.cureus.com/articles/6468-delayed-recognition-of-thoracic-and-lumbar-vertebral-compression-fractures-in-minor-accident-cases
.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364089</ArticleId><ArticleId IdType="pubmed">28367388</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundy GR. Osteoporosis and Inflammation. Nutrition Reviews. 2008;65:S147&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">18240539</ArticleId></ArticleIdList></Reference><Reference><Citation>Warriner AH, Patkar NM, Curtis JR, Delzell E, Gary L, Kilgore M, et al. Which fractures are most attributable to osteoporosis? Journal of Clinical Epidemiology. 2011;64:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5030717</ArticleId><ArticleId IdType="pubmed">21130353</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, vanStaa T, Grundy E, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. Journal of Public Health. 2014;36:684&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245896</ArticleId><ArticleId IdType="pubmed">24323951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427&#x2013;e3427.</Citation><ArticleIdList><ArticleId IdType="pubmed">22619194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Oden A, Johansson H, Borgstr&#xf6;m F, Str&#xf6;m O, McCloskey E. FRAX&#xae; and its applications to clinical practice. Bone. 2009;44:734&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19195497</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE Clinical guidance. Osteoporosis: assessing the risk of fragility fracture. 2017.  [Internet]. Available from:  www.nice.org.uk/guidance/cg146
.</Citation><ArticleIdList><ArticleId IdType="pubmed">32186835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34590684</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Synergies between centralized and federated approaches to data quality: a report from the national COVID cohort collaborative.</ArticleTitle><Pagination><StartPage>609</StartPage><EndPage>618</EndPage><MedlinePgn>609-618</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocab217</ELocationID><Abstract><AbstractText Label="OBJECTIVE">In response to COVID-19, the informatics community united to aggregate as much clinical data as possible to characterize this new disease and reduce its impact through collaborative analytics. The National COVID Cohort Collaborative (N3C) is now the largest publicly available HIPAA limited dataset in US history with over 6.4 million patients and is a testament to a partnership of over 100 organizations.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We developed a pipeline for ingesting, harmonizing, and centralizing data from 56 contributing data partners using 4 federated Common Data Models. N3C data quality (DQ) review involves both automated and manual procedures. In the process, several DQ heuristics were discovered in our centralized context, both within the pipeline and during downstream project-based analysis. Feedback to the sites led to many local and centralized DQ improvements.</AbstractText><AbstractText Label="RESULTS">Beyond well-recognized DQ findings, we discovered 15 heuristics relating to source Common Data Model conformance, demographics, COVID tests, conditions, encounters, measurements, observations, coding completeness, and fitness for use. Of 56 sites, 37 sites (66%) demonstrated issues through these heuristics. These 37 sites demonstrated improvement after receiving feedback.</AbstractText><AbstractText Label="DISCUSSION">We encountered site-to-site differences in DQ which would have been challenging to discover using federated checks alone. We have demonstrated that centralized DQ benchmarking reveals unique opportunities for DQ improvement that will support improved research analytics locally and in aggregate.</AbstractText><AbstractText Label="CONCLUSION">By combining rapid, continual assessment of DQ with a large volume of multisite data, it is possible to support more nuanced scientific questions with the scale and rigor that they require.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-6840-9756</Identifier><AffiliationInfo><Affiliation>Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>TriNetX LLC, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradwell</LastName><ForeName>Katie R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Sigfried</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7853-6137</Identifier><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loomba</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niehaus</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-4289-7632</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-2723-5902</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9114-8737</Identifier><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-5437-2545</Identifier><AffiliationInfo><Affiliation>Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Al-Shukri</LastName><ForeName>Shaymaa</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Anzalone</LastName><ForeName>Alfred</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Baghal</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Bernstam</LastName><ForeName>Elmer V</ForeName><Initials>EV</Initials></Author><Author ValidYN="Y"><LastName>Bernstam</LastName><ForeName>Elmer V</ForeName><Initials>EV</Initials></Author><Author ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chaudhari</LastName><ForeName>Deepa D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wenjin</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>San</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cimino</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Crandall</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Crooks</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Sara J Deakyne</ForeName><Initials>SJD</Initials></Author><Author ValidYN="Y"><LastName>DiPalazzo</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Eckrich</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Eltinge</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Fort</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Golovko</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Snehil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Hajagos</LastName><ForeName>Janos G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Hanauer</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Harnett</LastName><ForeName>Brett M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Horswell</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Khanipov</LastName><ForeName>Kamil</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kieler</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Luzuriaga</LastName><ForeName>Katherine Ruiz De</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Maidlow</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Jomol</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McClay</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>McMahan</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Melancon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Meystre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Miele</LastName><ForeName>Lucio</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Morizono</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pablo</LastName><ForeName>Ray</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Lav</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Popham</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Pulgarin</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Indra Neil</ForeName><Initials>IN</Initials></Author><Author ValidYN="Y"><LastName>Sazo</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Setoguchi</LastName><ForeName>Soko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Soby</LastName><ForeName>Selvin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Surampalli</LastName><ForeName>Sirisha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vangala</LastName><ForeName>Uma Maheswara Reddy</ForeName><Initials>UMR</Initials></Author><Author ValidYN="Y"><LastName>Visweswaran</LastName><ForeName>Shyam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Oehsen</LastName><ForeName>James von</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Kellie M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Zai</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001857</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK059311</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="N">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020408" MajorTopicYN="N">Health Insurance Portability and Accountability Act</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">data accuracy</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34590684</ArticleId><ArticleId IdType="pmc">PMC8500110</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocab217</ArticleId><ArticleId IdType="pii">6378250</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al.; N3C Consortium. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc 2020; 28 (3): 427&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Netw Open2021; 4 (7): e2116901.. doi:10.1001/jamanetworkopen.2021.16901</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>National COVID Cohort Collaborative. N3C Cohort Exploration. https://covid.cd2h.org/dashboard/ Accessed Jun 28, 2021.</Citation></Reference><Reference><Citation>NCATS. NIH COVID-19 Data Warehouse Data Transfer Agreement. 2020. https://ncats.nih.gov/files/NCATS_Data_Transfer_Agreement_05-11-2020_Updated%20508.pdf Accessed July 15, 2021.</Citation></Reference><Reference><Citation>Vogt TM, Lafata JE, Tolsma DD, et al.The role of research in integrated health care systems: the HMO research network. Perm J 2004; 8: 10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690686</ArticleId><ArticleId IdType="pubmed">26705313</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrman RE, Benner JS, Brown JS, et al.Developing the Sentinel System&#x2014;a national resource for evidence development. N Engl J Med 2011; 364 (6): 498&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226658</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, et al.Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc 2014; 21 (4): 578&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Visweswaran S, Becich MJ, D&#x2019;Itri VS, et al.Accrual to Clinical Trials (ACT): a clinical and translational science Award Consortium Network. JAMIA Open 2018; 1 (2): 147&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241502</ArticleId><ArticleId IdType="pubmed">30474072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacey J, Mehta M.. Using EHR data extraction to streamline the clinical trial process. Clin Res 2017; 4: 2&#x2013;7.</Citation></Reference><Reference><Citation>Stapff M. Use of electronic health data in clinical development. Pharm Ind 2017; 79: 204&#x2013;10.</Citation></Reference><Reference><Citation>Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9 (12): 252&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6304296</ArticleId><ArticleId IdType="pubmed">30588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O&#x2019;Hara DJ, et al.Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc 2010; 17 (6): 652&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al.Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153 (9): 600&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams L, Kennedy S, Allen L, et al.Innovative solutions for state medicaid programs to leverage their data, build their analytic capacity, and create evidence-based policy. EGEMS (Wash DC) 2019; 7 (1): 41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688544</ArticleId><ArticleId IdType="pubmed">31406698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie BW, Laurin L-P, Zinsser D, et al.Improving data quality in observational research studies: report of the Cure Glomerulonephropathy (CureGN) network. Contemp Clin Trials Commun 2021; 22: 100749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8039553</ArticleId><ArticleId IdType="pubmed">33851061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J, Lyu T, Loiacono A, et al.Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data. J Am Med Inform Assoc 2020; 27 (12): 1999&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727392</ArticleId><ArticleId IdType="pubmed">33166397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Raebel MA, Glanz JM, et al.A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research. Med Care 2012; 50 (Suppl): S21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833692</ArticleId><ArticleId IdType="pubmed">22692254</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare R, Utidjian LH, Razzaghi H, et al.Design and refinement of a data quality assessment workflow for a large pediatric research network. EGEMS (Wash DC) 2019; 7 (1): 36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676917</ArticleId><ArticleId IdType="pubmed">31531382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al.A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC) 2016; 4 (1): 1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Holve E, Kahn M, Nahm M, et al.A comprehensive framework for data quality assessment in CER. AMIA Jt Summits Transl Sci Proc 2013; 2013: 86&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845781</ArticleId><ArticleId IdType="pubmed">24303241</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C.. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc 2013; 20 (1): 144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley-Smith S, Boyle D, Gray K.. Improving a secondary use health data warehouse: proposing a multi-level data quality framework. EGEMS (Wash DC) 2019; 7 (1): 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676919</ArticleId><ArticleId IdType="pubmed">31531384</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KE, Kamineni A, Fuller S, et al.How the provenance of electronic health record data matters for research: a case example using system mapping. EGEMS (Wash DC) 2014; 2 (1): 1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371416</ArticleId><ArticleId IdType="pubmed">25821838</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Data Quality Dashboard. Github https://github.com/OHDSI/DataQualityDashboard Accessed Jul 8, 2021.</Citation></Reference><Reference><Citation>Qualls LG, Phillips TA, Hammill BG, et al.Evaluating foundational data quality in the national patient-centered clinical research network (PCORnet&#xae;). EGEMS (Wash DC) 2018; 6 (1): 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983028</ArticleId><ArticleId IdType="pubmed">29881761</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta S, Bachman D, Laws R, et al.Data quality assessment and multi-organizational reporting: tools to enhance network knowledge. EGEMS (Wash DC) 2019; 7 (1): 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450241</ArticleId><ArticleId IdType="pubmed">30972357</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP 5.3.1 Specification. https://ohdsi.github.io/CommonDataModel/cdm531.html Accessed Aug 17, 2021.</Citation></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, et al.Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform 2013; 46 (5): 830&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>NCATS_N3C_Data_Use_Agreement.pdf. https://ncats.nih.gov/files/NCATS_N3C_Data_Use_Agreement.pdf Accessed July 15, 2021.</Citation></Reference><Reference><Citation>Jiang G, Dhruva SS, Chen J, et al.Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: a fit-for-purpose informatics analysis report. J Am Med Inform Assoc 2021; 28 (10): 2241&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449615</ArticleId><ArticleId IdType="pubmed">34313748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm M. Data quality in clinical research. In: Rachel L, Richesson JEA, ed. Clinical Research Informatics. New York, NY: Springer; 2012: 175&#x2013;201.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34642814</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-2965</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</Title><ISOAbbreviation>Osteoporos Int</ISOAbbreviation></Journal><ArticleTitle>Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions.</ArticleTitle><Pagination><StartPage>315</StartPage><EndPage>326</EndPage><MedlinePgn>315-326</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00198-021-06190-0</ELocationID><Abstract><AbstractText>Blood pressure and bone metabolism appear to share commonalities in their physiologic regulation. Specific antihypertensive drug classes may also influence bone mineral density. However, current evidence from existing observational studies and randomised trials is insufficient to establish causal associations for blood pressure and use of blood pressure-lowering drugs with bone health outcomes, particularly with the risks of osteoporosis and fractures. The availability and access to relevant large-scale biomedical data sources as well as developments in study designs and analytical approaches provide opportunities to examine the nature of the association between blood pressure and bone health more reliably and in greater detail than has ever been possible. It is unlikely that a single source of data or study design can provide a definitive answer. However, with appropriate considerations of the strengths and limitations of the different data sources and analytical techniques, we should be able to advance our understanding of the role of raised blood pressure and its drug treatment on the risks of low bone mineral density and fractures. As elevated blood pressure is highly prevalent and blood pressure-lowering drugs are widely prescribed, even small effects of these exposures on bone health outcomes could be important at a population level.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canoy</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Deep Medicine, Nuffield Department of Women's and Reproductive Health, University of Oxford, Hayes House 1F, George St., Oxford, OX1 2BQ, UK. dexter.canoy@wrh.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. dexter.canoy@wrh.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>N C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>MRC Life Course Epidemiology Unit, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Life Course Epidemiology Unit, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Global Health, Faculty of Medicine, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc5;svold</LastName><ForeName>B O</ForeName><Initials>BO</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Clinic of Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazarzadeh</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Deep Medicine, Nuffield Department of Women's and Reproductive Health, University of Oxford, Hayes House 1F, George St., Oxford, OX1 2BQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Deep Medicine, Nuffield Department of Women's and Reproductive Health, University of Oxford, Hayes House 1F, George St., Oxford, OX1 2BQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>17702</GrantID><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_21003</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12011/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585819</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_21001</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A620_1014</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12011/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601019</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400491</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585824</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U147585827</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_21000</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Osteoporos Int</MedlineTA><NlmUniqueID>9100105</NlmUniqueID><ISSNLinking>0937-941X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Osteoporos Int. 2022 Oct;33(10):2241. doi: 10.1007/s00198-022-06537-1.</RefSource><PMID Version="1">35997785</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="Y">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensive drugs</Keyword><Keyword MajorTopicYN="N">Blood pressure</Keyword><Keyword MajorTopicYN="N">Bone fracture</Keyword><Keyword MajorTopicYN="N">Bone mineral density</Keyword><Keyword MajorTopicYN="N">Osteoporosis</Keyword></KeywordList><CoiStatement>Dexter Canoy received support from the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and the British Heart Foundation outside the submitted work. Nicholas C Harvey reports consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma outside the submitted work. Daniel Prieto-Alhambra&#x2019;s department reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier; consultancy service fee from Astra Zeneca; and grants from EMA, all outside the submitted work; Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by Daniel Prieto-Alhambra&#x2019;s department and open for external participants. Professor Cyrus Cooper has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestl&#xe9;, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work. Haakon E. Meyer and Bj&#xf8;rn Olav &#xc5;svold declare no conflict of interest. MN has received studentship from the British Heart Foundation for a project outside of this submitted work. KR received support from the NIHR Oxford BRC, British Heart Foundation and Oxford Martin School at University of Oxford outside of this submitted work. Funding organisations had no role in the conception, manuscript preparation, interpretation, review or approval to submit for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>7</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34642814</ArticleId><ArticleId IdType="pmc">PMC8813726</ArticleId><ArticleId IdType="doi">10.1007/s00198-021-06190-0</ArticleId><ArticleId IdType="pii">10.1007/s00198-021-06190-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A. 2003;100:11201&#x2013;11206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208734</ArticleId><ArticleId IdType="pubmed">14500910</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034190</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008;5:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781192</ArticleId><ArticleId IdType="pubmed">22460842</ArticleId></ArticleIdList></Reference><Reference><Citation>London GM. Soft bone - hard arteries: a link? Kidney Blood Press Res. 2011;34:203&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">21691122</ArticleId></ArticleIdList></Reference><Reference><Citation>Byon CH, Chen Y. Molecular mechanisms of vascular calcification in chronic kidney disease: the link between bone and the vasculature. Curr Osteoporos Rep. 2015;13:206&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489999</ArticleId><ArticleId IdType="pubmed">25947259</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res. 2014;59:243&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313884</ArticleId><ArticleId IdType="pubmed">24847766</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313828</ArticleId><ArticleId IdType="pubmed">22331383</ArticleId></ArticleIdList></Reference><Reference><Citation>Elefteriou F. Impact of the autonomic nervous system on the skeleton. Physiol Rev. 2018;98:1083&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088147</ArticleId><ArticleId IdType="pubmed">29717928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensrud KE. Epidemiology of fracture risk with advancing age. J Gerontol A Biol Sci Med Sci. 2013;68:1236&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833201</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (2012) Osteoporosis: assessing the risk of fragility fracture [CG146]. https://www.nice.org.uk/guidance/cg146.&#xa0;Accessed 8 Apr 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">32186835</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein D, Nagel G, Kleiner A, Ulmer H, Rehberger B, Concin H, Rapp K. Blood pressure and falls in community-dwelling people aged 60 years and older in the VHM&amp;PP cohort. BMC Geriatr. 2013;13:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3663706</ArticleId><ArticleId IdType="pubmed">23692779</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, Zhou B, Lin H. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4136657</ArticleId><ArticleId IdType="pubmed">24567036</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbee DE, Hackeng WH, Birkenhager JC, Hofman A. Raised plasma intact parathyroid hormone concentrations in young people with mildly raised blood pressure. Br Med J (Clin Res Ed) 1988;296:814&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2545104</ArticleId><ArticleId IdType="pubmed">3130926</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354:971&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501357</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarron DA. Low serum concentrations of ionized calcium in patients with hypertension. N Engl J Med. 1982;307:226&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol. 2000;13:169&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10928292</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001;14:704&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465657</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Castrillon JL, Martin-Escudero JC, Alvarez Manzanares P, Cortes Sancho R, Iglesias Zamora S, Garcia Alonso M. Hypertension as a risk factor for hip fracture. Am J Hypertens. 2005;18:146&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691630</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue Int. 2009;84:103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067019</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Bikai R, Tahir MR, Tremblay J, et al. Association of age-dependent height and bone mineral density decline with increased arterial stiffness and rate of fractures in hypertensive individuals. J Hypertens. 2015;33:727&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">25915877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between hypertension and fragility fracture: a longitudinal study. Osteoporos Int. 2014;25:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23892585</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res. 1995;10:106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">7747616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">8686694</ArticleId></ArticleIdList></Reference><Reference><Citation>Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol. 1996;49:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598504</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid IR. Effects of beta-blockers on fracture risk. J Musculoskelet Neuronal Interact. 2008;8:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">18622079</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP. Beta-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. 2014;25:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">24114396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE, Osteoporotic Fractures in Men Study G Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med. 2008;168:735&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413556</ArticleId></ArticleIdList></Reference><Reference><Citation>Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768730</ArticleId><ArticleId IdType="pubmed">26835847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse C, Eiken P, Vestergaard P. Optimal age of commencing and discontinuing thiazide therapy to protect against fractures. Osteoporos Int. 2016;27:1875&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pubmed">26659068</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DH, Ruppert K, Zhao Z, Lian YJ, Kuo IH, Greendale GA, Finkelstein JS. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. Osteoporos Int. 2016;27:1181&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4813302</ArticleId><ArticleId IdType="pubmed">26449354</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J, Freeman M, Low A, Fu R, Kerfoot A, Paynter R, Motu&#x2019;apuaka M, Kondo K, Kansagara D, Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis. Ann Intern Med. 2017;166:419&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">28114673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. Eur J Epidemiol. 2017;32:947&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684291</ArticleId><ArticleId IdType="pubmed">28752198</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzilay JI, Davis BR, Pressel SL, Ghosh A, Puttnam R, Margolis KL, Whelton PK. The impact of antihypertensive medications on bone mineral density and fracture risk. Curr Cardiol Rep. 2017;19:76.</Citation><ArticleIdList><ArticleId IdType="pubmed">28752275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerauer C, Kaushik N, Woodham A, Renom-Guiteras A, Martinez YV, Reeves D, Kunnamo I, Al Qur An T, Hubner S, Sonnichsen A. Thiazides in the management of hypertension in older adults - a systematic review. BMC Geriatr. 2017;17:228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5647553</ArticleId><ArticleId IdType="pubmed">29047359</ArticleId></ArticleIdList></Reference><Reference><Citation>N. C. D. Risk Factor Collaboration Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5220163</ArticleId><ArticleId IdType="pubmed">27863813</ArticleId></ArticleIdList></Reference><Reference><Citation>Concin H, Brozek W, Benedetto KP, et al. Hip fracture incidence 2003&#x2013;2013 and projected cases until 2050 in Austria: a population-based study. Int J Public Health. 2016;61:1021&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">27549873</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Ferrari S, on behalf of the IOF Board and Executive Committee (2019) IOF Compendium of osteoporosis. International Osteoporosis Foundation. https://www.osteoporosis.foundation/sites/iofbonehealth/files/2020-01/IOF-Compendium-of-Osteoporosis-web-V02.pdf: Accessed 12 April 2021</Citation></Reference><Reference><Citation>Sanchez-Riera L, Carnahan E, Vos T, et al. The global burden attributable to low bone mineral density. Ann Rheum Dis. 2014;73:1635&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">24692584</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgstrom F, Karlsson L, Ortsater G, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020;15:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166207</ArticleId><ArticleId IdType="pubmed">32306163</ArticleId></ArticleIdList></Reference><Reference><Citation>(1991) Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 90:107&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">1986575</ArticleId></ArticleIdList></Reference><Reference><Citation>(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646&#x2013;650</Citation><ArticleIdList><ArticleId IdType="pubmed">8506892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, Epidemiology IOFWGo, Quality of L A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421108</ArticleId><ArticleId IdType="pubmed">22419370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourlay ML, Overman RA, Ensrud KE. Bone density screening and re-screening in postmenopausal women and older men. Curr Osteoporos Rep. 2015;13:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623874</ArticleId><ArticleId IdType="pubmed">26408154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">7976495</ArticleId></ArticleIdList></Reference><Reference><Citation>(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva</Citation><ArticleIdList><ArticleId IdType="pubmed">7941614</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2003) Prevention and management of osteoporosis. World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/42841/WHO_TRS_921.pdf;jsessionid=D9C403A50A7262764ACA8573D859A58C?sequence=1. Accessed 4 March 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanis JA, Adachi JD, Cooper C, et al. Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int. 2013;24:2763&#x2013;2764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096926</ArticleId><ArticleId IdType="pubmed">23884436</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 Risk Factors Collaborators Global burden of 87 risk factors in 204 countries and territories, 1990&#x2013;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566194</ArticleId><ArticleId IdType="pubmed">33069327</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2019) Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension. Accessed 20 Jun 2021</Citation></Reference><Reference><Citation>Fat LN (2020) Health Survey for England 2019 Adults&#x2019; health. Centre HaSCI. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019. Accessed 12 April 2021</Citation></Reference><Reference><Citation>National Health Service Prevention. High blood pressure (hypertension). https://www.nhs.uk/conditions/high-blood-pressure-hypertension/prevention/. Accessed 12 April 2021</Citation></Reference><Reference><Citation>Rosano C, Longstreth WT, Jr, Boudreau R, Taylor CA, Du Y, Kuller LH, Newman AB. High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up. J Am Geriatr Soc. 2011;59:390&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637929</ArticleId><ArticleId IdType="pubmed">21391929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Xu M, Wang S, Jiang S, Chen X, Zhou X, He R. Decreased bone mineral density is an independent predictor for the development of atherosclerosis: a systematic review and meta-analysis. PLoS One. 2016;11:e0154740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4858264</ArticleId><ArticleId IdType="pubmed">27149062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominic E, Brozek W, Peter RS, Fromm E, Ulmer H, Rapp K, Concin H, Nagel G. Metabolic factors and hip fracture risk in a large Austrian cohort study. Bone Rep. 2020;12:100244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965713</ArticleId><ArticleId IdType="pubmed">31970265</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739&#x2013;1744.</Citation><ArticleIdList><ArticleId IdType="pubmed">23165923</ArticleId></ArticleIdList></Reference><Reference><Citation>SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA. 1991;265:3255&#x2013;3264.</Citation><ArticleIdList><ArticleId IdType="pubmed">2046107</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J, Swift C, Gil-Extremera B, Fletcher A, Bulpitt C. The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET) Age Ageing. 2010;39:609&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">20573778</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis KL, Palermo L, Vittinghoff E, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med. 2014;29:1599&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4242873</ArticleId><ArticleId IdType="pubmed">25127725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh M, Majumdar SR. Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine. 2014;46:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">24504763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XY, Masilamani S, Nielsen J, Kwon TH, Brooks HL, Nielsen S, Knepper MA. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001;108:215&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC203017</ArticleId><ArticleId IdType="pubmed">11457874</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermuller N, Bernstein P, Velazquez H, Reilly R, Moser D, Ellison DH, Bachmann S. Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. Am J Physiol. 1995;269:F900&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">8594886</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry EL, Gesek FA, Kaplan MR, Hebert SC, Friedman PA. Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol. 1997;272:C109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9038817</ArticleId></ArticleIdList></Reference><Reference><Citation>Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi D. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol. 2007;18:2509&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2216427</ArticleId><ArticleId IdType="pubmed">17656470</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmgreen J, Tougaard L, Leth A, Christensen MS. Elevated serum parathyroid hormone concentration during treatment with high ceiling diuretics. Eur J Clin Pharmacol. 1980;18:363&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">7439260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J Intern Med. 2005;257:176&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">15656876</ArticleId></ArticleIdList></Reference><Reference><Citation>Togari A, Arai M, Kondo A. The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets. 2005;9:931&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">16185149</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ, Atkinson EJ, Joyner MJ, Rosen CJ, Monroe DG, Farr JN. Sympathetic beta1-adrenergic signaling contributes to regulation of human bone metabolism. J Clin Invest. 2018;128:4832&#x2013;4842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205387</ArticleId><ArticleId IdType="pubmed">30153111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22:2465&#x2013;2475.</Citation><ArticleIdList><ArticleId IdType="pubmed">18256306</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000;109:362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokrantz T, Schioler L, Bostrom KB, Kahan T, Mellstrom D, Ljungman C, Hjerpe P, Hasselstrom J, Manhem K. Antihypertensive drug classes and the risk of hip fracture: results from the Swedish primary care cardiovascular database. J Hypertens. 2020;38:167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">31568060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;309:344&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">6866070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ. 1990;301:1303&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1664438</ArticleId><ArticleId IdType="pubmed">2271853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24:581&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok T, Leung J, Barrett-Connor E, Osteoporotic Fractures in Men Research G ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men. Age Ageing. 2017;46:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968636</ArticleId><ArticleId IdType="pubmed">28181652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Intern Med. 2006;259:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16336519</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrao G, Mazzola P, Monzio Compagnoni M, Rea F, Merlino L, Annoni G, Mancia G. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. Drugs Aging. 2015;32:927&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">26589307</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttnam R, Davis BR, Pressel SL, et al. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2017;177:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">27893045</ArticleId></ArticleIdList></Reference><Reference><Citation>(2020) Clinical Practice Research Datalink. Crown Copyright. https://www.cprd.com/. Accessed 21 Jun 2021</Citation></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288711</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwegian Prescription Database (NorPD). Norwegian Institute of Public Health. https://www.fhi.no/en/hn/health-registries/norpd/. Accessed 21 Jun 2021</Citation></Reference><Reference><Citation>Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798&#x2013;798f.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837522</ArticleId><ArticleId IdType="pubmed">27789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey NC, Matthews P, Collins R, Cooper C, Group UKBMA Osteoporosis epidemiology in UK Biobank: a unique opportunity for international researchers. Osteoporos Int. 2013;24:2903&#x2013;2905.</Citation><ArticleIdList><ArticleId IdType="pubmed">24057481</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohns TJ, Holliday J, Gibson LM, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat Commun. 2020;11:2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250878</ArticleId><ArticleId IdType="pubmed">32457287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G, Heggland J, Holmen J. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42:968&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">22879362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">26724178</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Pressure Lowering Treatment Trialists&#x2019; Collaboration Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102467</ArticleId><ArticleId IdType="pubmed">33933205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, Davis BR, Chalmers J, Pepine CJ, Blood Pressure Lowering Treatment Trialists Collaboration Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists&#x2019; Collaboration (BPLTTC) BMJ Open. 2019;9:e028698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538087</ArticleId><ArticleId IdType="pubmed">31123005</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Yoon YE, Kim KM, Hwang IC, Lee W, Cho GY (2021) Prognostic value of lower bone mineral density in predicting adverse cardiovascular disease in Asian women. Heart&#xa0;107:1040&#x2013;1046</Citation><ArticleIdList><ArticleId IdType="pubmed">33963047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutcheon JA, Chiolero A, Hanley JA. Random measurement error and regression dilution bias. BMJ. 2010;340:c2289.</Citation><ArticleIdList><ArticleId IdType="pubmed">20573762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Solares JR, Canoy D, Raimondi FED, et al. Long-term exposure to elevated systolic blood pressure in predicting incident cardiovascular disease: evidence from large-scale routine electronic health records. J Am Heart Assoc. 2019;8:e012129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6645648</ArticleId><ArticleId IdType="pubmed">31164039</ArticleId></ArticleIdList></Reference><Reference><Citation>Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993;8:567&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">8511983</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TM, Cundy TF. Determinants of total body and regional bone mineral density in normal postmenopausal women&#x2013;a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">1619030</ArticleId></ArticleIdList></Reference><Reference><Citation>De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928804</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong ME, Spencer EA, Cairns BJ, Banks E, Pirie K, Green J, Wright FL, Reeves GK, Beral V, Million Women Study C Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women. J Bone Miner Res. 2011;26:1330&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">21611971</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson H, Kanis JA, Oden A, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res. 2014;29:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">23775829</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Bhavsar NA, Phelan M, Pencina MJ. Controlling for informed presence bias due to the number of health encounters in an electronic health record. Am J Epidemiol. 2016;184:847&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5152663</ArticleId><ArticleId IdType="pubmed">27852603</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S, Arterburn D, Daniels MJ. Assessing missing data assumptions in EHR-based studies: a complex and underappreciated task. JAMA Netw Open. 2021;4:e210184.</Citation><ArticleIdList><ArticleId IdType="pubmed">33635321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells BJ, Chagin KM, Nowacki AS, Kattan MW. Strategies for handling missing data in electronic health record derived data. EGEMS (Wash DC) 2013;1:1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371484</ArticleId><ArticleId IdType="pubmed">25848578</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones BK, Lavage DR, Snyder JW, Moore JH, Pendergrass SA, Bauer CR. Characterizing and managing missing structured data in electronic health records: data analysis. JMIR Med Inform. 2018;6:e11&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845101</ArticleId><ArticleId IdType="pubmed">29475824</ArticleId></ArticleIdList></Reference><Reference><Citation>Canoy D, Copland E, Nazarzadeh M et al (2021) Effect of antihypertensive drug treatment on long-term blood pressure reduction: an individual patient-level data meta-analysis of 352,744 participants from 51 large-scale randomised clinical trials. medRxiv. 10.1101/2021.02.19.21252066</Citation></Reference><Reference><Citation>Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernan MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22:70&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613145</ArticleId><ArticleId IdType="pubmed">22016461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5124536</ArticleId><ArticleId IdType="pubmed">27237061</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25:1601&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7076561</ArticleId><ArticleId IdType="pubmed">31591592</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170722</ArticleId><ArticleId IdType="pubmed">25064373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Holmes MV. Mendelian randomisation in cardiovascular research: an introduction for clinicians. Heart. 2017;103:1400&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574403</ArticleId><ArticleId IdType="pubmed">28596306</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26:2333&#x2013;2355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642006</ArticleId><ArticleId IdType="pubmed">26282889</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11:376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6969055</ArticleId><ArticleId IdType="pubmed">31953392</ArticleId></ArticleIdList></Reference><Reference><Citation>International Consortium for Blood Pressure Genome-Wide Association Studies. Ehret GB, Munroe PB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340926</ArticleId><ArticleId IdType="pubmed">21909115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehret GB, Ferreira T, Chasman DI, et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet. 2016;48:1171&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042863</ArticleId><ArticleId IdType="pubmed">27618452</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412&#x2013;1425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284793</ArticleId><ArticleId IdType="pubmed">30224653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Dehghan A, Smith Byrne K, Bennett DA, Smith GD, Rahimi K. Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study. Genome Med. 2021;13:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934395</ArticleId><ArticleId IdType="pubmed">33663581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CJ, Gong H, Brown MJ, Harding SE. Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for &#x2018;putative&#x2019; beta 4-adrenoceptor pharmacology. Br J Pharmacol. 2004;141:813&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574257</ArticleId><ArticleId IdType="pubmed">14757703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill D, Georgakis MK, Koskeridis F, et al. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects. Circulation. 2019;140:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687408</ArticleId><ArticleId IdType="pubmed">31234639</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for the prevention of Alzheimer&#x2019;s disease: a Mendelian randomization study. Int J Epidemiol. 2020;49:1132&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751008</ArticleId><ArticleId IdType="pubmed">31335937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178:1177&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3783091</ArticleId><ArticleId IdType="pubmed">23863760</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338864</ArticleId><ArticleId IdType="pubmed">22504420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng HF, Forgetta V, Hsu YH, et al. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature. 2015;526:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755714</ArticleId><ArticleId IdType="pubmed">26367794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp JP, Morris JA, Medina-Gomez C, et al. Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. Nat Genet. 2017;49:1468&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621629</ArticleId><ArticleId IdType="pubmed">28869591</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Gomez C, Kemp JP, Trajanoska K, et al. Life-course genome-wide association study meta-analysis of total body BMD and assessment of age-specific effects. Am J Hum Genet. 2018;102:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777980</ArticleId><ArticleId IdType="pubmed">29304378</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JA, Kemp JP, Youlten SE, et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet. 2019;51:258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358485</ArticleId><ArticleId IdType="pubmed">30598549</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40:597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5082560</ArticleId><ArticleId IdType="pubmed">27625185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarzadeh M, Pinho-Gomes AC, Bidel Z, et al. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study. Eur Heart J. 2020;41:3913&#x2013;3920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654932</ArticleId><ArticleId IdType="pubmed">32076698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Frysz M, Kemp JP, Evans DM, Davey Smith G, Tobias JH. Use of Mendelian randomization to examine causal inference in osteoporosis. Front Endocrinol (Lausanne) 2019;10:807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6882110</ArticleId><ArticleId IdType="pubmed">31824424</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506233</ArticleId><ArticleId IdType="pubmed">28527048</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray TP, Moons KG, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RH, Reitsma JB, GetReal Methods Review G Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. 2015;6:293&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042043</ArticleId><ArticleId IdType="pubmed">26287812</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med. 2001;20:2219&#x2013;2241.</Citation><ArticleIdList><ArticleId IdType="pubmed">11468761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>